

PROGRAM

PROGRAM

AMERICAN PSYCHIATRIC ASSOCIATION 2005 ANNUAL MEETING



ATLANTA, GA ♦ MAY 21-26, 2005

2005 SCIENTIFIC PROGRAM COMMITTEE



Seated (left to right): Drs. Muskin, Jayaram, Pandya, Butterfield (*Chairperson*), McDowell (*Vice Chairperson*), Dickstein, Horton, Judge. **2ndnd Row Standing (left to right):** Drs. D'Alli, Boland, Lieff, Silk, Gitlin, Simon, Crone, Goldstein, Baron, Worley, Taylor, LeMelle, Ernst, Cheong, Rothschild, Hilty, Stabinsky, Casey. **Not Pictured:** Drs. Anderson, Baker, Licinio.

May 21, 2005

Dear Colleagues and Guests:


Welcome to the 158th Annual Meeting of the American Psychiatric Association. The coming week will highlight the best in our profession in the largest psychiatric meeting in the world. Our meeting has become an outstanding international forum to discuss the latest scientific advances and traditional humane values in psychiatry and how we will continue to integrate these bodies of knowledge to provide excellent patient care.

This year's Annual Meeting theme is "Psychosomatic Medicine: Integrating Psychiatry and Medicine." Many sessions throughout the week will highlight important aspects of the theme. In addition, please make a special effort to attend the Presidential Symposia, from 2:00-5:00 p.m., on Monday, Tuesday, and Wednesday. An entire track of sessions, presented in collaboration with the National Institute of Mental Health has been scheduled throughout the meeting.

I join our colleagues from North America in greeting the thousands of colleagues from other parts of the world who have joined us in Atlanta. At the Opening Session, from 5:00 p.m.-6:30 p.m., on Sunday, we will officially welcome the leaders from psychiatric societies in the U.S. and around the world. I will present my Presidential Address, and I look forward to seeing you there. Please also make sure to attend the Convocation of Distinguished Fellows on Monday night at 5:30 p.m., where we will honor all those being inducted as fellows and distinguished fellows and many receiving awards from APA. The William C. Menninger Memorial lecture will be presented during the Convocation by author, Trisha Meili, who will discuss her traumatic attack in her lecture entitled, "I am the Central Park Jogger: A Story of Hope and Possibility."

Organizing a meeting like ours represents the best in collaboration between our members and our staff. Special congratulations go to Dr. Marian Butterfield and the members of the Scientific Program Committee and to the APA staff who work on the Annual Meeting. Welcome to Atlanta.

Sincerely,


Michelle B. Riba, M.D.
APA President



American Psychiatric Association

1000 Wilson Boulevard
Suite 1825
Arlington, VA 22209-3901
Telephone: 703.907.7822
Fax: 703.907.1090
E-mail: apa@psych.org

May 21, 2005

158th Annual Meeting
Atlanta, GA
May 21-26, 2005

President
Michelle B. Riba, M.D.

Scientific Program Committee
2004-2005
Marian I. Butterfield, M.D.
Chairperson

David M. McDowell, M.D.
Vice-Chairperson

Tanya Anderson, M.D.
Robert W. Baker, M.D.
David A. Baron, D.O.
David A. Casey, M.D.
Joseph A. Cheong, M.D.
Catherine C. Crone, M.D.
Richard E. D'Alli, M.D.
Donald M. Hilty, M.D.
Leslie A. Horton, M.D.
Sheila Judge, M.D.
Stephanie LeMelle, M.D.
Philip R. Muskin, M.D.
Anthony J. Rothschild, M.D.
Kenneth R. Silk, M.D.
Harvey Stabinsky, M.D.
David H. Taylor, M.D.
Linda L.M. Worley, M.D.

Consultants
Robert J. Boland, M.D.
Leah J. Dickstein, M.D.
David F. Gitlin, M.D.
Marion Z. Goldstein, M.D.
Geetha Jayaram, M.D.
Julio Licinio, M.D.
Susan J. Lief, M.D.
Anand Pandya, M.D.

Committee on Commercial Support
David M. McDowell, M.D.
Chairperson
Linda Bueno, *Associate Director*
Commercially-Supported Activities
(703) 907-7841

Annual Meetings Department
Cathy L. Nash, *Director*
(703) 907-7822
Hope Ball-Mann, *Registrar*
(703) 907-7810
Vernetta V. Copeland,
Associate Director
(703) 907-7811
Akosua Kankam,
Scientific Program Coordinator
(703) 907-7807
Sharita M. Morse,
Scientific Program Coordinator
(703) 907-7807
Byron D. Phillips,
Scientific Program Coordinator
(703) 907-7379
Elizabeth Rumsey,
Administrator, CME Courses
(703) 907-7813
Desta L. Wallace,
Scientific Program Coordinator
(703) 907-7805

Dear APA Members and Guests:

Welcome to Atlanta, GA, and the 158th Annual Meeting of the American Psychiatric Association. This historic city, with its vibrancy, cultural diversity, and excitement, provides a perfect setting for the scientific presentations we have planned. As you read through the *Program Book*, you will notice a number of sessions related to the theme "Psychosomatic Medicine: Integrating Psychiatry and Medicine," chosen by our President, Dr. Michelle B. Riba. Let me draw your attention to just a few of the many exciting sessions presented this week. Several Presidential Symposia will be presented each day on Monday-Wednesday from 2:00 p.m.-5:00 p.m.

The Business Meeting and the Opening Session will be held at the Georgia World Congress Center on Sunday, May 22. The Convocation of Distinguished Fellows also will be held there on Monday evening, May 23, 5:30-6:30 p.m. During the Convocation, author Trisha Meili, will discuss her trauma narrative and story of healing and hope when she presents the William C. Menninger Memorial Lecture entitled, "I am the Central Park Jogger: A Story of Hope and Possibility."

The Advances in Research session will be held on Monday at 10:30 a.m. This session highlights the latest research findings in psychiatry and summarizes their relevance to clinical practice. We have chosen topics to interface with our Annual Meeting theme, including depression and cardiovascular disease and psycho-oncology. This session has become an excellent way to start off the Annual Meeting's research programs, in conjunction with the Young Investigators' Poster and Oral/Slide Sessions also on Monday. You will find an expanded number of small group sessions, including Discussion Groups; Research Consultations with selected experts in the field; and Master Educator Clinical Consultations, a series of clinically-based seminars with outstanding clinician educators, offered to APA members only.

A special series of sessions will be presented in collaboration with the National Institute of Mental Health. Outstanding leaders in psychiatry and neuroscience research will present across formats from lectures to symposia and discussion groups. Notably, Nobel Laureate Dr. Eric Kandel will discuss neuroscience and its relationship to the "self." The APA is very appreciative of their support of these sessions. For detailed information on the sessions, please consult the separate program on this series, which is included your registration packet.

It is extremely important that you fill out and return the evaluation forms for this meeting. The members of the Scientific Program Committee are interested in your opinion regarding the quality of the content of the Annual Meeting. The information we obtain will be used to plan next year's Annual Meeting. Once again, welcome to Atlanta. I look forward to sharing a week of exciting and professionally rewarding activities with you.

Sincerely,

Marian I. Butterfield, M.D.
Chairperson, Scientific Program Committee

APA 158th ANNUAL MEETING

Atlanta, GA • May 21-26, 2005

KEY LOCATIONS - GEORGIA WORLD CONGRESS CENTER

| | |
|---------------------------------------|-------------------------------------|
| <i>American Journal of Psychiatry</i> | APPI Bookstore, Halls A1-3, Level 1 |
| Annual Meetings Office | Room A313, Level 3 |
| APA Communications Office | Rooms A311/312, Level 3 |
| APA Member Center | Halls A1-3, Level 1 |
| A/V Preview Room | Room A315, Level 3 |
| CME Course Enrollment | Halls A1-3, Level 1 |
| Computerized Evaluation | Building A Foyer, Level 4 |
| <i>Daily Bulletin</i> | Rooms A311/312, Level 3 |
| Exhibit Office | Building A Foyer, Level 4 |
| Exhibits/Publishers' Bookfair | Halls A1-3, Level 1 |
| Information/Locator Center | Building A Foyer, Level 4 |
| Internet Village | Building A Foyer, Level 4 |
| Lost & Found | Building A Foyer, Level 4 |
| Message Center | Building A Foyer, Level 4 |
| On-Site Job Bank and Placement Center | APA Member Center, Halls A1-3 |
| <i>Psychiatric Services</i> | APPI Bookstore, Halls A1-3, Level 1 |
| Registration | Halls A1-3, Level 1 |

FIRST AID

Located in A2/A3 Foyer, Level 1, Georgia World Congress Center. Hours of operation: Tuesday, May 17, through Thursday, May 26, and opens one hour prior to show opening and closes one hour after the last event of the evening.

COURTESY SHUTTLE BUS SERVICE

Service will begin on Saturday, May 21, at 7:00 a.m. and will operate daily throughout the meeting commensurate with the scientific program schedule, concluding on Thursday, May 26, at 6:00 p.m. The Georgia World Congress Center will serve as the "hub" for all shuttle bus routes. A detailed Shuttle Bus Schedule will be included in each registration packet and posted in the lobbies of participating hotels. Refer to the city map on page XII for the location of hotels in relation to the Congress Center.

EXHIBITS

Commercial and educational exhibits will be located in Halls A1-3, Level 1, Georgia World Congress Center, along with the Publishers' Bookfair and the APA Member Center. The Publishers' Bookfair and APA Member Center will open on Saturday, May 21, 10:00 a.m.-5:00 p.m. Educational and commercial exhibit hours are: Sunday, May 22, 10:00 a.m.-4:30 p.m.; Monday, May 23, 10:00 a.m.-5:30 p.m.; Tuesday, May 24, 10:00 a.m.-6:00 p.m.; and the final day, Wednesday, May 25, 10:00 a.m.-3:00 p.m. **All exhibits close on Wednesday at 3:00 p.m.** Please refer to the *APA Exhibits Guide* for additional information on participating companies. APA periodicals will be located in the APPI Bookstore.

INFORMATION/LOCATOR CENTER

Located in the Building A Foyer, Level 4, Georgia World Congress Center and staffed during registration hours (with the exception of Thursday, May 26, when the Center will be open until 5:00 p.m.). Up-to-date general information about the program, component meetings, the local area, and the locations of various activities and events can be obtained there. Meeting participants can also find out where colleagues who are registered for the meeting are staying.

MESSAGE CENTER

Located in the Building A Foyer, Level 4, Georgia World Congress Center and staffed during registration hours (with the exception of Thursday, May 26, when the Center will be open until 5:00 p.m.). Messages can be left and picked up at the Message Center. Message monitors will be strategically located in the Exhibit Hall and elsewhere in the Georgia World Congress Center. Registrants whose names appear on these monitors should pick up their messages at the Message Center.

APA MEMBER CENTER

Located in Halls A1-3, Level 1, Georgia World Congress Center, adjacent to the APPI Bookstore. Hours of operation will be Saturday, May 21, 10:00 a.m.-5:00 p.m.; Sunday, May 22, 10:00 a.m.-4:30 p.m.; Monday, May 23, 10:00 a.m.-5:30 p.m.; Tuesday, May 24, 10:00 a.m.-6:00 p.m.; and Wednesday, May 25, 10:00 a.m.-3:00 p.m. A few of the many APA activities exhibited include: membership, APA's internet-based programs, continuing medical education, quality improvement, psychiatric services, clinical resources, advocacy tools, career development, and APA Periodicals. Also included are the American Psychiatric Foundation (APF) and the American Psychiatric Institute for Research and Education (APIRE).

APA JOB BANK

Visit the APA on-site Job Bank at APA 2005! The online APA Job Bank will power the popular on-site Job Bank providing improved tools for both employers and candidates at the APA's Annual Meeting. Candidates and employers are encouraged to activate their resume and job postings in advance of the meeting for best results. For more information on the Job Bank, visit www.psych.org/jobbank

APA COMMUNICATIONS OFFICE/PRESS OFFICE

Located in Rooms A311/312, Level 3, Georgia World Congress Center. Hours of operation will be: Saturday, May 21, 11:00 a.m.-5:00 p.m.; Sunday-Wednesday, May 22-25, 8:00 a.m.-6:00 p.m.; and Thursday, May 26, 8:00 a.m.-12 noon. **This room is for the use of registered press and credentialed public relations representatives only.**

DAILY BULLETIN

The *Daily Bulletin* accepts written requests from APA members for publicity of component, committee, and allied group events as space allows. Four issues are published. The issue for Saturday/Sunday is printed in advance. Copy for the Monday, Tuesday, and Wednesday/Thursday issues can be dropped off in Rooms A311/312, Level 3, by 12 noon prior to the date of publication.

RESIDENTS' RESOURCE CENTER

Located in International Meeting Rooms 2/3, International Level, Atlanta Marriott. The Residents' Resource Center will be open from 7:00 a.m. to 6:00 p.m., Sunday, May 22, through Wednesday, May 25. Daily activities are scheduled for residents (such as the Residents Only Discussion Groups and Resident Summits) and for medical students as well. Meet and network with leaders in psychiatry and your colleagues. Resources specifically for residents and medical students are available here.

BUSINESS CENTERS

Georgia World Congress Center: Kinko's Building A/B Lobby

Times of operation: Open during show hours

Omni: Location: Executive Offices, Lobby, South Tower

Times of operation: Saturday: 7:00 a.m.-5:00 p.m.; Sunday: 11 a.m.-7:00 p.m.; Monday-Friday: 7:00 a.m.-5:30 p.m.

Hilton: Location: Main Lobby

Times of operation: Saturday-Sunday: 7:00 a.m.-7:00 p.m.; Monday-Friday: 6:30 a.m.-11:00 p.m.

REGISTRATION

Admission to all sessions by registration badge

Located in the Halls A1-3, Level 1, Georgia World Congress Center. Hours of operation: Saturday, 10:00 a.m.-5:00 p.m.; Sunday, 7:30 a.m.-5:00 p.m.; Monday, 7:30 a.m.-5:30 p.m.; Tuesday, 7:30 a.m.-6:00 p.m.; Wednesday, 7:30 a.m.-5:00 p.m.; and Thursday, 7:30 a.m.-2:00 p.m.

On-Site Registration Fee Schedule:

APA MEMBERS

| | |
|--|--------------|
| Full-Time Registration (<i>North American Members</i>) | \$275.00 |
| Full-Time Registration (<i>International Members</i>) | \$275-\$470* |
| Members-in-Training (<i>Member Class MT</i>) | \$ 75.00 |
| Daily Registration (<i>North American Members</i>) | \$140.00 |
| Daily Registration (<i>International Members</i>) | \$215.00 |
| Medical Students | no charge |

*Fee determined by country's gross national income according to the World Bank.

NONMEMBERS

| | |
|--|-----------|
| Full-Time Registration | \$790.00 |
| Nonmember Residents, Students, Advocacy Group Members, or Mental Health Chaplains | 95.00 |
| Daily Registration (<i>all Nonmember categories</i>) | 400.00 |
| Medical Students | no charge |

GUEST REGISTRATION

One only per full-time registrant 100.00
Only one guest is allowed to register with each full-time meeting registrant. *The guest must reside in the same household and be able to receive mail at the same address. APA members cannot register as a "guest"; they must register as an APA member.*

One-Day Exhibit Hall Only Pass (18 and older) 10.00
(Only **paid** registrant can purchase an exhibit hall pass)

On-site fees can be paid by cash, check, money order, American Express, VISA, or MasterCard. Registration fees are waived **only** for *CME Course Faculty, APA Honorary Fellows (does not include APA Distinguished Fellows/Fellows/Life Fellows/Distinguished Life Fellows), medical students (with proper identification), District Branch Executive Staff (who are not APA members), active members of the Association of Mental Health Clergy (with proper identification), and nonmember program participants (only for the day(s) they present).*

NONMEMBER PSYCHIATRIC RESIDENTS AND OTHER FULL-TIME STUDENTS must present documentation to register in their respective category and qualify for the reduced fee. (Examples include: a valid full-time [12 + hours per semester] student ID; a letter from your instructor or director of training verifying your status as a psychiatric resident; or similar documentation.)

Note: There are no exemptions or reduced fees available for CME courses. The registration fee covers admission to all sessions (except courses), shuttle buses, and includes a badge and copy of the *Program Book, APA Member Center Guide, and New Research Program and Abstracts Books*, and for most categories, a copy of the *Syllabus*.

REGISTRATION BADGES

Badges are required for all sessions including the Opening Session and exhibit hall. Only an APA member badge will admit you to the Business Meeting.

Badge Color Codes: Blue-Members, Yellow-Nonmembers, Silver-Press, Red-Exhibitors, Green-APA Staff, and Clear-Temporary Personnel.

Registered exhibitors will receive red badges, which allow access only to his/her own booth in the exhibit hall and to ride the shuttle bus. If an exhibitor wants to attend sessions, he/she must register for the meeting and pay the appropriate fee.

CME COURSE ENROLLMENT

Ticket purchase required for CME Courses

Located in Halls A1-3 Level 1, Georgia World Congress Center. Hours of operation are the same as registration. Tickets for CME Courses not sold by April 23 will be on sale to all registrants beginning at 10:00 a.m. on Saturday, May 21. You must show your registration badge before you can enroll in courses.

APA ART ASSOCIATION

Located in the Exhibit Halls A1-3, Level 1, Georgia World Congress Center and open during the commercial exhibit hours, the exhibit includes paintings, photography, ceramics, and crafts created by APA members and/or their significant others. Stop by for information on joining the APA Art Association.

APA ALLIANCE BOOTH

Located in the Building A Foyer, Level 4, Georgia World Congress Center. Hours of operation: Saturday, May 21, through Wednesday, May 25, 9:00 a.m.-5:00 p.m. Stop by the booth to obtain information on the Alliance's program schedule and information on membership.

APA PERIODICALS

Staff of *The American Journal of Psychiatry, Psychiatric Services, Academic Psychiatry, The American Journal of Geriatric Psychiatry, Journal of Neuropsychiatry and Clinical Neuroscience, Psychosomatics*, and APA's CME journal, *Focus* will be on hand to demonstrate online access for subscribers, answer questions regarding submissions, and show authors and reviewers how to use Manuscript Central, the new web-based manuscript submission and review system. Visitors can also purchase or renew subscriptions to all APA/APPI journals at the booth. Complimentary copies of *Psychiatric News* will be available at stands located throughout Georgia World Congress Center. Persons who wish to contact editors or reporters of *Psychiatric News* are asked to leave a message on the message board in the Annual Meetings Office. Written announcements, suggestions for articles, letters to the editor, or other material for the newspaper's consideration may be left with staff at the Periodicals Exhibit.

CONTINUING MEDICAL EDUCATION

Educational Objectives: At the conclusion of this meeting, participants will be able to:

- Better understand new research findings in the fields of psychiatry and neuroscience;
- Acquire new knowledge and skills in clinical psychiatry, which can be utilized to improve patient care;
- Identify and remove barriers to the transfer of new knowledge for their practice, including provision of culturally competent care for diverse populations;
- Assess a variety of treatment choices, including psychotherapeutic and pharmacological options; and
- Better understand mental health service delivery issues, including barriers to care.

The APA is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 66 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Please note: Most portions of the scientific program, as outlined below, have been approved for CME credit. The scientific sessions on the official Annual Meeting program, with some exceptions, meet the criteria for category 1 CME credit. Sessions in the following program formats are designated as category 1: Advances in Psychotherapy, Advances in Psychosomatic Medicine, Advances in Research, Clinical Case and Continuous Clinical Case Conferences, CME Courses, Focus Live, Forums, Industry-Supported Symposia, Lectures, Medical Updates, New Research Young Investigators' Oral/Slide Sessions, Presidential Symposia, Research Advances in Medicine, Review of Psychiatry, Roundtable Discussion, Scientific and Clinical Reports, Symposia, and Workshops. Other scientific sessions not listed may be reported as category 2 (Debates, Discussion Groups, Master Educator Clinical Consultations, New Research Poster Sessions, and Research Consultation). Scientific sessions are open to all Annual Meeting registrants, except for the Clinical Case and Continuous Clinical Case Conferences and the Master Educator Clinical Consultations, which are open to APA members only.

PLEASE NOTE: APA MEMBERS ARE REQUIRED TO MAINTAIN THEIR OWN RECORDS OF CME HOURS. REPORTING OF CME CREDIT IS ON AN HONOR BASIS.

To document CME credit earned at the Annual Meeting, participants should record the sessions they attended on the *Certificate of Attendance* log sheet found in the front of the 2005 *Annual Meeting CME Syllabus & Proceedings Summary Book*. Credit is earned on an hour-for-hour basis. A parchment *Certificate of Attendance* is also available.

The *Certificate of Attendance* (or copy) may be forwarded to other organizations requiring verification of participation in the APA Annual Meeting.

The APA requires members to participate in a total of 150 credits of CME activities within a three-year reporting period. At least 60 credits must be in category 1 activities.

CME report forms may be obtained from the Department of CME at the APA or online at www.psych.org. Staff will be available in the APA Member Center to answer any of your questions about CME.

ANNUAL MEETING EVALUATION

The Annual Meeting Scientific Program Committee needs your recommendations and evaluations to plan next year's Annual Meeting. A participant evaluation form is enclosed with your registration packet and includes instructions for completing the form. **Before you leave the meeting, please complete your form and drop it in one of the evaluation boxes located throughout the meeting sites or consider the options below.**

You can receive a parchment *Certificate of Attendance* at the Annual Meeting by returning your completed form (to the Annual Meetings Office, Information/Locator Center, or APA Member Center, all located in Georgia World Congress Center). A personalized *Certificate of Attendance* will be available by completing the computerized general evaluation in the Building A Foyer, Level 4, Georgia World Congress Center, or after the meeting, by completing the online general evaluation on the APA website. Please complete the general evaluation one time only.

SESSION CAPACITY

So that all in attendance may benefit, we ask your assistance when overcrowding occurs:

- Please find seating as far forward as possible.
- Move to the center of the row and fill all seats so that chairs are available on aisles for additional attendees.
- Overcrowding of meeting rooms may subject the session to shutdown by the Fire Marshal; therefore, we urge all attendees to locate seating rather than stand in aisles or against walls.
- If space does not permit you to attend a session, an audiotape of that session may be available. Please check the order form included in your registration packet.

AUDIO RECORDINGS OF SESSIONS

Audiotapes and CDs of most sessions are available shortly after each session concludes and may be purchased at the Mobiltape Booth located in the Building A Foyer, Level 4, Georgia World Congress Center.

SMOKING POLICY

There will be **NO SMOKING** in scientific sessions or in the exhibit hall. Smoking will only be permitted in designated areas.



TAPE RECORDING AND VISUAL REPRODUCTION POLICIES

Audiotape recording is only permitted for personal use. Registrants are welcome to use their own small, portable audiotape recorders to record any session except Master Educator Clinical Consultations, the Clinical Case Conferences, and the Continuous Clinical Case Conferences, or unless prohibited by the presenters. Larger, professional tape recorders are not permitted except for use by registered members of the working press in accordance with APA Press Policies. APA has authorized a professional taping firm to audiotape sessions. Badges of personnel representing this firm will clearly identify them. Registrants are not permitted to photograph (including with cell phone cameras) or videotape any session because the intrusive nature of the recording may disrupt the session.

FUTURE APA MEETINGS

APA ANNUAL MEETINGS

| | |
|----------------|-----------------------|
| 2006 May 20-25 | Toronto, Ont., Canada |
| 2007 May 19-24 | San Diego, CA |
| 2008 May 3-8 | Washington, DC |
| 2009 May 16-21 | San Francisco, CA |

INSTITUTES ON PSYCHIATRIC SERVICES

| | |
|--------------------|-----------------|
| 2005 October 5-9 | San Diego, CA |
| 2006 October 6-10 | New York, NY |
| 2007 October 11-14 | New Orleans, LA |

Preliminary Programs for the 2005 Institute on Psychiatric Services are available at the Information/ Locator Center, located in the Building A Foyer, Level 4, Georgia World Congress Center.

GUIDE TO THE PROGRAM BOOK

Below you will find the table of contents for ease in locating information about this meeting. A topic index is included to assist you with finding sessions of interest. The individual program for each day's sessions is listed by start time with the formats listed alphabetically under those times. **NOTE: To make it easier for you to plan your day, we have prepared a separate "Days-at-a-Glance," which is included in your registration packet.**

If you have any questions about this book or the scientific sessions, please feel free to stop by the Annual Meetings Office in Georgia World Congress Center, and we will be glad to help you. Also, all APA staff will be wearing green badges. Please feel free to direct your questions to them.

TABLE OF CONTENTS

| | |
|--|------------|
| Floor Plans for Georgia World Congress Center, Atlanta Hilton, Omni, | VI-XI |
| City Map | XII |
| Local Information | XIII |
| Special Acknowledgments | XIV-XVI |
| Format Descriptions | XVII-XVIII |
| Disclosure Information | XIX-XXXIX |
| Saturday Sessions | 1-4 |
| Sunday Sessions | 5-12 |
| Monday Sessions | 13-37 |
| Audiotape Sales Information | 38 |
| Tuesday Sessions | 39-62 |
| Wednesday Sessions | 63-84 |
| Thursday Sessions | 85-99 |
| Topic Index | 100-115 |
| Participant Index | 116-126 |
| Call for 2006 Annual Meeting Papers | 127 |
| 2005 Institute on Psychiatric Service | 128 |
| American Psychiatric Foundation Special Events | 129 |
| American Psychiatric Publishing Inc. | 130-131 |
| Psychiatry Online.com | 132 |
| Industry-Supported Symposia | 133-155 |
| APA Member Center | Back Cover |

News reports or summaries of APA presentations contained in these program materials may not be published or broadcast before the local time and date of the presentation.


Refer to the *APA Exhibits Guide* for information on: Exhibits, Publishers' Bookfair, and Dining Facilities in the Georgia World Congress Center.

The information provided and views expressed by presenters on this program are not necessarily those of the American Psychiatric Association, nor does the American Psychiatric Association warrant the accuracy of any information reported.


Georgia World Congress Center

Building A

285 Andrew Young International Boulevard, Atlanta, GA 30313
404-223-4000




Georgia World Congress Center Building B



Hilton Atlanta

Third Floor




Third Floor

| Room | Dimensions LxW | Square Feet* | Ceiling Height | Theatre | Schoolroom 2 per 6' | Schoolroom 3 per 6' | Banquet | Reception** | Conference | Exhibits 10' x 10' | Exhibits 8' x 10' |
|--------------------|----------------|--------------|----------------|---------|---------------------|---------------------|---------|-------------|------------|--------------------|-------------------|
| Presidential Court | 130x48 | 5,987 | 9'10" | 400 | 144 | 216 | 350 | 550 | N.A. | N.A. | N.A. |
| Carter | 37x23 | 851 | 9'10" | 90 | 34 | 51 | 60 | 80 | 34 | N.A. | N.A. |
| Jackson | 48x30 | 1,440 | 9'10" | 120 | 46 | 69 | 80 | 130 | 40 | N.A. | N.A. |
| Madison | 48x23 | 1,104 | 9'10" | 110 | 44 | 66 | 90 | 105 | 40 | N.A. | N.A. |
| Monroe | 48x30 | 1,440 | 9'10" | 120 | 46 | 69 | 90 | 130 | 40 | N.A. | N.A. |
| Roosevelt | 48x24 | 1,152 | 9'10" | 110 | 44 | 66 | 90 | 105 | 40 | N.A. | N.A. |
| Jefferson | 26x23 | 598 | 10'8" | 50 | 18 | 27 | 40 | 50 | 26 | N.A. | N.A. |
| Washington | 26x23 | 598 | 10'8" | 50 | 18 | 27 | 40 | 50 | 26 | N.A. | N.A. |
| Adams | 26x23 | 598 | 10'8" | 50 | 18 | 27 | 40 | 50 | 26 | N.A. | N.A. |

THE SQUARE FEET NUMBERS ARE BASED ON USABLE SQUARE FOOTAGE. CAPACITIES TAKE INTO CONSIDERATION PLACEMENT OF BARS, COCKTAIL ROUNDS, FOOD STATIONS AND EXPERIENCE OF THE HOTEL.

Hilton Atlanta

Fourth Floor



Fourth Floor


| Room | Dimensions L x W | Square Feet* | Ceiling Height | Theatre | Schoolroom 2 per 6' | Schoolroom 3 per 6' | Banquet | Reception** | Conference | Exhibits 10' x 10' | Exhibits 8' x 10' |
|--------------------|------------------|--------------|----------------|---------|---------------------|---------------------|---------|-------------|------------|--------------------|-------------------|
| State Room | 26x24 | 624 | 9'11" | 70 | 22 | 33 | 40 | 70 | 24 | N.A. | N.A. |
| Club Room | 28x26 | 728 | 9'11" | 80 | 22 | 33 | 40 | 80 | 24 | N.A. | N.A. |
| State/Club | 52x26 | 1,352 | 9'11" | 115 | 42 | 63 | 90 | 115 | 40 | N.A. | N.A. |
| Council Room | 26x24 | 624 | 9'11" | 70 | 22 | 33 | 40 | 70 | 24 | N.A. | N.A. |
| Cabinet Room | 28x26 | 728 | 9'11" | 80 | 22 | 33 | 40 | 80 | 24 | N.A. | N.A. |
| Council/Cabinet | 52x26 | 1,352 | 9'11" | 115 | 42 | 63 | 90 | 115 | 40 | N.A. | N.A. |
| Embassy Room | 25x27 | 675 | 9'11" | 75 | 22 | 33 | 50 | 75 | 24 | N.A. | N.A. |
| Board Room | 25x23 | 575 | 9'11" | 65 | 20 | 30 | 40 | 65 | 24 | N.A. | N.A. |
| Directors Room | 25x27 | 675 | 9'11" | 75 | 22 | 33 | 50 | 75 | 24 | N.A. | N.A. |
| Board/Directors | 50x25 | 1,250 | 9'11" | 115 | 42 | 63 | 90 | 115 | 40 | N.A. | N.A. |
| Assembly Room | 19'3"x25'7" | 490 | 9'11" | 50 | 12 | 18 | 30 | 60 | 16 | N.A. | N.A. |
| Congressional Room | 21'9"x25'7" | 555 | 9'11" | 60 | 16 | 24 | 40 | 60 | 18 | N.A. | N.A. |
| Legislative Room | 21'9"x25'7" | 555 | 9'11" | 60 | 16 | 24 | 40 | 60 | 18 | N.A. | N.A. |

THE SQUARE FEET NUMBERS ARE BASED ON USABLE SQUARE FOOTAGE. CAPACITIES TAKE INTO CONSIDERATION PLACEMENT OF BARS, COCKTAIL ROUNDS, FOOD STATIONS AND EXPERIENCE OF THE HOTEL.


Omni Hotel

100 CNN Center, Atlanta, GA 30303
404-659-0000

M e e t i n g S p a c e



CITY MAP



MAP KEY:

- AM AmeriSuites Atlanta Downtown
- MQ Atlanta Marriott Marquis
- CT Courtyard Atlanta Downtown
- DA Days Inn
- ES Embassy Suites-Olympic Park
- FD Fairfield Inn Downtown
- HS Hampton Inn & Suites
- HA Hilton Atlanta & Towers

- HI Holiday Inn Downtown
- HR Hyatt Regency Atlanta
- MM Marriott Midtown Suites
- OM Omni Hotel@CNN Center
- RG Regency Suites Hotel
- RN Renaissance Hotel Downtown
- RS Residence Inn Downtown
- RA Ritz Carlton Atlanta

- RB Ritz Carlton Buckhead
- SA Sheraton Atlanta
- SB Sheraton Buckhead
- SC Sheraton Midtown-Colony Sq.
- WE Westin Atlanta Buckhead
- WP Westin Peachtree Plaza
- WY Windham Atlanta

LOCAL INFORMATION

Southern hospitality, hot attractions, and good weather year round lure visitors to Atlanta. Indoors and outdoors, there's plenty to do. A tour around Centennial Olympic Park and the CNN Center can't be missed, especially with both just steps away from the Georgia World Congress Center. Also downtown are the Underground Atlanta shopping and entertainment district, World of Coca-Cola, and an arts scene that's become one of the country's best. The Atlanta Ballet – the country's oldest ballet company, the Atlanta Opera, and the Atlanta Symphony Orchestra put on spectacular classical and contemporary performances, and the High Museum of Art features world-renowned paintings from well-known artists. The Atlanta Botanical Garden is great for individual exploration or a special group event, and the Martin Luther King Jr. National Historic Site, in historic Sweet Auburn, is a much-enjoyed group outing.

Sports fans – those who play and those who watch – will have a ball in Atlanta. Games featuring the Atlanta Braves (MLB), Hawks (NBA), Thrashers (NHL), and Falcons (NFL) are always full of excitement. Golfers will enjoy the city's 57 public golf courses, and those looking to relax or jog will find the city's 54 public parks have ample space. A day at Six Flags Over Georgia or Stone Mountain Park is also a nice treat.

TRANSPORTATION FACTS

Hartsfield-Jackson Atlanta International Airport

Largest passenger terminal complex in the world and world's busiest passenger airport. Eighty percent of the U.S. population is within a two-hour flight of Atlanta. It is just 10 miles from downtown Atlanta.

| | |
|----------------------|----------------|
| American Airlines | (800) 433-7300 |
| Continental Airlines | (800) 525-1700 |
| Delta Air Lines | (800) 325-1999 |
| Northwest Airlines | (800) 225-2525 |
| US Air | (800) 428-4322 |
| United Airlines | (800) 241-6522 |

MARTA – Metro Atlanta Rapid Transit Authority (404) 848-4711

39 rail stations and 154 bus routes
\$1.75 fare

Fare transfers between bus and rail

Taxis

Fare from airport to downtown and convention district:

\$25 for one passenger

\$13 per person for two passengers

\$10 per person for three or more passengers

Fare within the downtown business district:

\$6 for one passenger

\$1 per person for two or more passengers

TOURS/VISITOR INFORMATION

APA has contracted with Event Transportation System to provide a limited number of local tours. Detailed information may be viewed on pages 21 and 22. You may also sign up for tours by going to the APA website www.psych.org and clicking on the direct link to the tour company. For further information on Atlanta, visit www.atlanta.net

BANKS/FINANCIAL SERVICES

Bank of America (404) 581-2121
600 Peachtree Street, NE, 133 Peachtree Street, 44 Courtland Street, 66 Courtland Street, 250 Williams Street, 35 Broad Street, 140 Decatur Street, 200 Piedmont Avenue,

244 Washington Street, 333 Piedmont Avenue, 206 Mitchell Street

SunTrust Bank, Atlanta (404) 588-8234
225 Peachtree Street, 303 Peachtree Street, 449 Auburn Avenue, 100 Edgewood Avenue, 1 Park Place, 55 Park Place

Wachovia Bank, NA, Georgia
(404) 322-1320
191 Peachtree Street, NE, 240 Peachtree Street, 312 South Tower – 1 CNN Center, 645 State Street

MEDICAL EMERGENCIES

Grady Health System (404) 616-4382
80 Butler Street, SE

Grady Memorial Hospital (404) 616-4307
Emergency/1 Level Trauma, Urgent Care
(404) 616-0600

Piedmont Hospital (404) 605-5000
A full-service hospital located in Buckhead

APA GOLF TOURNAMENT

The Golfers of the APA (GAPA) invite you to participate in their 2005 golf tournament to benefit the American Psychiatric Foundation. We are tentatively scheduling afternoon rounds on three different courses. The three afternoons are Sunday, May 22; Monday, May 23; and Tuesday, May 24 with transportation from the Georgia World Congress Center. You may play one afternoon or any combination of days. If you are interested in registering for this event, please contact W. Stanley Jennings, Jr., M.D., at 804-320-7881 or by mail, W.S. Jennings, Jr., M.D., 7149 Jahnke Road, Richmond, VA 23225.

ATLANTA AT A GLANCE

Did You Know Atlanta Has ...

- 130 retail centers
- 57 public golf courses
- 100 streets that include the word Peachtree
- The largest toll-free telephone dialing area in the world (7,000 square miles of toll-free calling)

- The largest suburban office park in the United States (Perimeter Center, 3.5 million square feet of office and retail space on 400 acres)
- The largest cable-supported dome stadium in North America (Georgia Dome)
- The 14th largest mall in the country (Mall of Georgia, 1.7 million square feet)
- The world's largest bas-relief sculpture and the world's largest exposed mass of granite (Stone Mountain Park)
- The largest federal regional concentration outside of Washington, D.C.
- The largest 10K road race in the world (Peachtree Road Race, with 55,000 participants)
- The oldest continually operating ballet company in the nation (Atlanta Ballet, since 1929)
- The longest escalator in the Southeast (MARTA's Peachtree Center Station 192 feet)
- The largest unsupported escalator in the Southeast (CNN Center, eight stories)
- The tallest hotel in the Western Hemisphere (Westin Peachtree Plaza, 73 stories and 723 feet tall)
- The tallest building in the Southeast (Bank of America Plaza, 56 stories and 1,023 feet tall)
- The second-largest theater organ in the nation (Fox Theatre)
- More shopping center space per capita than any other U.S. city except Chicago.

SPECIAL ACKNOWLEDGMENTS

The American Psychiatric Association expresses its deep appreciation for the following:

Abbott Laboratories: partial support of the American Psychiatric Foundation Annual Benefit, Saturday, May 21, 7:00 p.m.

Alkermes: support of the Industry-Supported Symposium, "Alcoholism: Translating Emerging Science Into Clinical Practice," Tuesday, May 24, 7:00 p.m.

American Academy of Psychiatry and the Law: co-support of the Manfred S. Guttmacher Award Lecture, Sunday, May 22, 2:30 p.m.

American Association of Psychiatric Administrators: co-support of the Administrative Psychiatry Award Lecture, Monday, May 23, 9:00 a.m.

American Psychiatric Foundation: support of the Disaster Psychiatry Fellowship; and the APIRE Practice Research Network.

Association of Mental Health Clergy: co-support of the Oskar Pfister Award Lecture, Wednesday, May 25, 9:00 a.m.

Association of Women Psychiatrists: support of the joint AWP/APA Women's Caucus reception and meeting, Monday, May 23, 7:00 p.m.; co-support of the Alexandra Symonds Award Lecture, Monday, May 23, 11:00 a.m.

AstraZeneca Pharmaceuticals: support of the Industry-Supported Symposia, "Bipolar Disorder: Treating Through the Entire Spectrum," Sunday, May 22, 7:00 p.m.; "Dual Diagnosis: The Scope of the Problem," Monday, May 23, 7:00 p.m.; the Industry-Supported Breakfast Symposium, "Agitation and Psychosis in Alzheimer's Disease and Parkinson's Disease," Monday, May 23, and Tuesday, May 24, 7:00 a.m.; partial support of the American Psychiatric Foundation Annual Benefit, Saturday, May 21, 7:00 p.m.; support of the APA/AstraZeneca Minority Fellowship and reception, Tuesday, May 24, 7:00 p.m.; the American Psychiatric Foundation "Conversations" event, Tuesday, May 24, 5:30 p.m.; the George Tarjan Award Lecture, Monday, May 23, 2:00 p.m.; and the APIRE/AstraZeneca Young Minds in Psychiatry Award.

Bristol-Myers Squibb Company: co-support of the Industry Supported Symposia, "Expanding Uses of Atypical Antipsychotics: Addressing Real-World Challenges," Saturday, May 21, 6:00 p.m.; "Emerging Best Practices in the Management of Behavioral Emergencies," Sunday, May 22, 7:00 p.m.; and "Insulin Resistance and Metabolic Syndrome in Neuropsychiatry," Monday, May 23, 7:00 p.m.; the Industry-Supported Breakfast Symposium, "Managing the Spectrum of Bipolar Disorder: Minimizing the Burden of Disease," Monday and Tuesday, May 23-24, 7:00 a.m.; and the support of the President's Dessert and Reception.

Bristol-Myers Squibb Sweden: support of the Luncheon for U.S. and International Residents, "Patients Who Want to Die: Are they Suicidal and Where Do They Fit Into *DSM*?" Sunday, May 22, 12 noon; and Global Psychiatry: A Session for U.S. and International Residents, Sunday, May 22, 2:00 p.m.

Center for Mental Health Services: support of the APIRE Practice Research Network (PRN); and the APA's HIV-related education programs and materials.

Center for Substance Abuse Treatment: support of the APIRE Practice Research Network (PRN); and an audience response system for the course, "Office-Based Buprenorphine Treatment of Opioid-Dependent Patients."

Cephalon, Inc.: support of the Industry-Supported Symposia, "Achieving Remission in Depression: Is the Bar Set Too High or Too Low?" Saturday, May 21, 6:00 p.m.; "Exploring Cognitive Function: From Brain to Bedside," Sunday, May 22, 7:00 p.m.; and "Impact of Stress and Anxiety on Brain and Body," Wednesday, May 25, 7:00 p.m.

Cyberonics, Inc.: support of the Industry-Supported Symposium, "Brain Stimulation: New Treatments for Mood Disorders," Sunday, May 22, 8:00 a.m.; and partial support of the American Psychiatric Foundation Annual Benefit, Saturday, May 21, 7:00 p.m.

Eisai, Inc.: co-support of the Industry-Supported Symposium, "Advances in Cholinergic Therapy: Alzheimer's Disease and Beyond," Tuesday, May 24, 7:00 p.m.

Eli Lilly and Company: support of the Industry-Supported Symposia, "Dealing With Depression: The Added Burden to Medical Patients," Saturday, May 21, 6:00 p.m.; "BPD: Pathophysiology Treatment and Course," Sunday, May 22, 8:00 a.m.; and "Beyond Neurochemistry: The Implications of Neurocircuitry for Understanding and Managing Psychiatric Disorders," Sunday, May 22, 7:00 p.m.; partial support of the American Psychiatric Foundation Annual Benefit, Saturday, May 21, 7:00 p.m.; support for the "David Lozovsky Memorial Symposium on the 15-year Evolution of Russian-Soviet Psychiatry," Wednesday, May 25, 2:00 p.m.; and the APA/Lilly Resident Research Awards.

Estate of Agnes Purcell McGavin: support of the Agnes Purcell McGavin Awards for Distinguished Career Achievement in Child and Adolescent psychiatry, and for Prevention.

Estate of Dorothy C. Kempf: support of APIRE/Kempf Fund Award for Research Development in Psychobiological Psychiatry Awards.

Estate of Judd Marmor, M.D.: support of the Judd Marmor Award Lecture, Tuesday, May 24, 11:00 a.m.

Estate of Kun-Po Soo, M.D., Ph.D.: support of the Kun-Po Soo Award Lecture, Tuesday, May 24, 9:00 a.m.

Forest Laboratories, Inc.: support of the Industry-Supported Symposia, "Integrating Neurobiology and Psychopathology Into Evidence-Based Treatment of Social Anxiety Disorder," Saturday, May 21, 6:00 p.m.; "Spotlight on the Uniqueness of Depression and Anxiety in the Elderly," Sunday, May 22, 8:00 a.m.; "Alzheimer's Disease Pathways to Practice: Assessing Diagnosis and Outcome

SPECIAL ACKNOWLEDGMENTS

Measures," Sunday, May 22, 1:30 p.m.; and "Untangling Depression and Anxiety: A Challenge for Scientists and Clinicians," Sunday, May 22, 7:00 p.m.; partial support of the American Psychiatric Foundation Annual Benefit, Saturday, May 21, 7:00 p.m.; and support of the registration portfolios.

GlaxoSmithKline: support of the Industry-Supported Symposia, "Psychosomatic Illness: A 21st-Century Perspective," Saturday, May 21, 6:00 p.m.; "Systematic Treatment of Bipolar Disorder: Bringing Evidence into Practice," Sunday, May 22, 8:00 a.m.; "Bipolar Disorder Management: A New Edition," Monday, May 23, 7:00 p.m.; and "Seasonal Affective Disorder: New Concepts, Practical Strategies," Tuesday, May 24, 7:00 p.m.; the Industry-Supported Breakfast Symposium, "Bipolar Disorder Across the Life Cycle: Special Considerations," Wednesday, May 25 and Thursday, May 26, 7:00 a.m.; partial support of the American Psychiatric Foundation Annual Benefit, Saturday, May 21, 7:00 p.m.; support of the APA/GlaxoSmithKline Fellowship Program and reception; the annual contribution to the APA Presidential Fund; and the APA/GlaxoSmithKline Young Faculty Award for Research Development in Biological Psychiatry.

Harding Foundation: co-support of the Oskar Pfister Award Lecture, Wednesday, May 25, 9:00 a.m.

Ittleson Foundation: support of the Blanche F. Ittleson Award for Research in Child Psychiatry.

Janssen Pharmaceutica and Research Foundation: support of the Industry-Supported Symposia, "Management of Disruptive Behavioral and Pervasive Developmental Disorders," Saturday, May 21, 12:30 p.m.; "Antipsychotic Drugs, Mood Stabilizers, and the Metabolic Syndrome," Sunday, May 22, 8:00 a.m.; and "Relapse Prevention in Schizophrenia: Defining a Path From Pharmacologic Intervention to Long-Term Functional Recovery," Sunday, May 22, 1:30 p.m.; partial support of the American Psychiatric Foundation Annual Benefit, Saturday, May 21, 7:00 p.m.; support of the Committee of Asian-American Psychiatrists recruitment reception; and the American Psychiatric Institute for Research and Education/Janssen Resident Psychiatric Research Scholars.

Judd Marmor Endowment: support of the Judd Marmor Award.

Lilly Research Laboratories, a Division of Eli Lilly & Company: support of the APA/Lilly Psychiatric Research Fellowship.

Merck & Co., Inc.: support of the APA/Merck & Co., Inc. Early Academic Career Research Award.

National Institute of Mental Health: co-support of the APA/NIMH Vestermark Psychiatry Educator Award Lecture, Tuesday, May 24, 2:00 p.m.; and the Research Colloquium for Junior Investigators; support of the American Psychiatric Institute for Research in Education (APIRE) Annual Meeting activities for research trainees; the Program for Minority Research Training in Psychiatry (PMRTP); and the Special Annual Meeting Program Track.

National Institute on Alcohol Abuse and Alcoholism: co-support of the Research Colloquium for Junior Investigators.

National Institute on Drug Abuse: co-support of the Research Colloquium for Junior Investigators; support of annual meeting activities of trainees of the APIRE Drug Abuse Research Scholars Program.

Neurocrine Biosciences, Inc.: co-support of the Industry-Supported Symposium, "Clinical Interventions for the Treatment of Insomnia Associated With Psychiatric and Comorbid Medical Illnesses," Sunday, May 22, 1:30 p.m.

Ortho-McNeil Pharmaceuticals: support of the Industry-Supported Symposia, "The Developmental Trajectory of Impulsivity," Saturday, May 21, 6:00 p.m.; and "Too Little, Too Much: What Is Disordered Eating?" Sunday, May 22, 8:00 a.m.

Otsuka America Pharmaceutical, Inc.: co-support of the Industry Supported Symposia, "Expanding Uses of Atypical Antipsychotics: Addressing Real-World Challenges," Saturday, May 21, 6:00 p.m.; "Emerging Best Practices in the Management of Behavioral Emergencies," Sunday, May 22, 7:00 p.m.; "Insulin Resistance and Metabolic Syndrome in Neuropsychiatry," Monday, May 23, 7:00 p.m.; co-support of the Industry-Supported Breakfast Symposium, "Managing the Spectrum of Bipolar Disorder: Minimizing the Burden of Disease," Monday, May 23, and Tuesday, May 24, 7:00 a.m.; partial support of the American Psychiatric Foundation Annual Benefit, Saturday, May 21, 7:00 p.m.; partial support of the American Psychiatric Foundation Annual Benefit, Saturday, May 21, 7:00 p.m.; support of the International Medical Graduates (IMG) Resource Center; and the Minority Mental Health.

Pfizer, Inc.: support of the Industry-Supported Symposia, "The Impact of Depression and Anxiety on Well-Being Across the Life Cycle," Saturday, May 21, 12:30 p.m.; "Bipolar Disorder: Psychiatric and Medical Implications for Optimal Patient Management," Saturday, May 21, 6:00 p.m.; "Fibromyalgia: A Disorder at the Medicine and Psychiatry Interface," Sunday, May 22, 1:30 p.m.; and "From Molecular Insight to Clinical Outcomes: Recent Advances in Schizophrenia Treatment," Sunday, May 22, 7:00 p.m.; co-support of the Industry-Supported Symposia, "Clinical Interventions for the Treatment of Insomnia Associated With Psychiatric and Comorbid Medical Illnesses," Sunday, May 22, 1:30 p.m.; and "Advances in Cholinergic Therapy: Alzheimer's Disease and Beyond," Tuesday, May 24, 7:00 p.m.; support of the Residents' Session, "Meet the Experts: Sunny-Side Up," Monday, May 23, 7:00 a.m.; the Psychiatric Services Achievement Awards; the American Psychiatric Foundation Film Fest, Monday, May 23, 7:00 p.m.; the "Abstracts-On-Disk" Program; and the APA *Daily Bulletin* newspaper.

Professional Risk Management Services, Inc.: co-support of the Manfred S. Guttmacher Award Lecture, Sunday, May 22, 2:30 p.m.; and partial support of the American Psychiatric Foundation Annual Benefit, Saturday, May 21, 7:00 p.m.

SPECIAL ACKNOWLEDGMENTS

Sanofi-Aventis, Inc.: support of the Industry-Supported Symposium, "Challenges at the Interface of Psychiatric, Medical, and Sleep Disorders," Tuesday, May 24, 7:00 p.m.; and support of the Residents, Medical Students, and Training Directors Luncheon, Sunday, May 22, 12 noon.

Sepracor, Inc.: support of the Industry-Supported Symposium, "Insomnia in Special Populations: Is This Insomnia or Something Else?" Monday, May 23, 7:00 p.m.

Shire US, Inc.: support of the Industry-Supported Symposia, "ADHD Through the Lifecycle: New Findings and Clinical Implications," Sunday, May 22, 7:00 p.m.; "It's Not Just for Kids: ADHD in Adolescence and Adulthood," Tuesday, May 24, 7:00 p.m.; and the APA/Shire Child and Adolescent Psychiatry Fellowships.

Solvay Pharmaceuticals Inc.: support of the coffee service in the exhibit hall.

Substance Abuse and Mental Health Services Administration (CMHS, CSAP, CSAT): sponsorship of the APA/SAMHSA Minority Fellowship Program.

Takeda Pharmaceuticals North America, Inc.: support of the Industry-Supported Symposium, "Joining Night and Day: Insomnia and the Sleep/Wake Cycle," Sunday, May 22, 1:30 p.m.; and the Internet Village.

UCB Pharma, Inc.: support of the Industry-Supported Symposium, "Anxiety: Diverse Populations and Presentations, Unique Individuals and Treatments," Saturday, May 21, 12:30 p.m.

University of California-Davis, Department of Psychiatry: support of the Residents, Fellows, and Medical Student's Reception, Monday, May 23, 6:30 p.m.

University of Nebraska: support of the Frank J. Menolascino Award for Psychiatric Services for persons with Mental Retardation/Developmental Disabilities.

Van Ameringen Foundations: support of the Arnold van Ameringen Award in Psychiatric Rehabilitation.

Wyeth Pharmaceuticals: support of the Industry-Supported Symposia, "Panic Disorder: Current Concepts and Future Directions," Sunday, May 22, 8:00 a.m.; "Anxiety Disorders: Understanding the Interconnection Between Emotional and Physical Symptoms," Sunday, May 22, 1:30 p.m.; "Overcoming Traditional Dilemmas in Treating Depressive Illnesses: Evidence-Based Updates," Monday, May 23, 7:00 p.m.; the Industry-Supported Breakfast Symposium, "Advances in the Treatment of Mood and Anxiety Disorders in Women," Monday, May 23 and Tuesday, May 24, 7:00 a.m.; the APA/Wyeth Pharmaceuticals M.D., Ph.D., Research Fellowship; the Jeanne Spurlock, M.D. Congressional Fellowship; the daily in-house TV program, "APA News Network;" partial support of the American Psychiatric Foundation Annual Benefit, Saturday, May 21, 7:00 p.m.; and co-support of the Alexandra Symonds Award Lecture, Monday, May 23, 11:00 a.m.

FORMAT DESCRIPTIONS

ADVANCES IN PSYCHOSOMATIC MEDICINE

This three-and-one-half hour session will summarize important, new clinical and research findings in the care of psychiatric disorders in the medically ill. The symposium will be presented by selected authors from *The American Psychiatric Publishing Textbook of Psychosomatic Medicine*, edited by James L. Levenson, M.D. The first four presenters will cover heart disease, cancer, obstetrics and gynecology, and transplantation, reviewing the epidemiology, clinical features, diagnosis and assessment, etiology, differential diagnosis, and treatment of psychiatric disorders in their area of specialty. The fifth speaker will review in depth, psychopharmacology in the medically ill. The textbook is the official textbook of the Academy of Psychosomatic Medicine. Psychosomatic medicine is the newest, formally recognized psychiatric subspecialty, but this session will address issues of relevance to most psychiatrists.

ADVANCES IN PSYCHOTHERAPY

This three-and-one-half hour session will summarize important, new clinical and research findings in the treatments of selected psychiatric disorders, with an emphasis on psychotherapeutic interventions. The symposium will be based in part, on material contained in the American Psychiatric Publishing textbook edited by Glen Gabbard, M.D., and entitled, *The Treatments of Psychiatric Disorders, Third Edition*. Authors of selected chapters from the textbook will present material from their chapters. The topics were selected by the editor to represent disorders of particular current interest to psychiatrists and to focus on aspects of psychotherapy that may be of great importance to APA members.

ADVANCES IN RESEARCH

During this two-hour session, a brief overview of major advances in research in psychiatry and a preview of selected research presentations scheduled at the Annual Meeting, leading clinical researchers present the latest developments in four different, clinically-relevant areas of research.

CLINICAL CASE CONFERENCES

During these 90-minute sessions, clinical material is presented by videotape or the treating therapist. One or more experts then discuss the case. **THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.**

CONTINUOUS CLINICAL CASE CONFERENCES

The presenters will review the progress of psychotherapy in two successive three-hour sessions on consecutive days (Monday-Tuesday and Wednesday-Thursday, beginning at 9:00 a.m.). Audience participation is encouraged throughout. Participants are requested to attend both sessions in their entirety. **THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.**

COURSES

Courses are designed to emphasize learning experiences that actively involve participants and include the opportunity for informal exchange with the faculty. Offered in four-hour (half-day), six-hour (full-day), and eight-hour (full-day) sessions, courses either review basic concepts in a special subject area or present advanced material on a circumscribed topic. Participants must purchase tickets to attend.

DEBATE

Experts in the field, including psychiatrists and nonpsychiatrists, will debate a controversial topic in psychiatry. The debate format allows for members to hear both pro and con views about important, interesting and timely concerns for our members. Someone who has expertise in the topic area moderates the debate. A portion of the time is allocated for questions from the audience to the presenters with active participation by participants.

DISCUSSION GROUPS

This 90-minute format allows small groups to meet informally with selected experts in psychiatry to discuss topics chosen by the expert. Some of these are reserved for residents only. These sessions are limited to 25 participants on a first-come, first-served basis.

FOCUS LIVE

These 90-minute sessions allow participants to test their knowledge using an interactive Audience Response System (ARS), offering a new and entertaining way to learn. ARS sessions can make a group of 300 feel like they are having a small group consultation with an expert clinician. Experts, who served as guest editors of *FOCUS*, will lead lively multiple choice question-based discussions, and the audience will enter their answers with hand-held devices. Results are instantly tallied and projected on the screen.

FORUMS

These are flexible presentations that afford an opportunity to highlight and select topics that are of timely interest to psychiatrists. Speakers and panel members are chosen for their expertise and leadership in the field.

LECTURES

Lectures feature a small number of distinguished speakers discussing scientific and cultural topics, many of which will extend our understanding beyond the usual limits of clinical psychiatry. The Scientific Program Committee invites the lecturers.

MASTER EDUCATOR CLINICAL CONSULTATIONS

These 90-minute, clinically-based seminars are presented by outstanding educators. Formats and subject matter will vary, but all will utilize clinical material offered by participants. These sessions are limited to 25 participants on a first-come, first-served basis. **THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.**

MEDICAL UPDATES

These 90-minute sessions are designed to provide psychiatrists with the latest clinical developments in other areas of medicine. Topics may range from subspecialty areas of adult or pediatric medicine (infectious disease, cardiology, gastroenterology, etc.) to new techniques or procedures in surgery or radiology. The interface between psychiatry and these areas is not necessarily emphasized. The intent is to give participants an update from a physician in a particular specialty.

FORMAT DESCRIPTIONS

NEW RESEARCH

This format allows for presentation of the very recent findings. The three types of presentations include: Posters, which are visual, self-explanatory presentations; Young Investigators' Posters, with presentations from young investigators, residents, medical students, and research or clinical fellows; and Young Investigators' Oral/Slide which are fifteen-minute presentations with three minutes for discussion.

RESEARCH ADVANCES IN MEDICINE

This two-hour format presents an overview of cutting-edge research in various aspects of medicine. In contrast to the Medical Update series, which is more clinically focused, this session will help participants keep pace with the rapidly expanding knowledge base and technology in various branches of medicine. Several speakers, authorities in their fields, will present on their topics.

RESEARCH CONSULTATIONS WITH

This 90-minute format provides an opportunity, in a small group setting, for participants to obtain consultations around problems in research from outstanding senior researchers. Participants should come prepared to present a specific problem in research, whether it's one of research design, methodology, subject selection or data analysis, etc., which could be presented briefly to the consultant. These sessions are limited to 25 participants on a first-come, first-served basis.

REVIEW OF PSYCHIATRY

There will be four, three-and-one-half hour sessions presented, based on the annual American Psychiatric Publishing Review of Psychiatry Series. Each session includes an abridged presentation by the senior author from each of the chapters in each volume. The topics were selected by the overall editors of the series to represent current areas of new research, new developments in clinical care, and special issues of importance to APA members.

SCIENTIFIC AND CLINICAL REPORT SESSIONS

Scientific and Clinical Reports are oral presentations of papers prepared for submission before publication. In this 90-minute format, reports are grouped by topic, with floor discussion from the audience following the presentation of each paper. There is no formal discussant.

SYMPOSIA

Symposia are three-hour sessions consisting of four to six presentations that are thematically linked and focus on a specific topic relevant to clinical psychiatry. They are designed to provide comprehensive treatment of a topic or discussion of the topic from several points of view by the participants and stimulate discussion with the audience. Some symposia are supported by industry and are designated as "Industry-Supported Symposia" in this *Program Book*.

WORKSHOPS

Workshops are 90-minute sessions (either Issue or Component), which typically involve brief presentations from individual panel members, followed by the opportunity for lively and informative discussion. This format provides for substantial audience participation and should be highly interactive.

Media Workshops are three-hour sessions held Monday-Thursday, in which a feature-length film is shown and discussed.

AMERICAN PSYCHIATRIC ASSOCIATION CONTINUING MEDICAL EDUCATION POLICY ON FULL DISCLOSURE

The American Psychiatric Association requires disclosure, by presenters at CME activities, of any significant financial or other affiliation with commercial organization(s) regulated by the Food and Drug Administration, which may have a direct or indirect interest in the subject matter of the scientific program. A "financial interest" may include, but is not limited to, being a shareholder in the organization; being on retainer with the organization; or having research or honoraria paid by the organization. An "affiliation" may include, holding a position on an advisory committee or some other role or benefit to a supporting organization.

Under the ACCME Standards for Commercial Support that were in effect when the 2005 Annual Meeting was planned, the existence of such relationships does not necessarily constitute a conflict of interest; but the prospective audience must be informed of the presenter's affiliation with every commercial supporter by an acknowledgement in the printed program and verbal or visual disclosure to participants at the session (disclosure by slide or overhead is required if audiovisual equipment is used for the presentation). This policy is intended to openly identify any potential conflict(s) so that members of the audience in an educational activity are able to form their own judgments about the presentation. The APA also requires verbal disclosure of discussion of unlabeled uses of a commercial product or investigational use of a product not yet approved for this purpose.

The list of presenters below have indicated that either they or an immediate family member has a significant interest or other affiliation with a commercial supporter of this meeting and/or with the manufacturer(s) of a commercial product(s) and/or provider of commercial services(s). The presenter's name and the company's name are listed, along with the page number the presenter appears on in this *Program Book*. The nature of the presenter's relationship with the disclosed company is indicated by the following code: consultant or advisory board¹, full-time employment², research/grant support³, speakers' bureau⁴, stock or other financial options⁵, other financial or business relationships⁶. If a number has not been assigned, the presenter has not disclosed the relationship to the company.

The second list of presenters, beginning on page XXXVI, have indicated neither they nor an immediate family member has any significant relationship to disclose. Voting member of the Board of Trustees, Assembly officers, and member of the Scientific Program Committee cannot receive honoraria or travel reimbursement for participating in Industry-Supported Symposia.

| Presenter | Manufacturer(s) | Program Page # |
|------------------------------|---|----------------|
| Gene G. Abel, M.D. | Abel Screening, Inc. ⁶ ; Institute for Child Molestation Research and Prevention ⁶ | 41 |
| Donald E. Addington, M.D. | Eli Lilly and Company ³ | 71 |
| Marilyn Ader, Ph.D. | Janssen Pharmaceutica Products, LP. ^{1,3} | 7 |
| Nassima Ait-Daoud, M.D. | Ortho McNeil Pharmaceutical Inc. ¹ | 31, 56 |
| Hagop S. Akiskal, M.D. | GlaxoSmithKline ⁴ ; Abbott Laboratories, Inc. ⁴ ; Eli Lilly and Company ⁴ ; Sanofi-Synthelabo Pharmaceuticals, Inc. ⁴ ; Bristol-Myers Squibb ⁴ ; Pfizer Inc. ⁴ ; AstraZeneca Pharmaceuticals ⁴ ; Janssen Pharmaceutica Products, LP. ⁴ | 28 |
| George S. Alexopoulos, M.D. | Forest Pharmaceuticals, Inc. ^{1,3,4} ; Cephalon Inc. ^{3,4} ; Janssen Pharmaceutica Products, LP. ⁴ ; Pfizer Inc. ⁴ ; Lilly Research Laboratories, a division of Eli Lilly and Company ⁴ ; Bristol-Myers Squibb ⁴ ; Meyers ⁴ ; GlaxoSmithKline ⁴ | 6, 11 |
| Jon G. Allen, Ph.D. | American Psychiatric Publishing, Inc. ⁶ | 20 |
| Michael H. Allen, M.D. | Abbott Laboratories, Inc. ^{1,3,4} ; Janssen Pharmaceutica Products, LP. ^{1,3,4} ; Lilly Research Laboratories, a division of Eli Lilly and Company ^{1,3,4} ; GlaxoSmithKline ^{1,4} ; Bristol-Myers Squibb ^{1,3} ; Pfizer Inc. ^{1,4} ; Novartis Pharmaceuticals Corporation ³ ; AstraZeneca Pharmaceuticals ^{1,4} ; Alexza ¹ | 12 |
| Jonathan E. Alpert, M.D. | Organon Pharmaceuticals Inc. ^{3,4} ; Pharmanite ³ ; Eli Lilly and Company ³ ; Forest Pharmaceuticals, Inc. ³ ; Aspect Medical Systems, Inc. ³ ; Pfizer Inc. ³ | 4 |
| Sonia Ancoli-Israel, Ph.D. | King Pharmaceutical ⁴ ; Takeda Pharmaceuticals ^{4,1} ; Neurocrine Biosciences Inc. ¹ ; Sepracor Inc. ¹ | 9, 36 |
| Allan A. Anderson, M.D. | Pfizer Inc. ⁴ ; Novartis Pharmaceuticals Corporation ⁴ ; Janssen Pharmaceutica Products, LP. ⁴ ; Forest Pharmaceuticals, Inc. ⁴ | 49 |
| Raymond F. Anton, Jr., M.D. | Bristol-Myers Squibb ^{1,3} ; Ortho McNeil Pharmaceutical Inc. ^{1,3,4} ; Alkermes Pharmaceuticals ¹ ; Pfizer Inc. ^{1,3} | 31, 62 |
| Jose C. Appolinario, M.D. | Janssen Pharmaceutica Products, LP. ³ ; Abbott Laboratories, Inc. ³ | 59 |
| Michael R. Arambula, M.D. | Pfizer Inc. ⁴ ; AstraZeneca Pharmaceuticals ⁴ | 35 |
| Kimberly A. Arlinghaus, M.D. | UCB Pharmaceutics ¹ ; Bristol-Myers Squibb ³ ; Abbott Laboratories, Inc. ³ ; Pfizer Inc. ^{3,4} ; Forest Pharmaceuticals, Inc. ^{3,4} ; Wyeth Pharmaceuticals ^{3,4} ; AstraZeneca Pharmaceuticals ^{3,4} ; Janssen Pharmaceutica Products, LP. ^{3,4} ; Lilly Research Laboratories, a division of Eli Lilly and Company ^{1,3,4} | 49 |
| Scott C. Armstrong, M.D. | Pfizer Inc. ⁴ ; Lilly Research Laboratories, a division of Eli Lilly and Company ⁴ ; Janssen Pharmaceutica Products, LP. ⁴ ; Forest Pharmaceuticals, Inc. ⁴ | 41 |

DISCLOSURE INDEX

| Presenter | Manufacturer(s) | Program Page # |
|-----------------------------|---|----------------|
| Lesley M. Arnold, M.D. | Pfizer Inc. ^{1,3,4} ; Eli Lilly and Company ^{1,3,4} ; Wyeth Pharmaceuticals ^{3,4} ; Cypress Bioscience Inc. ^{1,3,4} | 10, 39 |
| Darryl Atherholt | Janssen Pharmaceutica Products, LP ² | 44 |
| Evelyn Attia, M.D. | Pfizer Inc. ³ | 59 |
| Alan A. Axelson, M.D. | Pfizer Inc. ⁴ ; Lilly Research Laboratories, a division of Eli Lilly and Company ⁴ ; Highmeirtz Blue Cross Blue Shield ¹ | 17 |
| Rahn K. Bailey, M.D. | Eli Lilly and Company ⁴ ; Janssen Pharmaceutica Products, LP ⁴ ; Bristol-Myers Squibb ⁴ | 66 |
| F. M. Baker, M.D. | Pfizer Inc. ⁴ | 79, 92 |
| Claudia F. Baldassano, M.D. | Elan Pharmaceuticals ³ ; AstraZeneca Pharmaceuticals ^{1,4} ; GlaxoSmithKline ⁴ ; Eli Lilly and Company ⁴ | 5, 13 |
| John J. Barry, M.D. | GlaxoSmithKline ^{1,4} ; Neupace ^{1,4} ; Cyberonics, Inc. ¹ | 95 |
| Bernard D. Beitman, M.D. | Pfizer Inc. ⁴ ; GlaxoSmithKline ⁴ | 27, 68, 93 |
| Ruth M. Benca, M.D. | Takeda Pharmaceuticals ^{1,3,4} ; Wyeth Pharmaceuticals ^{1,4} ; Neurocrine Biosciences Inc. ^{1,4} ; Pfizer Inc. ^{1,4} ; Sepracor Inc. ^{1,4} ; Sanofi-Synthelabo Pharmaceuticals, Inc. ^{1,4} ; King ^{1,4} | 36 |
| Dimitri Bennett, M.D. | GlaxoSmithKline ² | 54 |
| Sarah Berga, M.D. | Wyeth Pharmaceuticals ¹ ; Cerma ¹ ; Novogyn ¹ | 46 |
| Laura A.C. Berman, Ph.D. | Bayer Corporation, Pharmaceutical Division ^{1,3,4} ; Eli Lilly and Company ^{1,3,4} ; Medtronics ^{1,3,4} ; Pfizer Inc. ^{1,3,4} ; Proctor & Gamble ^{1,3,4} ; Ortho McNeil Pharmaceutical Inc. ^{1,3,4} ; Solvay Pharmaceuticals, Inc. ^{1,3,4} | 75 |
| John L. Beyer, M.D. | Eli Lilly and Company ^{1,4} ; GlaxoSmithKline ³ ; Eisai, Inc. ³ ; Boehringer-Ingelheim Pharmaceuticals ³ | 85 |
| Joseph Biederman, M.D. | Celltech Pharmaceuticals, Ltd ¹ ; Noven Pharmaceutical ¹ ; Johnson and Johnson PRD ¹ ; Sanofi-Synthelabo Pharmaceuticals, Inc. ^{1,3} ; Janssen Pharmaceutica Products, LP ^{1,3} ; Pfizer Inc. ^{1,3} ; Cephalon Inc. ^{1,3} ; Novartis Pharmaceuticals Corporation ^{1,4} ; Shire US Inc. ^{1,3,4} ; Eli Lilly and Company ^{1,3,4} ; Ortho McNeil Pharmaceutical Inc. ^{1,3,4} ; National Institute of Mental Health ³ ; Stanley Foundation ³ ; National Institute on Drug Abuse ³ ; Wyeth Pharmaceuticals ⁴ | 12, 48, 57, 80 |
| Angela Birnbaum, M.D. | Ovation Pharmaceuticals ¹ ; UCB Pharmaceuticals ¹ | 80 |
| Carlos Blanco-Jerez, M.D. | Pfizer Inc. ³ | 3 |
| Michael Blumenfeld, M.D. | Pfizer Inc. ^{3,4} ; Forest Pharmaceuticals, Inc. ³ ; Shire Ridgewood Pharmaceuticals ^{1,4} | 14 |
| William Blumentals, Ph.D. | Proctor & Gamble Pharmaceuticals ² | 54 |
| Curley Bonds, M.D. | Pfizer Inc. ⁴ ; Abbott Laboratories, Inc. ^{1,4} | 76 |
| Howard E. Book, M.D. | The American Psychological Association Press ⁶ | 5, 8, 93 |
| Charles L. Bowden, M.D. | Abbott Laboratories, Inc. ^{1,3,4} ; AstraZeneca Pharmaceuticals ⁴ ; Bristol-Myers Squibb ³ ; Elan Pharmaceuticals ³ ; GlaxoSmithKline ^{1,3,4} ; Janssen Pharmaceutica Products, LP ^{1,3,4} ; Lilly Research Laboratories, a division of Eli Lilly and Company ^{1,3,4} ; National Institute of Mental Health ³ ; Parke Davis ³ ; Pfizer Inc. ⁴ ; R.W. Johnson Pharmaceuticals Institute ³ ; Sanofi-Synthelabo Pharmaceuticals, Inc. ¹ ; Smith Kline Beecham ³ ; Stanley Foundation ³ ; UCB Pharmaceutical, Inc. ¹ | 55, 76 |
| Theron C. Bowers, Jr., M.D. | AstraZeneca Pharmaceuticals ⁴ | 25, 45 |
| John M. Bradford, M.B. | Pfizer Inc. ⁴ | 41 |
| Kathleen T. Brady, M.D. | Pfizer Inc. ^{1,4} ; Eli Lilly and Company ^{1,4} ; Abbott Laboratories, Inc. ^{1,3,4} ; Forest Pharmaceuticals, Inc. ^{1,3,4} ; GlaxoSmithKline ^{1,3,4} ; Wyeth Pharmaceuticals ³ | 2, 31 |
| William Breitbart, M.D. | Cephalon Inc. ^{1,4} | 49 |
| J. Douglas Bremner, M.D. | GlaxoSmithKline ^{1,3} | 20, 60 |
| Ronald Brenner, M.D. | Bristol-Myers Squibb ³ ; Eli Lilly and Company ³ ; Janssen Pharmaceutica Products, LP ³ | 43 |
| E. Sherwood Brown, M.D. | AstraZeneca Pharmaceuticals ³ ; GlaxoSmithKline ³ ; Forest Pharmaceuticals, Inc. ³ ; Bristol-Myers Squibb ^{1,3} | 36 |
| Thomas E. Brown, Ph.D. | Janssen Pharmaceutica Products, LP ^{1,4} ; Novartis Pharmaceuticals Corporation ^{1,4} ; Shire Ridgewood Pharmaceuticals ^{1,4} ; McNeil Consumer Healthcare ^{1,3,4} ; Eli Lilly and Company ^{1,3,4} | 1, 5, 51 |
| Robert W. Buchanan, M.D. | Janssen Pharmaceutica Products, LP ³ ; Organon Pharmaceuticals Inc. ¹ | 62, 80 |
| Peter F. Buckley, M.D. | Abbott Laboratories, Inc. ^{1,3,4} ; AstraZeneca Pharmaceuticals ^{1,3,4} ; Eli Lilly and Company ⁴ ; Bristol-Myers Squibb ^{1,3,4} ; Janssen Pharmaceutica Products, LP ^{1,3,4} ; Novartis Pharmaceuticals Corporation ^{1,3,4} ; Pfizer Inc. ^{1,3,4} | 12, 36, 68 |
| Cathy L. Budman, M.D. | Eli Lilly and Company ^{3,4} | 68 |
| Don Buesching, Ph.D. | Eli Lilly and Company ² | 25 |
| Stephen E. Buie, M.D. | Wyeth Pharmaceuticals ⁴ | 74 |
| Cynthia M. Bulik, Ph.D. | Ortho McNeil Pharmaceutical Inc. ⁴ ; Power Changes LLC ⁶ | 6, 59, 71 |
| Kathryn A. Burns, M.D. | Eli Lilly and Company ⁴ | 49 |

| Presenter | Manufacturer(s) | Program Page # |
|--------------------------------|---|------------------------|
| George Bush, M.D. | Eli Lilly and Company ^{1,3} ; Pfizer Inc. ³ ; Janssen Pharmaceutica Products, LP ³ ; Johnson and Johnson PRD ^{3,6} ; Novartis Pharmaceuticals Corporation ⁶ ; Shire Ridgewood Pharmaceuticals ⁶ ; McNeil Consumer Helathcare ⁶ | 12 |
| Marian I. Butterfield, M.D. | Bristol-Myers Squibb ^{1,3} ; Lilly Research Laboratories, a division of Eli Lilly and Company ⁴ | 10, 20, 28, 42, 57, 82 |
| Daniel J. Buysse, M.D. | Sepracor Inc. ¹ | 53 |
| Joseph R. Calabrese, M.D. | National Institute of Mental Health ³ ; Abbott Laboratories, Inc. ^{3,1} ; Ciba-Geigy Inc. ³ ; Merck & Co., Inc. ³ ; GlaxoSmithKline ^{3,1} ; Janssen Pharmaceutica Products, LP ^{3,1} ; Lilly Research Laboratories, a division of Eli Lilly and Company ³ ; MacArthur Foundation ³ ; National Alliance for Research in Schizophrenia and Affective Disorders ³ ; Parke-Davis Pharmaceuticals ³ ; R.W. Johnson Pharmaceuticals Research Institute ^{3,1} ; Sandoz Pharmaceuticals Corporation ³ ; AstraZeneca Pharmaceuticals ¹ ; Bristol-Myers Squibb ¹ ; Eli Lilly and Company ⁴ ; GlaxoSmithKline ^{3,1} ; Stanley Foundation ³ ; Tap Holdings, Inc. ^{3,1} ; UCB Pharmaceuticals ^{3,1} ; Wyeth Pharmaceuticals ³ ; Novartis Pharmaceuticals Corporation ¹ ; Parke-Davis Pharmaceuticals/Warner Lambert ¹ ; Shire Ridgewood Pharmaceuticals ¹ ; Teva Pharmaceuticals ¹ | 11, 25, 67, 76 |
| William H. Campbell, M.D. | Pfizer Inc. ⁴ | 7, 41, 65 |
| Ana E. Campo, M.D. | AstraZeneca Pharmaceuticals ⁴ ; Pfizer Inc. ⁴ ; Ortho McNeil Pharmaceutical Inc. ⁴ ; Lilly Research Laboratories, a division of Eli Lilly and Company ⁴ | 25 |
| John V. Campo, M.D. | Eli Lilly and Company ⁴ ; Forest Pharmaceuticals, Inc. ³ | 14, 40 |
| Gabrielle A. Carlson, M.D. | Eli Lilly and Company ^{1,3} ; Janssen Pharmaceutica Products, LP ^{1,3} ; Abbott Laboratories, Inc. ^{1,3} | 36 |
| Linda L. Carpenter, M.D. | Organon Pharmaceuticals Inc. ^{1,4} ; Cephalon Inc. ^{1,3} ; GlaxoSmithKline ¹ ; Pfizer Inc. ^{1,3,4} ; National Institute of Mental Health ³ ; US Dept of Defense ³ ; Cyberonics, Inc. ^{3,4} ; Merck & Co., Inc. ^{3,4} ; Corcept Therapeutics ³ ; Medtronics ³ ; UCB Pharmaceuticals ³ ; Somerset Pharmaceuticals Inc. ⁴ ; AstraZeneca Pharmaceuticals ⁴ | 4, 37 |
| Diana Carter, M.S. | GlaxoSmithKline ³ ; Lundbeck ³ | 63 |
| David A. Casey, M.D. | Pfizer Inc. ⁴ ; Janssen Pharmaceutica Products, LP ⁴ ; Forest Pharmaceuticals, Inc. ⁴ | 47, 69 |
| Daniel Castellanos, M.D. | Janssen Pharmaceutica Products, LP ³ ; AstraZeneca Pharmaceuticals ³ | 43 |
| Ruby C. Castilla-Puentes, M.D. | GlaxoSmithKline ² | 22, 54 |
| Carlyle H. Chan, M.D. | Eli Lilly and Company ⁴ ; Forest Pharmaceuticals, Inc. ⁴ ; Pfizer Inc. ⁴ | 26, 40, 51 |
| Kiki D. Chang, M.D. | Ortho McNeil Pharmaceutical Inc. ^{1,3,4} ; Abbott Laboratories, Inc. ^{1,3,4} ; AstraZeneca Pharmaceuticals ^{1,4} ; Eli Lilly and Company ^{1,4} ; GlaxoSmithKline ^{1,3,4} ; Janssen Pharmaceutica Products, LP ¹ ; Shire Ridgewood Pharmaceuticals ^{3,4} ; UCB Pharmaceuticals ¹ ; National Institute of Mental Health ³ ; Heinz C. Prechter Foundation ³ ; National Alliance for Research in Schizophrenia and Depression ³ ; Klingenstein Third Generation Foundation ³ ; American Psychiatric Association ³ | 11, 48, 76 |
| Joseph A. Cheong, M.D. | Janssen Pharmaceutica Products, LP ^{1,3,4} ; Wyeth Pharmaceuticals ^{1,3,4} ; SKB ^{1,3,4} ; GlaxoSmithKline ^{1,3,4} ; Organon Pharmaceuticals Inc. ^{1,3,4} ; Pfizer ^{1,3,4} ; AstraZeneca Pharmaceuticals ^{1,3,4} | 46, 65, 86 |
| John A. Chiles, M.D. | Janssen Pharmaceutica Products, LP ^{3,4} ; AstraZeneca Pharmaceuticals ⁴ ; Cortex Pharmaceuticals ⁶ ; Alkermes Pharmaceuticals ⁶ ; Ivax ⁶ ; Lilly Research Laboratories, a division of Eli Lilly and Company ³ | 45 |
| Eric J. Christopher, M.D. | Janssen Pharmaceutica Products, LP ⁴ | 81 |
| Michelle O. Clark, M.D. | Eli Lilly and Company ¹ ; Pfizer Inc. ¹ | 66, 76 |
| Daniel J. Clauw, M.D. | Cypress Bioscience, Inc. ^{1,3,5} | 10 |
| Paula Clayton, M.D. | Forest Pharmaceuticals, Inc. ^{1,3,4,5} | 31 |
| Emil F. Coccaro, M.D. | Eli Lilly and Company ^{1,3,4,6} ; Abbott Laboratories, Inc. ^{1,3,6} ; GlaxoSmithKline ⁶ ; Forest Pharmaceuticals, Inc. ⁶ ; Ortho McNeil Pharmaceutical Inc. ⁶ ; AstraZeneca Pharmaceuticals ⁶ | 32 |
| Lee S. Cohen, M.D. | Berlex Laboratories, Inc. ¹ ; Janssen Pharmaceutica Products, LP ^{1,3,4} ; Ortho McNeil Pharmaceutical Inc. ¹ ; Eli Lilly and Company ^{1,3,4} ; Wyeth Pharmaceuticals ^{1,3,4} ; Pfizer Inc. ⁴ ; AstraZeneca Pharmaceuticals ^{3,4} ; Forest Pharmaceuticals, Inc. ^{3,4} ; GlaxoSmithKline ^{1,3,4} | 66 |
| Michael Cohen, B.S. | EEG Spectrum International ² | 63, 74 |
| Ian A. Cook, M.D. | Aspect Medical Systems, Inc. ³ ; Eli Lilly and Company ³ ; Pfizer Inc. ^{3,4} ; Wyeth Pharmaceuticals ⁴ | 17 |
| Gabriela Cora-Locatelli, M.D. | Pfizer Inc. ^{1,4} ; GlaxoSmithKline ⁴ | 56 |
| Suzanne Craft, Ph.D. | GlaxoSmithKline ¹ | 37 |
| Leslie J. Crofford, M.D. | Pfizer Inc. ^{1,3} ; Lilly Research Laboratories, a division of Eli Lilly and Company ¹ ; Cypress Bioscience, Inc. ¹ | 10 |
| Catherine C. Crone, M.D. | Pfizer Inc. ⁴ | 47 |

DISCLOSURE INDEX

| Presenter | Manufacturer(s) | Program Page # |
|--|--|----------------------------|
| Scott J. Crow, M.D. | Eli Lilly and Company ³ ; Ortho McNeil Pharmaceutical Inc. ^{1,3} ; Pfizer Inc. ⁴ ; GlaxoSmithKline ³ | 6 |
| Jeffrey L. Cummings, M.D. | Pfizer Inc. ^{1,4} ; Eisai, Inc. ^{1,4} ; Janssen Pharmaceutica Products, LP ^{1,3,4} ; Novartis Pharmaceuticals Corporation ^{1,4} ; Praecis Pharmaceuticals ¹ ; Lilly Research Laboratories, a division of Eli Lilly and Company ¹ ; AstraZeneca Pharmaceuticals ¹ ; Forest Pharmaceuticals, Inc. ^{1,3,4,6} ; Bristol-Myers Squibb ¹ ; Roche Laboratories, a member of the Roche Group ¹ ; Aventis Pharmaceuticals ¹ ; Cortex Pharmaceuticals Pharmaceutical ³ ; Lundbeck ¹ ; Myriad Genetics, Inc. ¹ ; Ono Pharmaceuticals ¹ | 9, 13, 39 |
| Cheryl Davenport Jonathan S. Davine, M.D. | Merrill Lynch ^{5,6} Eli Lilly and Company ^{1,4} ; GlaxoSmithKline ^{1,4} ; Janssen Pharmaceutica Products, LP ^{1,4} ; Lundbeck ^{1,4} ; Organon Pharmaceuticals Inc. ^{1,4} ; Pfizer Inc. ^{1,4} ; Wyeth Pharmaceuticals ^{1,4} | 43 30, 86 |
| Lori L. Davis, M.D. | Ortho McNeil Pharmaceutical Inc. ³ ; Abbott Laboratories, Inc. ^{3,4} ; Bristol-Myers Squibb ³ ; Elan Pharmaceuticals ³ ; Forest Pharmaceuticals, Inc. ³ | 3 |
| Deborah Deas, M.D. Charles DeBattista, M.D. | Pfizer Inc. ³ ; Eli Lilly and Company ⁴ Corcept Therapeutics ^{1,5} ; GlaxoSmithKline ^{3,4} ; Wyeth Pharmaceuticals ^{3,4} ; Abbott Laboratories, Inc. ^{3,4} ; Lilly Research Laboratories, a division of Eli Lilly and Company ^{3,4} ; Pfizer Inc. ^{3,4} ; Cephalon Inc. ^{3,4} | 3, 36 4 |
| Melissa P. DelBello, M.D. | Abbott Laboratories, Inc. ^{3,4} ; AstraZeneca Pharmaceuticals ^{3,4} ; Eli Lilly and Company ^{1,3,4} ; Ortho McNeil Pharmaceutical Inc. ^{1,3,4} ; Janssen Pharmaceutica Products, LP ^{3,4} ; Pfizer Inc. ^{1,3,4} ; GlaxoSmithKline ⁴ ; Bristol-Myers Squibb ^{1,4} ; Shire Ridgewood Pharmaceuticals ¹ | 3, 35, 77 |
| Pedro L. Delgado, M.D. | National Institute of Mental Health ³ ; Eli Lilly and Company ^{1,3,4} ; GlaxoSmithKline ^{1,3,4} ; Organon Pharmaceuticals Inc. ^{1,3,4} ; Wyeth Pharmaceuticals ^{1,3,4} ; Forest Pharmaceuticals, Inc. ³ | 55, 64 |
| Diana L. Dell, M.D. | Eli Lilly and Company ^{1,3,4} ; Pfizer Inc. ^{1,3,4} ; Berlex Laboratories, Inc. ^{3,4} ; GlaxoSmithKline ^{3,4} ; Wyeth Pharmaceuticals ⁴ ; TAP Pharmaceuticals Product, Inc. ⁴ | 66 |
| Mark Demitrack, M.D. Davangere P. Devanand, M.D. | Neuronetics, Inc. ^{2,5} ; Wyeth Pharmaceuticals ⁵ ; Eli Lilly and Company ⁵ Pfizer Inc. ³ ; Wyeth Pharmaceuticals ³ ; Janssen Pharmaceutica Products, LP ¹ ; Organon Pharmaceuticals Inc. ¹ | 84 2 |
| Michael Devin, M.D. Mantosh J. Dewan, M.D. | Eli Lilly and Company ³ Pfizer Inc. ⁴ ; AstraZeneca Pharmaceuticals ⁴ ; GlaxoSmithKline ⁴ ; Lilly Research Laboratories, a division of Eli Lilly and Company ³ ; Janssen Pharmaceutica Products, LP ³ | 1 3, 18, 54, 79 |
| Andrea F. DiMartini, M.D. Lisa B. Dixon, M.D. | National Institute of Alcohol Abuse and Alcoholism (NIAAA) ³ Bristol-Myers Squibb ^{3,5} ; Pfizer Inc. ^{3,5} ; Lilly Research Laboratories, a division of Eli Lilly and Company ³ ; Janssen Pharmaceutica Products, LP ³ | 40 29, 55, 84, 93 |
| John P. Docherty, M.D. | Nutrition 21, Inc. ³ ; Bristol-Myers Squibb ^{1,3,4} ; Janssen Pharmaceutica Products, LP ^{1,4} ; Forest Pharmaceuticals, Inc. ^{3,4} ; AstraZeneca Pharmaceuticals ³ ; Abbott Laboratories, Inc. ³ ; Novartis Pharmaceuticals Corporation ³ ; GlaxoSmithKline ³ ; Eli Lilly and Company ³ | 31, 70 |
| Manfred Doepfner, M.D. Martin Dossenbach, M.D. Alysa Doyle, Ph.D. Robert Drake, M.D. Douglas A. Drossman, M.D. | Eli Lilly and Company ⁶ Eli Lilly and Company ² Eli Lilly and Company ⁴ ; McNeil Pharmaceuticals ⁴ Johnson and Johnson PRD ³ Novartis Pharmaceuticals Corporation ^{1,3} ; Solvay Pharmaceuticals, Inc. ^{1,3,4} ; GlaxoSmithKline ¹ | 34 89 57 29 53 |
| Roxanne Dryden-Edwards, M.D. Sanjay Dube, M.D. David W. Dunn, M.D. | Eli Lilly and Company ³ Eli Lilly and Company ² Eli Lilly and Company ^{1,3,4} ; Shire Ridgewood Pharmaceuticals ³ ; AstraZeneca Pharmaceuticals ³ ; The National Institute of Neurological Disorders and Stroke (NINDS) ³ ; O'Neil ⁴ ; UCB Pharmaceuticals ⁴ | 18 28, 67 95 |
| David L. Dunner, M.D. | Eli Lilly and Company ^{1,3,4} ; Pfizer Inc. ^{1,3,4} ; GlaxoSmithKline ^{1,3,4} ; Wyeth Pharmaceuticals ^{1,3,4} ; Bristol-Myers Squibb ^{1,4} ; Organon Pharmaceuticals Inc. ⁴ ; Forest Pharmaceuticals, Inc. ⁴ ; Cyberonics, Inc. ³ ; Merck & Co., Inc. ³ ; Cypress Bioscience, Inc. ¹ ; Corcept Therapeutics ¹ ; Janssen Pharmaceutica Products, LP ^{1,3} ; Novartis Pharmaceuticals Corporation ¹ ; Shire Ridgewood Pharmaceuticals ¹ ; Somerset Pharmaceuticals Inc. ¹ ; Otsuka America Pharmaceutical, Inc. ¹ | 37 |
| Helen L. Egger, M.D. Omar Elhaj, M.D. James M. Ellison, M.D. | Pfizer Inc. ³ AstraZeneca Pharmaceuticals ¹ ; Abbott Laboratories, Inc. ¹ ; Pfizer Inc. ¹ GlaxoSmithKline ^{3,4} ; Forest Pharmaceuticals, Inc. ⁴ ; Pfizer Inc. ⁴ ; Wyeth Pharmaceuticals ⁴ ; Bristol-Myers Squibb ⁴ | 19 25, 67 75 |

| Presenter | Manufacturer(s) | Program Page # |
|---------------------------|---|----------------|
| Graham J. Ernsie, M.D. | Eli Lilly and Company ^{1,3} ; Organon Pharmaceuticals Inc. ³ ; GlaxoSmithKline ¹ ; Forest Pharmaceuticals, Inc. ¹ ; Pfizer Inc. ¹ ; Wyeth Pharmaceuticals ¹ ; Ortho McNeil Pharmaceutical Inc. ⁴ | 42, 66 |
| Mary Jane England, M.D. | American Healthways, Inc. ³ ; US Behavioral Health ⁶ | 43, 83 |
| Milton K. Erman, M.D. | Cephalon Inc. ^{1,6,4,3,5} ; Elan Pharmaceuticals ^{1,3,6} ; King Pharmaceutical ^{1,3,4,6} ; Neurocrine Biosciences Inc. ^{1,3,6} ; Orphan ^{1,3,6} ; Sanofi-Synthelabo Pharmaceuticals, Inc. ^{1,3,6} ; Takeda Pharmaceuticals ^{1,6} ; Janssen Pharmaceutica Products, LP ¹ ; Mallinckrodt, Inc. ^{1,3,6} ; Somaxon Pharmaceuticals ¹ ; Aventis Pharmaceuticals ³ ; Pharmacia ³ ; Pfizer Inc. ^{3,5} ; Res-Med, Inc. ³ ; Merck & Co., Inc. ^{3,5} ; Sepracor Inc. ⁵ ; Forest Pharmaceuticals, Inc. ^{4,5} | 9 |
| Javier I. Escobar, M.D. | Eli Lilly and Company ^{1,4} ; Pfizer Inc. ^{1,4,5} ; Bristol-Myers Squibb ^{1,4,5} ; Otsuka America Pharmaceutical, Inc. ^{1,4} ; Johnson and Johnson PRD ⁵ ; Wyeth Pharmaceuticals ⁴ | 18, 59, 64 |
| Raymond A. Faber, M.D. | Forest Pharmaceuticals, Inc. ⁴ ; Bristol-Myers Squibb ⁴ ; Janssen Pharmaceutica Products, LP ⁴ ; Pfizer Inc. ⁴ | 1 |
| Warachal E. Faison, M.D. | National Institute on Health ³ ; Janssen Pharmaceutica Products, LP ^{3,4} ; Organon Pharmaceuticals Inc. ³ ; Eli Lilly and Company ⁴ ; Pfizer Inc. ⁴ ; Eisai Inc. ⁴ ; Bristol-Myers Squibb ⁴ ; Otsuka America Pharmaceutical ⁴ ; Forest Pharmaceuticals, Inc. ⁴ ; GlaxoSmithKline ^{2,5} | 9, 43, 47 |
| Bruno Falissard, M.D. | Eli Lilly and Company ⁶ | 34 |
| Stephen V. Faraone, Ph.D. | Noven Pharmaceutical ¹ ; Ortho McNeil Pharmaceutical Inc. ^{1,3,4} ; Shire Ridgewood Pharmaceuticals ^{1,3,4} ; Eli Lilly and Company ^{1,3,4} ; National Institute of Mental Health ³ ; National Institute of Child Health and Human Development ³ ; National Institute of Neurological Diseases and Stroke ³ | 12, 62, 80 |
| Douglas E. Faries, Ph.D. | Eli Lilly and Company ² | 25 |
| Maurizio Fava, M.D. | Loxex Pharmaceuticals ³ ; Lichtwer Pharma GmbH ³ ; Abbott Laboratories, Inc. and Compellis ^{3,6} ; Aspect Medical Systems, Inc. ^{3,6} ; AstraZeneca Pharmaceuticals ^{3,6} ; Bristol-Myers Squibb ^{3,6} ; Cephalon Inc. ^{3,6} ; Eli Lilly and Company ^{3,6} ; Forest Pharmaceuticals, Inc. ^{3,6} ; GlaxoSmithKline ^{3,6} ; Johnson and Johnson PRD ^{3,6} ; Novartis Pharmaceuticals Corporation ^{3,6} ; Organon Pharmaceuticals Inc. ^{3,6} ; Pharmavite ^{3,6} ; Pfizer Inc. ^{3,6} ; Roche Laboratories, a member of the Roche Group ^{3,6} ; Sanofi-Synthelabo Pharmaceuticals, Inc. ^{3,6} ; Solvay Pharmaceuticals, Inc. ^{3,6} ; Wyeth Pharmaceuticals ^{3,6} ; Bayer AG Corporation, Pharmaceutical Division ⁶ ; Janssen Pharmaceutica Products, LP ⁶ ; Knoll Pharmaceuticals ⁶ ; Lundbeck ⁶ ; Cypress Bioscience, Inc. ⁶ ; Somerset Pharmaceuticals Inc. ⁶ | 4, 55, 89 |
| Francisco Fernandez, M.D. | Wyeth Pharmaceuticals ^{1,4} ; Forest Pharmaceuticals, Inc. ^{1,4} ; Pfizer Inc. ^{1,4} ; Eli Lilly and Company ⁴ | 20, 43, 51 |
| Robert L. Findling, M.D. | Abbott Laboratories, Inc. ^{1,3,4} ; AstraZeneca Pharmaceuticals ^{1,3,4} ; Best Practices ¹ ; Bristol-Myers Squibb ^{1,3,4} ; Celltech-Medeva ^{1,3} ; Forest Pharmaceuticals, Inc. ^{1,3} ; GlaxoSmithKline ^{1,3,4} ; Johnson and Johnson PRD ^{1,3,4} ; Layton Biosciences, Inc. ³ ; Lilly Research Laboratories, a division of Eli Lilly and Company ^{1,3,4} ; Nature's Herbs ³ ; Novartis Pharmaceuticals Corporation ^{1,3} ; Noven Pharmaceutical ¹ ; Organon Pharmaceuticals Inc. ³ ; Otsuka America Pharmaceutical ^{1,3,4} ; PharmaStar, LLC ¹ ; Pharmaceutical Product Development, Inc. (PPD) ¹ ; Pfizer Inc. ^{1,3} ; Shire Ridgewood Pharmaceuticals ^{1,3,4} ; Solvay Pharmaceuticals, Inc. ³ ; Somerset Pharmaceuticals Inc. ^{1,3} ; Wyeth Pharmaceuticals ^{1,3,4} | 2, 25 |
| Naomi Fineberg, M.A. | AstraZeneca Pharmaceuticals ³ ; Janssen Pharmaceutica Products, LP ³ ; Lundbeck ¹ | 79 |
| David A. Fishbain, M.D. | Eli Lilly and Company ⁴ | 4 |
| Sebern F. Fisher, M.A. | EEG Spectrum International ^{1,4,5} | 74 |
| James N. Flack, M.D. | Janssen Pharmaceutica Products, LP ⁴ | 19 |
| Lois T. Flaherty, M.D. | Merck & Co., Inc. ^{6,5} ; Pfizer Inc. ⁵ | 20, 85 |
| Marshal Folstein, M.D. | CNS Vital Signs LLC | 68 |
| Brent P. Forester, M.D. | Eli Lilly and Company ^{3,4} ; Wyeth Pharmaceuticals ⁴ ; Novartis Pharmaceuticals Corporation ⁴ ; Janssen Pharmaceutica Products, LP ⁴ ; Abbott Laboratories, Inc. ^{3,4} ; AstraZeneca Pharmaceuticals ⁴ ; Pfizer Inc. ^{3,4} | 75 |
| Paul T. Francis, Ph.D. | Pfizer Inc./Eisai Inc. ⁴ ; Lundbeck ⁴ ; Forest Pharmaceuticals, Inc. ⁴ | 9 |
| Ellen Frank, Ph.D. | Pfizer Inc. ¹ ; Pfizer Italiana ¹ ; Eli Lilly and Company ⁴ ; Forest Pharmaceuticals, Inc. ³ | 4 |
| Robert Freedman, M.D. | Abbott Laboratories, Inc. ³ ; The Dept. of Veteran Affairs ⁶ | 41 |
| Matthew Friedman, M.D. | Shire Ridgewood Pharmaceuticals ¹ ; GlaxoSmithKline ⁴ ; Ortho McNeil Pharmaceutical Inc. ⁴ ; AstraZeneca Pharmaceuticals ⁴ | 19, 34, 95 |
| Lara R. Fuchs, M.D. | GlaxoSmithKline ⁶ | 66 |
| Manuel Garcia, M.D. | Pfizer Inc. ^{2,5} | 45 |
| Bradley N. Gaynes, M.D. | Pfizer Inc. ¹ | 58 |
| Oswaldo Gaytan, Jr., M.D. | Pfizer Inc. ⁴ ; AstraZeneca Pharmaceuticals ⁴ ; Janssen Pharmaceutica Products, LP ⁴ | 79 |

DISCLOSURE INDEX

| Presenter | Manufacturer(s) | Program Page # |
|-------------------------------|--|------------------------|
| Alan J. Gelenberg, M.D. | Pfizer Inc. ^{1,3,4} ; Wyeth Pharmaceuticals ^{1,3,4} ; Cyberonics, Inc. ^{1,4} ; Eli Lilly and Company ¹ ; Vela Pharmaceuticals ¹ ; Best Practice ¹ ; Bristol-Myers Squibb ¹ ; AstraZeneca Pharmaceuticals ¹ ; GlaxoSmithKline ¹ ; Roche Laboratories, a member of the Roche Group ¹ ; ZARS ¹ ; Express Scripts ¹ | 22 |
| Mark S. George, M.D. | Neotonus, Inc. (now Neuronetics Inc.) ^{1,3} ; Janssen Pharmaceutica Products, LP ^{3,4} ; Lilly Research Laboratories, a division of Eli Lilly and Company ^{3,4} ; GlaxoSmithKline ^{3,4} ; Solvay/Duphar ^{3,4} ; Parke Davis ^{3,4} ; Cortex Pharmaceuticals ³ ; Aventis Pharmaceuticals ¹ ; DarPharma, Inc. ³ ; Picker International (now Phillips) ^{3,4} ; Dantee (Medtronic) ³ ; Cyberonics, Inc. ^{1,3,4} ; Dupont Pharma ³ ; Medipysics/Amersham ^{3,4} ; Cephos Corp. ^{1,3} | 6, 15, 47 |
| Anna M. Georgiopoulos, M.D. | GlaxoSmithKline ³ | 82 |
| S. Nassir Ghaemi, M.D. | Janssen Pharmaceutica Products, LP ^{1,3,6} ; AstraZeneca Pharmaceuticals ^{1,3,6} ; Novartis Pharmaceuticals Corporation ³ ; Abbott Laboratories, Inc. ^{3,6} ; Elan Pharmaceuticals ³ ; GlaxoSmithKline ^{1,6} ; Forest Pharmaceuticals, Inc. ⁶ ; Eli Lilly and Company ⁶ | 33, 36, 56, 77 |
| Leslie H. Gise, M.D. | Medco Health ¹ | 14, 30 |
| Alexander H. Glassman, M.D. | Pfizer Inc. ^{1,4} ; GlaxoSmithKline ^{1,4} ; Eli Lilly and Company ¹ ; AstraZeneca Pharmaceuticals ^{1,4} ; Ono Pharma ¹ | 20 |
| Ira D. Glick, M.D. | Janssen Pharmaceutica Products, LP ^{1,3,4} ; Lilly Research Laboratories, a division of Eli Lilly and Company ^{1,3,4} ; Pfizer Inc. ^{1,3,4} ; Bristol-Myers Squibb ^{1,3,4} ; AstraZeneca Pharmaceuticals ^{1,3,4} | 15, 33, 59, 82 |
| Donald C. Goff, M.D. | Cortex Pharmaceuticals ³ ; Eli Lilly and Company ^{1,6} ; Janssen Pharmaceutica Products, LP ^{1,3,6} ; AstraZeneca Pharmaceuticals ^{1,6} ; Pfizer Inc. ^{1,6} ; Bristol-Myers Squibb ^{1,6} ; Cephalon Inc. ³ ; GlaxoSmithKline ³ ; Organon Pharmaceuticals Inc. ³ | 7 |
| Robert M. Goisman, M.D. | Bristol-Myers Squibb ¹ ; AstraZeneca Pharmaceuticals ⁴ ; Pfizer Inc. ⁴ | 64 |
| Joseph F. Goldberg, M.D. | Abbott Laboratories, Inc. ^{1,3,4} ; AstraZeneca Pharmaceuticals ^{1,3,4} ; Bristol-Myers Squibb ^{1,3,4} ; Eli Lilly and Company ^{1,3,4} ; GlaxoSmithKline ^{1,3,4} ; Johnson and Johnson PRD ¹ ; Novartis Pharmaceuticals Corporation ¹ ; Ortho McNeil Pharmaceutical Inc. ¹ ; Organon Pharmaceuticals Inc. ¹ ; Pfizer Inc. ^{4,4} ; UCB Pharmaceuticals ¹ | 23, 77 |
| Robert N. Golden, M.D. | Bristol-Myers Squibb ¹ ; Duke Clinical Research Institute (DCRI) ¹ ; Forest Pharmaceuticals, Inc. ³ ; GlaxoSmithKline ¹ ; Janssen Pharmaceutica Products, LP ¹ ; National Institute of Mental Health ³ ; Organon Pharmaceuticals Inc. ^{3,4} ; Ovation Pharmaceuticals ¹ ; Pfizer Inc. ^{1,3} ; Wyeth Pharmaceuticals ¹ | 69 |
| Stephen M. Goldfinger, M.D. | Bristol-Myers Squibb ¹ ; Mallinckrodt Pharmaceuticals ^{1,3,4} ; AstraZeneca Pharmaceuticals ^{1,3,4} ; Pfizer Inc. ^{1,3,4} ; Janssen Pharmaceutica Products, LP ^{1,4,5} ; IVAX Pharmaceuticals, Inc. ^{1,4,5} | 45, 68, 74, 92 |
| Morris B. Goldman, M.D. | Bristol-Myers Squibb ¹ | 27 |
| Andres Gomez-Camirero, Ph.D. | GlaxoSmithKline ⁵ ; Bristol-Myers Squibb ² | 54 |
| Karl Goodkin, M.D. | GlaxoSmithKline ³ ; Merck & Co., Inc. ^{1,4} ; BI ^{1,4} ; Advance ImmvriT, Inc. ⁶ ; American Society for Microbiology ⁶ | 43 |
| David Goodman, M.D. | Forest Pharmaceuticals, Inc. ^{1,3,4} ; Shire Ridgewood Pharmaceuticals ^{1,3,4} ; Ortho McNeil Pharmaceutical Inc. ^{1,3,4} ; GlaxoSmithKline ^{1,4} ; Pfizer Inc. ⁵ ; Eli Lilly and Company ⁴ ; Wyeth Pharmaceuticals ⁴ | 32 |
| Marianne Goodman, M.D. | Forest Pharmaceuticals, Inc. ³ | 33 |
| Frederick K. Goodwin, M.D. | Solvay Pharmaceuticals, Inc. ^{1,3,4} ; GlaxoSmithKline ^{1,3,4} ; Pfizer Inc. ^{1,3,4} ; Lilly Research Laboratories, a division of Eli Lilly and Company ^{1,3,4} ; Bristol-Myers Squibb ^{1,3,4} ; Abbott Laboratories, Inc. ³ ; Forest Pharmaceuticals, Inc. ³ ; Sanofi-Synthelabo Pharmaceuticals, Inc. ³ ; Janssen Pharmaceutica Products, LP ^{3,4} | 36, 56 |
| Kevin F. Gray, M.D. | Novartis Pharmaceuticals Corporation ^{4,1} ; Lilly Research Laboratories, a division of Eli Lilly and Company ^{4,1} ; Pfizer Inc. ^{4,1} ; Janssen Pharmaceutica Products, LP ⁴ ; Bristol-Myers Squibb ^{4,1} | 1 |
| John F. Greden, M.D. | Eli Lilly and Company ¹ ; Wyeth Pharmaceuticals ¹ ; Merck & Co., Inc. ¹ ; Cyberonics, Inc. ¹ ; Neurocrine Biosciences Inc. ¹ ; GlaxoSmithKline ¹ | 11, 20, 37, 41, 49, 84 |
| Alan I. Green, M.D. | Bristol-Myers Squibb ^{1,3,4} ; Otsuka America Pharmaceutical, Inc. ^{1,3,4} ; Eli Lilly and Company ^{1,3,4} ; Janssen Pharmaceutica Products, LP ^{1,3,4} ; AstraZeneca Pharmaceuticals ^{1,3,4} ; Forest Pharmaceuticals, Inc. ^{1,3} ; Novartis Pharmaceuticals Corporation ³ | 29, 36, 50 |
| Melva I. Green, M.D. | Pfizer Inc. ⁴ | 43 |
| Benjamin D. Greenberg, M.D. | Medtronic, Inc. ^{3,4} ; Aspect Medical Systems, Inc. ¹ | 6, 90 |
| Laurence L. Greenhill, M.D. | Novartis Pharmaceuticals Corporation ^{3,1} ; Eli Lilly and Company ^{1,3,4} ; Celltech Pharmaceuticals, Ltd. ^{1,4} ; Ortho McNeil Pharmaceutical Inc. ¹ ; Janssen Pharmaceutica Products, LP ¹ | 23 |
| Carl B. Greiner, M.D. | Janssen Pharmaceutica Products, LP ⁴ | 43, 64 |
| Dimitri E. Grigoriadis, Ph.D. | Neurocrine Biosciences Inc. ² | 32 |

| Presenter | Manufacturer(s) | Program Page # |
|------------------------------|--|-------------------|
| George T. Grossberg, M.D. | Abbott Laboratories, Inc. ^{1,3} ; Bristol-Myers Squibb ^{1,3} ; Forest Pharmaceuticals, Inc. ^{1,3} ; Pfizer Inc. ³ ; Janssen Pharmaceutica Products, LP ¹ ; AstraZeneca Pharmaceuticals ^{1,3} ; Lilly Research Laboratories, a division of Eli Lilly and Company ^{1,3} ; Organon Pharmaceuticals Inc. ^{1,3} ; Omnicare, Inc. ³ ; Wellcome ³ ; Eunoe, Inc. ³ ; Boehringer-Ingelheim Pharmaceuticals ³ ; Sanofi-Synthelabo Pharmaceuticals, Inc. ¹ ; Novartis Pharmaceuticals Corporation ^{1,3} | 9, 13 |
| Raquel E. Gur, M.D. | Pfizer Inc. ¹ ; AstraZeneca Pharmaceuticals ³ | 30 |
| Robert E. Hales, M.D. | Bristol-Myers Squibb ^{1,4} | 13, 24, 39 |
| Thomas E. Hansen, M.D. | AstraZeneca Pharmaceuticals ^{1,4} ; Pfizer Inc. ^{1,4} ; Bristol-Myers Squibb ^{1,4} ; Eli Lilly and Company ^{1,4} | 19 |
| Cynthia L. Harden, M.D. | Pfizer Inc. ³ ; AstraZeneca Pharmaceuticals ³ ; GlaxoSmithKline ^{1,3,4} ; UCB Pharmaceuticals ^{1,4} ; Novartis Pharmaceuticals Corporation ⁴ | 95 |
| Patrice A. Harris, M.D. | Eli Lilly and Company ^{1,4} ; Pfizer Inc. ¹ | 85 |
| David G. Harrison, M.D. | CV Therapeutics ⁶ ; AG1 ^{1,5} ; Novartis ¹ | 42 |
| Philip D. Harvey, Ph.D. | Janssen Pharmaceutica Products, LP ¹ ; Aventis Pharmaceuticals ¹ ; Lilly Research Laboratories, a division of Eli Lilly and Company ^{1,3,4} ; Pfizer Inc. ^{1,4} ; Novartis Pharmaceuticals Corporation ¹ ; Bristol-Myers Squibb ^{1,3,4} | 12 |
| Daniel W. Haupt, M.D. | Janssen Pharmaceutica Products, LP ³ ; Abbott Laboratories, Inc. ^{1,3,4} ; Pfizer Inc. ³ ; Bristol-Myers Squibb ^{1,3,4} ; AstraZeneca Pharmaceuticals ⁴ | 7 |
| David T. Healy, M.D. | AstraZeneca Pharmaceuticals ^{1,4} ; Vickery and Waldner, Baum Hedlund ⁶ | 56 |
| David C. Henderson, M.D. | Janssen Pharmaceutica Products, LP ^{1,3,4} ; Bristol-Myers Squibb ^{1,3,4} ; AstraZeneca Pharmaceuticals ^{1,3,4} ; Eli Lilly and Company ^{1,3,4} ; Pfizer Inc. ^{1,3,4} | 1, 32, 56 |
| Paula L. Hensley, M.D. | Forest Pharmaceuticals, Inc. ^{1,3,4} ; Pfizer Inc. ^{1,3,4} ; Janssen Pharmaceutica Products, LP ^{1,4} ; Eli Lilly and Company ³ ; Hoffman La Roche Ltd. ³ | 31 |
| Barry Herman, M.D. | Pfizer Inc. ² | 45 |
| Alan R. Hirsch, M.D. | Ayerst ⁴ ; GlaxoSmithKline ³ ; Eli Lilly and Company ⁴ ; UpJohn ⁴ ; Ciba-Geigy ⁴ ; Johnson and Johnson PRD ¹ ; Parke Davis ⁴ ; Abbott Laboratories, Inc. ⁴ ; Proctor & Gamble ¹ ; Pharmacia ³ | 87 |
| Robert M.A. Hirschfeld, M.D. | Wyeth Pharmaceuticals ^{1,3} ; Abbott Laboratories, Inc. ³ ; AstraZeneca Pharmaceuticals ³ ; Bristol-Myers Squibb ³ ; Forest Pharmaceuticals, Inc. ³ ; GlaxoSmithKline ³ ; Janssen Pharmaceutica Products, LP ³ ; Eli Lilly and Company ³ ; Novartis Pharmaceuticals Corporation ³ ; Organon Pharmaceuticals Inc. ³ ; Pfizer Inc. ³ ; Shire Ridgewood Pharmaceuticals ³ ; UCB Pharmaceuticals ³ | 77 |
| Max Hirshkowitz, Ph.D. | Cephalon Inc. ^{3,4} ; Sanofi-Synthelabo Pharmaceuticals, Inc. ^{3,4} ; Aventis Pharmaceuticals ³ ; Pfizer Inc. ³ ; Merck & Co., Inc. ³ ; Orphan ³ ; Takeda Pharmaceuticals ³ ; NBI, Inc. ³ | 40 |
| Eric Hollander, M.D. | Lilly Research Laboratories, a division of Eli Lilly and Company ³ ; Janssen Pharmaceutica Products, LP ³ ; Ortho McNeil Pharmaceutical Inc. ^{1,3} ; Pfizer Inc. ^{3,1} ; Wyeth Pharmaceuticals ^{1,3} ; Solvay Pharmaceuticals, Inc. ¹ ; UCB Pharmaceuticals ³ ; Abbott Laboratories, Inc. ^{1,3} | 3, 33, 61, 79, 98 |
| Robert C. Hsiung, M.D. | W.W. Norton & Company ⁶ | 40, 63 |
| Rona Hu, M.D. | AstraZeneca Pharmaceuticals ^{1,3,4} ; Bristol-Myers Squibb ^{1,3,4} ; Forest Pharmaceuticals, Inc. ³ ; Janssen Pharmaceutica Products, LP ^{1,3,4} ; Abbott Laboratories, Inc. ¹ ; Eli Lilly and Company ^{1,4} ; Pfizer Inc. ^{1,4} ; GlaxoSmithKline ⁴ ; Cephalon Inc. ⁴ | 11 |
| James I. Hudson, M.D. | Eli Lilly and Company ^{1,3} ; Ortho McNeil Pharmaceutical Inc. ^{1,3} | 6 |
| Dan V. Iosifescu, M.D. | Pfizer Inc. ¹ ; Aspect Medical Systems, Inc. ³ ; Janssen Pharmaceutica Products, LP ³ ; Forest Pharmaceuticals, Inc. ³ ; Eli Lilly and Company ⁴ | 48 |
| Waguih W. Ishak, M.D. | Pfizer Inc. ¹ ; AstraZeneca Pharmaceuticals ¹ ; Eli Lilly and Company ¹ ; Bristol-Myers Squibb ¹ | 69, 73, 75 |
| Saleem Ismail, M.D. | National Institute of Mental Health ³ ; Janssen Pharmaceutica Products, LP ⁴ ; AstraZeneca Pharmaceuticals ⁴ ; Forest Pharmaceuticals, Inc. ^{3,4} | 77 |
| Jeanne Jackson-Siegel, M.D. | Abbott Laboratories, Inc. ⁴ ; Janssen Pharmaceutica Products, LP ⁴ ; Eli Lilly and Company ⁴ ; Pfizer Inc. ⁴ ; Organon Pharmaceuticals Inc. ⁴ ; Novartis Pharmaceuticals Corporation ⁴ ; Forest Pharmaceuticals, Inc. ⁴ ; AstraZeneca Pharmaceuticals ⁴ | 39 |
| Kay Redfield Jamison, Ph.D. | GlaxoSmithKline ⁴ ; Eli Lilly and Company ⁴ ; AstraZeneca Pharmaceuticals ⁴ | 36 |
| Philip G. Janicak, M.D. | Pfizer Inc. ^{1,4} ; AstraZeneca Pharmaceuticals ^{1,3,4} ; Bristol-Myers Squibb ^{1,3,4} ; Janssen Pharmaceutica Products, LP ^{1,3,4} ; Abbott Laboratories, Inc. ⁴ ; Neurocrine Biosciences Inc. ³ ; Sanofi-Synthelabo Pharmaceuticals, Inc. ³ | 27 |
| Geetha Jayaram, M.D. | Pfizer Inc. ³ ; GlaxoSmithKline ⁴ ; Cephalon Inc. ⁴ ; Janssen Pharmaceutica Products, LP ⁴ | 23, 43, 52, 75 |
| Dilip V. Jeste, M.D. | Bristol-Myers Squibb ^{1,3} ; Eli Lilly and Company ^{1,3} ; AstraZeneca Pharmaceuticals ^{1,3} ; Pfizer Inc. ^{1,3} ; Janssen Pharmaceutica Products, LP ^{1,2,3,4,5} | 30, 77 |
| Wei Jiang, M.D. | Pfizer Inc. ^{3,4} | 81 |
| Hadine Joffe, M.D. | Abbott Laboratories, Inc. ³ ; Eli Lilly and Company ⁴ ; Berlex Laboratories, Inc. ⁶ ; Wyeth Pharmaceuticals ⁶ ; Sanofi-Synthelabo Pharmaceuticals, Inc. ⁶ | 3, 9 |

DISCLOSURE INDEX

| Presenter | Manufacturer(s) | Program Page # |
|---------------------------|--|----------------|
| Bankole A. Johnson, M.D. | Ortho McNeil Pharmaceutical Inc. ^{1,4} ; Forest Pharmaceuticals, Inc. ⁴ | 31, 56 |
| Jeffrey P. Kahn, M.D. | Work Psych Association, Inc. ⁶ | 72 |
| Amir H. Kalali, M.D. | AstraZeneca Pharmaceuticals ^{1,4,6} ; Eli Lilly and Company ^{1,4,6} ; Janssen Pharmaceutica Products, LP ^{1,4,6} ; Shire Ridgewood Pharmaceuticals ^{1,4,6} ; Bristol-Myers Squibb ^{1,6} ; Elan Pharmaceuticals ^{1,6} ; GlaxoSmithKline ^{1,6} ; Neurocrine Biosciences Inc. ^{1,6} ; Abbott Laboratories, Inc. ⁴ ; Forest Pharmaceuticals, Inc. ⁴ ; Novartis Pharmaceuticals Corporation ⁴ ; Organon Pharmaceuticals Inc. ⁴ ; Pfizer Inc. ⁴ ; Wyeth Pharmaceuticals ⁴ ; GlaxoSmithKline ⁴ | 56 |
| Ned H. Kalin, M.D. | National Institute of Health ³ ; Dana Foundation ³ ; Stanley Foundation ³ ; Wyeth Pharmaceuticals ^{3,4} ; Janssen Pharmaceutica Products, LP ^{1,4} ; GlaxoSmithKline ¹ ; Neuroscience Advisory Board ¹ ; Neurocrine Biosciences Inc. ¹ ; Novartis Pharmaceuticals Corporation ¹ ; Bristol-Myers Squibb ¹ ; Somerset Pharmaceuticals Inc. ¹ ; Corcept Therapeutics ¹ ; Cypress Bioscience, Inc. ¹ ; Sanofi-Synthelabo Pharmaceuticals, Inc. ¹ ; Otsuka America Pharmaceutical ¹ ; Eli Lilly and Company ¹ ; Petent Pharmaceuticals ¹ ; Tularik ¹ ; Neuronetics ¹ ; Neurocrine Biosciences Inc. ⁵ ; Promoter Neurosciences, LLC. ² ; Pfizer Inc. ⁵ | 9 |
| Eric R. Kandel, M.D. | Memory Pharmaceuticals ⁶ | 16 |
| John M. Kane, M.D. | Abbott Laboratories, Inc. ^{1,4} ; AstraZeneca Pharmaceuticals ^{1,4} ; Bristol-Myers Squibb ^{1,4} ; Novartis Pharmaceuticals Corporation ^{1,4} ; Janssen Pharmaceutica Products, LP ^{1,4} ; Eli Lilly and Company ^{1,4} ; Pfizer Inc. ⁴ | 10, 82 |
| Shitij Kapur, M.D. | AstraZeneca Pharmaceuticals ^{1,3,4} ; Eli Lilly and Company ^{1,3,4} ; Janssen Pharmaceutica Products, LP ^{1,3,4} ; Neuromolecular Inc. ³ ; Pfizer Inc. ^{1,3,4} ; Wyeth Pharmaceuticals ^{1,3,4} ; Bristol-Myers Squibb ^{1,4} ; GlaxoSmithKline ^{1,4} ; Solvay Pharmaceuticals, Inc. ¹ | 12, 80 |
| Jordan F. Karp, M.D. | AstraZeneca Pharmaceuticals ⁴ ; Pfizer Inc. ⁴ | 94 |
| Ira R. Katz, M.D. | AstraZeneca Pharmaceuticals ^{1,6} ; Eli Lilly and Company ^{1,6} ; Pfizer Inc. ^{1,6} ; Janssen Pharmaceutica Products, LP ^{1,6} | 23 |
| Nathaniel P. Katz, M.D. | Alza/Ortho McNeil Pharmaceutical Inc. ¹ ; Biovail Laboratories, Inc. ¹ ; Forest Pharmaceuticals, Inc. ¹ ; GlaxoSmithKline ¹ ; Janssen Pharmaceutica Products, LP ¹ ; Merck & Co., Inc. ¹ ; Ortho McNeil Pharmaceutical Inc. ¹ ; Purdue Pharma L.P. ¹ ; Cephalon Inc. ¹ | 60 |
| David J. Katzelnick, M.D. | Healthcare Technology Systems, Inc. ⁶ | 84 |
| Jerald Kay, M.D. | AstraZeneca Pharmaceuticals ⁴ ; Pfizer Inc. ⁴ | 68, 79 |
| Paul E. Keck, Jr., M.D. | Corcept Therapeutics ¹ ; Novartis Pharmaceuticals Corporation ¹ ; Shire Ridgewood Pharmaceuticals ¹ ; Wyeth Pharmaceuticals ¹ ; Abbott Laboratories, Inc. ^{1,3} ; AstraZeneca Pharmaceuticals ^{1,3} ; Bristol-Myers Squibb ^{1,3} ; GlaxoSmithKline ^{1,3} ; Janssen Pharmaceutica Products, LP ^{1,3} ; Eli Lilly and Company ^{1,3} ; Ortho McNeil Pharmaceutical Inc. ^{1,3} ; Pfizer Inc. ^{1,3} ; UCB Pharmaceuticals ^{1,3} ; American Diabetes Association ³ ; Merck & Co., Inc. ³ ; National Institute of Mental Health ³ ; National Institute of Drug Abuse (NIDA) ³ ; Organon Pharmaceuticals Inc. ³ ; Stanley Medical Research Institute (SMRI) ³ | 3, 4, 39 |
| Richard S.E. Keefe, Ph.D. | Eli Lilly and Company ^{1,3,4} ; Johnson and Johnson PRD ^{1,3,4} ; Pfizer Inc. ¹ ; AstraZeneca Pharmaceuticals ³ ; GlaxoSmithKline ¹ ; Abbott Laboratories, Inc. ¹ ; Organon Pharmaceuticals Inc. ¹ ; Aventis Pharmaceuticals ¹ ; Lundbeck ¹ ; Solvay Pharmaceuticals, Inc. ¹ ; Wyeth Pharmaceuticals ¹ ; Repligen ¹ ; Bristol-Myers Squibb ¹ ; Forest Pharmaceuticals, Inc. ¹ | 4 |
| Martin B. Keller, M.D. | Bristol-Myers Squibb ¹ ; Collegium ¹ ; Cypress Bioscience, Inc. ¹ ; Abbott Laboratories, Inc. ¹ ; Cyberonics, Inc. ¹ ; Cephalon Inc. ¹ ; Eli Lilly and Company ^{1,3} ; Forest Pharmaceuticals, Inc. ^{1,3} ; Janssen Pharmaceutica Products, LP ^{1,3} ; Merck & Co., Inc. ^{1,3} ; Organon Pharmaceuticals Inc. ^{1,3} ; Otsuka America Pharmaceutical ¹ ; Pfizer Inc. ^{1,3} ; Pharmacia ¹ ; Pharmastar ¹ ; Sepracor Inc. ¹ ; Sanofi-Synthelabo Pharmaceuticals, Inc. ¹ ; Wyeth Pharmaceuticals ^{1,3} ; Somerset Pharmaceuticals Inc. ¹ ; Vela Pharmaceuticals ¹ ; Scirex ¹ | 2, 11 |
| Charles H. Kellner, M.D. | Somatics, LLC ⁶ | 26 |
| Douglas K. Kelsey, M.D. | Eli Lilly and Company ² | 34 |
| Sidney H. Kennedy, M.D. | Eli Lilly and Company ¹ ; Pfizer Inc. ¹ ; Organon Pharmaceuticals Inc. ¹ ; AstraZeneca Pharmaceuticals ^{1,3} ; GlaxoSmithKline ^{1,3} ; Janssen Pharmaceutica Products, LP ^{1,3} ; Lundbeck ^{1,3,4} ; Wyeth Pharmaceuticals ⁴ ; Biovail Laboratories, Inc. ^{1,4} ; Merck & Co., Inc. ^{3,4} ; Boehringer-Ingelheim ^{1,4} ; Ortho McNeil Pharmaceutical Inc. ^{3,4} ; Servier ⁴ ; Janssen Pharmaceutica Products, LP ^{3,4} | 32 |
| Justine M. Kent, M.D. | Pfizer Inc. ¹ | 6 |
| Terence A. Ketter, M.D. | Cephalon Inc. ¹ ; Pfizer Inc. ^{1,4} ; Abbott Laboratories, Inc. ^{1,3,4} ; AstraZeneca Pharmaceuticals ^{1,3,4} ; Bristol-Myers Squibb ^{1,3,4} ; Elan Pharmaceuticals ^{1,3} ; Eli Lilly and Company ^{1,3,4} ; GlaxoSmithKline ^{1,3,4} ; Janssen Pharmaceutica Products, LP ^{1,3,4} ; Novartis Pharmaceuticals Corporation ^{1,3,4} ; Shire Ridgewood Pharmaceuticals ^{1,3} | 13, 36, 76 |
| Bryan H. King, M.D. | Janssen Pharmaceutica Products, LP ⁴ | 66 |

| Presenter | Manufacturer(s) | Program Page # |
|---------------------------------|--|----------------|
| David G. Kingdon, M.D. | Eli Lilly and Company ⁶ ; Bristol-Myers Squibb ⁶ ; AstraZeneca Pharmaceuticals ⁶ ; GlaxoSmithKline ⁶ ; Novartis Pharmaceuticals Corporation ⁶ ; Janssen Pharmaceutica Products, LP ⁶ ; Pfizer Inc. ⁶ | 8, 92 |
| Joel I. Kirson, M.D. | GlaxoSmithKline ⁴ | 23, 71 |
| Herbert D. Kleber, M.D. | Reckitt Benckiser Pharmaceuticals ³ ; Purdue Pharma L.P. ¹ | 15, 60, 80 |
| Scott Kollins, Ph.D. | Ortho McNeil Pharmaceutical Inc. ^{1,4} ; Shire Ridgewood Pharmaceuticals ^{1,3} ; Celltech Pharmaceuticals, Ltd. ³ ; Lilly Research Laboratories, a division of Eli Lilly and Company ³ | 11 |
| George F. Koob, Ph.D. | Merck & Co., Inc./Lipha ¹ ; Titan Pharmaceuticals ¹ ; Addex Pharmaceuticals ¹ ; Forest Pharmaceuticals, Inc. ¹ | 56, 62, 96 |
| Lorin M. Koran, M.D. | Forest Pharmaceuticals, Inc. ^{3,4} ; Pfizer Inc. ^{3,4} ; AstraZeneca Pharmaceuticals ³ ; GlaxoSmithKline ³ | 79 |
| Susan G. Kornstein, M.D. | Pfizer Inc. ^{1,3} ; Bristol-Myers Squibb ^{1,3} ; Eli Lilly and Company ^{1,3} ; Merck & Co., Inc. ³ ; Forest Pharmaceuticals, Inc. ³ ; Wyeth Pharmaceuticals ^{3,1} ; Berlex Laboratories, Inc. ³ ; Sepracor Inc. ³ ; Novartis Pharmaceuticals Corporation ³ ; Warner-Chilcott ¹ ; Biovail Laboratories Inc. ³ | 13, 39, 66 |
| Diana M. Koziupa, M.D. | Eli Lilly and Company ^{3,4} ; Bristol-Myers Squibb ^{1,4} ; Otsuka America Pharmaceutical ⁴ ; Forest Pharmaceuticals, Inc. ⁴ ; GlaxoSmithKline ⁴ ; Sanofi-Synthelabo Pharmaceuticals, Inc. ⁴ ; Wyeth Pharmaceuticals ⁴ | 60 |
| Henry R. Kranzler, M.A. | Alkermes Pharmaceuticals ¹ ; Forest Pharmaceuticals, Inc. ¹ ; Bristol-Myers Squibb ¹ ; Ortho McNeil Pharmaceutical Inc. ³ ; Drug Abuse Sciences ⁴ | 31 |
| Christopher J. Kratochvil, M.D. | Eli Lilly and Company ^{1,3,4} ; Forest Pharmaceuticals, Inc. ³ ; Cephalon Inc. ³ ; GlaxoSmithKline ³ ; Ortho McNeil Pharmaceutical Inc. ^{3,4} | 34, 62 |
| John E. Kraus, Jr., M.D. | Bristol-Myers Squibb ^{1,3,4} ; Pfizer Inc. ^{1,3,4} ; Eli Lilly and Company ^{1,3,4} ; AstraZeneca Pharmaceuticals ^{1,3,4} | 4 |
| K. Ranga R. Krishnan, M.D. | GlaxoSmithKline ¹ ; Pfizer Inc. ¹ ; Eli Lilly and Company ¹ ; Vela Pharmaceuticals ¹ ; Lundbeck ¹ ; Abbott Laboratories, Inc. ¹ ; Amgen ¹ ; Johnson and Johnson PRD ¹ ; Merck & Co., Inc. ¹ ; NPS Pharmaceuticals ¹ ; Organon Pharmaceuticals Inc. ¹ ; Otsuka America Pharmaceutical ¹ ; Pfizer Inc. ¹ ; Somerset Pharmaceuticals Inc. ¹ ; Wyeth Pharmaceuticals ¹ ; Synaptic ¹ | 2, 41, 62, 81 |
| Kurt Kroenke, M.D. | AstraZeneca Pharmaceuticals ¹ ; Wyeth Pharmaceuticals ^{1,3} ; Eli Lilly and Company ^{1,3} ; Pfizer Inc. ^{1,3} | 25 |
| Larry A. Kroutil, M.P.H. | Eli Lilly and Company ³ | 90 |
| John H. Krystal, M.D. | Organon Pharmaceuticals Inc. ¹ ; Janssen Pharmaceutica Products, LP ¹ ; Aventis Pharmaceuticals ¹ ; GlaxoSmithKline ¹ ; Pfizer Inc. ¹ ; Eli Lilly and Company ¹ ; Forest Pharmaceuticals, Inc. ¹ ; Takeda Pharmaceuticals ¹ ; Merz Pharmaceuticals ¹ ; Centre de Recherche Pierre Fabre ¹ ; UCB Pharmaceuticals ¹ ; Sumitomo Pharmaceuticals America, Ltd. ¹ | 11, 29 |
| Elisabeth J.S. Kunkel, M.D. | Pfizer Inc. ⁴ ; Intramed ⁴ ; Forest Pharmaceuticals, Inc. ⁴ ; Wyeth Pharmaceuticals ⁴ | 40, 91, 96 |
| David J. Kupfer, M.D. | Pfizer Inc. ¹ ; Eli Lilly and Company ¹ ; Forest Pharmaceuticals, Inc. ¹ ; F. Hoffmann-La Roche, LTD. ¹ ; Servier Amerique ¹ | 9, 20, 30 |
| Raymond W. Lam, M.D. | Biovail Laboratories Inc. ⁴ ; Canadian Network for Mood and Anxiety Treatments ⁴ ; Eli Lilly and Company ^{3,4} ; GlaxoSmithKline ^{3,4} ; Litebook Company, Inc. ⁴ ; Lundbeck ^{3,4} ; Shire Ridgewood Pharmaceuticals ⁴ ; Wyeth Pharmaceuticals ^{3,4} ; AstraZeneca Pharmaceuticals ³ ; Canadian Institutes of Health Research ³ ; Janssen Pharmaceutica Products, LP ³ ; Merck & Co., Inc. ³ ; Roche Laboratories, a member of the Roche Group ³ ; Servier Canada ³ ; Vancouver Hospital Foundation ³ | 61 |
| Jeanne Landgraf, M.A. | Shire Ridgewood Pharmaceuticals ³ | 32 |
| Edward C. Lauterbach, M.D. | Bristol-Myers Squibb ³ ; Forest Pharmaceuticals, Inc. ⁴ | 5, 48, 71, 89 |
| Helen Lavretsky, M.D. | Forest Pharmaceuticals, Inc. ^{3,4,1} ; Janssen Pharmaceutica Products, LP ^{4,1} ; Pfizer Inc. ⁴ ; AstraZeneca Pharmaceuticals ^{1,3} ; Bristol-Myers Squibb ^{1,3} | 62, 64 |
| William Lawson, M.D. | Abbott Laboratories, Inc. ^{3,4} ; Lilly Research Laboratories, a division of Eli Lilly and Company ^{3,4} ; Pfizer Inc. ^{3,4} | 25, 56 |
| Arthur L. Lazarus, M.D. | AstraZeneca Pharmaceuticals ^{2,5} | 22 |
| Eric J. Lenze, M.D. | Forest Pharmaceuticals, Inc. ³ ; Janssen Pharmaceutica Products, LP ³ | 6 |
| Stefan M. Leucht, M.D. | Johnson and Johnson PRD ^{1,4} ; Eli Lilly and Company ⁴ ; Sanofi-Synthelabo Pharmaceuticals, Inc. ^{3,4} | 10 |
| Alan I. Levenson, M.D. | Psychiatrists' Purchasing Group, Inc. ⁶ | 19 |
| James L. Levenson, M.D. | Eli Lilly and Company ¹ | 40, 67, 91 |
| Frances R. Levin, M.D. | Eli Lilly and Company ¹ ; Ortho McNeil Pharmaceutical Inc. ³ ; UCB Pharmaceuticals ^{1,3} | 50, 81 |
| Ronald W. Levin, M.D. | Pfizer Inc. ⁵ ; Amgen ⁵ ; Cezaene ⁵ ; Icos ⁵ | 78 |

DISCLOSURE INDEX

| Presenter | Manufacturer(s) | Program Page # |
|-------------------------------|--|-------------------|
| Jeffrey A. Lieberman, M.D. | Abbott Laboratories, Inc. ¹ ; AstraZeneca Pharmaceuticals ^{1,3} ; Aventis Pharmaceuticals ¹ ; Bristol-Myers Squibb ^{1,3} ; Cyberonics, Inc. ⁵ ; Cypress Bioscience, Inc. ⁵ ; Eli Lilly and Company ^{1,3} ; GlaxoSmithKline ^{1,3} ; Janssen Pharmaceutica Products, LP ³ ; Novartis Pharmaceuticals Corporation ^{1,3} ; Organon Pharmaceuticals Inc. ^{1,3} ; Pfizer Inc. ¹ ; Solvay Pharmaceuticals, Inc. ¹ | 4, 12, 31, 51 |
| Michael R. Liebowitz, M.D. | Forest Pharmaceuticals, Inc. ¹ ; Pfizer Inc. ^{1,3,4} ; Wyeth Pharmaceuticals ^{1,3,4} ; Roche Laboratories, a member of the Roche Group ¹ ; Solvay Pharmaceuticals, Inc. ¹ ; Eli Lilly and Company ¹ ; GlaxoSmithKline ^{1,3} | 3, 6 |
| Kevin O. Lim | Eli Lilly and Company ^{1,3} ; Avertis ¹ | 80 |
| Jean-Pierre Lindenmayer, M.D. | Novartis Pharmaceuticals Corporation ¹ ; Eli Lilly and Company ^{1,3,4} ; Janssen Pharmaceutica Products, LP ^{1,4} ; Bristol-Myers Squibb ⁴ ; Pfizer Inc. ³ ; AstraZeneca Pharmaceuticals ³ | 68 |
| Marsha Lineham, Ph.D. | Eli Lilly and Company ³ | 7 |
| Sarah H. Lisanby, M.D. | National Institute of Mental Health ³ ; National Alliance for Research in Schizophrenia and Depression ³ ; Stanley Foundation ³ ; American Federation for Aging Research (AFAR) ³ ; The Defense Advances Research Project Agency (DARPA) ³ ; Magstim Company ³ ; Cyberonics, Inc. ⁴ | 6, 37, 47, 51, 69 |
| Sheila M. Loboprabhu, M.D. | AstraZeneca Pharmaceuticals ⁴ | 25, 45 |
| Eric B. London, M.D. | Wyeth Pharmaceuticals ⁴ ; Pfizer Inc. ⁴ ; GlaxoSmithKline ⁴ ; Eli Lilly and Company ⁴ ; Cephalon Inc. ⁴ | 61 |
| Shari I. Lusskin, M.D. | Wyeth Pharmaceuticals ⁴ ; AstraZeneca Pharmaceuticals ⁴ ; Pfizer Inc. ⁴ ; GlaxoSmithKline ⁴ | 63 |
| R. Bruce Lydiard, M.D. | Pfizer Inc. ¹ | 9 |
| Contantine Lyketsos, M.D. | Eisai ^{1,4} ; Forest Laboratories ^{1,3,4} ; DuPont ^{1,4} ; Janssen Pharmaceutica Products, LP ^{1,3,4} ; Lilly Research Laboratories, a division of Eli Lilly and Company ^{1,3,4} ; Pfizer Inc. ^{1,4} ; NeuroLogic ^{1,3} ; AstraZeneca Pharmaceuticals ¹ ; Bristol-Myers Squibb ^{1,3,4} ; Organon Pharmaceuticals Inc. ¹ ; GlaxoSmithKline ¹ ; Novartis ^{1,4} ; Park-Davis (Warner-Lambert) ^{3,4} ; Abbott Laboratories, Inc. ^{3,4} ; Bayer ^{3,4} ; Pfizer, Inc./Eisai ³ ; Lundbeck ⁴ ; National Institute of Mental Health ³ ; National Institute on Aging ³ ; Cover White Foundation ³ ; Helen Bader Foundation ³ ; Alzheimer Association ³ | 28, 67, 76 |
| JoAnn E. Macbeth, J.D. | American Psychiatric Association ⁶ | 18 |
| Wayne Macfadden, M.D. | AstraZeneca Pharmaceuticals, Wilmington, Delaware, USA ² | 48 |
| Jose R. Maldonado, M.D. | Hospira/Abbott Laboratories, Inc. ³ ; Forest Pharmaceuticals, Inc. ⁴ ; Eli Lilly and Company ⁴ ; Pfizer Inc. ⁴ | 1, 8, 15, 90 |
| Catherine L. Mancini, M.D. | Lundbeck ^{1,3} ; GlaxoSmithKline ^{1,3,4} ; AstraZeneca Pharmaceuticals ³ ; Bristol-Myers Squibb ³ ; Eli Lilly and Company ³ ; Janssen Pharmaceutica Products, LP ³ ; Solvay Pharmaceuticals, Inc. ³ ; Pfizer Inc. ³ | 89 |
| Lauren B. Marangell, M.D. | National Institute of Health ³ ; Stanley Foundation ³ ; Cyberonics, Inc. ^{6,5,3} ; Eli Lilly and Company ^{6,5,3} ; Abbott Laboratories, Inc. ³ ; Pfizer Inc. ¹ ; GlaxoSmithKline ^{1,6} ; Medtronics ¹ ; Forest Pharmaceuticals, Inc. ⁶ ; Wyeth Pharmaceuticals ⁶ | 6 |
| John S. March, M.D. | Pfizer Inc. ^{1,3,4} ; Wyeth Pharmaceuticals ^{1,3} ; Lilly Research Laboratories, a division of Eli Lilly and Company ³ ; Organon Pharmaceuticals Inc. ³ ; AstraZeneca Pharmaceuticals ³ | 31, 42, 66, 92 |
| Stephen R. Marder, M.D. | Janssen Pharmaceutica Products, LP ^{1,3,4} ; Lilly Research Laboratories, a division of Eli Lilly and Company ^{1,3,4} ; Bristol-Myers Squibb ^{1,3,4} ; AstraZeneca Pharmaceuticals ^{1,3,4} ; Pfizer Inc. ^{1,3,4} | 27, 55, 93 |
| John C. Markowitz, M.D. | Forest Pharmaceuticals, Inc. ³ ; Basic Books ⁶ ; American Psychiatric Publishing ⁶ | 5, 57 |
| Randall D. Marshall, M.D. | Pfizer Inc. ^{3,4,6} ; GlaxoSmithKline ^{3,4,6} ; Wyeth Pharmaceuticals ⁴ | 31, 58, 71 |
| James M. Martinez, M.D. | UCB Pharmaceuticals ¹ ; Cyberonics, Inc. ^{1,3,4} ; Eli Lilly and Company ^{1,3,4} ; GlaxoSmithKline ^{1,3,4} ; Bristol-Myers Squibb ^{1,3,4} ; Wyeth Pharmaceuticals ⁴ ; Janssen Pharmaceutica Products, LP ⁴ ; AstraZeneca Pharmaceuticals ⁴ ; Forest Pharmaceuticals, Inc. ⁴ | 4 |
| Prakash S. Masand, M.D. | Forest Pharmaceuticals, Inc. ^{1,3,4,5} ; Janssen Pharmaceutica Products, LP ^{1,3,4,5} ; AstraZeneca Pharmaceuticals ^{3,4} ; Bristol-Myers Squibb ^{1,3,4,5} ; GlaxoSmithKline ^{1,3,4} ; Ortho McNeil Pharmaceutical Inc. ³ ; Wyeth Pharmaceuticals ^{1,3,4} ; Health Care Technology ² ; Organon Pharmaceuticals Inc. ¹ ; Pfizer Inc. ^{1,4} ; Abbott Laboratories, Inc. ⁴ ; Eli Lilly and Company ⁵ ; Novartis Pharmaceuticals Corporation ⁴ ; PsychCME Inc. ⁵ | 3, 21, 70 |
| Barbara J. Mason, Ph.D. | Sanofi-Synthelabo Pharmaceuticals, Inc. ¹ ; Somaxon Pharmaceuticals ¹ ; Titan Pharmaceuticals ¹ ; Pfizer Inc. ³ ; Merck & Co., Inc. ¹ ; Forest Pharmaceuticals, Inc. ¹ | 56 |
| Annette M. Matthews, M.D. | Bristol-Myers Squibb ⁶ | 54 |
| Helen S. Mayberg, M.D. | GlaxoSmithKline ¹ ; Cyberonics, Inc. ¹ ; Advanced Neuromodulation Systems ¹ | 12, 27, 46, 54 |
| W. Vaughn McCall, M.S. | Sepracor Inc. ^{1,2,3} ; Sanofi-Synthelabo Pharmaceuticals, Inc. ^{1,3} ; Takeda Pharmaceuticals ³ | 26, 47 |

| Presenter | Manufacturer(s) | Program Page # |
|-------------------------------|---|----------------------------|
| William M. McDonald, M.D. | American Foundation for Suicide Prevention ³ ; National Alliance for Research in Schizophrenia and Depression ³ ; American Foundation for Suicide Prevention ³ ; Fuqua Foundation ³ ; National Institute of Mental Health ³ ; National Institute of Neurological Disease and Stroke ³ ; Neuronetics Inc. ^{3,1} ; Janssen Pharmaceutica Products, LP ^{1,3,4} ; Organon Pharmaceuticals Inc. ^{3,4} ; Forest Pharmaceuticals, Inc. ^{1,4} ; GlaxoSmithKline ⁴ ; AstraZeneca Pharmaceuticals ⁴ ; Wyeth Pharmaceuticals ⁴ ; Amgen ⁵ ; Teva ⁵ ; Millenium ⁵ ; Pfizer Inc. ³ ; Abbott Laboratories, Inc. ⁵ ; Neurobiological Tech. ⁵ | 84 |
| Christopher J. McDougle, M.D. | Janssen Pharmaceutica Products, LP ^{1,3,4} ; Pfizer Inc. ^{1,3,4} ; Eli Lilly and Company ^{1,3} ; AstraZeneca Pharmaceuticals ³ ; Bristol-Myers Squibb ^{1,3,4} ; Repligen Corp. ^{1,3} | 2, 87 |
| David M. McDowell, M.D. | Wyeth Pharmaceuticals ⁴ ; Bristol-Myers Squibb ⁴ ; Mallinckrodt ⁴ ; Recked-Benheisey ⁴ | 80, 81, 92 |
| Susan L. McElroy, M.D. | Abbott Laboratories, Inc. ¹ ; Bristol-Myers Squibb ^{1,3} ; GlaxoSmithKline ^{1,3} ; Janssen Pharmaceutica Products, LP ¹ ; Eli Lilly and Company ^{1,3} ; Novartis Pharmaceuticals Corporation ¹ ; Ortho McNeil Pharmaceutical Inc. ^{1,3} ; Wyeth Pharmaceuticals ¹ ; Forest Pharmaceuticals, Inc. ³ ; Eisai Inc. ³ ; Merck & Co., Inc. ³ ; Pfizer Inc. ³ ; Sanofi-Synthelabo Pharmaceuticals, Inc. ³ ; UCB Pharmaceuticals ³ ; AstraZeneca Pharmaceuticals ³ | 3, 6 |
| Joseph P. McEvoy, M.D. | AstraZeneca Pharmaceuticals ³ ; Bristol-Myers Squibb ^{3,6} ; GlaxoSmithKline ³ ; Janssen Pharmaceutica Products, LP ^{3,6} ; Eli Lilly and Company ^{1,3,6} ; Pfizer Inc. ^{1,3,6} ; Sanofi-Synthelabo Pharmaceuticals, Inc. ³ | 12 |
| William R. McFarlane, M.D. | Bristol-Myers Squibb ³ | 30 |
| Thomas H. McGlashan, M.D. | Eli Lilly and Company ³ | 30, 77 |
| Jack S. McIntyre, M.D. | Janssen Pharmaceutica Products, LP ⁴ ; GlaxoSmithKline ⁴ ; Eli Lilly and Company ⁴ | 17, 25, 51, 67 |
| Jacqueline M. Melonas, J.D. | Professional Risk Management Services, Inc. ² | 19, 44, 63 |
| Herbert Y. Meltzer, M.D. | ACADIA ¹ ; AstraZeneca Pharmaceuticals ³ ; Bristol-Myers Squibb ^{1,3} ; Eli Lilly and Company ^{1,3} ; Janssen Pharmaceutica Products, LP ^{1,3} ; Novartis Pharmaceuticals Corporation ^{1,3} ; Organon Pharmaceuticals Inc. ^{1,3} ; Pfizer Inc. ^{1,3} ; Solvay Pharmaceuticals, Inc. ^{1,3} ; Sanofi-Synthelabo Pharmaceuticals, Inc. ¹ | 7 |
| Ricardo P. Mendoza, M.D. | AstraZeneca Pharmaceuticals ⁵ | 25 |
| Jeffrey L. Metzner, M.D. | Abbott Laboratories, Inc. ¹ ; AstraZeneca Pharmaceuticals ⁴ | 67, 72 |
| Richard J. Metzner, M.D. | GlaxoSmithKline ⁴ ; Forest Pharmaceuticals, Inc. ⁴ | 90 |
| Eric Mick, Sc.D. | McNeil Consumer Healthcare ⁶ ; Janssen Pharmaceutica Products, LP ¹ | 80 |
| David J. Miklowitz, Ph.D. | Eli Lilly and Company ⁴ | 5 |
| Alexander L. Miller, M.D. | Abbott Laboratories, Inc. ^{3,4} ; Almirall ³ ; AstraZeneca Pharmaceuticals ^{1,3,4} ; Bristol-Myers Squibb ^{1,3,4} ; Lilly Research Laboratories, a division of Eli Lilly and Company ³ ; Janssen Pharmaceutica Products, LP ^{1,3,4} ; Pfizer Inc. ³ ; Informedix ¹ | 33, 51 |
| Andrew H. Miller, M.D. | Schering-Plough Corporation ³ ; GlaxoSmithKline ³ ; Janssen Pharmaceutica Products, LP ³ | 20 |
| Del D. Miller, M.D. | Eli Lilly and Company ³ ; Janssen Pharmaceutica Products, LP ⁴ | 33 |
| Mark A. Mintun, M.D. | Molecular Imaging Corp. ⁴ | 9 |
| Jacobo E. Mintzer, M.D. | Voyager Pharmaceutical ³ ; Abbott Laboratories, Inc. ^{1,3,4} ; AstraZeneca Pharmaceuticals ^{1,3,4} ; Boehringer-Ingelheim Pharmaceuticals ^{1,4} ; Bristol-Myers Squibb ^{1,3,4} ; Eli Lilly and Company ^{1,3,4} ; Forest Pharmaceuticals, Inc. ^{1,3,4} ; Janssen Pharmaceutica Products, LP ^{1,3,4} ; Johnson and Johnson PRD ³ ; Mitsubishi Pharma Corporation ³ ; Novartis Pharmaceuticals Corporation ³ ; Pfizer Inc. ^{1,3,4} ; Predix ^{1,4} ; Targacept ^{1,4} ; Gerson Lehrman GRP ^{1,4} ; Deutsche Bank ^{1,4} ; Capital Research ^{1,4} ; Paraxel International Corp. ³ ; American Association of Geriatric Psychiatry ⁴ ; American Psychiatric Association ¹ ; Alzheimer's Organization (local and national) ¹ ; Eisai Inc. ³ | 55, 64 |
| Karen Miotto, M.D. | Rickett Benckiser ⁴ | 2 |
| Shaila Misri, M.D. | GlaxoSmithKline ^{1,3,4} ; Lundbeck ^{1,3,4} ; Wyeth Pharmaceuticals ^{1,4} ; Biovail Laboratories Inc. ^{1,4} ; AstraZeneca Pharmaceuticals ⁴ | 63 |
| Lisa A. Mistler, M.D. | Schering-Plough Corporation ³ | 29 |
| James E. Mitchell, M.D. | Lilly Research Laboratories, a division of Eli Lilly and Company ³ ; Abbott Laboratories, Inc. ³ | 1, 97 |
| Frederick G. Moeller, M.D. | Ortho McNeil Pharmaceutical Inc. ¹ ; National Institute on Drug Abuse ³ | 97 |
| Rodrigo A. Munoz, M.D. | Eli Lilly and Company ¹ | 18, 33, 61, 67, 82, 87, 93 |
| Philip R. Muskin, M.D. | Bristol-Myers Squibb ^{1,3,4} ; Forest Pharmaceuticals, Inc. ^{1,3,4} ; GlaxoSmithKline ^{1,4} ; Cephalon Inc. ^{1,4} ; Pfizer Inc. ^{1,4} ; AstraZeneca Pharmaceuticals ^{1,4} ; Janssen Pharmaceutica Products ^{1,4} | 22, 28, 51, 67 |
| Hugh Myrick, M.D. | Abbott Laboratories, Inc. ^{1,3,4} ; Forest Pharmaceuticals, Inc. ⁴ ; Ortho McNeil Pharmaceutical Inc. ⁴ ; Bristol-Myers Squibb ⁴ | 62 |
| David Nace, M.D. | Wyeth Pharmaceuticals ^{1,4} ; Bristol-Myers Squibb ¹ ; United Health Group ⁵ | 17 |
| Ziad H. Nahas, M.D. | Neuronetics, Inc. ^{1,3} ; Cyberonics, Inc. ^{1,3} | 51 |

DISCLOSURE INDEX

| Presenter | Manufacturer(s) | Program Page # |
|-------------------------------|--|----------------|
| Joseph C. Napoli, M.D. | Solvay Pharmaceuticals, Inc. ³ ; Wyeth Pharmaceuticals ³ ; Bristol-Myers Squibb ³ ; Eli Lilly and Company ³ ; Forest Pharmaceuticals, Inc. ³ ; Janssen Pharmaceutica Products, LP ³ ; Neuronetics, Inc. ³ ; AstraZeneca Pharmaceuticals ^{3,4} ; GlaxoSmithKline ^{3,4} ; Pfizer Inc. ^{3,4} | 14 |
| Jeffrey A. Naser, M.D. | Wyeth Pharmaceuticals ⁴ ; Novartis Pharmaceuticals Corporation ⁴ ; Forest Pharmaceuticals, Inc. ⁴ | 94 |
| George S. Nasra, M.D. | Forest Pharmaceuticals, Inc. ⁴ ; GlaxoSmithKline ⁴ ; Wyeth Pharmaceuticals ⁴ ; Pfizer Inc. ⁴ ; Organon Pharmaceuticals Inc. ⁴ | 92 |
| J. Craig Nelson, M.D. | Abbott Laboratories, Inc. ^{1,4} ; Eli Lilly and Company ^{1,3,4} ; Forest Pharmaceuticals, Inc. ^{3,4} ; GlaxoSmithKline ^{3,4} ; Janssen Pharmaceutica Products, LP ^{3,4} ; Organon Pharmaceuticals Inc. ^{3,1,4} ; Pfizer Inc. ^{1,3,4} ; Wyeth Pharmaceuticals ⁴ ; Bristol-Myers Squibb ¹ ; Orexigen ¹ ; Shire Ridgewood Pharmaceuticals ¹ | 55 |
| Charles B. Nemeroff, M.D. | Abbott Laboratories, Inc. ^{1,3,4} ; American Foundation for Suicide Prevention (AFSP) ³ ; Acadia Pharmaceuticals ¹ ; AstraZeneca Pharmaceuticals ^{1,3,4} ; Bristol-Myers Squibb ^{1,3,4} ; Eli Lilly and Company ^{1,3,4} ; Corcept ^{1,5} ; Cypress Bioscience, Inc. ¹ ; Cyberonics, Inc. ¹ ; Forest Pharmaceuticals, Inc. ^{1,3,4} ; GlaxoSmithKline ^{1,3,4} ; Janssen Pharmaceutica Products, LP ^{1,3,4} ; National Alliance for Research in Schizophrenia and Depression ³ ; National Institute of Mental Health ³ ; Jazz Pharmaceuticals ¹ ; Neurocrine Biosciences Inc. ^{1,5} ; Ono Pharma ¹ ; Otsuka America Pharmaceutical ^{1,4} ; Quintiles ¹ ; Pfizer Inc. ^{3,4} ; Somerset Pharmaceuticals Inc. ¹ ; Sanofi-Synthelabo Pharmaceuticals, Inc. ¹ ; Stanley Foundation/NAMI ³ ; Wyeth Pharmaceuticals ^{1,3,4} ; American Psychiatric Institute for Research and Education (APIRE) ¹ ; George West Health Foundation ¹ ; Novadel Pharma ¹ ; Organon Pharmaceuticals Inc. ⁴ | 42 |
| David N. Neubauer, M.D. | Neurocrine Biosciences Inc./Pfizer Inc. ¹ ; Takeda Pharmaceuticals ¹ ; Sanofi-Synthelabo Pharmaceuticals, Inc. ⁴ | 62 |
| Antonia S. New, M.D. | Eli Lilly and Company ³ | 7, 98 |
| John W. Newcomer, M.D. | Bristol-Myers Squibb ^{3,1} ; Otsuka America Pharmaceutical ³ ; National Institute of Mental Health ³ ; National Alliance for Research in Schizophrenia and Depression ³ ; Sidney Baer Foundation ³ ; Pfizer Inc. ^{3,1} ; Janssen Pharmaceutica Products, LP ^{3,1} ; AstraZeneca Pharmaceuticals ^{1,3} ; Wyeth Pharmaceuticals ¹ ; GlaxoSmithKline ¹ ; Eli Lilly and Company ^{1,3} | 37 |
| Cassandra F. Newkirk, M.D. | Pfizer Inc. ¹ ; Abbott Laboratories, Inc. ⁴ | 43, 49, 66 |
| Anthony T. Ng, M.D. | Pfizer Inc. ⁶ | 2, 19, 43, 61 |
| Andrew A. Nierenberg, M.D. | Cyberonics, Inc. ^{1,3} ; Innapharma ¹ ; Neuronetics, Inc. ¹ ; Shire Ridgewood Pharmaceuticals ¹ ; Eli Lilly and Company ^{1,3} ; GlaxoSmithKline ^{1,3} ; National Institute of Mental Health ^{1,3} ; Bristol-Myers Squibb ³ ; Cederroth ³ ; National Alliance for Research in Schizophrenia and Depression ³ ; Stanley Foundation ³ ; Organon Pharmaceuticals Inc. ⁴ ; Janssen Pharmaceutica Products ¹ , LP; Wyeth Pharmaceuticals ^{1,3} ; Lichtwer ³ | 5, 70, 84 |
| Philip T. Ninan, M.D. | Bristol-Myers Squibb ⁴ ; Cephalon Inc. ^{1,3,4} ; Cyberonics, Inc. ³ ; Eli Lilly and Company ^{1,3} ; Forest Pharmaceuticals, Inc. ^{1,3,4} ; GlaxoSmithKline ^{3,4} ; Janssen Pharmaceutica Products, LP ^{3,4} ; Solvay Pharmaceuticals, Inc. ^{1,3} ; UCB Pharmaceuticals ^{1,3} ; Wyeth Pharmaceuticals ^{1,3,4} ; National Institute of Mental Health ³ ; Pfizer Inc. ³ | 3, 11 |
| Ruta M. Nonacs, M.D. | GlaxoSmithKline ⁴ | 2, 66 |
| Carol S. North, M.D. | UCB Pharmaceuticals ¹ ; GlaxoSmithKline ^{1,4} ; King Pharmaceuticals ¹ | 19 |
| Andrei Novac, M.D. | GlaxoSmithKline ⁴ ; Pfizer Inc. ⁴ ; Forest Pharmaceuticals, Inc. ⁴ | 91 |
| Douglas K. Novins, M.D. | Ortho McNeil Pharmaceutical Inc. ¹ | 50 |
| H. George Nurnberg, M.D. | R.W. Johnson Pharmaceuticals ³ ; LIPHA Pharmaceuticals ³ ; Parke-Davis Pharmaceuticals ³ ; Wyeth Pharmaceuticals ^{3,4} ; Abbott Laboratories, Inc. ^{3,4} ; Pfizer Inc. ^{1,3,4} ; Eli Lilly and Company ^{1,3,4} ; GlaxoSmithKline ^{1,3,4} ; Bristol-Myers Squibb ^{1,3,4} | 70 |
| R. Michael O'Bannon, Ph.D. | EEG Spectrum International ^{4,5,6} | 63, 74 |
| Charles P. O'Brien, M.D. | Alkermes Pharmaceuticals ¹ ; Drug Abuse Sciences ^{1,5} | 62 |
| Elizabeth OFili, M.D. | Novartis Pharmaceuticals Corporation ^{1,4} ; Sanofi-Synthelabo Pharmaceuticals, Inc. ¹ ; Merck & Co., Inc. ⁴ ; Schering-Plough Corporation ⁴ | 42 |
| Mark Olfson, M.D. | Bristol-Myers Squibb ^{1,3} ; Eli Lilly and Company ³ ; Ortho McNeil Pharmaceutical Inc. ¹ ; Janssen Pharmaceutica Products, LP ⁴ | 51 |
| Mary B. O'Malley, M.D. Ph.D. | Cephalon Inc. ⁴ | 73 |
| Lewis A. Opler, M.D. | Multi-Health Systems, Inc. ⁶ | 8, 18, 92 |
| Patricia I. Ordorica, M.D. | Pfizer Inc. ^{1,4} | 52 |
| Urban P. Osby, M.D. | Bristol-Myers Squibb ³ | 23 |
| Michael J. Ostacher, M.D. | AstraZeneca Pharmaceuticals ^{4,6} ; Forest Pharmaceuticals, Inc. ^{4,6} ; GlaxoSmithKline ^{4,6} | 5 |
| Michael W. Otto, Ph.D. | GlaxoSmithKline ³ ; Pfizer Inc. ³ ; Lilly Research Laboratories, a division of Eli Lilly and Company ³ | 2 |
| Elizabeth Pappadopulos, Ph.D. | Bristol-Myers Squibb ^{1,2} ; Janssen Pharmaceutica Products, LP ⁴ | 2 |

| Presenter | Manufacturer(s) | Program Page # |
|-------------------------------|---|----------------|
| Sagar Parikh, M.D. | Wyeth Pharmaceuticals ^{1,3,4} ; AstraZeneca Pharmaceuticals ^{1,3,4} ; Janssen Pharmaceutica Products, LP-Ortho McNeil Pharmaceutical Inc. ^{1,3,4} ; Eli Lilly and Company ^{1,3,4} ; Biovail Laboratories Inc. ^{1,3,4} ; Novartis Pharmaceuticals Corporation ^{1,3,4} ; GlaxoSmithKline ^{1,3,4} | 74 |
| Joseph J. Parks III, M.D. | Lilly Research Laboratories, a division of Eli Lilly and Company ^{2,3,5} ; Bristol-Myers Squibb ¹ ; Abbott Laboratories, Inc. ³ ; AstraZeneca Pharmaceuticals ³ ; Janssen Pharmaceutica Products, LP ³ | 15 |
| Joseph V. Penn, M.D. | Celltech Pharmaceuticals, Ltd. ⁴ ; Ortho McNeil Pharmaceutical Inc. ⁴ | 78 |
| Jennifer K. Pennell, M.D. | Wyeth Pharmaceuticals ⁶ | 61 |
| Diana O. Perkins, M.D. | Bristol-Myers Squibb ^{1,3,4} ; Lilly Research Laboratories, a division of Eli Lilly and Company ^{3,4} ; Pfizer Inc. ³ ; Otsuka America Pharmaceutical ³ ; AstraZeneca Pharmaceuticals ^{3,4} | 30, 52 |
| Roy H. Perlis, M.D. | Eisai Inc. ³ ; Pfizer Inc. ¹ ; GlaxoSmithKline ⁴ ; Eli Lilly and Company ^{4,4} ; Bristol-Myers Squibb ^{1,4} ; AstraZeneca Pharmaceuticals ^{1,4} ; Elan Pharmaceuticals ³ | 3, 47 |
| Eric D. Pesclow, M.D. | Pfizer Inc. ⁴ ; GlaxoSmithKline ⁴ | 19, 48 |
| Ronald C. Petersen, M.D. | Pfizer Inc. ³ ; Eisai Inc. ³ ; Elan Pharmaceuticals ¹ ; GE Global Research ¹ | 62 |
| Christopher B. Peterson, M.D. | Bristol-Myers Squibb ⁶ | 17 |
| Francois C. Petitjean, M.D. | Bristol-Myers Squibb ¹ ; Janssen Pharmaceutica Products, LP ⁵ | 55 |
| Helen M. Pettinati, Ph.D. | Alkermes Pharmaceuticals ^{1,3} ; AstraZeneca Pharmaceuticals ^{1,3} ; Bristol-Myers Squibb ³ ; Ortho McNeil Pharmaceutical Inc. ³ | 62 |
| Katharine A. Phillips, M.D. | Eli Lilly and Company ³ ; UCB Pharmaceuticals ³ ; Pfizer Inc. ^{3,4} ; Forest Pharmaceuticals, Inc. ^{3,4} | 24, 30 |
| Lawrence S. Phillips, M.D. | Novartis ^{1,3,4} ; Pfizer Inc. ^{1,3} ; Novo Nordisk ³ ; Sankyo ³ ; Lilly Research Laboratories, a division of Eli Lilly and Company ³ | 42 |
| Teresa A. Pigott, M.D. | Lilly Research Laboratories, a division of Eli Lilly and Company ³ ; GlaxoSmithKline ³ ; Pfizer Inc. ³ ; Forest Pharmaceuticals, Inc. ³ | 13 |
| Harold Alan Pincus, M.D. | UPMC Health Plan ¹ | 52 |
| Marie France Poirier, M.D. | Janssen Pharmaceutica Products, LP ³ ; Bristol-Myers Squibb ³ | 55 |
| Mark H. Pollack, M.D. | Bristol-Myers Squibb ¹ ; Cephalon Inc. ^{1,3} ; Forest Pharmaceuticals, Inc. ^{1,3,4} ; GlaxoSmithKline ^{1,3,4} ; Janssen Pharmaceutica Products, LP ^{1,3,4} ; Lilly Research Laboratories, a division of Eli Lilly and Company ^{1,3,4} ; Novartis Pharmaceuticals Corporation ¹ ; Otsuka America Pharmaceutical ¹ ; Pfizer Inc. ^{1,3,4} ; Roche Laboratories, a member of the Roche Group ¹ ; UCB Pharmaceuticals ^{1,3} ; Wyeth Pharmaceuticals ^{1,3,4} ; Solvay Pharmaceuticals, Inc. ⁴ ; Sepracor Inc. ¹ | 6, 84 |
| Robert Popozian, Ph.D. | Pfizer Inc. ² | 67 |
| David J. Posey, M.D. | Janssen Pharmaceutica Products, LP ^{3,4} ; Eli Lilly and Company ^{1,3} ; AstraZeneca Pharmaceuticals ³ | 2 |
| Robert M. Post, M.D. | Abbott Laboratories, Inc. ¹ ; AstraZeneca Pharmaceuticals ¹ ; Bristol-Myers Squibb ¹ ; Elan Pharmaceuticals ¹ ; GlaxoSmithKline ¹ ; Janssen Pharmaceutica Products, LP ¹ ; Shire Ridgewood Pharmaceuticals ¹ ; UCB Pharmaceuticals ¹ | 56, 77 |
| William Potter, M.D. | Eli Lilly and Company ⁵ ; Merck & Co., Inc. ² | 84 |
| Ulrich Preuss, M.D. | Eli Lilly and Company ⁶ | 34 |
| Annelle B. Primm, M.D. | Pfizer Inc. ^{1,3,4,6} ; Eli Lilly and Company ¹ ; Janssen Pharmaceutica Products, LP ¹ | 76, 82, 92 |
| India Primm-Spencer | Pfizer Inc. ^{3,4} ; Eli Lilly and Company ¹ | 43 |
| Jefferson B. Prince, M.D. | McNeil Pharmaceutical Inc. ⁴ ; Eli Lilly and Company ⁴ ; Forest Pharmaceuticals, Inc. ⁴ ; GlaxoSmithKline ⁶ ; Shire Ridgewood Pharmaceuticals ⁶ ; Novartis Pharmaceuticals Corporation ⁶ | 1, 5, 51 |
| Peter V. Rabins, M.D. | Pfizer Inc. ^{3,4} ; Eli Lilly and Company ⁴ ; Janssen Pharmaceutica Products, LP ⁴ ; Wyeth Pharmaceuticals ⁴ | 17, 77 |
| Charles Raison, M.D. | Wyeth Pharmaceuticals ⁴ ; Eli Lilly and Company ⁴ ; Schering-Plough Corporation ⁴ | 51 |
| Luis F. Ramirez, M.D. | Bristol-Myers Squibb ⁴ ; Organon Pharmaceuticals Inc. ^{1,4} ; Pfizer Inc. ^{1,4} ; Janssen Pharmaceutica Products, LP ⁴ | 39 |
| Paul M. Ramirez, Ph.D. | Multi-Health Systems Publishers ⁶ | 8 |

DISCLOSURE INDEX

| Presenter | Manufacturer(s) | Program Page # |
|-------------------------------|--|---|
| Mark H. Rapaport, M.D. | Forest Pharmaceuticals, Inc. ^{5,1,3,4} ; Organon Pharmaceuticals Inc. ¹ ; Roche Laboratories, a member of the Roche Group ¹ ; Sumitomo ¹ ; AstraZeneca Pharmaceuticals ³ ; Bristol-Myers Squibb ³ ; Abbott Laboratories, Inc. ³ ; Solvay Pharmaceuticals, Inc. ³ ; Novartis Pharmaceuticals Corporation ³ ; GlaxoSmithKline ^{1,3,4} ; Lilly Research Laboratories, a division of Eli Lilly and Company ^{1,3,4} ; Pfizer Inc. ^{1,3,4} ; Wyeth Pharmaceuticals ^{1,3,4} ; Janssen Pharmaceutica Products, LP ^{1,3,4} ; Sanofi-Synthelabo Pharmaceuticals, Inc. ³ ; Stanley Foundation ³ ; UCB Pharmaceuticals ³ ; National Institute of Mental Health ^{3,1} ; Cyberonics, Inc. ^{1,4} ; Pharmacia Upjohn ^{4,1} ; Neurocrine Biosciences Inc. ¹ ; National Institute on Drug Abuse (NIDA) ¹ | 9, 16, 20, 27 |
| Natalie L. Rasgon, M.D. | Wyeth Pharmaceuticals ^{1,4} ; Forest Pharmaceuticals, Inc. ^{1,3,4} ; Abbott Laboratories, Inc. ^{1,3,4} ; GlaxoSmithKline ^{1,4} ; UCLA General Clinical Research Center Medical Advisory Committee ¹ ; National Institute on Aging ³ ; National Institute of Mental Health ³ ; Eli Lilly and Company ⁴ ; Pfizer Inc. ⁴ ; Novartis Pharmaceuticals Corporation ⁴ | 37, 63 |
| Shanaya Rathod, M.D. | Janssen Cilag Pharmaceuticals Inc. | 92 |
| Norman Relkin, M.D. | Eisai Inc. ^{1,3,4} ; Pfizer Inc. ^{1,4} | 62 |
| Roy O. Resnikoff, M.D. | AstraZeneca Pharmaceuticals ³ ; Bristol-Myers Squibb ³ ; GlaxoSmithKline ³ ; Lilly Research Laboratories, a division of Eli Lilly and Company ³ ; Pfizer Inc. ³ ; Wyeth Pharmaceuticals ³ | 5 |
| Charles F. Reynolds III, M.D. | Forest Pharmaceuticals, Inc. ³ ; GlaxoSmithKline ³ ; Pfizer Inc. ³ | 30, 94 |
| Michelle B. Riba, M.D. | Eli Lilly and Company ¹ | 8, 10, 13, 17, 28, 35, 43, 49, 53, 67, 83, 92, 93 |
| Gary S. Richardson, M.D. | King Pharmaceutical ¹ ; Neurocrine Biosciences Inc./Pfizer Inc. ^{3,1} ; Sepracor Inc. ^{1,3} ; Takeda Pharmaceuticals ^{1,3} ; Sanofi-Synthelabo Pharmaceuticals, Inc. ⁴ | 62 |
| Michael J. Robinson, M.D. | Eli Lilly and Company ² | 40 |
| Rebecca L. Robinson, M.S. | Eli Lilly and Company ² | 89 |
| Robert G. Robinson, M.D. | Forest Pharmaceuticals, Inc. ⁴ | 32 |
| Steven P. Roose, M.D. | Wyeth Pharmaceuticals ^{1,2} ; Forest Pharmaceuticals, Inc. ^{1,2} ; Bristol-Myers Squibb ¹ ; Eli Lilly and Company ^{1,2} ; Organon Pharmaceuticals Inc. ² | 2, 6, 94 |
| Jerrold F. Rosenbaum, M.D. | Pfizer Inc. ¹ ; Bristol-Myers Squibb ¹ ; Cyberonics, Inc. ¹ ; Eli Lilly and Company ¹ ; Forest Pharmaceuticals, Inc. ^{1,4} ; GlaxoSmithKline ¹ ; Janssen Pharmaceutica Products, LP ⁴ ; Organon Pharmaceuticals Inc. ⁴ ; Somerset Pharmaceuticals Inc. ¹ ; Wyeth Pharmaceuticals ^{1,4} | 1 |
| Michael B. Rosenbluth, M.D. | Wyeth Pharmaceuticals ⁴ ; Organon Pharmaceuticals Inc. ⁴ ; Eli Lilly and Company ⁴ ; Johnson and Johnson PRD ⁴ | 32 |
| Miriam Rosenthal, M.D. | Pfizer Inc. ⁴ ; Forest Pharmaceuticals, Inc. ⁴ | 69 |
| Norman E. Rosenthal, M.D. | GlaxoSmithKline ^{1,3} | 31, 61 |
| Richard N. Rosenthal, M.D. | Alkermes Pharmaceuticals ¹ ; Forest Pharmaceuticals, Inc. ^{1,4} | 83 |
| Thomas J. Rosko, M.D. | Pfizer Inc. ⁴ | 87 |
| Anthony L. Rostain, M.D. | Ortho McNeil Pharmaceutical Inc. ⁴ ; Eli Lilly and Company ⁴ | 22, 68, 85 |
| Anthony J. Rothschild, M.D. | Cephalon Inc. ³ ; Wyeth Pharmaceuticals ³ ; Forest Pharmaceuticals, Inc. ⁴ ; Pfizer Inc. ⁴ ; Eli Lilly and Company ^{3,4} ; Bristol-Myers Squibb ^{3,4} ; Abbott Laboratories, Inc. ⁴ | 16, 41, 55 |
| Peter P. Roy-Byrne, M.D. | GlaxoSmithKline ^{1,3,4} ; Pfizer Inc. ^{1,3,4} ; Forest Pharmaceuticals, Inc. ^{1,3,4} ; Alza/McNeil Pharmaceuticals ¹ ; Cephalon Inc. ¹ ; Eli Lilly and Company ⁴ ; Janssen Pharmaceutica Products, LP ¹ ; Pharmacia ¹ ; Roche Laboratories, a member of the Roche Group ¹ ; Wyeth Pharmaceuticals ^{1,4} ; Novartis Pharmaceuticals Corporation ⁴ | 1, 3 |
| A. John Rush, M.D. | GlaxoSmithKline ^{1,4} ; Robert Wood Johnson Foundation ³ ; National Institute of Mental Health ³ ; Cyberonics, Inc. ^{1,4} ; Stanley Foundation ³ ; Bristol-Myers Squibb ¹ ; Eli Lilly and Company ^{1,4} ; Forest Pharmaceuticals, Inc. ^{1,4} ; Organon Pharmaceuticals Inc. ¹ ; Urban Institute ¹ | 6, 31 |
| Leo J. Russo, Ph.D. | Johnson & Johnson PRD ² | 54 |
| Gary S. Sachs, M.D. | Abbott Laboratories, Inc. ^{1,3} ; GlaxoSmithKline ¹ ; Eli Lilly and Company ¹ ; Janssen Pharmaceutica Products, LP ^{1,3} ; Bristol-Myers Squibb ¹ ; Novartis Pharmaceuticals Corporation ¹ ; Elan Pharmaceuticals ¹ ; Sanofi-Synthelabo Pharmaceuticals, Inc. ¹ ; Sigma-Tau ¹ ; AstraZeneca Pharmaceuticals ¹ ; Solvay Pharmaceuticals, Inc. ¹ ; Pfizer Inc. ¹ | 5, 11, 23, 31, 55, 76 |
| Harold A. Sackeim, Ph.D. | MECTA Corp. ^{1,3} ; Neurocrine Biosciences Inc. ^{1,3} ; Cyberonics, Inc. ^{1,3} ; Magstim Corp. ³ | 6, 47 |
| Martha Sajatovic, M.D. | Eli Lilly and Company ^{1,3} ; GlaxoSmithKline ^{1,4} ; AstraZeneca Pharmaceuticals ^{1,4} ; Bristol-Myers Squibb ^{1,3,4} ; Abbott Laboratories, Inc. ³ ; Pfizer Inc. ⁴ ; Janssen Pharmaceutica Products, LP ⁴ | 64 |
| David Satcher, M.D. | Johnson & Johnson PRD ⁶ | 30 |
| Lawrence Scahill, Ph.D. | Janssen Pharmaceutica Products, LP ^{1,4} ; Pfizer Inc. ¹ ; Bristol-Myers Squibb ¹ | 61 |

| Presenter | Manufacturer(s) | Program Page # |
|---------------------------------|--|------------------------------|
| Alan F. Schatzberg, M.D. | Abbott Laboratories, Inc. ¹ ; Aventis Pharmaceuticals ¹ ; Bristol-Myers Squibb ^{1,3} ; Concept Therapeutics ^{1,5} ; Eli Lilly and Company ^{1,3} ; Forest Pharmaceuticals, Inc. ^{1,5} ; GlaxoSmithKline ¹ ; Innapharma ¹ ; Janssen Pharmaceutica Products, LP ¹ ; Merck & Co., Inc. ^{1,5} ; Novartis Pharmaceuticals Corporation ¹ ; Organon Pharmaceuticals Inc. ¹ ; Pharmacia ¹ ; Solvay Pharmaceuticals, Inc. ¹ ; Somerset Pharmaceuticals Inc. ¹ ; Wyeth Pharmaceuticals ^{1,3} ; Cypress Bioscience, Inc. ⁵ ; Elan Pharmaceuticals ⁵ ; Pfizer Inc. ⁵ | 9, 16, 33, 45 |
| Randolph B. Schiffer, M.D. | Pfizer Inc. ⁵ ; Janssen Pharmaceutica Products, LP ³ | 1 |
| Christian Schmahl, M.D. | Eli Lilly and Company ^{1,3} | 7, 97, 98 |
| Christopher D. Schneck, M.D. | AstraZeneca Pharmaceuticals ^{1,4} ; Bristol-Myers Squibb ^{1,3} ; UCB Pharmaceuticals ¹ | 5 |
| Lon Schneider, M.D. | Bristol-Myers Squibb ¹ ; Forest Pharmaceuticals, Inc. ¹ ; Janssen Pharmaceutica Products, LP ¹ ; AstraZeneca Pharmaceuticals ¹ | 76 |
| Franklin R. Schneier, M.D. | Forest Pharmaceuticals, Inc. ³ ; Pfizer Inc. ⁴ ; UCB Pharmaceuticals ³ | 3 |
| Nina R. Schooler, Ph.D. | Janssen Pharmaceutica Products, LP ^{1,3} ; Bristol-Myers Squibb ^{1,3} ; AstraZeneca Pharmaceuticals ³ ; Eli Lilly and Company ^{3,1} ; Pfizer Inc. ^{1,3} ; Johnson and Johnson PRD ¹ ; Organon Pharmaceuticals Inc. ¹ | 10 |
| Marc A. Schuckit, M.D. | Ortho McNeil Pharmaceutical Inc. ¹ ; Forest Pharmaceuticals, Inc. ¹ | 56 |
| S. Charles Schulz, M.D. | AstraZeneca Pharmaceuticals ^{1,3,4} ; Lilly Research Laboratories, a division of Eli Lilly and Company ^{1,3,4} ; Abbott Laboratories, Inc. ³ ; Janssen Pharmaceutica Products, LP ³ | 7, 80 |
| Thomas L. Schwartz, M.D. | Wyeth Pharmaceuticals ^{1,4} ; Cephalon Inc. ³ ; Bristol-Myers Squibb ³ | 37, 70 |
| Larry J. Seidman, Ph.D. | Shire Ridgewood Pharmaceuticals ^{1,3} ; Eli Lilly and Company ^{1,3} ; Janssen Pharmaceutica Products, LP ³ | 57 |
| Michael J. Sernyak, M.D. | AstraZeneca Pharmaceuticals ³ ; Janssen Pharmaceutica Products, LP ¹ ; Eli Lilly and Company ¹ ; Pfizer Inc. ¹ | 55 |
| David D. Servan-Schreiber, M.D. | Institute Francais d'EMDR ⁴ | 94 |
| Peter A. Shapiro, M.D. | Pfizer Inc. ⁴ | 40, 67 |
| Tonmoy Sharma, M.D. | Pfizer Inc. ³ | 23, 89 |
| Shawn C. Shea, M.D. | GlaxoSmithKline ⁴ | 64 |
| M. Katherine Shear, M.D. | Eli Lilly and Company ⁴ ; Forest Pharmaceuticals, Inc. ^{1,3,4} ; Pfizer Inc. ^{1,3,4} | 6, 31, 41 |
| David S. Sheps, M.D. | Pfizer Inc. ^{3,4} | 53 |
| Larry J. Siever, M.D. | Ortho McNeil Pharmaceutical Inc. ^{1,6} ; Lilly Research Laboratories, a division of Eli Lilly and Company ^{1,3,4} | 3, 7, 22, 33, 57, 80, 97, 98 |
| Joel M. Silberberg, M.D. | Abbott Laboratories, Inc. ⁴ ; Pfizer Inc. ⁴ ; Eli Lilly and Company ⁴ | 26 |
| Samuel M. Silverman, M.D. | Reckitt Benckiser Pharmaceuticals ¹ | 73 |
| Gregory E. Simon, M.D. | Pfizer Inc. ¹ ; Wyeth Pharmaceuticals ³ ; Eli Lilly and Company ³ | 98 |
| Naomi M. Simon, M.D. | AstraZeneca Pharmaceuticals ³ ; Cephalon Inc. ³ ; Forest Pharmaceuticals, Inc. ^{3,4} ; Janssen Pharmaceutica Products, LP ³ ; Lilly Research Laboratories, a division of Eli Lilly and Company ³ ; Pfizer Inc. ⁴ ; UCB Pharmaceuticals ³ ; Wyeth Pharmaceuticals ³ | 1, 11, 41 |
| Samuel G. Siris, M.D. | Eli Lilly and Company ^{1,4} ; Merck & Co., Inc. ^{1,4} ; Novartis Pharmaceuticals Corporation ⁴ ; Pfizer Inc. ⁴ ; Proctor & Gamble Pharmaceuticals/Aventis Pharmaceuticals ⁴ | 33 |
| Christine Skotzko, M.D. | Pfizer Inc. ⁴ ; AstraZeneca Pharmaceuticals ⁴ | 44 |
| Claudio N. Soares, M.D. | Pfizer Inc. ⁴ ; Sepracor Inc. ¹ ; Wyeth Pharmaceuticals ^{1,4} ; Forest Pharmaceuticals, Inc. ^{1,4} ; GlaxoSmithKline ^{1,4} | 36, 37, 39 |
| H. Brent Solvason, M.D. | Forest Pharmaceuticals, Inc. ^{3,4} ; Eli Lilly and Company ^{3,4} ; Pfizer Inc. ⁴ ; Cephalon Inc. ^{3,4} | 37 |
| Shamsah B. Sonawalla, M.D. | Forest Pharmaceuticals, Inc. ³ | 32 |
| Thomas J. Spencer, M.D. | Abbott Laboratories, Inc. ^{1,3,4} ; Alza/McNeil Pharmaceuticals ^{1,3,4} ; Boston Life Sciences ^{1,3,4} ; Cephalon Inc. ^{1,3,4} ; Bristol-Myers Squibb ^{1,3,4} ; Celltech Pharmaceuticals, Ltd. ^{1,3,4} ; Eisai Inc. ^{1,3,4} ; GlaxoSmithKline ^{1,3,4} ; Gliatech ^{1,3,4} ; Lilly Research Laboratories, a division of Eli Lilly and Company ^{1,3,4} ; Ortho McNeil Pharmaceutical Inc. ^{1,3,4} ; Novartis Pharmaceuticals Corporation ^{1,3,4} ; Pfizer Inc. ^{1,3,4} ; Shire Ridgewood Pharmaceuticals ^{1,3,4} ; Solvay Pharmaceuticals, Inc. ^{1,3,4} ; Wyeth Pharmaceuticals ^{1,3,4} | 11, 12, 32, 57 |
| Margaret G. Spinelli, M.D. | Pfizer Inc. ⁴ | 2 |
| Murray B. Stein, M.D. | Eli Lilly and Company ^{1,3,4} ; Forest Pharmaceuticals, Inc. ^{1,3} ; Novartis Pharmaceuticals Corporation ³ ; Pfizer Inc. ^{1,3} ; GlaxoSmithKline ^{1,3,4} ; Solvay Pharmaceuticals, Inc. ^{1,3,4} ; UCB Pharmaceuticals ^{1,3} ; Wyeth Pharmaceuticals ^{1,3,4} ; Alza/McNeil Pharmaceuticals ¹ ; Allergan ¹ ; Alexza Molecular Delivery ¹ ; AstraZeneca Pharmaceuticals ¹ ; Bristol-Myers Squibb ¹ ; Cephalon Inc. ¹ ; Janssen Pharmaceutica Products, LP ¹ ; Hoffmann-La Roche Pharmaceuticals ¹ ; Johnson and Johnson PRD ¹ ; Vela Pharmaceuticals ¹ | 3, 84 |
| Donna E. Stewart, M.D. | Eli Lilly and Company ^{1,3,4} ; Wyeth Pharmaceuticals ^{1,4} | 24, 33, 40, 93 |
| Nada L. Stotland, M.D. | GlaxoSmithKline ⁴ | 8, 15, 49, 83, 85 |

DISCLOSURE INDEX

| Presenter | Manufacturer(s) | Program Page # |
|---------------------------------|---|----------------|
| Zachary N. Stowe, M.D. | GlaxoSmithKline ^{1,3,4} ; Pfizer Inc. ^{1,3,4} ; Wyeth Pharmaceuticals ^{3,4} ; Eli Lilly and Company ⁴ | 63, 85, 99 |
| Eric C. Strain, M.D. | Reckitt Benckiser Pharmaceuticals ⁶ | 14 |
| Joshua Straus, M.D. | Pfizer Inc. ¹ | 63 |
| Joel Streim, M.D. | AstraZeneca Pharmaceuticals ^{1,3} ; Bristol-Myers Squibb ^{1,3} ; Forest Pharmaceuticals, Inc. ^{1,3} ; Janssen Pharmaceutica Products, LP ¹ | 1, 64 |
| Thomas S. Stroup, M.D. | Eli Lilly and Company ³ | 12 |
| Scott Stuart, M.D. | Eli Lilly and Company ⁴ ; Pfizer Inc. ⁴ ; Wyeth Pharmaceuticals ⁴ | 19, 54, 64 |
| Donna M. Sudak, M.D. | GlaxoSmithKline ⁴ | 98 |
| David L. Sultzer, M.D. | Pfizer Inc. ^{3,4} ; Forest Pharmaceuticals, Inc. ^{3,4} ; Janssen Pharmaceutica Products, LP ⁴ ; Abbott Laboratories, Inc. ⁴ ; Bristol-Myers Squibb ⁴ ; AstraZeneca Pharmaceuticals ⁴ | 4, 13 |
| Calvin R. Sumner, M.D. | Eli Lilly and Company ^{2,5} | 34 |
| Trisha Suppes, M.D. | Abbott Laboratories, Inc. ^{1,3,4} ; AstraZeneca Pharmaceuticals ^{1,3,4} ; Bristol-Myers Squibb ^{1,3,4} ; GlaxoSmithKline ^{1,3,4} ; Janssen Pharmaceutica Products, LP ^{1,3,4} ; National Institute of Mental Health ³ ; Novartis Pharmaceuticals Corporation ^{1,3,4} ; R.W. Johnson Pharmaceuticals ³ ; Stanley Foundation ³ ; Eli Lilly and Company ^{1,4} ; Johnson and Johnson PRD ^{1,4} ; Pfizer Inc. ^{1,4} ; Pharmaceutical Research Institute (PRI) ^{1,4} ; Ortho McNeil Pharmaceutical Inc. ^{1,4} ; UCB Pharmaceuticals ^{1,4} | 4, 11 |
| James M. Swanson, M.D. | Celgene ^{1,2,3,4} ; Novartis Pharmaceuticals Corporation ^{1,3,4} ; Celltech Pharmaceuticals, Ltd. ^{1,3,4} ; Cephalon Inc. ^{1,3,4} ; Alza/McNeil Pharmaceuticals ^{1,3,4} ; Eli Lilly and Company ^{1,3,4} ; Janssen Pharmaceutica Products, LP ^{1,3,4} ; McNeil Consumer Healthcare ^{1,3,4} ; Shire Ridgewood Pharmaceuticals ^{1,3,4} ; Targacept ¹ | 48 |
| Marvin S. Swartz, M.D. | Eli Lilly and Company ³ | 28, 81 |
| Rajiv Tandon, M.D. | AstraZeneca Pharmaceuticals ^{1,4} ; Bristol-Myers Squibb ^{1,4} ; Eli Lilly and Company ^{1,4} ; Pfizer Inc. ^{1,4} ; Janssen Pharmaceutica Products, LP ^{1,4} | 15, 27 |
| Andre Tapp, M.D. | AstraZeneca Pharmaceuticals ^{3,4} ; Eli Lilly and Company ⁴ ; Janssen Pharmaceutica Products ⁴ | 33 |
| Pierre N. Tariot, M.D. | Novartis Pharmaceuticals Corporation ¹ ; Bristol-Myers Squibb ^{1,3} ; Eli Lilly and Company ^{1,3} ; AstraZeneca Pharmaceuticals ^{1,3,4} ; Forest Pharmaceuticals, Inc. ^{1,3,4} ; Pfizer Inc. ^{1,3,4} ; Janssen Pharmaceutica Products, LP ^{1,3,4} | 39, 47, 62, 77 |
| Humberto Temporini, M.D. | Pfizer Inc. ⁴ ; AstraZeneca Pharmaceuticals ⁴ | 26 |
| Michael E. Thase, M.D. | Bristol-Myers Squibb ¹ ; Cephalon Inc. ¹ ; Cyberonics, Inc. ¹ ; Forest Pharmaceuticals, Inc. ¹ ; Janssen Pharmaceutica Products, LP ¹ ; Novartis Pharmaceuticals Corporation ¹ ; Pfizer Inc. ¹ ; AstraZeneca Pharmaceuticals ^{1,4} ; Eli Lilly and Company ^{1,4} ; GlaxoSmithKline ^{1,4} ; Organon Pharmaceuticals Inc. ^{1,4} ; Wyeth Pharmaceuticals ^{1,4} | 26, 70 |
| Timothy L. Thistlethwaite, M.D. | Eli Lilly and Company ⁴ ; GlaxoSmithKline ⁴ | 67 |
| Maria L.A. Tiamson, M.D. | Janssen Pharmaceutica Products, LP ⁴ | 88 |
| Martin G. Tracy, J.D. | Professional Risk Management Services, Inc. ² | 19, 44 |
| Robert L. Trestman, M.D. | Abbott Laboratories, Inc. ^{1,3} | 26, 73 |
| Madhukar H. Trivedi, M.D. | Abbott Laboratories, Inc. ³ ; Akzo (Organon Pharmaceuticals Inc.) ^{3,4} ; Bayer ³ ; Bristol-Myers Squibb ^{3,4} ; Eli Lilly and Company ^{3,4} ; Forest Pharmaceuticals, Inc. ^{3,4} ; GlaxoSmithKline ³ ; Janssen Pharmaceutica Products, LP ^{3,4} ; Johnson and Johnson PRD ³ ; Parke-Davis Pharmaceuticals ³ ; National Institute of Mental Health ³ ; Meade Johnson ³ ; Pharmacia & Upjohn ^{3,4} ; Solvay Pharmaceuticals, Inc. ^{3,4} ; Wyeth Pharmaceuticals ^{3,4} ; National Alliance for Research in Schizophrenia and Depression ³ | 4, 67, 73 |
| Paula T. Trzepacz, M.D. | Eli Lilly and Company ² | 12, 76 |
| John W. Tsuang, M.D. | Abbott Laboratories, Inc. ⁴ ; Janssen Pharmaceutica Products, LP ⁴ ; Eli Lilly and Company ⁴ | 2 |
| Phebe M. Tucker, M.D. | GlaxoSmithKline ^{1,3,4} ; Bristol-Myers Squibb ^{1,3,4} ; Ortho McNeil Pharmaceutical Inc. ^{3,4} ; Pfizer Inc. ³ | 2 |
| Tim Tully, Ph.D. | Helicon Therapeutics, Inc. ^{1,5} | 81 |
| Sandra L. Tunis, Ph.D. | Eli Lilly and Company ^{2,3} | 25 |
| Robert J. Ursano, M.D. | Abbott Laboratories, Inc. ³ | 19, 95 |
| Michael A. Van Ameringen, M.D. | Biovail Laboratories Inc. ¹ ; Cephalon Inc. ¹ ; Novartis Pharmaceuticals Corporation ¹ ; AstraZeneca Pharmaceuticals ^{1,3} ; Solvay Pharmaceuticals, Inc. ^{1,3} ; Wyeth Pharmaceuticals ^{1,3} ; GlaxoSmithKline ^{1,3,4} ; Janssen Pharmaceutica Products, LP ^{1,3,4} ; Pfizer Inc. ^{1,3,4} ; Bristol-Myers Squibb ³ ; Eli Lilly and Company ³ ; Lundbeck ³ | 90 |
| Donna Vanderpool, J.D. | Professional Risk Management Services, Inc. ² | 19 |
| Kaycia L. Vansickle, M.D. | Pfizer Inc. ⁴ ; AstraZeneca Pharmaceuticals ⁴ ; Wyeth Pharmaceuticals ⁴ | 64 |
| Dawn I. Velligan, Ph.D. | AstraZeneca Pharmaceuticals ^{1,3,4} ; Bristol-Myers Squibb ^{1,3} ; Eli Lilly and Company ^{1,3} ; InfoMedix ¹ ; Janssen Pharmaceutica Products, LP ^{1,3} ; Pfizer Inc. ^{1,3,4} | 87 |
| George I. Viamontes, M.D. | Johnson and Johnson PRD ⁵ ; Pfizer Inc. ¹ ; GlaxoSmithKline ¹ ; Janssen Pharmaceutica Products, LP ¹ ; Bristol-Myers Squibb ¹ ; Wyeth Pharmaceuticals ¹ | 27, 68 |

| Presenter | Manufacturer(s) | Program Page # |
|------------------------------|---|------------------------------|
| Adele C. Viguera, M.D. | GlaxoSmithKline ⁴ | 66, 99 |
| Albert V. Vogel, M.D. | Joint Commission on Accreditation of Healthcare Organization ⁶ | 72 |
| Karen D. Wagner, M.D. | Abbott Laboratories, Inc. ^{1,3,4} ; Eli Lilly and Company ^{1,3,4} ; Forest Pharmaceuticals, Inc. ^{1,3,4} ; GlaxoSmithKline ^{1,3,4} ; Janssen Pharmaceutica Products, LP ^{1,4} ; Novartis Pharmaceuticals Corporation ^{1,4} ; Pfizer Inc. ^{1,3,4} ; Bristol-Myers Squibb ^{1,3} ; National Institute of Mental Health ^{1,3} ; Otsuka America Pharmaceutical ¹ ; UCB Pharmaceuticals ¹ ; Wyeth Pharmaceuticals ^{1,3} ; Organon Pharmaceuticals Inc. ³ ; Ortho McNeil Pharmaceutical Inc. ⁶ | 4, 63 |
| John T. Walkup, M.D. | Lilly Research Laboratories, a division of Eli Lilly and Company ^{1,3,4} ; Pfizer Inc. ^{3,4} ; Abbott Laboratories, Inc. ³ ; Janssen Pharmaceutica Products, LP ⁴ | 42, 68, 93 |
| B. Timothy Walsh, M.D. | Eli Lilly and Company ³ ; Ortho McNeil Pharmaceutical Inc. ³ | 59, 71 |
| G. Scott Waterman, M.D. | Lilly Research Laboratories, a division of Eli Lilly and Company ³ ; Bristol-Myers Squibb ³ | 33 |
| Peter J. Weiden, M.D. | Bristol-Myers Squibb ^{1,3,4} ; Otsuka America Pharmaceutical ³ ; AstraZeneca Pharmaceuticals ^{1,3,4} ; Pfizer Inc. ^{1,3,4} ; Janssen Pharmaceutica Products, LP ^{1,3,4} | 51, 87 |
| Daniel R. Weinberger, M.D. | Bristol-Myers Squibb ¹ ; AstraZeneca Pharmaceuticals ¹ ; Janssen Pharmaceutica Products, LP ¹ ; Eli Lilly and Company ¹ ; Otsuka America Pharmaceutical ¹ ; Pfizer Inc. ¹ | 11, 52 |
| Richard D. Weiner, M.D. | Mecta Corp. ⁴ | 26 |
| Margaret D. Weiss, M.D. | Johnson and Johnson PRD ¹ ; Pharmacia & Upjohn Company, Inc. ¹ ; Purdue Pharma L.P. ^{1,3} ; Eli Lilly and Company ^{1,3,4} ; Novartis Pharmaceuticals Corporation ^{1,3,4} ; Shire Ridgewood Pharmaceuticals ^{1,3,4} ; GlaxoSmithKline ³ ; Circa Dia ³ | 23, 32 |
| Steven Wengel, M.D. | Pfizer Inc. ⁴ ; Forest Pharmaceuticals, Inc. ⁴ | 64 |
| Sharon B. Wigal, Ph.D. | Alza/McNeil Pharmaceuticals ^{1,3,4} ; McNeil Consumer & Specialty Pharmaceuticals ^{1,3,4} ; Celltech Pharmaceuticals, Ltd. ^{1,3,4} ; Novartis Pharmaceuticals Corporation ^{1,3,4} ; Shire Ridgewood Pharmaceuticals ^{1,3,4} ; Celgene ^{3,4} ; Cephalon Inc. ^{3,4} ; Eli Lilly and Company ^{3,4} ; Janssen Pharmaceutica Products, LP ³ | 62 |
| Timothy E. Wilens, M.D. | Lilly Research Laboratories, a division of Eli Lilly and Company ^{1,3,4} ; Abbott Laboratories, Inc. ^{1,3,4} ; Alza/McNeil Pharmaceuticals ^{1,3,4} ; Celltech Pharmaceuticals, Ltd. ^{1,3,4} ; GlaxoSmithKline ^{1,3,4} ; National Institute on Drug Abuse ^{1,3,4} ; National Institute of Mental Health ^{1,3,4} ; NICMH ^{1,3,4} ; Neurosearch ^{1,3,4} ; Pfizer Inc. ^{1,3,4} ; Shire Ridgewood Pharmaceuticals ^{1,3,4} | 12, 22, 62, 80 |
| Jill Williams, M.D. | Pfizer Inc. ³ | 26 |
| John W. Winkelman, M.D. | Cephalon Inc. ^{1,4} ; GlaxoSmithKline ^{1,3,4} ; Pfizer Inc. ^{1,3} ; UCB Pharmaceuticals ³ ; Sanofi-Synthelabo Pharmaceuticals, Inc. ^{4,1} ; Eli Lilly and Company ⁴ ; Elan Pharmaceuticals ¹ ; King Pharmaceutical ^{1,4} ; Sepracor Inc. ¹ ; Boehringer-Ingelheim Pharmaceuticals ³ ; Novartis Pharmaceuticals Corporation ¹ ; Schwarz ¹ | 9, 26, 37, 53 |
| Katherine L. Wisner, M.D. | Pfizer Inc. ⁴ ; GlaxoSmithKline ⁴ | 2, 23, 30, 41, 58 |
| Madelaine M. Wohlreich, M.D. | Eli Lilly and Company ² | 90 |
| William C. Wood, M.D. | Aventis ¹ ; Genomic Health ¹ | 49 |
| Scott W. Woods, M.D. | Bristol-Myers Squibb ³ ; UCB Pharmaceuticals ³ | 30 |
| Janet Wozniak, M.D. | Janssen Pharmaceutica Products, LP ⁴ ; Eli Lilly and Company ^{3,4} ; Shire Ridgewood Pharmaceuticals ¹ | 35 |
| Jesse H. Wright, M.D. | Mindstreet ^{5,6} ; Eli Lilly and Company ⁶ | 8, 26, 50 |
| Joel Yager, M.D. | Ortho McNeil Pharmaceutical Inc. ¹ ; Janssen Pharmaceutica Products, LP ⁶ | 1, 6, 17, 25, 45, 68, 83, 97 |
| Kimberly A. Yonkers, M.D. | Berlex Laboratories, Inc. ^{1,3} ; GlaxoSmithKline ^{1,3} ; Wyeth Pharmaceuticals ¹ ; Pfizer Inc. ¹ ; National Institute on Drug Abuse ³ ; National Institute of Mental Health ³ ; HRSA ³ | 13, 30 |
| Mary Zanarini, Ed.D. | Eli Lilly and Company ^{1,3} | 7 |
| Phyllis C. Zee, M.D. | Sanofi-Synthelabo Pharmaceuticals, Inc. ⁴ ; Takeda Pharmaceuticals ^{1,3} | 9, 53 |
| Douglas M. Ziedonis, M.D. | Lilly Research Laboratories, a division of Eli Lilly and Company ^{1,3,4} ; Janssen Pharmaceutica Products, LP ^{1,3,4} ; Bristol-Myers Squibb ^{1,3,4} | 26 |
| Robert B. Zipursky, M.D. | Eli Lilly and Company ^{3,4} ; Novartis Pharmaceuticals Corporation ^{4,3} ; AstraZeneca Pharmaceuticals ^{3,4} ; Pfizer Inc. ⁵ | 10, 12 |
| Sidney Zisook, M.D. | GlaxoSmithKline ^{1,4} ; AstraZeneca Pharmaceuticals ⁴ ; Janssen Pharmaceutica Products, LP ⁴ ; Pfizer Inc. ⁴ ; Eli Lilly and Company ⁴ ; Wyeth Pharmaceuticals ⁴ ; Forest Pharmaceuticals, Inc. ⁴ | 31, 82 |
| Joseph Zohar, M.D. | Solvay Pharmaceuticals, Inc. ³ ; Eli Lilly and Company ³ | 79 |

DISCLOSURE INDEX

The following presenters indicated neither they nor an immediate member of their family have any significant relationship to disclose.

Ronald D. Abramson, M.D.
A. Reese Abrigh, M.D.
Curtis N. Adams, Jr., M.D.
Babatunde A. Adetunji, M.D.
Davin A. Agustines, M.D.
Iqbal Ahmed, M.D.
Jeffrey Akaka, M.D.
Mayada Akil, M.D.
Antti Alaräisänen, M.D.
Renato D. Alarcon, M.D.
David B. Albert, Ph.D.
Ian E. Alger, M.D.
David M. Allen, M.D.
Mona H. Al-Sawaf, M.D.
Steven I. Altchuler, M.D.
Margaret Altemus, M.D.
Carol L. Alter, M.D.
Lori L. Altshuler, M.D.
Jean-Marie E. Alves-Bradford, M.D.
Antoinette Ambrosino-Wyszynski, M.D.
Abdel F. Amin, M.D.
Shahrad R. Amiri, M.D.
Jambur V. Ananth, M.D.
Karneya J. Ancselovits, M.D.
Kelly C. Anderson
Naleen N. Andrade, M.D.
Angel Angelov, M.D.
James Annesi, Ph.D.
Francesca Antognini, Ph.D.
Joan M. Anzia, M.D.
Paul S. Appelbaum, M.D.
Gisèle Apter-Danon, Ph.D.
William Arroyo, M.D.
Kenneth Ashley, M.D.
Raymond R. Auger, M.D.
Julia C. Babcock, Ph.D.
Florence Baingana, M.D.
Donald Bakal, Ph.D.
Richard Balon, M.D.
Peter A. Bandettini, Ph.D.
Claudio E.M. Banzato, M.D.
Yoram Barak, M.D.
Nigel M. Bark, M.D.
Ernest S. Barratt, Ph.D.
Arthur J. Barsky, M.D.
Stephen J. Bartels, M.D.
Monica Basco, Ph.D.
William R. Beardslee, M.D.
Judith S. Beck, Ph.D.
Daniel F. Becker, M.D.
Judith V. Becker, Ph.D.
Alan R. Beeber, M.D.
Julian Beezhold, M.R.C.
Kristin S. Beizai, M.D.
Carl C. Bell, M.D.
Selim Benbadis, M.D.
Donna S. Bender, Ph.D.
David M. Benedek, M.D.
Elissa P. Benedek, M.D.
Robert S. Benson, M.D.
Brian T. Benton, M.D.
Thomas P. Beresford, M.D.
Eugene V. Beresin, M.D.
Gretchen Bergman
Ellen Berkowitz, M.D.
Jeffrey A. Berman, M.D.
Carol A. Bernstein, M.D.
David Bernstein
Philip A. Bialer, M.D.
Scott I. Bienenfeld, M.D.
Stephen B. Billick, M.D.
Boris Birmaher, M.D.
Adam M. Bisaga, M.D.
Leigh C. Bishop, M.D.
Johannes Bitzer, M.D.
Donald W. Black, M.D.
John L. Black, M.D.
Walter P. Bland, M.D.
Roger Blashfield, Ph.D.
Dan G. Blazer II, M.D.
Barton J. Blinder, M.D.
Nancee Blum, M.S.W.
Crystal R. Blyler, Ph.D.
Olivera J. Bogunovic, M.D.
Robert J. Boland, M.D.
Angelo S. Bolea, Ph.D.
George A. Bonanno, Ph.D.
Richard Bonnie, J.D.
Benedicto R. Borja, M.D.
Thomas H. Bornemann, Ed.D.
Nashaat N. Boutros, M.D.
Robert L. Boyd, M.D.
Nancy Boyd-Franklin, Ph.D.
John E. Bragg, Jr., M.D.
Jennifer S. Brasch, M.D.
Joel T. Braslow, M.D.
Joel D. Bregman, M.D.
Hans C. Breiter, M.D.
David H. Brendel, M.D.
Richard M. Brockman, M.D.
Thomas M. Brod, M.D.
Amy C. Brodkey, M.D.
Seth Brody, M.D.
David W. Brook, M.D.
Frank N. Brown, M.D.
Larry K. Brown, M.D.
Richard P. Brown, M.D.
Mary F. Brunette, M.D.
Antonio E. Bullon, M.D.
Daphne F. Burdman, M.D.
Page Burkholder, M.D.
Margit Burmeister, Ph.D.
Bill Burmester, M.A.
Harold J. Bursztajn, M.D.
Jeremy R. Butler, M.D.
Robert P. Cabaj, M.D.
Eric D. Caine, M.D.
Jose M. Caldas de Almeida, M.D.
Eve Caligor, M.D.
William E. Callahan, Jr., M.D.
Enoch Callaway III, M.D.
Robert Cancro, M.D.
Philip Candilis, M.D.
Philip Candillis, M.D.
Angel A. Caraballo, M.D.
Giovanni Caracci, M.D.
Alex A. Cardoni, M.S.
Graca Cardoso, M.D.
William T. Carpenter, Jr., M.D.
Cameron Carter, M.D.
Debbie Carter, M.D.
Andy Casimir, M.D.
Carol L.M. Caton
Josephine Caubel, M.D.
John R. Chamberlain, M.D.
Jacquelyn B. Chang, M.D.
Daniel P. Chapman, Ph.D.
John N. Chappel, M.D.
Robert P. Charrow, Esq.
Navjot Chaudhary, B.S.C.
Haroon R. Chaudhry, M.D.
Linda H. Chaudron, M.D.
Mark Chavez
Rosa A. Chavez-Eakle, M.D.
Jennifer K. Cheng, M.D.
Adam R. Chester, D.O.
Larissa Chism, M.D.
Charles Chiu, M.D.
Daniel T. Chrzanowski, M.D.
James A. Chu, M.D.
Christopher K. Chung, M.D.
Connie Clark, M.A.
David L. Clark, Ph.D.
Lee Anna Clark, Ph.D.
Marlene Clark
John F. Clarkin, Ph.D.
Norman A. Clemens, M.D.
Jeffrey L. Clothier, M.D.
Joseph J. Cocozza, Ph.D.
Katie Coerver, M.D.
C. Edward Coffey, M.D.
Carl I. Cohen, M.D.
Judith A. Cohen, M.D.
Lisa J. Cohen, Ph.D.
Mary Ann Cohen, M.D.
Steven A. Cole, M.D.
Yolonda R. Coleman, M.D.
Gary R. Collins, M.D.
Lee Combrinck-Graham, M.D.
Wilson M. Compton III, M.D.
Edi Cooke, Psy.D.
Kim A. Coon, Ed.D.
Barbara A. Cornblatt, Ph.D.
Jack R. Cornelius, M.D.
Maria R. Corral, M.D.
Jennifer Correale, J.D.
Patrick W. Corrigan, Psy.D.
Rebecca L. Corwin, Ph.D.
Gad Cotter, M.D.
Francine Courmos, M.D.
Rex W. Cowdry, M.D.
John L. Cox, M.D.
Joyce Cox
Paul D. Cox, M.D.
Stephen J. Cozza, M.D.
Alex Crosby, M.D.
Judith H. W. Crossett, M.D.
Brian Crowley, M.D.
Timothy Cuerdo, Ph.D.
Klara I. Curtis, M.D.
Rodney C. Curtis, M.D.
Bruce Guthbert, Ph.D.
Richard E. D'Alli, M.D.
Patricia A. Daly, M.D.
Gail L. Daumit, M.D.
Donald A. Davidoff, Ph.D.
Elizabeth A. Davis, M.D.
Jack Davis, M.S.
John M. Davis, M.D.
Claire M. De Souza, M.D.
John DeFigueiredo, M.D.
Lea E. DeFrancisci, M.D.
David Deitch, Ph.D.
Jack J. Dekker, Ph.D.
Mary Lynn Dell, M.D.
David DeMaso, M.D.
William C. Dement, M.D.
Ellen B. Dennehy, Ph.D.
Deborah Denno, J.D.
Alain Dervaux, M.D.
Gagan Dhaliwal, M.D.
Daniel Dickerson, D.O.
Daniel P. Dickstein, M.D.
Leah J. Dickstein, M.D.
Allen J. Dietrich, M.D.
JoAnn Difede, Ph.D.
Nesrin Dilbaz, M.D.
Caroline C. Doebbeling, M.D.
Karl Doghramji, M.D.
Regina Dolan-Sewell, Ph.D.
Barbara D'Orio, M.D.
Allison V. Downer, M.D.
Jack Drescher, M.D.
Laura Drury, M.S.W.
Benjamin G. Druss, M.D.
Nang Du, M.D.
Kenneth S. Duckworth, M.D.
Farifteh F. Duffy, Ph.D.
Kent E. Dunn, M.D.
Laura B. Dunn, M.D.
Michael H. Ebert, M.D.
Ulrich W. Ebner-Priemer, Ph.D.
Gabriel Eckermann, M.D.
Judith G. Edersheim, M.D.
Kathryn J. Ednie, M.D.
Susan M. Edwards-Loidl, M.D.
Mark J. Ehrenreich, M.D.
Harold I. Eist, M.D.
Eric B. Elbogen, Ph.D.
Mark B. Elliot, M.D.
Sukru Emre, M.D.
Anna G. Engel, M.D.
Charles C. Engel, M.D.
Joseph T. English, M.D.
Steven A. Epstein, M.D.
Jeffrey Lee Erickson, M.D.
Carrie L. Ernst, M.D.
Spencer Eth, M.D.
Karleyton C. Evans, M.D.
Anita S. Everett, M.D.
Ariel Eytan, M.D.
Robert M. Factor, M.D.
Sheri A. Faggiano, R.N.
Laura Fagiolo-Petrillo, M.D.
Rodolfo D. Fahrner, M.D.
Mathea Falco
Brian A. Fallon, M.D.
Alexander H. Fan, M.D.
Tiffany R. Farchione, M.D.
David Fassler, M.D.
Rudolf A. Feijen, M.D.
David T. Feinberg, M.D.
Joel S. Feiner, M.D.
Marc D. Feldman, M.D.

Alan R. Felthous, M.D.
 Wayne S. Fenton, M.D.
 Stephen J. Ferrando, M.D.
 Christopher G. Fichtner, M.D.
 Carla Fine, M.S.
 Michael B. First, M.D.
 Ellen R. Fischbein, M.D.
 Laura A. Flashman, Ph.D.
 Heather Flynn, Ph.D.
 Laura J. Fochtman, M.D.
 Peter Fonagy, Ph.D.
 Timothy W. Fong, M.D.
 Brad Foote, M.D.
 William W. Foote, M.D.
 Daniel E. Ford, M.D.
 Robert F. Forman, Ph.D.
 Marshall Forstein, M.D.
 Mary Ellen Foti, M.D.
 Edward F. Foulks, M.D.
 Howard Fradkin, Ph.D.
 Nancy Frasure-Smith, Ph.D.
 Arthur M. Freeman III, M.D.
 Gregory L. Fricchione, M.D.
 Joseph I. Friedman, M.D.
 John A. Fromson, M.D.
 Mindy J. Fullilove, M.D.
 Glen O. Gabbard, M.D.
 Raymond R. Gaeta, M.D.
 Marc Galanter, M.D.
 Sandro Galea, M.D.
 Leo L. Gallofin, M.D.
 Igor I. Galynker, M.D.
 Keming Gao, M.D.
 Michael Garrett, M.D.
 Richard Gartner, Ph.D.
 Daniel Garza, M.D.
 Robert Gatchel, Ph.D.
 Norma I. Gavin, Ph.D.
 Albert C. Gaw, M.D.
 Rose Geist, M.D.
 Barbara G. Geller, M.D.
 Michael H. Gendel, M.D.
 Patricia L. Gerbarg, M.D.
 Elizabeth V. Getter, M.D.
 Kareem D. Ghalib, M.D.
 A. Hamid Ghodse, Ph.D.
 Marisa A. Giggie, M.D.
 Kenneth G. Gilbert, M.D.
 Lisa L. Giles, M.D.
 Mona H. Gill, M.D.
 David Gitlin, M.D.
 John W. Goethe, M.D.
 Marcia K. Goin, M.D.
 Philip W. Gold, M.D.
 David A. Goldberg, M.D.
 Ivan K. Goldberg, M.D.
 Charles R. Goldman, M.D.
 Alberto M. Goldwaser, M.D.
 Junius J. Gonzales, M.D.
 Gerardo Gonzalez, M.D.
 Luisa S. Gonzalez, M.D.
 Francisco J. Gonzalez-Franco, M.D.
 Byron J. Good, Ph.D.
 James S. Goodwin, M.D.
 Edward Gordon, M.D.
 Lawrence Gordon
 Tracy R. Gordy, M.D.
 Jack M. Gorman, M.D.
 Bonnie Gorscak, Ph.D.
 Diane B. Gottlieb, M.D.
 Jennifer G. Gotto, M.D.
 Tana A. Grady-Weliky, M.D.
 Marc Graff, M.D.
 Robert P. Granacher, Jr., M.D.
 Jon E. Grant, M.D.
 Henry J. Grass, M.D.
 Gregory E. Gray, M.D.
 Sheila Hafter Gray, M.D.
 Yuli Grebchenko, M.D.
 Roger P. Greenberg, Ph.D.
 James A. Greene, M.D.
 James L. Griffith, M.D.
 John A.R. Grimaldi, Jr., M.D.
 Thomas Grisso, Ph.D.
 Rachel Gropper
 Raz Gross, M.D.
 Linda S. Grossman, Ph.D.
 Leon J. Grunhaus, M.D.
 Salvador M. Guinjoan, M.D.
 John G. Gunderson, M.D.
 Marianne T. Guschwan, M.D.
 Ann L. Hackman, M.D.
 Silvia Hafliger, M.D.
 Deborah J. Hales, M.D.
 Molly J. Hall, M.D.
 Ellen Haller, M.D.
 Katherine A. Halmi, M.D.
 James P. Halper, M.D.
 Hamada Hamid, M.D.
 Tom Hamilton
 W. Rodney Hammond, Ph.D.
 Ken Hanes
 Della M. Hann, Ph.D.
 Annette L. Hanson, M.D.
 Richard K. Harding, M.D.
 Catherine J. Harmer, D.Phil.
 Larry J. Harmon, Ph.D.
 Theresa L. Harpold, M.D.
 Martin Harrow
 Carl Hart, Ph.D.
 David E. Hartman, Ph.D.
 Lawrence Hartmann, M.D.
 Deborah S. Hasin, Ph.D.
 Susan J. Hatters-Friedman, M.D.
 Shivkumar Hatti, M.D.
 Gary Heffner, M.A.
 Robert K. Heinssen, Ph.D.
 Gerardo Heinze, M.D.
 Rene Hen, Ph.D.
 Shanta P. Henderson, M.D.
 Mariëlle Hendriksen, M.A.
 Fran Henry, M.B.A.
 Sarah E. Herbert, M.D.
 Sabine Herpertz, M.D.
 Helen Herrman, M.D.
 Richard G. Hersh, M.D.
 Alison M. Heru, M.D.
 Alfred Herzog, M.D.
 David B. Herzog, M.D.
 John F. Hiatt, M.D.
 Daniel W. Hicks, M.D.
 Napoleon B. Higgins, Jr., M.D.
 Britton A. Hill, M.D.
 Karen M. Hochman, M.D.
 Bartley G. Hoebel, Ph.D.
 Perry D. Hoffman, Ph.D.
 Rosalind G. Hoffman, M.D.
 Charles W. Hoge, M.D.
 Jimmie C. Holland, M.D.
 William Holmes, M.D.
 Richard Horton, M.D.
 Abram M. Hostetter, M.D.
 Rory P. Houghtalen, M.D.
 Edmund G. Howe, M.D.
 Frederick Y. Huang, M.D.
 William Huang, M.D.
 Michael C. Hughes, M.D.
 Damir Huremovic, M.D.
 Matthew O. Hurford, M.D.
 Thomas D. Hurwitz, M.D.
 Mohammad Z. Hussain, M.D.
 Janice G. Hutchinson, M.D.
 Steven E. Hyler, M.D.
 Lawrence B. Inderbitzin, M.D.
 Thomas R. Insel, M.D.
 Gail Ironson, M.D.
 Tracey L. Irvin, M.D.
 JoAnne Isbey, A.B.D.
 Joshua A. Israel, M.D.
 Yad Jabbarpour, M.D.
 Selby C. Jacobs, M.D.
 Wendy Jacobson, M.D.
 Richard L. Jaffe, M.D.
 Vivek Jain, M.D.
 Gilbert Jarvis
 Nimali Jayasinghe, Ph.D.
 Michael M. Jeavons, M.D.
 Michael D. Jibson, M.D.
 David C. Jimerson, M.D.
 Bradley R. Johnson, M.D.
 Hillary Johnson, M.A.
 Ian R. Jones, M.R.C.
 Ricardo Jorge, M.D.
 Linda M. Jorgenson, J.D.
 Robert C. Joseph, M.D.
 Allan M. Josephson, M.D.
 Charles R. Joy, M.D.
 Tony Juneja, M.D.
 Nalini Juthani, M.D.
 Henry S. Kahn, M.D.
 Michael A. Kalm, M.D.
 Shimi Kang, M.D.
 Allan S. Kaplan, M.D.
 Gabriel Kaplan, M.D.
 Sandra J. Kaplan, M.D.
 Dan H. Karasic, M.D.
 T. Byram Karasu, M.D.
 Niranjan S. Karnik, M.D.
 Connie Kasari, Ph.D.
 Marianne C. Kastrup, M.D.
 Wayne J. Katon, M.D.
 Kostas Katsavdakis, Ph.D.
 David L. Kaye, M.D.
 Walter H. Kaye, M.D.
 Pamela K. Keel, Ph.D.
 V. Alex Kehayan, Ed.D.
 Zurab Kekelidze, M.D.
 Robert Kelly, M.D.
 Robert S. Kennedy, M.A.
 Otto F. Kernberg, M.D.
 Clarice J. Kestenbaum, M.D.
 Scott Y. Kim, M.D.
 Thomas M. Kim, M.D.
 Gillian Kirsh, M.A.
 Stephen R. Kisely, M.D.
 Andrew M. Kleiman, M.D.
 Ehud M. Klein, M.D.
 Harold W. Koenigsberg, M.D.
 George F. Kolodner, M.D.
 B. Waine Kong, J.D.
 Simone Kool, M.D.
 Alex J. Kopelowicz, M.D.
 Brett A. Koplin, M.D.
 Hannu J. Koponen, M.D.
 Robert Kores, Ph.D.
 Harriett Koskoff
 Ida Kosza, M.D.
 Raymond J. Kotwicki, M.D.
 Igor Koutsemok, M.D.
 Beatrice Kovaszny, M.D.
 Gabriel Koz, M.D.
 Lois Krahn, M.D.
 Menahem I. Krakowski, M.D.
 Milton Kramer, M.D.
 Thomas A.M. Kramer, M.D.
 Valery N. Krasnov, M.D.
 John S. Kruse, M.D.
 Harold Kudler, M.D.
 Manoj Kumar, M.D.
 Jack Kuo, M.D.
 Helen H. Kyomen, M.D.
 W. Curt LaFrance, Jr., M.D.
 Gonzalo E. Laje, M.D.
 H. Richard Lamb, M.D.
 Ruth M. Lamdan, M.D.
 Friedhelm Lamprecht, M.D.
 Rebecca Landa, Ph.D.
 Richard D. Lane, M.D.
 Joan A. Lang, M.D.
 Alan Langlieb, M.D.
 Ruth A. Lanius, M.D.
 Umar Latif, M.D.
 Vassilios Latoussakis, M.D.
 Thomas P. Laughren, M.D.
 Erika Lauronen, B.Med.
 Andrew L. Lautin, M.D.
 Malcolm Lazin
 Barry D. Lebowitz, Ph.D.
 Pamela Leck, Ph.D.
 James F. Leckman, M.D.
 Jennifer R. Lee, M.D.
 Karen L. Lee, M.A.
 Li-Ching Lee, Ph.D.
 Steven J. Lee, M.D.
 Susan Lee, M.D.
 Arlette M. LeFebvre, M.D.
 Laurent S. Lehmann, M.D.
 Hoyle Leigh, M.D.
 Ubaldo Leli, M.D.
 Francois Lesperance, M.D.
 Philip G. Levendusky, Ph.D.
 Petros Levounis, M.D.
 Joslyn Levy, R.N.
 David Lewis, M.D.
 David A. Lewis, M.D.
 Roya Lewis, M.D.
 Roberto Lewis-Fernandez, M.D.
 Alfred J. Lewy, M.D.
 Jonathan E. Lichtmacher, M.D.
 Klaus Lieb, M.D.
 Paul B. Lieberman, M.D.
 Russell F. Lim, M.D.

- Sabina Lim, M.D.
 Frederic Limosin, M.D.
 Heather Lin, M.D.
 Keh-Ming Lin, M.D.
 Jeffrey Lindeman, Psy.D.
 Don R. Lipsitt, M.D.
 Joshua D. Lipsitz, Ph.D.
 Steven H. Lipsius, M.D.
 John Livesley, Ph.D.
 Anton J.M. Loonen, M.D.
 Barbara Lopes-Cardozo, M.D.
 Eugene M. Lowenkopf, M.D.
 Nasser F. Loza, M.B.
 Francis G. Lu, M.D.
 Joan L. Luby, M.D.
 Antonia Ludwig-Noble, M.F.T.
 John Luo, M.D.
 Lawrence B. Lurie, M.D.
 Susan Lutgendorf, Ph.D.
 Maria T. Lymberis, M.D.
 Thomas R. Lynch, Ph.D.
 Lisa Lyons, Ph.D.
 Duncan C. MacCourt, M.D.
 Avram H. Mack, M.D.
 Holly V. MacKenna, M.D.
 Glenda M. MacQueen, M.D.
 Jed G. Magen, D.O.
 Michael Magera, M.D.
 Julie D. Maggi, M.D.
 Gerald A. Maguire, M.D.
 Ishmeal Major, M.D.
 Pirjo H. Maki, M.D.
 David B. Mallott, M.D.
 Carl P. Malmquist, M.D.
 Alan Z.A. Manevitz, M.D.
 Paolo Mannelli, M.D.
 John Manning, M.D.
 Peter Manu, M.D.
 Donatella Marazziti, M.D.
 Eric R. Marcus, M.D.
 Sheila M. Marcus, M.D.
 Humberto Marin, M.D.
 Dimitri D. Markov, M.D.
 Charles R. Marmar, M.D.
 Janet A. Martin, M.D.
 Michael J. Martin, M.D.
 Cervando Martinez, M.D.
 Humberto Martinez, M.D.
 Paolo Marzorati, M.D.
 Mary Jane Massie, M.D.
 Maju Mathews, M.D.
 Manuel Matos, M.D.
 Marlin R.A. Mattson, M.D.
 Nathalie Maullin, M.D.
 Martin H. Maurer, M.D.
 Randall Maxey, M.D.
 Edward J. Maxwell, M.D.
 Matthew May, M.D.
 Laurel Mayer, M.D.
 Scot G. McAfee, M.D.
 Kara L. McCunn, M.D.
 Bruce S. McEwen, Ph.D.
 Pamela McGeoch, M.A.
 Paul R. McHugh, M.D.
 Judy S. McKay, M.D.
 Jennifer L. McLain, M.D.
 Tom McLaren, Ph.D.
 Alexandra McLean, M.D.
 Diane E. McLean, M.D.
 A. Thomas McLellan, Ph.D.
 Stephen McLeod-Bryant, M.D.
 Laura F. McNicholas, M.D.
 Joy D. McQuery, M.D.
 Michael Meaney, Ph.D.
 Rolando A. Medina, M.D.
 Maria E. Medina-Mora, Ph.D.
 David Mee-Lee, M.D.
 Trisha Meili
 Lisa A. Mellman, M.D.
 Samantha E. Meltzer-Brody, M.D.
 Michaela Mendelsohn, Ph.D.
 Edgardo J. Menvielle, M.D.
 Philip T. Merideth, M.D.
 Donald Jay Meyer, M.D.
 Andreas Meyer-Lindenberg, M.D.
 Robert Michels, M.D.
 Cecilia M. Mikalac, M.D.
 Albert A. Mikhail, M.D.
 Dennis J. Milke, M.D.
 Claudia Miller, M.D.
 Paul R. Miller, M.D.
 Sheldon I. Miller, M.D.
 Robert Millman, M.D.
 Barbara L. Milrod, M.D.
 Nancy Minshew, M.D.
 David L. Mintz, M.D.
 Michael J. Minzenberg, M.D.
 Karoly Mircics, M.D.
 David Mischoulon, M.D.
 Sahana Misra, M.D.
 Alex J. Mitchell, M.D.
 Mahmoud A. Mohamed, M.D.
 Paul C. Mohl, M.D.
 Richard Montgomery, M.D.
 Leslie C. Morey, Ph.D.
 David J. Moser, Ph.D.
 Jeffrey Mothersell, C.S.W.
 Driss Moussaoui, M.D.
 David A. Mrazek, M.D.
 Kristina H. Muenzenmaier, M.D.
 Cheryl Munday, Ph.D.
 Cyndi R. Murrer, B.S.
 Michael F. Myers, M.D.
 Wade C. Myers, M.D.
 Carol C. Nadelson, M.D.
 DeeAnna Merz Nagel, M.Ed.
 Gene A. Nakajima, M.D.
 Surinder S. Nand, M.D.
 Syed S. A. Naqvi, M.D.
 Antonio E. Nardi, M.D.
 William E. Narrow, M.D.
 Margaret Nazarey, M.S.N.
 J. Charles Ndlela, M.D.
 Yuval Y. Neria, Ph.D.
 Randolph M. Nesse, M.D.
 Eric J. Nestler, M.D.
 Alexander Neumeister, M.D.
 Craig Newschaffer, Ph.D.
 Armand M. Nicholi, Jr., M.D.
 Autumn Ning, M.D.
 Frank G. Njenga, M.D.
 Florence Noble, Ph.D.
 Michael A. Norko, M.D.
 Matthew W. Norman, M.D.
 Grayson S. Norquist, M.D.
 Donna M. Norris, M.D.
 Colleen J. Northcott, M.D.
 Malkah T. Notman, M.D.
 Edward V. Nunes, M.D.
 Sherry A. Nykiel, B.A.
 Margaret O'Connor, Ph.D.
 Bastiaan L. Oele, M.D.
 Jessica R. Oesterheld, M.D.
 Julian Offsay, M.D.
 Ahmed M.F. Okasha, M.D.
 Tarek A. Okasha, M.D.
 N. Kalaya Okereke, M.D.
 Silvia W. Olarte, M.D.
 John M. Oldham, M.D.
 Jacqueline Olds, M.D.
 Maria A. Oquendo, M.D.
 David Oslin, M.D.
 Ossama T. Osman, M.D.
 David N. Osser, M.D.
 Eugene A. Oulvey, Ph.D.
 Stefano Pallanti, M.D.
 Regina Pally, M.D.
 Barton W. Palmer, Ph.D.
 Maryland Pao, M.D.
 Herbert Pardes, M.D.
 Rajesh M. Parikh, M.D.
 Carlos N. Pato, M.D.
 Roger Peele, M.D.
 Dixianne Penney, Ph.D.
 Carol B. Perez, M.D.
 Jon Perez, Ph.D.
 Oscar E. Perez, M.D.
 Margaret A. Pericak-Vance, Ph.D.
 Julia L. Perilla, Ph.D.
 Christian D. Perring, Ph.D.
 Bernice A. Pescosolido, Ph.D.
 John R. Peteet, M.D.
 Timothy J. Petersen, Ph.D.
 Nancy M. Petry, Ph.D.
 Herbert S. Peyser, M.D.
 Steven E. Pflanz, M.D.
 Bruce M. Pfohl, M.D.
 Jo C. Phelan, Ph.D.
 Edmond H.T. Pi, M.D.
 Pier V. Piazza, Ph.D.
 Ronald W. Pies, M.D.
 William Pirl, M.D.
 Mary Pittman, M.S.
 Gloria Pitts, D.O.
 Eric M. Plakun, M.D.
 Richard R. Pleak, M.D.
 Jonathan Pollock, Ph.D.
 Svetlana Polubinskaya, Ph.D.
 Michael K. Popkin, M.D.
 Jerrold M. Post, M.D.
 Claire L. Pouncey, M.D.
 June A. Powell, M.D.
 Seth M. Powsner, M.D.
 Mary Anne Pressman, M.D.
 Maurice Preter, M.D.
 Marilyn Price, M.D.
 Trevor R.P. Price, M.D.
 Christina M. Puchalski, M.D.
 Manisha R. Punwani, M.D.
 Gonzalo F. Quesada, M.D.
 Gary M. Quinn, M.D.
 Gregory Quirk, Ph.D.
 Charles J. Rainey, M.D.
 Y. Pritham Raj, M.D.
 Armit D. Rajparia, M.D.
 Dilip Ramchandani, M.D.
 J. Russell Ramsay, Ph.D.
 Aruna S. Rao, M.D.
 Nyapati Rao, M.D.
 Beverley Raphael, M.D.
 Lawrence Ratna, M.D.
 Guiseppe Raviola, M.D.
 Paula Ravitz, M.D.
 Maryam Razavi, M.D.
 Gerald Reaven, M.D.
 Patricia R. Recupero, M.D.
 Darrel A. Regier, M.D.
 James H. Reich, M.D.
 Walter J. Reich, M.D.
 Burton V. Reifler, M.D.
 David Reiss, M.D.
 John Renner, M.D.
 Cynthia I. Resendez, M.D.
 Phillip J. Resnick, M.D.
 Wenda Restall, L.C.S.W.
 Victor I. Reus, M.D.
 Raymond M. Reyes, M.D.
 Carson Reynolds, M.S.
 Elliott Richelson, M.D.
 Judith A. Richman, Ph.D.
 Ronald O. Rieder, M.D.
 Marie-Claude Rigaud, M.D.
 Eva C. Ritvo, M.D.
 Maribel Rivera, M.D.
 David C.S. Roberts, Ph.D.
 Jennifer Roberts, Ph.D.
 Laura W. Roberts, M.D.
 Carolyn B. Robinowitz, M.D.
 Gail E. Robinson, M.D.
 Mia J. Robinson, M.D.
 Catherine A. Roca, M.D.
 Phillip Rodgers, Ph.D.
 Kenneth M. Rogers, M.D.
 Kelly J. Rohan, Ph.D.
 John S. Rolland, M.D.
 Vernon A. Rosario, M.D.
 Mark L. Rosenberg, M.D.
 Stanley Rosenberg, Ph.D.
 Robert A. Rosenheck, M.D.
 Erik Roskes, M.D.
 Andrew J. Roth, M.D.
 Loren H. Roth, M.D.
 Barbara Rothbaum, Ph.D.
 Eugenio M. Rothe, M.D.
 Albert Rothenberg, M.D.
 David Rothstein, M.D.
 Raphael A. Rovere, M.D.
 A. Kenison Roy III, M.D.
 Maritza Rubio-Stipec, Sc.D.
 Pedro Ruiz, M.D.
 Katherine G. Ruiz-Mellot, M.D.
 Gerald F.M. Russell, M.D.
 Bret R. Rutherford, M.D.
 Abe M. Rychik, J.D.
 Gregory B. Saathoff, M.D.
 David A. Sack, M.D.
 John Sadler, M.D.
 Sy Ateaz Saeed, M.D.
 Laura T. Safar, M.D.
 Marc A. Safran, M.D.
 Steven A. Safren, Ph.D.

Tewfik Said, M.D.
 Roger Z. Samuel, M.D.
 Francis M. Sanchez, M.D.
 Neil B. Sandson, M.D.
 Charles A. Sanislow, Ph.D.
 Norman Sartorius, M.D.
 Usha G. Satish, Ph.D.
 Ramotse Saunders, M.D.
 Daniel M. Savin, M.D.
 Pedro Saz, M.D.
 Murray D. Schane, M.D.
 Michael S. Scheeringa, M.D.
 Stephen C. Scheiber, M.D.
 Neil E. Scheurich, M.D.
 Richard Schifter
 Barbara K. Schindler, M.D.
 Chester W. Schmidt, Jr., M.D.
 Paul Schnur, Ph.D.
 Gary R. Schoener, Psy.D.
 Frank B. Schoenfeld, M.D.
 Robert A. Schoevers, M.D.
 James Q. Schubmehl, M.D.
 Robert T. Schultz, Ph.D.
 Susan K. Schultz, M.D.
 Bruce J. Schwartz, M.D.
 Ilene Schwartz, Ph.D.
 Richard S. Schwartz, M.D.
 Andres Sciolla, M.D.
 Marcia A. Scott, M.D.
 William C. Scott, B.S.W.
 James H. Scully, Jr., M.D.
 Soraya Seedat, M.D.
 Beth J. Seelig, M.D.
 Gerald Segal, MS.
 Atsuo Sekiyama, Ph.D.
 Michael Selditch
 Roni L. Seltzberg, M.D.
 Tom Sensky, M.B.
 Lydia Sermons-Ward
 Arieh Y. Shalev, M.D.
 David Shannahoff-Khalsa, B.A.
 Edward R. Shapiro, M.D.
 Steven S. Sharfstein, M.D.
 Jon A. Shaw, M.D.
 Stacy Shaw-Welch, Ph.D.
 M. Tracie Shea, Ph.D.
 Eyal Shemesh, M.D.
 Cathy Sherbourne, Ph.D.
 Naotaka Shinfuku, M.D.
 Ellen Harris Sholevar, M.D.
 G. Pirooz Sholevar, M.D.
 James H. Shore, M.D.
 Aditi M. Shrikhande, M.D.
 Daniel W. Shuman, J.D.
 David Shurtleff, Ph.D.
 Glenn N. Siegel, M.D.
 Frederick S. Sierles, M.D.
 Edward K. Silberman, M.D.
 David A. Silbersweig, M.D.
 Kenneth Silk, M.D.
 Roxane C. Silver, Ph.D.
 Stuart B. Silver, M.D.
 Joel J. Silverman, M.D.
 Morton M. Silverman, M.D.
 Neil Silverman, M.D.
 Erin Silvertooth, M.D.
 Asher B. Simon, M.D.
 Robert I. Simon, M.D.
 Sherri M. Simpson, M.D.
 Kenneth Singer, M.S.W.
 Gail Singletary, R.N.
 E. Yusuf Sivrioglu, M.D.
 Pamela Sklar, M.D.
 Andrew E. Skodol II, M.D.
 Marcia J. Slattery, M.D.
 Samuel Slipp, M.D.
 Susan E. Smiley, B.S.
 Elton Smith, M.D.
 Kevin L. Smith, M.D.
 Mary Kay Smith, M.D.
 Richard Smith, M.D.
 Jordan W. Smoller, M.D.
 Roman R. Snihurowych, M.D.
 Brenda C. Solomon, M.D.
 Stephen M. Soltys, M.D.
 Renee M. Sorrentino, M.D.
 Rosalind A. Spells, M.D.
 David M. Spiegel, M.D.
 Deborah Spitz, M.D.
 Henry I. Spitz, M.D.
 Robert L. Spitzer, M.D.
 Jacques St. Laurent, M.D.
 Harvey Stabinsky, M.D.
 Susan Stabinsky, M.D.
 Matthew S. Stanford, Ph.D.
 Shay B. Stanford, M.D.
 Joy E. Stankowski, M.D.
 Barbara H. Stanley, Ph.D.
 Brett Steenbarger, Ph.D.
 Jeanne L. Steiner, D.O.
 Joanna E. Steinglass, M.D.
 Harriet C. Stern, M.D.
 Michael P. Stern, M.D.
 Emily Stevens, Ph.D.
 S. Evelyn Stewart, M.D.
 Robert Stickgold, Ph.D.
 James L. Stinnett, M.D.
 David Stoff, Ph.D.
 Andrea G. Stolar, M.D.
 Kenneth Stoller, M.D.
 Michael H. Stone, M.D.
 Chris Stout, Psy.D.
 Norman L. Straker, M.D.
 Jon M. Streltzer, M.D.
 Margaret L. Stuber, M.D.
 Craig A. Stuck, M.D.
 Rima Strya, M.D.
 Howard S. Sudak, M.D.
 Steve Sugden, M.D.
 Ann Marie T. Sullivan, M.D.
 Carl R. Sullivan, M.D.
 Craig B. Surman, M.D.
 Ezra S. Susser, M.D.
 Jeffrey W. Swanson, Ph.D.
 Susan E. Swedo, M.D.
 Eva M. Szigethy, M.D.
 Zebulon Taintor, M.D.
 John A. Talbott, M.D.
 Mary Tantillo, Ph.D.
 Allan Tasman, M.D.
 Cathy Tasman
 Ludger Tebartz Van Elst, M.D.
 Brenda Temblador, Ph.D.
 Bryce Templeton, M.D.
 Roelof J.A. Ten Doesschate, M.D.
 Stephen M. Thielke, M.D.
 Samuel B. Thielman, M.D.
 Ole Thienhaus, M.D.
 Jean M. Thomas, M.D.
 Prakash K. Thomas, M.D.
 Leonti H. Thompson, M.D.
 Steven L. Thornton, M.D.
 Jane G. Tillman, Ph.D.
 Kay Titchenal
 Trish Tivnan
 Marie B. Tobin, M.D.
 Hendry Ton, M.D.
 Lowell D. Tong, M.D.
 Bryan K. Touchet, M.D.
 Elizabeth O. Trawick, M.D.
 Glenn J. Treisman, M.D.
 Nhi-Ha T. Trinh, M.D.
 Anton C. Trinidad, M.D.
 Benedict I. Truman, M.D.
 Guochuan Tsai, M.D.
 Werner Tschan, M.D.
 Lawrence V. Tucker, M.D.
 Pamela G. Tucker, M.D.
 William M. Tucker, M.D.
 Willem C. Tuinebreijer
 Farris Tuma, Sc.D.
 Atilla Turgay, M.D.
 Ann R. Turkel, M.D.
 Susan B. Turkel, M.D.
 Douglas Turkington, M.D.
 Hillarie Turner
 Carolyn L. Turvey, Ph.D.
 John C. Urbaitis, M.D.
 Bedirhan T. Ustun, M.D.
 Viola Vaccarino, M.D.
 Per Vaglum, M.D.
 Ronald O. Valdiserri, M.D.
 Henricus L. Van, M.D.
 Gerda van Aalst, M.D.
 Fredric J. Van Rheenen, M.D.
 Sudeepa Varma, M.D.
 Meera Vaswani, Ph.D.
 Susan C. Vaughan, M.D.
 Juha M. Veijola, Ph.D.
 Vytas P. Velyvis, M.A.
 Roel Verheul, Ph.D.
 Eric Vermetten, M.D.
 Milton Viederman, M.D.
 Rendueles Villalba, M.D.
 Roberto Villarreal, M.D.
 Ramaswamy Viswanathan, M.D.
 Benedetto Vitiello, M.D.
 Suzanne E. Vogel-Scibilia, M.D.
 Elena Volfson, M.D.
 Edward A. Volkman, M.D.
 Nora D. Volkow, M.D.
 Serena Yuan Volpp, M.D.
 Ann Wagner, Ph.D.
 Carl M. Wahlstrom, Jr., M.D.
 Khakasa H. Wapenyi, M.D.
 Stephen Warren, Ph.D.
 Carole L. Warshaw, M.D.
 Frank W. Weathers, Ph.D.
 Carmen T. Webb, M.D.
 Priyanthy Weerasekera, M.D.
 Thomas A. Wehr, M.D.
 Pamela A. Weinberg, M.D.
 Stevan M. Weine, M.D.
 Elyse D. Weiner, M.D.
 Henry C. Weinstein, M.D.
 Daniel Weintraub, M.D.
 Jeffrey Weiss, Ph.D.
 Myrna M. Weissman, Ph.D.
 Eric Weitzner, M.D.
 Jonathan L. Weker, M.D.
 Christopher J. Welsh, M.D.
 Theodore E. Weltzin, M.D.
 Drew Westen, Ph.D.
 Cornelia M. Weyand, M.D.
 Susan Wheeler
 Patti Obrow White
 Thomas A. Widiger, Ph.D.
 Joshua E. Wilk, Ph.D.
 Jeffery Wilkins, M.D.
 Adedapo B. Williams, M.D.
 Caroline B. Williams, M.D.
 Eric R. Williams, M.D.
 Richard Williams, M.D.
 David J. Williamson
 Janice Wilson, M.D.
 James T. Winslow, Ph.D.
 Michael E. Wise, M.R.C.
 Robert A. Wise, M.D.
 Thomas N. Wise, M.D.
 Nicole Wolfe, M.D.
 Adam Wolkin, M.D.
 William M. Womack, M.D.
 Stephen B. Woolley, M.P.H.
 Linda L.M. Worley, M.D.
 Harry H. Wright, M.D.
 Jay Wung, M.D.
 John D. Wynn, M.D.
 Mitsuhiro Yamada, M.D.
 Alayne Yates, M.D.
 Frank E. Yeomans, M.D.
 Albert Yeung, M.D.
 Patrick Ying, M.D.
 Keith W. Young, M.D.
 Van Yu, M.D.
 Rose Yu-Chin, M.D.
 Stuart C. Yudofsky, M.D.
 Theresa A. Yuschok, M.D.
 Peter Zachar, Ph.D.
 Robert Zachariae, M.D.
 Douglas F. Zatzick, M.D.
 John S. Zil, M.D.
 Mark Zimmerman, M.D.
 Fran Zito, L.C.S.W.
 Beata A. Zolovska
 Howard V. Zonana, M.D.
 Marion Zucker-Goldstein, M.D.
 Allan Zuckoff, Ph.D.

This page intentionally left blank

SATURDAY, MAY 21, 2005

158TH ANNUAL MEETING

8:00 a.m. Sessions



COURSES 1-3

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

COURSE 1 8:00 a.m.-12 noon
Room B301, Level 3, Georgia World Congress Center

DSM-IV-TR CULTURAL FORMULATIONS: DIAGNOSIS AND THERAPY

Director: Russell F. Lim, M.D.
Faculty: Frank N. Brown, M.D., David C. Henderson, M.D., Renato D. Alarcon, M.D., Francis G. Lu, M.D., J. Charles Ndlela, M.D.

COURSE 2 8:00 a.m.-12 noon
Room B308, Level 3, Georgia World Congress Center

THE EVALUATION AND IDENTIFICATION OF THE MAJOR DEMENTIAS

Director: Raymond A. Faber, M.D.
Faculty: Kevin F. Gray, M.D., Randolph B. Schiffer, M.D.

COURSE 3 8:00 a.m.-12 noon
Room B314, Level 3, Georgia World Congress Center

ADD IN CHILDREN AND ADOLESCENTS

Director: Thomas E. Brown, Ph.D.
Faculty: Jefferson B. Prince, M.D.

9:00 a.m. Sessions



COURSES 4-7

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

COURSE 4 9:00 a.m.-4:00 p.m.
Room B304, Level 3, Georgia World Congress Center

ESSENTIALS OF GERIATRIC PSYCHIATRY

Director: Joel Streim, M.D.

COURSE 5 9:00 a.m.-4:00 p.m.
Room B310, Level 3, Georgia World Congress Center

TRANSPERSONAL PSYCHIATRY: CLINICAL APPLICATIONS

Co-Directors: John F. Hiatt, M.D., William W. Foote, M.D.

COURSE 6 9:00 a.m.-4:00 p.m.
Room B311, Level 3, Georgia World Congress Center

THERAPEUTIC INTERVENTIONS IN EATING DISORDERS: BASIC PRINCIPLES

Director: David C. Jimerson, M.D.
Faculty: Michael Devin, M.D., Katherine A. Halmi, M.D., James E. Mitchell, M.D., Joel Yager, M.D.

COURSE 7 9:00 a.m.-4:00 p.m.
Room B316, Level 3, Georgia World Congress Center

UPDATES IN NEUROPSYCHIATRY: DELIRIUM, TRAUMATIC BRAIN INJURY, AND POST-STROKE AND POST-MI DEPRESSION

Director: Jose R. Maldonado, M.D.

12:30 p.m. Sessions

INDUSTRY-SUPPORTED SYMPOSIA 1-3

INDUSTRY-SUPPORTED SYMPOSIUM 1
12:30 p.m.-3:30 p.m.
Grand Ballroom, Second Floor, Hilton Atlanta

ANXIETY: DIVERSE POPULATIONS AND PRESENTATIONS, UNIQUE INDIVIDUALS AND TREATMENTS

Supported by UCB Pharma, Inc.

Chp.: Naomi M. Simon, M.D.

- A Untangling the Role of Gender: The Course and Treatment of Anxiety Disorders in Women
Naomi M. Simon, M.D.
- B Evaluation and Treatment of Anxiety in Patients With Comorbid Mental Illness
Peter P. Roy-Byrne, M.D.
- C Improving the Treatment of Anxiety, One Individual at a Time
Jerrold F. Rosenbaum, M.D.

(Continued on next page)

- D **Bridging Cultures and Languages: Modifying Therapy for Refugees With PTSD**
Michael W. Otto, Ph.D.
- E **Anxiety and Substance Abuse: Complexities and Solutions**
Kathleen T. Brady, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 2

12:30 p.m.-3:30 p.m.

Marquis Ballrooms III & IV, Convention Level, Marriott Marquis Atlanta

THE IMPACT OF DEPRESSION AND ANXIETY ON WELL-BEING ACROSS THE LIFE CYCLE

Supported by Pfizer Inc

Chp.: Steven P. Roose, M.D.

- A **Comorbid Depression and Anxiety: When to Start and Continue With Psychotherapy and Pharmacotherapy**
Martin B. Keller, M.D.
- B **Comorbid Depression and Anxiety in Youth With Asthma**
Marcia J. Slattery, M.D.
- C **Depression and Anxiety in Elderly Patients With Dementia**
Davangere P. Devanand, M.D., Gregory H. Pelton, M.D.
- D **Depression and Anxiety as They Relate to Cardiovascular Illness**
K. Ranga R. Krishnan, M.D.
- E **Impact of Depression and Anxiety in Women of Reproductive Age**
Ruta M. Nonacs, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 3

12:30 p.m.-3:30 p.m.

Grand Ballroom, North Tower, Grand Ballroom Level, Omni Hotel

MANAGEMENT OF DISRUPTIVE BEHAVIORAL AND PERSISTENT DEVELOPMENTAL DISORDERS

Supported by Janssen Pharmaceutica and Research Foundation

Chp.: Christopher J. McDougle, M.D.

- A **The Unmet Treatment Needs of Youth With Severe Behavioral Problems**
David J. Posey, M.D., Kimberly A. Stigler, M.D., Christopher J. McDougle, M.D.
- B **Pharmacological Management of Aggression in Disruptive Behavioral Disorders**
Robert L. Findling, M.D.

- C **Pharmacotherapy of Behavioral Symptoms in Pervasive Developmental Disorders**
Christopher J. McDougle, M.D., David J. Posey, M.D., Kimberly A. Stigler, M.D.
- D **Nonpharmacologic Approaches to the Management of Behavioral Symptoms**
Elizabeth Pappadopulos, Ph.D.

1:00 p.m. Sessions



COURSES 8-12

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

COURSE 8 1:00 p.m.-5:00 p.m.
Room B301, Level 3, Georgia World Congress Center

INFANTICIDE: A DIALOGUE BETWEEN ATTORNEY AND PSYCHIATRIST

Director: Margaret G. Spinelli, M.D.

Faculty: Katherine L. Wisner, M.D., Deborah Denno, J.D.

COURSE 9 1:00 p.m.-5:00 p.m.
Room B305, Level 3, Georgia World Congress Center

PSYCHIATRIC INTERVENTIONS IN DISASTERS AND PUBLIC HEALTH EMERGENCIES: THEORY TO PRACTICE

APA Committee on Psychiatric Dimensions of Disasters

Director: Anthony T. Ng, M.D.

Faculty: Molly J. Hall, M.D., Judith A. Cohen, M.D., Phebe M. Tucker, M.D.

COURSE 10 1:00 p.m.-5:00 p.m.
Room B306, Level 3, Georgia World Congress Center

STREET DRUGS AND MENTAL DISORDERS: OVERVIEW AND TREATMENT

Director: John W. Tsuang, M.D.

Faculty: Timothy W. Fong, M.D., Karen A. Miotto, M.D.

COURSE 11 1:00 p.m.-5:00 p.m.
Room B308, Level 3, Georgia World Congress Center

MELATONIN AND LIGHT TREATMENT OF SAD, SLEEP, AND OTHER BODY CLOCK DISORDERS

Director: Alfred J. Lewy, M.D.

COURSE 12 1:00 p.m.-5:00 p.m.

Room B315, Level 3, Georgia World Congress Center

DOING RESEARCH ON A SHOESTRING BUDGET

Director: Mantosh J. Dewan, M.D.

Faculty: Michele T. Pato, M.D., Edward K. Silberman, M.D.

6:00 p.m. Sessions

INDUSTRY-SUPPORTED SYMPOSIA 4-10

INDUSTRY-SUPPORTED SYMPOSIUM 4

6:00 p.m.-9:00 p.m.

Grand Ballroom, Second Floor, Hilton Atlanta

PSYCHOSOMATIC ILLNESS: A 21ST-CENTURY PERSPECTIVE

Supported by GlaxoSmithKline

Chp.: Murray B. Stein, M.D.

Co-Chp.: Prakash S. Masand, M.D.

- A Impact of Anxiety and Mood Disorders on Physical Disease: The Worried Not-So-Well
Murray B. Stein, M.D.
- B Facilitating Treatment for Anxious Patients With Comorbid Medical Illness
Peter P. Roy-Byrne, M.D.
- C Chronic Pain Syndromes: A Psychiatric Perspective
Prakash S. Masand, M.D.
- D Interface of Women's Mental and Reproductive Health
Hadine Joffe, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 5

6:00 p.m.-9:00 p.m.

Imperial Ballroom, Convention Level, Marriott Marquis Atlanta

THE DEVELOPMENTAL TRAJECTORY OF IMPULSIVITY

Supported by Ortho-McNeil Pharmaceuticals

Chp.: Eric Hollander, M.D.

- A Comorbidities of Impulse Control Disorders Across the Lifespan
Eric Hollander, M.D.
- B The Relationship of Trauma and Impulsivity in Posttraumatic Stress Disorder
Lori L. Davis, M.D.

C Adolescent Substance Abuse and Impulse Dyscontrol
Deborah Deas, M.D.

D Bipolar Disorder From Adolescence to Adulthood
Melissa P. DelBello, M.D.

E Potential Treatment for Impulsivity: Drive Versus Brake
Larry J. Siever, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 6

6:00 p.m.-9:00 p.m.

Marquis Ballrooms I & II, Convention Level, Marriott Marquis Atlanta

INTEGRATING NEUROBIOLOGY AND PSYCHOPATHOLOGY INTO EVIDENCE-BASED TREATMENT OF SOCIAL ANXIETY DISORDER

Supported by Forest Laboratories, Inc.

Chp.: Michael R. Liebowitz, M.D.

- A Social Anxiety Disorder: Epidemiology, Diagnosis, and Comorbidities
Michael R. Liebowitz, M.D.
- B Recent Advances in the Cognitive Neurosciences of Social Behavior
Philip T. Ninan, M.D.
- C Neurobiological Mechanisms of Social Anxiety Disorder
Franklin R. Schneier, M.D.
- D Evidence-Based Pharmacotherapy of Social Anxiety Disorder
Carlos Blanco-Jerez, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 7

6:00 p.m.-9:00 p.m.

Marquis Ballrooms III & IV, Convention Level, Marriott Marquis Atlanta

BIPOLAR DISORDER: PSYCHIATRIC AND MEDICAL IMPLICATIONS FOR OPTIMAL PATIENT MANAGEMENT

Supported by Pfizer Inc.

Chp.: Paul E. Keck, Jr., M.D.

- A Psychiatric Comorbidity in Bipolar Disorder
Susan L. McElroy, M.D.
- B Treatment and Monitoring Guidelines for the Patient With Bipolar Disorder
Trisha Suppes, M.D.

(Continued next page)

C **Bipolar Disorder Complicated by Medical Comorbidity**
Roy H. Perlis, M.D.

D **Management of the Complicated Bipolar Patient**
Paul E. Keck, Jr., M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 8

6:00 p.m.-9:00 p.m.

International Ballroom, North Tower, Ballroom Level,
Omni Hotel

EXPANDING USES OF ATYPICAL ANTIPSYCHOTICS: ADDRESSING REAL-WORLD CHALLENGES

Supported by Bristol-Myers Squibb Company and Otsuka America Pharmaceutical, Inc.

Chp.: Karen D. Wagner, M.D.

A **Differential Pharmacology of Antipsychotic Agents: Clinical Implications**
Jeffrey A. Lieberman, M.D.

B **Use of Atypical Antipsychotic Medications in Children**
Karen D. Wagner, M.D.

C **Comparative Effectiveness of Antipsychotic Medications for Optimizing the Management of Psychosis in Geriatric Patients**
David L. Sultzer, M.D.

D **Managing Psychosis in the Acute Care Setting**
John E. Kraus, Jr., M.D.

E **Improving Neurocognition With Atypical Antipsychotics**
Richard S.E. Keefe, Ph.D.

INDUSTRY-SUPPORTED SYMPOSIUM 9

6:00 p.m.-9:00 p.m.

Grand Ballroom, North Tower, Grand Ballroom Level,
Omni Hotel

ACHIEVING REMISSION IN DEPRESSION: IS THE BAR SET TOO HIGH OR TOO LOW?

Supported by Cephalon, Inc.

Chp.: Jonathan E. Alpert, M.D.

A **Remission in Depression: Definition and Treatment Approaches**
Joshua A. Israel, M.D.

B **Augmentation and Combination Strategies in Partial and Nonresponders to Antidepressants**
Charles DeBattista, M.D.

C **The Role of Psychotherapy to Enhance the Efficacy of Antidepressants**
Timothy J. Petersen, Ph.D.

D **Pharmacological Approaches to the Treatment of Residual Symptoms**
Maurizio Fava, M.D.

E **Neurotherapeutics in Resistant Depression**
Linda L. Carpenter, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 10

6:00 p.m.-9:00 p.m.

Peachtree Ballroom, Level 8, Westin Peachtree Plaza

DEALING WITH DEPRESSION: THE ADDED BURDEN TO MEDICAL PATIENTS

Supported by Eli Lilly and Company

Chp.: Madhukar H. Trivedi, M.D.

A **General Medical Comorbidities Associated With Depression**
Wayne J. Katon, M.D.

B **The Impact of Psychosomatic Symptoms on Depression and Its Treatment**
David A. Fishbain, M.D.

C **Strategies and Tactics of Treatment for Complicated Depression: An Algorithmic Approach**
Madhukar H. Trivedi, M.D.

D **The Role of Psychotherapy in the Treatment of Complicated Depression**
Ellen Frank, Ph.D.

E **Maintaining Remission in Depression**
James M. Martinez, M.D.

8:00 a.m. Sessions



COURSES 13-19

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

COURSE 13 8:00 a.m.-12 noon
Room B301, Level 3, Georgia World Congress Center

SHORT-TERM PSYCHODYNAMIC SUPPORTIVE PSYCHOTHERAPY TREATMENT OF DEPRESSION

Co-Directors: Simone Kool, M.D., Jack J. Dekker, Ph.D.
Faculty: Robert A. Schoevers, M.D., Mariëlle Hendriksen, M.A., Gerda van Aalst, M.D., Henricus L. Van, M.D.

COURSE 14 8:00 a.m.-12 noon
Room B306, Level 3, Georgia World Congress Center

USING BOUNDARY CROSSINGS AS CREATIVE THERAPY INSTEAD OF SLIPPERY SLOPES

Director: Gail E. Robinson, M.D.
Faculty: Gary R. Schoener, Psy.D., Howard E. Book, M.D., Linda M. Jorgenson, J.D.

COURSE 15 8:00 a.m.-12 noon
Room B308, Level 3, Georgia World Congress Center

RISK ASSESSMENT FOR VIOLENCE

Director: Phillip J. Resnick, M.D.

COURSE 16 8:00 a.m.-12 noon
Room B310, Level 3, Georgia World Congress Center

BEHAVIORAL NEUROANATOMY: AN INTRODUCTION

Director: Nashaat N. Boutros, M.D.
Faculty: Edward C. Lauterbach, M.D., David L. Clark, Ph.D.

COURSE 17 8:00 a.m.-12 noon
Room B311, Level 3, Georgia World Congress Center

INTERPERSONAL PSYCHOTHERAPY

Director: John C. Markowitz, M.D.

COURSE 18 8:00 a.m.-12 noon
Room B314, Level 3, Georgia World Congress Center

ADD IN ADULTS

Director: Thomas E. Brown, Ph.D.
Faculty: Jefferson B. Prince, M.D.

COURSE 19 8:00 a.m.-12 noon
Room B315, Level 3, Georgia World Congress Center

PERSONALITY DISORDERS: COMBINING RELATIONAL THERAPY AND PSYCHOPHARMACOLOGY

Director: Roy O. Resnikoff, M.D.

INDUSTRY-SUPPORTED SYMPOSIA 11-17

INDUSTRY-SUPPORTED SYMPOSIUM 11
8:00 a.m.-11:00 a.m.
Grand Ballroom, Second Floor, Hilton Atlanta

SYSTEMATIC TREATMENT OF BIPOLAR DISORDER: BRINGING EVIDENCE INTO PRACTICE

Supported by GlaxoSmithKline

Chp.: Gary S. Sachs, M.D.

- A Approach to Treatment: Integration of Measurement and Management**
Andrew A. Nierenberg, M.D.
- B View of the Illness: Course and Comorbidity Findings**
Claudia F. Baldassano, M.D.
- C What Is the Best Treatment for Manic and Mixed Episodes?**
Gary S. Sachs, M.D.
- D What Is the Best Treatment for Bipolar Depression?**
Michael J. Ostacher, M.D.
- E What Is the Best Treatment for Rapid Cycling?**
Christopher D. Schneck, M.D.
- F Managing Comorbidity**
Michael J. Ostacher, M.D.
- G Psychosocial Interventions**
David J. Miklowitz, Ph.D.
- H Multiphase Suicide Prevention Strategies in Bipolar Disorder**
Ellen B. Denney, Ph.D.

INDUSTRY-SUPPORTED SYMPOSIUM 12

8:00 a.m.-11:00 a.m.

Imperial Ballroom, Convention Level, Marriott Marquis Atlanta

TOO LITTLE, TOO MUCH: WHAT IS DISORDERED EATING?

Supported by Ortho-McNeil Pharmaceuticals

Chp.: Joel Yager, M.D.

- A **Medical Morbidity of Eating Disorders**
Laurel Mayer, M.D.
- B **Genetic Epidemiology of Eating Disorders**
James I. Hudson, M.D.
- C **Psychiatric Comorbidity of Eating Disorders: Understanding the Contribution of Impulsivity**
Susan L. McElroy, M.D.
- D **Psychotherapy for Eating Disorders: When Yes, When No**
Cynthia M. Bulik, Ph.D.
- E **Pharmacotherapy Trends in the Eating Disorder Spectrum**
Scott J. Crow, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 13

8:00 a.m.-11:00 a.m.

Marquis Ballrooms I & II, Convention Level, Marriott Marquis Atlanta

SPOTLIGHT ON THE UNIQUENESS OF DEPRESSION AND ANXIETY IN THE ELDERLY

Supported by Forest Laboratories, Inc.

Chp.: M. Katherine Shear, M.D.

- A **Late-Onset Depression: A Distinctive Disease Associated With the Elderly**
Steven P. Roose, M.D.
- B **Recognizing Depressive Disorders Comorbid With Medical Illnesses in the Elderly**
Eric J. Lenze, M.D.
- C **Bereavement-Related Depression and Anxiety**
M. Katherine Shear, M.D.
- D **Antidepressants and Anxiolytics in the Elderly: A Focus on Safety**
George S. Alexopoulos, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 14

8:00 a.m.-11:00 a.m.

Marquis Ballrooms III & IV, Convention Level, Marriott Marquis Atlanta

BRAIN STIMULATION: NEW TREATMENTS FOR MOOD DISORDERS

Supported by Cyberonics, Inc.

Chp.: A. John Rush, M.D.

- A **Optimization of the Therapeutic Elements of ECT**
Harold A. Sackeim, Ph.D.
- B **Current Status of Repeated Transcranial Magnetic Stimulation**
Mark S. George, M.D.
- C **Current Status of Magnetic Stimulation Therapy (MST)**
Sarah H. Lisanby, M.D.
- D **Current Status of Vagus Nerve Stimulation (VNS)**
Lauren B. Marangell, M.D.
- E **Current Status of Deep Brain Stimulation**
Benjamin D. Greenberg, M.D., Gerhard Frieks, M.D., David Marlone, M.D., Ali Rezai, M.D., Scott L. Rauch, M.D., Lawrence H. Price, M.D., Steven A. Rasmussen, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 15

8:00 a.m.-11:00 a.m.

International Ballroom, North Tower, Ballroom Level, Omni Hotel

PANIC DISORDER: CURRENT CONCEPTS AND FUTURE DIRECTIONS

Supported by Wyeth Pharmaceuticals

Chp.: Mark H. Pollack, M.D.

- A **Window Into the Brain: Imaging Panic Disorder and the Neurocircuitry of Fear**
Justine M. Kent, M.D.
- B **Genetics of Panic Disorder: What Have We Learned?**
Jordan W. Smoller, M.D.
- C **Cross-Cultural Aspects of Panic and Other Anxiety Disorders**
Michael R. Liebowitz, M.D., Randall D. Marshall, M.D., Roberto Lewis-Fernandez, M.D., Carlos Blanco-Jerez, M.D.
- D **Panic Symptoms and the Interface of Mind and Body**
Karleyton C. Evans, M.D.
- E **Treating Panic Disorder: Acute Therapy and Beyond**
Mark H. Pollack, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 16

8:00 a.m.-11:00 a.m.

Grand Ballroom, North Tower, Grand Ballroom Level,
Omni HotelANTIPSYCHOTIC DRUGS, MOOD STABILIZERS,
AND THE METABOLIC SYNDROME*Supported by Janssen Pharmaceutica Products*

Chp.: Herbert Y. Meltzer, M.D.

Co-Chp.: Donald C. Goff, M.D.

- A Effects of Atypical Antipsychotics on Weight, Glucose Metabolism, and Diabetes Mellitus
Daniel W. Haupt, M.D.
- B The Effect of Antipsychotic Drugs on Lipids and Other Elements of the Metabolic Syndrome
Herbert Y. Meltzer, M.D., John H. Gilliam, M.D., Tianlai Tang, M.D.
- C Insulin Resistance, Dyslipidemia, and Cardiovascular Disease
Gerald Reaven, M.D.
- D Metabolic Sequelae of Atypical Antipsychotics: Obesity and Type II Diabetes
Marilyn Ader, Ph.D.
- E A Clinician's Guide to Managing Cardiac Risk Factors
Donald C. Goff, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 17

8:00 a.m.-11:00 a.m.

Peachtree Ballroom, Level 8, Westin Peachtree Plaza

BORDERLINE PERSONALITY DISORDER:
PATHOPHYSIOLOGY, TREATMENT, AND COURSE*Supported by Eli Lilly and Company*

Chp.: Mary Zanarini, Ed.D.

- A Ten-Year Course of Borderline Personality Disorder
Mary Zanarini, Ed.D.
- B Neurobiology of Borderline Personality Disorder: An Update
Christian Schmahl, M.D.
- C Borderline Personality Disorder: Pharmacotherapy Steps Up
S. Charles Schulz, M.D., A. Adityanjee, M.D., Eric Brown, M.D.
- D Neural Circuitry Dysfunction in Borderline Personality Disorder
Antonia S. New, M.D., Marianne Goodman, M.D., Monte Buchsbaum, M.D., Erin Hazlett, Ph.D., Harold W. Koenigsberg, M.D., Janine Flory, Ph.D., Larry J. Siever, M.D.

- E Update on Dialectical Behavioral Therapy for Borderline Personality Disorder
Marsha Lineham, Ph.D.

Discussant: Larry J. Siever, M.D.

9:00 a.m. Sessions



COURSES 20-25

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

COURSE 20 9:00 a.m.-4:00 p.m.
Room B302, Level 3, Georgia World Congress Center

LIMBIC BRAIN: ANATOMIC THEORIES OF
EMOTIONAL DISTURBANCE: THE BASICS

Co-Directors: Andrew L. Lautin, M.D., Jack Davis, M.S.
Faculty: Adam Wolkin, M.D., Hamada Hamid, M.D.

COURSE 21 9:00 a.m.-4:00 p.m.
Room B303, Level 3, Georgia World Congress Center

KUNDALINI YOGA MEDITATION TECHNIQUES
FOR PSYCHIATRIC DISORDERS

Director: David Shannahoff-Khalsa, B.A.

COURSE 22 9:00 a.m.-4:00 p.m.
Room B304, Level 3, Georgia World Congress Center

REBUILDING SHATTERED LIVES: TREATING
COMPLEX POST-TRAUMATIC STRESS DISORDER

Director: James A. Chu, M.D.

COURSE 23 9:00 a.m.-4:00 p.m.
Room B305, Level 3, Georgia World Congress Center

PSYCHOTHERAPY OF BORDERLINE
PERSONALITY

Co-Directors: Otto F. Kernberg, M.D., Frank E. Yeomans, M.D.
Faculty: John F. Clarkin, Ph.D., Eve Caligor, M.D.

COURSE 24 9:00 a.m.-4:00 p.m.
Room B309, Level 3, Georgia World Congress Center

UNDERSTANDING THE PERSON BEHIND THE
ILLNESS: AN APPROACH TO PSYCHODYNAMIC
FORMULATION

Director: William H. Campbell, M.D.

COURSE 25 9:00 a.m.-4:00 p.m.

Room B316, Level 3, Georgia World Congress Center

BASIC HYPNOSIS: PRINCIPLES AND APPLICATIONS

Director: Jose R. Maldonado, M.D.

Faculty: David M. Spiegel, M.D., Matthew May, M.D.

12:30 p.m. Session

BUSINESS MEETING

(Voting Members Only*)

12:30 p.m.-1:30 p.m.

Thomas Murphy Ballroom 1-3, Level 5, Georgia World Congress Center

CALL TO ORDER

Michelle B. Riba, M.D., *President*

MEMORIAL TO DECEASED MEMBERS

ANNOUNCEMENT OF ELECTION RESULTS

Liza H. Gold, M.D., *Chairperson, Committee of Tellers*

REPORTS TO THE MEMBERSHIP

Secretary: Nada L. Stotland, M.D.*Treasurer:* Carolyn B. Robinowitz, M.D.*Speaker, Assembly:* James E. Nininger, M.D.*Speaker-Elect, Assembly:* Joseph E.V. Rubin, M.D.*Chairperson, By-Laws Committee:* Derek Puddester, M.D.*Chairperson, Elections Committee:* Yvonne B. Ferguson, M.D.*Chairperson, Membership Committee:* Mary K. Marrocco, M.D.*Medical Director:* James H. Scully, Jr., M.D.

ANNUAL FORUM

ADJOURNMENT

*Members-in-Training, General Members, Distinguished Fellows, Fellows, Life Fellows, Distinguished Life Fellows, and Life Members. Badge or APA membership card necessary for admission. No cameras or tape recorders will be permitted.

1:00 p.m. Sessions



COURSES 26-32

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

COURSE 26 1:00 p.m.-5:00 p.m.

Room B301, Level 3, Georgia World Congress Center

DREAM TRANSLATION: ONE EMPIRICALLY-BASED APPROACH

Director: Milton Kramer, M.D.

COURSE 27 1:00 p.m.-5:00 p.m.

Room B306, Level 3, Georgia World Congress Center

HOW TO GIVE A MORE EFFECTIVE LECTURE: PUNCH, PASSION, AND POLISH

Director: Phillip J. Resnick, M.D.

COURSE 28 1:00 p.m.-5:00 p.m.

Room B308, Level 3, Georgia World Congress Center

ASSESSING THE RISK OF VIOLENCE IN FORENSIC AND SEX OFFENDER SETTINGS

Director: Bradley R. Johnson, M.D.

Faculty: Judith V. Becker, Ph.D.

COURSE 29 1:00 p.m.-5:00 p.m.

Room B310, Level 3, Georgia World Congress Center

ASSESSING POSITIVE AND NEGATIVE SYMPTOMS IN PSYCHOSIS WITH THE PANSS

Co-Directors: Lewis A. Opler, M.D., Paul M. Ramirez, Ph.D.

COURSE 30 1:00 p.m.-5:00 p.m.

Room B311, Level 3, Georgia World Congress Center

PSYCHIATRIC REVOLUTIONS: A HISTORY OF PSYCHIATRY

Director: Albert Rothenberg, M.D.

Faculty: Paul R. McHugh, M.D.

COURSE 31 1:00 p.m.-5:00 p.m.

Room B314, Level 3, Georgia World Congress Center

COGNITIVE THERAPY FOR SCHIZOPHRENIA

Director: Jesse H. Wright, M.D.

Faculty: Douglas Turkington, M.D., David G. Kingdon, M.D.

COURSE 32 1:00 p.m.-5:00 p.m.

Room B315, Level 3, Georgia World Congress Center

BRIEF PSYCHODYNAMIC PSYCHOTHERAPY: THE CORE CONFLICTUAL RELATIONSHIP THEME

Director: Howard E. Book, M.D.

1:30 p.m. Sessions

INDUSTRY-SUPPORTED SYMPOSIA 18-23

INDUSTRY-SUPPORTED SYMPOSIUM 18

1:30 p.m.-4:30 p.m.

Grand Ballroom, Second Floor, Hilton Atlanta

JOINING NIGHT AND DAY: INSOMNIA AND THE SLEEP/WAKE CYCLE

Supported by Takeda Pharmaceuticals North America, Inc.

Chp.: Karl Doghramji, M.D.

- A **Insomnia: Prevalence, Impact, and Current Approaches to Evaluation and Management**
Karl Doghramji, M.D.
- B **Medical Causes of Insomnia**
Gerald A. Maguire, M.D.
- C **The Sleep/Wake Cycle and Circadian Phase in Psychiatric Disorders**
Alfred J. Lewy, M.D.
- D **Current and Emerging Treatments for Insomnia**
Milton K. Erman, M.D.
- E **Special Concerns in Aging**
Sonia Ancoli-Israel, Ph.D.

INDUSTRY-SUPPORTED SYMPOSIUM 19

1:30 p.m.-4:30 p.m.

Imperial Ballroom, Convention Level, Marriott Marquis Atlanta

CLINICAL INTERVENTIONS FOR THE TREATMENT OF INSOMNIA ASSOCIATED WITH PSYCHIATRIC AND COMORBID MEDICAL ILLNESSES

Supported by Neurocrine Biosciences, Inc. and Pfizer Inc.

Chp.: Alan F. Schatzberg, M.D.

Co-Chp.: Ned H. Kalin, M.D.

- A **Clinical Approaches to Insomnia**
David J. Kupfer, M.D.
- B **Interrelationship of Insomnia to Medical Illnesses and Neurological Disorders**
Phyllis C. Zee, M.D.
- C **Effect of Chronic Pain Syndromes on Sleep**
Raymond R. Gaeta, M.D.
- D **Gender-Specific Sleep Considerations in Women**
Hadine Joffe, M.D.
- E **New Pharmacologic Approaches for the Treatment of Insomnia**
John W. Winkelman, M.D.

Discussant: Ned F. Kalin, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 20

1:30 p.m.-4:30 p.m.

Marquis Ballrooms I & II, Convention Level, Marriott Marquis Atlanta

ALZHEIMER'S DISEASE PATHWAYS TO PRACTICE: ASSESSING DIAGNOSIS AND OUTCOME MEASURES

Supported by Forest Laboratories, Inc.

Chp.: George T. Grossberg, M.D.

- A **The Interplay of Neurotransmitters in Alzheimer's Disease**
Paul T. Francis, Ph.D.
- B **Formulating a Clinical Practice Care Plan for the Diagnosis and Assessment of Alzheimer's Disease**
Warachal E. Faison, M.D.
- C **Utilizing Advanced Imaging and Surrogate Markers Across the Spectrum of Alzheimer's Disease**
Mark A. Mintun, M.D.
- D **Rationalizing Therapeutic Approaches in Alzheimer's Disease**
George T. Grossberg, M.D.
- E **Behavioral Neuropsychiatric Outcomes in Alzheimer's Disease**
Jeffrey L. Cummings, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 21

1:30 p.m.-4:30 p.m.

International Ballroom, North Tower, Ballroom Level, Omni Hotel

ANXIETY DISORDERS: UNDERSTANDING THE INTERCONNECTION BETWEEN EMOTIONAL AND PHYSICAL SYMPTOMS

Supported by Wyeth Pharmaceuticals

Chp.: Mark H. Rapaport, M.D.

- A **Worried Sick: How Patients Experience GAD**
R. Bruce Lydiard, M.D.
- B **Addressing the Full Spectrum of Symptoms of Social Anxiety Disorder**
Nathalie Maullin, M.D.
- C **Pharmacotherapy and Psychotherapy in the Treatment of PTSD**
Barbara Rothbaum, Ph.D.
- D **Panic Disorder: The Interconnection Between Emotional and Physical Symptoms**
Mark H. Rapaport, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 22

1:30 p.m.-4:30 p.m.

Grand Ballroom, North Tower, Grand Ballroom Level,
Omni HotelRELAPSE PREVENTION IN SCHIZOPHRENIA:
DEFINING A PATH FROM PHARMACOLOGIC
INTERVENTION TO LONG-TERM FUNCTIONAL
RECOVERY*Supported by Janssen Pharmaceutica and Research Foundation*

Chp.: John M. Kane, M.D.

- A **The Neurobiology of Relapse in Schizophrenia: Implications for Disease Course and Patient Outcomes**
Robert B. Zipursky, M.D.
- B **Defining the Key Clinical Parameters That Contribute to Relapse in Schizophrenia**
Stefan M. Leucht, M.D.
- C **Can Relapse Be Prevented Through Pharmacologic Intervention?**
John M. Kane, M.D.
- D **Remission and Functional Recovery in Schizophrenia: Raising the Bar for Clinical Outcomes**
Nina R. Schooler, Ph.D.

INDUSTRY-SUPPORTED SYMPOSIUM 23

1:30 p.m.-4:30 p.m.

Peachtree Ballroom, Level 8, Westin Peachtree Plaza

FIBROMYALGIA: A DISORDER AT THE MEDICINE
AND PSYCHIATRY INTERFACE*Supported by Pfizer Inc.*

Chp.: Lesley M. Arnold, M.D.

- A **The Pathophysiological Basis of Fibromyalgia: Emerging Evidence**
Daniel J. Clauw, M.D.
- B **Management of Psychiatric Comorbidity in Patients With Fibromyalgia**
Lesley M. Arnold, M.D.
- C **Recent Developments in the Pharmacotherapy of Fibromyalgia**
Leslie J. Crofford, M.D.
- D **Nonpharmacological Treatment of Fibromyalgia**
Shay B. Stanford, M.D.

2:30 p.m. Session

LECTURE 1

2:30 p.m.-4:00 p.m.

Rooms B312/313, Level 3
Georgia World Congress CenterAAPL/APA'S MANFRED S. GUTTMACHER
AWARD LECTURE

Robert I. Simon, M.D.

Suicide Risk Assessment: Evidence-Based Psychiatry

Chp.: Michael A. Norko, M.D.

Robert I. Simon, M.D., is Clinical Professor of Psychiatry and Director of the Program in Psychiatry and Law at Georgetown University School of Medicine in Washington, D.C. He is also Adjunct Professor of Psychiatry at the F. Edward Hebert School of Medicine of the Uniformed Services University of the Health Sciences in Bethesda, Maryland, and Chairman of the Department of Psychiatry at Suburban Hospital in Bethesda. In addition, he maintains a private practice in Potomac, Maryland. Dr. Simon is President-Elect of the American Academy of Psychiatry and the Law. He has received several awards for his contributions to forensic psychiatry, including the Isaac Ray Award (2004), Golden Apple Award (1995), Seymour Pollack Award (1994), and the Manfred S. Guttmacher Award (1993). Dr. Simon is the author and editor of more than 20 books and numerous book chapters and articles in the fields of clinical and forensic psychiatry. His most recent publications include *The American Psychiatric Publishing Textbook of Forensic Psychiatry and Assessing and Managing Suicide Risk: Guidelines for Clinically Based Risk Management*. A graduate of Tufts University School of Medicine, Dr. Simon completed his residency in psychiatry at Jackson Memorial Hospital and the University of Miami, School of Medicine in Miami, Florida.

THIS SESSION WILL BE AUDIOTAPED.

5:00 p.m. Session

OFFICIAL OPENING SESSION

5:00 p.m.-6:30 p.m.

Sydney B. Marcus Auditorium, Level 4, Georgia
World Congress Center

CALL TO ORDER

Michelle B. Riba, M.D., *President*

INTRODUCTION OF STAGE GUESTS

INTRODUCTION OF CHAIRPERSON OF
THE SCIENTIFIC PROGRAM COMMITTEE

Marian I. Butterfield, M.D.

Chairperson, Annual Meeting Scientific Program Committee

INTRODUCTION OF VISITING DIGNITARIES

PRESIDENTIAL ADDRESS

Michelle B. Riba, M.D.

To be introduced by John F. Greden, M.D.

RESPONSE OF THE PRESIDENT-ELECT

Steven S. Sharfstein, M.D.

To be introduced by Lawrence Hartmann, M.D.

ADJOURNMENT

7:00 p.m. Sessions

INDUSTRY-SUPPORTED SYMPOSIA 24-30

INDUSTRY-SUPPORTED SYMPOSIUM 24

7:00 p.m.- 10:00 p.m.

Grand Ballroom, Second Floor, Hilton Atlanta

EXPLORING COGNITIVE FUNCTION: FROM BRAIN TO BEDSIDE

Supported by Cephalon, Inc.

Chp.: Philip T. Ninan, M.D.

- A **The Neurology of Cognition: A Glimpse Into the Brain**
Daniel R. Weinberger, M.D.
- B **Remission in Major Depression: The Vitality of Cognition**
Philip T. Ninan, M.D.
- C **Can Clinicians Impact Cognition in Schizophrenia?**
Rona Hu, M.D.
- D **The Complexities of Cognitive Dysfunction in Late-Life Depression**
George S. Alexopoulos, M.D.
- E **The Evidence and Relevance of Cognitive Dysfunction in ADHD**
Scott Kollins, Ph.D.

INDUSTRY-SUPPORTED SYMPOSIUM 25

7:00 p.m.- 10:00 p.m.

Imperial Ballroom, Convention Level, Marriott Marquis Atlanta

BIPOLAR DISORDER: TREATING THROUGH THE ENTIRE SPECTRUM

Supported by AstraZeneca Pharmaceuticals

Chp.: Trisha Suppes, M.D.

- A **The Neuroscience of Bipolar Disorder Across the Age Spectrum**
Kiki D. Chang, M.D.
- B **Issues in Treating Bipolar Depression**
Joseph R. Calabrese, M.D.
- C **The Acute Setting: Achieving Stabilization**
Trisha Suppes, M.D.
- D **From Acute to Maintenance Therapy**
Gary S. Sachs, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 26

7:00 p.m.- 10:00 p.m.

Marquis Ballrooms I & II, Convention Level, Marriott Marquis Atlanta

UNTANGLING DEPRESSION AND ANXIETY: A CHALLENGE FOR SCIENTISTS AND CLINICIANS

Supported by Forest Laboratories, Inc.

Chp.: Martin B. Keller, M.D.

- A **Genetic Models of Depression and Anxiety**
Rene Hen, Ph.D.
- B **Serotonergic Targets as Mediators of Anxiety**
Alexander Neumeister, M.D.
- C **Neuroanatomical Pathways Underlying Major Depression and Anxiety Disorders**
John H. Krystal, M.D.
- D **Presentation and Diagnosis of Comorbid MDD and Anxiety Disorders**
Naomi M. Simon, M.D.
- E **Making Treatment Decisions for Comorbid MDD and Anxiety Disorders**
Martin B. Keller, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 27

7:00 p.m.- 10:00 p.m.

Marquis Ballrooms III & IV, Convention Level, Marriott Marquis Atlanta

ADHD THROUGH THE LIFE CYCLE: NEW FINDINGS AND CLINICAL IMPLICATIONS

Supported by Shire US, Inc.

Chp.: Thomas J. Spencer, M.D.

- A **Adult ADHD Diagnostic and Self-Report Symptom Scales: Assessment Methodology for Diagnosing and Monitoring Treatment of Adults With ADHD**
Craig B. Surman, M.D.

(Continued on next page)

- B **Functional Impairments in Adult ADHD: Implications for Diagnosis**
Stephen V. Faraone, Ph.D., Joseph Biederman, M.D.
- C **New Research on ADHD and Substance Use Disorders**
Timothy E. Wilens, M.D.
- D **Long-Term Tolerability and Effectiveness of Once-Daily Mixed Amphetamine Salts in Children With ADHD**
Thomas J. Spencer, M.D.
- E **Long-Term Outcome of Adults Treated With Extended Release Mixed Amphetamine Salts**
Joseph Biederman, M.D., Thomas J. Spencer, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 28

7:00 p.m.-10:00 p.m.

International Ballroom, North Tower, Ballroom Level, Omni Hotel

EMERGING BEST PRACTICES IN THE MANAGEMENT OF BEHAVIORAL EMERGENCIES

Supported by Bristol-Myers Squibb Company and Otsuka Pharmaceutical, Inc.

Chp.: Peter F. Buckley, M.D.

- A **Is Agitation Inevitably a Precursor to Aggression?**
Rosalind A. Spels, M.D.
- B **Assessment of the Acutely Agitated Patient With Psychosis**
Joseph P. McEvoy, M.D.
- C **Considering Consumer Choice During the Management of Behavioral Emergencies**
Michael H. Allen, M.D.
- D **Do Atypical Antipsychotics Work Fast Enough in Behavioral Emergencies?**
Robert B. Zipursky, M.D.
- E **Acute Stabilization With Atypical Antipsychotics: New Therapeutic Options**
Peter F. Buckley, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 29

7:00 p.m.-10:00 p.m.

Grand Ballroom, North Tower, Grand Ballroom Level, Omni Hotel

BEYOND NEUROCHEMISTRY: THE IMPLICATIONS OF NEUROCIRCUITRY FOR UNDERSTANDING AND MANAGING PSYCHIATRIC DISORDERS

Supported by Eli Lilly and Company

Chp.: Paula T. Trzepacz, M.D.

Co-Chp.: Stuart C. Yudofsky, M.D.

- A **Neuroanatomy of Behavior 101**
Paula T. Trzepacz, M.D.
- B **Neurocircuitry of Schizophrenia**
David A. Lewis, M.D.
- C **Neurobiological Substrates of ADHD**
George Bush, M.D.
- D **In Search of Depression Circuits**
Helen S. Mayberg, M.D.
- E **Neural Pathways and Behavior in Anorexia Nervosa**
Walter H. Kaye, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 30

7:00 p.m.-10:00 p.m.

Peachtree Ballroom, Level 8, Westin Peachtree Plaza

FROM MOLECULAR INSIGHT TO CLINICAL OUTCOMES: RECENT ADVANCES IN SCHIZOPHRENIA TREATMENT

Supported by Pfizer Inc.

Chp.: Jeffrey A. Lieberman, M.D.

- A **How Antipsychotics Work: From Receptors to Reality**
Shitij Kapur, M.D.
- B **Clinical Effectiveness of Atypical Antipsychotic Therapy**
Thomas S. Stroup, M.D.
- C **Cognitive Effectiveness of Atypical Antipsychotic Therapy**
Philip D. Harvey, Ph.D.
- D **Enhancing Clinical Care in Schizophrenia: Primary Health Care Needs**
Gail L. Daumit, M.D.
- E **Translating Scientific Research Into Clinical Practice**
Jeffrey A. Lieberman, M.D.

7:00 a.m. Sessions

PART 1 OF INDUSTRY-SUPPORTED BREAKFAST SYMPOSIA 31-33

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 31, PART 1

7:00 a.m.-8:30 a.m.

Imperial Ballroom, Convention Level, Marriott Marquis Atlanta

AGITATION AND PSYCHOSIS IN ALZHEIMER'S DISEASE AND PARKINSON'S DISEASE

Supported by AstraZeneca Pharmaceuticals

Chp.: Jeffrey L. Cummings, M.D.

- A **Diagnosis and Assessment of Parkinson's Disease and Alzheimer's Disease**
Daniel Weintraub, M.D.
- B **Imaging and Neurobiological Underpinnings: Psychosis and Agitation**
David L. Sultzer, M.D.
- C **Treatment of Psychosis in Parkinson's Disease**
Jeffrey L. Cummings, M.D., Daniel Weintraub, M.D., Jeanne Jackson-Siegel, M.D., Pierre N. Tariot, M.D., David L. Sultzer, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 32, PART 1

7:00 a.m.-8:30 a.m.

International Ballroom, North Tower, Ballroom Level, Omni Hotel

MANAGING THE SPECTRUM OF BIPOLAR DISORDER: MINIMIZING THE BURDEN OF DISEASE

Supported by Bristol-Myers Squibb Company and Otsuka America Pharmaceutical, Inc.

Chp.: Robert E. Hales, M.D.

Co-Chp.: Stuart C. Yudofsky, M.D.

- A **Practical Approaches to the Diagnosis of Bipolar Disorders**
Claudia F. Baldassano, M.D.
- B **Optimizing Pharmacotherapy in the Treatment of Acute Mania**
Terence A. Ketter, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 33, PART 1

7:00 a.m.-8:30 a.m.

Grand Ballroom, North, Grand Ballroom Level, Omni Hotel

ADVANCES IN THE TREATMENT OF MOOD AND ANXIETY DISORDERS IN WOMEN

Supported by Wyeth Pharmaceuticals

Chp.: Susan G. Kornstein, M.D.

- A **Anxiety Disorders in Women**
Teresa A. Pigott, M.D.
- B **Antidepressant Treatment of PMS and PMDD**
Susan G. Kornstein, M.D.
- C **Perinatal Consequences of Mood and Anxiety Disorders**
Kimberly A. Yonkers, M.D.

RESIDENTS' SESSION

7:00 a.m.-8:30 a.m.

International Rooms 4/5/6, International Level, Marriott Marquis Atlanta

MEET THE EXPERTS: SUNNY-SIDE UP

Chp.: Michelle B. Riba, M.D.

Co-Chp.: Steven S. Sharfstein, M.D.

At this breakfast, nationally recognized "experts" will sit at tables with small groups of residents and discuss a variety of career issues and opportunities in psychiatry. Topic areas include: Addiction/Substance Abuse, AIDS/HIV, Child and Adolescent Psychiatry, Consultation-Liaison, Cultural Competence, Forensic, Law and Ethics in Psychiatry, Geriatric, Medical Student Issues, Public and Community Mental Health, Professional and Leadership Development, Psychodynamic Psychotherapy, and Research in Psychiatry.

8:00 a.m. Sessions



COURSES 33-41

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

COURSE 33

8:00 a.m.-12 noon

Newton Room, Second Floor, Hilton Atlanta

PSYCHIATRIC CONSULTATION IN LONG-TERM CARE

Director: George T. Grossberg, M.D.

Faculty: Judith H. W. Crossett, M.D., Abhilash K. Desai, M.D.

MONDAY

COURSE 34 8:00 a.m.-12 noon

Rockdale Room, Second Floor, Hilton Atlanta

ENGAGING RESISTANT AND DIFFICULT-TO-TREAT PATIENTS

Director: David Mee-Lee, M.D.

COURSE 35 8:00 a.m.-12 noon

Forsythe Room, Second Floor, Hilton Atlanta

CURRENT CPT CODING AND DOCUMENTATION REQUIREMENTS

Co-Directors: Chester W. Schmidt, Jr., M.D., Tracy R. Gordy, M.D.

COURSE 36 8:00 a.m.-12 noon

Paulding Room, Second Floor, Hilton Atlanta

TEACHING PSYCHIATRY? LET HOLLYWOOD HELP!

Director: Steven E. Hyler, M.D.
Faculty: Carol A. Bernstein, M.D., Michael B. First, M.D.,
Jeremy R. Butler, M.D.

COURSE 37 8:00 a.m.-12 noon

Jackson Room, Third Floor, Hilton Atlanta

DISASTER PSYCHIATRY: TERRORISM, TRAUMA, AND THINGS TO DO

Director: Joseph C. Napoli, M.D.
Faculty: Michael Blumenfield, M.D., V. Alex Kehayan, Ed.D.

COURSE 38 8:00 a.m.-12 noon

Madison Room, Third Floor, Hilton Atlanta

FAMILIES COPING WITH MEDICAL ILLNESS: AN INTEGRATIVE TREATMENT APPROACH

Director: John S. Rolland, M.D.

COURSE 39 8:00 a.m.-12 noon

Monroe/Roosevelt Room, Third Floor, Hilton Atlanta

THE PSYCHIATRIST AS EXPERT WITNESS

Director: Phillip J. Resnick, M.D.

COURSE 40 8:00 a.m.-12 noon

Cabinet/Council Rooms, Fourth Floor, Hilton Atlanta

PSYCHIATRIC GENOMICS: APPLICATIONS FOR CLINICAL PRACTICE

Director: David A. Mrazek, M.D.
Faculty: John L. Black, M.D., Brett A. Koplin, M.D.

COURSE 41 8:00 a.m.-5:00 p.m.

Grand Salon A, Second Floor, Hilton Atlanta

OFFICE-BASED BUPRENORPHINE TREATMENT OF OPIOID-DEPENDENT PATIENTS

Co-Directors: Gerardo Gonzalez, M.D., Eric C. Strain, M.D.
Faculty: Laura F. McNicholas, M.D.

9:00 a.m. Sessions

CLINICAL CASE CONFERENCE 1

9:00 a.m.-10:30 a.m.

Room A402, Level 4, Georgia World Congress Center

HOUSE CALL: TREADING ON PRIVACY IN PUBLIC PSYCHIATRY

Moderator: Jeffrey Akaka, M.D.

Presenters: Edward F. Foulks, M.D., Leslie H. Gise, M.D.,
Susan Stabinsky, M.D.

THIS SESSION IS OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

CONTINUOUS CLINICAL CASE CONFERENCE 1: PART 1

9:00 a.m.-12 noon

Room A403, Level 4, Georgia World Congress Center

CONTROL WHAT YOU CAN: SUCCESSFUL TREATMENT OF TEENAGERS IN CHRONIC PAIN

Moderator: Eva M. Szigethy, M.D.

Presenters: John Campo, M.D., David DeMaso, M.D., Eyal Shemesh, M.D.

THIS SESSION IS OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.



COURSES 42-48

Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 42 9:00 a.m.-4:00 p.m.
Cherokee Room, Second Floor, Hilton Atlanta

**A PSYCHODYNAMIC APPROACH TO TREATMENT
REFRACTORY MOOD DISORDERS**

Director: Eric M. Plakun, M.D.
Faculty: David L. Mintz, M.D., Edward R. Shapiro, M.D.

COURSE 43 9:00 a.m.-4:00 p.m.
Fulton Room, Second Floor, Hilton Atlanta

**PERSONNEL MANAGEMENT FOR CLINICIAN-
ADMINISTRATORS**

Director: Stephen M. Soltys, M.D.
Faculty: Joseph J. Parks III, M.D., Kay Titchenal

COURSE 44 9:00 a.m.-4:00 p.m.
Cobb Room, Second Floor, Hilton Atlanta

**MONEY MATTERS I: USING THEORY IN CLINICAL
PRACTICE**

Director: Cecilia M. Mikalac, M.D.

COURSE 45 9:00 a.m.-4:00 p.m.
Clayton Room, Second Floor, Hilton Atlanta

**ADVANCED HYPNOSIS: APPLICATIONS IN
PSYCHIATRY**

Director: Jose R. Maldonado, M.D.
Faculty: David M. Spiegel, M.D., Matthew May, M.D.

COURSE 46 9:00 a.m.-4:00 p.m.
Grand Salon B, Second Floor, Hilton Atlanta

**TREATING THE SELF AND INTERPERSONAL
PROBLEMS OF PERSONALITY DISORDER**

Director: John Livesley, Ph.D.

COURSE 47 9:00 a.m.-4:00 p.m.
Grand Salon D, Second Floor, Hilton Atlanta

ADVANCES IN NEUROPSYCHIATRY

Director: C. Edward Coffey, M.D.
Faculty: Mark S. George, M.D., Michael R. Trimble, M.D.

COURSE 48 9:00 a.m.-4:00 p.m.
Club/State Rooms, Fourth Floor, Hilton Atlanta

**DAVANLOO'S INTENSIVE SHORT-TERM DYNAMIC
PSYCHOTHERAPY IN CLINICAL PRACTICE**

Director: James Q. Schubmehl, M.D.
Faculty: Alan R. Beeber, M.D., Tewfik Said, M.D.

DEBATE

9:00 a.m.-10:30 a.m.
Room A404, Level 4, Georgia World Congress Center

**RESOLVED: SECOND GENERATION
ANTIPSYCHOTICS ARE UNIFORMLY SUPERIOR IN
SAFETY AND EFFICACY TO FIRST-GENERATION
ANTIPSYCHOTICS**

Moderator: Richard E. D'Alli, M.D.
Affirmative: Ira D. Glick, M.D., John M. Davis, M.D.
Negative: Rajiv Tandon, M.D., William T. Carpenter, Jr., M.D.
THIS SESSION WILL BE AUDIOTAPED.

DISCUSSION GROUPS 1-5

9:00 a.m.-10:30 a.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

- 1 **Antoinette Ambrosino-Wyszynski, M.D.**, on Medically Cleared for Transfer to Psychiatry: How to Evaluate the Medical Patient With Changed Mental Status (*Meet the Authors for Residents Only*)
International Rooms 2-3, International Level, Marriott Marquis Atlanta
- 2 **Herbert D. Kleber, M.D.**, on Prescription Drug Abuse: The Psychiatrist's Role in Recognition, Prevention, and Management
Cedar Room, South Tower, Lobby Level, Omni Hotel
- 3 **Maria A. Oquendo, M.D.**, on Suicidal Behavior in Major Mood Disorders
Collaborative Session With the National Institute of Mental Health
Chestnut Room, North Tower, Meeting Level, Omni Hotel
- 4 **Nada L. Stotland, M.D.**, on Practical Psychosomatics: Treating Women Patients
Hazelnut Room, North Tower, Meeting Level, Omni Hotel
- 5 **Jon E. Grant, M.D.**, on Pathological Gambling and Its Clinical Management (*Meet the Authors*)
Pecan Room, North Tower, Meeting Level, Omni Hotel

FOCUS LIVE SESSION 1

9:00 a.m.-10:30 a.m.

Room A405, Level 4, Georgia World Congress Center

MAJOR DEPRESSIVE DISORDER

Moderators: Deborah J. Hales, M.D., Mark H. Rapaport, M.D.

Presenter: Alan F. Schatzberg, M.D.

Expert clinicians, who served as the guest editors of the first two issues of *Focus*, will lead lively multiple-choice, question-based discussions. This session covers Major Depressive Disorder, the second session at 11:00 a.m. covers Psychosomatic Medicine, and the third session at 2:00 p.m. covers Child and Adolescent Psychiatry. Presented with multiple-choice questions, participants will test their knowledge with an interactive audience response system, which instantly presents the audience responses as a histogram on the screen. Each participant is able to take a self-assessment exam with answers and discussion led by the expert faculty.

LECTURES 2-4

LECTURE 2

9:00 a.m.-10:30 a.m.

Sydney B. Marcus Auditorium, Level 4

Georgia World Congress Center

Eric R. Kandel, M.D.

**Human Psychiatric Disorders:
Genetic Models in Mice**

*Collaborative Session With the National
Institute of Mental Health*

Chp.: Anthony J. Rothschild, M.D.

Co-Chp.: Daniel P. Dickstein, M.D.

Eric R. Kandel, M.D., is University Professor of Physiology and Psychiatry at Columbia University College of Physicians and Surgeons in New York City, Fred Kavli Professor and Director of the Kavli Institute for Brain Sciences at Columbia University, and a Senior Investigator at the Howard Hughes Medical Institute. He joined the faculty at Columbia University in 1974 as the founding director of the Center for Neurobiology and Behavior. Dr. Kandel's research has been concerned with the molecular mechanisms of memory storage in *Aplysia* and mice. Dr. Kandel received the Nobel Prize for Physiology or Medicine in 2000 and has been recognized with the Albert Lasker Award for Basic Medical Research, the Dr. A. H. Heineken Prize for Medicine from the Royal Netherlands Academy of Arts and Sciences, the Gairdner Foundation International Award for Excellence in Medical Science, the Wolf Prize in Medicine, and the United States National Medal of Science. He is a member of the U.S. National

Academy of Sciences, as well as the national science academies of Germany and France. A graduate of New York University School of Medicine, Dr. Kandel trained in neurobiology at the National Institutes of Health and in psychiatry at Harvard Medical School.
Distinguished Psychiatrist Series
THIS SESSION WILL BE AUDIOTAPED.

LECTURE 3

9:00 a.m.-10:30 a.m.

Room A411, Level 4

Georgia World Congress Center

Beverly Raphael, M.D.

**Terrorism and Disaster: Population
Mental Health Approaches**

Chp.: Carol C. Nadelson, M.D.

Co-Chp.: Harold Kudler, M.D.

Beverly Raphael, M.D. is Director of the Centre for Mental Health in North Sydney, Australia, and Emeritus Professor of Psychiatry at the University of Queensland in Brisbane. She has a long-term interest in prevention in mental health, with special reference to child and adolescent mental health, women's mental health, family issues, and issues affecting consumers in mental health care systems. She also has expertise in research and management in the areas of trauma, grief, disasters, and, more recently, the mental health consequences of responses to terrorism. She has been a leader in the development of prevention and public health approaches to mental health in Australia and is responsible for coordinating the national mental health service response to disasters and terrorism. In that role, she was involved in preparation for potential terrorism for the 2000 Sydney Olympics and in the response to the 2002 Bali bombing. Dr. Raphael is the author of numerous scientific articles and the author or editor of several books, including *Anatomy of Bereavement*; *When Disaster Strikes: How Individuals and Communities Cope With Disasters*; *The International Handbook of Traumatic Stress Syndromes*; *Handbook of Studies of Preventive Psychiatry*; and *Psychological Debriefing: Theory, Practice and Evidence*.

International Psychiatrist Lecture Series

THIS SESSION WILL BE AUDIOTAPED.

LECTURE 4

9:00 a.m.-10:30 a.m.
Room A412, Level 4
Georgia World Congress Center

APA's ADMINISTRATIVE PSYCHIATRY
AWARD LECTURE

Gabriel Koz, M.D.

Administrative Adventures in Public
Psychiatry: 1967-2005

Chp.: Beth Ann Brooks, M.D.

Gabriel Koz, M.D., is Professor of Psychiatry, NYU School of Medicine and Professor of Clinical Psychiatry, Eastern Virginia Medical School. Dr. Koz was born in Johannesburg, South Africa, on December 2, 1933, to a calm English postal worker and a wild Russian typist and homemaker. He is their middle child and only son. Although sport (rugby, cricket, and soccer) was his "religion," his academics were good enough to admit him to Witwatersrand Medical School. After completing the six-year program, two-and-a-half years of rotation half-year internships followed in medicine, surgery, pediatrics, ObGyn, and neurosurgery. Then his first love, psychiatry, returned to the fore. One year of psychiatry in England was more reified than he had expected; so he accepted a Fulbright scholarship to Harvard and Boston City Hospital with high hopes. According to Dr. Koz, the following years did not disappoint, professionally or personally. Married with three children, he began professionally with ten years at Albert Einstein College of Medicine, which included seven tumultuous years as Psychiatry Director at Lincoln Hospital in the South Bronx, (a.k.a. Fort Apache), during the Vietnam War era. After Lincoln, a search committee tapped Dr. Koz to unify three state hospitals into Manhattan Psychiatric Center. In 1982, he founded the Psychiatry Departments at Woodhull Hospital, Brooklyn, serving a multicultural population. Finally, in 1999, John Favret invited him to Williamsburg, Virginia, as the Medical Director of Eastern State Hospital--the nation's first public psychiatric institution (1773).

THIS SESSION WILL BE AUDIOTAPED.

MASTER EDUCATOR CLINICAL
CONSULTATIONS 1-2

9:00 a.m.-10:30 a.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

- 1 Kenneth Silk, M.D., on Clinical and Pharmacologic Management of BPD
Collaborative Session With the National Institute of Mental Health
Room B317, Level 3, Georgia World Congress Center

- 2 Michelle B. Riba, M.D., on Split and Integrated Treatment: Pharmacotherapy and Psychotherapy
Room B318, Level 3, Georgia World Congress Center

THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

NEW RESEARCH YOUNG INVESTIGATORS'
POSTER SESSION 1

9:00 a.m.-10:30 a.m.
Room B302/303/304/305, Level 3, Georgia World Congress Center

For further information on new Research Sessions, please refer to the *New Research Program Book* included in your registration packet.

WORKSHOPS

COMPONENTS 1-12

COMPONENT WORKSHOP 1 9:00 a.m.-10:30 a.m.
Room A410, Level 4, Georgia World Congress Center

MANAGED CARE: PAST, PRESENT, AND FUTURE
APA Committee on Managed Care

Chp.: Lawrence B. Lurie, M.D.
Participants: Kevin L. Smith, M.D., Raphael A. Rovere, M.D., Jonathan L. Weker, M.D., Jennifer R. Lee, M.D., Alan A. Axelson, M.D., David Nace, M.D.

COMPONENT WORKSHOP 2 9:00 a.m.-10:30 a.m.
Room B301, Level 3, Georgia World Congress Center

KEEPING APA PRACTICE GUIDELINES CURRENT:
ALZHEIMER'S, DELIRIUM, AND EATING
DISORDERS
APA Steering Committee on Practice Guidelines

Chp.: Jack S. McIntyre, M.D.
Participants: Ian A. Cook, M.D., Laura J. Fochtmann, M.D., Joel Yager, M.D., Peter V. Rabins, M.D.

COMPONENT WORKSHOP 3 9:00 a.m.-10:30 a.m.
Room B306, Level 3, Georgia World Congress Center

WHAT NOT TO DO: THE MEDIA TALKS BACK
ABOUT PUBLIC AFFAIRS
APA Committee on Public Affairs

Co-Chps.: Marc Graff, M.D., Lydia Sermons-Ward
Participants: Robert S. Benson, M.D., Christopher B. Peterson, M.D.

COMPONENT WORKSHOP 4 9:00 a.m.-10:30 a.m.

Room B307, Level 3, Georgia World Congress Center

PSYCHIATRIC LEADERSHIP: PUTTING OUT FIRES AND BEYOND!

APA Committee on Psychiatric Administration and Management

Chp.: Stuart B. Silver, M.D.

Participants: Christopher G. Fichtner, M.D., Sy Atezaz Saeed, M.D., Nalini Juthani, M.D.

COMPONENT WORKSHOP 5 9:00 a.m.-10:30 a.m.

Room B308, Level 3, Georgia World Congress Center

EARLY CAREER PSYCHIATRISTS AS LEADERS

APA Assembly Committee of Early Career Psychiatrists

Chp.: Adam R. Chester, D.O.

Participants: Benedicto R. Borja, M.D., Matthew W. Norman, M.D., John R. Chamberlain, M.D.

COMPONENT WORKSHOP 6 9:00 a.m.-10:30 a.m.

Room B309, Level 3, Georgia World Congress Center

CHILDREN UNDER FIRE: ENHANCING PSYCHIATRY'S GLOBAL RESPONSE

APA Corresponding Committee on Juvenile Justice Issues

Chp.: Niranjan S. Karnik, M.D.

Participants: Shanta P. Henderson, M.D., Roxanne Dryden-Edwards, M.D., Janet A. Martin, M.D., Sandra J. Kaplan, M.D.

COMPONENT WORKSHOP 7 9:00 a.m.-10:30 a.m.

Room B310, Level 3, Georgia World Congress Center

SERODISCORDANT COUPLES: ISSUES AND PSYCHODYNAMICS IN THE THIRD DECADE OF AIDS

APA New York County District Branch's AIDS Committee

Chp.: Elizabeth V. Getter, M.D.

Participants: Kenneth Ashley, M.D., Mary Ann Cohen, M.D., John A.R. Grimaldi, Jr., M.D.

COMPONENT WORKSHOP 8 9:00 a.m.-10:30 a.m.

Room B314, Level 3, Georgia World Congress Center

TEN WAYS TO STAY OUT OF TROUBLE: ETHICS AND ETIQUETTE

APA Ethics Appeal Board

Chp.: Spencer Eth, M.D.

Participants: Wade C. Myers, M.D., William Arroyo, M.D., Harriet C. Stern, M.D., Scott Y. Kim, M.D., Richard D. Milone, M.D., JoAnn Macbeth, J.D., Philip T. Merideth, M.D.

COMPONENT WORKSHOP 9 9:00 a.m.-10:30 a.m.

Birch Room, South Tower, Atrium Terrace Level, Omni Hotel

U.S. RESEARCH AND SERVICES BRIDGE WITH LATIN AMERICA

APA Council on Global Psychiatry

Co-Chps.: Rodrigo A. Munoz, M.D., Pedro Ruiz, M.D.

Participants: Jose M. Caldas de Almeida, M.D., Javier I. Escobar, M.D., Gerardo Heinze, M.D.

COMPONENT WORKSHOP 10 9:00 a.m.-10:30 a.m.

Pine Room, South Tower, Atrium Terrace Level, Omni Hotel

FUNDING FOR PSYCHIATRY: FROM THE IRRATIONAL AND RATIONAL

APA Council on Healthcare Systems and Financing

Chp.: Selby C. Jacobs, M.D.

Participants: Mantosh J. Dewan, M.D., Anita S. Everett, M.D., Edward J. Maxwell, M.D.

COMPONENT WORKSHOP 11 9:00 a.m.-10:30 a.m.

Spruce Room, South Tower, Atrium Terrace Level, Omni Hotel

SOMATIZATION AND STIGMA IN ASIANS: CULTURAL CHALLENGES IN PRACTICE

APA Committee of Asian-American Psychiatrists

Chp.: John Luo, M.D.

Participants: Mona H. Gill, M.D., Sabina Lim, M.D., Nang Du, M.D.

COMPONENT WORKSHOP 12 9:00 a.m.-10:30 a.m.

Cottonwood Room, North Tower, Street Level, Omni Hotel

BEHIND CLOSED DOORS: THE HIDDEN FAMILY: DOMESTIC VIOLENCE, CROSS-CULTURAL, AND ETHNIC INFLUENCES

APA Alliance

Co-Chps.: Carole L. Warshaw, M.D., Cathy Tasman

Participants: Julia L. Perilla, Ph.D., Surinder S. Nand, M.D.

ISSUES 1-13

ISSUE WORKSHOP 1 9:00 a.m.-10:30 a.m.

Room B311, Level 3, Georgia World Congress Center

TREATING PTSD: COMBINING PSYCHOTHERAPY AND PHARMACOTHERAPY

Co-Chps.: Lewis A. Opler, M.D., Kristina H. Muenzenmaier, M.D.

Participants: David B. Albert, Ph.D., Michaela Mendelsohn, Ph.D.

ISSUE WORKSHOP 2 9:00 a.m.-10:30 a.m.

Room B315, Level 3, Georgia World Congress Center

ORAL BOARDS BOOT CAMP UPDATED

Co-Chps.: Elyse D. Weiner, M.D., Eric D. Peselow, M.D.

ISSUE WORKSHOP 3 9:00 a.m.-10:30 a.m.

Room B316, Level 3, Georgia World Congress Center

COGNITIVE THERAPY FOR PERSONALITY DISORDERS

Chp.: Judith S. Beck, Ph.D.

ISSUE WORKSHOP 4 9:00 a.m.-10:30 a.m.

Room B401, Level 4, Georgia World Congress Center

DOCTOR, WHY DO I STILL HAVE THIS PAIN? THE PHYSICIAN'S PSYCHOSOMATIC DILEMMACo-Chps.: Don R. Lipsitt, M.D., Malkah T. Notman, M.D.
Participants: Donald Jay Meyer, M.D., Robert C. Joseph, M.D.**ISSUE WORKSHOP 5** 9:00 a.m.-10:30 a.m.

Room B402, Level 4, Georgia World Congress Center

RISK MANAGEMENT ISSUES IN PSYCHIATRIC PRACTICEChp.: Alan I. Levenson, M.D.
Participants: Ellen R. Fischbein, M.D., Martin G. Tracy, J.D.,
Jacqueline M. Melonas, J.D., Donna Vanderpool, J.D.**ISSUE WORKSHOP 6** 9:00 a.m.-10:30 a.m.

Room B403, Level 4, Georgia World Congress Center

MANAGING DISTRESS AND PSYCHIATRIC DISORDER AFTER TERRORISM*Collaborative Session With the National Institute of Mental Health*Co-Chps.: Farris Tuma, Sc.D., Anthony T. Ng, M.D.
Participants: Carol S. North, M.D., Sandro Galea, M.D.,
Matthew Friedman, M.D., Robert J. Ursano, M.D.**ISSUE WORKSHOP 7** 9:00 a.m.-10:30 a.m.

Room B404, Level 4, Georgia World Congress Center

THE PSYCHIATRIC CONSEQUENCES OF THE WORLD TRADE CENTER ATTACK IN DISASTER RELIEF WORKERS*Collaborative Session With the National Institute of Mental Health*Chp.: JoAnn Difede, Ph.D.
Participants: Jennifer Roberts, Ph.D., Pamela Leck, Ph.D.,
Margaret Altemus, M.D.**ISSUE WORKSHOP 8** 9:00 a.m.-10:30 a.m.

Room B408, Level 4, Georgia World Congress Center

MENTAL HEALTH OF PHYSICIANS: WHOSE BUSINESS IS IT?Chp.: Jeffrey L. Clothier, M.D.
Participants: Laura W. Roberts, M.D., Linda L.M. Worley, M.D.**ISSUE WORKSHOP 9** 9:00 a.m.-10:30 a.m.

Room B409, Level 4, Georgia World Congress Center

PHYSICIAN SUICIDE: WHAT CAN BE DONE?Chp.: Thomas E. Hansen, M.D.
Participants: Henry J. Grass, M.D., Carla Fine, M.S., Michael F.
Myers, M.D.**ISSUE WORKSHOP 10** 9:00 a.m.-10:30 a.m.

Oak Room, South Tower, Lobby Level, Omni Hotel

JEALOUS DELUSIONS, GUMMAS, AND EEG TRACINGSCo-Chps.: Sherri M. Simpson, M.D., James N. Flack, M.D.
Participant: Katie Coerver, M.D.**ISSUE WORKSHOP 11** 9:00 a.m.-10:30 a.m.

Dogwood B, North Tower, Street Level, Omni Hotel

PSYCHIATRISTS' INVOLVEMENT IN WORKPLACE SAFETY

Chp.: Marie-Claude Rigaud, M.D.

ISSUE WORKSHOP 12 9:00 a.m.-10:30 a.m.

Redwood Room, North Tower, Street Level, Omni Hotel

ISSUES AND CHALLENGES IN INTEGRATING INTERPERSONAL PSYCHOTHERAPY INTO PSYCHIATRY DEPARTMENTSChp.: Heather Flynn, Ph.D.
Participants: Scott Stuart, M.D., Jonathan E. Lichtmacher, M.D.**ISSUE WORKSHOP 13** 9:00 a.m.-10:30 a.m.

Juniper Room, North Tower, Ballroom Level, Omni Hotel

DIAGNOSTIC ISSUES FOR INFANCY AND EARLY CHILDHOOD: A WHITE PAPER FOR DSM-VChp.: Michael S. Scheeringa, M.D.
Participants: Joan L. Luby, M.D., Helen L. Egger, M.D.,
William E. Narrow, M.D.

MEDIA 1-3

MEDIA WORKSHOP 1 9:00 a.m.-12 noon

Room A406, Level 4, Georgia World Congress Center

Fixing Frank: The Good, the Bad, and the Ugly of Psychotherapy With Gay Men

Chp.: Petros Levounis, M.D.

Participants: Ken Hanes, Michael Selditch, Jack Drescher, M.D., Francisco J. Gonzalez-Franco, M.D.

MEDIA WORKSHOP 2 9:00 a.m.-12 noon

Room A407, Level 4, Georgia World Congress Center

Postgenocide Psychological Trauma in Film:
Forbidden Games

Co-Chps.: Maurice Preter, M.D., Harold J. Bursztajn, M.D.

Participants: Leonti H. Thompson, M.D., Beata A. Zolovska, Robindra K. Paul, M.D.

MEDIA WORKSHOP 3 9:00 a.m.-12 noon

Room A408, Level 4, Georgia World Congress Center

Super Size Me: Exploring Causes, Effects, and Solutions to Obesity in Children and Adolescents

Co-Chps.: Patricia A. Daly, M.D., Lois T. Flaherty, M.D.

10:30 a.m. Session

ADVANCES IN RESEARCH

10:30 a.m.-12:30 p.m.

Rooms B405/406/407, Level 4, Georgia World Congress Center

RESEARCH FRONTIERS: BRIDGING PSYCHIATRY AND MEDICINE

APA Scientific Program Committee and APA Council on Research

Chp.: Herbert Pardes, M.D.

Co-Chps.: Marian I. Butterfield, M.D., John F. Greden, M.D.

Participants: Alexander H. Glassman, M.D., on *Treating Depression After a Heart Attack: Influencing Death?*
Andrew H. Miller, M.D., on *Psycho-Oncology*
David J. Kupfer, M.D., on *Risk Factors*
J. Douglas Bremner, M.D., on *Applications of Brain Imaging to Psychiatry*

THIS SESSION WILL BE AUDIOTAPED.

11:00 a.m. Sessions

DISCUSSION GROUPS 6-8

11:00 a.m.-12:30 p.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

- 6 Carl C. Bell, M.D., on *Tips on How to Be an Effective Psychiatrist (For Residents Only)*
International Rooms 2-3, International Level, Marriott Marquis Atlanta
- 7 Mary Jane Massie, M.D., on *Breast Cancer: Issues in Psychotherapy*
Hazelnut Room, North Tower, Meeting Level, Omni Hotel
- 8 Jon G. Allen, Ph.D., on *Coping With Trauma (Meet the Authors)*
Pecan Room, North Tower, Meeting Level, Omni Hotel

FOCUS LIVE SESSION 2

11:00 a.m.-12:30 p.m.

Room A405, Level 4, Georgia World Congress Center

PSYCHOSOMATIC MEDICINE: CONSULTATION-LIAISON PSYCHIATRY AND BEYOND

Moderators: Deborah J. Hales, M.D., Mark H. Rapaport, M.D.
Presenter: Jennifer G. Gotto, M.D., Francisco Fernandez, M.D.

Expert clinicians, who served as the guest editors of the first two issues of *Focus*, will lead lively multiple-choice, question-based discussions. This session covers Psychosomatic Medicine, the first session at 9:00 a.m. covers Major Depressive Disorder, and the third session at 2:00 p.m. covers Child and Adolescent Psychiatry. Presented with multiple-choice questions, participants will test their knowledge with an interactive audience response system, which instantly presents the audience responses as a histogram on the screen. Each participant is able to take a self-assessment exam with answers and discussion led by the expert faculty.

LECTURES 5-6

LECTURE 5

11:00 a.m.-12:30 p.m.
Sydney B. Marcus Auditorium, Level 4
Georgia World Congress Center

Bruce S. McEwen, Ph.D.

**Stress and the Mind-Body Connection:
Lessons From Neuroendocrinology**
*Collaborative Session With the National
Institute of Mental Health*

Chp.: Jack M. Gorman, M.D.
Co-Chp.: Sanjay Mathew, M.D.

Bruce S. McEwen, Ph.D., discusses a new model of the adaptive and damaging effects of the mediators of the physiological stress response. The model focuses on the pivotal role of brain areas involved in memory and emotion and provides a basis for understanding the comorbidity of mental disorders with systemic disorders such as cardiovascular disease, obesity, and diabetes. Dr. McEwen is Alfred E. Mirsky Professor and Head of the Harold and Margaret Milliken Hatch Laboratory of Neuroendocrinology at Rockefeller University in New York City. His research examines environmentally-regulated, variable gene expression in the brain that is mediated by circulating steroid hormones and endogenous neurotransmitters in relation to brain sexual differentiation and the actions of sex, stress, and thyroid hormones on the adult brain. He is a member of the MacArthur Foundation Research Network on Socioeconomic Status and Health, in which he is helping to reformulate concepts and measurements related to stress and stress hormones in the context of human societies. A Past President of the Society for Neuroscience, Dr. McEwen is a member of the U.S. National Academy of Sciences, the Institute of Medicine, and the American Academy of Arts and Sciences. He received his doctoral degree in cell biology from Rockefeller University and completed postdoctoral studies in neurobiology at the Institute of Neurobiology in Goteborg, Sweden.

Frontiers of Science Lecture Series
THIS SESSION WILL BE AUDIOTAPED.

LECTURE 6

11:00 a.m.-12:30 p.m.
Room A412, Level 4
Georgia World Congress Center

**APA'S ALEXANDRA SYMONDS
AWARD LECTURE**

Kathryn J. Zerbe, M.D.

**Eating Disorders in Middle and Late Life:
Diagnosis and Treatment of Neglected Problem**

Chp.: Leah J. Dickstein, M.D.

Kathryn J. Zerbe, M.D., is Professor and Vice Chairperson for Psychotherapy in the Department of Psychiatry at Oregon Health and Science University (OHSU). In addition, she holds a joint appointment as Professor in the Department of Obstetrics and Gynecology and is Director of Behavioral Medicine in the Center for Women's Health at OHSU. She is also a Training and Supervising Psychoanalyst at the San Francisco Psychoanalytic Institute and the Oregon Psychoanalytic Institute. Dr. Zerbe is the author of several clinical papers and book chapters and four books, including *Women's Mental Health in Primary Care*, *The Body Betrayed: Women, Eating Disorders, and Treatment*, and the forthcoming *Integrated Treatment of Eating Disorders*. A Distinguished Fellow of the American Psychiatric Association and a Fellow of the Academy of Eating Disorders, Dr. Zerbe serves on the Program Committee of the American Psychoanalytic Association and on the Editorial Board of several journals, including *Bulletin of the Menninger Clinic*, *Eating Disorders Review*, *Eating Disorders, Postgraduate Medicine*, and *Current Psychiatry*. Dr. Zerbe graduated from Temple University School of Medicine in Philadelphia. She completed her psychiatric residency at the Karl Menninger School of Psychiatry and Mental Health Sciences in Topeka, Kansas, and her psychoanalytic training at the Topeka Institute for Psychoanalysis.

THIS SESSION WILL BE AUDIOTAPED.

**MASTER EDUCATOR CLINICAL
CONSULTATIONS 3-4**

11:00 a.m.-12:30 p.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

- 3 **Prakash S. Masand, M.D.**, on Treatment-Refractory Depression
Room B317, Level 3, Georgia World Congress Center
- 4 **Marion Zucker-Goldstein, M.D.**, on Case-Centered Issues in Cognitive and Functional Changes and Other Medical Comorbidities in Aging
Room B318, Level 3, Georgia World Congress Center

THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

MEDICAL UPDATE 1

11:00 a.m.-12:30 p.m.

Room B403, Level 4, Georgia World Congress Center

GET SMART NATURALLY

Presenter: Richard P. Brown, M.D.

Chp.: Philip R. Muskin, M.D.

THIS SESSION WILL BE AUDIOTAPED.

RESEARCH CONSULTATION WITH

11:00 a.m.-12:30 p.m.

This session is limited to 25 participants on a first-come, first-served basis.

- 1 **Larry J. Siever, M.D.**, on Biological Studies in Personality Disorders
Collaborative Session With the National Institute of Mental Health
Chestnut Room, North Tower, Meeting Level, Omni Hotel

SCIENTIFIC AND CLINICAL REPORT SESSIONS 1-9

SCIENTIFIC AND CLINICAL REPORT SESSION 1

11:00 a.m.-12:30 p.m.

Room A402, Level 4, Georgia World Congress Center

PSYCHOSOMATIC MEDICINE: INTEGRATING PSYCHIATRY AND MEDICINE

Chp.: Arthur L. Lazarus, M.D.

Co-Chp.: Carrie L. Ernst, M.D.

11:00 a.m.

- 2 **Teaching Psychosomatic Medicine in Primary Care Residencies: Current Status**
Hoyle Leigh, M.D., Deborah C. Stewart, M.D., Ronna Mallios, M.P.H.

11:30 a.m.

- 3 **Use of Simulated Patients to Assess Primary Care Physicians' Treatment of Depression**
Collaborative Session With the National Institute of Mental Health
Steven A. Epstein, M.D., Lisa M. Hooper, Ph.D., Kevin P. Weinfurt, Ph.D., William Hahless, Ph.D., Lisa A. Cooper, M.D.

12 noon

- 4 **Psychosocial Aspects of Automatic Internal Cardioverter Defibrillator Use**
Maryam Razavi, M.D., Vincenzo Holder-Perkins, M.D., Mehdi Razavi, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 2

11:00 a.m.-12:30 p.m.

Room A404, Level 4, Georgia World Congress Center

SUICIDE

Chp.: David C. Purselle, M.D.

Co-Chp.: Steven J. Garlow, M.D.

11:00 a.m.

- 5 **Exposure to SSRIs Reduces Suicidality in Elderly Patients With Depression**
Yoram Barak, M.D., Ahikam Olmer, M.D., Dov Alzenberg, M.D.

11:30 a.m.

- 6 **Suicidality in Youth With Bipolar Disorder: A Community-Based, Multisite Investigation**
Ruby C. Castilla-Puentes, M.D., Sandra R. Castilla-Puentes, M.D., Ivan S. Gomez, M.D., Wilma I. Castilla-Puentes, M.D., Sandra Lopez, M.D., Maria Teresa Alvarado, Ph.D., Carlos A. Sanchez-Russi, Ph.D.

12 noon

- 7 **Peripheral Benzodiazepine Receptors in Suicide**
Donatella Marazziti, M.D., Bernardo Dell'Osso, M.D., Luciano Conti, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 3

11:00 a.m.-12:30 p.m.

Room B301, Level 3, Georgia World Congress Center

ISSUES IN PHARMACOTHERAPY AND PSYCHOTHERAPY

Chp.: Alan J. Gelenberg, M.D.

Co-Chp.: Allan M. Josephson, M.D.

11:00 a.m.

- 8 **A Combined Treatment Approach for Adults With ADHD: Results of a Pilot Study of 45 Patients**
Anthony L. Rostain, M.D., J. Russell Ramsay, Ph.D.

11:30 a.m.

- 9 **Characteristics of Diversion and Misuse of ADHD Medications**
Timothy E. Wilens, M.D., Martin Gignac, M.D., Joseph Biederman, M.D.

12 noon

- 10 **Combined Treatment of Venlafaxin and ECT in Treatment-Resistant Depressive Patients**
Nesrin Dilbaz, M.D., Cem Sengul, M.D., Tuncer Okay, M.D., Goksel Bayam, M.D., Ali Turkoglu, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 4

11:00 a.m.- 12:30 p.m.

Room B306, Level 3, Georgia World Congress Center

ADHD

Chp.: Nashaat N. Boutros, M.D.

Co-Chp.: Joel Kirson, M.D.

11:00 a.m.

- 11 Sleep Hygiene and Melatonin Treatment for ADHD Sleep-Onset Delay
Margaret D. Weiss, M.D., Melissa Bomben, M.S., Michael Wasdell, M.A.

11:30 a.m.

- 12 Comorbidity Differences in ADHD Throughout the Life Cycle
Atilla Turgay, M.D., Rubaba Ansari, M.A., Michael Schwartz, Ph.D., David Ng, M.D., Llewelyn W. Joseph, M.D., Joanna Blanchard, M.A., Nadeem Chaudhry, M.D.

12 noon

- 13 ADHD Symptoms and Behavior Improved With Modafinil Pediatric Formulation
Laurence L. Greenhill, M.D., Sharon B. Wigal, Ph.D., Christopher J. Kratochvil, M.D., Samuel Boellner, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 5

11:00 a.m.- 12:30 p.m.

Room B408, Level 4, Georgia World Congress Center

ISSUES IN BIPOLAR DISORDER

Chp.: Katherine L. Wisner, M.D.

Co-Chp.: Meera Vaswani, Ph.D.

11:00 a.m.

- 14 Excess Mortality in Bipolar and Unipolar Disorder
Urban P. Osby, M.D., Lena Brandt, B.S.C., Nestor Correia, Ph.D., Anders Ekblom, M.D., Par Sparen, Ph.D.

11:30 a.m.

- 15 Do Antidepressants Help or Hinder Recovery From Mixed Mania?
Joseph F. Goldberg, M.D., Christine J. Truman, M.D., Charles L. Bowden, M.D., John Fordis, B.A., Stephen R. Wisniewski, Ph.D., Michael E. Thase, M.D., Gary S. Sachs, M.D.

12 noon

- 16 Mixed Episodes: Illness Characteristics
Gary S. Sachs, M.D., Megan F. Joseph, B.A., Cindy H. Hwang, B.A., Gianna Marzilli, B.A., Tanya B. Tran, B.A., David J. Borrelli, M.D., Andrew A. Nierenberg, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 6

11:00 a.m.- 12:30 p.m.

Room B409, Level 4, Georgia World Congress Center

PSYCHOTHERAPY

Chp.: T. Byram Karasu, M.D.

Co-Chp.: Everett R. Siegel, M.D.

11:00 a.m.

- 17 Affect Change in Dreams in Psychotherapy
Milton Kramer, M.D., Myron L. Glucksman, M.D.

11:30 a.m.

- 18 The Empathic Stance
Steven H. Lipsius, M.D.

12 noon

- 19 Creative Thinking: A Door to the Interior Life That Enhances the Psychotherapeutic Process
Rosa A. Chavez-Eakle, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 7

11:00 a.m.- 12:30 p.m.

Pine Room, South Tower, Atrium Terrace Level, Omni Hotel

SAFETY AND EFFICACY IN ANTIPSYCHOTIC THERAPIES

Chp.: Geetha Jayaram, M.D.

Co-Chp.: John M. Rowles, M.D.

11:00 a.m.

- 20 Efficacy and Safety of Ziprasidone in First-Episode Psychosis
Tonmoy Sharma, M.D., Veena Kumari, Ph.D., Ravi Mehrotra, Ph.D., Anil Kumar

11:30 a.m.

- 21 Atypical Antipsychotics and Falls in the Elderly
Ira R. Katz, M.D.

12 noon

- 22 Metabolic Syndrome in Schizophrenia
Hannu J. Koponen, M.D., Kaisa Saari, M.D., Sari Lindeman, M.D., Markku Savolainen, M.D., Matti K. Isohanni, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 8

11:00 a.m.-12:30 p.m.

Cottonwood Room, North Tower, Street Level, Omni Hotel

CROSS-CULTURAL AND MINORITY ISSUES

Chp.: Leslie A. Horton, M.D.

Co-Chp.: Francis G. Lu, M.D.

11:00 a.m.

- 23 **Ethnicity and the Prediction of Substance Abuse in Hospitalized Adolescents**

Daniel F. Becker, M.D., Carlos M. Grilo, Ph.D.

11:30 a.m.

- 24 **Stigmatization of Mental Illnesses Among Chinese Psychiatric Patients in China and the U.S.**

Collaborative Session With the National Institute of Mental Health

Albert Yeung, M.D., Yong Xu, M.D., Wendy Guyker, B.S., Raymond Kam, M.D., Paul Yin, M.D., Maurizio Fava, M.D.

12 noon

- 25 **Use of the PHQ9 for Screening and Treatment of Major Depressive Disorders in Chinese Americans**

Frederick Y. Huang, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 9

11:00 a.m.-12:30 p.m.

Dogwood B, North Tower, Street Level, Omni Hotel

PERSONALITY DISORDERS

Chp.: Ossama T. Osman, M.D.

Co-Chp.: Robert Kelly, M.D.

11:00 a.m.

- 26 **Emotion Processing in BPD: An fMRI Perspective**

Harold W. Koenigsberg, M.D., Larry J. Siever, M.D., Xiaodong Guo, Ph.D., Antonia S. New, M.D., Marianne Goodman, M.D., Hu Cheng, Ph.D., Isak Prohovnik, Ph.D.

11:30 a.m.

- 27 **Personality Traits in Patients With Panic Disorder**

Mary Anne Pressman, M.D., Eric D. Peselow, M.D., Caroline B. Williams, M.D.

12 noon

- 28 **Is Peripartum Depression a Borderline Condition?**

Gisèle Apter-Danon, Ph.D., Rozenn Graognic-Philippe, M.A., Marina Gianoli-Valente, Psy.D., Emmanuel Devouche, Ph.D., Annick Le Nestour, M.D.

THIS SESSION WILL BE AUDIOTAPED.

WORKSHOPS

COMPONENT WORKSHOPS 13-17

COMPONENT WORKSHOP 13 11:00 a.m.-12:30 p.m.

Room B307, Level 3, Georgia World Congress Center

PRACTICAL TIPS ON HOW TO BE A SUCCESSFUL AUTHOR

American Psychiatric Publishing Inc. Editorial Board

Chp.: Robert E. Hales, M.D.

Participants: Glen O. Gabbard, M.D., Katharine A. Phillips, M.D., John M. Oldham, M.D., Donna E. Stewart, M.D.

COMPONENT WORKSHOP 14 11:00 a.m.-12:30 p.m.

Room B308, Level 3, Georgia World Congress Center

PSYCHIATRIC ETHICS IN THE U.S. AND THROUGHOUT THE WORLD

APA Ethics Committee

Co-Chps.: Spencer Eth, M.D., Driss Moussaoui, M.D.

Participants: Wade C. Myers, M.D., Philip T. Merideth, M.D., Ahmed M.F. Okasha, M.D.

COMPONENT WORKSHOP 15 11:00 a.m.-12:30 p.m.

Spruce Room, South Tower, Atrium Terrace Level, Omni Hotel

THE MULTICULTURAL DIMENSION OF DEPRESSION: A CLINICAL APPROACH

APA/AstraZeneca Minority Fellows

Chp.: Gonzalo E. Laje, M.D.

Participants: Angel A. Caraballo, M.D., Yolanda R. Colemon, M.D., Daniel Dickerson, D.O., Luisa S. Gonzalez, M.D., Jennifer R. Lee, M.D., Aditi M. Shrikhande, M.D.

COMPONENT WORKSHOP 16 11:00 a.m.-12:30 p.m.

Oak Room, South Tower, Lobby Level, Omni Hotel

EARLY DIAGNOSIS IN SPECIFIC MENTAL DISORDERS IN TODDLERS AND PRESCHOOLERS

APA Corresponding Committee on Infancy and Early Childhood

Co-Chps.: Judy S. McKay, M.D., Harry H. Wright, M.D.

Participants: Jean M. Thomas, M.D., Joan L. Luby, M.D.

COMPONENT WORKSHOP 17 11:00 a.m.-12:30 p.m.

Juniper Room, North Tower, Ballroom Level, Omni Hotel

GENDER BENDERS: PSYCHIATRIC ASPECTS OF TRANSGENDER CARE

APA New York County District Branch's Committee on Gay, Lesbian, Bisexual, and Transgender Issues

Chp.: Serena Yuan Volpp, M.D.

Participants: Steven J. Lee, M.D., Khakasa H. Wapenyi, M.D., Daniel Garza, M.D., Ubaldo Leli, M.D.

ISSUES 14-26

ISSUE WORKSHOP 14 11:00 a.m.-12:30 p.m.

Room B309, Level 3, Georgia World Congress Center

ETHNICITY AND PSYCHOPHARMACOLOGY: RESEARCH AND CLINICAL IMPLICATIONS

Co-Chps.: Pedro Ruiz, M.D., Key-Ming Lim, M.D.

Participants: William Lawson, M.D., Edmond H.T. Pi, M.D., Ricardo P. Mendoza, M.D., Tarek A. Okasha, M.D.

ISSUE WORKSHOP 15 11:00 a.m.-12:30 p.m.

Room B310, Level 3, Georgia World Congress Center

MAKING IT HAPPEN: IMPLEMENTING PRACTICE GUIDELINES IN EVERYDAY PRACTICE

Chp.: Rory P. Houghtalen, M.D.

Participants: Jack S. McIntyre, M.D., Jeffrey Mothersell, C.S.W., Joel Yager, M.D.

ISSUE WORKSHOP 16 11:00 a.m.-12:30 p.m.

Room B311, Level 3, Georgia World Congress Center

PRACTICAL CLINICAL TRIALS COMPARING PSYCHOPHARMACOLOGICAL TREATMENTS

Co-Chps.: Sandra L. Tunis, Ph.D., Don Buesching, Ph.D.

Participants: Douglas E. Faries, Ph.D., Kurt Kroenke, M.D., Wayne J. Katon, M.D.

ISSUE WORKSHOP 17 11:00 a.m.-12:30 p.m.

Room B315, Level 3, Georgia World Congress Center

SPLIT THERAPY: PSYCHOTHERAPY AND PHARMACOTHERAPY PROCEDURES AND STRATEGIES

Chp.: Malkah T. Notman, M.D.

Participants: Carl P. Malmquist, M.D., Brenda C. Solomon, M.D., Amit D. Rajparia, M.D.

ISSUE WORKSHOP 18 11:00 a.m.-12:30 p.m.

Room B316, Level 3, Georgia World Congress Center

TREATMENT OF DEPRESSION DURING PREGNANCY

Co-Chps.: Janet A. Martin, M.D., Neil Silverman, M.D.

Participants: Leo L. Gallofin, M.D., Syed S.A. Naqvi, M.D.

ISSUE WORKSHOP 19 11:00 a.m.-12:30 p.m.

Room B401, Level 4, Georgia World Congress Center

BINGE-EATING DISORDER IN OBESITY AND IMPLICATIONS FOR BARIATRIC SURGERY

Co-Chps.: Jennifer L. McLain, M.D., Edi Cooke, Psy.D.

Participant: Alexander H. Fan, M.D.

ISSUE WORKSHOP 20 11:00 a.m.-12:30 p.m.

Room B402, Level 4, Georgia World Congress Center

DUAL-CAREER COUPLES: MULTIPLE ROLES, INNOVATIVE SOLUTIONS

Association of Women Psychiatrists

Chp.: Silvia W. Olarte, M.D.

Participants: Linda H. Chaudron, M.D., Ana E. Campo, M.D., Mary Kay Smith, M.D.

ISSUE WORKSHOP 21 11:00 a.m.-12:03 p.m.

Birch Room, South Tower, Atrium Terrace Level, Omni Hotel

PRACTICE RESTRICTIONS ON PHYSICIANS: DISABILITY, ADA, AND FUTURE EMPLOYMENT

Co-Chps.: Andrea G. Stolar, M.D., Marilyn Price, M.D.

Participant: Marcia A. Scott, M.D.

ISSUE WORKSHOP 22 11:00 a.m.-12:30 p.m.

Maple Room, South Tower, Atrium Terrace Level, Omni Hotel

RESEARCH TRAINING AND CAREER DEVELOPMENT: NIMH OPPORTUNITIES

Collaborative Session With the National Institute of Mental Health

Co-Chps.: Della M. Hann, Ph.D., Joseph R. Calabrese, M.D.

Participants: Mark Chavez, Robert L. Findling, M.D., Omar Elhaj, M.D.

ISSUE WORKSHOP 23 11:00 a.m.-12:30 p.m.

Dogwood A, North Tower, Street Level, Omni Hotel

COLLABORATIVE CARE MODELS FOR DEPRESSION IN PRIMARY CARE

Chp.: Ann Marie T. Sullivan, M.D.

Participants: Steven A. Cole, M.D., Joslyn Levy, R.N., Karneya J. Anselovits, M.D., Martin H. Maurer, M.D.

ISSUE WORKSHOP 24 11:00 a.m.-12:30 p.m.

Magnolia Room, North Tower, Ballroom Level, Omni Hotel

COMPARING CAREGIVING ISSUES OF AGING PATIENTS WITH SCHIZOPHRENIA AND DEMENTIA

Co-Chps.: Sheila M. Loboprabhu, M.D., Michael D. Jibson, M.D.

Participant: Theron C. Bowers, Jr., M.D.

ISSUE WORKSHOP 25 11:00 a.m.-12:30 p.m.
Hickory Room, North Tower, Meeting Level, Omni Hotel

THE PSYCHIATRY RESIDENT AS EDUCATOR: IMPLEMENTATION OF A CURRICULUM

Co-Chps.: Ruth M. Lamdan, M.D., Autumn Ning, M.D.
Participants: Roya Lewis, M.D., Diane B. Gottlieb, M.D., Edward A. Volkman, M.D., Robert L. Boyd, M.D., Elton Smith, M.D.

ISSUE WORKSHOP 26 11:00 a.m.-12:30 p.m.
Walnut Room, North Tower, Meeting Level, Omni Hotel

MEETING THE CHALLENGES OF CORRECTIONAL MENTAL HEALTH RESEARCH

Collaborative Session With the National Institute of Mental Health

Chp.: Robert L. Trestman, M.D.
Participants: Humberto Temporini, M.D., Philip Candillis, M.D., Joel M. Silberberg, M.D.

12 noon Sessions

FORUMS 1-3

FORUM 1 12 noon-1:30 p.m.
Room A410, Level 4, Georgia World Congress Center

RESEARCH PLANNING FOR DSM-V
APA Committee on Psychiatric Diagnosis and Assessment in Collaboration With the National Institute of Mental Health

Chp.: Darrel A. Regier, M.D.
Participants: Wilson M. Compton III, M.D., Bruce Cuthbert, Ph.D., Michael B. First, M.D., William E. Narrow, M.D., Maritza Rubio-Stipec, Sc.D., Norman Sartorius, M.D.

FORUM 2 12 noon-1:30 p.m.
Room B314, Level 3, Georgia World Congress Center

SHOULD PSYCHIATRISTS AND OTHER MENTAL HEALTH PROFESSIONALS TAKE A LEAD IN TOBACCO DEPENDENCE TREATMENT?

Co-Chps.: Jill Williams, M.D., Douglas M. Ziedonis, M.D.
Participant: Nora D. Volkow, M.D.

FORUM 3 12 noon-1:30 p.m.
Room B404, Level 4, Georgia World Congress Center

GETTING INTO RESEARCH WITH AFRICAN-AMERICAN PATIENTS

Chp.: Mindy J. Fullilove, M.D.
Participants: Vivian Pinn, M.D., Ronald O. Valdiserri, M.D., Benedict I. Truman, M.D., Carl C. Bell, M.D.

1:00 p.m. Sessions



COURSES 49-57

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

COURSE 49 1:00 p.m.-5:00 p.m.
Henry Room, Second Floor, Hilton Atlanta

THE ADVANCED PRACTICE OF PSYCHOTHERAPY

Director: T. Byram Karasu, M.D.

COURSE 50 1:00 p.m.-5:00 p.m.
Newton Room, Second Floor, Hilton Atlanta

ASSESSMENT AND TREATMENT OF DRUG-INDUCED MOVEMENT DISORDERS

Director: Anton J.M. Loonen, M.D.

COURSE 51 1:00 p.m.-5:00 p.m.
Forsythe Room, Second Floor, Hilton Atlanta

COGNITIVE THERAPY FOR SEVERE MENTAL DISORDERS

Director: Jesse H. Wright, M.D.
Faculty: Michael E. Thase, M.D., Monica Basco, Ph.D.

COURSE 52 1:00 p.m.-5:00 p.m.
Paulding Room, Second Floor, Hilton Atlanta

PSYCHIATRY AND THE INTERNET

Director: Robert S. Kennedy, M.A.
Faculty: Thomas A.M. Kramer, M.D., Carlyle H. Chan, M.D.

COURSE 53 1:00 p.m.-5:00 p.m.
Gwinnett Room, Second Floor, Hilton Atlanta

ECT PRACTICE UPDATE

Director: Charles H. Kellner, M.D.
Faculty: Richard L. Jaffe, M.D., W. Vaughn McCall, M.S., Richard D. Weiner, M.D.

COURSE 54 1:00 p.m.-5:00 p.m.
Grand Salon C, Second Floor, Hilton Atlanta

OVERVIEW AND UPDATE OF SLEEP DISORDERS MEDICINE

Director: Karl Doghramji, M.D.
Faculty: John W. Winkelman, M.D., Thomas D. Hurwitz, M.D.

COURSE 55 1:00 p.m.-5:00 p.m.

Jackson Room, Third Floor, Hilton Atlanta

TREATING MEDICAL STUDENTS AND PHYSICIANS

Co-Directors: Michael F. Myers, M.D., Leah J. Dickstein, M.D.

COURSE 56 1:00 p.m.-5:00 p.m.

Monroe/Roosevelt Room, Third Floor, Hilton Atlanta

CHILD MURDER BY PARENTS

Director: Phillip J. Resnick, M.D.

COURSE 57 1:00 p.m.-5:00 p.m.

Cabinet/Council Rooms, Fourth Floor, Hilton Atlanta

DRUG TREATMENT OF SCHIZOPHRENIA

Director: Philip G. Janicak, M.D.

Faculty: Morris B. Goldman, M.D., Stephen R. Marder, M.D., Rajiv Tandon, M.D.

NEW RESEARCH YOUNG INVESTIGATORS' ORAL/SLIDE SESSION 2-4

1:00 p.m.-2:30 p.m.

- 2 The Mind and Body
Room B301, Level 3, Georgia World Congress Center
- 3 Surprising Influences
Room B306, Level 3, Georgia World Congress Center
- 4 Child/Adolescent and Other Topics
Room B408, Level 4, Georgia World Congress Center

For further information on New Research Sessions, please refer to the *New Research Program Book* included in your registration packet.

2:00 p.m. Sessions

ADVANCES IN PSYCHOTHERAPY

2:00 p.m.-5:30 p.m.

Rooms B405/406/407, Level 4, Georgia World Congress Center

NEUROBIOLOGICAL UNDERPINNINGS OF PSYCHOTHERAPY

Chp.: Glen O. Gabbard, M.D.

- A Mapping Basic Psychotherapeutic Processes Onto the Brain
Bernard D. Beitman, M.D.
- B A Neurobiological Understanding of Transference
Glen O. Gabbard, M.D.
- C Neural Circuits in Psychotherapy
George I. Viamontes, M.D.

D How the Brain Uses the Past to Predict the Future: Implications for Psychotherapy
Regina Pally, M.D.

E Brain Imaging of Psychotherapy: Capturing Meaning and Change
Barton J. Blinder, M.D.

F Differential Brain Effects of Medication and Psychotherapy
Helen S. Mayberg, M.D.

FOCUS LIVE SESSION 3

2:00 p.m.-3:30 p.m.

Room A405, Level 4, Georgia World Congress Center

CHILD AND ADOLESCENT PSYCHIATRY

Moderators: Deborah J. Hales, M.D., Mark H. Rapaport, M.D.
Presenters: David L. Kaye, M.D., Eugene V. Beresin, M.D.

Expert clinicians, who served as the guest editors of the first two issues of *Focus*, will lead lively multiple-choice, question-based discussions. This session covers Child and Adolescent Psychiatry, the first session at 9:00 a.m. covers Major Depressive Disorder, and the second session at 11:00 a.m. covers Psychosomatic Medicine. Presented with multiple-choice questions, participants will test their knowledge with an interactive audience response system, which instantly presents the audience responses as a histogram on the screen. Each participant is able to take a self-assessment exam with answers and discussion led by the expert faculty.

LECTURES 7-8

LECTURE 7

2:00 p.m.-3:30 p.m.

Room A411, Level 4

Georgia World Congress Center

Michael Meaney, Ph.D.

Epigenetic Programming of Stress Responses Through Variations in Maternal Care: The Nurture of Nature
Collaborative Session With the National Institute of Mental Health

Chp.: Michelle T. Pato, M.D.

Co-Chp.: Olivera J. Bogunovic, M.D.

Michael Meaney, Ph.D., is James McGill Professor of Medicine and Professor of Psychiatry at McGill University, Director of the McGill Program for the Study of Behaviour, Genes and Environment, and Associate Director of the Douglas Hospital Research Centre in Montreal. He is also a Canadian Institutes of Health Research Scientist in Health Research.
(Continued next page)

Health Research Senior Scientist. His research interests include early environmental regulation of gene expression and brain development, development of individual differences in behavioral and endocrine responses to stress, and environmental and neuroendocrine mechanisms influencing maternal behavior. His research honors include the Distinguished Investigator Award from the National Alliance for Research on Schizophrenia and Depression and the Patricia R. Barchas Award in Sociophysiology from the American Psychosomatic Society. Dr. Meaney is the author of more than 200 scientific papers and a Member of the Editorial Board of the *Journal of Neuroendocrinology*, *Hormones and Behavior*, *Journal of Endocrinology*, *Biological Psychiatry*, and *Stress*. He received his doctorate in psychobiology at Concordia University in Montreal and completed a Natural Sciences and Engineering Research Council (NSERC) of Canada postdoctoral fellowship in neuroendocrinology at Rockefeller University in New York City and an NSERC University Research Fellowship at Concordia University.

Frontiers of Science Lecture Series
THIS SESSION WILL BE AUDIOTAPED.

LECTURE 8

2:00 p.m.-3:30 p.m.
 Room A412, Level 4
 Georgia World Congress Center

APA'S GEORGE TARJAN AWARD LECTURE

Hagop S. Akiskal, M.D.

**Temperament, Mood Disorder,
 and Human Nature**

Chp.: Sanjay Dube, M.D.

Hagop S. Akiskal, M.D., is Professor of Psychiatry and Director of the International Mood Center at the University of California, San Diego. Dr. Akiskal's research and clinical work address the range of mood disorders from dysthymia to bipolar spectrum disorders, and his mood clinics are distinguished by their integration of service, training, and research. The author of numerous scientific papers and several books, Dr. Akiskal is Editor-in-Chief of *Journal of Affective Disorders*. He currently chairs the Private Practice section of the World Psychiatric Association. A Distinguished Fellow of the American Psychiatric Association (APA), Dr. Akiskal has received the Clinical Research Award from the American Academy of Clinical Psychiatrists for his work on dysthymia, the Gold Medal for Pioneer Work in Biological Psychiatry from the Society of Biological Psychiatry, the Anna-Monika Foundation Prize for his work on depression, a Presidential Commendation from the APA, and the Jean Delay Prize for international collaborative research from the World Psychiatric Association. In 2003, he

was awarded the Ellis Island Medal of Honor for exceptional humanitarian national service. Dr. Akiskal received his medical degree from the American University of Beirut and his psychiatric training at the University of Tennessee in Memphis and the University of Wisconsin in Madison.

THIS SESSION WILL BE AUDIOTAPED.

PRESIDENTIAL SYMPOSIA 1-2

PRESIDENTIAL SYMPOSIUM 1

2:00 p.m.-5:00 p.m.

Room A305, Level 3, Georgia World Congress Center

ADVANCES IN PSYCHOSOMATIC MEDICINE

International College of Psychosomatic Medicine in Collaboration With the National Institute of Mental Health

Chp.: Michelle B. Riba, M.D.

- A A Model for Psychosomatic Medicine: Care in a U.S. Cancer Center**
Michelle B. Riba, M.D.
- B Ethical Issues in Psychosomatics**
George Christodoulou, M.D.
- C Recent Advances in Depression and Cardiovascular Disease Research**
Constantine Lyketsos, M.D.
- D Suffering: Another Frontier in Psychosomatic Medicine**
Tom Sensky, M.B.

Discussant: Philip R. Muskin, M.D.

THIS SESSION WILL BE AUDIOTAPED.

PRESIDENTIAL SYMPOSIUM 2

2:00 p.m.-5:00 p.m.

Room B401, Level 4, Georgia World Congress Center

ADDRESSING HEPATITIS C AND RELATED DISEASES IN PERSONS WITH SEVERE MENTAL ILLNESS

Chp.: Marvin S. Swartz, M.D.

- A Hepatitis C and Other Blood-Borne Infections in the Severely Mentally Ill**
Stanley Rosenberg, Ph.D.
- B Access to Medical Care for Persons With Severe Mental Illness, Hepatitis C and Related Disorders**
Marvin S. Swartz, M.D.
- C Gender Differences in HCV and Associated Risks With Severe Mental Illnesses**
Marian I. Butterfield, M.D.

- D **A Public Approach to Blood-Borne Infection With Severe Mental Illness: The STIRR Intervention**
Mary F. Brunette, M.D.
- E **Antiviral Treatment of Hepatitis C in Persons With Severe Mental Illnesses**
Lisa A. Mistler, M.D.
- F **Integrating Care for Persons With Severe Mental Illness**
Lisa B. Dixon, M.D.

Discussant: Lisa B. Dixon, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIA 1-26

SYMPOSIUM 1 2:00 p.m.-5:00 p.m.
Room A302, Level 3, Georgia World Congress Center

STEPS TREATMENT MODEL FOR BPD
Collaborative Session With the National Institute of Mental Health

Chp.: Donald W. Black, M.D.

- A **Steps: A New Cognitive Skills Treatment for Borderline Personality**
Nancee Blum, M.S.W., Donald W. Black, M.D., Bruce M. Pfohl, M.D., Don St. John, M.D.
- B **Randomized Clinical Trial of Steps Versus Treatment as Usual**
Donald W. Black, M.D., Nancee Blum, M.S.W., Bruce M. Pfohl, M.D., Don St. John, M.D.
- C **Can Staff Attitudes Regarding BPD Be Changed?**
Bruce M. Pfohl, M.D., Connie Shanks, B.A., Nancee Blum, M.S.W.
- D **Introduction of Steps in the Netherlands**
Roelof J.A. Ten Doesschate, M.D., E. Bass Van Wel, M.D., W.M.J. Kockmann

Discussants: Robert L. Spitzer, M.D., Roger Blashfield, Ph.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 2 2:00 p.m.-5:00 p.m.
Room A402, Level 4, Georgia World Congress Center

9/11 IN NEW YORK CITY: LEARNING FROM THE PAST AND LOOKING TO THE FUTURE

Chp.: Joseph T. English, M.D.

- A **Lessons From 9/11: Psychiatric Care of Victims**
Scot G. McAfee, M.D.
- B **Children and Schools in the Years After a Terror Attack**
A. Reese Abright, M.D.

- C **Vicarious Traumatization of Psychotherapists**
Lea E. DeFrancisci, M.D.
- D **Preventive Interventions Following Acute Trauma**
Arieh Y. Shalev, M.D.

Discussant: Spencer Eth, M.D.

SYMPOSIUM 3 2:00 p.m.-5:00 p.m.
Room A403, Level 4, Georgia World Congress Center

QUEER THINK FOR THE STRAIGHT SHRINK: EXPERT TIPS

American Academy of Child and Adolescent Psychiatry

Chp.: Richard R. Pleak, M.D.

- A **Queer as Kids: Attitude Enhancement**
Richard R. Pleak, M.D.
- B **High Heels and Show Tunes: Boys Under the Spell**
Edgardo J. Menvielle, M.D.
- C **The L Teen and Lesbian Chic**
Sarah E. Herbert, M.D.
- D **Studs, Stems, and Jotas: Queer Latino Youth**
Vernon A. Rosario, M.D.

Discussant: William M. Womack, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 4 2:00 p.m.-5:00 p.m.
Room A404, Level 4, Georgia World Congress Center

COMORBID PSYCHOSIS AND SUBSTANCE USE: DIAGNOSIS, COURSE, AND OUTCOME

Chp.: Michael B. First, M.D.

- A **Does Longitudinal Follow-Up Improve Diagnostic Accuracy in Dual-Diagnosis Patients?**
Michael B. First, M.D.
- B **The Stability of Early-Phase Psychotic Disorders With Substance Use**
Deborah S. Hasin, Ph.D.
- C **Substance-Induced Psychosis Presages Primary Psychosis**
Robert Drake, M.D.
- D **Outcome of Substance-Induced Psychosis and Primary Psychotic Disorders**
Carol L.M. Caton
- E **The Neurobiology of Substance-Induced Psychoses**
John H. Krystal, M.D.

Discussant: Alan I. Green, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 5 2:00 p.m.-5:00 p.m.

Room A406, Level 4, Georgia World Congress Center

A SEX/GENDER RESEARCH AGENDA FOR *DSM-V*

Chp.: Katharine A. Phillips, M.D.

- A **Opportunities for Advancement in Psychiatric Science: Sex and Gender-Specific Analyses**
Katherine L. Wisner, M.D.
- B **Gender Differences in Rates of Psychiatric Disorders: An Update**
Myrna M. Weissman, Ph.D., Bridget F. Grant, Ph.D.
- C **Sex Differences in Neurobiology**
Margaret Altemus, M.D.
- D **Gender Issues in the *DSM***
Kimberly A. Yonkers, M.D., Katherine A. Halmi, M.D., William E. Narrow, M.D.
- E **Gender in the History and Future of the *DSM***
Thomas A. Widiger, Ph.D.

Discussant: David J. Kupfer, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 6 2:00 p.m.-5:00 p.m.

Room A407, Level 4, Georgia World Congress Center

RESEARCH ADVANCES IN LATE-LIFE MENTAL DISORDERS: TOWARD *DSM-V*

Collaborative Session With the National Institute of Mental Health

Chp.: Dilip V. Jeste, M.D.

- A **Age-Related Diagnostic Variations: Presentations, Course, and Outcome**
Dilip V. Jeste, M.D., Dan G. Blazer II, M.D.
- B **The Use of Biomarkers in the Elderly: Current and Future Challenges**
Raquel E. Gur, M.D., Steven E. Arnold, M.D., Trey Sunderland, M.D.
- C **Biology and Pathophysiology: Psychosocial and Behavioral Correlates**
Charles F. Reynolds III, M.D., Patricia Arean, Ph.D.
- D **Comorbidity: Medical and CNS Factors in Late-Life Disorders**
Susan K. Schultz, M.D., George S. Alexopoulos, M.D., Linda K. Ganzini, M.D., Ira R. Katz, M.D., Barry D. Lebowitz, Ph.D.

Discussants: Barry D. Lebowitz, Ph.D., Darrel A. Regier, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 7 2:00 p.m.-5:00 p.m.

Room A408, Level 4, Georgia World Congress Center

HEALTH CARE MELTDOWN: WHAT CAN WE DO?

Chp.: Leslie H. Gise, M.D.

- A **Evaluating One State's Single-Payer Health Care Proposal: Georgia**
Henry S. Kahn, M.D.
- B **How Would a Canadian-Style Single-Payer Health System Impact the Practice of Community Psychiatry in America?**
Karen M. Hochman, M.D.
- C **Working Under a Universal Health Care Plan**
Jonathan S. Davine, M.D.
- D **Fiscal Federalism and Mental Health Care for Homeless Persons**
Raymond J. Kotwicki, M.D.

Discussants: Steven S. Sharfstein, M.D., David Satcher, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 8 2:00 p.m.-5:00 p.m.

Room A410, Level 4, Georgia World Congress Center

CLINICAL ADVANCES IN EARLY DETECTION, PREVENTION, AND TREATMENT OF PSYCHOSIS

Collaborative Session With the National Institute of Mental Health

Chp.: Robert K. Heiassen, Ph.D.

Co-Chp.: Thomas H. McGlashan, M.D.

- A **Accurate Prediction of At-Risk Patients**
Diana O. Perkins, M.D.
- B **Family Intervention in the Prodrome of Psychosis**
William R. McFarlane, M.D., William L. Cook
- C **Pharmacological Intervention During the Prodromal Phase**
Scott W. Woods, M.D.
- D **Nonadherence: A Major Risk Factor for Psychosis in Prodromal Adolescents**
Barbara A. Cornblatt, Ph.D., Christopher Smith, M.A., Andrea Auther, Ph.D., Todd Lencz, Ph.D., Christoph Currell, M.D., Ruth Olsen, B.S., Emilie Nakayana, Ph.D.
- E **Reducing Duration of Untreated First-Episode Psychosis**
Thomas H. McGlashan, M.D., Ingrid Melle, M.D., Svein Friis, M.D., Tor K. Larsen, M.D., Jan O. Johannessen, M.D., Ulrik Haahr, M.D., Per Vaglum, M.D.

Discussant: Crystal R. Blyler, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 9 2:00 p.m.-5:00 p.m.

Room B307, Level 3, Georgia World Congress Center

CLINICAL EFFECTIVENESS TRIALS IN THE REAL WORLD: STATUS AND FINDINGS OF THE NIMH TREATMENT TRIALS

Collaborative Session With the National Institute of Mental Health

Chp.: Grayson S. Norquist, M.D.

- A **Current Status and Controversies in Antipsychotic Drug Effectiveness: Update From the CATIE Study**
Jeffrey A. Lieberman, M.D.
- B **Treatment for Adolescents With Depression Study (TADS)**
John S. March, M.D.
- C **An Update on the STAR*D Trial**
A. John Rush, M.D., Madhukar H. Trivedi, M.D.,
Stephen R. Wisniewski, Ph.D., Maurizio Fava, M.D.
- D **Treatment of Bipolar Depression: Effectiveness of Antidepressants' Observational Outcomes in STEP-BD**
Gary S. Sachs, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 10 2:00 p.m.-5:00 p.m.

Room B308, Level 3, Georgia World Congress Center

NEW PHARMACOLOGIC APPROACHES TO ALCOHOLISM

American Academy of Addiction Psychiatry

Chp.: Marc Galanter, M.D.

- A **Neurochemical Basis for Alcohol Pharmacotherapy**
Raymond F. Anton, Jr., M.D.
- B **Matching Serotonergic Medications to Alcoholism Subtypes**
Henry R. Kranzler, M.D.
- C **Combination Medication Strategies for Alcoholism**
Bankole A. Johnson, M.D.
- D **Relationship Between 5HT Transporter Function and Craving Among Hispanic Patients With Alcoholism**
Nassima Ait-Daoud, M.D.

Discussants: Kathleen T. Brady, M.D., Michael H. Gendel, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 11 2:00 p.m.-5:00 p.m.

Room B309, Level 3, Georgia World Congress Center

CARBOHYDRATE CRAVING AND MOOD DISORDERS: NEW AND COMPLEMENTARY TREATMENTS

Chp.: John P. Docherty, M.D.

- A **Mediators of Carbohydrate Craving in Depression May Also Shorten Lifespan**
Philip W. Gold, M.D.
- B **An Animal Model of Addiction to Sugar**
Bartley G. Hoebel, Ph.D.
- C **Implications of Carbohydrate Craving in SAD**
Norman E. Rosenthal, M.D.
- D **Atypical Depression, Carbohydrate Craving, and Clinical Response**
David A. Sack, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 12 2:00 p.m.-5:00 p.m.

Room B310, Level 3, Georgia World Congress Center

BEREAVEMENT, DEPRESSION, AND PTSD: BOUNDARY AND TREATMENT ISSUES

Chp.: Sidney Zisook, M.D.

Co-Chp.: M. Katherine Shear, M.D.

- A **Grief: Myths, Evidence, and Unresolved Questions**
George A. Bonanno, Ph.D.
- B **Bereavement-Related Depression: Diagnostic and Treatment Guidelines**
Sidney Zisook, M.D., M. Katherine Shear, M.D.
- C **Distinguishing Trauma and Traumatic Loss: PTSD Versus Traumatic Grief**
Randall D. Marshall, M.D.
- D **Depression Following Bereavement and the Occurrence of Comorbid PTSD**
Paula L. Hensley, M.D., Paula Clayton, M.D.
- E **Traumatic Grief and Its Treatment**
M. Katherine Shear, M.D.

Discussant: Paula Clayton, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 13 2:00 p.m.-5:00 p.m.
 Room B311, Level 3, Georgia World Congress Center

**UNDERSTANDING COMPLEX MOOD DISORDERS:
 THE ROLE OF PERSONALITY VARIABLES**

Chp.: Sidney H. Kennedy, M.D.
 Co-Chp.: R. Michael Bagby, Ph.D.

- A **Personality Dimensions and Disorders: A Psychobiology Update**
 Emil F. Coccaro, M.D.
- B **Optimizing Outcome in Patients With Bipolar Disorder and Personality Psychopathology**
 Glenda M. MacQueen, M.D.
- C **Key Psychotherapy Issues in Patients With Major Depression and Personality Psychopathology**
 Michael B. Rosenbluth, M.D.
- D **The Influence of Personality Variables on Pharmacotherapy Outcomes in Major Depression**
 Sidney H. Kennedy, M.D., R. Michael Bagby, Ph.D.

Discussant: Paul T. Costa, Jr., Ph.D.
 THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 14 2:00 p.m.-5:00 p.m.
 Room B314, Level 3, Georgia World Congress Center

DIAGNOSIS, ASSESSMENT, MANAGEMENT, AND QUALITY-OF-LIFE ISSUES IN ADULT ADHD

Chp.: Thomas J. Spencer, M.D.

- A **Diagnosing Adult ADHD**
 Thomas J. Spencer, M.D.
- B **Functional Impairment in Adults With ADHD**
 Margaret D. Weiss, M.D.
- C **Pharmacologic Treatment of Adults With ADHD**
 David Goodman, M.D.
- D **Measuring Quality of Life in Adults With ADHD**
 Jeanne Landgraf, M.A.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 15 2:00 p.m.-5:00 p.m.
 Room B315, Level 3, Georgia World Congress Center

ETHNOPSYCHOPHARMACOLOGY: AN UPDATE ON CROSS-CULTURAL ASPECTS OF MOOD AND ANXIETY DISORDERS

Chp.: Shamsah B. Sonawalla, M.D.
 Co-Chp.: Gregory L. Fricchione, M.D.

- A **Ethnopsychopharmacology Update**
 David C. Henderson, M.D.

- B **Psychiatric Management of Hispanic Patients: Cross-Cultural Issues and Ethnopsychopharmacology**
 David Mischoulon, M.D.
- C **Impact of Cultural Beliefs on the Treatment of Depressed Chinese Americans**
 Albert Yeung, M.D.
- D **Mood and Anxiety Disorder Diagnosis and Treatment in the Asian-Indian Population**
 Rajesh M. Parikh, M.D.

Discussant: Gregory L. Fricchione, M.D.
 THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 16 2:00 p.m.-5:00 p.m.
 Room B316, Level 3, Georgia World Congress Center

PSYCHOSOMATIC MEDICINE: MANAGING THE HIGH RATES OF MORTALITY AND MORBIDITY

Chp.: Robert G. Robinson, M.D.

- A **Poststroke Depression and Mortality**
 Robert G. Robinson, M.D.
- B **Heart Failure and Major Depression**
 Carolyn L. Turvey, Ph.D.
- C **Mortality and CHD: New Targets for Treatment Studies**
 Francois Lesperance, M.D.
- D **The Effect of Antidepressants on Mortality After Stroke**
 Ricardo Jorge, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 17 2:00 p.m.-5:00 p.m.
 Room B402, Level 4, Georgia World Congress Center

NOVEL TARGETS FOR NOVEL NEUROPSYCHIATRIC DRUGS

Chp.: Elliott Richelson, M.D.

- A **Neurokinin Receptor Antagonists as Antidepressants and Anxiolytics**
 Klaus Lieb, M.D.
- B **Inhibitors of Enkephalin-Degrading Enzymes and Delta Opioid Responses**
 Florence Noble, Ph.D.
- C **Discovery of Nonpeptide CRF1 Receptor Antagonists as Novel Psychotherapeutic Agents**
 Dimitri E. Grigoriadis, Ph.D.
- D **Neurotensin Agonist NT69L: A Drug for Neuropsychiatric Diseases**
 Elliott Richelson, M.D.

E Antidepressant-Elicited Changes in Gene Expression
Mitsuhiko Yamada, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 18 2:00 p.m.-5:00 p.m.
Room B403, Level 4, Georgia World Congress Center

**USE OF CONCOMITANT OR ADJUNCTIVE
MEDICATIONS IN SCHIZOPHRENIA**

Chp.: Ira D. Glick, M.D.

Co-Chp.: Alexander L. Miller, M.D.

- A Use of Combination Antipsychotics**
Alexander L. Miller, M.D.
- B Utilization of Combinations of Antipsychotics in the
Department of Veterans Affairs**
Andre Tapp, M.D.
- C The Use of Antidepressants in Chronic Schizophrenia**
Samuel G. Siris, M.D., Paul C. Bermanzohn, M.D.
- D Use of Adjunctive Medications for Anxiety, Agitation,
and Sleep in Schizophrenia**
Del D. Miller, M.D.
- E Efficacy of Concomitant Medications for Stabilized
Patients With Schizophrenia**
Ira D. Glick, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 19 2:00 p.m.-5:00 p.m.
Room B404, Level 4, Georgia World Congress Center

**MALADAPTIVE PERSONALITY TRAITS: DRUG
TREATMENT, GENETICS, AND BIOLOGY**

Chp.: James H. Reich, M.D.

- A General Approach to Drug Treatment of Maladaptive
Personality Traits**
James H. Reich, M.D.
- B Antipsychotic and Antidepressant Use in Personality
Traits Treatment**
Alan F. Schatzberg, M.D.
- C Mood Stabilizers in Personality Disorder Treatment**
Eric Hollander, M.D., Daphne Simeon, M.D., Bryann
Baker, M.D.
- D New Research Perspectives on the Neurobiology of
Personality Disorders**
Larry J. Siever, M.D.
- E The Neurobiology of Social and Emotional
Dysfunction in BPD**
Michael J. Minzenberg, M.D., Antonia S. New, M.D.,
Harold W. Koenigsberg, M.D., Jin Fan, Erin
Hazlett, Ph.D., Larry J. Siever, M.D.

**F Psychotherapy and Combined Treatment in BPD:
Possible Effects**

Marianne Goodman, M.D., Antonia S. New, M.D.,
Harold W. Koenigsberg, M.D., Erin Hazlett, Ph.D., Janine
Flory, Ph.D., Larry J. Siever, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 20 2:00 p.m.-5:00 p.m.
Room B409, Level 4, Georgia World Congress Center

**THE END OF THE BIOPSYCHOSOCIAL MODEL? AN
ASSESSMENT AND ALTERNATIVES**

Association for the Advancement of Philosophy and Psychiatry

Chp.: S. Nassir Ghaemi, M.D.

Co-Chp.: Rodrigo A. Munoz, M.D.

- A The Limitations of the Biopsychosocial Model in
Psychiatry**
G. Scott Waterman, M.D.
- B The Biopsychosocial Model: Strengths Versus
Weaknesses Related to Assumptions About Good
Scientific Categories**
Peter Zachar, Ph.D.
- C Karl Jaspers and a Pluralist Model of Psychiatry**
S. Nassir Ghaemi, M.D.
- D Healing Psychiatry: The Need for Pragmatism**
David H. Brendel, M.D.
- E Six Questions for Clinical Models**
John Sadler, M.D.

Discussant: Paul R. McHugh, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 21 2:00 p.m.-5:00 p.m.
Birch Room, South Tower, Atrium Terrace Level, Omni
Hotel

**BEHIND CLOSED DOORS: THE HIDDEN FAMILY:
VIOLENCE AND ABUSE ISSUES WORLDWIDE**

APA Alliance

Chp.: Helen Herrman, M.D.

Co-Chp.: Marianne C. Kastrup, M.D.

- A Human Trafficking in Women: Behind Closed Doors**
Donna E. Stewart, M.D., Olga Gajic-Veljanoski
- B Domestic Abuse in the Land of the Devis**
Surinder S. Nand, M.D.
- C Behind Closed Doors in Africa: The Case of Women
and Children**
Frank G. Njenga, M.D.

(Continued next page)

D Specific Aspects Related to Traumatized Women and Their Children
Marianne C. Kastrup, M.D.

E Clinical and Public Health Aspects of Intimate Partner Violence
Helen Herrman, M.D.

SYMPOSIUM 22 2:00 p.m.-5:00 p.m.
Maple Room, South Tower, Atrium Terrace Level, Omni Hotel

LARGE OBSERVATIONAL STUDIES OF ADHD: METHODOLOGY AND RESULTS

Chp.: Calvin R. Sumner, M.D.

A Effect of Atomoxetine in a Naturalistic Pediatric ADHD Treatment Setting
Douglas K. Kelsey, M.D., S. Malcolm, B.S., Rosalie Bakken, Ph.D., M. Paczkowski, M.P.H., Virginia Sutton, Ph.D., Calvin R. Sumner, M.D.

B A Two-Year, Pan-European, Observational Study of ADHD: Overview and Baseline
Ulrich Preuss, M.D., Airbert Rothenberger, Lauren Vlasveld, Stephen J. Ralston, Maria J. Lorenzo

C A Factorial and Graphical Multidimensional Analysis of Patients in ADORE
Bruno Falissard, M.D., Anne W. Riley, Ph.D., Hans-Christoph Steinhausen, Stephen J. Ralston, Maria J. Lorenzo

D Outcomes and Regression Analysis: ADHD Observational Research in Europe
Manfred Doepfner, M.D., Torunn S. Novick, Rob R. Pereira, Stephen J. Ralston, Maria J. Lorenzo

Discussant: Christopher J. Kratochvil, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 23 2:00 p.m.-5:00 p.m.
Pine Room, South Tower, Atrium Terrace Level, Omni Hotel

IMPROVING CARE FOR TRAUMA-RELATED PSYCHIATRIC DISORDERS IN GENERAL MEDICAL SETTINGS

Chp.: Charles C. Engel, M.D.

A Barriers to Care and Psychiatric Disorders Among Iraq and Afghanistan Veterans
Charles W. Hoge, M.D., Carl A. Castro, Ph.D., Stephen C. Messer, Ph.D.

B Improving Primary Care for PTSD: Lessons From the RESPECT-Depression Project
Allen J. Dietrich, M.D.

C Early PTSD and Risk Behavior Intervention After Admission for Acute Surgical Trauma
Douglas F. Zatzick, M.D.

Discussant: Matthew Friedman, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 24 2:00 p.m.-5:00 p.m.
Cottonwood Room, North Tower, Street Level, Omni Hotel

THE PSYCHIATRIC EFFECTS OF THE WORLD TRADE CENTER ATTACK IN DISASTER RELIEF WORKERS

Collaborative Session With the National Institute of Mental Health

Chp.: JoAnn Difede, Ph.D.

A Prevalence and Predictors of PTSD in 2,960 Male Disaster Relief Workers Following the World Trade Center Attack
JoAnn Difede, Ph.D.

B Childhood Sexual Abuse as a Predictor of Psychiatric Symptoms in a Sample of Disaster Relief Workers Following a Terrorist Attack
Pamela Leck, Ph.D.

C Treatment-Readiness in World Trade Center Attack Disaster Workers
Nimali Jayasinghe, Ph.D.

D Self-Report Versus Clinical Assessment of World Trade Center Disaster Workers With PTSD
Frank W. Weathers, Ph.D.

Discussant: Charles R. Marmar, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 25 2:00 p.m.-5:00 p.m.
Dogwood A, North Tower, Street Level, Omni Hotel

RESEARCH UPDATE ON PEDIATRIC BIPOLAR DISORDER

Collaborative Session With the National Institute of Mental Health

Chp.: Daniel P. Dickstein, M.D.

A Course and Outcome of Bipolar Youth
Boris Birmaher, M.D., Martin Retter, M.D., Michael Strober, Ph.D., David A. Axelson, M.D., Neal D. Ryan, M.D., Henrietta L. Leonard, M.D., Mary K. Gill, R.N., Sylvia Valeri, Ph.D.

B Prepubertal Mania: Diagnosis, Prognosis, Family, and Molecular Genetics
Barbara G. Geller, M.D.

- C Pharmacological Treatment Options for Children and Adolescents With Bipolar Disorder**
Melissa P. DelBello, M.D.
- D Pediatric Bipolar Disorder and the Utility of Cardinal Symptoms**
Janet Wozniak, M.D., Joseph Biederman, M.D., Anne Kwon, M.S., Eric Milk, Ph.D.
- E Neurobiological Evidence of Pediatric Phenotypes**
Daniel P. Dickstein, M.D., Brendan Rich, Ph.D., Michael Milham, M.D., Erin McClure, Ph.D., Daniel S. Pine, M.D., Ellen Leibenluft, M.D.

SYMPOSIUM 26 2:00 p.m.-5:00 p.m.
Dogwood B, North Tower, Street Level, Omni Hotel

THE BIOETHICS OF TREATING PSYCHOSES

Chp.: Edmund G. Howe, M.D.

- A Influence of Mood State on Capacity to Consent to Research in Bipolar Patients**
Sahana Misra, M.D., Linda K. Ganzini, M.D.
- B The Unintended Consequences of Antipsychotic Therapy for Schizophrenia**
Michael R. Arambula, M.D.
- C The Unique Case of Psychotic Criminal Defendants**
Paul S. Appelbaum, M.D.
- THIS SESSION WILL BE AUDIOTAPED.**

3:00 p.m. Session

NEW RESEARCH POSTER SESSION 5
3:00 p.m.-5:00 p.m.
Room B302/303/304/305, Level 3, Georgia World Congress Center

PSYCHOSIS AND ADDICTION

For further information on New Research Sessions, please refer to the *New Research Program and Abstracts Book* included in your registration packet.

5:30 p.m. Session

CONVOCAATION OF DISTINGUISHED FELLOWS

5:30 p.m.-6:30 p.m.
Sydney B. Marcus Auditorium, Level 4
Georgia World Congress Center

All Distinguished Life Fellows, Distinguished Fellows, Life Fellows, International Fellows, members, and registered guests are invited.

Presiding: Michelle B. Riba, M.D., *President*

Grand Marshals: Leah J. Dickstein, M.D., Philip M. Margolis, M.D.

Marshals: Peter Ash, M.D., Nathan D. Feibelman, M.D.

INTRODUCTION OF DISTINGUISHED LIFE FELLOWS

Steven S. Sharfstein, M.D., *President-Elect*

INDUCTION OF DISTINGUISHED FELLOWS

Steven S. Sharfstein, M.D.

INTRODUCTION OF FIFTY-YEAR DISTINGUISHED LIFE FELLOWS, FIFTY-YEAR LIFE MEMBERS, AND INTERNATIONAL FELLOWS

Michelle B. Riba, M.D.

INTRODUCTION OF FELLOWS

Michelle B. Riba, M.D.

PRESENTATION OF THE HONORARY FELLOWSHIP MEDALLION

Michelle B. Riba, M.D.

PRESENTATION OF SPECIAL PRESIDENTIAL COMMENDATIONS

Michelle B. Riba, M.D.

PRESENTATION OF DISTINGUISHED SERVICE AWARDS

Michelle B. Riba, M.D.

INTRODUCTION OF THE MEMBERSHIP COMMITTEE CHAIRPERSON AND AWARD BOARD CHAIRPERSONS

Michelle B. Riba, M.D.

PRESENTATION OF AWARDS

Michelle B. Riba, M.D.

APA/Lilly Resident Research Awards
APIRE/Kempf Fund Awards for Research
Development in Psychobiological Psychiatry
Human Rights Awards
Blanche F. Ittleson Award for Research
in Child Psychiatry
Agnes Purcell McGavin Awards
Isaac Ray Award
Jack Weinberg Memorial Award for
Geriatric Psychiatry

WILLIAM C. MENNINGER MEMORIAL CONVOCAATION LECTURE

Trisha Meili

LECTURE 9

5:30 p.m.-6:30 p.m.
 Sydney B. Marcus Auditorium, Level 4
 Georgia World Congress Center

WILLIAM C. MENNINGER MEMORIAL
 LECTURE

Trisha Meili

**I Am the Central Park Jogger:
 A Story of Hope and Possibility**

On April 19, 1989, a young woman went for a run in New York's Central Park shortly after 9:00 p.m. Hours later, she was found near death—in a coma, with 75% blood loss, a fierce blow to the head, and severe exposure—after a brutal beating and rape. The story seized the headlines, as people contemplated what the savagery of the attack said about our society. Fourteen years later, Trisha Meili, known to the world as the Central Park Jogger, revealed her story of survival and recovery in her memoir, *I Am the Central Park Jogger: A Story of Hope and Possibility*. In this lecture, Ms. Meili shares how her journey of healing clearly linked the mind, body, and spirit and allowed her to move beyond being a victim and reclaim her life. Born in Paramus, New Jersey, Ms. Meili attended Wellesley College and was a double graduate degree recipient (M.B.A. and M.A.) at Yale University. After graduation, she worked at the investment bank Salomon Brothers until her life was violently interrupted. Ms. Meili now speaks to groups about her recovery and gives her time to the organizations vital to her healing, including the Sexual Assault and Violence Intervention Program at Mount Sinai Hospital; Gaylord Hospital, where she did much of her rehabilitation; and the Achilles Track Club, which helped her run the New York City Marathon in 1995.

THIS SESSION WILL BE AUDIOTAPED.

7:00 p.m. Sessions

INDUSTRY-SUPPORTED SYMPOSIA 34-38

INDUSTRY-SUPPORTED SYMPOSIUM 34

7:00 p.m.-10:00 p.m.
 Grand Ballroom, Second Floor, Hilton Atlanta

**BIPOLAR DISORDER MANAGEMENT: A NEW
 EDITION**

Supported by GlaxoSmithKline

Chp.: Frederick K. Goodwin, M.D.

- A **When and How to Use Antidepressants for Bipolar Depression**
 S. Nassir Ghaemi, M.D.

- B **Clinical Strategies for Bipolar Depression**
 Terence A. Ketter, M.D.

- C **How to Combine Medications for Long-Term Stabilization**
 Frederick K. Goodwin, M.D.

- D **Recognizing and Treating Bipolar Disorder in Children**
 Gabrielle A. Carlson, M.D.

- E **New Understanding of Psychological Issues and of Effective Psychotherapy**
 Kay Redfield Jamison, Ph.D.

INDUSTRY-SUPPORTED SYMPOSIUM 35

7:00 p.m.-10:00 p.m.
 Imperial Ballroom, Convention Level, Marriott Marquis Atlanta

DUAL DIAGNOSIS: THE SCOPE OF THE PROBLEM
Supported by AstraZeneca Pharmaceuticals

Chp.: Alan I. Green, M.D.

- A **Prevalence and Consequences of Dual Diagnosis**
 Peter F. Buckley, M.D.
- B **Adolescent Substance Abuse and Psychiatric Comorbidities**
 Deborah Deas, M.D.
- C **Psychosocial Intervention for Dual Diagnosis**
 Mary F. Brunette, M.D., Robert Drake, M.D., Kim T. Mueser, Ph.D., Greg McHugo, Ph.D.
- D **Treatment of Bipolar Disorder and Substance Abuse**
 E. Sherwood Brown, M.D.
- E **Treatment of Schizophrenia and Substance Abuse**
 Alan I. Green, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 36

7:00 p.m.-10:00 p.m.
 Marquis Ballrooms I & II, Convention Level, Marriott Marquis Atlanta

INSOMNIA IN SPECIAL POPULATIONS: IS THIS
 INSOMNIA OR SOMETHING ELSE?

Supported by Sepracor, Inc.

Chp.: Ruth M. Benca, M.D.
 Co-Chp.: Claudio N. Soares, M.D.

- A **Insomnia in the Elderly**
 Sonia Ancoli-Israel, Ph.D.
- B **Insomnia in Depressed Patients**
 Ruth M. Benca, M.D.

- C **Insomnia in Women: An Overlooked Epidemic?**
Claudio N. Soares, M.D.

- D **Novel Strategies to Treat Insomnia**
John W. Winkelman, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 37

7:00 p.m.-10:00 p.m.

International Ballroom, North Tower, Ballroom Level,
Omni Hotel

INSULIN RESISTANCE AND METABOLIC SYNDROME IN NEUROPSYCHIATRY

*Supported by Bristol-Myers Squibb Company and Otsuka America
Pharmaceutical, Inc.*

Chp.: Natalie L. Rasgon, M.D.

- A **The Insulin Resistance Syndrome: What Is It? Why Is It Important?**
Gerald Reaven, M.D.
- B **Insulin Resistance and Metabolic Risk During Antipsychotic Treatment**
John W. Newcomer, M.D.
- C **Risk, Assessment, and Management of Insulin Resistance in Affective Disorders**
H. Brent Solvason, M.D.
- D **Insulin Resistance and Cognitive Disorders**
Suzanne Craft, Ph.D.
- E **Insulin Resistance: The Link Between Affective Disorders and Alzheimer's Disease**
Natalie L. Rasgon, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 38

7:00 p.m.-10:00 p.m.

Grand Ballroom, North Tower, Grand Ballroom Level,
Omni Hotel

OVERCOMING TRADITIONAL DILEMMAS IN TREATING DEPRESSIVE ILLNESSES: EVIDENCE- BASED UPDATES

Supported by Wyeth Pharmaceuticals

Chp.: John F. Greden, M.D.

- A **Improved Remission Rates: Do Any Antidepressants Stand Out?**
Linda L. Carpenter, M.D.
- B **Influence of Comorbidity on the Treatment of Depression**
David L. Dunner, M.D.
- C **Combining Antidepressant Treatments for Better Efficacy: What Does the Literature Say?**
Thomas L. Schwartz, M.D.
- D **Brain Stimulation in Psychiatric Treatment: State of the Evidence**
Sarah H. Lisanby, M.D.
- E **Effectiveness of Antidepressant Treatments for Preventing Recurrences: Several Decades of Evidence**
John F. Greden, M.D.

American Psychiatric Association

Audiotapes and CDs
Recorded Live!



*High Quality Continues for
the 2005 Annual Meeting ...*

Live recordings will be available
for most of the following:

- Lectures • Advances in Research
- Advances in Psychotherapy • Advances in Psychosomatic Medicine
- Presidential Symposia • Medical Updates
- Scientific and Clinical Reports • Symposia
- Debate • Roundtable Discussion
- Research Advances in Medicine

Tapes may be purchased on site at Mobiltape's booth at the Georgia World Congress Center.

Mobiltape Company, Incorporated

24730 Avenue Tibbitts, Suite 170

Valencia, CA 91355

Phone: (661) 295-0504 □ (800) 369-5718

Fax: (661) 295-8474

Website: www.mobiltape.com

TUESDAY, MAY 24, 2005

158TH ANNUAL MEETING

7:00 a.m. Sessions

PART 2 OF INDUSTRY-SUPPORTED BREAKFAST SYMPOSIA 31-33

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 31, PART 2

7:00 a.m.-8:30 a.m.

Imperial Ballroom, Convention Level, Marriott Marquis Atlanta

AGITATION AND PSYCHOSIS IN ALZHEIMER'S DISEASE AND PARKINSON'S DISEASE

Supported by AstraZeneca Pharmaceuticals

Chp.: Jeffrey L. Cummings, M.D.

A Efficacy and Tolerability of Atypical Antipsychotics in Agitation and Psychosis: Research Results

Pierre N. Tariot, M.D.

B Efficacy and Tolerability of Atypical Antipsychotics in Agitation and Psychosis: Clinical Applications

Jeanne Jackson-Siegel, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 32, PART 2

7:00 a.m.-8:30 a.m.

International Ballroom, North Tower, Ballroom Level, Omni Hotel

MANAGING THE SPECTRUM OF BIPOLAR DISORDER: MINIMIZING THE BURDEN OF DISEASE

Supported by Bristol-Myers Squibb Company and Otsuka America Pharmaceutical, Inc.

Chp.: Robert E. Hales, M.D.

Co-Chp.: Stuart C. Yudofsky, M.D.

A The Impact of Safety and Tolerability on Patient Satisfaction With Therapy

Paul E. Keck, Jr., M.D.

B The Impact of Bipolar Maintenance Therapy on Patient Outcomes

Loi L. Altshuler, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 33, PART 2

7:00 a.m.-8:30 a.m.

Grand Ballroom, North Tower, Grand Ballroom Level, Omni Hotel

ADVANCES IN THE TREATMENT OF MOOD AND ANXIETY DISORDERS IN WOMEN

Supported by Wyeth Pharmaceuticals

Chp.: Susan G. Kornstein, M.D.

A Menopausal Transition: Impact on Mood, Sleep, and Quality of Life

Claudio N. Soares, M.D.

B Managing Bipolar Disorder in Women

Lesley M. Arnold, M.D.

8:00 a.m. Sessions



COURSES 58-65

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

COURSE 58 - WITHDRAWN

COURSE 59

8:00 a.m.-12 noon

Newton Room, Second Floor, Hilton Atlanta

IMPROVING YOUR PRESENTATION SKILLS: A COACHING APPROACH

Director: Luis F. Ramirez, M.D.

COURSE 60

8:00 a.m.-12 noon

Rockdale Room, Second Floor, Hilton Atlanta

DYNAMIC PSYCHOTHERAPY FOR CANCER PATIENTS AND THEIR SPOUSES

Director: Norman L. Straker, M.D.

COURSE 61 8:00 a.m.-12 noon
 Gwinnett Room, Second Floor, Hilton Atlanta

EXPANDING HEALTH CARE DELIVERY? LET TELEPSYCHIATRY HELP!

Director: Steven E. Hyler, M.D.
Faculty: William M. Tucker, M.D., Gerald Segal, M.S., Scott I. Bienenfeld, M.D.

COURSE 62 8:00 a.m.-12 noon
 Grand Salon A, Second Floor, Hilton Atlanta

THE WAY OF YOGA AND HERBS IN THE TREATMENT OF STRESS, DEPRESSION, AND AGGRESSION

Co-Directors: Richard P. Brown, M.D., Patricia L. Gerbarg, M.D.

COURSE 63 8:00 a.m.-12 noon
 Grand Salon B, Second Floor, Hilton Atlanta

SLEEP MEDICINE UPDATE: ADVANCED TOPICS

Director: Thomas D. Hurwitz, M.D.
Faculty: Max Hirshkowitz, Ph.D., Lois Krahn, M.D.

COURSE 64 8:00 a.m.-12 noon
 Monroe/Roosevelt Room, Third Floor, Hilton Atlanta

THE DETECTION OF MALINGERED MENTAL ILLNESS

Director: Phillip J. Resnick, M.D.

COURSE 65 8:00 a.m.-12 noon
 Board/Directors Rooms, Fourth Floor, Hilton Atlanta

HOW TO USE YOUR PALM OS PDA IN PSYCHIATRIC PRACTICE: BASIC

Co-Directors: John Luo, M.D., Richard Montgomery, M.D.
Faculty: Umar Latif, M.D., Robert J. Boland, M.D., Carlyle H. Chan, M.D., Robert C. Hsiung, M.D., Charles J. Rainey, M.D.

9:00 a.m. Sessions

ADVANCES IN PSYCHOSOMATIC MEDICINE

9:00 a.m.-12:30 p.m.
 Rooms B405/406/407, Level 4, Georgia World Congress Center

ADVANCES IN PSYCHOSOMATIC MEDICINE: PSYCHIATRIC CARE OF THE MEDICALLY ILL

American Psychiatric Publishing Inc. Editorial Board

Chp.: James L. Levenson, M.D.

A Psychiatric Aspects of Heart Disease
 Peter A. Shapiro, M.D.

B Psychiatric Aspects of Cancer
 Mary Jane Massie, M.D.

C Psychiatric Aspects of Obstetrics and Gynecology
 Donna E. Stewart, M.D.

D Psychiatric Aspects of Organ Transplantation
 Andrea F. DiMartini, M.D.

E Psychopharmacology in the Medically Ill
 Michael J. Robinson, M.D.

CLINICAL CASE CONFERENCE 2

9:00 a.m.-10:30 a.m.
 Room A402, Level 4, Georgia World Congress Center

CONSULTATION/LIAISON CASEBOOK CHALLENGE: STRATEGIES AND LIMITATIONS IN ESTABLISHING COMPETENCY

Moderator: Elisabeth J.S. Kunkel, M.D.
Presenters: Angel Angelov, M.D., Larissa Chism, M.D., Dimitri D. Markov, M.D.

THIS SESSION IS OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

CONTINUOUS CLINICAL CASE CONFERENCE 1: PART 2

9:00 a.m.-12 noon
 Room A403, Level 4, Georgia World Congress Center

CONTROL WHAT YOU CAN: SUCCESSFUL TREATMENT OF TEENAGERS IN CHRONIC PAIN

Moderator: Eva M. Szigethy, M.D.
Presenters: John Campo, M.D., David DeMaso, M.D., Eyal Shemesh, M.D.

THIS SESSION IS OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.



COURSES 66-72

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

COURSE 66 9:00 a.m.-4:00 p.m.
Fulton Room, Second Floor, Hilton Atlanta

THE ASSESSMENT AND TREATMENT OF CHILD SEXUAL ABUSERS

Co-Directors: Gene G. Abel, M.D., John M. Bradford, M.B.
Faculty: Tracey L. Irvin, M.D.

COURSE 67 9:00 a.m.-4:00 p.m.
Cobb Room, Second Floor, Hilton Atlanta

MONEY MATTERS II: ADVANCED AD HOC CLINICAL SEMINAR

Director: Cecilia M. Mikalac, M.D.

COURSE 68 9:00 a.m.-4:00 p.m.
Clayton Room, Second Floor, Hilton Atlanta

TRAUMATIC BRAIN INJURY: NEUROPSYCHIATRIC ASSESSMENT

Director: Robert P. Granacher, Jr., M.D.

COURSE 69 9:00 a.m.-4:00 p.m.
Grand Salon D, Second Floor, Hilton Atlanta

MED-PSYCH DRUG-DRUG INTERACTIONS

Co-Directors: Neil B. Sandson, M.D., Scott C. Armstrong, M.D.
Faculty: David M. Benedek, M.D., Gabriel Eckermann, M.D.,
Jessica R. Oesterheld, M.D.

COURSE 70 9:00 a.m.-4:00 p.m.
Jackson Room, Third Floor, Hilton Atlanta

PERSONALITY AND POLITICAL BEHAVIOR
APA Council on Global Psychiatry

Director: Jerrold M. Post, M.D.

COURSE 71 9:00 a.m.-4:00 p.m.
Madison Room, Third Floor, Hilton Atlanta

RECOGNITION AND TREATMENT OF COMPLICATED GRIEF

Director: M. Katherine Shear, M.D.
Faculty: Bonnie Gorscak, Ph.D., Allan Zuckoff, Ph.D., Naomi M. Simon, M.D.

COURSE 72 9:00 a.m.-4:00 p.m.
Club/State Rooms, Fourth Floor, Hilton Atlanta

PROVIDER PROTECT THYSELF: MANAGED CARE CONTRACTING FOR MENTAL HEALTH PROVIDERS

Director: William H. Campbell, M.D.

DISCUSSION GROUPS 9-12

9:00 a.m.-10:30 a.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

- 9 **Pedro Ruiz, M.D.**, on the Role of Culture in Psychiatric Practice (*For Residents Only*)
International Rooms 2-3, International Level, Marriott Marquis Atlanta
- 10 **K. Ranga R. Krishnan, M.D.**, on Psychiatric Diagnosis: Approaches in the Post-Genomic Era
Collaborative Session With the National Institute of Mental Health
Chestnut Room, North Tower, Meeting Level, Omni Hotel
- 11 **Katherine L. Wisner, M.D.**, on Postpartum Mood Disorders
Hazelnut Room, North Tower, Meeting Level, Omni Hotel
- 12 **Ronald W. Pies, M.D.**, on the Great Bipolar Depression Controversy: A Pragmatic Approach (*Meet the Authors*)
Pecan Room, North Tower, Meeting Level, Omni Hotel

LECTURES 10-11

LECTURE 10

9:00 a.m.-10:30 a.m.
Sydney B. Marcus Auditorium, Level 4
Georgia World Congress Center

Robert Freedman, M.D.

From Genes to Therapeutics:
New Approaches to Schizophrenia
*Collaborative Session With the National
Institute of Mental Health*

Chp.: John F. Greden, M.D.
Co-Chp.: Anthony J. Rothschild, M.D.

(Continued next page)

Robert Freedman, M.D., is Chairman of the Department of Psychiatry, Professor of Psychiatry and Pharmacology, and Director of the Schizophrenia Research Center at the University of Colorado Health Sciences Center in Denver and the Denver Veterans Affairs Mental Illness Research, Education and Clinical Center. His research interest is in the application of basic findings in neurobiology and molecular biology to the treatment of psychoses. The author of more than 200 scientific articles, Dr. Freedman has received the A.E. Bennett Research Award of the Society of Biological Psychiatry, the William K. Warren Award of the International Congress of Schizophrenia Research, the Stanley R. Dean Award of the American College of Psychiatrists, and the Distinguished Investigator Award of the National Alliance for Research on Schizophrenia and Depression. He is a Distinguished Fellow of the American Psychiatric Association and a member of the Institute of Medicine, the Board of Scientific Counselors of the National Institute on Drug Abuse, and the National Advisory Council of the National Institutes of Health. Dr. Freedman received his medical degree from Harvard Medical School in Boston and trained in psychiatry at the National Institute of Mental Health in Bethesda, Maryland, and the University of Chicago Hospital and Clinics.

Distinguished Psychiatrist Series

THIS SESSION WILL BE AUDIOTAPED.

LECTURE 11

9:00 a.m.-10:30 a.m.

Room A412, Level 4

Georgia World Congress Center

APA'S KUN-PO SOO AWARD LECTURE

K. Patrick Okura, Ph.D. (*Posthumously*)

**Leadership Through Example:
Mentorship and Networking**

Chp.: John Luo, M.D.

Co-Chp.: Russell F. Lim, M.D.

This lecture will be an open discussion focusing on K. Patrick Okura's life as a dynamic example of leadership through example. He served as the unofficial mayor of the Santa Anita Assembly Center (a Japanese American Internment Camp) in 1941, the National President for the Japanese American Citizen's League from 1962-64, where he led the effort to join Martin Luther King, Jr., in his march on Washington, DC, and as the Director of the Okura Mental Health Foundation, in addition to other leadership positions.
THIS SESSION WILL BE AUDIOTAPED.

MASTER EDUCATOR CLINICAL CONSULTATIONS 5-6

9:00 a.m.-10:30 a.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

5 **Harold Kudler, M.D., on PTSD and Deployment Mental Health**
Room B317, Level 3, Georgia World Congress Center

6 **John D. Wynn, M.D., on Psychosomatics and the Medically Complex Patient: Sorting Out Axis I, II, and III**
Room B318, Level 3, Georgia World Congress Center

THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

RESEARCH ADVANCES IN MEDICINE

9:00 a.m.-11:00 a.m.

Room A302, Level 3, Georgia World Congress Center

EXPLORING NEW FRONTIERS AND CLINICAL APPLICATIONS

Chp.: Charles B. Nemeroff, M.D.

Co-Chp.: Marian I. Butterfield, M.D.

Participants: Cornelia M. Weyand, M.D., on **Immunosenescence and Rheumatoid Arthritis**
Elizabeth Ofili, M.D., on **Research Advances in Cardiovascular Diseases**

Lawrence S. Phillips, M.D., on **Diabetes Update 2005**

David G. Harrison, M.D., on **Vascular Diseases, Oxidative Stress, and Depression**

Viola Vaccarino, M.D., on **Stress, Depression, and the Metabolic Syndrome**

ROUND TABLE DISCUSSION

9:00 a.m.-10:30 a.m.

Room A404, Level 4, Georgia World Congress Center

SAFETY AND EFFICACY OF SSRI ANTIDEPRESSANTS IN CHILDREN AND ADOLESCENTS: WHAT DO WE KNOW AND WHEN DID WE KNOW IT?

Moderator: Richard E. D'Alli, M.D.

Participants: Graham J. Emslie, M.D., John S. March, M.D., John T. Walkup, M.D., Benedetto Vitiello, M.D.

WORKSHOPS

COMPONENTS 18-26

COMPONENT WORKSHOP 18

9:00 a.m.-10:30 a.m.

Room A304, Level 3, Georgia World Congress Center

"Y" PSYCHOTHERAPY: AN INTEGRATED, EVIDENCE-BASED PSYCHOTHERAPY COMPETENCY MODEL

APA Committee on Psychotherapy by Psychiatrists

Co-Chps.: Eric M. Plakun, M.D., Lisa A. Mellman, M.D.

Participants: Daniel T. Chrzanowski, M.D., Allison V. Downer, M.D., Asher B. Simon, M.D.

COMPONENT WORKSHOP 19 9:00 a.m.-10:30 a.m.

Room A405, Level 4, Georgia World Congress Center

PATIENT SAFETY: EVALUATING AN ADVERSE EVENT AND IMPLEMENTING SAFEGUARDS*APA Committee on Patient Safety***Chp.:** Paul R. McHugh, M.D.**Participants:** Alfred Herzog, M.D., Geetha Jayaram, M.D., Robert A. Wise, M.D., Kathryn J. Ednie, M.D., Bruce W. Hinrichs, M.D., Carl B. Greiner, M.D., Carol B. Perez, M.D.**COMPONENT WORKSHOP 20** 9:00 a.m.-10:30 a.m.

Room B307, Level 3, Georgia World Congress Center

CLOSING PRACTICE: WHAT EVERY PSYCHIATRIST'S OFFICE AND HIS/HER FAMILY SHOULD KNOW*APA Corresponding Committee on Physician Health, Illness, and Impairment***Chp.:** John A. Fromson, M.D.**Participants:** Michael F. Myers, M.D., Cheryl Davenport**COMPONENT WORKSHOP 21** 9:00 a.m.-10:30 a.m.

Room B311, Level 3, Georgia World Congress Center

NOVEL CAREERS IN PSYCHIATRY: WOMEN WHO HAVE MADE THEIR OWN WAY*APA Committee on Women***Co-Chps.:** Melva I. Green, M.D., Carrie L. Ernst, M.D.**Participants:** Catherine A. Roca, M.D., Francine Cournos, M.D., Cassandra F. Newkirk, M.D., Mary Jane England, M.D.**COMPONENT WORKSHOP 22** 9:00 a.m.-10:30 a.m.

Room B315, Level 3, Georgia World Congress Center

REVERSING THE CRIMINALIZATION OF THE SERIOUSLY MENTALLY ILL*APA Corresponding Committee on Jails and Prisons***Chp.:** Henry C. Weinstein, M.D.**Participants:** Tom Hamilton, H. Richard Lamb, M.D., Erik Roskes, M.D.**COMPONENT WORKSHOP 23** 9:00 a.m.-10:30 a.m.

Room B408, Level 4, Georgia World Congress Center

DISASTER PSYCHIATRY: CHALLENGES AND NOVEL STRATEGIES FOR RESIDENCY TRAINING*APA Committee on Psychiatric Dimensions of Disasters***Co-Chps.:** Diane E. McLean, M.D., Anthony T. Ng, M.D.**Participants:** Davin A. Agustines, M.D., Holly V. MacKenna, M.D., Roman R. Snihurowych, M.D., Molly J. Hall, M.D.**COMPONENT WORKSHOP 24** 9:00 a.m.-10:30 a.m.

Spruce Room, South Tower, Atrium Terrace Level, Omni Hotel

ETHNICITY, CULTURE, AND RESPONSE TO DISASTER AMONG HISPANICS*APA Committee of Hispanic Psychiatrists***Chp.:** Eugenio M. Rothe, M.D.**Participant:** Daniel Castellanos, M.D.**COMPONENT WORKSHOP 25** 9:00 a.m.-10:30 a.m.

Oak Room, South Tower, Lobby Level, Omni Hotel

SUICIDE AMONG ETHNIC ELDERLY*APA Committee on Ethnic Minority Elderly***Co-Chps.:** Iqbal Ahmed, M.D., Warachal E. Faison, M.D.**Participants:** Carl I. Cohen, M.D., Mia J. Robinson, M.D., Yolonda R. Coleman, M.D., Cynthia I. Resendez, M.D., Nhi-Ha T. Trinh, M.D., Ronald Brenner, M.D.**COMPONENT WORKSHOP 26** 9:00 a.m.-10:30 a.m.

Dogwood B, North Tower, Street Level, Omni Hotel

USING THE HIV DEMENTIA SCALE IN THE CLINICAL SETTING*APA Committee on AIDS***Chp.:** Karl Goodkin, M.D.**Participants:** Francisco Fernandez, M.D., Stephen J. Ferrado, M.D., Giovanni Caracci, M.D., Marshall Forstein, M.D.**ISSUES 27-43****ISSUE WORKSHOP 27** 9:00 a.m.-10:30 a.m.

Room A410, Level 4, Georgia World Congress Center

ARE THERE LIMITS TO BOUNDARY LIMITS?**Chp.:** Malkah T. Notman, M.D.**Participants:** Carl P. Malmquist, M.D., Linda M. Jorgenson, J.D., Elissa P. Benedek, M.D., Lawrence B. Inderbitzin, M.D.**ISSUE WORKSHOP 28** 9:00 a.m.-10:30 a.m.

Room B301, Level 3, Georgia World Congress Center

CHILDREN OF PSYCHIATRISTS: LISTEN AND LEARN**Co-Chps.:** Leah J. Dickstein, M.D., Michelle B. Riba, M.D.**Participants:** Sarah Sharfstein, Cory Butterfield, India Primm-Spencer, Sudepta Varma, M.D.

ISSUE WORKSHOP 29 9:00 a.m.-10:30 a.m.

Room B306, Level 3, Georgia World Congress Center

ABPN AND APA PERSPECTIVES ON MAINTENANCE OF CERTIFICATION**Chp.:** Stephen C. Scheiber, M.D.**Participants:** Victor I. Reus, M.D., Deborah J. Hales, M.D., David B. Mallott, M.D.**ISSUE WORKSHOP 30** 9:00 a.m.-10:30 a.m.

Room B308, Level 3, Georgia World Congress Center

HOW TO LAUNCH A SUCCESSFUL PRIVATE PRACTICE, PART 1**Co-Chps.:** William E. Callahan, Jr., M.D., Keith W. Young, M.D.**Participants:** Jacqueline M. Melonas, J.D., Martin G. Tracy, J.D.**ISSUE WORKSHOP 31** 9:00 a.m.-10:30 a.m.

Room B309, Level 3, Georgia World Congress Center

PAIN MANAGEMENT OF THE CHEMICALLY-DEPENDENT PATIENT**Chp.:** Jeffrey A. Berman, M.D.**Participants:** Christine Skotzko, M.D., Elena Volfson, M.D.**ISSUE WORKSHOP 32** 9:00 a.m.-10:30 a.m.

Room B310, Level 3, Georgia World Congress Center

STRATEGIES FOR SUCCESS FOR EARLY CAREER ACADEMIC PSYCHIATRISTS, PART 1: WRITING FOR PUBLICATION*Collaborative Session With the National Institute of Mental Health***Chp.:** Laura W. Roberts, M.D.**ISSUE WORKSHOP 33** 9:00 a.m.-10:30 a.m.

Room B314, Level 3, Georgia World Congress Center

DECISIONAL CAPACITY IN THE CONSULTATION/LIAISON SETTING: CONTROVERSIES AND DIFFICULTIES**Chp.:** Ramaswamy Viswanathan, M.D.**Participants:** Paul S. Appelbaum, M.D., Barbara K. Schindler, M.D., Scott Y. Kim, M.D., Laura B. Dunn, M.D.**ISSUE WORKSHOP 34** 9:00 a.m.-10:30 a.m.

Room B316, Level 3, Georgia World Congress Center

PSYCHIATRIC HOSPICE ON AN ACT TEAM: WHEN MENTAL ILLNESS IS TERMINAL**Co-Chps.:** Curtis N. Adams, Jr., M.D., Ann L. Hackman, M.D.**ISSUE WORKSHOP 35** 9:00 a.m.-10:30 a.m.

Room B403, Level 4, Georgia World Congress Center

DETECTION OF MALINGERING IN DISABILITY EVALUATIONS**Chp.:** Roger Z. Samuel, M.D.**Participants:** Tom McLaren, Ph.D., Lawrence Gordon**ISSUE WORKSHOP 36** 9:00 a.m.-10:30 a.m.

Room B404, Level 4, Georgia World Congress Center

TEACHING PSYCHOSOMATIC MEDICINE FOR PRIMARY CARE PHYSICIANS: WHAT, HOW, AND WHERE?**Chp.:** Hoyle Leigh, M.D.**Participants:** Don R. Lipsitt, M.D., Seth M. Powsner, M.D.**ISSUE WORKSHOP 37** 9:00 a.m.-10:30 a.m.

Room B409, Level 4, Georgia World Congress Center

SHAKESPEARE, PSYCHIATRY, AND PSYCHOPATHOLOGY**Chp.:** Steven E. Pflanz, M.D.**Participant:** Charles R. Joy, M.D.**ISSUE WORKSHOP 38** 9:00 a.m.-10:30 a.m.

Birch Room, South Tower, Atrium Terrace Level, Omni Hotel

UNCOVERING MEDICAL CAUSES OF FUNCTIONAL DECLINE IN THE DEVELOPMENTALLY DISABLED**Chp.:** Stephen M. Soltys, M.D.**Participants:** Rodney C. Curtis, M.D., Klara I. Curtis, M.D., Steven L. Thornton, M.D.**ISSUE WORKSHOP 39** 9:00 a.m.-10:30 a.m.

Maple Room, South Tower, Atrium Terrace Level, Omni Hotel

DRUG COMPANIES IN TRAINING CLINICS: ECONOMIC NECESSITY VERSUS UNDUE INFLUENCE**Co-Chps.:** Edward A. Volkman, M.D., Ruth M. Lamdan, M.D.**Participants:** Roya Lewis, M.D., Robert L. Boyd, M.D., Autumn Ning, M.D., Darryl Atherholt, Diane B. Gottlieb, M.D.

ISSUE WORKSHOP 40 9:00 a.m.-10:30 a.m.

Pine Room, South Tower, Atrium Terrace Level, Omni Hotel

DRIVING MISS DAISY

Co-Chps.: Theron C. Bowers, Jr., M.D., Sheila M. Loboprabhu, M.D.

Participants: Jeffrey Lindeman, Psy.D., Kelly C. Anderson

ISSUE WORKSHOP 41 9:00 a.m.-10:30 a.m.

Cottonwood Room, North Tower, Street Level, Omni Hotel

PSYCHIATRISTS INTERVENING UPSTREAM: GOOD PRACTICES FOR PREVENTING VIOLENCE IN CHILDREN, YOUTH, AND FAMILIES

Collaborative Session With the National Institute of Mental Health

Chp.: Giuseppe Raviola, M.D.

Participants: Carl C. Bell, M.D., W. Rodney Hammond, Ph.D., Fran Henry, M.B.A., Mark L. Rosenberg, M.D.

ISSUE WORKSHOP 42 9:00 a.m.-10:30 a.m.

Redwood Room, North Tower, Street Level, Omni Hotel

CULTURAL COMPETENCE IN THE CLINICAL ENCOUNTER: IRMA BLAND AND EVELYN LEE

Chp.: Francis G. Lu, M.D.

Participant: Harriett Koskoff

ISSUE WORKSHOP 43 9:00 a.m.-10:30 a.m.

Juniper Room, North Tower, Ballroom Level, Omni Hotel

A NEW MODEL FOR THE TREATMENT OF RELATIONAL DISORDERS

Co-Chps.: Glenn N. Siegel, M.D., Mary Pittman, M.S.

MEDIA 4-6

MEDIA WORKSHOP 4 9:00 a.m.-12 noon

Room A406, Level 4, Georgia World Congress Center

Jim in Bold: Gay, Lesbian, and Transgender Teens on Film
American Academy of Child and Adolescent Psychiatry's Sexual Orientation Committee

Co-Chps.: Richard R. Pleak, M.D., Sarah E. Herbert, M.D.

Participants: Malcolm Lazin, Susan Wheeler

MEDIA WORKSHOP 5

9:00 a.m.-12 noon

Room A407, Level 4, Georgia World Congress Center

Long-Term Management of Schizophrenia in the Film *Out of the Shadow*

Co-Chps.: Stephen M. Goldfinger, M.D., Susan E. Smiley, B.S.

Participant: Kenneth S. Duckworth, M.D.

MEDIA WORKSHOP 6

9:00 a.m.-12 noon

Room A408, Level 4, Georgia World Congress Center

Intergenerational Family Abuse: A Documentary Film

Chp.: Barry Herman, M.D.

Participants: Patti Obrow White, Manuel Garcia, M.D., Harold I. Eist, M.D.

11:00 a.m. Sessions

DISCUSSION GROUPS 13-15

11:00 a.m.-12:30 p.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

- 13 Joel Yager, M.D., on Career Building in Academic and Nonacademic Psychiatry (*For Residents Only*)
International Rooms 2-3, International Level, Marriott Marquis Atlanta
- 14 Tana A. Grady-Weliky, M.D., on Effective Teaching: What Psychiatry Residents Need to Know
Hazelnut Room, North Tower, Meeting Level, Omni Hotel
- 15 John A. Chiles, M.D., on Assessment and Treatment of Suicidal Patients (*Meet the Authors*)
Pecan Room, North Tower, Meeting Level, Omni Hotel

LECTURE 12

11:00 a.m.-12:30 p.m.

Sydney B. Marcus Auditorium, Level 4
Georgia World Congress Center

APA'S JUDD MARMOR AWARD LECTURE

Thomas R. Insel, M.D.

Psychiatry in the Genomic Era
Collaborative Session With the National Institute of Mental Health

Chp.: Alan F. Schatzberg, M.D.

Co-Chp.: David M. Spiegel, M.D.

(Continued next page)

Thomas R. Insel, M.D., is the Director of the National Institute of Mental Health in Bethesda, Maryland. He formerly was the W.E. Timmie Professor of Psychiatry and Behavioral Sciences and Director of the Center for Behavioral Neuroscience at Emory University in Atlanta. In his research, Dr. Insel has used molecular, cellular, and pharmacological approaches to explore the neurobiology of complex social behaviors, including maternal behavior, pairbond formation, and aggression, and examine the role of the neuropeptides oxytocin and vasopressin in these behaviors. Dr. Insel serves on the editorial boards of *Critical Reviews in Neurobiology*, *Psychoneuroendocrinology*, and *Biological Psychiatry*. A Fellow of the American College of Neuropsychopharmacology, Dr. Insel has received the Distinguished Investigator Award from the National Alliance for Research on Schizophrenia and Depression, the A.E. Bennett Research Award from the Society of Biological Psychiatry, and the Outstanding Service Award from the U.S. Public Health Service. He is the author of more than 200 scientific articles and book chapters and the author or editor of four books, including *The Psychobiology of Obsessive Compulsive Disorder* and *Oxytocin in Maternal, Sexual and Social Behaviors*. Dr. Insel received his medical degree from Boston University Medical School and completed his residency in psychiatry at Langley Porter Neuropsychiatric Institute, University of California, San Francisco.

THIS SESSION WILL BE AUDIOTAPED.

MASTER EDUCATOR CLINICAL CONSULTATIONS 7-8

11:00 a.m.-12:30 p.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

- 7 **Josepha A. Cheong, M.D.**, on Geriatric Psychiatry
Room B317, Level 3, Georgia World Congress Center
- 8 **Silvia W. Olarte, M.D.**, on Psychodynamics in the Era of Psychopharmacology
Room B318, Level 3, Georgia World Congress Center

THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

MEDICAL UPDATE 2

11:00 a.m.-12:30 p.m.

Room B403, Level 4, Georgia World Congress Center

STRESS-INDUCED ANOVULATION: MIND OVER MATTER

Presenter: Sara Berga, M.D.

Chp.: Jennifer I. Downey, M.D.

THIS SESSION WILL BE AUDIOTAPED.

RESEARCH CONSULTATION WITH

11:00 a.m.-12:30 p.m.

This session is limited to 25 participants on a first-come, first-served basis.

- 2 **Helen S. Mayberg, M.D.**, on Functional Neuroimaging Strategies in Affective Disorders Research
Collaborative Session With the National Institute of Mental Health Chestnut Room, North Tower, Meeting Level, Omni Hotel

SCIENTIFIC AND CLINICAL REPORT SESSIONS 10-18

SCIENTIFIC AND CLINICAL REPORT SESSION 10

11:00 a.m.-12:30 p.m.

Room A402, Level 4, Georgia World Congress Center

EPIDEMIOLOGY AND OTHER ISSUES IN PSYCHIATRY

Chp.: Steven A. Epstein, M.D.

Co-Chp.: Daniel P. Chapman, Ph.D.

11:00 a.m.

- 29 **Parental Separation at Birth and Schizophrenia and Depression**
Pirjo H. Maki, M.D., Juha M. Veijola, Ph.D., Matti Joukamaa, M.D., Helinä Hakko, Ph.D., Matti K. Isohanni, Ph.D.

11:30 a.m.

- 30 **Parental Separation at Birth and Substance-Use Disorder**
Juha M. Veijola, Ph.D., Pirjo H. Maki, M.D., Matti Joukamaa, M.D., Marianne Haapea, M.B., Matti K. Isohanni, Ph.D.

12 noon

- 31 **Pica Syndrome: Review and Relevance**
Jambur V. Ananth, M.D., Virginia Corpuz, M.D., Belinda A. Hara, M.D., Sharat Parameswaran, B.S., Sarath Gunatilake, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 11

11:00 a.m.-12:30 p.m.

Room A404, Level 4, Georgia World Congress Center

SOMATIC THERAPIES

Chp.: C. Edward Coffey, M.D.

Co-Chp.: Carrie L. Ernst, M.D.

11:00 a.m.

- 32 The Impact of Electroconvulsive Therapy on Quality of Life and Function

W. Vaughn McCall, M.S.

11:30 a.m.

- 33 Seizures Targeted to Circuitry: New Forms of Convulsive Therapy

Collaborative Session With the National Institute of Mental Health

Sarah H. Lisanby, M.D.

12 noon

- 34 Ethical and Legal Implications of Psychiatric Evaluation of Pediatric Gastric Bypass

Gagan Dhaliwal, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 12

11:00 a.m.-12:30 p.m.

Room B301, Level 3, Georgia World Congress Center

COGNITIVE DISORDERS

Chp.: Frank N. Brown, M.D.

Co-Chp.: Warachal E. Faison, M.D.

11:00 a.m.

- 35 Is Depression a Risk Factor for Cognitive Impairment? A Meta-Analysis of 20 Cohort Studies

Alex J. Mitchell, M.D.

11:30 a.m.

- 36 Treatment of Agitation and Psychosis in Elderly Patients With Dementia

Pierre N. Tariot, M.D.

12 noon

- 37 Prevalence of Dementia in a Southern European Population in Two Different Time Periods

Pedro Saz, M.D., Antonio Lobo, M.D., Guillermo Marcos, M.D., José-Luis DÍa, M.D., Concepción De-la-Cámara, M.D., Tirso Ventura, M.D., José-Ángel Montañés, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 13

11:00 a.m.-12:30 p.m.

Room B306, Level 3, Georgia World Congress Center

PSYCHOSOMATIC MEDICINE

Chp.: David A. Casey, M.D.

Co-Chp.: Catherine C. Crone, M.D.

11:00 a.m.

- 38 Somatization Increases Medical Care Utilization and Costs

Arthur J. Barsky, M.D., E. John Orav, Ph.D., David Bates, M.D.

11:30 a.m.

- 39 The Integrated Management of Medically Unexplained Symptoms

Donald Bakal, Ph.D., Patrick Coll, M.D., Jeffrey Schaefer, M.D.

12 noon

- 40 Medical and Psychiatric Comorbidities of a Substance Abusing Public Assistance Population

Bruce J. Schwartz, M.D., Scott Wetzler, Ph.D., Tami Videon, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 14

11:00 a.m.-12:30 p.m.

Room B408, Level 4, Georgia World Congress Center

BIOLOGICAL PSYCHIATRY AND NEUROSCIENCE

Chp.: Roy H. Perlis, M.D.

Co-Chp.: Wayne J. Katon, M.D.

11:00 a.m.

- 41 Brainstem Control of Neurotic and Psychotic Processes

Jacques St. Laurent, M.D.

11:30 a.m.

- 42 Brain Stimulation: Why, Where, and How?

Collaborative Session With the National Institute of Mental Health
Harold A. Sackeim, Ph.D.

12 noon

- 43 New Findings on Daily Prefrontal Repetitive Transcranial Magnetic Stimulation for Depression

Collaborative Session With the National Institute of Mental Health
Mark S. George, M.D.

SCIENTIFIC AND CLINICAL REPORT SESSION 15

11:00 a.m.- 12:30 p.m.

Room B409, Level 4, Georgia World Congress Center

ASPECTS OF BIPOLAR DISORDER

Chp.: Thomas R. Thompson, M.D.

Co-Chp.: Meera Vaswani, Ph.D.

11:00 a.m.

44 Negative Impact of Medical Comorbidity on the Course of Bipolar Disorder

Dan V. Iosifescu, M.D., Polina Eidelman, B.A., Michael J. Ostacher, M.D., Stephanie V.M. Gironde, B.A., Andrew A. Nierenberg, M.D., Gary S. Sachs, M.D.

11:30 a.m.

45 Lithium Continuation/Discontinuation After Four Years of Stability

Eric D. Peselow, M.D., Matthew G. Biel, M.D., Caroline B. Williams, M.D., Ronald R. Fieve, M.D., Mary Anne Pressman, M.D.

12 noon

46 Magnitude of the Effects of Quetiapine Treatment in Bipolar Disorder

Wayne Macfadden, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 16

11:00 a.m.- 12:30 p.m.

Pine Room, South Tower, Atrium Terrace Level, Omni Hotel

CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY

Chp.: Kiki D. Chang, M.D.

Co-Chp.: Martha J. Little M.D.

11:00 a.m.

47 Pediatric Formulation of Modafinil Effective in Children and Adolescents With ADHD

James M. Swanson, M.D., Samuel Boellner, M.D., Thomas Rugino, M.D., R. Bart Sangal, M.D., Sharon B. Wigal, Ph.D.

11:30 a.m.

48 Modafinil Pediatric Formulation Has Early and Sustained Effect in ADHD

Joseph Biederman, M.D., Timothy E. Wilens, M.D., Frank A. Lopez, M.D.

12 noon

49 Polypharmacy Among Youths: How Prevalent Is It?

Farifteh F. Duffy, Ph.D., William E. Narrow, M.D., Donald S. Rae, M.A., Joyce C. West, Ph.D., Darrel A. Regier, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 17

11:00 a.m.- 12:30 p.m.

Cottonwood Room, North Tower, Street Level, Omni Hotel

PTSD AND ANXIETY

Chp.: Andrea Bradford, M.D.

Co-Chp.: Asher B. Simon, M.D.

11:00 a.m.

50 PTSD Depression and Anger in Patients Recovered From SARS

Rima Styra, M.D., Allison McGeer, M.D., Sonja Kasapinovic, M.S.C., Marie Louie, M.D., Wayne L. Gold, M.D.

11:30 a.m.

51 Are Anxiety Disorders Underdiagnosed and Undertreated in Psychiatry?

Joshua E. Wilk, Ph.D., Joyce C. West, Ph.D., William E. Narrow, M.D., Donald S. Rae, M.A., Darrel A. Regier, M.D.

12 noon

52 Biological Findings in PTSD: Can They Be Changed by Psychotherapy?

Friedhelm Lamprecht, M.D., Martin Sack, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 18

11:00 a.m.- 12:30 p.m.

Dogwood B, North Tower, Street Level, Omni Hotel

ISSUES IN BIOLOGICAL PSYCHIATRY

Chp.: Nashaat N. Boutros, M.D.

Co-Chp.: Edward C. Lauterbach, M.D.

11:00 a.m.

53 The Family Genetic Study of Pathological Gambling

Donald W. Black, M.D., Patrick Monahan, Ph.D.

11:30 a.m.

54 Metabolic Syndrome in Psychiatric Inpatients Receiving Antipsychotics

John W. Goethe, M.D., Bonnie L. Szarek, R.N., Charles F. Caley, Pharm.D.

12 noon

55 Anger Discomfort Predicts Disordered Eating Among College Students With Obesity

Alayne Yates, M.D., Jeanne L. Edman, Ph.D., Mara S. Aruguete, Ph.D., Kurt A. Debord

THIS SESSION WILL BE AUDIOTAPED.

WORKSHOPS

COMPONENTS 27-33

COMPONENT WORKSHOP 27 11:00 a.m.-12:30 p.m.
Room A304, Level 3, Georgia World Congress Center

BENZODIAZEPINES AND OPIATES IN THE ELDERLY: USE, MISUSE, AND ABUSE
APA Committee on Access and Effectiveness of Psychiatric Services for the Elderly

Chp.: Allan A. Anderson, M.D.
Participants: Julian Offsay, M.D., Colleen J. Northcott, M.D., James A. Greene, M.D.

COMPONENT WORKSHOP 28 11:00 a.m.-12:30 p.m.
Room A405, Level 4, Georgia World Congress Center

RE-ENGINEERING CLINICAL RESEARCH TRAINING: THE NPTC
APA Council on Research

Co-Chps.: John F. Greden, M.D., James F. Leckman, M.D.
Participants: Michael H. Ebert, M.D., Joel J. Silverman, M.D., Michele T. Pato, M.D., Michelle B. Riba, M.D., Paul C. Mohl, M.D.

COMPONENT WORKSHOP 29 11:00 a.m.-12:30 p.m.
Room B309, Level 3, Georgia World Congress Center

I DO, BUT I CAN'T: MENTAL HEALTH ISSUES AROUND GAY MARRIAGE
APA Committee on Gay, Lesbian, and Bisexual Issues

Chp.: Serena Yuan Volpp, M.D.
Participants: Jack Drescher, M.D., Kimberly A. Arlinghaus, M.D., Kent E. Dunn, M.D., Daniel W. Hicks, M.D.

COMPONENT WORKSHOP 30 11:00 a.m.-12:30 p.m.
Spruce Room, South Tower, Atrium Terrace Level, Omni Hotel

QUOTES AND MISQUOTES: RESIDENT PHYSICIANS WORKING WITH THE MEDIA
APA Committee of Residents and Fellows and the APA Office of Communications and Public Affairs

Co-Chps.: William C. Wood, M.D., Hillarie Turner
Participant: Nada L. Stotland, M.D.

COMPONENT WORKSHOP 31 11:00 a.m.-12:30 p.m.
Oak Room, South Tower, Atrium Terrace Level, Omni Hotel

PRACTICING REWARDING PSYCHIATRY IN JAILS AND PRISONS: A PRACTICUM
APA Caucus of Psychiatrists Working in Correctional Settings

Chp.: Henry C. Weinstein, M.D.
Participants: Kathryn A. Burns, M.D., Kenneth G. Gilbert, M.D., Annette L. Hanson, M.D., Cassandra F. Newkirk, M.D., John S. Zil, M.D.

COMPONENT WORKSHOP 32 11:00 a.m.-12:30 p.m.
Juniper Room, North Tower, Ballroom Level, Omni Hotel

THE VOICE OF APA PAST AND PRESENT: CONSIDERATIONS FOR AN ORAL HISTORY PROJECT
APA Corresponding Committee on History and Library

Chp.: Avram H. Mack, M.D.
Participants: Joel T. Braslow, M.D., John A. Talbott, M.D.

COMPONENT WORKSHOP 33 11:00 a.m.-12:30 p.m.
Walnut Room, North Tower, Meeting Level, Omni Hotel

WHEN IT'S NOT ALL IN YOUR HEAD: HEALTH, MENTAL ILLNESS, ETHNICITY, AND RECOVERY
APA Council on Social Issues and Public Psychiatry

Co-Chps.: Robert P. Cabaj, M.D., Matthew O. Hurford, M.D.
Participants: Gloria Pitts, D.O., Joy D. McQuery, M.D., Stephen M. Thielke, M.D., Gail L. Daumit, M.D.

ISSUES 44-56

ISSUE WORKSHOP 44 11:00 a.m.-12:30 p.m.
Room B307, Level 3, Georgia World Congress Center

TOPICS IN PSYCHOSOMATIC MEDICINE: FATIGUE IN CANCER AND AIDS
Collaborative Session With the National Institute of Mental Health

Co-Chps.: William Breitbart, M.D., Andrew J. Roth, M.D.
Participant: William Pirl, M.D.

ISSUE WORKSHOP 45 11:00 a.m.-12:30 p.m.
Room B308, Level 3, Georgia World Congress Center

HOW TO LAUNCH A SUCCESSFUL PRIVATE PRACTICE, PART 2

Co-Chps.: William E. Callahan, Jr., M.D., Keith W. Young, M.D.
Participants: Tracy R. Gordy, M.D., Chester W. Schmidt, Jr., M.D.

ISSUE WORKSHOP 46 11:00 a.m.-12:30 p.m.
Room B310, Level 3, Georgia World Congress Center

STRATEGIES FOR SUCCESS FOR EARLY CAREER ACADEMIC PSYCHIATRISTS, PART 2: PROMOTION
Collaborative Session With the National Institute of Mental Health

Chp.: Laura W. Roberts, M.D.

ISSUE WORKSHOP 47 11:00 a.m.-12:30 p.m.
Room B311, Level 3, Georgia World Congress Center

RESPONDING TO THE IMPACT OF SUICIDE ON CLINICIANS

Chp.: Eric M. Plakun, M.D.
Participants: Jane G. Tillman, Ph.D., Edward R. Shapiro, M.D.

ISSUE WORKSHOP 48 11:00 a.m.-12:30 p.m.
Room B315, Level 3, Georgia World Congress Center

CANNABIS DEPENDENCE TREATMENT: WHERE WE ARE, WHERE WE ARE GOING
National Institute on Drug Abuse

Chp.: Francis J. Vocci, Ph.D.
Participants: Carl Hart, Ph.D., Jack R. Cornelius, M.D., Frances R. Levin, M.D., Alan I. Green, M.D.

ISSUE WORKSHOP 49 11:00 a.m.-12:30 p.m.
Room B316, Level 3, Georgia World Congress Center

BOUNDARIES AND SUPERVISION: AVOIDING LEGAL RISKS AND DOING GOOD CLINICAL WORK

Chp.: Werner Tschan, M.D.
Participants: Robert I. Simon, M.D., Linda M. Jorgenson, J.D., Gary R. Schoener, Psy.D.

ISSUE WORKSHOP 50 11:00 a.m.-12:30 p.m.
Room B401, Level 4, Georgia World Congress Center

PSYCHIATRIC COMORBIDITIES IN HIV INFECTION
Collaborative Session With the National Institute of Mental Health

Chp.: David Stoff, Ph.D.
Participants: Francine Cournos, M.D., Marshall Forstein, M.D., Stanley Rosenberg, Ph.D., Larry K. Brown, M.D., Ezra S. Susser, M.D.

ISSUE WORKSHOP 51 11:00 a.m.-12:30 p.m.
Room B402, Level 4, Georgia World Congress Center

RENEWING INTEGRITY THROUGH FILM: AN ESSENTIAL VIRTUE OF PROFESSIONALISM

Chp.: Francis G. Lu, M.D.

ISSUE WORKSHOP 52 11:00 a.m.-12:30 p.m.
Birch Room, South Tower, Atrium Terrace Level, Omni Hotel

THE LONG-TERM EFFECTS OF VIOLENCE IN SHAPING MINORITY COMMUNITIES

Co-Chps.: Napoleon B. Higgins, Jr., M.D., Aruna S. Rao, M.D.
Participants: Jean-Marie E. Alves-Bradford, M.D., Eric R. Williams, M.D.

ISSUE WORKSHOP 53 11:00 a.m.-12:30 p.m.
Maple Room, South Tower, Atrium Terrace Level, Omni Hotel

THE MOVIES AND THE MIND

Chp.: Willem C. Tuinebreijer
Participants: Rudolf A. Feijen, M.D., Bastiaan L. Oele, M.D., Josephine Caubel, M.D.

ISSUE WORKSHOP 54 11:00 a.m.-12:30 p.m.
Dogwood A, North Tower, Street Level, Omni Hotel

AMERICAN INDIAN TELEPSYCHIATRY: BRIDGING CULTURE AND DISTANCE

Chp.: James H. Shore, M.D.
Participants: Douglas K. Novins, M.D., Gilbert Jarvis, Daniel M. Savin, M.D.

ISSUE WORKSHOP 55 11:00 a.m.-12:30 p.m.
Magnolia Room, North Tower, Ballroom Level, Omni Hotel

CHRONIC FATIGUE SYNDROME AND GULF WAR ILLNESS: PATHOLOGY OR ABNORMAL ILLNESS BEHAVIOR?

Chp.: Peter Manu, M.D.

ISSUE WORKSHOP 56 11:00 a.m.-12:30 p.m.
Hickory Room, North Tower, Meeting Level, Omni Hotel

COMPUTER-ASSISTED CBT IN EDUCATION AND TREATMENT

Chp.: Jesse H. Wright, M.D.
Participant: Douglas Turkington, M.D.

12 noon Sessions

FORUMS 4-6

FORUM 4 12 noon-1:30 p.m.

Room A410, Level 4, Georgia World Congress Center

PSYCHIATRIC MANAGEMENT OF TREATMENT-RESISTANT SCHIZOPHRENIA

Chp.: Jack S. McIntyre, M.D.

Co-Chp.: Darrel A. Regier, M.D.

Participants: Alexander L. Miller, M.D., Jeffrey A. Lieberman, M.D., Peter J. Weiden, M.D., Mark Olfson, M.D.

FORUM 5 12 noon-1:30 p.m.

Room B314, Level 3, Georgia World Congress Center

HOW PSYCHO-ONCOLOGY CAME TO BE

Chp.: Philip R. Muskin, M.D.

Participant: Jimmie C. Holland, M.D.

FORUM 6 12 noon-1:30 p.m.

Room B404, Level 4, Georgia World Congress Center

IDENTITY AS PSYCHIATRISTS: HERITAGE AND CREATIVITY IN THIS UNIQUE SPECIALTY

Chp.: Carlyle H. Chan, M.D.

Co-Chp.: Charles Raison, M.D.

Participant: Thomas P. Beresford, M.D.

NEW RESEARCH POSTER SESSION 6

12 noon-2:00 p.m.

Room B302/303/304/305, Level 3, Georgia World Congress Center

MOOD AND GENDER ISSUES

For further information on New Research Sessions, please refer to the *New Research Program Book* included in your registration packet.

1:00 p.m. Sessions



COURSES 73-79

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

COURSE 73 1:00 p.m.-5:00 p.m.

Henry Room, Second Floor, Hilton Atlanta

BASIC FAMILY SKILLS FOR AN INPATIENT PSYCHIATRIST

Director: Alison M. Heru, M.D.

Faculty: Laura Drury, M.S.W.

COURSE 74 1:00 p.m.-5:00 p.m.

Paulding Room, Second Floor, Hilton Atlanta

BIOETHICS UPDATE 2005

Director: Edmund G. Howe, M.D.

COURSE 75 1:00 p.m.-5:00 p.m.

DeKalb Room, Second Floor, Hilton Atlanta

MAPSS: COMPUTER-ASSISTED SCREENING OF MEDICAL PATIENTS FOR MENTAL DISORDERS

Co-Directors: Paul R. Miller, M.D., Charles Chiu, M.D.

COURSE 76 1:00 p.m.-5:00 p.m.

Grand Salon A, Second Floor, Hilton Atlanta

ADVANCED ASSESSMENT AND TREATMENT OF ADD

Director: Thomas E. Brown, Ph.D.

Faculty: Jefferson B. Prince, M.D.

COURSE 77 1:00 p.m.-5:00 p.m.

Grand Salon C, Second Floor, Hilton Atlanta

PSYCHOGENIC ILLNESS: WHAT TO DO WHEN THE SYMPTOMS DON'T MAKE SENSE

Director: Selim Benbadis, M.D.

Faculty: Francisco Fernandez, M.D., David J. Williamson

COURSE 78 1:00 p.m.-5:00 p.m.

Board/Directors Rooms, Fourth Floor, Hilton Atlanta

HOW TO USE YOUR PALM OS PDA IN PSYCHIATRIC PRACTICE: ADVANCED TOPICS

Director: John Luo, M.D.

Faculty: Charles J. Rainey, M.D., Robert J. Boland, M.D., Hendry Ton, M.D., Richard Montgomery, M.D., Umar Latif, M.D.

COURSE 79 1:00 p.m.-5:00 p.m.

Cabinet/Council Rooms, Fourth Floor, Hilton Atlanta

INTRODUCTION TO TRANSCRANIAL MAGNETIC STIMULATION (TMS)

Co-Directors: Ziad H. Nahas, M.D., Leon J. Grunhaus, M.D.

Faculty: Sarah H. Lisanby, M.D., Ehud M. Klein, M.D.

2:00 p.m. Sessions

LECTURES 13-15

LECTURE 13

2:00 p.m.-3:30 p.m.
Sydney B. Marcus Auditorium, Level 4
Georgia World Congress Center

Daniel R. Weinberger, M.D.

Genes, Cognition, and Emotion
*Collaborative Session With the National
Institute of Mental Health*

Chp.: Diana O. Perkins, M.D.

Co-Chp.: Christine E. Marx, M.D.

Daniel R. Weinberger, M.D., is Director of the Genes, Cognition, and Psychosis Program of the Intramural Research Program at the National Institute of Mental Health. Dr. Weinberger's research has focused on brain mechanisms involved in the pathogenesis and treatment of neuropsychiatric disorders, especially schizophrenia. His laboratory identified the first specific genetic mechanism of risk for schizophrenia and the first genetic effects that account for variation in specific human cognitive functions and in human temperament. He is the recipient of many awards, including the Research Prize of the World Federation of Societies of Biological Psychiatry, the Gold Medal Award of the Society of Biological Psychiatry, the Foundation's Fund Prize of the American Psychiatric Association, and the Lieber Prize of the National Alliance for Research on Schizophrenia and Depression. A Past President of the Society of Biological Psychiatry, Dr. Weinberger has been elected to the Institute of Medicine and is currently President of the American College of Neuropsychopharmacology. He is the author of more than 400 scientific articles and the author or editor of six books. Dr. Weinberger graduated from University of Pennsylvania School of Medicine and completed residencies in psychiatry at Harvard Medical School and in neurology at George Washington University in Washington, D.C.

Frontiers of Science Lecture Series

THIS SESSION WILL BE AUDIOTAPED.

LECTURE 14

2:00 p.m.-3:30 p.m.
Room A411, Level 4
Georgia World Congress Center

Robert P. Charrow, Esq.

**The Federal Regulation of Biomedical Research:
A Study in Quid Pro Quos**

Chp.: Geetha Jayaram, M.D.

Co-Chp.: David W. Brook, M.D.

Starting in the 1980s, the impetus for government regulation of science, including regulation in the areas of scientific integrity, protection of human subjects, conflicts of interest, and access to raw data, grew as the amount of government spending on scientific research grew. Robert P. Charrow, Esq., explores the impact of government regulation on the practice and funding of research by examining the effectiveness of a variety of regulatory programs and assessing whether they are cost justified. Mr. Charrow is a shareholder in the Washington, D.C., office of Greenberg Traurig LLP, where he specializes in legal problems associated with biomedical research, health care law, food and drug law, and legal issues associated with biotechnology. He represents academic and research institutions, learned societies, pharmaceutical companies, health care providers, and insurers, with respect to a broad range of issues arising under the Medicare and Medicaid programs and federal laws affecting research and the delivery of health care. Mr. Charrow has written extensively on health care law and the effects of the legal system on scientific research and product development. He is the co-author of a leading law school text and the author of more than 100 articles and monographs. He received his law degree from Stanford University.

THIS SESSION WILL BE AUDIOTAPED.

LECTURE 15

2:00 p.m.-3:30 p.m.
Room A412, Level 4
Georgia World Congress Center

**APA/NIMH VESTERMARK PSYCHIATRY
EDUCATOR AWARD LECTURE**

Harold Alan Pincus, M.D.

**The Future of Psychiatric
Education: Six Bridges to Cross**

Chp.: Patricia I. Ordorica, M.D.

Harold Alan Pincus, M.D., is Professor and Executive Vice Chairman of the Department of Psychiatry at the University of Pittsburgh School of Medicine. He is also a Senior Scientist at RAND and directs the RAND-University of Pittsburgh Health Institute. In addition, Dr. Pincus directs the Robert Wood Johnson Foundation's National Program on Depression in Primary Care. He also maintains a small private practice specializing in major affective disorders, attends at the emergency department of Western Psychiatric Institute and Clinic, and spends one evening a week at a public mental health clinic, caring for patients with severe mental illnesses. A former Deputy Medical Director of the American Psychiatric Association (APA) and Executive Director of the American Psychiatric Institute for Research and Education, Dr. Pincus was the founding director of APA's Office of Research, Vice

Chair of the Task Force on *DSM-IV*, and Co-Chair of the Work Group to Update the Text of *DSM-IV (DSM-IV-TR)*. He has received numerous awards for his contributions to the science of mental health, including APA's Health Services Research Senior Scholar Award and the William C. Menninger Memorial Award of the American College of Physicians. A graduate of Albert Einstein College of Medicine in New York, Dr. Pincus completed his residency in psychiatry at George Washington University Medical Center in Washington, D.C.

THIS SESSION WILL BE AUDIOTAPED.

PRESIDENTIAL SYMPOSIA 3-4

PRESIDENTIAL SYMPOSIUM 3

2:00 p.m.-5:00 p.m.

Room A305, Level 3, Georgia World Congress Center

TOWARD AN INTEGRATED SUBSPECIALTY OF PSYCHOSOMATIC MEDICINE

American Psychosomatic Society

Chp.: Richard D. Lane, M.D.

- A Acute Psychological Stress and Coronary Artery Disease
David S. Sheps, M.D.
- B Biobehavioral Contributions to Cancer Risk and Disease Progression
Susan Lutgendorf, Ph.D.
- C A Biopsychosocial Approach to Irritable Bowel Syndrome
Douglas A. Drossman, M.D.
- D Positive and Negative Psychosocial Predictors of CD4 and Viral Load in HIV
Gail Ironson, M.D.
- E Depression and Diabetes: Epidemiology and Intervention
Wayne J. Katon, M.D.

PRESIDENTIAL SYMPOSIUM 4

2:00 p.m.-5:00 p.m.

Room B401, Level 4, Georgia World Congress Center

MENTAL HEALTH AND SUB-SAHARAN AFRICA: A 21ST CENTURY PERSPECTIVE

World Psychiatric Association's Efforts

Chp.: Michelle B. Riba, M.D.

Co-Chp.: Ahmed M.F. Okasha, M.D.

- A Uganda Region
Florence Baingana, M.D.

B World Psychiatric Association's Efforts

Ahmed M.F. Okasha, M.D.

C Kenya

Frank G. Njenga, M.D.

D Eastern Africa

Sylvia Kaaya, M.D.

E The World Health Organization's Efforts and Namibia

Custodia Mandhlate, M.D.

THIS SESSION WILL BE AUDIOTAPED.

REVIEW OF PSYCHIATRY: SECTION 1

2:00 p.m.-5:30 p.m.

Rooms B405/406/407, Level 4, Georgia World Congress Center

SLEEP DISORDERS AND PSYCHIATRY

Chp.: Daniel J. Buysse, M.D.

- 1 Insomnia
Daniel J. Buysse, M.D., Anne Germain, Ph.D., Douglas E. Moul, M.D.
- 2 Sleep-Related Breathing Disorders
Patrick J. Strollo, M.D., Nilesh Dave, M.D.
- 3 Restless Leg Syndrome and Parasomnias
John W. Winkelman, M.D., Lindsay Jonston, B.A.
- 4 Circadian Rhythm Sleep Disorders
Phyllis C. Zee, M.D., Prasanth Manthana, Ph.D.

SYMPOSIA 27-55

SYMPOSIUM 27

2:00 p.m.-5:00 p.m.

Room A302, Level 3, Georgia World Congress Center

NEUROSCIENCE FOR THE PSYCHIATRIST, PART 1: NEUROIMAGING FROM GENOMICS TO THERAPY

Collaborative Session With the National Institute of Mental Health

Chp.: Andreas Meyer-Lindenberg, M.D.

Co-Chp.: Mayada Akil, M.D.

- A Imaging Genomics in Psychiatry
Andreas Meyer-Lindenberg, M.D.

- B fMRI: Basics and Beyond
Peter A. Bandettini, Ph.D.

(Continued next page)

C Understanding Schizophrenia Using Functional Brain Imaging
Cameron Carter, M.D.

D Linking Imaging and Treatment Mechanisms for Depression
Helen S. Mayberg, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 28 2:00 p.m.-5:00 p.m.

Room A402, Level 4, Georgia World Congress Center

REAL LIFE MEDICAL MANAGEMENT OF HIV

Chp.: Francine Cournos, M.D.

A HIV Treatment Update
Jeff D. Lenox, M.D.

B Managing Mood Disorders
Sanjay M. Sharma, M.D.

C Managing Hepatitis C, Syphilis, and HIV Infection
Annette M. Matthews, M.D.

D Managing Psychosis
Shahrad R. Amiri, M.D.

E Managing Metabolic Syndromes
Marshall Forstein, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 29 2:00 p.m.-5:00 p.m.

Room A403, Level 4, Georgia World Congress Center

PSYCHOSOMATIC MEDICINE: INTEGRATING EPIDEMIOLOGY, PSYCHIATRY, AND MEDICINE

Chp.: Ruby C. Castilla-Puentes, M.D.

Co-Chp.: Robert C. Joseph, M.D.

A Risk of Myocardial Infraction Associated With Panic Disorder
Andres Gomez-Caminero, Ph.D., William Blumentals, Ph.D., Leo Russo, Ph.D., Ruby C. Castilla-Puentes, M.D.

B The Prevalence of Depressive Disorders in Patients With Dementia in IHCS
Dimitri Bennett, M.D., Tim Sampson, B.S.

C Diabetes and Lipid Profile Risks With Neuroleptics: Two- to Five-Year Outcome
Robert C. Joseph, M.D., Nicole Danforth, M.D., Gayle Goren, M.D., Marianne Kardos, M.D., Tamara B. Pardo, B.A., Grace Wyshak, Ph.D., S. Nassir Ghaemi, M.D.

D Somatic Complaints in Traumatized Children
Ruby C. Castilla-Puentes, M.D., Ivan S. Gomez, M.D., Sandra R. Castilla-Puentes, M.D., Wilma I. Castilla-Puentes, M.D., Gilma R. De Contreras, M.S.W., Maria C. Caballero, R.N., Miguel Habeych, M.D.

E A Case-Control Study of Erectile Dysfunction Among Men Diagnosed With Panic Disorder
William Blumentals, Ph.D., Andres Gomez-Caminero, Ph.D., Leo Russo, Ph.D., Regina Brown, M.S., Vanni Jannappagari, M.S.

Discussants: Leo Russo, Ph.D., Carlos A. Sanchez-Russi, Ph.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 30 2:00 p.m.-5:00 p.m.

Room A405, Level 4, Georgia World Congress Center

THE ART AND SCIENCE OF BRIEF THERAPIES

Chp.: Mantosh J. Dewan, M.D.

A Expectancy, the Ignored Common Factor: Creating Hope in Psychotherapy
Roger P. Greenberg, Ph.D.

B Solution-Focused Brief Therapy: Doing What Works
Brett Steenbarger, Ph.D.

C Brief Interpersonal Therapy
Scott Stuart, M.D.

D Cognitive Therapy: Practice and Training
Judith S. Beck, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 31 2:00 p.m.-5:00 p.m.

Room A406, Level 4, Georgia World Congress Center

POSTTRAUMATIC STRESS AND MEDICAL ILLNESS: INTERDISCIPLINARY PERSPECTIVES

Chp.: Eyal Shemesh, M.D.

Co-Chp.: Margaret L. Stuber, M.D.

A PTSD in Medically Ill Adults and Children: A Review
Eyal Shemesh, M.D.

B PTSD Symptoms in Children Who Had Transplants: One Center's Experience
Sukru Emre, M.D.

C The Study of PTSD in the Medically Ill: Choice of Outcome Measures
Gad Cotter, M.D.

D The National Child Traumatic Network Medical Trauma Toolkit
Margaret L. Stuber, M.D.

Discussant: Jack M. Gorman, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 32 2:00 p.m.-5:00 p.m.

Room A407, Level 4, Georgia World Congress Center

MEDICAL COMORBIDITY IN THE U.S. AND FRANCE:
VIVE LA DIFFERENCE!*French Federation of Psychiatry*

Chp.: John A. Talbott, M.D.

Co-Chp.: Francois C. Petitjean, M.D.

- A **Mortality in a Cohort of Patients With Schizophrenia**
Frederic Limosin, M.D., Jean-Yves Lore, M.D., Alain Philippe, Frederic Rouillon, M.D., Françoise Casadebaig
- B **Prevalence, Treatment, and Prevention of HIV/Hepatitis in the U.S.**
Lisa B. Dixon, M.D., Stanley Rosenberg, Ph.D., Richard L. Goldberg, M.D.
- C **Adverse Metabolic Effects of Antipsychotics in Schizophrenia**
Marie France Poirier, M.D., Celine Goldberger
- D **Diabetes and Other Metabolic Disorders in Schizophrenia**
Michael J. Sernyak, M.D.
- E **The Impact of Smoking in Patients With Schizophrenia**
Alain Dervaux, M.D.
- F **Medical Comorbidities and Health Behaviors: Smoking, Exercise, and Weight**
Gail L. Daumit, M.D.

Discussant: Alexandra McLean, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 33 2:00 p.m.-5:00 p.m.

Room A408, Level 4, Georgia World Congress Center

MEDICAL AND PSYCHIATRIC ISSUES IN THE
MEXICAN-AMERICAN POPULATION IN THE U.S.

Chp.: Cervando Martinez, M.D.

- A **Health Status of Mexican Americans**
Michael P. Stern, M.D.
- B **Depression as Comorbid Condition With Type-2 Diabetes in a U.S.-Mexico Border Community Clinic**
Roberto Villarreal, M.D.
- C **Insights on Schizophrenia in Three Countries**
Rolando A. Medina, M.D.

Discussant: Charles L. Bowden, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 34

2:00 p.m.-5:00 p.m.

Room A410, Level 4, Georgia World Congress Center

ATYPICAL ANTIPSYCHOTICS: TREATMENT OF
AGITATION ACROSS MENTAL DISORDERS

Chp.: Jacobo E. Mintzer, M.D.

- A **Treatment of Agitation With Atypical Antipsychotics in Schizophrenia**
Stephen R. Marder, M.D.
- B **Treatment of Agitation With Atypical Antipsychotics in Bipolar Affective Disorder**
Gary S. Sachs, M.D.
- C **Treatment of Agitation With Atypical Antipsychotics in Alzheimer's Disease**
Jacobo E. Mintzer, M.D.
- D **Assessing the Data in the Context of Clinical Care**
Eric D. Caine, M.D.

Discussant: Eric D. Caine, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 35

2:00 p.m.-5:00 p.m.

Room B301, Level 3, Georgia World Congress Center

THE MANY FACES OF DEPRESSION: DO
ANTIDEPRESSANTS TREAT DIFFERENT
SYMPTOMS?

Chp.: J. Craig Nelson, M.D.

- A **Do Antidepressants Treat Different Core Symptoms of Depression?**
J. Craig Nelson, M.D.
- B **Anger Attacks in Depression: Does 5HT Matter?**
Maurizio Fava, Ph.D.
- C **Positive and Negative Affect and Antidepressant Response**
Pedro L. Delgado, M.D.
- D **How Do Antidepressants Affect the Processing of Positive and Negative Emotional Information?**
Catherine J. Harmer, D.Phil.
- E **The Role of Dopamine in Depression: Implications for Treatment**
Anthony J. Rothschild, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 36 2:00 p.m.-5:00 p.m.

Room B306, Level 3, Georgia World Congress Center

UNDERSTANDING AND TREATING ALCOHOL DEPENDENCE

Chp.: Bankole A. Johnson, M.D.

- A **Neuropharmacological Basis of Alcohol Dependence**
George F. Koob, Ph.D.
- B **New Pharmacological Strategies for Treating Alcohol Dependence**
Barbara J. Mason, Ph.D.
- C **Recent Developments in the Genetics of Alcohol Dependence**
Marc A. Schuckit, M.D.
- D **New Medications: The Use of Anticonvulsants, Both Alone and in Combination, With Various Forms of Psychotherapy**
Bankole A. Johnson, M.D.

- E **Differential Effects of Pharmacological Agents on Craving**
Nassima Ait-Daoud, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 37 2:00 p.m.-5:00 p.m.

Room B307, Level 3, Georgia World Congress Center

EVIDENCE-BASED PSYCHIATRY: WHAT IT IS AND WHAT IT IS NOT

Chp.: S. Nassir Ghaemi, M.D.

- A **Evidence-Based Medicine in Psychiatry: An Overview**
Gregory E. Gray, M.D.
- B **Evidence-Based Approaches to Teaching and Practicing Psychopharmacology**
David N. Osser, M.D.
- C **Uses and Abuses of EBM in Psychiatry**
S. Nassir Ghaemi, M.D.
- D **Evidence-Based Medicine: How It Can Be Misused**
David T. Healy, M.D.
- E **EBM and Pharmaceutical Industry-Sponsored Clinical Trials**
Amir H. Kalali, M.D.

Discussant: Frederick K. Goodwin, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 38 2:00 p.m.-5:00 p.m.

Room B308, Level 3, Georgia World Congress Center

HOW TO LAUNCH A SUCCESSFUL PRIVATE PRACTICE, PART 3

Chp.: William E. Callahan, Jr., M.D.

Co-Chp.: Keith W. Young, M.D.

- A **Personal Factors Leading to a Successful Private Practice**
William E. Callahan, Jr., M.D.
- B **Office Location and Design for Efficiency and Success**
Keith W. Young, M.D.
- C **Streamlining Overhead and Managing Your Business in Private Practice**
Keith W. Young, M.D.
- D **Marketing Your Unique Private Practice**
William E. Callahan, Jr., M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 39 2:00 p.m.-5:00 p.m.

Room B309, Level 3, Georgia World Congress Center

COMPLEX PHARMACOTHERAPY VERSUS POLYPHARMACY

Chp.: William Lawson, M.D.

Co-Chp.: Roger Peele, M.D.

- A **Polypharmacy and Ethnic Minorities**
William Lawson, M.D.
- B **Impulsive Behavior in Children and Adolescents**
Janice G. Hutchinson, M.D., William Lawson, M.D.
- C **Polypharmacy in Depression and Anxiety: What, When, and How to Implement**
Gabriela Cora-Locatelli, M.D.
- D **Complexities of Bipolar Illness Typically Require Complex Combination Therapy**
Robert M. Post, M.D.
- E **Polypharmacy in Schizophrenia Treatment**
David C. Henderson, M.D.

Discussant: Roger Peele, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 40 2:00 p.m.-5:00 p.m.

Room B310, Level 3, Georgia World Congress Center

INTEGRATING AND SEQUENCING TREATMENTS FOR BORDERLINE PATIENTS

Chp.: John C. Markowitz, M.D.

Co-Chp.: Andrew E. Skodol II, M.D.

- A Phases and Stages of Change in the Treatment of Personality Disorder
John Livesley, Ph.D.
- B Adapting Dialectical Behavior Therapy for the Psychiatric Practitioner
Barbara H. Stanley, Ph.D.
- C Common Mechanisms in Psychological Theories: Attachment and Mentalization
Peter Fonagy, Ph.D., Anthony Bateman, M.D.
- D Toward a Rational Pharmacotherapy of BPD
Larry J. Siever, M.D.
- E Psychoeducation for Family Members With a Relative With BPD
Perry D. Hoffman, Ph.D.

Discussant: Andrew E. Skodol II, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 41 2:00 p.m.-5:00 p.m.

Room B311, Level 3, Georgia World Congress Center

MATERNAL DEPRESSION AND COMORBIDITIES: IMPACT ON INFANTS

Chp.: Gisèle Apter-Danon, Ph.D.

- A Maternal Depression and Comorbidities: PTSD and BPD
Marian I. Butterfield, M.D., Jennifer L. Strauss, Ph.D.
- B Perinatal Depression: Impact of Maternal Distress on Neonatal Outcomes and Attachment
Sheila M. Marcus, M.D.
- C Impact of Maternal BPD on Infant Emotional Regulation
Gisèle Apter-Danon, Ph.D., Rozenn Graignic-Philippe, Marina Gianoli-Valente, Psy.D., Emmanuel Devouche, Ph.D., Annick Crivile-Le-Nestour, M.D.

- D How Early Life Experience Affects the Development of Optimism's Neural Circuitry
Susan C. Vaughan, M.D.

Discussant: Carol C. Nadelson, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 42

2:00 p.m.-5:00 p.m.

Room B314, Level 3, Georgia World Congress Center

ADHD: FROM NEUROSCIENCE TO PRACTICE

Collaborative Session With the National Institute of Mental Health

Chp.: Joseph Biederman, M.D.

- A Psychiatric and Functional Outcome of Adolescent Females With ADHD: A Large, Controlled, Five-Year Longitudinal Follow-Up Study
Joseph Biederman, M.D., Stephen V. Faraone, Ph.D., Eric Mick, Sc.D.
- B Nonstimulant Treatment of Adult ADHD
Thomas J. Spencer, M.D.
- C Neuropsychology of ADHD: Clinical and Scientific Implications of Recent Findings
Alysa E. Doyle, Ph.D., Stephen V. Faraone, Ph.D., Larry J. Seidman, Ph.D., Joseph Biederman, M.D.
- D Heritability: New Genetic Findings in ADHD
Pamela Sklar, M.D.
- E Looking at the ADHD Brain: Neuroimaging Studies in ADHD
Larry J. Seidman, Ph.D., Eve M. Valera, Ph.D., Joseph Biederman, M.D., Thomas J. Spencer, M.D., Stephen V. Faraone, Ph.D., George Bush, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 43

2:00 p.m.-5:00 p.m.

Room B315, Level 3, Georgia World Congress Center

ASSOCIATIONS BETWEEN STRESS/ ANXIETY AND PERSONALITY STYLES AND DISORDERS

Association for Research in Personality Disorders

Chp.: James H. Reich, M.D.

- A A Selective Overview of Relationship of Anxiety and Personality Disorders
James H. Reich, M.D.
- B Schema Therapy for Maladaptive Personality Traits Involving Anxiety
David Bernstein

(Continued next page)

C Personality and Stress in Three Phases of the Physician's Career: A Longitudinal Nationwide Study
Per Vaglum, M.D., Reidar Tyssen, M.D., Oivind Ekeberg, M.D., Tore Gude, M.D., Erlend Hem, M.D., Jan Ole Rovik

D Panic, Rage, and Family Discord in BPD
David M. Allen, M.D.

E Is Emotional Dyscontrol and Impulsivity Related to Suicidal Ideation in BPD Patients?
Navjot Chaudhary, B.S.C., Paul S. Links, M.D., Rahel Eynan, M.A., Aiala Barr, Ph.D.

F Stress, Personality Disorders, and Opioid Receptors
Kenneth Silk, M.D., Jon-Kar Zubietta, M.D.

Discussant: Donald W. Black, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 44 2:00 p.m.-5:00 p.m.
Room B316, Level 3, Georgia World Congress Center

PERINATAL DEPRESSION: PREVALENCE, SCREENING ACCURACY, AND INTERVENTION

Chp.: Bradley N. Gaynes, M.D.

A A Systematic Review of the Evidence on the Incidence and Prevalence of Perinatal Depression
Norma I. Gavin, Ph.D.

B What Is the Accuracy of Different Screening Tools for Detecting Depression During the Perinatal Period?
Bradley N. Gaynes, M.D.

C Does Perinatal Screening for Depressive Symptoms With Subsequent Intervention Lead to Improved Outcomes? A Systematic Review of the Evidence
Samantha E. Meltzer-Brody, M.D.

Discussants: Katherine L. Wisner, M.D., Seth Brody, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 45 2:00 p.m.-5:00 p.m.
Room B402, Level 4, Georgia World Congress Center

THE LONG-TERM PSYCHOLOGICAL AFTERMATH OF 9/11-RELATED TRAUMATIC LOSS

Chp.: Yuval Y. Neria, Ph.D.

A Traumatic Grief Among 9/11 Victims
Yuval Y. Neria, Ph.D.

B Trauma, Bereavement, and Traumatic Loss
George A. Bonanno, Ph.D.

C A Nationwide Longitudinal Study of Responses to the 9/11 Terrorist Attacks
Roxane C. Silver, Ph.D.

D Loss and Consequences After Mass Trauma: Examples From the 9/11 Terrorist Attacks in New York City
Sandro Galea, M.D.

E 9/11-Related Traumatic Loss and Its Psychopathology in Primary Care Patients in New York City
Raz Gross, M.D.

Discussant: Randall D. Marshall, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 46 2:00 p.m.-5:00 p.m.
Room B403, Level 4, Georgia World Congress Center

REHABILITATION OF THE MAD OR BAD: GLOBALLY
American Association for Psychosocial Rehabilitation and the World Psychiatric Association's Section on Rehabilitation

Chp.: Zebulon Taintor, M.D.
Co-Chp.: Robert Cancro, M.D.

A Mad or Bad? Japan
Naotaka Shinfuku, M.D.

B Mad or Bad? United States
Zebulon Taintor, M.D.

C Mad or Bad? Hungary
Ida Kosza, M.D.

D Mad or Bad? Pakistan
Afzal Javed, M.D.

E Mad or Bad? International Efforts
Humberto Martinez, M.D.

Discussant: Henry C. Weinstein, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 47 2:00 p.m.-5:00 p.m.
Room B404, Level 4, Georgia World Congress Center

NEW DEVELOPMENTS IN THE TREATMENT OF SOMATOFORM DISORDERS

Chp.: Arthur J. Barsky, M.D.
Co-Chp.: Brian A. Fallon, M.D.

A Pharmacotherapy of Somatoform Disorders
Brian A. Fallon, M.D.

B Managing Common Somatic Presentations in Primary Care: Cultural Considerations
 Javier I. Escobar, M.D., Michael A. Gara, Ph.D., Angelica Diaz-Martinez, Psy.D., Lesley A. Allen, Ph.D., Alex Interian, Ph.D., Melissa Warman, Ph.D.

C Cognitive-Behavior Therapy for Hypochondriasis: A Randomized, Controlled Intervention Trial
 Arthur J. Barsky, M.D., David K. Ahern, Ph.D.

D Treatment of Unexplained Somatic Symptoms in Children and Adolescents
 Joshua D. Lipsitz, Ph.D., Merav Gur, Ph.D., Daniel Kamins, B.A.

E Integrative Treatment for Fibromyalgia/Chronic Fatigue Syndrome
 Richard P. Brown, M.D., Patricia L. Gerbarg, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 48 2:00 p.m.-5:00 p.m.
 Room B408, Level 4, Georgia World Congress Center

INPATIENT PSYCHIATRY: CRISIS AND RESPONSE

Chp.: Ira D. Glick, M.D.
Co-Chp.: Steven S. Sharfstein, M.D.

A Public Policy and Inpatient Psychiatric Care
 Anita S. Everett, M.D.

B An Updated Model for Inpatient Psychiatric Care
 Ira D. Glick, M.D., Grady Carter, M.D., Rajiv Tandon, M.D.

C Crisis Residential Care for Patients With Serious Mental Illness: Outcomes and Cost
 Wayne S. Fenton, M.D.

D A National Referral Center for Treatment-Resistant Patients
 Edward R. Shapiro, M.D.

E Trends and Characteristics of Inpatient Treatment in Routine Psychiatric Practice in the U.S.
 Joshua E. Wilk, Ph.D., Joyce C. West, Ph.D., Darrel A. Regier, M.D.

Discussant: Steven S. Sharfstein, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 49 2:00 p.m.-5:00 p.m.
 Room B409, Level 4, Georgia World Congress Center

ADVANCES AND INNOVATIONS IN ASSESSING DECISION-MAKING CAPACITY

Chp.: Philip Candilis, M.D.
Co-Chp.: Laura B. Dunn, M.D.

A Evaluating Decisional Capacity in Older Patients
 Barton W. Palmer, Ph.D., Laura B. Dunn, M.D., Paul S. Appelbaum, M.D., Sunder Mudaliar, M.D., Robert Henry, M.D., Shanokh Golshan, Ph.D., Dilip V. Jeste, M.D.

B Error Behaviors in Capacity Interviews
 Scott Y. Kim, M.D., Paul S. Appelbaum, M.D.

C Distinguishing Research From Clinical Care
 Laura B. Dunn, M.D.

D Capacity for Informed Consent in Patients With Schizophrenia
 David J. Moser, Ph.D.

Discussant: Paul S. Appelbaum, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 50 2:00 p.m.-5:00 p.m.
 Birch Room, South Tower, Atrium Terrace Level, Omni Hotel

NOVEL RESEARCH TREATMENTS FOR EATING DISORDERS

Collaborative Session With the National Institute of Mental Health

Chp.: Evelyn Attia, M.D.
Co-Chp.: Joanna E. Steinglass, M.D.

A Atypical Antipsychotic Medication for Anorexia Nervosa
 Evelyn Attia, M.D., Allan S. Kaplan, M.D., Laura Schroeder, B.A.

B New Medication Treatments for Binge Eating Disorder
 Jose C. Appolinario, M.D.

C CD-Rom-Based Treatment for Binge Eating Disorder and Obesity
 Cynthia M. Bulik, Ph.D.

D How the Study of Mechanism May Inform Treatment of Bulimia Nervosa
 B. Timothy Walsh, M.D., Michael J. Devlin, M.D., Gillian Boudreau, B.A.

E D-Cycloserine and Anorexia Nervosa: Clinical Implications of Translational Research
 Joanna E. Steinglass, M.D., Robyn Sysko, M.S., Michael J. Devlin, M.D., Michael Strober, Ph.D., B. Timothy Walsh, M.D.

Discussant: Allan S. Kaplan, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 51 2:00 p.m.-5:00 p.m.

Maple Room, South Tower, Atrium Terrace Level, Omni Hotel

NEUROSCIENCE AND DYNAMIC PSYCHIATRY

American Academy of Psychoanalysis and Dynamic Psychiatry

Chp.: Ann R. Turkel, M.D.

- A Psychotherapy and Neurobiology
Richard M. Brockman, M.D.
- B Contemporary Affect Theory and Controversies
Regarding Drive Theory in Psychoanalysis
Otto F. Kernberg, M.D.
- C Imaging the Mind-Brain Interface Bridging the
Psychoanalysis-Neuroscience Gap
David A. Silbersweig, M.D.
- D How Neuroscience Can Help the Clinician
Samuel Slipp, M.D.

Discussant: Michael H. Stone, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 52 2:00 p.m.-5:00 p.m.

Pine Room, South Tower, Atrium Terrace Level, Omni Hotel

DISTURBED FRONTO-LIMBIC BRAIN CIRCUITRY:
HOW SPECIFIC IS IT FOR DIFFERENT PSYCHIATRIC
DISORDERS?

Chp.: Klaus Lieb, M.D.

- A Fronto-Limbic Brain Pathology: Evidence From Animal
Research
Gregory Quirk, Ph.D.
- B Fronto-Limbic Brain Pathology in PTSD
Eric Vermetten, M.D.
- C Prefrontal and Limbic Pathology in BPD
Klaus Lieb, M.D.
- D Stress-Induced Brain Structural Plasticity: What Do
Animal Models Tell Us?
Bruce S. McEwen, Ph.D.
- E Neural Circuits in Trauma Spectrum Disorders
J. Douglas Bremner, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 53 2:00 p.m.-5:00 p.m.

Cottonwood Room, North Tower, Street Level, Omni Hotel

INCREASES IN OPIOID ANALGESIC ABUSE:
CONCERNS AND STRATEGIES*National Institute on Drug Abuse*

Chp.: Wilson M. Compton III, M.D.

- A Increases in Opioid Analgesic Use, Misuse, and
Addiction
Wilson M. Compton III, M.D.
- B The Availability of Opioid Medications Over the
Internet Without a Prescription
Robert F. Forman, Ph.D.
- C Managing Chronic Pain in the Patient With Comorbid
Substance Abuse
Nathaniel P. Katz, M.D.
- D Treatment of Prescription Analgesic Abuse
Herbert D. Kleber, M.D.

Discussant: Nora D. Volkow, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 54 2:00 p.m.-5:00 p.m.

Dogwood A, North Tower, Street Level, Omni Hotel

PSYCHIATRY AND THE PHARMACEUTICAL
INDUSTRY: WHERE IS THE BOUNDARY?

Chp.: Amy C. Brodkey, M.D.

- A Pharmaceutical Promotions: Effects on the Practice of
Psychiatry
Amy C. Brodkey, M.D.
- B Academic Medicine, Medical Education, and the
Pharmaceutical Industry
Frederick S. Sierles, M.D.
- C The Pharmaceutical Industry, Psychiatry, and the
Public Interest
Robert M. Factor, M.D.
- D Dancing With Porcupines: Dilemmas Faced by
Speakers for the Pharmaceutical Industry
Diana M. Koziupa, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 55

2:00 p.m.-5:00 p.m.

Dogwood B, North Tower, Street Level, Omni Hotel

AUTISM: A COMMON, SEVERE, TREATABLE, AND NEGLECTED PSYCHIATRIC ILLNESS

Collaborative Session With the National Institute of Mental Health

Chp.: Eric Hollander, M.D.

Co-Chp.: Eric B. London, M.D.

A **A Comprehensive Review of Major Research Findings in Autism From the Past Decade**
Eric B. London, M.D.

B **Biology of Social Behavior From Mice to Monkeys**
James T. Winslow, Ph.D.

C **fMRI Studies of Social Perception and Social Cognition in Autistic Disorder**
Robert T. Schultz, Ph.D.

D **Targeted Treatments for the Repetitive Behavior Domain in Autism**
Eric Hollander, M.D., Stacey Wasserman, M.D., Evdokia Anagnostou, M.D., Ann Phillips, Ph.D., Karen Zagursky, B.A., Bill Chaplin, Ph.D., Sherie L. Novotny, M.D.

E **Atypical Antipsychotics in Children With Pervasive Developmental Disorders**
Lawrence Scahill, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

3:00 p.m. Session

NEW RESEARCH POSTER SESSION 7

3:00 p.m.-5:00 p.m.

Room B302/303/304/305, Level 3, Georgia World Congress Center

ANXIETY AND DISORDERS OF CHILDHOOD

For further information on New Research Sessions, please refer to the *New Research Program Book* included in your registration packet.

6:00 p.m. Session

SPECIAL SESSION

6:00 p.m.-8:00 p.m.

Cypress Room, Carter Center

GLOBAL DISASTERS: PSYCHIATRIC MEDICINE AND PUBLIC HEALTH CHALLENGES

APA Council on Global Psychiatry and the World Psychiatric Association's Conflict Management and Conflict Resolution Section

Co-Chps: Rodrigo A. Munoz, M.D., Eliot Sorel, M.D.

Participants: Srinivasi Murthy, M.D., M. Parameshva Deva, M.D., Lennart Levi, M.D., Frank G. Njenga, M.D.

Discussants: Mordechai Benyakar, M.D., Anthony T. Ng, M.D., Dori B. Reissman, M.D.

7:00 p.m. Sessions

INDUSTRY-SUPPORTED SYMPOSIA 39-43

INDUSTRY-SUPPORTED SYMPOSIUM 39

7:00 p.m.-10:00 p.m.

Grand Ballroom, Second Floor, Hilton Atlanta

SEASONAL AFFECTIVE DISORDER: NEW CONCEPTS, PRACTICAL STRATEGIES

Supported by GlaxoSmithKline

Chp.: Norman E. Rosenthal, M.D.

A **The Clinical Picture and Epidemiology of Seasonal Affective Disorder**
Norman E. Rosenthal, M.D.

B **Pathophysiology of Seasonal Affective Disorder**
Thomas A. Wehr, M.D.

C **Light Treatment for Winter Depression: Status Report**
Raymond W. Lam, M.D.

D **Medical Treatment Including Mechanism of Action, New Study Data**
Jennifer K. Pennell, M.D.

E **Integrating Cognitive-Behavioral Therapy Into Seasonal Affective Disorder Treatment**
Kelly J. Rohan, Ph.D., K.A. Roecklein, B.A., Lindsey K. Tierney, M.S., Leigh G. Johnson, B.S., Robert D. Lippy, B.S., Timothy J. Lacy, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 40

7:00 p.m.-10:00 p.m.

Imperial Ballroom, Convention Level, Marriott Marquis
AtlantaALCOHOLISM: TRANSLATING EMERGING SCIENCE
INTO CLINICAL PRACTICE*Supported by Alkermes*

Chp.: Raymond F. Anton, Jr., M.D.

Co-Chp.: Charles P. O'Brien, M.D.

- A **Animal Models Point the Way to Novel Therapies**
George F. Koob, Ph.D.
- B **Brain Imaging of Craving and the Effects of Anticraving Medications**
Charles P. O'Brien, M.D.
- C **Advances in the Pharmacotherapy of Alcoholism**
Helen M. Pettinati, Ph.D.
- D **Treatment of Alcoholism Combined With Other Mental Disorders**
Hugh Myrick, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 41

7:00 p.m.-10:00 p.m.

Marquis Ballrooms I & II, Convention Level, Marriott
Marquis AtlantaADVANCES IN CHOLINERGIC THERAPY:
ALZHEIMER'S DISEASE AND BEYOND*Supported by Eisai, Inc. and Pfizer Inc.*

Chp.: Pierre N. Tariot, M.D.

- A **Revisiting the Cholinergic Hypothesis: Are Cholinesterase Inhibitors More Than Symptomatic Treatments for Alzheimer's Disease?**
Norman Relkin, M.D.
- B **The Role of Imaging in the Study and Treatment of Dementia**
K. Ranga R. Krishnan, M.D.
- C **Clinical Trials in Mild Cognitive Impairment**
Ronald C. Petersen, M.D.
- D **Pharmacological Treatment of Cognitive Impairments in Schizophrenia**
Robert W. Buchanan, M.D.
- E **Behavioral Disturbances in Alzheimer's Disease: Diagnosis and Treatment**
Helen Lavretsky, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 42

7:00 p.m.-10:00 p.m.

International Ballroom, North Tower, Ballroom Level, Omni
HotelCHALLENGES AT THE INTERFACE OF
PSYCHIATRIC, MEDICAL, AND SLEEP DISORDERS*Supported by Sanofi-Aventis, Inc.*

Chp.: David N. Neubauer, M.D.

- A **Epidemiologic and Longitudinal Perspectives on Insomnia and Psychiatric Illness**
Daniel E. Ford, M.D.
- B **Changing Women's Sleep Vulnerabilities Across the Life Cycle**
Lois Krahn, M.D.
- C **Sleep Disturbances and Neurodegenerative Disorders**
Raymond R. Auger, M.D.
- D **Metabolic Consequences of Insomnia: Implications for Medicine and Psychiatry**
Gary S. Richardson, M.D.
- E **Therapeutic Challenges in Treating Insomnia With Comorbid Psychiatric and Medical Disorders**
David N. Neubauer, M.D.

Discussant: William C. Dement, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 43

7:00 p.m.-10:00 p.m.

Peachtree Ballroom, Level 8, Westin Peachtree Plaza

IT'S NOT JUST FOR KIDS: ADHD IN ADOLESCENCE
AND ADULTHOOD*Supported by Shire US, Inc.*

Chp.: Timothy E. Wilens, M.D.

- A **The Course of ADHD From Adolescence Into Adulthood**
Christopher J. Kratochvil, M.D.
- B **Neurobiological Update on ADHD in Adolescence and Adulthood**
Stephen V. Faraone, Ph.D., Joseph Biederman, M.D.
- C **College Considerations in Young Adults With ADHD**
Sharon B. Wigal, Ph.D.
- D **New Psychotherapies Directed at Young Adults With ADHD**
Steven A. Safren, Ph.D.
- E **Medication Considerations in Young Adults With ADHD**
Timothy E. Wilens, M.D.

WEDNESDAY, MAY 25, 2005

158TH ANNUAL MEETING

7:00 a.m. Session

PART 1 OF INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 44

7:00 a.m.-8:30 a.m.

Grand Ballroom, Second Floor, Hilton Atlanta

BIPOLAR DISORDER ACROSS THE LIFE CYCLE: SPECIAL CONSIDERATIONS

Supported by *GlaxoSmithKline*

Chp.: Zachary N. Stowe, M.D.

- A Bipolar Disorder in Children: Importance of Early Intervention
Karen D. Wagner, M.D.
- B Bipolar Disorder: Impact of Reproductive Hormones
Natalie L. Rasgon, M.D.

8:00 a.m. Sessions



COURSES 80-87

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

COURSE 80 8:00 a.m.-12 noon
Cherokee Room, Second Floor, Hilton Atlanta

DRUGS AND ALCOHOL TAKE TWO: TEACHING ADDICTION MEDICINE USING POPULAR FILMS

Director: Petros Levounis, M.D.

Faculty: Tony Juneja, M.D., Christopher J. Welsh, M.D.

COURSE 81 8:00 a.m.-12 noon
Forsythe Room, Second Floor, Hilton Atlanta

USING NEUROFEEDBACK IN YOUR PRACTICE I: DEMONSTRATION

Co-Directors: Thomas M. Brod, M.D., Michael Cohen, B.S.
Faculty: Angelo S. Bolea, Ph.D., R. Michael O'Bannon, Ph.D., Emily Stevens, Ph.D.

COURSE 82 8:00 a.m.-12 noon
Paulding Room, Second Floor, Hilton Atlanta

HOW TO USE YOUR POCKET PC PDA IN PSYCHIATRIC PRACTICE

Director: Robert J. Boland, M.D.

Faculty: John Luo, M.D., Elizabeth V. Getter, M.D., Joshua Straus, M.D.

COURSE 83 8:00 a.m.-12 noon
DeKalb Room, Second Floor, Hilton Atlanta

COMPUTER-ASSISTED DIAGNOSTIC INTERVIEW (CADI)

Co-Directors: Paul R. Miller, M.D., Margaret Nazarey, M.S.N.

COURSE 84 8:00 a.m.-12 noon
Gwinnett Room, Second Floor, Hilton Atlanta

CONTEMPORARY MALPRACTICE LIABILITY: A PRACTICAL GUIDE

Co-Directors: Eugene M. Lowenkopf, M.D., Abe M. Rychik, J.D.

Faculty: Richard G. Hersh, M.D., Jacqueline M. Melonas, J.D.

COURSE 85 8:00 a.m.-12 noon
Fulton Room, Second Floor, Hilton Atlanta

ONLINE COMMUNICATION IN MENTAL HEALTH: DIFFERENT CONTEXTS, DIFFERENT ISSUES

Director: Robert C. Hsiung, M.D.

Faculty: Ivan K. Goldberg, M.D., Ronald W. Pies, M.D., Alfred Herzog, M.D., DeeAnna Merz Nagel, M.Ed.

COURSE 86 8:00 a.m.-12 noon
Madison Room, Third Floor, Hilton Atlanta

INSANITY DEFENSE EVALUATIONS

Director: Phillip J. Resnick, M.D.

COURSE 87 8:00 a.m.-12 noon
Monroe/Roosevelt Room, Third Floor, Hilton Atlanta

MANAGEMENT OF PSYCHIATRIC DISORDERS IN PREGNANT AND POSTPARTUM MOTHERS

Co-Directors: Shaila Misri, M.D., Diana Carter, M.S.

Faculty: Maria R. Corral, M.D., Shari Lusskin, M.D., Shimi Kang, M.D.

9:00 a.m. Sessions

CLINICAL CASE CONFERENCE 3

9:00 a.m.-10:30 a.m.

Room A402, Level 4, Georgia World Congress Center

CROSSING THE LINE: DETERMINING YOUR PATIENT IS TOO DANGEROUS TO DRIVE

Moderator: Carl B. Greiner, M.D.

Presenters: Laura W. Roberts, M.D., Steven Wengel, M.D., Nicole Wolfe, M.D.

THIS SESSION IS OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

CONTINUOUS CLINICAL CASE CONFERENCE 2: PART 1

9:00 a.m.-12 noon

Room A403, Level 4, Georgia World Congress Center

WEATHERING THE STORM: MANAGEMENT OF COMPLEX TRANSFERENCE

Moderator: Beth J. Seelig, M.D.

Presenter: Otto F. Kernberg, M.D.

Discussants: John M. Oldham, M.D., Wendy Jacobson, M.D.

THIS SESSION IS OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.



COURSES 88-95

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

COURSE 88

9:00 a.m.-4:00 p.m.

Henry Room, Second Floor, Hilton Atlanta

ESSENTIALS OF GERIATRIC PSYCHOPHARMACOLOGY

Director: Helen Lavretsky, M.D.

Faculty: Joel Streim, M.D., Martha Sajatovic, M.D., David Oslin, M.D.

COURSE 89

9:00 a.m.-4:00 p.m.

Newton Room, Second Floor, Hilton Atlanta

INTERPERSONAL PSYCHOTHERAPY

Director: Scott Stuart, M.D.

Faculty: Paula Ravitz, M.D.

COURSE 90

9:00 a.m.-4:00 p.m.

Rockdale Room, Second Floor, Hilton Atlanta

PSYCHIATRY UPDATE: IN SPANISH

Co-Directors: Gabriel Kaplan, M.D., Javier I. Escobar, M.D.

Faculty: Pedro L. Delgado, M.D., Jacobo E. Mintzer, M.D., Humberto Marin, M.D.

COURSE 91

9:00 a.m.-4:00 p.m.

Clayton Room, Second Floor, Hilton Atlanta

MEN SEXUALLY ABUSED AS BOYS: MEANINGS, CONSEQUENCES, AND TREATMENTS

Director: Murray D. Schane, M.D.

Faculty: Howard Fradkin, Ph.D., Richard Gartner, Ph.D., William Holmes, M.D., Kenneth Singer, M.S.W., Bill Burmester, M.A.

COURSE 92

9:00 a.m.-4:00 p.m.

Grand Salon B, Second Floor, Hilton Atlanta

PSYCHIATRY IN CORRECTIONS

Co-Directors: Ole Thienhaus, M.D., Gail Singletary, R.N.

Faculty: John N. Chappel, M.D., Richard Horton, M.D., Thomas M. Kim, M.D., Kaycia L. Vansicle, M.D., Fran Zito, L.C.S.W.

COURSE 93

9:00 a.m.-4:00 p.m.

Jackson Room, Third Floor, Hilton Atlanta

INTRODUCTION TO COGNITIVE-BEHAVIORAL THERAPY

Co-Directors: Robert M. Goisman, M.D., Philip G.

Levendusky, Ph.D.

COURSE 94

9:00 a.m.-4:00 p.m.

Board/Directors Rooms, Fourth Floor, Hilton Atlanta

ADVANCED INTERVIEWING TECHNIQUES

Director: Shawn C. Shea, M.D.

COURSE 95 9:00 a.m.-4:00 p.m.

Club/State Rooms, Fourth Floor, Hilton Atlanta

SEEING THE FOREST AND THE TREES: AN APPROACH TO BIOPSYCHOSOCIAL FORMULATION

Director: William H. Campbell, M.D.

DISCUSSION GROUPS 16-18

9:00 a.m.-10:30 a.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

- 16 Michele T. Pato, M.D. and Carlos N. Pato, M.D., on Residency to a Research Career (*For Residents Only*)
Collaborative Session With the National Institute of Mental Health
International Rooms 2-3, International Level, Marriott Marquis Atlanta
- 17 Wayne J. Katon, M.D., on Improving Outcomes of Patients With Anxiety and Depressive Disorders Within Primary Care Settings
Chestnut Room, North Tower, Meeting Level, Omni Hotel
- 18 Glen O. Gabbard, M.D., on Psychodynamic Psychiatry in Clinical Practice (*Meet the Authors*)
Pecan Room, North Tower, Meeting Level, Omni Hotel

LECTURES 16-17

LECTURE 16

9:00 a.m.-10:30 a.m.

Room A412, Level 4

Georgia World Congress Center

APA'S OSKAR PFISTER AWARD LECTURE

Armand M. Nicholi, Jr., M.D.

The Conflicting Worldviews of Sigmund Freud and Oskar Pfister: Keys to Understanding Patients

Chp.: John R. Peteet, M.D.

Armand M. Nicholi, Jr., M.D. is Associate Clinical Professor of Psychiatry at Harvard Medical School and Massachusetts General Hospital. He teaches a popular course at Harvard that served as the basis for his 2002 book *The Question of God: C. S. Lewis and Sigmund Freud Debate God, Love, Sex, and the Meaning of Life*. The book was adapted as a PBS television series that first aired in

2004. Dr. Nicholi's research has ranged from the study of changes in the structure of the American family and their impact on the psychological development of children to the study of object relations theory and its application to the success of organizations. His investigation of college dropouts, which focuses on the causes and effects of the widespread nontherapeutic use of drugs in this population, is the first large-scale epidemiological study of that age group. Dr. Nicholi is the author of more than 120 scientific articles, chapters, and abstracts and is the editor and co-author of *The Harvard Guide to Psychiatry*. A Distinguished Life Fellow of the American Psychiatric Association (APA), Dr. Nicholi formerly served on the APA Committee on Health Services Research. He has been elected to the Harvard Chapter of Sigma Xi, the Scientific Research Society. **THIS SESSION WILL BE AUDIOTAPED.**

LECTURE 17

9:00 a.m.-10:30 a.m.

Rooms B312/313, Level 3

Georgia World Congress Center

Nancy Frasure-Smith, Ph.D.

Depression and Heart Disease: Cause, Effect, or Coincidence

Chp.: Josepha A. Cheong, M.D.

Co-Chp.: Stephen M. Saravay, M.D.

Depression may be a risk factor for the development and worsening of coronary artery disease, and depression and cardiac disease may have common causes, including inflammation, generalized atherosclerosis, and lower levels of omega-3 fatty acid. Dr. Nancy Frasure-Smith, discusses the evidence for depression as a cardiac risk factor, as well as the potential pathophysiological and behavioral mechanisms that may account for links between depression and cardiac disease. Dr. Frasure-Smith is Professor of Psychiatry and Adjunct Professor of Nursing at McGill University in Montreal, Senior Research Associate at the Montreal Heart Institute, Associate Professor of Psychiatry at the University of Montreal, and Associate Researcher at the Centre Hospitalier de l'Université de Montréal. She is also Past President of the American Psychosomatic Society. With her colleague Dr. François Lespérance, Dr. Frasure-Smith is known internationally for bringing depression to the forefront of research in behavioral cardiology. She recently received funding from the Canadian Institutes of Health Research for a multi-site, randomized trial of interpersonal psychotherapy and citalopram in patients with stable coronary artery disease. Dr. Frasure-Smith received her doctorate in social relations from Johns Hopkins University in Baltimore and completed a National Institute of Mental Health postdoctoral fellowship in psychology at McGill University. **Frontiers of Science Lecture Series**
THIS SESSION WILL BE AUDIOTAPED.

MASTER EDUCATOR CLINICAL CONSULTATIONS 9-10

9:00 a.m.-10:30 a.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

- 9 Diana Dell, M.D., on Managing Menopause
Room B317, Level 3, Georgia World Congress Center
- 10 Susan G. Kornstein, M.D., on Premenstrual Mood Disorders
Room B318, Level 3, Georgia World Congress Center

THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

REVIEW OF PSYCHIATRY: SECTION 2

9:00 a.m.-2:30 p.m.

Rooms B405/406/407, Level 4, Georgia World Congress Center

PREGNANCY AND POSTPARTUM DEPRESSION

Chp.: Lee S. Cohen, M.D.

- 5 Course of Psychiatric Disorder During Pregnancy
Laura Fagiolo-Petrillo, M.D.
- 6 Psychotropic Drug Use During Pregnancy
Lee S. Cohen, M.D.
- 7 Diagnosis and Treatment of Postpartum Mood Disorder
Ruta M. Nonacs, M.D.
- 8 Uses of Psychotropics During Lactation
Adele C. Viguera, M.D., Ruta M. Nonacs, M.D.

WORKSHOPS

COMPONENT WORKSHOPS 34-43

COMPONENT WORKSHOP 34 9:00 a.m.-10:30 a.m.
Room A304, Level 3, Georgia World Congress Center

A BITTER PILL? TAILORING MEDICAL TRAINING TO FIT OUR CONTEMPORARY PRACTICE
APA/GlaxoSmithKline Fellows

Co-Chps.: Steve Sugden, M.D., Lara R. Fuchs, M.D.
Participants: Tiffany R. Farchione, M.D., Marisa A. Giggie, M.D., Prakash K. Thomas, M.D.

COMPONENT WORKSHOP 35 9:00 a.m.-10:30 a.m.
Room A404, Level 4, Georgia World Congress Center

ROADMAP TO RECERTIFICATION: LIFELONG LEARNING

APA Council on Medical Education and Lifelong Learning

Co-Chps.: Richard Balon, M.D., Sheldon I. Miller, M.D.
Participants: Deborah J. Hales, M.D., Joan M. Anzia, M.D., Lowell D. Tong, M.D., Trish Tivnan

COMPONENT WORKSHOP 36 9:00 a.m.-10:30 a.m.
Room A405, Level 4, Georgia World Congress Center

CPT CODING AND DOCUMENTATION UPDATE

APA Committee on RBRVS, Codes, and Reimbursements

Chp.: Chester W. Schmidt, Jr., M.D.
Participants: Tracy R. Gordy, M.D., Edward Gordon, M.D., Napoleon B. Higgins, Jr., M.D.

COMPONENT WORKSHOP 37 9:00 a.m.-10:30 a.m.
Room A410, Level 4, Georgia World Congress Center

SSRIS AND SUICIDE: LESSONS LEARNED AND IMPLICATIONS FOR FUTURE TREATMENT GUIDELINES

APA Council on Children, Adolescents, and Their Families

Chp.: Graham J. Emslie, M.D.
Participants: John S. March, M.D., David Fassler, M.D., Jennifer K. Cheng, M.D.

COMPONENT WORKSHOP 38 9:00 a.m.-10:30 a.m.
Room B301, Level 3, Georgia World Congress Center

TO DOSE OR NOT TO DOSE: PSYCHOPHARMACOLOGY IN THE DEVELOPMENTALLY DISABLED

APA Committee on Developmental Disabilities

Chp.: Bryan H. King, M.D.
Participants: Joel D. Bregman, M.D., John DeFigueiredo, M.D., Lee Combrinck-Graham, M.D.

COMPONENT WORKSHOP 39 9:00 a.m.-10:30 a.m.
Room B306, Level 3, Georgia World Congress Center

FROM CRADLE TO GRAVE: THE IMPACT OF INCARCERATION ON AFRICAN-AMERICAN FAMILIES

APA Committee of Black Psychiatrists

Co-Chps.: Michelle O. Clark, M.D., N. Kalaya Okereke, M.D.
Participants: Rahn K. Bailey, M.D., Cassandra F. Newkirk, M.D., William M. Womack, M.D., Nancy Boyd-Franklin, Ph.D.

COMPONENT WORKSHOP 40 9:00 a.m.-10:30 a.m.
Room B307, Level 3, Georgia World Congress Center

DOCTOR, YOUR CHILD IS CALLING
APA Corresponding Committee on Psychiatry in the Workplace

Co-Chps.: Jacquelyn B. Chang, M.D., Andrea G. Stolar, M.D.
Participant: Marcia A. Scott, M.D.

COMPONENT WORKSHOP 41 9:00 a.m.-10:30 a.m.
Room B308, Level 3, Georgia World Congress Center

PSYCHOSOMATIC MEDICINE: AN UPDATE ON A NEW SUBSPECIALTY
APA Council on Psychosomatic Medicine

Co-Chps.: Philip R. Muskin, M.D., Carol L. Alter, M.D.
Participants: Peter A. Shapiro, M.D., James L. Levenson, M.D., Constantine Lyketsos, M.D., David Gitlin, M.D., Stephen C. Scheiber, M.D.

COMPONENT WORKSHOP 42 9:00 a.m.-10:30 a.m.
Room B309, Level 3, Georgia World Congress Center

IMPROVING DIAGNOSTIC AND THERAPEUTIC SKILLS: A CROSS-CULTURAL PERSPECTIVE
APA Committee on International Medical Graduates

Chp.: Sanjay Dube, M.D.
Participants: Nalini Juthani, M.D., Francis M. Sanchez, M.D., Oscar E. Perez, M.D., Michelle B. Riba, M.D.

COMPONENT WORKSHOP 43 9:00 a.m.-10:30 a.m.
Room B310, Level 3, Georgia World Congress Center

SAME SEX MARRIAGES: MENTAL HEALTH AND PERSONAL PERSPECTIVES
APA Northern California Psychiatric Society's Committee on Lesbian, Gay, Bisexual, and Transgender Issues

Co-Chps.: Gene A. Nakajima, M.D., Ellen Haller, M.D.
Participants: Dan H. Karasic, M.D., John S. Kruse, M.D., Marshall Forstein, M.D.

ISSUES 57-77

ISSUE WORKSHOP 57 9:00 a.m.-10:30 a.m.
Room B311, Level 3, Georgia World Congress Center

IMPACT OF VIOLENCE ON PREGNANCY, BIRTH, AND PARENTHOOD: THE INTERFACE BETWEEN PSYCHIATRY AND OBSTETRICS

Chp.: Johannes Bitzer, M.D.
Participant: Werner Tschan, M.D.

ISSUE WORKSHOP 58 9:00 a.m.-10:30 a.m.
Room B314, Level 3, Georgia World Congress Center

CLINICAL DECISIONS: GUIDELINES, INDICATORS, AND ALGORITHMS

Co-Chps.: Rodrigo A. Munoz, M.D., Jack S. McIntyre, M.D.
Participants: Robert Popozian, Ph.D., Richard Smith, M.D., Madhukar H. Trivedi, M.D., Britton A. Hill, M.D.

ISSUE WORKSHOP 59 9:00 a.m.-10:30 a.m.
Room B315, Level 3, Georgia World Congress Center

TREATMENT OF MENTAL ILLNESS IN U.S. JAILS AND PRISONS

Co-Chps.: Joseph R. Calabrese, M.D., Omar Elhaj, M.D.
Participants: Jeffrey L. Metzner, M.D., Timothy L. Thistlethwaite, M.D.

ISSUE WORKSHOP 60 9:00 a.m.-10:30 a.m.
Room B316, Level 3, Georgia World Congress Center

IN FROM THE COLD: PERSPECTIVES ON SOCIAL SUPPORT IN PSYCHIATRY AND MEDICINE

Chp.: Jacqueline Olds, M.D.
Participants: David M. Spiegel, M.D., James S. Goodwin, M.D., Bruce S. McEwen, Ph.D., Richard S. Schwartz, M.D.

ISSUE WORKSHOP 61 9:00 a.m.-10:30 a.m.
Room B401, Level 4, Georgia World Congress Center

RELIGIOUS AND SPIRITUAL ASSESSMENT IN CLINICAL PRACTICE

Co-Chps.: Francis G. Lu, M.D., Christina M. Puchalski, M.D.
Participant: James L. Griffith, M.D.

ISSUE WORKSHOP 62 9:00 a.m.-10:30 a.m.
Room B402, Level 4, Georgia World Congress Center

ANGER MANAGEMENT: EVALUATION AND TREATMENT

Chp.: Eva C. Ritvo, M.D.
Participants: Larry J. Harmon, Ph.D., Gonzalo F. Quesada, M.D.

ISSUE WORKSHOP 63 9:00 a.m.-10:30 a.m.
Room B403, Level 4, Georgia World Congress Center

DYNAMIC THERAPY WITH SELF-DESTRUCTIVE BORDERLINE PATIENTS

Co-Chps.: Eric M. Plakun, M.D., Edward R. Shapiro, M.D.

ISSUE WORKSHOP 64 9:00 a.m.-10:30 a.m.

Room B404, Level 4, Georgia World Congress Center

**WHEN USUAL TREATMENTS FAIL:
AUGMENTATION STRATEGIES FOR REFRACTORY
SCHIZOPHRENIA**

Chp.: Jean-Pierre Lindenmayer, M.D.
Participants: Joseph I. Friedman, M.D., Guochuan Tsai, M.D.,
Richard P. Brown, M.D., Peter F. Buckley, M.D.

ISSUE WORKSHOP 65 9:00 a.m.-10:30 a.m.

Room B408, Level 4, Georgia World Congress Center

**REINVENTING CAREERS: TRANSITIONS AND
LATER-LIFE STRATEGIES FOR PSYCHIATRISTS**

Chp.: Carolyn B. Robinowitz, M.D.
Participants: Joel Yager, M.D., Jerald Kay, M.D., Carol C.
Nadelson, M.D.

ISSUE WORKSHOP 66 9:00 a.m.-10:30 a.m.

Room B409, Level 4, Georgia World Congress Center

**PSYCHOTHERAPY TRAINING AND IMGs: THE
INFLUENCE OF CULTURAL FACTORS**

Chp.: Nyapati Rao, M.D.
Participants: Michael Garrett, M.D., Stephen M.
Goldfinger, M.D., Damir Huremovic, M.D.

ISSUE WORKSHOP 67 9:00 a.m.-10:30 a.m.

Birch Room, South Tower, Atrium Terrace Level, Omni
Hotel

**CARDIOVASCULAR COMPLICATIONS OF
PSYCHIATRIC TREATMENTS**

Chp.: Peter Manu, M.D.

ISSUE WORKSHOP 68 9:00 a.m.-10:30 a.m.

Maple Room, South Tower, Atrium Terrace Level, Omni
Hotel

**THE MARKETING OF PSYCHIATRIC MEDICATIONS
TO PATIENTS: WHERE DO WE STAND?**

Chp.: Patrick Ying, M.D.
Participant: Marshal Folstein, M.D.

ISSUE WORKSHOP 69 9:00 a.m.-10:30 a.m.

Spruce Room, South Tower, Atrium Terrace Level, Omni
Hotel

**SELF-AWARENESS DEFICITS IN SCHIZOPHRENIA
AND COCAINE ABUSE**

Chp.: Bernard D. Beitman, M.D.
Participants: Laura A. Flashman, Ph.D., George I.
Viamontes, M.D.

ISSUE WORKSHOP 70 9:00 a.m.-10:30 a.m.

Oak Room, South Tower, Lobby Level, Omni Hotel

**RECOGNIZING AND MANAGING OPIOID-INDUCED
HYPERALGESIA IN CHRONIC PAIN PATIENTS**

Chp.: Jon M. Streltzer, M.D.
Participants: Carl R. Sullivan, M.D., A. Kenison Roy III, M.D.

ISSUE WORKSHOP 71 9:00 a.m.-10:30 a.m.

Cottonwood Room, North Tower, Street Level, Omni Hotel

**FAST TRACKING INTO CHILD PSYCHIATRY: WHO
BENEFITS? WHO SUFFERS?**

Co-Chps.: Kareem D. Ghalib, M.D., Lisa A. Mellman, M.D.
Participants: Eugene V. Beresin, M.D., Jed G. Magen, D.O.,
David L. Kaye, M.D., Marc E. Dalton, M.D.

ISSUE WORKSHOP 72 9:00 a.m.-10:30 a.m.

Dogwood B, North Tower, Street Level, Omni Hotel

THE REACH OF MENTAL ILLNESS STIGMA

Collaborative Session With the National Institute of Mental Health

Chp.: Bernice A. Pescosolido, Ph.D.
Participants: Patrick W. Corrigan, Psy.D., Cathy
Sherbourne, Ph.D., Jo C. Phelan, Ph.D.

ISSUE WORKSHOP 73 9:00 a.m.-10:30 a.m.

Redwood Room, North Tower, Street Level, Omni Hotel

**BENEATH THE SWORD OF DAMOCLES: LIVING IN
THE LIMBO OF REMISSION FROM CANCER**

Chp.: Fredric J. Van Rheenen, M.D.

ISSUE WORKSHOP 74 9:00 a.m.-10:30 a.m.

Juniper Room, North Tower, Ballroom Level, Omni Hotel

BECOME A DELIRIUM DETECTIVE

Chp.: Arthur M. Freeman III, M.D.
Participants: Kristin S. Beizai, M.D., Marie B. Tobin, M.D.,
Robert Kores, Ph.D.

ISSUE WORKSHOP 75 9:00 a.m.-10:30 a.m.

Magnolia Room, North Tower, Ballroom Level, Omni Hotel

**TREATMENT OF TOURETTE'S SYNDROME
THROUGH THE LIFE CYCLE**

National Tourette's Syndrome Association

Chp.: Cathy L. Budman, M.D.
Participants: John T. Walkup, M.D., Anthony L. Rostain, M.D.

ISSUE WORKSHOP 76 9:00 a.m.-10:30 a.m.
Hickory Room, North Tower, Meeting Level, Omni Hotel

ACCEPTANCE VERSUS CHANGE: DIALECTICS OF IMPLEMENTING DBT IN RESIDENCY TRAINING

Co-Chps.: Maribel Rivera, M.D., Lisa Lyons, Ph.D.
Participants: Brad Foote, M.D., Kara L. McCunn, M.D.

ISSUE WORKSHOP 77 9:00 a.m.-10:30 a.m.
Walnut Room, North Tower, Meeting Level, Omni Hotel

SEXUAL HISTORY: THE ART AND THE SCIENCE

Chp.: Waguih W. Ishak, M.D.
Participants: Shahrar R. Amiri, M.D., Danni Michaeli, M.D.

11:00 a.m. Sessions

DISCUSSION GROUPS 19-21

11:00 a.m.-12:30 p.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

- 19 Richard Balon, M.D. and Carol A. Bernstein, M.D., on Core Competencies (*For Residents Only*)
International Rooms 2-3, International Level, Marriott Marquis Atlanta
- 20 Laura W. Roberts, M.D., on Ethics Evidence and Ethical Skills in Psychiatry (*Meet the Authors*)
Hazelnut Room, North Tower, Meeting Level, Omni Hotel
- 21 Sarah H. Lisanby, M.D., on Emerging Brain Stimulation Techniques in Psychiatry (*Meet the Authors*)
Collaborative Session With the National Institute of Mental Health
Pecan Room, North Tower, Meeting Level, Omni Hotel

LECTURE 18

11:00 a.m.-12:30 p.m.
Room A411, Level 4
Georgia World Congress Center

Stuart C. Yudofsky, M.D.

Neuropsychiatry and the Future of
Psychiatry and Neurology

Chp.: David A. Casey, M.D.
Co-Chp.: Nicole Wolfe, M.D.

Stuart C. Yudofsky, M.D., is the D.C. and Irene Ellwood Professor and Chairman of the Menninger Department of Psychiatry and Behavioral Sciences at Baylor College of Medicine in Houston. He is also Chief of Psychiatry Service at Methodist Hospital in Houston and is responsible for oversight of academic activities in psychiatry at Ben Taub General Hospital, Houston Veterans Affairs Medical Center, St. Luke's Episcopal Hospital, and Texas Children's Hospital. Dr. Yudofsky's research and clinical practice focus on psychopharmacology and neuropsychiatry. He is Editor of *The Journal of Neuropsychiatry and Clinical Neuroscience*, the author or co-author of numerous scientific articles and book chapters, and the editor or co-editor of 27 books, including *The American Psychiatric Publishing Textbook of Clinical Psychiatry* and *The American Psychiatric Publishing Textbook of Neuropsychiatry and Clinical Neuroscience*, both in their fourth editions. A Distinguished Fellow of the American Psychiatric Association, Dr. Yudofsky is also a Fellow of the American Neuropsychiatric Association and the American College of Psychiatrists, Past President of the American Neuropsychiatric Association, and a recipient of the National Alliance for the Mentally Ill's Exemplary Psychiatrist Award. He graduated from Baylor College of Medicine and completed his residency in psychiatry at Columbia University College of Physicians and Surgeons. **Distinguished Psychiatrist Lecture Series**
THIS SESSION WILL BE AUDIOTAPED.

MASTER EDUCATOR CLINICAL CONSULTATIONS 11-12

11:00 a.m.-12:30 p.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

- 11 Miriam Rosenthal, M.D., on Psychiatric Aspects of Reproduction in Chronically Mentally Ill Women
Room B317, Level 3, Georgia World Congress Center
- 12 Robert N. Golden, M.D., on the Approaches to Treatment-Refractory Depression
Room B318, Level 3, Georgia World Congress Center

THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR

MEDICAL UPDATE 3

11:00 a.m.-12:30 p.m.
Room B403, Level 4, Georgia World Congress Center

OKAY INSIDE THEIR HEAD, BUT WHAT'S UNDER THEIR NOSE?

Presenter: Claudia Miller, M.D.
Chp.: Joan A. Lang, M.D.

RESEARCH CONSULTATION WITH

11:00 a.m.-12:30 p.m.

This session is limited to 25 participants on a first-come, first-served basis.

- 3 Michael E. Thase, M.D., on Evaluating the Effects of Treatment for Depression
Chestnut Room, North Tower, Meeting Level, Omni Hotel

SCIENTIFIC AND CLINICAL REPORT SESSIONS 19-27

SCIENTIFIC AND CLINICAL REPORT SESSION 19

11:00 a.m.-12:30 p.m.

Room A402, Level 4, Georgia World Congress Center

ADDICTION PSYCHIATRY

Chp.: Shelly F. Greenfield, M.D.

Co-Chp.: Kenneth Stoller, M.D.

11:00 a.m.

- 56 Virtual Reality Cue Exposure for Crack Cocaine Dependence
Barbara Rothbaum, Ph.D., Michael Saladin, Ph.D., Ken Graap, M.A., Kathleen T. Brady, M.D.

11:30 a.m.

- 57 Low-Dose Naltrexone for Opioid Dependence
Paolo Mannelli, M.D., Charles Thornton, Ph.D., Heather Murray, Ashwin A. Patkar, M.D.

12 noon

- 58 Buprenorphine Versus Methadone Treatments in Addicted Opioid Patients: A Two-Year Observational Study
Paolo Marzorati, M.D., Livia Guglielmino, M.D., Pierluigi Vigezzi, M.D., Rosella Silenzio, M.D., Margherita de Chiara, M.D., Filomena Corrado, M.D., Edoardo Cozzolino, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 20

11:00 a.m.-12:30 p.m.

Room A404, Level 4, Georgia World Congress Center

ADVERSE DRUG EFFECTS

Chp.: Prakash S. Masand, M.D.

Co-Chp.: J. Richard Navarre, M.D.

11:00 a.m.

- 59 Thinking About Adverse Drug Effects: Lessons From the Psychology of Risk and Decision Making for Clinical Psychopharmacology
Andrew A. Nierenberg, M.D., Yelena Wu, B.A., Polina Eidelman, B.A., Jordan W. Smoller, M.D.

11:30 a.m.

- 60 Sildenafil Treatment of SSRIs-Associated Sexual Dysfunction in Nonresponders of a Double-Blind, Placebo-Controlled Study: Single-Blind, Open-Label Results
H. George Nurnberg, M.D., Paula L. Hensley, M.D., Maurizio Fava, Ph.D., Alan J. Gelenberg, M.D., John Lauriello, M.D., Susan Paine, M.P.H.

12 noon

- 61 Association Between SSRI Side Effects and Adherence to Modern SSRIs
Stephen B. Woolley, M.P.H., John W. Goethe, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 21

11:00 a.m.-12:30 p.m.

Room B301, Level 3, Georgia World Congress Center

DEPRESSION

Chp.: Thomas L. Schwartz, M.D.

Co-Chp.: Glenn J. Treisman, M.D.

11:00 a.m.

- 62 Last Observation Carried Forward Use in Antidepressant Efficacy Trials: Review of 260 Studies
Alex A. Cardoni, M.S., Stephen B. Woolley, M.P.H., John W. Goethe, M.D.

11:30 a.m.

- 63 The Effect of Chromium Picolinate on Carbohydrate Craving in Atypical Depression
John P. Docherty, M.D., James Komorowski, M.S., David A. Sack, M.D., Mark Roffman, Ph.D., Manley Finch

12 noon

- 64 Does Remission of Acute Depression Predict Long-Term Efficacy
Caroline B. Williams, M.D., Eric D. Peselow, M.D., Mary Anne Pressman, M.D., Gonzalo E. Laje, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 22

11:00 a.m.-12:30 p.m.

Room B306, Level 3, Georgia World Congress Center

EATING DISORDERS

Collaborative Session With the National Institute of Mental Health

Chp.: Regina Dolan-Sewell, Ph.D.

Co-Chp.: Theodore E. Weltzin, M.D.

11:00 a.m.

- 65 Anorexia Nervosa and Bulimia Nervosa: From Culture to Genes
Pamela K. Keel, Ph.D.

11:30 a.m.

- 66 Psychosocial Treatment of Eating Disorders
Cynthia M. Bulik, Ph.D.

12 noon

- 67 Psychopharmacology of Eating Disorders
B. Timothy Walsh, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 23

11:00 a.m.-12:30 p.m.

Room B408, Level 4, Georgia World Congress Center

VIOLENCE AND TRAUMA

Chp.: Randall D. Marshall, M.D.

Co-Chp.: Barbara D'Orio, M.D.

11:00 a.m.

- 68 Effects of Terrorism on Psychopathology: Two Years After 9/11
Judith A. Richman, Ph.D., Kenneth W. Zlotoper, M.S.,
Joseph A. Flaherty, M.D., Kathleen Rospenda, Ph.D.

11:30 a.m.

- 69 9/11: Terrorism, Psychiatric Symptoms, Service Utilization, and Alcohol Intake
Linda S. Grossman, Ph.D., Judith A. Richman, Ph.D.,
Kenneth W. Zlotoper, M.S., Cherise Rosen, M.A.

12 noon

- 70 Clozapine, Olanzapine, and Haloperidol Treatment of Violent Patients With Schizophrenia
Menahem I. Krakowski, M.D., Pal Czobor, Ph.D., Leslie L. Citrome, M.D., Fabien Tremeau, M.D., Biman B. Roy, M.D., Linda Kline, R.N.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 24

11:00 a.m.-12:30 p.m.

Room B409, Level 4, Georgia World Congress Center

SCHIZOPHRENIA AND OTHER PSYCHOTIC DISORDERS

Chp.: David Walker, M.D.

Co-Chp.: Mark Hutto, M.D.

11:00 a.m.

- 71 Premorbid Developmental Achievements and Later Recovery in Schizophrenia
Martin Harrow, Thomas H. Jobe, M.D., Linda S. Grossman, Ph.D., Joseph F. Goldberg, M.D., Robert Faull, B.S.

11:30 a.m.

- 72 Pain Insensitivity in Schizophrenia: State or Trait Marker?
Lisa L. Giles, M.D., Manpreet Singh, M.D., Henry A. Nasrallah, M.D.

12 noon

- 73 Effectiveness of an Early Psychosis Treatment Service
Donald E. Addington, M.D., Jean M. Addington, Ph.D.,
Scott B. Patten, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 25

11:00 a.m.-12:30 p.m.

Pine Room, South Tower, Atrium Terrace Level, Omni Hotel

TREATMENT TECHNIQUES

Chp.: Joel Kirson, M.D.

Co-Chp.: Jennifer Heath, M.D.

11:00 a.m.

- 74 Does Exercise Have a Place in Psychiatry?
James Annesi, Ph.D., Sheldon B. Cohen, M.D.

11:30 a.m.

- 75 Restraint Stress Elevates Plasma Cytokines Levels in Superoxide Dependent Manner
Atsuo Sekiyama, Ph.D., Haruyasu Ueda, Ph.D., Shinichiro Kashiwamura, Ph.D., Masatoshi Takeda, M.D., Haruki Okamura, Ph.D.

12 noon

- 76 Treating Depression in a VA Primary Care Integrated Behavioral Health Model
Anna G. Engel, M.D., Cheryl A. Aquilino, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 26

11:00 a.m.-12:30 p.m.

Cottonwood Room, North Tower, Street Level, Omni Hotel

MEDICAL ILLNESS AND PSYCHIATRIC DISORDERS

Chp.: Michael Burke, M.D.

Co-Chp.: Jeffrey Lee Erickson, M.D.

11:00 a.m.

- 77 Depression Correlates With Left Nigrostriatopallidal Circuit Focal Lesions
Edward C. Lauterbach, M.D., Julia B. Tolley, M.Ed.,
William F. Bina, M.D., Thomas D. Hope, M.D.

11:30 a.m.

- 78 Depression-Related Impairment of Baroreflex in Heart Failure
Salvador M. Guinjoan, M.D., Carlos Berbara, M.D., Maria Gabrielli, B.A., Daniel E. Vigo, M.D., Ricardo Perez-De-La-Hoz, M.D., Alfredo Ortiz-Fragola, Daniel P. Cardinali, M.D., Rodolfo D. Fahrer, M.D.

12 noon

- 79 Respiratory Panic Disorder in a Long-Term Clonazepam Follow-Up
Antonio E. Nardi, M.D., Alexandre M. Valenca, M.D.,
Fabiana L. Lopes, M.D., Isabella Nascimento, M.D.,
Marco A. Mezzasalma, M.D., Rafael C. Freire, M.D.,
Walter A. Zin, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 27
11:00 a.m.-12:30 p.m.
Redwood Room, North Tower, Street Level, Omni Hotel

PSYCHIATRIC ADMINISTRATION AND SERVICES

Chp.: Ossama T. Osman, M.D.
Co-Chp.: Amit D. Rajparia, M.D.

11:00 a.m.

80 **Changing Trends in Psychiatric Emergency Room Patients in Large Urban Hospitals**
Christopher K. Chung, M.D., Davin A. Agustines, M.D., Steve Brown, Ph.D., Jambur V. Ananth, M.D.

11:30 a.m.

81 **Data From a Psychiatric Emergency Service Using an Electronic Medical Record**
Jennifer S. Brasch, M.D., Rolf Sebalt, M.D., Christopher Webster, Ph.D., Marilyn Craven, M.D.

12 noon

82 **Implementing a Mixed Psychiatric and Somatic Care Unit in a General Hospital**
Ariel Eytan, M.D., Christel Alberque, M.D., Marianne Gex-Fabry, M.S.C.

THIS SESSION WILL BE AUDIOTAPED.

WORKSHOPS

COMPONENTS 44-51

COMPONENT WORKSHOP 44 11:00 a.m.-12:30 p.m.
Room A304, Level 3, Georgia World Congress Center

MENTAL STATUS AFTER CABG: IMPLICATIONS FOR PSYCHIATRISTS' COMPETENCE
APA Lifes

Co-Chps.: Abram M. Hostetter, M.D., Sheila Hafter Gray, M.D.
Participants: Margaret O'Connor, Ph.D., Alberto M. Goldwasser, M.D.

COMPONENT WORKSHOP 45 11:00 a.m.-12:30 p.m.
Room B308, Level 3, Georgia World Congress Center

CURRENT ISSUES IN PSYCHIATRY AND LAW AT APA
APA Council on Psychiatry and Law

Chp.: Paul S. Appelbaum, M.D.
Participants: Richard Bonnie, J.D., Howard V. Zonana, M.D., Jeffrey L. Metzner, M.D., Patricia R. Recupero, M.D.

COMPONENT WORKSHOP 46 11:00 a.m.-12:30 p.m.
Room B401, Level 4, Georgia World Congress Center

THE CONFLICTING WORLDVIEWS OF SIGMUND FREUD AND C.S. LEWIS
APA Corresponding Committee on Religion, Spirituality, and Psychiatry

Chp.: John R. Peteet, M.D.
Participants: Dan G. Blazer II, M.D., Armand M. Nicholi, Jr., M.D.

COMPONENT WORKSHOP 47 11:00 a.m.-12:30 p.m.
Spruce Room, South Tower, Atrium Terrace Level, Omni Hotel

HOW TO LEAD AN EFFECTIVE TREATMENT TEAM
APA Caucus of State Hospital Psychiatrists

Chp.: Beatrice Kovaszny, M.D.
Participants: Joel S. Feiner, M.D., Pamela A. Weinberg, M.D., Yad Jabbarpour, M.D.

COMPONENT WORKSHOP 48 11:00 a.m.-12:30 p.m.
Juniper Room, North Tower, Ballroom Level, Omni Hotel

WHY BUSINESS NEEDS QUALITY CARE FOR DEPRESSION, ANXIETY, AND SUBSTANCE-USE DISORDERS
APA Committee on APA/Business Relationships

Chp.: Norman A. Clemens, M.D.
Participants: Jeffrey P. Kahn, M.D., Alan Langlieb, M.D., Herbert S. Peysner, M.D.

COMPONENT WORKSHOP 49 11:00 a.m.-12:30 p.m.
Magnolia Room, North Tower, Ballroom Level, Omni Hotel

COME AND COMPLAIN: DO PSYCHIATRISTS HAVE A ROLE IN ACCREDITATION? A DEBATE
APA Committee on Standards and Survey Procedures

Chp.: Steven I. Altchuler, M.D.
Participants: Marlin R.A. Mattson, M.D., Dennis J. Milke, M.D., Albert V. Vogel, M.D.

COMPONENT WORKSHOP 50 11:00 a.m.-12:30 p.m.
Hickory Room, North Tower, Meeting Level, Omni Hotel

INDIAN HEALTH SERVICE MENTAL HEALTH UPDATE AND PLANNING FOR THE FUTURE
APA Committee of American Indian, Alaska Native, and Native Hawaiian Psychiatrists

Chp.: Frank Brown, M.D.
Participants: Jon Perez, Ph.D., Brian T. Benton, M.D.

COMPONENT WORKSHOP 51 11:00 a.m.-12:30 p.m.

Walnut Room, North Tower, Meeting Level, Omni Hotel

NEED AN OXYCONTIN FIX? THE ROLE OF BUPRENORPHINE IN THE OUTPATIENT TREATMENT OF PRESCRIPTION NARCOTIC PROBLEMS

APA Corresponding Committee on Treatment Services for Patients With Addictive Disorders

Chp.: George F. Kolodner, M.D.

Participants: Marianne T. Guschwan, M.D., John Renner, M.D., Samuel M. Silverman, M.D.

ISSUES 78-89

ISSUE WORKSHOP 78 11:00 a.m.-12:30 p.m.

Room A405, Level 4, Georgia World Congress Center

SLEEP DISORDERS IN PATIENTS WITH MEDICAL AND PSYCHIATRIC ILLNESS

Chp.: Dimitri D. Markov, M.D.

Participants: Karl Doghramji, M.D., Mary B. O'Malley, M.D.

ISSUE WORKSHOP 79 11:00 a.m.-12:30 p.m.

Room B307, Level 3, Georgia World Congress Center

FEMALE KNOCKOUTS: WOMEN PERPETRATORS AND VICTIMS OF PARTNER VIOLENCE

Chp.: Susan J. Hatters-Friedman, M.D.

Participants: Joy E. Stankowski, M.D., Renee M. Sorrentino, M.D.

ISSUE WORKSHOP 80 11:00 a.m.-12:30 p.m.

Room B309, Level 3, Georgia World Congress Center

POLYPHARMACY: NEW ADVANCES IN SUPPORTING PSYCHIATRIC PRACTICE

Collaborative Session With the National Institute of Mental Health

Co-Chps.: Junius J. Gonzales, M.D., Graca Cardoso, M.D.

Participants: Madhukar H. Trivedi, M.D., Robert L. Trestman, M.D.

ISSUE WORKSHOP 81 11:00 a.m.-12:30 p.m.

Room B310, Level 3, Georgia World Congress Center

PHILIP PULLMAN'S *THE GOLDEN COMPASS*: COMING OF AGE IN A FRACTURED WORLD

Chp.: JoAnne Isbey, A.B.D.

Participants: Theresa A. Yuschok, M.D., Eva M. Szigethy, M.D., Leah J. Dickstein, M.D., Cheryl Munday, Ph.D.

ISSUE WORKSHOP 82 11:00 a.m.-12:30 p.m.

Room B311, Level 3, Georgia World Congress Center

THE DIFFICULT-TO-TREAT BULIMIA NERVOSA PATIENT

Chp.: Waguih W. Ishak, M.D.

Participants: Jennifer L. McLain, M.D., Antonia Ludwig-Noble, M.F.T., Marlene Clark

ISSUE WORKSHOP 83 11:00 a.m.-12:30 p.m.

Room B315, Level 3, Georgia World Congress Center

PSYCHOSOMATIC MEDICINE WITH A DEVELOPMENTAL TWIST: CHILD CONSULTATION/LIAISON FOR ADULT PSYCHIATRISTS

Chp.: Maryland Pao, M.D.

Participant: Susan B. Turkel, M.D.

ISSUE WORKSHOP 84 11:00 a.m.-12:30 p.m.

Room B316, Level 3, Georgia World Congress Center

VIRTUAL REALITY AND OTHER FORMS OF CYBERTHERAPY: AN EVIDENCE-BASED REVIEW

Chp.: Jack Kuo, M.D.

Participants: William Huang, M.D., Carson Reynolds, M.S., Jeffery Wilkins, M.D.

ISSUE WORKSHOP 85 11:00 a.m.-12:30 p.m.

Birch Room, South Tower, Atrium Terrace Level, Omni Hotel

THERAPEUTIC USE OF MOVIE CLIPS IN OUTPATIENT AND INPATIENT GROUP TREATMENT

Chp.: Michael A. Kalm, M.D.

ISSUE WORKSHOP 86 11:00 a.m.-12:30 p.m.

Maple Room, South Tower, Atrium Terrace Level, Omni Hotel

INDIVIDUALS AND CONJOINT APPROACHES TO COUPLES THERAPY

Chp.: Eva C. Ritvo, M.D.

Participants: Michael C. Hughes, M.D., Jon A. Shaw, M.D.

ISSUE WORKSHOP 87 11:00 a.m.-12:30 p.m.
Oak Room, South Tower, Lobby Level, Omni Hotel

RESIDENTS IN THE TRENCHES, BUT NOT OUT IN THE COLD: INTEGRATING SHELTER-BASED OUTPATIENT ROTATIONS WITH ONLINE EDUCATIONAL TOOLS

American Association of Community Psychiatrists

Chp.: Stephen M. Goldfinger, M.D.
Participants: Ellen Berkowitz, M.D., Eric Weitzner, M.D., Van Yu, M.D., Ramotse Saunders, M.D., Damir Huremovic, M.D.

ISSUE WORKSHOP 88 11:00 a.m.-12:30 p.m.
Dogwood A, North Tower, Street Level, Omni Hotel

GRANDPARENTS AND GRANDCHILDREN: CHILD PSYCHIATRIC AND FAMILY PERSPECTIVES

Co-Chps.: G. Pirooz Sholevar, M.D., Ellen Harris Sholevar, M.D.

ISSUE WORKSHOP 89 11:00 a.m.-12:30 p.m.
Dogwood B, North Tower, Street Level, Omni Hotel

UNEXPLAINED MEDICAL SYMPTOMS IN A PEDIATRIC POPULATION

Chp.: Rose Geist, M.D.
Participants: Gillian Kirsh, M.A., Rachel Gropper

12 noon Sessions

FORUMS 7-9

FORUM 7 12 noon-1:30 p.m.
Room A410, Level 4, Georgia World Congress Center

ABPN UPDATE: CERTIFICATION IN PSYCHIATRY AND ITS SUBSPECIALTIES

Chp.: Stephen C. Scheiber, M.D.
Participants: Naleen N. Andrade, M.D., Michael H. Ebert, M.D., David A. Mrazek, M.D., Burton V. Reifler, M.D., Victor I. Reus, M.D., James H. Scully, Jr., M.D.

FORUM 8 12 noon-1:30 p.m.
Room B314, Level 3, Georgia World Congress Center

CULTURE, SPIRITUALITY, AND FOLK BELIEF

Chp.: Edward F. Foulks, M.D.
Participant: Pedro Ruiz, M.D.

FORUM 9 12 noon-1:30 p.m.
Room B404, Level 4, Georgia World Congress Center

CDC MENTAL HEALTH AND ILLNESSES

Chp.: Marc A. Safran, M.D.
Participants: Alex Crosby, M.D., Pamela G. Tucker, M.D., Daniel P. Chapman, Ph.D., Barbara Lopes-Cardozo, M.D.

NEW RESEARCH POSTER SESSION 8

12 noon-2:00 p.m.
Room B302/303/304/305, Level 3, Georgia World Congress Center

OTHER TOPICS

For further information on New Research Sessions, please refer to the *New Research Program Book* included in your registration packet.

1:00 p.m. Sessions



COURSES 96-100

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

COURSE 96 1:00 p.m.-5:00 p.m.
Forsythe Room, Second Floor, Hilton Atlanta

USING NEUROFEEDBACK IN YOUR PRACTICE II: APPLICATIONS

Co-Directors: Thomas M. Brod, M.D., Michael Cohen, B.S.
Faculty: Sebern F. Fisher, M.A., Angelo S. Bolea, Ph.D., Stephen E. Buie, M.D., Emily Stevens, Ph.D., R. Michael O'Bannon, Ph.D., William C. Scott, B.S.W.

COURSE 97 1:00 p.m.-5:00 p.m.
DeKalb Room, Second Floor, Hilton Atlanta

RECOVERY FROM MENTAL ILLNESS AND STIGMA: INTEGRATING MEDICINE AND REHABILITATION

Co-Directors: Eugene A. Oulvey, Ph.D., Karen L. Lee, M.A.
Faculty: Vivek Jain, M.D., Connie Clark, M.A., Michael J. Martin, M.D.

COURSE 98 1:00 p.m.-5:00 p.m.
Gwinnett Room, Second Floor, Hilton Atlanta

RATING SCALES IN PSYCHIATRY

Co-Directors: Sagar Parikh, M.D., Vytas P. Velyvis, M.D.

COURSE 99 1:00 p.m.-5:00 p.m.

Madison Room, Third Floor, Hilton Atlanta

SEXUAL MEDICINE

Director: Waguih W. Ishak, M.D.

Faculty: Shahrar R. Amiri, M.D., Laura A.C. Berman, Ph.D.,
Albert A. Mikhail, M.D.

COURSE 100 1:00 p.m.-5:00 p.m.

Monroe/Roosevelt Room, Third Floor, Hilton Atlanta

MOOD DISORDERS IN LATER LIFE: AN INTERDISCIPLINARY APPROACH

Director: James M. Ellison, M.D.

Faculty: Francesca Antognini, Ph.D., Donald A. Davidoff, Ph.D.,
Brent P. Forester, M.D., E. Yusuf Sivrioglu, M.D.

2:00 p.m. Sessions

LECTURES 19-20

LECTURE 19

2:00 p.m.-3:30 p.m.
Room A411, Level 4
Georgia World Congress Center

Randolph M. Nesse, M.D.

Evolution: The Missing Basic Science That Brings Psychiatry Coherence and Deeper Empathy

Chp.: Francine Cournos, M.D.
Co-Chp.: Stephen Hersh, M.D.

Randolph M. Nesse, M.D., is Professor of Psychiatry and Professor of Psychology at the University of Michigan in Ann Arbor, where he is also Research Professor in the Research Center for Group Dynamics at the Institute for Social Research. He directs the Evolution and Human Adaptation Program at the University of Michigan and was a founder of the Human Behavior and Evolution Society. Dr. Nesse is the editor of the book *Evolution and the Capacity for Commitment*, which explores the question of whether the capacities for making, assessing, and keeping commitments have been shaped by natural selection. His book, coauthored with George Williams, *Why We Get Sick: The New Science of Darwinian Medicine*, explains why natural selection has left humans with bodies that are vulnerable to so many diseases. In his current work, he applies these same principles to the questions of why humans are so vulnerable to depression and how this knowledge can foster more effective research and treatment. Dr. Nesse received his medical degree from the University of Michigan Medical School.

Distinguished Psychiatrist Lecture Series
THIS SESSION WILL BE AUDIOTAPED.

LECTURE 20

2:00 p.m.-3:30 p.m.
Room A412, Level 4
Georgia World Congress Center

Gerald F.M. Russell, M.D.

The 25th Anniversary of Bulimia Nervosa: A New Disorder

Chp.: Geetha Jayaram, M.D.
Co-Chp.: Kathryn J. Zerbe, M.D.

Gerald F.M. Russell, M.D., is Emeritus Professor of Psychiatry at the University of London and Consultant Psychiatrist at Priory Hospital Hayes Grove in Kent, U.K. Dr. Russell's research has been in the investigation and treatment of human disorders of eating. This work has spanned some 45 years and led to the elucidation of the nutritional and endocrine aspects of anorexia nervosa and a measurement of the disturbance of body image in this illness. His most influential work was the delineation of the syndrome of bulimia nervosa in 1979; the diagnostic criteria originally proposed were incorporated into the main systems of classification of psychiatric disorders. Between 1981 and 2000, his primary emphasis was on the development and evaluation of psychological treatments in eating disorders. This research resulted in demonstration of the specific value of family therapy in young patients with anorexia nervosa. Dr. Russell has received numerous awards for his contributions to eating disorders research and treatment, including the Outstanding Research Publication Award of the American Association for Marriage and Family Therapy, the Paul Hoch Award of the American Psychopathological Association, and the Eating Disorders National Award from the Eating Disorders Association of the United Kingdom. Dr. Russell was educated at George Watson's College in Edinburgh.

International Psychiatrist Lecture Series
THIS SESSION WILL BE AUDIOTAPED.

PRESIDENTIAL SYMPOSIA 5-6

PRESIDENTIAL SYMPOSIUM 5

2:00 p.m.-5:00 p.m.
Room A305, Level 3, Georgia World Congress Center

THE INTERFACE OF PSYCHIATRY AND MEDICINE: DISORDERS OF AFFECT, BEHAVIOR, AND COGNITION

Academy of Psychosomatic Medicine

Chp.: Theodore A. Stern, M.D.

(Continued next page)

- A **Psychiatric Aspects of Dementia**
Constantine Lyketsos, M.D.
- B **The Management of Depression and Comorbid Medical Illness**
Michael K. Popkin, M.D.
- C **Reproductive Mood Disorders: The Brain in Context**
David R. Rubinow, M.D.
- D **The Interface of Psychiatry and Medicine: Disorders of Affect, Behavior, and Cognition**
Theodore A. Stern, M.D.
- E **Etiologies and Neuropathogenesis of Delirium: Management Implications**
Paula T. Trzepacz, M.D.

PRESIDENTIAL SYMPOSIUM 6

2:00 p.m.-5:00 p.m.

Room B401, Level 4, Georgia World Congress Center

HEART, MIND, AND SOUL: PSYCHIATRIC ISSUES IN CARDIAC HEALTH FOR AFRICAN AMERICANS

Association of Black Cardiologists

Chp.: Michelle O. Clark, M.D.

Co-Chp.: B. Wayne Kong, J.D.

- A **The Link Between Depression and Cardiovascular Disease**
Richard Williams, M.D.
- B **Racial Disparities: The Metabolic Breakdown**
Randall Maxey, M.D.
- C **Psychotropic Medication Use With the African-American Cardiology Patient**
Curley L. Bonds, M.D.
- D **Cultural Change: A Psychosocial Adjustment for the African-American Cardiology Patient**
Annelle B. Primm, M.D.

Discussant: B. Wayne Kong, J.D.

REVIEW OF PSYCHIATRY: SECTION 3

2:00 p.m.-5:30 p.m.

Rooms B405/406/407, Level 4, Georgia World Congress Center

BIPOLAR DISORDERS

Chp.: Terence A. Ketter, M.D.

Co-Chps.: Charles L. Bowden, M.D., Joseph R. Calabrese, M.D.

- 9 **Treatment of Acute Mania**
Terence A. Ketter, M.D.
- 10 **Treatment of Acute Depression**
Gary S. Sachs, M.D.
- 11 **Maintenance Treatment**
Charles L. Bowden, M.D.
- 12 **Treatment of Rapid Cycling**
Joseph R. Calabrese, M.D.
- 13 **Treatment of Children and Adolescents**
Kiki D. Chang, M.D.

SYMPOSIA 56-86

SYMPOSIUM 56

2:00 p.m.-5:00 p.m.

Cypress Room, Carter Center

SOVIET/RUSSIAN PSYCHIATRY: 15-YEAR EVOLUTION, DAVID LOZOVSKY MEMORIAL

APA Council on Global Psychiatry in Collaboration With the National Institute of Mental Health

Chp.: Darrel A. Regier, M.D.

- A **Ending Soviet Abuse of Psychiatry**
Richard Schifter
- B **Assessing Soviet Psychiatry: Visit of the 1989 U.S. Delegation**
Loren H. Roth, M.D.
- C **Unraveling Soviet Psychiatry: Changes in 15 Years**
Richard Bonnie, J.D.
- D **Reform of Russian Psychiatry: Problems and Prospects**
Svetlana Polubinskaya, Ph.D.
- E **Disaster Psychiatry in Russia: Example of the Beslan Tragedy**
Zurab Kekelidze, M.D.
- F **Reforming Russian Psychiatry: Role of Russian-American Collaboration**
Valery N. Krasnov, M.D.

Discussants: Walder J. Reich, M.D., Thomas H. Borneman, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 57

2:00 p.m.-5:00 p.m.

Room A302, Level 3, Georgia World Congress Center

THE NIMH CLINICAL ANTIPSYCHOTIC TRIAL OF INTERVENTION EFFECTIVENESS FOR ALZHEIMER'S DISEASE (CATIE-AD): FIRST OUTCOMES

Collaborative Session With the National Institute of Mental Health

Chp.: Lon Schneider, M.D.

A An Overview of Main Outcomes in CATIE-AD

Pierre N. Tariot, M.D.

B AD: Safety and Tolerability of Antipsychotics and Citalopram

Saleem Ismail, M.D.

C Quality of Life of Patient and Caregiver: Caregiver-Rated Assessments and Outcomes

Peter V. Rabins, M.D.

D CATIE-AD: Economic Utilization

Robert A. Rosenheck, M.D.

Discussants: Dilip V. Jeste, M.D., Barry D. Lebowitz, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 58

2:00 p.m.-5:00 p.m.

Room A402, Level 4, Georgia World Congress Center

DIAGNOSTIC AND TREATMENT IMPLICATIONS OF A NEW MODEL OF PERSONALITY DISORDERS*Collaborative Session With the National Institute of Mental Health*

Chp.: Andrew E. Skodol II, M.D.

Co-Chp.: John G. Gunderson, M.D.

A Course of Symptoms and Impairments in Patients With Personality Disorders

Andrew E. Skodol II, M.D., M. Tracie Shea, Ph.D., Carlos M. Grilo, Ph.D., Robert L. Stout, Ph.D., John G. Gunderson, M.D., Maria E. Pagano, Ph.D., Thomas H. McGlashan, M.D.

B Association of Course Changes in Personality Disorders and Axis I Disorders

M. Tracie Shea, Ph.D., Robert L. Stout, Ph.D., Carlos M. Grilo, Ph.D., John G. Gunderson, M.D., Andrew E. Skodol II, M.D., Shirley Yen, Ph.D., Leslie C. Morey, Ph.D.

C A Hybrid Model of Personality Disorders: Traits and Symptomatic Behaviors

Charles A. Sanislow, Ph.D., Carlos M. Grilo, Ph.D., John G. Gunderson, M.D., Leslie C. Morey, Ph.D., M. Tracie Shea, Ph.D., Andrew E. Skodol II, M.D., Thomas H. McGlashan, M.D.

D Comparative Validity of Three Alternative Personality Disorder Models

Leslie C. Morey, Ph.D.

E Implications for Research on the Treatment of BPD From the CLPS

John G. Gunderson, M.D.

Discussant: Thomas A. Widiger, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 59

2:00 p.m.-5:00 p.m.

Room A403, Level 4, Georgia World Congress Center

ADVANCES IN PREVENTION: SCIENCE AND CLINICAL STRATEGIES

Chp.: Thomas H. McGlashan, M.D.

Co-Chp.: David Reiss, M.D.

A Early Recognition and Treatment of Psychosis: Initial Findings and Prospects

Thomas H. McGlashan, M.D., Per Vaglum, M.D., Ingrid Melle, M.D., Scott W. Woods, M.D., Diana O. Perkins, M.D., Jean M. Addington, Ph.D., Robert B. Zipursky, M.D.

B Need for Early Intervention Trials in Prepubertal Bipolar Disorder

Robert M. Post, M.D.

C Prevention of Depression in Childhood: Review and Implications

William R. Beardslee, M.D.

D Preventing Secondary Substance Use Disorders

Wilson M. Compton III, M.D.

E Putting Genetics to Work for Preventive Interventions

David Reiss, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 60

2:00 p.m.-5:00 p.m.

Room A404, Level 4, Georgia World Congress Center

BIPOLAR DISORDER: OPTIMIZING OUTCOME THROUGH EARLY RECOGNITION AND INTERVENTION

Chp.: Joseph F. Goldberg, M.D.

A Screening for Bipolar Spectrum Disorders in the Community

Robert M.A. Hirschfeld, M.D.

B Pediatric and Adult Bipolar Patients: Neuroimaging and Pharmacological Differences

Melissa P. DelBello, M.D.

C Impact of Delayed Treatment on Illness Course and Suicide Risk in Bipolar Disorders

Joseph F. Goldberg, M.D.

D Overcoming Obstacles to Medication Adherence

Jan L. Scott, M.D.

E Do FDA Concerns About Antidepressant Safety Reflect Early Bipolar Risk?

S. Nassir Ghaemi, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 61 2:00 p.m.-5:00 p.m.

Room A405, Level 4, Georgia World Congress Center

THE BIOPSYCHOSOCIAL CONSEQUENCES OF PATHOLOGICAL GAMBLING

Chp.: Timothy W. Fong, M.D.

- A The Medical Consequences of Pathological Gambling
Timothy W. Fong, M.D.
- B Problem Gambling: Psychosocial Problems in Special Populations and Treatments
Nancy M. Petry, Ph.D.
- C The Impact of Pathological Gambling on the Family
Donald W. Black, M.D.
- D Pathological Gambling and the Law
Jon E. Grant, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 62 2:00 p.m.-5:00 p.m.

Room A406, Level 4, Georgia World Congress Center

PSYCHOANALYSIS AND PSYCHOSOMATIC ILLNESS: A MODERN MIND-BODY PERSPECTIVE

Chp.: Regina Pally, M.D.

- A The Therapeutic Consultation of Patients With Psychosomatic Symptoms
Milton Viederman, M.D.
- B Psychoanalysis and Psychosomatic Processes in the Brain and Mind
Ronald W. Levin, M.D.
- C Psychoanalytic Treatment of a Patient With Irritable Bowel Syndrome
Beth J. Seelig, M.D.
- D The Developmental Line of Human Feeding: Covariant Roots of Psychopathology and Neurobiological Dysregulation in Eating Disorders
Barton J. Blinder, M.D.

Discussant: Elizabeth O. Trawick, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 63 2:00 p.m.-5:00 p.m.

Room A407, Level 4, Georgia World Congress Center

THE DOCTOR'S DILEMMA: MANAGING PEDIATRIC CHRONIC UNEXPLAINED SYMPTOMS

Chp.: Rose Geist, M.D.

- A Shifting the Focus: Family-Oriented Rehabilitation for Chronic Unexplained Medical Symptoms
Rose Geist, M.D., Louis Peltz, M.D., Caroline Ho, Ph.D., Hasmig Halajian, C.Y.C.

- B Back to the Land of the Living: Dealing With Chronic Fatigue Syndrome/Fibromyalgia
Arlette M. LeFebvre, M.D.

- C Making It Through Treatment: The Role of Medical Psychiatry in Oncology
Claire M. De Souza, M.D.

- D Mastering Pain: Taking Back Your Life
Michael M. Jeavons, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 64 2:00 p.m.-5:00 p.m.

Room A408, Level 4, Georgia World Congress Center

EMERGING FRONTIER OF PSYCHIATRY: JUVENILE JUSTICE

APA Corresponding Committee on Juvenile Justice Issues

Chp.: William Arroyo, M.D.

- A Prevalence of Mental Health Symptoms and Disorders Among Juvenile Offenders
Joseph J. Cocozza, Ph.D., Sarah McLean, Ph.D., Kathleen Skowrya, B.A.

- B AACAP Practice Parameter for the Assessment and Treatment of Youth in Juvenile Detention and Correctional Facilities
Joseph V. Penn, M.D., Christopher R. Thomas, M.D.

- C Issues of Informed Consent Relevant to the Use of Psychotropic Medication in Juvenile Detention
Lawrence V. Tucker, M.D., William Arroyo, M.D.

- D Mental Health Court for Children in Los Angeles
David T. Feinberg, M.D.

- E The MacArthur Juvenile Competence Study: Results and Implications for Law and Practice
Thomas Grisso, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 65 2:00 p.m.-5:00 p.m.

Room A410, Level 4, Georgia World Congress Center

NEUROSCIENCE FOR THE PSYCHIATRIST, PART 2
Collaborative Session With the National Institute of Mental Health

Chp.: Mayada Akil, M.D.

Co-Chp.: David A. Lewis, M.D.

A Strategies for Investigating the Genetics of Psychiatric Disorders
Margit Burmeister, Ph.D.

B Transcriptome Profiling of Brain Tissue: Implications for Schizophrenia Research
Karoly Mirnics, M.D.

C Gene Expression Abnormalities in Schizophrenia: What Do They Mean?
David A. Lewis, M.D.

D From Phenotype to Genotype and Back: How to Put It All Together
Mayada Akil, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 66 2:00 p.m.-5:00 p.m.
Room B301, Level 3, Georgia World Congress Center

THE MAKING OF A COMPETENT PSYCHOTHERAPIST: ADDRESSING THE NEW RRC GUIDELINES

Chp.: Mantosh J. Dewan, M.D.

A The Making of a Competent Psychotherapist: Developing the Program
Priyanthy Weerasekera, M.D.

B Combining a Common Factors Approach With Specific Psychotherapies
John Manning, M.D.

C Future Directions: Simulation-Based Training and Evaluation
Usha G. Satish, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 67 2:00 p.m.-5:00 p.m.
Room B306, Level 3, Georgia World Congress Center

VIOLENCE FROM CRADLE TO GRAVE: BATTERING, STALKING, CHILD ABUSE, AND ELDER ABUSE
APA Committee on Family Violence and Abuse

Chp.: Deborah Spitz, M.D.

A Domestic Violence, Trauma, and Mental Health: Critical Issues for Clinical Practice
Carole L. Warshaw, M.D.

B Stalking: Causes, Consequences, and Therapeutic Considerations
Gail E. Robinson, M.D., Karen M. Abrams, M.D.

C The Role of the Mother-Daughter Dyad in Response to Child Abuse
Osvaldo Gaytan, Jr., M.D.

D Elder Abuse and Neglect
F.M. Baker, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 68 2:00 p.m.-5:00 p.m.
Room B307, Level 3, Georgia World Congress Center

SEQUENCED TREATMENT ALGORITHMS FOR RESISTANT OCD: AN INTERNATIONAL APPROACH
Collaborative Session With the National Institute of Mental Health

Chp.: Eric Hollander, M.D.

Co-Chp.: Joseph Zohar, M.D.

A Odds of Response in OCD to Switching SRIs, Increasing SRI Dose or Treatment Time
Lorin M. Koran, M.D.

B Switching From SSRIs to SNRIs in Resistant OCD
Eric Hollander, M.D., Stacey Wasserman, M.D., Andrea Allen, Ph.D., Alicia J. Kaplan, M.D., Sallie J. Hadley, M.D., Bryann Baker, M.D., Suah Kim, B.A.

C Reviewing the Role of Antipsychotic Agents in OCD
Naomi Fineberg, M.A., Tim M. Gale, Ph.D., Thanusha Sivakumaran, B.S.C.

D Long-Term Efficacy of Intravenous and Oral-Label Citalopram in Resistant OCD
Stefano Pallanti, M.D., Leonardo Quercioli, M.D.

Discussant: Joseph Zohar, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 69 2:00 p.m.-5:00 p.m.
Room B308, Level 3, Georgia World Congress Center

ADVANCES AND ISSUES IN PSYCHODYNAMIC PSYCHOTHERAPY

Chp.: Jerald Kay, M.D.

A Evidence-Based Psychodynamic Psychotherapy
Jerald Kay, M.D.

B Dynamic Psychotherapy of Personality Disorders
Glen O. Gabbard, M.D.

C Psychodynamic Psychotherapy in the Treatment of Panic Disorder
Barbara L. Milrod, M.D.

(Continued next page)

- D **The Role of Psychotherapeutic Techniques in Pharmacotherapy**
Allan Tasman, M.D.
- E **Unique Contributions of Psychodynamic Psychotherapy to Residency Training**
David A. Goldberg, M.D.

Discussant: Joan A. Lang, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 70 2:00 p.m.-5:00 p.m.
Room B309, Level 3, Georgia World Congress Center

THE USE OF NEUROSCIENCE TO UNDERSTAND MEDICATION TREATMENT

Chp.: S. Charles Schulz, M.D.

- A **Imaging Antipsychotics: From Bench to Bedside**
Shitij Kapur, M.D.
- B **MRI in Assessing Drug Response**
Kelvin Lim, M.D.
- C **Population Pharmacokinetic Approaches in Neuropharmacology Research**
Angela Birnbaum, M.D.
- D **Cognitive Neuroscience and New Schizophrenia Treatments**
Robert W. Buchanan, M.D.
- E **PET Imaging of Treatment-Resistant Depression**
Sohail A. Sheikh, M.D., Jose Pardo, M.D., Joseph Lee, M.S., Matthew Hagen, Farouk S. Abuzzahab, Sr., M.D., David E. Adson, M.D., Barry Rittberg, M.D.

Discussant: Richard Brundage, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 71 2:00 p.m.-5:00 p.m.
Room B310, Level 3, Georgia World Congress Center

PEDIATRIC BIPOLAR DISORDER: PHENOMENOLOGY AND NEW TREATMENT OPTIONS

Chp.: Joseph Biederman, M.D.

- A **Molecular Genetics of Pediatric Bipolar Disorder**
Stephen V. Faraone, Ph.D.
- B **Revisiting the Diagnostic Utility of Irritability in Pediatric Bipolar Disorder**
Eric Mick, Sc.D.

- C **Examining the Association Between Pediatric Bipolar Disorder and Anxiety Disorders in Psychiatrically-Referred Children and Adolescents**
Theresa L. Harpold, M.D., Joseph Biederman, M.D., Anne Kwon, M.S., Jennifer Gilbert, M.S., Julia Wood, B.A., Laura Smith, B.A.

- D **Neuropsychological Deficits in Children With Bipolar Disorder**
Timothy E. Wilens, M.D., Alysa E. Doyle, Ph.D.

- E **Comparative Efficacy of Atypical Antipsychotics for Pediatric Bipolar Disorder**
Joseph Biederman, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 72 2:00 p.m.-5:00 p.m.
Room B311, Level 3, Georgia World Congress Center

EMOTION REGULATION IN BPD

Chp.: Ulrich W. Ebner-Priemer, Ph.D.

- A **Autonomic Reactivity and Borderline Features Among Intimate Partner Abusers**
Julia C. Babcock, Ph.D.
- B **Emotional Response to Parasuicide Imagery in BPD**
Stacy Shaw-Welch, Ph.D.
- C **Calculating Instability in BPD**
Ulrich W. Ebner-Priemer, Ph.D.
- D **Emotional Sensitivity and Reactivity in BPD: Empirical Evidence**
Thomas R. Lynch, Ph.D.
- E **Neurofunctional Correlates of Affective Dysregulation and Changes Under Psychotherapy**
Sabine Herpertz, M.D.

Discussant: Larry J. Siever, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 73 2:00 p.m.-5:00 p.m.
Room B314, Level 3, Georgia World Congress Center

CHOOSING THE RIGHT TREATMENT FOR SUBSTANCE ABUSE

Chp.: Herbert D. Kleber, M.D.
Co-Chp.: David M. McDowell, M.D.

- A **Choosing the Right Treatment for Opioid Dependence**
Herbert D. Kleber, M.D.

B Choosing the Right Treatment for Cocaine Dependence
Adam M. Bisaga, M.D.

C Choosing the Right Treatment: Marijuana and Club Party Drugs
David M. McDowell, M.D.

D Treatment of Comorbid Conditions
Frances R. Levin, M.D.

E Choosing the Right Psychosocial Treatments for Substance Dependence
Edward V. Nunes, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 74 2:00 p.m.-5:00 p.m.
Room B315, Level 3, Georgia World Congress Center

A WORLD VIEW OF MEDICAL AND PSYCHIATRIC COMORBIDITY

Chp.: Nigel M. Bark, M.D.
Co-Chp.: A. Hamid Ghodse, Ph.D.

A Soma and Psyche in Middle Eastern Cultures: A Historical Review
Nasser F. Loza, M.B.

B An International Study of Physical and Psychiatric Comorbidity in Primary Care
Stephen R. Kisely, M.D., Gregory E. Simon, M.D.

C Psychiatry and Medicine in Pakistan
Haroon R. Chaudhry, M.D., Muhammad M. Iqbal, Fahd A. Cheema, Khalid A. Mufti, M.D.

D What Kills Our Patients: A Kenyan Perspective
Frank G. Njenga, M.D.

E Comorbidity Between Psychiatric Disorders and Substance Dependence: Results From a National Survey
Maria E. Medina-Mora, Ph.D., Guilherme Borges, Ph.D., Carmen Lara, Ph.D.

Discussant: John L. Cox, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 75 2:00 p.m.-5:00 p.m.
Room B316, Level 3, Georgia World Congress Center

RUNNING A MEDICINE/PSYCHIATRY SERVICE: THE DUKE EXPERIENCE

Chp.: K. Ranga R. Krishnan, M.D.

A Caring for Patients on a Combined Internal Medicine/Psychiatry Service: Advantages Over Consultation-Liaison Psychiatry
Y. Pritham Raj, M.D., Jane P. Gagliardi, M.D.

B Training Internist/Psychiatrists: An Overview of the Literature, Current Practice, and Future Directions
Erin Silvertooth, M.D., Jane P. Gagliardi, M.D.

C Research in Medicine/Psychiatry: Investigating Interactions Between Body and Mind
Wei Jiang, M.D.

D Administrative Considerations in Operating a Medicine/Psychiatry Service
Eric J. Christopher, M.D., Jane P. Gagliardi, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 76 2:00 p.m.-5:00 p.m.
Room B402, Level 4, Georgia World Congress Center

NEW SCIENTIFIC ADVANCES IN THE NEUROBIOLOGY OF BEHAVIOR
National Institute on Drug Abuse

Chp.: David Shurtleff, Ph.D.
Co-Chp.: Jonathan Pollock, Ph.D.

A Molecular Mechanisms of Drug Addiction
Eric J. Nestler, M.D.

B Environmentally-Induced Modifications in Chromatin Structure as a Potential Mediator for the Effects of Early Experience on Later Vulnerability
Michael Meaney, Ph.D.

C Neural Substrates of Memory: From Synapse to System
Tim Tully, Ph.D.

D Neuroimaging Human Reward Circuitry and Using It for Across-Scale Systems Biology in Addiction
Hans C. Breiter, M.D.

Discussant: Nora D. Volkow, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 77 2:00 p.m.-5:00 p.m.
Room B403, Level 4, Georgia World Congress Center

PSYCHIATRIC ADVANCE DIRECTIVES: KEY ISSUES AND CLINICAL CHALLENGES
Collaborative Session With the National Institute of Mental Health

Chp.: Eric B. Elbogen, Ph.D.

A Psychiatrists' Attitudes About Psychiatric Advance Directives
Marvin S. Swartz, M.D.

B Prevalence and Demand for Psychiatric Advance Directives in the U.S.
Jeffrey W. Swanson, Ph.D.

(Continued next page)

- C **Psychiatric Advance Directives: Issues for Veterans With Mental Illness**
 Marian I. Butterfield, M.D., Jennifer L. Strauss, Ph.D., Eugene Oddone, M.D., Morris Weinberger, Ph.D., Timothy Wompler, M.S.W., Jennifer Zervakis, Ph.D.

- D **Psychiatric Advance Directives: What Are Patients' Preferences?**
 Eric B. Elbogen, Ph.D.

Discussant: Paul S. Appelbaum, M.D.
 THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 78 2:00 p.m.-5:00 p.m.
 Room B404, Level 4, Georgia World Congress Center

TEACHING PSYCHOPHARMACOLOGY FOR THE 21ST CENTURY
American Society of Clinical Psychopharmacology

Chp.: Richard Balon, M.D.

- A **The Challenge of Teaching Psychopharmacology in the New Millennium: The Role of Curricula**
 Ira D. Glick, M.D., Sidney Zisook, M.D.

- B **Alternate Teaching Venues**
 Sidney Zisook, M.D., Richard Balon, M.D., Richard Benjamin, M.D., Ira D. Glick, M.D., Alan Louie, M.D., Cynthia Santos, M.D.

- C **Teaching Collaborative and Integrated Treatments for Psychiatrists**
 Richard Balon, M.D.

- D **Resident as Teacher: Are We Ready for Some Changes?**
 Andres Sciolla, M.D.

- E **Psychopharmacologic Education: Interactions With Drug Companies**
 Paul C. Mohl, M.D.

Discussants: Anna M. Georgiopoulos, M.D., John M. Kane, M.D.
 THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 79 2:00 p.m.-5:00 p.m.
 Room B408, Level 4, Georgia World Congress Center

TOXIC LOVE: CINEMA ON ROMANTIC LOVE AND ITS PATHOLOGIES

Chp.: Anton C. Trinidad, M.D.

- A **Using Movies to Portray Pathologic Interpersonal Styles**
 Robert J. Boland, M.D.

- B **Obsessive Love and Loss of the Self in Film Narratives**
 Anton C. Trinidad, M.D.

- C **Recent Films on the Spectrum of Love From Normality to Pathology**
 Anton C. Trinidad, M.D., Robert J. Boland, M.D.
 THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 80 2:00 p.m.-5:00 p.m.
 Room B409, Level 4, Georgia World Congress Center

DEFINING MENTAL DISORDER IN DSM-V: PROBLEMS AND CHALLENGES

Chp.: Claire L. Pouncey, M.D.

- A **What Can a DSM Definition of Mental Disorder Do? What Should It Do?**
 John Sadler, M.D.

- B **Theoretical Models of Scientific Classification and the DSM-V**
 Peter Zachar, Ph.D.

- C **Can a Family Have a Mental Disorder?**
 Christian D. Perring, Ph.D.

- D **The Concept of Mental Disorder: Psychiatry's Gordian Knot**
 Claudio E.M. Banzato, M.D.

Discussant: Robert L. Spitzer, M.D.
 THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 81 2:00 p.m.-5:00 p.m.
 Birch Room, South Tower, Atrium Terrace Level, Omni Hotel

CULTURAL ASPECTS OF PSYCHIATRIC DIAGNOSIS: TOWARD A NEW CLASSIFICATION
APA Council on Global Psychiatry

Chp.: Renato D. Alarcon, M.D.
 Co-Chp.: Rodrigo A. Munoz, M.D.

- A **Cultural Views From U.S. Minorities and Relevance of the Cultural Formulation**
 Annelle B. Primm, M.D., Russell F. Lim, M.D.

- B **An Update on Race, Ethnicity, and Culture in Current Psychiatric Literature**
 Roberto Lewis-Fernandez, M.D., Maria A. Oquendo, M.D., Ivan Balan, Ph.D., Dana Wachtel, Ph.D., Naelys Diaz, M.S.W., Anne O'Connell, M.D., Renato D. Alarcon, M.D.

- C **Epidemiology, Diagnosis, and Culture**
Bedirhan T. Ustun, M.D.
- D **Diversity in Diagnosis Across Cultures**
Ahmed M.F. Okasha, M.D.
- E **APA's Work Toward DSM-V: The Cultural Component**
William E. Narrow, M.D.
- F **Acute Psychoses: Cross-Cultural and Cross-System Comparisons**
Byron J. Good, Ph.D.

Discussant: Renato D. Alarcon, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 82 2:00 p.m.-5:00 p.m.
Maple Room, South Tower, Atrium Terrace Level, Omni Hotel

DEPRESSION AND COMORBID PERSONALITY DISORDERS: IMPLICATIONS FOR TREATMENT

Chp.: John Livesley, Ph.D.

- A **Efficacy of Pharmacotherapy Compared With Combined Therapy for Depressed Patients With or Without Personality Disorders**
Mariëlle Hendriksen, M.A.
- B **The Influence of Personality Pathology on the Efficacy of Psychotherapy and Combined Therapy for Depressive Disorders**
Henricus L. Van, M.D.
- C **Changes in Personality Pathology After Treatment of Major Depression With Comorbid Personality Pathology**
Simone Kool, M.D.
- D **Nonadherence to Pharmacotherapy, Psychotherapy, or Combined Therapy in the Treatment of Depressed Outpatients With or Without Comorbid Personality Disorder**
Gerda van Aalst, M.D.
- E **A Meta-Analysis of Treatment Studies in Depressed Patients With or Without Personality Disorder**
Robert A. Schoevers, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 83 2:00 p.m.-5:00 p.m.
Pine Room, South Tower, Atrium Terrace Level, Omni Hotel

APA WOMEN PRESIDENTS: LESSONS LEARNED, ROAD AHEAD
Association of Women Psychiatrists

Chp.: Silvia W. Olarte, M.D.
Co-Chp.: Nada L. Stotland, M.D.

- A **How to Open Doors and Keep Them Open**
Carol C. Nadelson, M.D.
- B **Creating Change, Evaluating Responses, and Participating in the New Course**
Elissa P. Benedek, M.D.
- C **Beyond APA Presidency: Leadership as a Way of Life**
Mary Jane England, M.D.
- D **Assertive or Aggressive?**
Marcia K. Goin, M.D.
- E **Success Is a Team Effort**
Michelle B. Riba, M.D.

Discussant: Leah J. Dickstein, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 84 2:00 p.m.-5:00 p.m.
Cottonwood Room, North Tower, Street Level, Omni Hotel

NATIONAL HEALTH INFORMATION INITIATIVE AND PSYCHIATRY

American Association for Social Psychiatry and American Association for Technology in Psychiatry

Chp.: Zebulon Taintor, M.D.
Co-Chp.: Roger Peele, M.D.

- A **Health Information Technology: A Framework for Strategic Action**
Rex W. Cowdry, M.D.
- B **National Health Information: General Medicine**
Zebulon Taintor, M.D.
- C **National Health Information: Psychiatric Treatment Systems and the APA**
Steven S. Sharfstein, M.D.
- D **National Health Information: General Hospital and Addiction Psychiatry**
Richard N. Rosenthal, M.D.
- E **National Health Information: Private Practice, Rural, and Academic Psychiatry**
Joel Yager, M.D.

Discussant: Lawrence Hartmann, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 85 2:00 p.m.-5:00 p.m.

Dogwood A, North Tower, Street Level, Omni Hotel

DISSEMINATION OF EVIDENCE-BASED MENTAL HEALTH MODELS

Collaborative Session With the National Institute of Mental Health

Chp.: Wayne J. Katon, M.D.

Co-Chp.: Lisa B. Dixon, M.D.

- A Successful Models for Treatment of Depression and Anxiety in Primary Care
David J. Katzelnick, M.D.
 - B Dissemination of Family Psychoeducation in Schizophrenia
Lisa B. Dixon, M.D.
 - C Systematic Review of Models for Integrating Medical Care Into Behavioral Settings
Benjamin G. Druss, M.D., Silke Von Esenwein, Ph.D.
 - D Depression and Diabetes: The Pathways Study
Wayne J. Katon, M.D., Michael Von Korff, Sc.D., Elizabeth H.B. Lin, M.D., Paul S. Ciechanowski, M.D., Gregory E. Simon, M.D., Evette J. Ludman, Ph.D.
- THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 86 2:00 p.m.-5:00 p.m.

Dogwood B, North Tower, Street Level, Omni Hotel

DIFFICULT DEPRESSION: LOOKING FOR OUR KEYS: BEYOND THE LIGHT, WE CAN SEE

Chp.: Mark Demitrack, M.D.

- A Difficult-to-Treat Depression: Better Choices, Better Outcomes
William Potter, M.D.
- B The Study of Difficult Depression: The Right Tool for the Right Job
William Potter, M.D.
- C A Critique of Current and Future Treatments for Difficult-To-Treat Depression
Andrew A. Nierenberg, M.D.
- D New Antidepressant Treatments: Integrating New Techniques in Practice
William M. McDonald, M.D.

Discussant: John F. Greden, M.D.

THIS SESSION WILL BE AUDIOTAPED.

3:00 p.m. Session

NEW RESEARCH POSTER SESSION 9

3:00 p.m.-5:00 p.m.

Room B302/303/304/305, Level 3, Georgia World Congress Center

PSYCHOSOMATIC AND RESEARCH ISSUES

For further information on New Research Sessions, please refer to the *New Research Program Book* included in your registration packet.

7:00 p.m. Session

INDUSTRY-SUPPORTED SYMPOSIUM 45

7:00 p.m.-10:00 p.m.

International Ballroom, North Tower, Ballroom Level, Omni Hotel

IMPACT OF STRESS AND ANXIETY ON BRAIN AND BODY

Supported by Cephalon, Inc.

Chp.: Samantha E. Meltzer-Brody, M.D.

Co-Chp.: Murray B. Stein, M.D.

- A Sick and Tired: Anxiety, Stress, and Insomnia
Murray B. Stein, M.D.
- B Impact of Anxiety on Women's Health: Focusing on the Link Between Trauma and Chronic Pain
Samantha E. Meltzer-Brody, M.D.
- C Health Effects of Exposure to Violence in Women
Soraya Seedat, M.D.
- D Neuroimaging and the Traumatized Brain: PTSD and Emotion
Ruth A. Lanius, M.D.
- E Treatment of Anxiety: The Pharmacotherapy of Psyche and Soma
Mark H. Pollack, M.D.

THURSDAY, MAY 26, 2005

158TH ANNUAL MEETING

7:00 a.m. Session

PART 2 OF INDUSTRY-SUPPORTED BREAKFAST SYMPOSIA 44

7:00 a.m.-8:30 a.m.

Grand Ballroom, Second Floor, Hilton Atlanta

BIPOLAR DISORDER ACROSS THE LIFE CYCLE: SPECIAL CONSIDERATIONS

Supported by *GlaxoSmithKline*

Chp.: Zachary N. Stowe, M.D.

A Bipolar Disorder in Pregnancy: A Clinician's Dilemma
Zachary N. Stowe, M.D.

B Bipolar Disorder in the Elderly: Special Treatment Considerations
John L. Beyer, M.D.

8:00 a.m. Sessions



COURSES 101-103

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

COURSE 101 8:00 a.m.-12 noon
Forsythe Room, Second Floor, Hilton Atlanta

TREATING COMORBID ADULT ADHD BY COMBINING MEDICATION AND COGNITIVE THERAPY

Co-Directors: Anthony L. Rostain, M.D., J. Russell Ramsay, Ph.D.

COURSE 102- WITHDRAWN

COURSE 103 8:00 a.m.-12 noon
Gwinnett Room, Second Floor, Hilton Atlanta

ADOLESCENT PSYCHIATRY: ENHANCING CLINICAL SKILLS

American Society for Adolescent Psychiatry

Co-Directors: Stephen B. Billick, M.D., Lois T. Flaherty, M.D.

9:00 a.m. Sessions

CLINICAL CASE CONFERENCE 4

9:00 a.m.-10:30 a.m.

Room A402, Level 4, Georgia World Congress Center

COMMANDED TO KILL: APPROACHING THE TREATMENT OF A MURDEROUS GRANDMOTHER

Moderator: June A. Powell, M.D.

Presenters: Patrice A. Harris, M.D., Nada L. Stotland, M.D.

THIS SESSION IS OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

CONTINUOUS CLINICAL CASE CONFERENCE 2: PART 2

9:00 a.m.-12 noon

Room A403, Level 4, Georgia World Congress Center

WEATHERING THE STORM: MANAGEMENT OF COMPLEX TRANSFERENCE, PART 2

Moderator: Beth J. Seelig, M.D.

Presenter: Otto F. Kernberg, M.D.

Discussants: John M. Oldham, M.D., Wendy Jacobson, M.D.

THIS SESSION IS OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

DISCUSSION GROUP 22

9:00 a.m.-10:30 a.m.

This session is limited to 25 participants on a first-come, first-served basis.

22 Richard P. Brown, M.D., on the Benefits of Yoga in Psychiatry
Chestnut Room, North Tower, Meeting Level, Omni Hotel

LECTURES 21-22

LECTURE 21

9:00 a.m.-10:30 a.m.
Room A411, Level 4
Georgia World Congress Center

Laura W. Roberts, M.D.

**Inspiring Ethics: Ethical Milestones and
Preparation in Psychiatric Education**
*Collaborative Session With the National
Institute of Mental Health*

Chp.: Josepha A. Cheong, M.D.
Co-Chp.: Daniel K. Winstead, M.D.

Laura W. Roberts, M.D., is Professor and Chair of the Department of Psychiatry and Behavioral Medicine and Professor of Bioethics in the Health Policy Institute at the Medical College of Wisconsin in Milwaukee. She is also Founder and Director of the Empirical Ethics Group, a clinical ethics resource and research team currently based at the Medical College of Wisconsin. Dr. Roberts is Editor-in-Chief of *Academic Psychiatry* and Associate Editor of *International Review of Psychiatry*. She is Scientific Advisor to the Office of Minority Health of the Department of Health and Human Services and a member of several scientific advisory groups, including the Council for Human Subjects Research Workgroup of the National Institute of Mental Health. A Fellow of the American Psychiatric Association (APA), Dr. Roberts chairs the APA Task Force to Update the Ethics Annotations. She is the author of more than 80 peer-reviewed articles and co-author of the book *Concise Guide to Ethics in Mental Health Care*. She graduated from the University of Chicago Pritzker School of Medicine, where she also completed a fellowship in clinical ethics. She completed her residency in psychiatry and a fellowship in child and adolescent psychiatry at the University of New Mexico School of Medicine in Albuquerque.

Distinguished Psychiatrist Series
THIS SESSION WILL BE AUDIOTAPED.

LECTURE 22

9:00 a.m.-10:30 a.m.
Room A412, Level 4
Georgia World Congress Center

Margaret A. Pericak-Vance, Ph.D.

**Sifting Through the Haystack: Finding
Genes for Complex Traits**

Chp.: Stephen M. Saravay, M.D.
Co-Chp.: Michael Slifer, M.D.

Margaret A. Pericak-Vance, Ph.D., is a James B. Duke Professor of Medicine and Director of the Center for Human Genetics at Duke University Medical Center in Durham, North Carolina, where she is also Professor of Genetics, Professor of Biostatistics and Bioinformatics, and Professor in Ophthalmology. Her research focuses on the underlying causes of both single-gene disorders and more complex phenotypes where several genes as well as environmental forces act together. Her investigations have examined the genetics of autism, amyotrophic lateral sclerosis, Alzheimer disease, multiple sclerosis, primary open-angle glaucoma, age-related macular degeneration, Parkinson disease, and various muscular dystrophies. Dr. Pericak-Vance is Editor of *Genetic Epidemiology* and co-editor of the book *Approaches to Gene Mapping in Complex Human Diseases*. A Founding Fellow of the American College of Medical Genetics, she serves on the National Institute of Mental Health Board of Scientific Counselors. She is a member of the Institute of Medicine and a recipient of the Louis-D Scientific Award from the Institut de France for her contributions to the field of genetic research in Alzheimer disease. Dr. Pericak-Vance received her doctorate in Medical Genetics from Indiana University in Indianapolis and completed postdoctoral work in biostatistics at the University of North Carolina in Chapel Hill.

Frontiers of Science Lecture Series
THIS SESSION WILL BE AUDIOTAPED.

WORKSHOPS

ISSUES 90-113

ISSUE WORKSHOP 90 9:00 a.m.-10:30 a.m.
Room A304, Level 3, Georgia World Congress Center

**USING AUDIOVISUAL TECHNOLOGY TO TEACH
BEHAVIORAL SCIENCE**

Chp.: Jonathan S. Davine, M.D.

ISSUE WORKSHOP 91 9:00 a.m.-10:30 a.m.
Room A404, Level 4, Georgia World Congress Center

**NEUTRALITY RE VISITED: IS AUTONOMY WHAT WE
MOST WANT?**

Chp.: John R. Peteet, M.D.
Participants: Samuel B. Thielman, M.D., Allan M. Josephson, M.D., Leigh C. Bishop, M.D.

ISSUE WORKSHOP 92 9:00 a.m.-10:30 a.m.
Room A405, Level 4, Georgia World Congress Center

FIBROMYALGIA: CURRENT UNDERSTANDING AND FUTURE DIRECTIONS

Chp.: Alan Z.A. Manevitz, M.D.
Participant: James P. Halper, M.D.

ISSUE WORKSHOP 93 9:00 a.m.-10:30 a.m.
Room A408, Level 4, Georgia World Congress Center

SUBSTANCE ABUSE IN THE PRISON SETTING

Co-Chps.: Leo L. Gallofin, M.D., Jeffery Wilkins, M.D.
Participants: Thomas J. Rosko, M.D., Janet A. Martin, M.D.,
Katherine G. Ruiz-Mellot, M.D.

ISSUE WORKSHOP 94 9:00 a.m.-10:30 a.m.
Room A410, Level 4, Georgia World Congress Center

ASSESSMENT OF CAPACITY: LAW, ALGORITHMS, AND VIDEOTAPE

Chp.: Michael E. Wise, M.R.C.
Participant: Julian Beezhold, M.R.C.

ISSUE WORKSHOP 95 9:00 a.m.-10:30 a.m.
Room B301, Level 3, Georgia World Congress Center

AUTISM: PARENTS AS THERAPISTS

Co-Chps.: Gary Heffner, M.A., Joyce Cox

ISSUE WORKSHOP 96 9:00 a.m.-10:30 a.m.
Room B306, Level 3, Georgia World Congress Center

PENAL JUSTICE AND INJUSTICE

Chp.: Rodrigo A. Munoz, M.D.
Participants: Igor Koutsemok, M.D., David Deitch, Ph.D.,
Gretchen Bergman

ISSUE WORKSHOP 97 9:00 a.m.-10:30 a.m.
Room B307, Level 3, Georgia World Congress Center

GUESS WHAT'S IN YOUR GENES? TALKING ABOUT GENETIC ILLNESS IN THE FAMILY

Chp.: Arlette M. LeFebvre, M.D.

ISSUE WORKSHOP 98 9:00 a.m.-10:30 a.m.
Room B308, Level 3, Georgia World Congress Center

BARIATRIC SURGERY: PSYCHIATRIC CONSIDERATIONS

Chp.: Laura T. Safar, M.D.
Participants: Brenda Temblador, Ph.D., Wenda Restall, L.C.S.W.

ISSUE WORKSHOP 99 9:00 a.m.-10:30 a.m.
Room B309, Level 3, Georgia World Congress Center

HITCHCOCK'S *PSYCHO*: MADNESS, MOTHERS, AND MURDER

Chp.: Hillary Johnson, M.A.
Participant: Lawrence Ratna, M.D.

ISSUE WORKSHOP 100 9:00 a.m.-10:30 a.m.
Room B310, Level 3, Georgia World Congress Center

CARING FOR THE MEDICALLY ILL PSYCHOTIC PATIENT: CLINICAL, LEGAL, AND ETHICAL DILEMMAS

Chp.: Robert C. Joseph, M.D.
Participants: Judith G. Edersheim, M.D., Duncan C.
MacCourt, M.D., Elizabeth A. Davis, M.D.

ISSUE WORKSHOP 101 9:00 a.m.-10:30 a.m.
Room B311, Level 3, Georgia World Congress Center

DETECTION OF MALINGERING

Chp.: Alan R. Hirsch, M.D.
Participants: David E. Hartman, Ph.D., Roni L. Seltzberg, M.D.,
Carl M. Wahlstrom, Jr., M.D.

ISSUE WORKSHOP 102 9:00 a.m.-10:30 a.m.
Room B314, Level 3, Georgia World Congress Center

ADHERENCE IN SCHIZOPHRENIA: ROLE OF ATTITUDE, FAMILY, AND ENVIRONMENT
Collaborative Session With the National Institute of Mental Health

Chp.: Timothy Cuedon, Ph.D.
Participants: Alex J. Kopelowicz, M.D., Peter J. Weiden, M.D.,
Dawn I. Velligan, Ph.D.

ISSUE WORKSHOP 103 9:00 a.m.-10:30 a.m.
Room B315, Level 3, Georgia World Congress Center

CONVERSION DISORDERS IN CHILDREN: DIAGNOSTIC AND CULTURAL CHALLENGES

Co-Chps.: Richard K. Harding, M.D., Craig A. Stuck, M.D.
Participants: John E. Bragg, Jr., M.D., Ishmeal Major, M.D.

ISSUE WORKSHOP 104 9:00 a.m.-10:30 a.m.
Room B316, Level 3, Georgia World Congress Center

DEVELOPING TARGETED INTERVENTIONS FOR AUTISTIC SPECTRUM DISORDERS
Collaborative Session With the National Institute of Mental Health

Chp.: Ann Wagner, Ph.D.
Participants: Christopher J. McDougle, M.D., Connie
Kasari, Ph.D., Robert T. Schultz, Ph.D., Nancy Minshew, M.D.

ISSUE WORKSHOP 105 9:00 a.m.-10:30 a.m.
Room B401, Level 4, Georgia World Congress Center

HELPING PATIENTS COPE WITH CANCER: HOW TO MAKE A DIFFERENCE

Chp.: Alex J. Mitchell, M.D.
Participants: Robert Zachariae, M.D., Manoj Kumar, M.D.

ISSUE WORKSHOP 106 9:00 a.m.-10:30 a.m.
Room B402, Level 4, Georgia World Congress Center

CHALLENGES WHEN PSYCHIATRISTS SEEK TREATMENT FOR THEMSELVES

National Alliance for the Mentally Ill

Co-Chps.: Michael F. Myers, M.D., Leah J. Dickstein, M.D.
Participants: Raymond M. Reyes, M.D., Francine Cournos, M.D., Jack Drescher, M.D., Suzanne E. Vogel-Scibilia, M.D.

ISSUE WORKSHOP 107 9:00 a.m.-10:30 a.m.
Room B403, Level 4, Georgia World Congress Center

GOT PSYCH? INCREASING STUDENT INVOLVEMENT IN PSYCHIATRY

Chp.: Paul D. Cox, M.D.
Participants: Cyndi R. Murrer, B.S., Sherry A. Nykiel, B.A., Deborah J. Hales, M.D.

ISSUE WORKSHOP 108 9:00 a.m.-10:30 a.m.
Room B404, Level 4, Georgia World Congress Center

OUTCOMES AND THERAPEUTIC PROCESSES OF ACUTE PARTIAL HOSPITALIZATION

Chp.: Paul B. Lieberman, M.D.
Participants: Mark B. Elliot, M.D., Rendueles Villalba, M.D.

ISSUE WORKSHOP 109 9:00 a.m.-10:30 a.m.
Room B405, Level 4, Georgia World Congress Center

THE DOUBLE-EDGED SWORD: MENTAL HEALTH CHALLENGES IN HIV AND HEPATITIS C

Society for Liaison Psychiatry

Chp.: Maria L.A. Tiamson, M.D.
Participants: Kenneth Ashley, M.D., Silvia Hafliger, M.D.

ISSUE WORKSHOP 110 9:00 a.m.-10:30 a.m.
Room B406, Level 4, Georgia World Congress Center

EDUCATING PATIENTS AND FAMILIES ABOUT BPD

National Education Alliance for Borderline Personality Disorder in Collaboration With the National Institute of Mental Health

Chp.: Richard G. Hersh, M.D.
Participants: Kenneth Silk, M.D., Dixianne Penney, Ph.D., Perry D. Hoffman, Ph.D.

ISSUE WORKSHOP 111 9:00 a.m.-10:30 a.m.
Room B407, Level 4, Georgia World Congress Center

CASE CONSULTATION IN FORENSIC PSYCHIATRY: FACTITIOUS DISORDER WITH PSYCHOLOGICAL AND PHYSICAL SYMPTOMS

Chp.: Jay Wung, M.D.
Participants: Henry C. Weinstein, M.D., Marc D. Feldman, M.D., Renee M. Sorrentino, M.D.

ISSUE WORKSHOP 112 9:00 a.m.-10:30 a.m.
Room B408, Level 4, Georgia World Congress Center

USING ADULT LEARNING PRINCIPLES IN RESIDENT PSYCHOTHERAPY EDUCATION

Chp.: Kim A. Coon, Ed.D.
Participant: Bryan K. Touchet, M.D.

ISSUE WORKSHOP 113 9:00 a.m.-10:30 a.m.
Room B409, Level 4, Georgia World Congress Center

CHALLENGES IN TEACHING CULTURAL ISSUES TO PSYCHIATRIC RESIDENTS: PERSPECTIVES FROM RESIDENTS AND FACULTY

Chp.: Francis G. Lu, M.D.
Participants: Antonio E. Bullon, M.D., Jennifer R. Lee, M.D., David J. Geltman, M.D.

11:00 a.m. Sessions

MEDICAL UPDATE 4

11:00 a.m.-12:30 p.m.
Room B403, Level 4, Georgia World Congress Center

A PRIMER OF GENETICS FOR PSYCHIATRY

Presenter: Stephen Warren, Ph.D.
Chp.: Elizabeth Binder, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSIONS 28-35

SCIENTIFIC AND CLINICAL REPORT SESSION 28
11:00 a.m.-12:30 p.m.
Room A402, Level 4, Georgia World Congress Center

EPIDEMIOLOGY AND COMMUNITY ISSUES IN PSYCHIATRY

Chp.: Shivkumar Hatti, M.D.
Co-Chp.: Andrea Bradford, M.D.

11:00 a.m.

- 83 **Mortality Among Psychotic Patients Within the Northern Finland 1966 Birth Cohort**
Antti Alaraisänen, M.D., Jouko Miettunen, Ph.D., Erika Lauronen, B.Med., Pirkko Räsänen, Ph.D., Matti K. Isohanni, Ph.D.

11:30 a.m.

- 84 **Outcome and Its Predictors in Schizophrenia in the Northern Finland 1966 Birth Cohort**
Erika Lauronen, B.Med., Juha M. Veijola, Ph.D., Jouko Miettunen, Ph.D., Peter B. Jones, Ph.D., Wayne S. Fenton, M.D., Johanna Koskinen

12 noon

- 85 **Psychiatric Practices and Patient Outcomes in Assertive Community Treatment**
Paul R. Miller, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 29

11:00 a.m.-12:30 p.m.

Room A404, Level 4, Georgia World Congress Center

TREATMENT OF SCHIZOPHRENIA

- Chp.: David M. Walker, M.D.
Co-Chp.: Francine Courmos, M.D.

11:00 a.m.

- 86 **Effectiveness and Tolerability of Antipsychotic Treatments for Schizophrenia: Two-Year Results From the Intercontinental Schizophrenia Outpatient Health Outcomes Study (IC-SOHO)**
Martin Dossenbach, M.D., C.Y. Kim, M.D., W.W. Lin, M.D., S. Singh, M.D., Y. Dyachkova, M.S.C., Margaret E. McBride, Ph.D., P. Lee, M.D.

11:30 a.m.

- 87 **An Investigation of Cognitive Effects of Rivastigmine in Schizophrenia**
Collaborative Session With the National Institute of Mental Health
Tonmoy Sharma, M.D., Catherine Hughes, Ph.D., Ingrid Aasen, Veena Kumari, Ph.D.

12 noon

- 88 **Rivastigmine or Galantamine for the Treatment of Schizophrenic Cognitive Impairment**
Mohammad Z. Hussain, M.D., Zubaida Chaudhry, M.D., Waqar Waheed, M.D., Seema Hussain, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 30

11:00 a.m.-12:30 p.m.

Room B301, Level 3, Georgia World Congress Center

ISSUES IN MOOD DISORDERS AND PSYCHIATRIC TRAINING

- Chp.: Richard G. Hersh, M.D.
Co-Chp.: Edward C. Lauterbach, M.D.

11:00 a.m.

- 89 **The Uses of Reading Poetry for General Psychiatric Education**
Neil E. Scheurich, M.D.

11:30 a.m.

- 90 **Variations in Depression Treatment Quality: Medicaid Versus Commercial Claims**
Rebecca Robinson, M.S., Stephen Able, Ph.D., Stacey Long, M.S., Stella Chang, M.P.H., Onur Baser, Ph.D., Robert Obenchain, Ph.D., Ralph W. Swindle, M.D.

12 noon

- 91 **Antidepressants for Depression in the Medically Ill: Are They Effective?**
Steven A. Cole, M.D., Evan Delucia-Deranja, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 31

11:00 a.m.-12:30 p.m.

Room B306, Level 3, Georgia World Congress Center

CONSULTATION-LIAISON PSYCHIATRY

- Chp.: Wayne J. Katon, M.D.
Co-Chp.: Andy Casimir, M.D.

11:00 a.m.

- 92 **The Prevalence of Migraine Headaches in an Anxiety Disorders Clinic Sample**
Catherine L. Mancini, M.D., Michael A. Van Ameringen, M.D., Mark Bennett, B.A., Beth Pipe, B.S.N., Deirdre Dejean

11:30 a.m.

- 93 **Assessing Anxiety With the Memorial Anxiety Scale for Prostate Cancer**
Andrew J. Roth, M.D., Christian Nelson, Ph.D., Barry D. Rosenfeld, Ph.D., Adam Warshowski, M.A., Noelle O'Shea, R.N., Howard Scher, M.D., William Breitbart, M.D.

12 noon

- 94 **Modafinil Augmentation of SSRI Therapy in MDD**
Maurizio Fava, M.D., Charles DeBattista, M.D., Michael E. Thase, M.D., Joseph G. Fanelli, M.D., Karl Doghramji, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 32

11:00 a.m.- 12:30 p.m.

Room B408, Level 4, Georgia World Congress Center

BIPOLAR DISORDER THROUGH THE LIFE CYCLE

Chp.: Douglas G. Jacobs, M.D.

Co-Chp.: Meera Vaswani, Ph.D.

11:00 a.m.

- 95 **Bipolar Prodromal Patterns Among Amish Youth**
Jon A. Shaw, M.D., Janice A. Egelad, Ph.D., Jean Endicott, Ph.D., Cleona R. Allen, B.A., Abram M. Hostetter, M.D.

11:30 a.m.

- 96 **Typical and Atypical Antipsychotics in Bipolar Depression**
Keming Gao, M.D., Joseph R. Calabrese, M.D.

12 noon

- 97 **Childhood Disorders in Early- Versus Late-Onset Bipolar Disorder**
Aude I. Henin, Ph.D., Eric Mick, Sc.D., Joseph Biederman, M.D., Stephanie V.M. Gironde, B.A., Tanya B. Tran, B.A., Megan F. Joseph, B.A., Andrew A. Nierenberg, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 33

11:00 a.m.- 12:30 p.m.

Room B409, Level 4, Georgia World Congress Center

MEASURING MOOD DISORDERS

Chp.: Susan Stabinsky, M.D.

Co-Chp.: Kisha James, M.D.

11:00 a.m.

- 98 **The Targeted Treatment of Depression Inventory: New Depression Inventory Designed to Guide Antidepressant Selection**
Richard J. Metzner, M.D.

11:30 a.m.

- 99 **Is It Time to Replace the Hamilton Depression Rating Scale?**
Mark Zimmerman, M.D., Michael Posternak, M.D., Iwona Chelminski, Ph.D.

12 noon

- 100 **Daily Measurements Elucidate Effects of Initial Dosing of Duloxetine**
Madelaine M. Wohlreich, M.D., Heidi Moore, Ph.D., James C. Mundt, Ph.D., Craig H. Mallinckrodt, Ph.D., John H. Greist, M.D., Lesley M. Arnold, M.D., Maurizio Fava, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 34

11:00 a.m.- 12:30 p.m.

Pine Room, South Tower, Atrium Terrace Level, Omni Hotel

OCD AND ANXIETY

Chp.: Oscar J. Bienvenu III, M.D.

Co-Chp.: Daniel P. Chapman, Ph.D.

11:00 a.m.

- 101 **Deep Brain Stimulation in Intractable OCD and Intractable Depression**
Benjamin D. Greenberg, M.D.

11:30 a.m.

- 102 **Clinical Characteristics of OCD With and Without Comorbid BDD**
S. Evelyn Stewart, M.D., Sabine Wilhelm, Ph.D.

12 noon

- 103 **The Burden Experienced by Families of Individuals With Anxiety Disorders**
Michael A. Van Ameringen, M.D., Catherine L. Mancini, M.D., Mark Bennett, B.A., Beth Pipe, B.S.N.

SCIENTIFIC AND CLINICAL REPORT SESSION 35

11:00 a.m.- 12:30 p.m.

Cottonwood Room, North Tower, Street Level, Omni Hotel

ALCOHOL AND DRUG RELATED DISORDERS

Chp.: Harvey Stabinsky, M.D.

Co-Chp.: Susan K. Blank, M.D.

11:00 a.m.

- 104 **A Comparison of Lorazepam Versus Diazepam Treatment of Alcohol Withdrawal**
Jose R. Maldonado, M.D., John O. Brooks, M.D., Long H. Nguyen, B.A., Merritt Schader, B.A.

11:30 a.m.

- 105 **Suboxone in Private Practice**
Ronald D. Abramson, M.D.

12 noon

- 106 **Nonmedical Use and Diversion of Stimulants in the U.S.: 2002**
Larry A. Kroutil, M.P.H., David L. Van Brunt, Ph.D., Robert M. Bray, Ph.D., Mindy Herman-Stahl, Ph.D., David C. Heller, B.S.

THIS SESSION WILL BE AUDIOTAPED.

WORKSHOPS

ISSUES 114-129

ISSUE WORKSHOP 114 11:00 a.m.-12:30 p.m.
Room A304, Level 3, Georgia World Congress Center

GROUP THERAPY OF SUBSTANCE ABUSE

Co-Chps.: David W. Brook, M.D., Henry I. Spitz, M.D.

ISSUE WORKSHOP 115 11:00 a.m.-12:30 p.m.
Room A405, Level 4, Georgia World Congress Center

SCULPTING THE SCULPTURE: REDEFINING ETHICAL BOUNDARIES IN FACULTY-RESIDENT RELATIONSHIPS

Chp.: Manisha R. Punwani, M.D.

Participants: Mahmoud A. Mohamed, M.D., Paul S. Appelbaum, M.D., Eugene V. Beresin, M.D., Laura W. Roberts, M.D.

ISSUE WORKSHOP 116 11:00 a.m.-12:30 p.m.
Room A408, Level 4, Georgia World Congress Center

FELLOWSHIP TRAINING IN PSYCHOSOMATIC MEDICINE: WHAT TO EXPECT FROM ACCREDITED PROGRAMS IN A NEW SUBSPECIALTY

Chp.: Philip A. Bialer, M.D.

Participants: James L. Levenson, M.D., Vassilios Latoussakis, M.D., Susan Lee, M.D., Mark J. Ehrenreich, M.D.

ISSUE WORKSHOP 117 11:00 a.m.-12:30 p.m.
Room B307, Level 3, Georgia World Congress Center

WORLD VIEW AND SPIRITUALITY IN CLINICAL PRACTICE

Chp.: Allan M. Josephson, M.D.

Participants: John R. Peteet, M.D., Mary Lynn Dell, M.D.

ISSUE WORKSHOP 118 11:00 a.m.-12:30 p.m.
Room B308, Level 3, Georgia World Congress Center

WOMEN AS LEADERS: OPPORTUNITIES AND STRATEGIES FOR SUCCESS

American Association of Psychiatric Administrators

Chp.: Jeanne L. Steiner, D.O.

Participants: Page Burkholder, M.D., Mary Ellen Foti, M.D., Elisabeth J.S. Kunkel, M.D., June A. Powell, M.D., Rose Yu-Chin, M.D.

ISSUE WORKSHOP 119 11:00 a.m.-12:30 p.m.
Room B309, Level 3, Georgia World Congress Center

BUILDING TRAUMA RESILIENCY: THE IMPACT OF MUSIC ON THE LIFE OF HOLOCAUST SURVIVORS

Chp.: Andrei Novac, M.D.

Participant: Bonita Jaros, Ph.D.

ISSUE WORKSHOP 120 11:00 a.m.-12:30 p.m.
Room B310, Level 3, Georgia World Congress Center

HOMELESSNESS, ADDICTION, AND SEVERE MENTAL ILLNESS IN PERSONS WITH HIV/AIDS

Co-Chps.: Mary Ann Cohen, M.D., Jack M. Gorman, M.D.

Participants: Jeffrey Weiss, Ph.D., Julie D. Maggi, M.D., Rosalind G. Hoffman, M.D.

ISSUE WORKSHOP 121 11:00 a.m.-12:30 p.m.
Room B311, Level 3, Georgia World Congress Center

EFFECT OF MATERNAL DEPRESSION ON THE COGNITIVE AND EMOTIONAL DEVELOPMENT OF CHILDREN

Co-Chps.: Syed S. A. Naqvi, M.D., Heather Lin, M.D.

ISSUE WORKSHOP 122 11:00 a.m.-12:30 p.m.
Room B315, Level 3, Georgia World Congress Center

KENDRA'S LAW BECOMES REALITY: MANDATING OUTPATIENT TREATMENT IN MANHATTAN

Chp.: Andrew M. Kleiman, M.D.

Participants: Michael Magera, M.D., Gary R. Collins, M.D., Jennifer Correale, J.D.

ISSUE WORKSHOP 123 11:00 a.m.-12:30 p.m.
Room B316, Level 3, Georgia World Congress Center

PRESENTEEISM AND ABSENTEEISM: UNDERRECOGNIZED AND UNDERTREATED AT WORK

Chp.: Steven E. Pflanz, M.D.

ISSUE WORKSHOP 124 11:00 a.m.-12:30 p.m.
Room B401, Level 4, Georgia World Congress Center

TREATING PHYSICIANS IN A CULTURAL CONTEXT: SOME UNIQUE ISSUES

Co-Chps.: Michael F. Myers, M.D., Leah J. Dickstein, M.D.

Participants: Nyapati Rao, M.D., Renato D. Alarcon, M.D., Carmen T. Webb, M.D.

ISSUE WORKSHOP 125 11:00 a.m.-12:30 p.m.

Room B402, Level 4, Georgia World Congress Center

COGNITIVE THERAPY FOR PSYCHOSIS FOR PSYCHIATRISTS: BASIC TECHNIQUE

Chp.: Shanaya Rathod, M.D.

Participants: Douglas Turkington, M.D., David G. Kingdon, M.D.

ISSUE WORKSHOP 126 11:00 a.m.-12:30 p.m.

Room B404, Level 4, Georgia World Congress Center

FINDING EFFECTIVE ADOLESCENT DRUG TREATMENT: ASSESSMENT OF 144 LEADING PROGRAMS

Chp.: Mathea Falco

Participants: Robert Millman, M.D., A. Thomas McLellan, Ph.D., David Lewis, M.D.

ISSUE WORKSHOP 127 11:00 a.m.-12:30 p.m.

Room B405, Level 4, Georgia World Congress Center

THE MARRIAGE OF PSYCHIATRY AND MEDICINE IN INTEGRATED TREATMENT FOR ANOREXIA NERVOSA

Co-Chps.: George S. Nasra, M.D., Mary Tantillo, Ph.D.

Participants: Manuel Matos, M.D., Sheri A. Faggiano, R.N.

ISSUE WORKSHOP 128 11:00 a.m.-12:30 p.m.

Room B406, Level 4, Georgia World Congress Center

THE FUTURE OF PSYCHOSOMATIC MEDICINE IN THE U.S. AND ABROAD

World Psychiatric Association's Section of Psychiatry, Medicine, and Primary Care

Co-Chps.: Michelle B. Riba, M.D., Rodolfo D. Fahrner, M.D.

Participants: Allan Tasman, M.D., Pedro Ruiz, M.D., Don R. Lipsitt, M.D.

ISSUE WORKSHOP 129 11:00 a.m.-12:30 p.m.

Room B407, Level 4, Georgia World Congress Center

ADVANCES IN EARLY INTERVENTION IN THE PRODROMAL PHASE OF SCHIZOPHRENIA

Chp.: Ian E. Alger, M.D.

Participants: Lewis A. Opler, M.D., Eric R. Marcus, M.D., Clarice J. Kestenbaum, M.D.

12 noon Sessions

FORUMS 10-11

FORUM 10 12 noon-1:30 p.m.

Room A410, Level 4, Georgia World Congress Center

APA AND THE PHARMACEUTICAL INDUSTRY

Chp.: David M. McDowell, M.D.

Participants: Richard Balon, M.D., Stephen M. Goldfinger, M.D., Charles R. Goldman, M.D., Trevor R.P. Price, M.D., Anand Pandya, M.D., David B. Mallott, M.D.

FORUM 11 12 noon-1:30 p.m.

Room B314, Level 3, Georgia World Congress Center

A STITCH IN TIME: PSYCHIATRIC AND MEDICAL COMORBIDITY IN AFRICAN AMERICANS ACROSS THE LIFE CYCLE

Chp.: Annelle B. Primm, M.D.

Participants: Kenneth M. Rogers, M.D., Debbie Carter, M.D., Stephen McLeod-Bryant, M.D., F.M. Baker, M.D.

NEW RESEARCH POSTER SESSION 10

12 noon-2:00 p.m.

Room B302/303/304/305, Level 3, Georgia World Congress Center

TREATMENT ISSUES

For further information on New Research Sessions, please refer to the *New Research Program and Abstracts Book* included in your registration packet.

2:00 p.m. Sessions

SYMPOSIA 87-113

SYMPOSIUM 87 2:00 p.m.-5:00 p.m.

Room A302, Level 3, Georgia World Congress Center

EFFICACY AND SAFETY OF SSRI MEDICATIONS IN CHILDREN AND ADOLESCENTS)

Collaborative Session With the National Institute of Mental Health

Chp.: Susan E. Swedo, M.D.

A SSRI Risk and Benefits: Lessons From the Treatment for Adolescents With Depression Study (TADS)
John S. March, M.D.

B Searching for Moderators and Mediators of Treatment in Adolescent Depression
Benedetto Vitiello, M.D.

C Efficacy and Safety of SSRIs in OCD and Other Anxiety Disorders
John T. Walkup, M.D.

D Antidepressants and Suicide-Related Events: An Analysis of Pediatric Trials
Thomas P. Laughren, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 88 2:00 p.m.-5:00 p.m.
Room A305, Level 3, Georgia World Congress Center

NEW DIRECTIONS IN PSYCHIATRIC ASPECTS OF TERRORISM: CAUSES, CONSEQUENCES, RESPONSES
APA Council on Global Psychiatry

Chp.: Stevan M. Weine, M.D.
Co-Chp.: Jerrold M. Post, M.D.

A Psychological Mechanisms Underlying Martyrdom Among Palestinian Youth
Daphne F. Burdman, M.D.

B Dying to Kill: The Socio-Cultural Foundations of Suicide Terrorism
Jerrold M. Post, M.D.

C Muslim Immigrant Youth in Difficult Times
Stevan M. Weine, M.D.

D Using Psychology to Counter Terrorism at the Personal and Community Level
Chris Stout, Psy.D.

E Thinkers and Doers: Integrating Academe Into Terrorism's Reality
Gregory B. Saathoff, M.D.

Discussant: David Rothstein, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 89 2:00 p.m.-5:00 p.m.
Room A402, Level 4, Georgia World Congress Center

LEADERSHIP IN PSYCHIATRY: WOMEN LEADERS IN ADVOCACY AND SERVICES

Chp.: Helen Herrman, M.D.
Co-Chp.: Michelle B. Riba, M.D.

A Women and Leadership in Psychiatry
Michelle B. Riba, M.D.

B The Need for Female Leadership in International Professional Organizations
Marianne C. Kastrup, M.D.

C Aspects of Leadership Required in Developing a National Mental Health Plan
Janice Wilson, M.D.

D Evidence and Accountability for Women's Mental Health
Donna E. Stewart, M.D.

E The Psychiatrist as Clinical Leader
Helen Herrman, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 90 2:00 p.m.-5:00 p.m.
Room A403, Level 4, Georgia World Congress Center

IMPROVING MEDICAL CARE FOR PATIENTS WITH SERIOUS MENTAL DISORDERS
Collaborative Session With the National Institute of Mental Health

Chp.: Benjamin G. Druss, M.D.
Co-Chp.: Lisa B. Dixon, M.D.

A Co-Occurring Somatic Disorders and Quality of Care in SMI
Lisa B. Dixon, M.D.

B Psychiatrists' Role in Addressing Cardiovascular Risk Factors in Serious Mental Disorders
Gail L. Daumit, M.D.

C Targeted Delivery of Clinical Preventive Services to the Seriously Mentally Ill
Caroline C. Doebbeling, M.D.

D Health Monitoring in Schizophrenia
Stephen R. Marder, M.D.

Discussant: Benjamin G. Druss, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 91 2:00 p.m.-5:00 p.m.
Room A404, Level 4, Georgia World Congress Center

PSYCHOTHERAPY IS UNIVERSALLY FUTURE ORIENTED

Chp.: Rodrigo A. Munoz, M.D.
Co-Chp.: Carol C. Nadelson, M.D.

A Expectation Videos
Bernard D. Beitman, M.D.

B Mentalizing's Future
Howard E. Book, M.D.

(Continued next page)

C Using the Future in the Psychotherapeutic Treatment of Depression
Maria T. Lymberis, M.D.

D Future-Focused Brief Psychotherapy in Clinical Practice
James L. Griffith, M.D.

SYMPOSIUM 92 2:00 p.m.-5:00 p.m.
Room A405, Level 4, Georgia World Congress Center

PSYCHOSOMATIC MEDICINE IN PSYCHIATRIC PRIVATE PRACTICE

Chp.: Thomas N. Wise, M.D.
Co-Chp.: Maryam Razavi, M.D.

- A Comprehensive Psychiatry: Patients With Medical Illnesses in Child and Adolescent Psychiatry
Jeffrey A. Naser, M.D.
- B Irritable Bowel, Interstitial Cystitis, and Fibromyalgia in Private Practice
Ronald D. Abramson, M.D.
- C Comprehensive Psychiatry: Patients With Medically-Unexplained Physical Symptoms and PTSD
Brian Crowley, M.D.
- D Comprehensive Psychiatry: Patients With Medical Illness
John C. Urbaitis, M.D., Roger Peele, M.D.
- E Psychosomatic Aspects of the Private Practice of Psychiatry in a Geriatric Practice
Walter P. Bland, M.D.

Discussant: Donna M. Norris, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 93 2:00 p.m.-5:00 p.m.
Room A406, Level 4, Georgia World Congress Center

REVIEW AND UPDATE OF EYE MOVEMENT DESENSITIZATION AND REPROCESSING

Chp.: Enoch Callaway III, M.D.

- A Eye Movement Desensitization and Reprocessing With Victims of Traffic Accidents, Suicide Bus Bombings, and Terrorist Attacks in Israel
Gary M. Quinn, M.D.
- B A Pilot Blinded, Randomized Study of Alternating Stimulation in Eye Movement Desensitization and Reprocessing for PTSD
David D. Servan-Schreiber, M.D., Johnathan Schooler, Ph.D., Mary A. Dew, Ph.D., Cameron Carter, M.D., Patricia Bartone, R.N.

C Sleep, Memory, and Trauma
Robert Stickgold, Ph.D.

Discussant: Frank B. Schoenfeld, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 94 2:00 p.m.-5:00 p.m.
Room A408, Level 4, Georgia World Congress Center

RESEARCH DURING PSYCHIATRY RESIDENCY: SHOULD IT BE REQUIRED OR BANNED?

Chp.: Bret R. Rutherford, M.D.
Co-Chp.: Steven P. Roose, M.D.

- A What Should Psychiatric Residents Know About Research?
Ronald O. Rieder, M.D.
 - B A Resident's Perspective on Research During Psychiatry Training
Bret R. Rutherford, M.D.
 - C The Way to A K: A Research Fellow's Experience
Jordan F. Karp, M.D.
 - D Training Future Generations of Psychiatrist Researchers: The Functions of Residency Research Track
Charles F. Reynolds III, M.D.
 - E Research in Psychodynamics and Psychotherapy During Residency
Robert Michels, M.D.
- THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 95 2:00 p.m.-5:00 p.m.
Room A410, Level 4, Georgia World Congress Center

THE WAR COMES HOME: PSYCHOSOCIAL AND PSYCHOSOMATIC CONSEQUENCES OF DEPLOYMENT

APA Caucus of VA Psychiatrists

Chp.: Laurent S. Lehmann, M.D.
Co-Chp.: Albert C. Gaw, M.D.

- A Rehabilitation/Recovery Orientation Towards Returning Veterans
Laurent S. Lehmann, M.D.
- B VA Outreach, Psychoeducation, and Care Efforts
Harold Kudler, M.D.
- C Department of Defense Care for Injured Troops and Their Families
Stephen J. Cozza, M.D.

- D **Deployment Research Issues: Stress and Physical Disorders**
Matthew Friedman, M.D.

Discussant: Robert J. Ursano, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 96 2:00 p.m.-5:00 p.m.

Room B301, Level 3, Georgia World Congress Center

RESEARCH AGENDA FOR A DIMENSIONAL CLASSIFICATION OF PERSONALITY DISORDER

Chp.: John Livesley, Ph.D.

Co-Chp.: Thomas A. Widiger, Ph.D.

- A **Alternative Dimensional Models: Toward Integration**
Thomas A. Widiger, Ph.D.
- B **Is an Etiological Classification of Personality Disorder Feasible for *DSM-V*?**
John Livesley, Ph.D.
- C **Personality Dimensions Integrate Axis I and Axis II Classification Systems**
Lee Anna Clark, Ph.D.
- D **Clinical Utility of Dimensional Models of Personality Pathology**
Roel Verheul, Ph.D.

Discussant: Michael B. First, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 97 2:00 p.m.-5:00 p.m.

Room B306, Level 3, Georgia World Congress Center

TRANSCULTURAL ARAB PERSPECTIVE ON SUBSTANCE ABUSE AND DEPENDENCE

Arab American Psychiatric Association

Chp.: Ossama T. Osman, M.D.

Co-Chp.: Abdel F. Amin, M.D.

- A **Highlights on Dependence: An Egyptian Perspective**
Ahmed M.F. Okasha, M.D.
- B **Dual Diagnosis in Substance Abuse in an Egyptian Sample**
Tarek A. Okasha, M.D., Afaf Hamed Khalil, M.D., Tarek A. Asaad, M.D., Mohamed Abouzied, M.D., Hisham Hatata
- C **Substance Abuse and Comorbidities Among Men in Saudi Arabia**
Ossama T. Osman, M.D.

- D **Substance Abuse Among Arab Women: A Saudi Perspective**

Mona H. Al-Sawaf, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 98

2:00 p.m.-5:00 p.m.

Room B307, Level 3, Georgia World Congress Center

DEPRESSION AND EPILEPSY: A UNIQUE AND COMPLEX RELATIONSHIP

Chp.: John J. Barry, M.D.

- A **The Unique Relationship Between Depression and Epilepsy**
Cynthia L. Harden, M.D.
- B **Manifestations and Treatment of Depression in Epilepsy**
John J. Barry, M.D.
- C **Mood Disorders in Children With Epilepsy**
David W. Dunn, M.D.
- D **Psychological Nonepileptic Seizures**
W. Curt LaFrance, Jr., M.D.

Discussants: W. Curt LaFrance, Jr., M.D., David W. Dunn, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 99

2:00 p.m.-5:00 p.m.

Room B308, Level 3, Georgia World Congress Center

CHILDHOOD SEXUAL ABUSE: VICTIMS AND PERPETRATORS

Chp.: Lisa J. Cohen, Ph.D.

- A **The Assessment and Treatment of Sexual Offenders**
Kostas Katsavdakakis, Ph.D., David Schaich, Ph.D., Sam Langer, M.D.
- B **Association of Different Types of Childhood Abuse and Personality Pathology**
Pamela McGeoch, M.A., Jeffrey Johnson, Ph.D.
- C **Personality Pathology in Male Pedophiles Compared With Two Control Groups**
Yuli Grebchenko, M.D., Matthew Steinfeld, B.A., Mustafa Kaleem, M.D., Lauren Kunik, B.A., Ken Cullen, M.S.W., Igor I. Galynker, M.D., Lisa J. Cohen, Ph.D.

(Continued next page)

- D Relationship of Childhood Sexual Abuse Histories to Adult Pedophilic Behavior**
 Lisa J. Cohen, Ph.D., Yakov Semenov, M.D., Mustafa Kalim, Yuli Grebchenko, M.D., Matthew Steinfeld, B.A., Lauren Kunik, B.A., Igor I. Galynker, M.D.

Discussant: Igor I. Galynker, M.D.
 THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 100 2:00 p.m.-5:00 p.m.
 Room B309, Level 3, Georgia World Congress Center

HOW TO DETERMINE CAPACITY FOR MEDICAL DECISION MAKING IN PATIENTS ON MEDICAL-SURGICAL SERVICES

Chp.: Elisabeth J.S. Kunkel, M.D.
 Co-Chp.: Dimitri D. Markov, M.D.

- A Medical Decision-Making Capacity**
James L. Stinnett, M.D.
- B How to Determine Maternal Capacity in Patients on Medical-Surgical Services**
Barbara K. Schindler, M.D.
- C Dispositional Capacity**
Dilip Ramchandani, M.D.
- D End-of-Life Decision-Making Capacity**
Dimitri D. Markov, M.D.

Discussant: Paul S. Appelbaum, M.D.
 THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 101 2:00 p.m.-5:00 p.m.
 Room B310, Level 3, Georgia World Congress Center

LONG-TERM CARE AND TREATMENT OF ELDERLY PATIENTS WITH SCHIZOPHRENIA

APA Corresponding Committee on Long-Term Care and Treatment for the Elderly

Chp.: Helen H. Kyomen, M.D.

- A The Impact on the Health Care System of Elderly Patients With Schizophrenia**
Helen H. Kyomen, M.D.
- B Long-Term Care, Health Management, and Rehabilitation of Elderly Patients With Schizophrenia**
Stephen J. Bartels, M.D.
- C Evolution of Treatment Interventions for Elderly Patients With Schizophrenia**
Susan M. Edwards-Loidl, M.D.

- D Ethnic and Cultural Issues in the Care of Elderly Patients With Schizophrenia**
Iqbal Ahmed, M.D.

Discussant: Carl I. Cohen, M.D.
 THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 102 2:00 p.m.-5:00 p.m.
 Room B311, Level 3, Georgia World Congress Center

NEUROBIOLOGY OF COMPULSIVE REWARD-SEEKING

National Institute on Drug Abuse

Chp.: Paul Schnur, Ph.D.
 Co-Chp.: David Shurtleff, Ph.D.

- A Compulsive Drug Use and the Dysregulation of Brain Reward and Stress Systems**
George F. Koob, Ph.D.
- B A Behavioral Model of Binge-Type Eating: Relevance to Substance Abuse**
Rebecca L. Corwin, Ph.D.
- C Increasing Motivation to Self-Administer Cocaine: Importance of Binge-Abstinence Cycles**
David C.S. Roberts, Ph.D.
- D Addiction-Like Behavior in the Rodent: Insight Into the True Nature of Addiction**
Pier V. Piazza, Ph.D.

Discussant: Nora D. Volkow, M.D.

SYMPOSIUM 103 2:00 p.m.-5:00 p.m.
 Room B314, Level 3, Georgia World Congress Center

BARRIERS TO THE EFFECTIVE TREATMENT OF PERSONALITY DISORDERS

Chp.: Donna S. Bender, Ph.D.
 Co-Chp.: Andrew E. Skodol II, M.D.

- A Utilization and Barriers to Treatment by Patients With Personality Disorders**
Donna S. Bender, Ph.D., Andrew E. Skodol II, M.D., Ingrid R. Dyck, M.P.H., Maria E. Pagano, Ph.D.
- B Recognition of Personality Disorders in Mental Health and Medical Settings**
Andrew E. Skodol II, M.D., Donna S. Bender, Ph.D.
- C Personality Disorders: Patterns and Barriers in Psychiatric Practice**
William E. Narrow, M.D., Joyce C. West, Ph.D., Donald S. Rae, M.A.

D Barriers to Effective Research on Treatment of Personality Disorder
Drew Westen, Ph.D.

E Stigma, Countertransference, and Personality Disorders
Glen O. Gabbard, M.D.

Discussant: John M. Oldham, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 104 2:00 p.m.-5:00 p.m.
Room B315, Level 3, Georgia World Congress Center

IMPULSIVE AGGRESSION AND CRIMINAL RESPONSIBILITY

Chp.: Alan R. Felthous, M.D.

A Assessing and Treating Aggressive Behavior: The Importance of Subtyping
Matthew S. Stanford, Ph.D.

B Impulsivity Risk Factor or Symptom in Psychopathology?
Ernest S. Barratt, Ph.D.

C The Biology of Impulsive Aggression: Implications for Forensic Psychiatry
Frederick G. Moeller, M.D., Ernest S. Barratt, Ph.D., Joel L. Steinberg, M.D., Ignacio H. Valdes, M.D., Alan C. Swann, M.D.

D Impulsivity and the Criminal Law
Daniel W. Shuman, J.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 105 2:00 p.m.-5:00 p.m.
Room B316, Level 3, Georgia World Congress Center

OPTIMIZING PATIENT RESPONSE THROUGH THE INTEGRATION OF PSYCHIATRY AND MEDICINE

Chp.: Gerald A. Maguire, M.D.

A Remembering the Whole Person: Providing Comprehensive Psychiatric Care of the Severely Medically Ill
Noel Gardner, M.D.

B Treating Psychiatrically Hospitalized, Agitated Children
Gabrielle A. Carlson, M.D., David Margulies, M.D., Zinovy Gutkovitch, M.D.

C Treatment of Acute Agitation in the Emergency Department
Scott Rudkin, M.D.

D Diabetes and Schizophrenia: Guidelines, Evidence, and Practical Implementation for Improved Patient Outcomes
John Buse, M.D.

E Cultural Issues in Psychopharmacologic Management
Charles Nguyen, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 106 2:00 p.m.-5:00 p.m.
Room B401, Level 4, Georgia World Congress Center

EATING DISORDERS 2005: FROM SCIENCE TO PRACTICE

Chp.: Joel Yager, M.D.

Co-Chp.: David B. Herzog, M.D.

A Defining the Neuroanatomy of Anorexia and Bulimia Nervosa
Walter H. Kaye, M.D., Frank Guido, M.D., Ursula Bailer, M.D., Angela Wagner, M.D., Shannan Henry, B.S., Claire McConaha, B.S.

B The Genetics of Anorexia Nervosa and Bulimia Nervosa
Katherine A. Halmi, M.D.

C Does Participation in Osteoporosis Treatment Studies Influence Eating Disorder Symptoms in Patients With Anorexia?
David B. Herzog, M.D., Debra L. Franko, Ph.D., David J. Dorer, Ph.D., Safia C. Jackson, B.S., Mary Patricia Manzo, A.B., Karen K. Miller, M.D., Anne Klibanski, M.D.

D CBT for Bulimia Nervosa Delivered via Telemedicine Versus Face-to-Face
James E. Mitchell, M.D., Ross D. Crosby, Ph.D., Stephen A. Wonderlich, Ph.D., James Roerig, Pharm.D., Tricia Myers, Ph.D., Lorraine Swan-Kremier, Ph.D., Kathy Lancaster

E Updating APA Eating Disorders Practice Guidelines: What's New for Practice?
Joel Yager, M.D., Michael J. Devlin, M.D., James E. Mitchell, M.D., Katherine A. Halmi, M.D., Pauline Powers, M.D., David B. Herzog, M.D., Kathryn J. Zerbe, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 107- CANCELLED

SYMPOSIUM 108 2:00 p.m.-5:00 p.m.
Room B403, Level 4, Georgia World Congress Center

NEW DEVELOPMENTS IN NEUROIMAGING IN BPD

Chp.: Christian Schmahl, M.D.

Co-Chp.: Larry J. Siever, M.D.

(Continued next page)

- A Overview of New Neuroimaging Research Strategies for BPD
Larry J. Siever, M.D.
- B MR-Morphometric and Spectroscopic Findings in Patients With BPD
Ludger Tebartz Van Elst, M.D., Juergen Hennig, Ph.D., Dieter Ebert, M.D., Martin Bohus, M.D., Klaus Lieb, M.D.
- C Amygdala/Frontal Circuitry Dysfunction in BPD
Antonia S. New, M.D., Monte Buchsbaum, M.D., Erin Hazlett, Ph.D., Randall Newmark, B.A., Serge A. Mitelman, M.D., Marianne Goodman, M.D., Larry J. Siever, M.D.
- D Neural Correlates of BPD Patients With and Without PTSD
Charles A. Sanislow, Ph.D., Nelson H. Donegan, Ph.D., Thomas H. McGlashan, M.D.
- E Neural Correlates of Antinociception in BPD
Christian Schmahl, M.D., Erich Seifritz, M.D., Rolf-Detlef Treede, M.D., Martin Bohus, M.D.

Discussant: Kenneth Silk, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 109 2:00 p.m.-5:00 p.m.
Room B404, Level 4, Georgia World Congress Center

EVIDENCE-BASED PRACTICES IN SUICIDE PREVENTION

Chp.: Howard S. Sudak, M.D.

- A Risk and Protective Factors in Suicide Prevention
Morton M. Silverman, M.D.
 - B Safety and Harm Issues in Suicide Prevention
Phillip Rodgers, Ph.D.
 - C Examples of Evidence-Based Practices in Suicide Prevention
Howard S. Sudak, M.D.
- THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 110 2:00 p.m.-5:00 p.m.
Room B405, Level 4, Georgia World Congress Center

TREATMENT AND INTERVENTION FOR AUTISM SPECTRUM DISORDERS

Chp.: Craig Newschaffer, Ph.D.
Co-Chp.: Li-Ching Lee, Ph.D.

- A Detecting Signs of Autism in Infancy
Rebecca Landa, Ph.D.

- B Effective Early Intervention for Very Young Children With Autism Spectrum Disorders
Ilene Schwartz, Ph.D.
 - C Psychopharmacological Treatments for Autism Spectrum Disorders
Eric Hollander, M.D.
 - D Natural History, Prognosis, and Outcomes of Autism Spectrum Disorders
Li-Ching Lee, Ph.D.
- THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 111 2:00 p.m.-5:00 p.m.
Room B407, Level 4, Georgia World Congress Center

HOW TO PRACTICE EVIDENCE-BASED MEDICINE

Chp.: Donna M. Sudak, M.D.

- A Introduction to Evidence-Based Psychiatry
Bryce Templeton, M.D.
 - B Review of Basic Statistical Concepts
Maju Mathews, M.D.
 - C Critical Appraisal of Randomized, Controlled Trials
Adedapo B. Williams, M.D.
 - D Critical Appraisal of Systematic Reviews and Meta-Analysis
Babatunde A. Adetunji, M.D.
- THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 112 2:00 p.m.-5:00 p.m.
Room B408, Level 4, Georgia World Congress Center

TRANSLATING RISK RESEARCH INTO COMORBIDITY INTERVENTION RESEARCH
APA Council on Psychosomatic Medicine

Chp.: Junius J. Gonzales, M.D.

- A Early Identification and Intervention With High Risk, Low Back Pain Patients
Robert Gatchel, Ph.D.
- B Depression and Diabetes
Wayne J. Katon, M.D., Michael Von Korff, Sc.D., Elizabeth H.B. Lin, M.D., Paul S. Ciechanowski, M.D., Gregory E. Simon, M.D., Evette J. Ludman, Ph.D.
- C Comorbidity of Obesity and Depression
Gregory E. Simon, M.D., Evette J. Ludman, Ph.D.

- D Depression and Breast Cancer: Treatment Response and HPA Dysregulation**
David M. Spiegel, M.D., Janine Giese-Davis, Ph.D., Lisa D. Butler, Ph.D., Catherine Classen, Ph.D., Gary Norrow, M.D.

Discussant: Theodore A. Stern, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 113 2:00 p.m.-5:00 p.m.

Room B409, Level 4, Georgia World Congress Center

POSTPARTUM MOOD DISORDERS

Collaborative Session With the National Institute of Mental Health

Chp.: Catherine A. Roca, M.D.

- A Reproductive Hormones and Postpartum Depression**
Catherine A. Roca, M.D., David R. Rubinow, M.D.
- B Uncovering the Nature of the Puerperal Trigger: Genetic Studies of Postpartum Mood Disorders**
Ian R. Jones, M.R.C.
- C Bipolar Disorder and the Postpartum Period**
Adele C. Viguera, M.D., Lee S. Cohen, M.D.
- D Postpartum Mental Illness: Impact and Treatment**
Zachary N. Stowe, M.D., Donald J. Newport, M.D., Kimberly A. Ragan, M.S.W.

2005 ANNUAL MEETING

TOPIC AREAS FOR THE SCIENTIFIC PROGRAM

DISORDERS

1. AIDS and HIV-Related Disorders
2. Alcohol and Drug-Related Disorders
3. Anxiety Disorders
4. Attention Spectrum Disorders
5. Cognitive Disorders (Delirium, Dementia, Amnesic, etc.)
6. Eating Disorders
7. Mental Retardation (Child/Adolescent/Adult)
8. Mood Disorders
9. Personality Disorders
10. Schizophrenia and Other Psychotic Disorders
11. Sexual and Gender Identity Disorders
12. Sleep Disorders
13. Somatoform Disorders

PRACTICE AREAS/SETTINGS

14. Psychiatric Administration and Services: Public, Private, and University

SUBSPECIALTY AREAS OR SPECIAL INTERESTS

15. Addiction Psychiatry
16. Biological Psychiatry and Neuroscience
17. Brain Imaging
18. Child and Adolescent Psychiatry and Disorders
19. Consultation-Liaison and Emergency Psychiatry
20. Cross-Cultural and Minority Issues
21. Diagnostic Issues
22. Epidemiology
23. Ethics and Human Right
24. Forensic Psychiatry
25. Genetics
26. Geriatric Psychiatry
27. Neuropsychiatry
28. Pain Management
29. Psychiatric Education
30. Psychiatric Rehabilitation
31. Psychoanalysis
32. Psychoimmunology
33. Research Issues

34. Social and Community Psychiatry
35. Stress
36. Suicide
37. Violence, Trauma, and Victimization

TREATMENTS

38. Behavior and Cognitive Therapies
39. Combined Pharmacotherapy and Psychotherapy
40. Couple and Family Therapies
41. Group Therapy
42. Individual Psychotherapies
43. Other Somatic Therapies
44. Psychopharmacology
45. Treatment Techniques and Outcome Studies

OTHER ISSUES

46. Creativity and the Arts
47. Gender Issues
48. Health Services Research
49. Historical Questions
50. Information Technology
51. Internet
52. Lesbian/Gay/Bisexual/Transgender Issues
53. Managed Care and Health Care Funding
54. National Institute of Mental Health
55. Patient Safety
56. Personal Digital Assistants (PDAs)
57. Presidential Theme: "Psychosomatic Medicine: Integrating Psychiatry & Medicine"
58. Professional and Personal Issues
59. Religion, Spirituality, and Psychiatry
60. Resident and Medical Student Concerns
61. Stigma/Advocacy
62. Telepsychiatry
63. Women's Health Issues

GUIDE TO USING THE TOPIC INDEX

Use this index to find sessions of interest to you. There are five overall topics: Disorders, Practice Areas/Settings, Subspecialty Areas or Special Interests, Treatments, and Other Issues. Under each overall topic, you will find subtopics listed in alphabetical order with the formats (type of session) listed alphabetically underneath. Within each format, you will find the title of the individual session listed by number. The listing will also show the page number the session appears on. You should refer to the page number in this *Program Book* to obtain further details about the session.

| DISORDERS | Page # | | Page # |
|---|--------|---|--------|
| TOPIC 1: AIDS AND HIV-RELATED DISORDERS | | TOPIC 3: ANXIETY DISORDERS | |
| SYMPOSIUM | | DISCUSSION GROUP | |
| 28 Real Life Medical Management of HIV | 54 | 17 Improving Outcomes of Patients With Anxiety and Depressive Disorders Within Primary Care Settings | 65 |
| COMPONENT WORKSHOPS | | INDUSTRY-SUPPORTED SYMPOSIA | |
| 7 Serodiscordant Couples: Issues and Psychodynamics in the Third Decade of AIDS | 18 | 1 Anxiety: Diverse Populations and Presentations, Unique Individuals and Treatments | 1 |
| 26 Using the HIV Dementia Scale in the Clinical Setting | 43 | 6 Integrating Neurobiology and Psychopathology Into Evidence-Based Treatment of Social Anxiety Disorder | 3 |
| ISSUE WORKSHOPS | | 15 Panic Disorder: Current Concepts and Future Directions | 6 |
| 109 The Double-Edged Sword: Mental Health Challenges in HIV and Hepatitis C | 88 | 21 Anxiety Disorders: Understanding the Interconnection Between Emotional and Physical Symptoms | 9 |
| 120 Homelessness, Addiction, and Severe Mental Illness in Persons With HIV/AIDS | 91 | SCIENTIFIC AND CLINICAL REPORTS | |
| TOPIC 2: ALCOHOL AND DRUG-RELATED DISORDERS | | 27 Personality Traits in Patients With Panic Disorder | 24 |
| COURSES | | 50 PTSD Depression and Anger in Patients Recovered From SARS | 48 |
| 10 Street Drugs and Mental Disorders: Overview and Treatment | 2 | 51 Are Anxiety Disorders Underdiagnosed and Undertreated in Psychiatry? | 48 |
| 80 Drugs and Alcohol Take Two: Teaching Addiction Medicine Using Popular Films | 63 | 52 Biological Findings in PTSD: Can They Be Changed by Psychotherapy? | 48 |
| FORUM | | 79 Respiratory Panic Disorder in a Long-Term Clonazepam Follow-Up | 71 |
| 2 Should Psychiatrists and Other Mental Health Professionals Take a Lead in Tobacco Dependence Treatment | 26 | 92 The Prevalence of Migraine Headaches in an Anxiety Disorders Clinic Sample | 89 |
| INDUSTRY-SUPPORTED SYMPOSIA | | 102 Clinical Characteristics of OCD With and Without Comorbid BDD | 90 |
| 35 Dual Diagnosis: The Scope of the Problem | 36 | 103 The Burden Experienced by Families of Individuals With Anxiety Disorders | 90 |
| 40 Alcoholism: Translating Emerging Science Into Clinical Practice | 62 | SYMPOSIUM | |
| SCIENTIFIC AND CLINICAL REPORTS | | 45 The Long-Term Psychological Aftermath of 9/11-Related Traumatic Loss | 58 |
| 30 Parental Separation at Birth and Substance-Use Disorder | 46 | TOPIC 4: ATTENTION SPECTRUM DISORDERS | |
| 104 A Comparison of Lorazepam Versus Diazepam Treatment of Alcohol Withdrawal | 90 | COURSES | |
| 105 Suboxone in Private Practice | 90 | 3 ADD in Children and Adolescents | 1 |
| 106 Nonmedical Use and Diversion of Stimulants in the U.S.: 2002 | 90 | 18 ADD in Adults | 5 |
| SYMPOSIA | | 76 Advanced Assessment and Treatment of ADD | 51 |
| 4 Comorbid Psychosis and Substance Use: Diagnosis, Course, and Outcome | 29 | INDUSTRY-SUPPORTED SYMPOSIA | |
| 10 New Pharmacologic Approaches to Alcoholism | 31 | 24 Exploring Cognitive Function: From Brain to Bedside | 11 |
| 36 Understanding and Treating Alcohol Dependence | 56 | 27 ADHD Through the Lifecycle: New Findings and Clinical Implications | 11 |
| 53 Increases in Opioid Analgesic Abuse: Concerns and Strategies | 60 | 43 It's Not Just for Kids: ADHD in Adolescence and Adulthood | 62 |
| 73 Choosing the Right Treatment for Substance Abuse | 80 | SCIENTIFIC AND CLINICAL REPORTS | |
| COMPONENT WORKSHOP | | 11 Sleep Hygiene and Melatonin Treatment for ADHD Sleep-Onset Delay | 23 |
| 51 Need an Oxycontin Fix? The Role of Buprenorphine in the Outpatient Treatment of Prescription Narcotic Problems | 73 | 12 Comorbidity Differences in ADHD Throughout the Life Cycle | 23 |
| ISSUE WORKSHOP | | SYMPOSIUM | |
| 48 Cannabis Dependence Treatment: Where We Are, Where We Are Going | 50 | 14 Diagnosis, Assessment, Management, and Quality-of-Life Issues in Adult ADHD | 32 |
| | | 22 Large Observational Studies of ADHD: Methodology and Results | 34 |

| | Page # | | Page # |
|---|--------|--|--------|
| TOPIC 5: COGNITIVE DISORDERS (DELIRIUM, DEMENTIA, AMNESTIC, ETC.) | | MEDIA WORKSHOP | |
| COURSE | | 3 <i>Super Size Me</i> : Exploring Causes, Effects, and Solutions to Obesity in Children and Adolescents | 20 |
| 2 The Evaluation and Identification of the Major Dementias | 1 | TOPIC 7: MENTAL RETARDATION (CHILD/ADOLESCENT/ADULT) | |
| INDUSTRY-SUPPORTED SYMPOSIA | | COMPONENT WORKSHOP | |
| 20 Alzheimer's Disease Pathways to Practice: Assessing Diagnosis and Outcome Measures | 9 | 38 To Dose or Not to Dose: Psychopharmacology in the Developmentally Disabled | 66 |
| 31 Agitation and Psychosis in Alzheimer's Disease and Parkinson's Disease, Part 1 | 13 | ISSUE WORKSHOP | |
| 31 Agitation and Psychosis in Alzheimer's Disease and Parkinson's Disease, Part 2 | 39 | 38 Uncovering Medical Causes of Functional Decline in the Developmentally Disabled | 44 |
| 41 Advances in Cholinergic Therapy: Alzheimer's Disease and Beyond | 62 | TOPIC 8: MOOD DISORDERS | |
| MEDICAL UPDATE | | COURSE | |
| 1 Get Smart Naturally | 22 | 11 Melatonin and Light Treatment of SAD, Sleep, and Other Body Clock Disorders | 2 |
| SCIENTIFIC AND CLINICAL REPORT | | DISCUSSION GROUPS | |
| 35 Is Depression a Risk Factor for Cognitive Impairment? A Meta-Analysis of 20 Cohort Studies | 47 | 11 Postpartum Mood Disorders | 41 |
| SYMPOSIUM | | 12 The Great Bipolar Depression Controversy: A Pragmatic Approach (<i>Meet the Authors</i>) | 41 |
| 17 Advances and Innovations in Assessing Decision-Making Capacity | 59 | FOCUS LIVE SESSION | |
| ISSUE WORKSHOPS | | 1 Major Depressive Disorder | 16 |
| 40 Driving Miss Daisy | 45 | FORUM | |
| 74 Become a Delirium Detective | 68 | 9 CDC Mental Health and Illnesses | 74 |
| TOPIC 6: EATING DISORDERS | | INDUSTRY-SUPPORTED SYMPOSIA | |
| COURSE | | 2 The Impact of Depression and Anxiety on Well-Being Across the Life Cycle | 2 |
| 6 Therapeutic Interventions in Eating Disorders: Basic Principles | 1 | 5 The Developmental Trajectory of Impulsivity | 3 |
| INDUSTRY-SUPPORTED SYMPOSIUM | | 7 Bipolar Disorder: Psychiatric and Medical Implications for Optimal Patient Management | 3 |
| 12 Too Little, Too Much: What Is Disordered Eating? | 6 | 9 Achieving Remission in Depression: Is the Bar Set Too High or Too Low? | 4 |
| LECTURES | | 10 Dealing With Depression: The Added Burden to Medical Patients | 4 |
| 6 Eating Disorders in Middle and Late Life: Diagnosis and Treatment of a Neglected Problem | 21 | 11 Systematic Treatment of Bipolar Disorder: Bringing Evidence Into Practice | 5 |
| 20 The 25th Anniversary of Bulimia Nervosa: A New Disorder | 75 | 26 Untangling Depression and Anxiety: A Challenge for Scientists and Clinicians | 11 |
| SCIENTIFIC AND CLINICAL REPORTS | | 32 Managing the Spectrum of Bipolar Disorder: Minimizing the Burden of Disease, Part 1 | 13 |
| 31 Pica Syndrome: Review and Relevance | 46 | 32 Managing the Spectrum of Bipolar Disorder: Minimizing the Burden of Disease, Part 2 | 39 |
| 55 Anger Discomfort Predicts Disordered Eating Among College Students With Obesity | 48 | 34 Bipolar Disorder Management: A New Edition | 36 |
| SYMPOSIUM | | 38 Overcoming Traditional Dilemmas in Treating Depressive Illnesses: Evidence-Based Updates | 37 |
| 106 Eating Disorders 2005: From Science to Practice | 97 | 39 Seasonal Affective Disorder: New Concepts, Practical Strategies | 61 |
| ISSUE WORKSHOPS | | 44 Bipolar Disorder Across the Life Cycle: Special Considerations, Part 1 | 63 |
| 19 Binge-Eating Disorder in Obesity and Implications for Bariatric Surgery | 25 | 44 Bipolar Disorder Across the Life Cycle: Special Considerations, Part 2 | 85 |
| 82 The Difficult-to-Treat Bulimia Nervosa Patient | 73 | LECTURES | |
| 127 The Marriage of Psychiatry and Medicine in Integrated Treatment for Anorexia Nervosa | 92 | 8 Temperament, Mood Disorder, and Human Nature | 28 |
| | | 17 Depression and Heart Disease: Cause, Effect, or Coincidence | 65 |

| | Page # |
|--|--------|
| MASTER EDUCATOR CLINICAL CONSULTATIONS | |
| 3 Treatment-Refractory Depression | 21 |
| 12 The Approaches to Treatment-Refractory Depression | 69 |

| | |
|--|----|
| REVIEW OF PSYCHIATRY: SECTION 2 | |
| Pregnancy and Postpartum Depression | 66 |

| | |
|--|----|
| SCIENTIFIC AND CLINICAL REPORTS | |
| 14 Excess Mortality in Bipolar and Unipolar Disorder | 23 |
| 15 Do Antidepressants Help or Hinder Recovery From Mixed Mania? | 23 |
| 16 Mixed Episodes: Illness Characteristics | 23 |
| 28 Is Peripartum Depression a Borderline Condition? | 24 |
| 45 Lithium Continuation/Discontinuation After Four Years of Stability | 48 |
| 46 Magnitude of the Effects of Quetiapine Treatment in Bipolar Disorder | 48 |
| 62 Last Observation Carried Forward Use in Antidepressant Efficacy Trials: Review of 260 Studies | 70 |
| 63 The Effect of Chromium Picolinate on Carbohydrate Craving in Atypical Depression | 70 |
| 64 Does Remission of Acute Depression Predict Long-Term Efficacy | 70 |
| 77 Depression Correlates With Left Nigrostriatopallidal Circuit Focal Lesions | 71 |
| 94 Modafinil Augmentation of SSRI Therapy in MDD | 89 |
| 96 Typical and Atypical Antipsychotics in Bipolar Depression | 90 |
| 98 The Targeted Treatment of Depression Inventory: New Depression Inventory Designed to Guide Antidepressant Selection | 90 |
| 99 Is It Time to Replace the Hamilton Depression Rating Scale? | 90 |
| 100 Daily Measurements Elucidate Effects of Initial Dosing of Duloxetine | 90 |

| | |
|--|----|
| SYMPOSIA | |
| 11 Carbohydrate Craving and Mood Disorders: New and Complementary Treatments | 31 |
| 13 Understanding Complex Mood Disorders: The Role of Personality Variables | 32 |
| 35 The Many Faces of Depression: Do Antidepressants Treat Different Symptoms? | 55 |
| 60 Bipolar Disorder: Optimizing Outcome Through Early Recognition and Intervention | 77 |
| 82 Depression and Comorbid Personality Disorders: Implications for Treatment | 83 |
| 86 Difficult Depression: Looking for Our Keys: Beyond the Light, We Can See | 84 |
| 98 Depression and Epilepsy: A Unique and Complex Relationship | 95 |

| | |
|---|----|
| COMPONENT WORKSHOP | |
| 15 The Multicultural Dimension of Depression: A Clinical Approach | 24 |

TOPIC 9: PERSONALITY DISORDERS

| | |
|---|----|
| COURSES | |
| 19 Personality Disorders: Combining Relational Therapy and Psychopharmacology | 5 |
| 23 Psychotherapy of Borderline Personality | 7 |
| 46 Treating the Self and Interpersonal Problems of Personality Disorder | 15 |

| | |
|--|---|
| INDUSTRY-SUPPORTED SYMPOSIUM | |
| 17 BPD: Pathophysiology Treatment and Course | 7 |

| | |
|--|----|
| REVIEW OF PSYCHIATRY: SECTION 3 | |
| Bipolar Disorders | 76 |

| | |
|---|----|
| SYMPOSIA | |
| 19 Maladaptive Personality Traits: Drug Treatment, Genetics, and Biology | 33 |
| 43 Associations Between Stress/Anxiety and Personality Styles and Disorders | 57 |
| 72 Emotion Regulation in BPD | 80 |
| 96 Research Agenda for a Dimensional Classification of Personality Disorder | 95 |
| 103 Barriers to the Effective Treatment of Personality Disorders | 96 |

| | |
|---|----|
| ISSUE WORKSHOP | |
| 3 Cognitive Therapy for Personality Disorders | 19 |

TOPIC 10: SCHIZOPHRENIA AND OTHER PSYCHOTIC DISORDERS

| | |
|---|---|
| COURSE | |
| 29 Assessing Positive and Negative Symptoms in Psychosis With the PANSS | 8 |

| | |
|---|----|
| DEBATE | |
| Resolved: Second Generation Antipsychotics Are Uniformly Superior in Safety and Efficacy to First-Generation Antipsychotics | 15 |

| | |
|---|----|
| FORUM | |
| 4 Psychiatric Management of Treatment-Resistant Schizophrenia | 51 |

| | |
|--|----|
| INDUSTRY-SUPPORTED SYMPOSIA | |
| 16 Antipsychotic Drugs, Mood Stabilizers, and the Metabolic Syndrome | 7 |
| 22 Relapse Prevention in Schizophrenia: Defining a Path From Pharmacologic Intervention to Long-Term Functional Recovery | 10 |
| 30 From Molecular Insight to Clinical Outcomes: Recent Advances in Schizophrenia Treatment | 12 |

| | |
|--|----|
| SCIENTIFIC AND CLINICAL REPORTS | |
| 71 Premorbid Developmental Achievements and Later Recovery in Schizophrenia | 71 |
| 72 Pain Insensitivity in Schizophrenia: State or Trait Marker? | 71 |
| 73 Effectiveness of an Early Psychosis Treatment Service | 71 |
| 86 Effectiveness and Tolerability of Antipsychotic Treatments for Schizophrenia: Two-Year Results From the Intercontinental Schizophrenia Outpatient Health Outcomes Study (IC-SOHO) | 89 |

| | |
|---|----|
| ISSUE WORKSHOPS | |
| 64 When Usual Treatments Fail: Augmentation Strategies for Refractory Schizophrenia | 68 |
| 129 Advances in Early Intervention in the Prodromal Phase of Schizophrenia | 92 |

| | |
|--|----|
| MEDIA WORKSHOP | |
| 4 Long-Term Management of Schizophrenia in the Film <i>Out of the Shadow</i> | 45 |

TOPIC 11: SEXUAL AND GENDER IDENTITY DISORDERS

| | |
|---|----|
| COURSES | |
| 66 The Assessment and Treatment of Child Sexual Abusers | 41 |
| 99 Sexual Medicine | 75 |

| | Page # | | Page # |
|--|--------|---|--------|
| TOPIC 12: SLEEP DISORDERS | | SYMPOSIUM | |
| COURSES | | 48 Inpatient Psychiatry: Crisis and Response | 59 |
| 54 Overview and Update of Sleep Disorders Medicine | 26 | COMPONENT WORKSHOPS | |
| 63 Sleep Medicine Update: Advanced Topics | 40 | 4 Psychiatric Leadership: Putting Out Fires and Beyond! | 18 |
| INDUSTRY-SUPPORTED SYMPOSIA | | 9 U.S. Research and Services Bridge With Latin America | 18 |
| 18 Joining Night and Day: Insomnia and the Sleep/Wake Cycle | 9 | 49 Come and Complain: Do Psychiatrists Have a Role in Accreditation? A Debate | 72 |
| 19 Clinical Interventions for the Treatment of Insomnia Associated With Psychiatric and Comorbid Medical Illnesses | 9 | ISSUE WORKSHOP | |
| 36 Insomnia in Special Populations: Is This Insomnia or Something Else? | 36 | 15 Making It Happen: Implementing Practice Guidelines in Everyday Practice | 25 |
| 42 Challenges at the Interface of Psychiatric, Medical, and Sleep Disorders | 62 | SUBSPECIALTY AREAS OR SPECIAL INTERESTS | |
| REVIEW OF PSYCHIATRY: SECTION 1 | | TOPIC 15: ADDICTION PSYCHIATRY | |
| Sleep Disorders and Psychiatry | 53 | DISCUSSION GROUPS | |
| ISSUE WORKSHOP | | 2 Prescription Drug Abuse: The Psychiatrist's Role in Recognition, Prevention, and Management | 15 |
| 78 Sleep Disorders in Patients With Medical and Psychiatric Illness | 73 | 5 Pathological Gambling and Its Clinical Management (<i>Meet the Authors</i>) | 15 |
| TOPIC 13: SOMATOFORM DISORDERS | | SCIENTIFIC AND CLINICAL REPORTS | |
| COURSE | | 56 Virtual Reality Cue Exposure for Crack Cocaine Dependence | 70 |
| 77 Psychogenic Illness: What to Do When the Symptoms Don't Make Sense | 51 | 57 Low-Dose Naltrexone for Opioid Dependence | 70 |
| SCIENTIFIC AND CLINICAL REPORT | | 58 Buprenorphine Versus Methadone Treatments in Addicted Opioid Patients: A Two-Year Observational Study | 70 |
| 38 Somatization Increases Medical Care Utilization and Cost | 47 | SYMPOSIUM | |
| SYMPOSIA | | 61 The Biopsychosocial Consequences of Pathological Gambling | 7 |
| 47 New Developments in the Treatment of Somatoform Disorders | 58 | ISSUE WORKSHOP | |
| 63 The Doctor's Dilemma: Managing Pediatric Chronic Unexplained Symptoms | 78 | 93 Substance Abuse in the Prison Setting | 87 |
| ISSUE WORKSHOPS | | TOPIC 16: BIOLOGICAL PSYCHIATRY AND NEUROSCIENCE | |
| 55 Chronic Fatigue Syndrome and Gulf War Illness: Pathology or Abnormal Illness Behavior? | 50 | COURSE | |
| 103 Conversion Disorders in Children: Diagnostic and Cultural Challenges | 87 | 16 Behavioral Neuroanatomy: An Introduction | 5 |
| PRACTICE AREAS/SETTINGS | | INDUSTRY-SUPPORTED SYMPOSIUM | |
| TOPIC 14: PSYCHIATRIC ADMINISTRATION AND SERVICES: PUBLIC, PRIVATE, AND UNIVERSITY | | 29 Beyond Neurochemistry: The Implications of Neurocircuitry for Understanding and Managing Psychiatric Disorders | 12 |
| COURSES | | LECTURE | |
| 43 Personnel Management for Clinician-Administrators | 15 | 19 Evolution: The Missing Basic Science That Brings Psychiatry Coherence and Deeper Empathy | 75 |
| 44 Money Matters I: Using Theory in Clinical Practice | 15 | SCIENTIFIC AND CLINICAL REPORT | |
| 67 Money Matters II: Advanced Ad Hoc Clinical Seminar | 41 | 41 Brainstem Control of Neurotic and Psychotic Processes | 47 |
| LECTURE | | SYMPOSIA | |
| 4 Administrative Adventures in Public Psychiatry: 1967-2005 | 17 | 51 Neuroscience and Dynamic Psychiatry | 60 |
| SCIENTIFIC AND CLINICAL REPORT | | 52 Disturbed Fronto-Limbic Brain Circuitry: How Specific Is It for Different Psychiatric Disorders? | 60 |
| 80 Changing Trends in Psychiatric Emergency Room Patients in Large Urban Hospitals | 72 | 76 New Scientific Advances in the Neurobiology of Behavior | 81 |
| | | 102 Neurobiology of Compulsive Reward-Seeking | 96 |
| | | ISSUE WORKSHOP | |
| | | 69 Self-Awareness Deficits in Schizophrenia and Cocaine Abuse | 68 |

| | Page # | | Page # |
|---|--------|--|--------|
| TOPIC 17: BRAIN IMAGING | | ISSUE WORKSHOPS | |
| COURSE | | 89 Unexplained Medical Symptoms in a Pediatric Population | 74 |
| 79 Introduction to Transcranial Magnetic Stimulation (TMS) | 51 | 95 Autism: Parents as Therapists | 87 |
| SCIENTIFIC AND CLINICAL REPORT | | 121 Effect of Maternal Depression on the Cognitive and Emotional Development of Children | 91 |
| 26 Emotion Processing in BPD: An fMRI Perspective | 24 | TOPIC 19: CONSULTATION-LIAISON PSYCHIATRY | |
| SYMPOSIUM | | ADVANCES IN RESEARCH | |
| 108 New Developments in Neuroimaging in BPD | 97 | Risk Factors | 20 |
| | | Psycho-Oncology | 20 |
| TOPIC 18: CHILD AND ADOLESCENT PSYCHIATRY AND DISORDERS | | CLINICAL CASE CONFERENCE | |
| CONTINUOUS CLINICAL CASE CONFERENCES | | 2 Consultation/Liaison Casebook Challenge: Strategies and Limitations in Establishing Competency | 40 |
| 1 Control What You Can: Successful Treatment of Teenagers in Chronic Pain, Part 1 | 14 | COURSES | |
| 1 Control What You Can: Successful Treatment of Teenagers in Chronic Pain, Part 2 | 40 | 33 Psychiatric Consultation in Long-Term Care | 13 |
| COURSE | | 60 Dynamic Psychotherapy for Cancer Patients and Their Spouse | 39 |
| 103 Adolescent Psychiatry: Enhancing Clinical Skills | 85 | FOCUS LIVE SESSION | |
| FOCUS LIVE SESSION | | 3 Psychosomatic Medicine: Consultation-Liaison Psychiatry and Beyond | 20 |
| 3 Child and Adolescent Psychiatry | 27 | FORUM | |
| INDUSTRY-SUPPORTED SYMPOSIUM | | 5 How Psycho-Oncology Came to Be | 51 |
| 3 Management of Disruptive Behavioral and Pervasive Developmental Disorders | 2 | INDUSTRY-SUPPORTED SYMPOSIUM | |
| ROUND TABLE DISCUSSION | | 28 Emerging Best Practices in the Management of Behavioral Emergencies | 12 |
| Safety and Efficacy of SSRI Antidepressants in Children and Adolescents: What Do We Know and When Did We Know It? | 42 | RESEARCH ADVANCES IN MEDICINE | |
| SCIENTIFIC AND CLINICAL REPORTS | | Immunosenescence and Rheumatoid Arthritis | 42 |
| 13 ADHD Symptoms and Behavior Improved With Modafinil Pediatric Formulation | 23 | Research Advances in Cardiovascular Diseases | 42 |
| 23 Ethnicity and the Prediction of Substance Abuse in Hospitalized Adolescents | 24 | Diabetes Update 2005 | 42 |
| 47 Pediatric Formulation of Modafinil Effective in Children and Adolescents With ADHD | 48 | Vascular Diseases, Oxidative Stress, and Depression | 42 |
| 48 Modafinil Pediatric Formulation Has Early and Sustained Effect in ADHD | 48 | Stress, Depression, and the Metabolic Syndrome | 42 |
| 49 Polypharmacy Among Youths: How Prevalent Is It? | 48 | SCIENTIFIC AND CLINICAL REPORTS | |
| 95 Bipolar Prodromal Patterns Among Amish Youth | 90 | 2 Teaching Psychosomatic Medicine in Primary Care Residencies: Current Status | 22 |
| 97 Childhood Disorders in Early- Versus Late-Onset Bipolar Disorder | 90 | 78 Depression-Related Impairment of Baroreflex in Heart Failure | 71 |
| SYMPOSIA | | 81 Data From a Psychiatric Emergency Service Using an Electronic Medical Record | 72 |
| 64 Emerging Frontier of Psychiatry: Juvenile Justice | 78 | 82 Implementing a Mixed Psychiatric and Somatic Care Unit in a General Hospital | 72 |
| 71 Pediatric Bipolar Disorder: Phenomenology and New Treatment Options | 80 | 93 Assessing Anxiety With the Memorial Anxiety Scale for Prostate Cancer | 89 |
| COMPONENT WORKSHOPS | | SYMPOSIUM | |
| 16 Early Diagnosis in Specific Mental Disorders in Toddlers and Preschoolers | 24 | 112 Translating Risk Research Into Comorbidity Intervention Research | 98 |
| 37 SSRIs and Suicide: Lessons Learned and Implications for Future Treatment Guidelines | 66 | COMPONENT WORKSHOPS | |
| | | 41 Psychosomatic Medicine: An Update on a New Subspecialty | 67 |
| | | 47 How to Lead an Effective Treatment Team | 72 |
| | | ISSUE WORKSHOPS | |
| | | 33 Decisional Capacity in the Consultation/Liaison Setting: Controversies and Difficulties | 44 |

(Continued next page)

| | Page # |
|--|--------|
| 36 Teaching Psychosomatic Medicine for Primary Care Physicians: What, How, and Where? | 44 |
| 58 Clinical Decisions: Guidelines, Indicators, and Algorithms | 67 |
| 92 Fibromyalgia: Current Understanding and Future Directions | 87 |
| 98 Bariatric Surgery: Psychiatric Considerations | 87 |
| 100 Caring for the Medically Ill Psychotic Patient: Clinical, Legal, and Ethical Dilemmas | 87 |
| 105 Helping Patients Cope With Cancer: How to Make a Difference | 88 |
| 116 Fellowship Training in Psychosomatic Medicine: What to Expect From Accredited Programs in a New Subspecialty | 91 |
| 128 The Future of Psychosomatic Medicine in the U.S. and Abroad | 92 |

TOPIC 20: CROSS-CULTURAL AND MINORITY ISSUES

COURSE

| | |
|---|---|
| 1 <i>DSM-IV-TR</i> Cultural Formulations: Diagnosis and Therapy | 1 |
|---|---|

SCIENTIFIC AND CLINICAL REPORT

| | |
|--|----|
| 25 Use of the PHQ-9 for Screening and Treatment of Major Depressive Disorders in Chinese Americans | 24 |
|--|----|

SYMPOSIA

| | |
|---|----|
| 15 Ethnopsychopharmacology: An Update on Cross-Cultural Aspects of Mood and Anxiety Disorders | 32 |
| 32 Medical Comorbidity in the U.S. and France: Vive La Difference! | 55 |
| 81 Cultural Aspects of Psychiatric Diagnosis: Toward a New Classification | 82 |
| 97 Transcultural Arab Perspective on Substance Abuse and Dependence | 95 |

COMPONENT WORKSHOPS

| | |
|---|----|
| 11 Somatization and Stigma in Asians: Cultural Challenges in Practice | 18 |
| 24 Ethnicity, Culture, and Response to Disaster Among Hispanics | 43 |
| 39 From Cradle to Grave: The Impact of Incarceration on African-American Families | 66 |
| 42 Improving Diagnostic and Therapeutic Skills: A Cross-Cultural Perspective | 67 |
| 50 Indian Health Service Mental Health Update and Planning for the Future | 72 |

ISSUE WORKSHOPS

| | |
|--|----|
| 42 Cultural Competence in the Clinical Encounter: Irma Bland and Evelyn Lee | 45 |
| 52 The Long-Term Effects of Violence in Shaping Minority Communities | 50 |
| 113 Challenges in Teaching Cultural Issues to Psychiatric Residents: Perspectives From Residents and Faculty | 88 |

TOPIC 21: DIAGNOSTIC ISSUES

SYMPOSIUM

| | |
|---|----|
| 80 Defining Mental Disorder in <i>DSM-V</i> : Problems and Challenges | 82 |
|---|----|

ISSUE WORKSHOPS

| | |
|--|----|
| 13 Diagnostic Issues for Infancy and Early Childhood: A White Paper for <i>DSM-V</i> | 19 |
| 77 Sexual History: The Art and the Science | 69 |
| 94 Assessment of Capacity: Law, Algorithms, and Videotape | 87 |

TOPIC 22: EPIDEMIOLOGY

SCIENTIFIC AND CLINICAL REPORTS

| | |
|--|----|
| 29 Parental Separation at Birth and Schizophrenia and Depression | 46 |
| 83 Mortality Among Psychotic Patients Within the Northern Finland 1966 Birth Cohort | 89 |
| 84 Outcome and Its Predictors in Schizophrenia in the Northern Finland 1966 Birth Cohort | 89 |

TOPIC 23: ETHICS AND HUMAN RIGHTS

COURSE

| | |
|--------------------------|----|
| 74 Bioethics Update 2005 | 51 |
|--------------------------|----|

DISCUSSION GROUP

| | |
|---|----|
| 20 Ethics Evidence and Ethical Skills in Psychiatry (<i>Meet the Authors</i>) | 69 |
|---|----|

FORUM

| | |
|--|----|
| 10 APA and the Pharmaceutical Industry | 92 |
|--|----|

SCIENTIFIC AND CLINICAL REPORT

| | |
|---|----|
| 34 Ethical and Legal Implications of Psychiatric Evaluation of Pediatric Gastric Bypass | 47 |
|---|----|

SYMPOSIA

| | |
|--|----|
| 26 The Bioethics of Treating Psychoses | 35 |
| 56 Soviet/Russian Psychiatry: 15-Year Evolution, David Lozovsky Memorial | 76 |

COMPONENT WORKSHOPS

| | |
|--|----|
| 8 Ten Ways to Stay Out of Trouble: Ethics and Etiquette | 18 |
| 14 Psychiatric Ethics in the U.S. and Throughout the World | 24 |

ISSUE WORKSHOPS

| | |
|--|----|
| 27 Are There Limits to Boundary Limits? | 43 |
| 91 Neutrality Revisited: Is Autonomy What We Most Want? | 86 |
| 115 Sculpting the Sculpture: Redefining Ethical Boundaries in Faculty-Resident Relationships | 91 |

TOPIC 24: FORENSIC PSYCHIATRY

CLINICAL CASE CONFERENCE

| | |
|---|----|
| 3 Crossing the Line: Determining Your Patient Is Too Dangerous to Drive | 64 |
|---|----|

COURSES

| | |
|---|----|
| 8 Infanticide: A Dialogue Between Attorney and Psychiatrist | 2 |
| 15 Risk Assessment for Violence | 5 |
| 28 Assessing the Risk of Violence in Forensic and Sex Offender Settings | 8 |
| 39 The Psychiatrist as Expert Witness | 14 |
| 56 Child Murder by Parents | 27 |
| 64 The Detection of Malingered Mental Illness | 40 |
| 84 Contemporary Malpractice Liability: A Practical Guide | 63 |
| 86 Insanity Defense Evaluations | 63 |

SYMPOSIA

| | |
|--|----|
| 100 How to Determine Capacity for Medical Decision Making in Patients on Medical-Surgical Services | 96 |
| 104 Impulsive Aggression and Criminal Responsibility | 97 |

| | Page # | | Page # |
|---|--------|---|--------|
| COMPONENT WORKSHOPS | | SYMPOSIUM | |
| 22 | 43 | 101 | 96 |
| 31 | 49 | | |
| 44 | 72 | COMPONENT WORKSHOP | |
| 45 | 72 | 27 | 49 |
| ISSUE WORKSHOPS | | ISSUE WORKSHOP | |
| 11 | 19 | 23 | 25 |
| 21 | 25 | TOPIC 27: NEUROPSYCHIATRY | |
| 35 | 44 | ADVANCES IN RESEARCH | |
| 96 | 87 | Applications of Brain Imaging to Psychiatry | 20 |
| 101 | 87 | COURSES | |
| 111 | 88 | 7 | 1 |
| 121 | 91 | 20 | 7 |
| | | 47 | 15 |
| | | 68 | 41 |
| | | 83 | 63 |
| | | INDUSTRY-SUPPORTED SYMPOSIUM | |
| | | 37 | 37 |
| TOPIC 25: GENETICS | | LECTURE | |
| COURSE | | 18 | 69 |
| 40 | 14 | SYMPOSIA | |
| LECTURE | | 70 | 80 |
| 21 | 86 | 110 | 98 |
| MEDICAL UPDATE | | ISSUE WORKSHOPS | |
| 4 | 88 | 10 | 19 |
| SCIENTIFIC AND CLINICAL REPORT | | 75 | 68 |
| 53 | 48 | TOPIC 28: PAIN MANAGEMENT | |
| ISSUE WORKSHOP | | ISSUE WORKSHOPS | |
| 97 | 87 | 31 | 44 |
| | | 70 | 68 |
| TOPIC 26: GERIATRIC PSYCHIATRY | | TOPIC 29: PSYCHIATRIC EDUCATION | |
| COURSES | | COURSES | |
| 4 | 1 | 27 | 8 |
| 88 | 64 | 36 | 14 |
| 100 | 75 | 95 | 65 |
| INDUSTRY-SUPPORTED SYMPOSIUM | | DISCUSSION GROUPS | |
| 12 | 6 | 14 | 45 |
| MASTER EDUCATOR CLINICAL CONSULTATIONS | | 19 | 69 |
| 4 | 21 | | |
| 7 | 46 | | |
| SCIENTIFIC AND CLINICAL REPORTS | | | |
| 21 | 23 | | |
| 36 | 47 | | |
| 37 | 47 | | |

| | Page # | | Page # |
|---|--------|---|--------|
| LECTURE | | SCIENTIFIC AND CLINICAL REPORT | |
| 15 The Future of Psychiatric Education: Six Bridges to Cross | 52 | 75 Restraint Stress Elevates Plasma Cytokines Levels in Superoxide Dependent Manner | 71 |
| SCIENTIFIC AND CLINICAL REPORT | | TOPIC 33: RESEARCH ISSUES | |
| 89 The Uses of Reading Poetry for General Psychiatric Education | 89 | COURSES | |
| SYMPOSIUM | | 12 Doing Research on a Shoestring Budget | 3 |
| 66 The Making of a Competent Psychotherapist: Addressing the New RRC Guidelines | 79 | 98 Rating Scales in Psychiatry | 74 |
| COMPONENT WORKSHOPS | | FORUM | |
| 13 Practical Tips on How to Be a Successful Author | 24 | 3 Getting Into Research With African-American Patients | 26 |
| 23 Disaster Psychiatry: Challenges and Novel Strategies for Residency Training | 43 | LECTURE | |
| 28 Re-Engineering Clinical Research Training: The NPTC | 49 | 13 The Federal Regulation of Biomedical Research: A Study in Quid Pro Quos | 52 |
| 34 A Bitter Pill? Tailoring Medical Training to Fit Our Contemporary Practice | 66 | SYMPOSIA | |
| 35 Roadmap to Recertification: Lifelong Learning | 66 | 20 The End of the Biopsychosocial Model? An Assessment and Alternatives | 33 |
| ISSUE WORKSHOPS | | 37 Evidence-Based Psychiatry: What It Is and What It Is Not | 56 |
| 12 Issues and Challenges in Integrating Interpersonal Psychotherapy Into Psychiatry Departments | 19 | 94 Research During Psychiatry Residency: Should It Be Required or Banned? | 94 |
| 25 The Psychiatry Resident as Educator: Implementation of a Curriculum | 26 | TOPIC 34: SOCIAL AND COMMUNITY PSYCHIATRY | |
| 49 Boundaries and Supervision: Avoiding Legal Risks and Doing Good Clinical Work | 50 | SPECIAL SESSION | |
| 66 Psychotherapy Training and IMGs: The Influence of Cultural Factors | 68 | Global Disasters: Psychiatric Medicine and Public Health Challenges | |
| 71 Fast Tracking Into Child Psychiatry: Who Benefits? Who Suffers? | 68 | 61 | |
| 76 Acceptance Versus Change: Dialectics of Implementing DBT in Residency Training | 69 | CLINICAL CASE CONFERENCE | |
| 87 Residents in the Trenches, But Not Out in the Cold: Integrating Shelter-Based Outpatient Rotations With Online Educational Tools | 74 | 1 House Call: Treading on Privacy in Public Psychiatry | |
| 90 Using Audiovisual Technology to Teach Behavioral Science | 86 | 14 | |
| 107 Got Psych? Increasing Student Involvement in Psychiatry | 88 | COURSE | |
| 112 Using Adult Learning Principles in Resident Psychotherapy Education | 88 | 92 Psychiatry in Corrections | |
| 88 | | 64 | |
| TOPIC 30: PSYCHIATRIC REHABILITATION | | SCIENTIFIC AND CLINICAL REPORT | |
| COURSE | | 85 Psychiatric Practices and Patient Outcomes in Assertive Community Treatment | |
| 97 Recovery From Mental Illness and Stigma: Integrating Medicine and Rehabilitation | 74 | 89 | |
| SYMPOSIUM | | ISSUE WORKSHOPS | |
| 46 Rehabilitation of the Mad or Bad: Globally | 58 | 34 Psychiatric Hospice on an ACT Team: When Mental Illness Is Terminal | 44 |
| TOPIC 31: PSYCHOANALYSIS | | 59 Treatment of Mental Illness in U.S. Jails and Prisons | 67 |
| LECTURE | | TOPIC 35: STRESS | |
| 16 The Conflicting Worldviews of Sigmund Freud and Oskar Pfister: Keys to Understanding Patients | 65 | DISCUSSION GROUP | |
| SYMPOSIUM | | 8 Coping With Trauma (<i>Meet the Authors</i>) | |
| 62 Psychoanalysis and Psychosomatic Illness: A Modern Mind-Body Perspective | 78 | 20 | |
| TOPIC 32: PSYCHOIMMUNOLOGY | | MASTER EDUCATOR CLINICAL CONSULTATION | |
| MEDICAL UPDATE | | 5 PTSD and Deployment Mental Health | |
| 3 Okay Inside Their Head, But What's Under Their Nose? | 69 | 42 | |
| 69 | | SYMPOSIUM | |
| TOPIC 33: RESEARCH ISSUES | | 95 The War Comes Home: Psychosocial and Psychosomatic Consequences of Deployment | |
| COURSES | | 94 | |
| FORUM | | ISSUE WORKSHOP | |
| LECTURE | | 122 Presenteeism and Absenteeism: Underrecognized and Undertreated at Work | |
| 13 The Federal Regulation of Biomedical Research: A Study in Quid Pro Quos | | 91 | |

Page #

TOPIC 36: SUICIDE

DISCUSSION GROUP

- 15 Assessment and Treatment of Suicidal Patients (*Meet the Authors*) 45

LECTURE

- 1 Suicide Risk Assessment: Evidence-Based Psychiatry 10

SCIENTIFIC AND CLINICAL REPORTS

- 5 Exposure to SSRIs Reduces Suicidality in Elderly Patients With Depression 22
- 6 Suicidality in Youth With Bipolar Disorder: A Community-Based, Multisite Investigation 22
- 7 Peripheral Benzodiazepine Receptors in Suicide 22

SYMPOSIUM

- 109 Evidence-Based Practices in Suicide Prevention 98

COMPONENT WORKSHOP

- 25 Suicide Among Ethnic Elders 43

ISSUE WORKSHOPS

- 9 Physician Suicide: What Can Be Done? 19
- 47 Responding to the Impact of Suicide on Clinicians 50

TOPIC 37: VIOLENCE, TRAUMA, AND VICTIMIZATION

CLINICAL CASE CONFERENCE

- 4 Commanded to Kill: Approaching the Treatment of a Murderous Grandmother 85

COURSES

- 9 Psychiatric Interventions in Disasters and Public Health Emergencies: Theory to Practice 2
- 22 Rebuilding Shattered Lives: Treating Complex Post-Traumatic Stress Disorder 7
- 37 Disaster Psychiatry: Terrorism, Trauma, and Things to Do 14
- 70 Personality and Political Behavior 41
- 91 Men Sexually Abused as Boys: Meanings, Consequences, and Treatments 64

LECTURES

- 3 Terrorism and Disaster: Population Mental Health Approaches 16
- 9 I Am the Central Park Jogger: A Story of Hope and Possibility 36

SCIENTIFIC AND CLINICAL REPORTS

- 68 Effects of Terrorism on Psychopathology: Two Years After 9/11 71
- 69 9/11: Terrorism, Psychiatric Symptoms, Service Utilization, and Alcohol Intake 71

SYMPOSIA

- 2 9/11 in New York City: Learning From the Past and Looking to the Future 29
- 21 Behind Closed Doors: The Hidden Family: Violence and Abuse Issues Worldwide 33
- 67 Violence From Cradle to Grave: Battering, Stalking, Child Abuse, and Elder Abuse 79
- 88 New Directions in Psychiatric Aspects of Terrorism: Causes, Consequences, Responses 93
- 99 Childhood Sexual Abuse: Victims and Perpetrators 95

Page #

COMPONENT WORKSHOPS

- 6 Children Under Fire: Enhancing Psychiatry's Global Response 18
- 12 Behind Closed Doors: The Hidden Family: Domestic Violence, Cross-Cultural, and Ethnic Influences 18

ISSUE WORKSHOP

- 119 Building Trauma Resiliency: The Impact of Music on the Life of Holocaust Survivors 91

MEDIA WORKSHOPS

- 2 Postgenocide Psychological Trauma in Film: *Forbidden Games* 20
- 6 *Intergenerational Family Abuse*: A Documentary Film 45

TREATMENTS

TOPIC 38: BEHAVIOR AND COGNITIVE THERAPIES

COURSES

- 31 Cognitive Therapy for Schizophrenia 8
- 34 Engaging Resistant and Difficult-to-Treat Patients 14
- 51 Cognitive Therapy for Severe Mental Disorders 26
- 93 Introduction to Cognitive-Behavioral Therapy 64

ISSUE WORKSHOPS

- 56 Computer-Assisted CBT in Education and Treatment 50
- 62 Anger Management: Evaluation and Treatment 67
- 125 Cognitive Therapy for Psychosis for Psychiatrists: Basic Technique 92

TOPIC 39: COMBINED PHARMACOTHERAPY AND PSYCHOTHERAPY

COURSES

- 42 A Psychodynamic Approach to Treatment Refractory Mood Disorders 15
- 101 Treating Comorbid Adult ADHD by Combining Medication and Cognitive Therapy 85

MASTER EDUCATOR CLINICAL CONSULTATIONS

- 2 Split and Integrated Treatment: Pharmacotherapy and Psychotherapy 17
- 8 Psychodynamics in the Era of Psychopharmacology 46

SCIENTIFIC AND CLINICAL REPORT

- 8 A Combined Treatment Approach for Adults With ADHD: Results of a Pilot Study of 45 Patients 22

ISSUE WORKSHOPS

- 1 Treating PTSD: Combining Psychotherapy and Pharmacotherapy 18
- 17 Split Therapy: Psychotherapy and Pharmacotherapy Procedures and Strategies 25

| | Page # | | Page # |
|--|--------|---|--------|
| TOPIC 40: COUPLE AND FAMILY THERAPIES | | COMPONENT WORKSHOP | |
| COURSES | | 18 "Y" Psychotherapy: An Integrated, Evidence-Based Psychotherapy Competency Model | 42 |
| 38 Families Coping With Medical Illness: An Integrative Treatment Approach | 14 | ISSUE WORKSHOP | |
| 73 Basic Family Skills for an Inpatient Psychiatrist | 51 | 63 Dynamic Therapy With Self-Destructive Borderline Patients | 67 |
| ISSUE WORKSHOP | | TOPIC 43: OTHER SOMATIC THERAPIES | |
| 86 Individuals and Conjoint Approaches to Couples Therapy | 73 | COURSES | |
| TOPIC 41: GROUP THERAPY | | 21 Kundalini Yoga Meditation Techniques for Psychiatric Disorders | 7 |
| ISSUE WORKSHOPS | | 53 ECT Practice Update | 26 |
| 85 Therapeutic Use of Movie Clips in Outpatient and Inpatient Group Treatment | 73 | 62 The Way of Yoga and Herbs in the Treatment of Stress, Depression, and Aggression | 40 |
| 114 Group Therapy of Substance Abuse | 91 | 81 Using Neurofeedback in Your Practice I: Demonstration | 63 |
| TOPIC 42: INDIVIDUAL PSYCHOTHERAPIES | | 96 Using Neurofeedback in Your Practice II: Applications | 74 |
| ADVANCES IN PSYCHOTHERAPY | | INDUSTRY-SUPPORTED SYMPOSIUM | |
| Neurobiological Underpinnings of Psychotherapy | 27 | 14 Brain Stimulation: New Treatments for Mood Disorders | 6 |
| CONTINUOUS CLINICAL CASE CONFERENCES | | SCIENTIFIC AND CLINICAL REPORT | |
| 2 Weathering the Storm: Management of Complex Transferences, Part 1 | 64 | 32 The Impact of Electroconvulsive Therapy on Quality of Life and Function | 47 |
| 2 Weathering the Storm: Management of Complex Transferences, Part 2 | 85 | TOPIC 44: PSYCHOPHARMACOLOGY | |
| COURSES | | COURSES | |
| 13 Short-Term Psychodynamic Supportive Psychotherapy Treatment of Depression | 5 | 57 Drug Treatment of Schizophrenia | 27 |
| 17 Interpersonal Psychotherapy | 5 | 69 Med-Psych Drug-Drug Interactions | 41 |
| 24 Understanding the Person Behind the Illness: An Approach to Psychodynamic Formulation | 7 | 90 Psychiatry Update: In Spanish | 64 |
| 25 Basic Hypnosis: Principles and Applications | 8 | INDUSTRY-SUPPORTED SYMPOSIA | |
| 26 Dream Translation: One Empirically-Based Approach | 8 | 8 Expanding Uses of Atypical Antipsychotics: Addressing Real-World Challenges | 4 |
| 32 Brief Psychodynamic Psychotherapy: The Core Conflictual Relationship Theme | 8 | 25 Bipolar Disorder: Treating Through the Entire Spectrum | 11 |
| 45 Advanced Hypnosis: Applications in Psychiatry | 15 | SCIENTIFIC AND CLINICAL REPORTS | |
| 48 Davanloo's Intensive Short-Term Dynamic Psychotherapy in Clinical Practice | 15 | 9 Characteristics of Diversion and Misuse of ADHD Medications | 22 |
| 49 The Advanced Practice of Psychotherapy | 26 | 10 Combined Treatment of Venlafaxin and ECT in Treatment-Resistant Depressive Patients | 22 |
| 89 Interpersonal Psychotherapy | 64 | 20 Efficacy and Safety of Ziprasidone in First-Episode Psychosis | 23 |
| 94 Advanced Interviewing Techniques | 64 | 22 Metabolic Syndrome in Schizophrenia | 23 |
| DISCUSSION GROUP | | 59 Thinking About Adverse Drug Effects: Lessons From the Psychology of Risk and Decision Making for Clinical Psychopharmacology | 70 |
| 18 Psychodynamic Psychiatry in Clinical Practice (<i>Max the Axioms</i>) | 65 | 60 Sildenafil Treatment of SSRIs-Associated Sexual Dysfunction in Nonresponders of a Double-Blind, Placebo-Controlled Study: Single-Blind, Open-Label Results | 70 |
| SCIENTIFIC AND CLINICAL REPORTS | | 61 Association Between SSRI Side Effects and Adherence to Modern SSRIs | 70 |
| 17 Affect Change in Dreams in Psychotherapy | 23 | 70 Clozapine, Olanzapine, and Haloperidol Treatment of Violent Patients With Schizophrenia | 71 |
| 18 The Empathic Stance | 23 | 87 An Investigation of Cognitive Effects of Rivastigmine in Schizophrenia | 89 |
| SYMPOSIA | | 88 Rivastigmine or Galantamine for the Treatment of Schizophrenic Cognitive Impairment | 89 |
| 30 The Art and Science of Brief Therapies | 54 | 91 Antidepressants for Depression in the Medically Ill: Are They Effective? | 89 |
| 69 Advances and Issues in Psychodynamic Psychotherapy | 79 | | |
| 91 Psychotherapy Is Universally Future Oriented | 93 | | |

| | Page # |
|--|--------|
| SYMPOSIA | |
| 17 Novel Targets for Novel Neuropsychiatric Drugs | 32 |
| 18 Use of Concomitant or Adjunctive Medications in Schizophrenia | 33 |
| 34 Atypical Antipsychotics: Treatment of Agitation Across Mental Disorders | 55 |
| 39 Complex Pharmacotherapy Versus Polypharmacy | 56 |
| 78 Teaching Psychopharmacology for the 21st Century | 82 |

| | |
|---|----|
| ISSUE WORKSHOPS | |
| 14 Ethnicity and Psychopharmacology: Research and Clinical Implications | 25 |
| 67 Cardiovascular Complications of Psychiatric Treatments | 68 |

TOPIC 45: TREATMENT TECHNIQUES AND OUTCOME STUDIES

| | |
|--|----|
| COURSES | |
| 14 Using Boundary Crossings as Creative Therapy Instead of Slippery Slopes | 5 |
| 41 Office-Based Buprenorphine Treatment of Opioid-Dependent Patients | 14 |
| 50 Assessment and Treatment of Drug-Induced Movement Disorders | 26 |
| 71 Recognition and Treatment of Complicated Grief | 41 |

| | |
|---|----|
| DISCUSSION GROUP | |
| 1 Medically Cleared for Transfer to Psychiatry: How to Evaluate the Medical Patient With Changed Mental Status (<i>Meet the Authors, for Residents</i>) | 15 |

| | |
|---|----|
| RESEARCH CONSULTATION | |
| 3 Evaluating the Effects of Treatments for Depression | 70 |

| | |
|--|----|
| SCIENTIFIC AND CLINICAL REPORT | |
| 74 Does Exercise Have a Place in Psychiatry? | 71 |

| | |
|---|----|
| SYMPOSIA | |
| 40 Integrating and Sequencing Treatments for Borderline Patients | 57 |
| 59 Advances in Prevention: Science and Clinical Strategies | 77 |
| 93 Review and Update of Eye Movement Desensitization and Reprocessing | 94 |
| 111 How to Practice Evidence-Based Medicine | 98 |

| | |
|--|----|
| COMPONENT WORKSHOP | |
| 1 Keeping APA Practice Guidelines Current: Alzheimer's, Delirium, and Eating Disorders | 17 |

| | |
|---|----|
| ISSUE WORKSHOPS | |
| 16 Practical Clinical Trials Comparing Psychopharmacological Treatments | 25 |
| 43 A New Model for the Treatment of Relational Disorders | 45 |
| 108 Outcomes and Therapeutic Processes of Acute Partial Hospitalization | 88 |

OTHER ISSUES

TOPIC 46: CREATIVITY AND THE ARTS

| | |
|---|----|
| FORUM | |
| 5 Identity as Psychiatrists: Heritage and Creativity in This Unique Specialty | 51 |

| | Page # |
|---|--------|
| SCIENTIFIC AND CLINICAL REPORT | |
| 19 Creative Thinking: A Door to the Interior Life That Enhances the Psychotherapeutic Process | 23 |

| | |
|--|----|
| SYMPOSIUM | |
| 79 Toxic Love: Cinema on Romantic Love and Its Pathologies | 82 |

| | |
|--|----|
| ISSUE WORKSHOPS | |
| 37 Shakespeare, Psychiatry, and Psychopathology | 44 |
| 51 Renewing Integrity Through Film: An Essential Virtue of Professionalism | 50 |
| 53 The Movies and the Mind | 50 |
| 81 Philip Pullman's <i>The Golden Compass</i> : Coming of Age in a Fractured World | 73 |
| 99 Hitchcock's <i>Psycho</i> : Madness, Mothers, and Murder | 87 |

TOPIC 47: GENDER ISSUES

| | |
|---|----|
| ISSUE WORKSHOPS | |
| 20 Dual-Career Couples: Multiple Roles, Innovative Solutions | 25 |
| 79 Female Knockouts: Women Perpetrators and Victims of Partner Violence | 73 |

TOPIC 48: HEALTH SERVICES RESEARCH

| | |
|--|----|
| SCIENTIFIC AND CLINICAL REPORTS | |
| 76 Treating Depression in a VA Primary Care Integrated Behavioral Health Model | 71 |
| 90 Variations in Depression Treatment Quality: Medicaid Versus Commercial Claims | 89 |

| | |
|--|----|
| SYMPOSIUM | |
| 23 Improving Care for Trauma-Related Psychiatric Disorders in General Medical Settings | 34 |

| | |
|---|----|
| COMPONENT WORKSHOP | |
| 48 Why Business Needs Quality Care for Depression, Anxiety, and Substance-Use Disorders | 72 |

| | |
|---|----|
| ISSUE WORKSHOP | |
| 126 Finding Effective Adolescent Drug Treatment: Assessment of 144 Leading Programs | 92 |

TOPIC 49: HISTORICAL QUESTIONS

| | |
|---|---|
| COURSE | |
| 30 Psychiatric Revolutions: A History of Psychiatry | 8 |

| | |
|--|----|
| COMPONENT WORKSHOP | |
| 32 The Voice of APA Past and Present: Considerations for an Oral History Project | 49 |

TOPIC 50: INFORMATION TECHNOLOGY

| | |
|--|----|
| SYMPOSIUM | |
| 84 National Health Information Initiative and Psychiatry | 83 |

| | Page # |
|--|--------|
| 87 Efficacy and Safety of SSRI Medications in Children and Adolescents | 92 |
| 90 Improving Medical Care for Patients With Serious Mental Disorders | 93 |
| 113 Postpartum Mood Disorders | 99 |
| ISSUE WORKSHOPS | |
| 6 Managing Distress and Psychiatric Disorder After Terrorism | 19 |
| 7 The Psychiatric Consequences of the World Trade Center Attack in Disaster Relief Workers | 19 |
| 22 Research Training and Career Development: NIMH Opportunities | 25 |
| 26 Meeting the Challenges of Correctional Mental Health Research | 26 |
| 32 Strategies for Success for Early Career Academic Psychiatrists, Part 1: Writing for Publication | 44 |
| 41 Psychiatrists Intervening Upstream: Good Practices for Preventing Violence in Children, Youth, and Families | 45 |
| 44 Topics in Psychosomatic Medicine: Fatigue in Cancer and AIDS | 49 |
| 46 Strategies for Success for Early Career Academic Psychiatrists, Part 2: Promotion | 50 |
| 50 Psychiatric Comorbidities in HIV Infection | 50 |
| 72 The Reach of Mental Illness Stigma | 68 |
| 80 Polypharmacy: New Advances in Supporting Psychiatric Practice | 73 |
| 102 Adherence in Schizophrenia: Role of Attitude, Family, and Environment | 87 |
| 104 Developing Targeted Interventions for Autistic Spectrum Disorders | 87 |
| 110 Educating Patients and Families About BPD | 88 |

TOPIC 55: PATIENT SAFETY

COMPONENT WORKSHOP

| | |
|--|----|
| 20 Patient Safety: Evaluating an Adverse Event and Implementing Safeguards | 43 |
|--|----|

TOPIC 56: PERSONAL DIGITAL ASSISTANT'S (PDA)

COURSES

| | |
|---|----|
| 65 How to Use your Palm OS PDA in Psychiatric Practice: Basic | 40 |
| 78 How to Use Your Palm OS PDA in Psychiatric Practice: Advanced Topics | 51 |
| 82 How to Use Your Pocket PC PDA in Psychiatric Practice | 63 |

TOPIC 57: PRESIDENTIAL THEME: "PSYCHOSOMATIC MEDICINE: INTEGRATING PSYCHIATRY & MEDICINE"

ADVANCES IN PSYCHOSOMATIC MEDICINE

| | |
|---|----|
| Advances in Psychosomatic Medicine: Psychiatric Care of the Medically Ill | 40 |
|---|----|

ADVANCES IN RESEARCH

| | |
|--|----|
| Treating Depression After a Heart Attack: Influencing Death? | 20 |
|--|----|

COURSE

| | |
|--|----|
| 75 MAPSS: Computer-Assisted Screening of Medical Patients for Mental Disorders | 51 |
|--|----|

DISCUSSION GROUPS

| | |
|---|----|
| 4 Practical Psychosomatics: Treating Women Patients | 15 |
| 7 Breast Cancer: Issues in Psychotherapy | 20 |

FORUM

| | |
|---|----|
| 11 A Stitch in Time: Psychiatric and Medical Comorbidity in African Americans Across the Life Cycle | 92 |
|---|----|

INDUSTRY-SUPPORTED SYMPOSIA

| | |
|--|----|
| 4 Psychosomatic Illness: A 21st-Century Perspective | 3 |
| 23 Fibromyalgia: A Disorder at the Medicine and Psychiatry Interface | 10 |
| 45 Impact of Stress and Anxiety on Brain and Body | 84 |

MASTER EDUCATOR CLINICAL CONSULTATION

| | |
|---|----|
| 6 Psychosomatics and the Medically Complex Patient: Sorting Out Axis I, II, and III | 42 |
|---|----|

PRESIDENTIAL SYMPOSIA

| | |
|--|----|
| 3 Toward an Integrated Subspecialty of Psychosomatic Medicine | 53 |
| 4 Mental Health and Sub-Saharan Africa: A 21st Century Perspective | 53 |
| 5 The Interface of Psychiatry and Medicine: Disorders of Affect, Behavior, and Cognition | 75 |
| 6 Heart, Mind, and Soul: Psychiatric Issues in Cardiac Health for African Americans | 76 |

SCIENTIFIC AND CLINICAL REPORTS

| | |
|--|----|
| 4 Psychosocial Aspects of Automatic Internal Cardioverter Defibrillator Use | 22 |
| 39 The Integrated Management of Medically Unexplained Symptoms | 47 |
| 40 Medical and Psychiatric Comorbidities of a Substance Abusing Public Assistance Population | 47 |
| 54 Metabolic Syndrome in Psychiatric Inpatients Receiving Antipsychotics | 48 |

SYMPOSIA

| | |
|--|----|
| 12 Bereavement, Depression, and PTSD: Boundary and Treatment Issues | 31 |
| 16 Psychosomatic Medicine: Managing the High Rates of Mortality and Morbidity | 32 |
| 29 Psychosomatic Medicine: Integrating Epidemiology, Psychiatry, and Medicine | 54 |
| 31 Posttraumatic Stress and Medical Illness: Interdisciplinary Perspectives | 54 |
| 33 Medical and Psychiatric Issues in the Mexican-American Population in the U.S. | 55 |
| 74 A World View of Medical and Psychiatric Comorbidity | 81 |
| 75 Running a Medicine/Psychiatry Service: The Duke Experience | 81 |
| 92 Psychosomatic Medicine in Psychiatric Private Practice | 94 |

COMPONENT WORKSHOP

| | |
|--|----|
| 33 When It's Not All in Your Head: Health, Mental Illness, Ethnicity, and Recovery | 49 |
|--|----|

ISSUE WORKSHOPS

| | |
|--|----|
| 4 Doctor, Why Do I Still Have This Pain? The Physician's Psychosomatic Dilemma | 19 |
| 23 Collaborative Care Models for Depression in Primary Care | 25 |
| 57 Impact of Violence on Pregnancy, Birth, and Parenthood: The Interface Between Psychiatry and Obstetrics | 67 |
| 60 In From the Cold: Perspectives on Social Support in Psychiatry and Medicine | 67 |
| 73 Beneath the Sword of Damocles: Living in the Limbo of Remission From Cancer | 68 |
| 83 Psychosomatic Medicine With a Developmental Twist: Child Consultation/Liaison for Adult Psychiatrists | 73 |

TOPIC 58: PROFESSIONAL AND PERSONAL ISSUES

COURSES

- 55 Treating Medical Students and Physicians 27
- 59 Improving Your Presentation Skills: A Coaching Approach 39

DISCUSSION GROUP

- 22 The Benefits of Yoga in Psychiatry 85

LECTURE

- 11 Leadership Through Example: Mentorship and Networking 42

SYMPOSIA

- 38 How to Launch a Successful Private Practice, Part 3 56
- 54 Psychiatry and the Pharmaceutical Industry: Where Is the Boundary? 60
- 83 APA Women Presidents: Lessons Learned, Road Ahead 83

COMPONENT WORKSHOPS

- 5 Early Career Psychiatrists as Leaders 18
- 20 Closing Practice: What Every Psychiatrist's Office and His/Her Family Should Know 43
- 21 Novel Careers in Psychiatry: Women Who Have Made Their Own Way 43
- 40 Doctor, Your Child Is Calling 67

ISSUE WORKSHOPS

- 5 Risk Management Issues in Psychiatric Practice 19
- 8 Mental Health of Physicians: Whose Business Is It? 19
- 28 Children of Psychiatrists: Listen and Learn 43
- 29 ABPN and APA Perspectives on Maintenance of Certification 44
- 30 How to Launch a Successful Private Practice, Part 1 44
- 45 How to Launch a Successful Private Practice, Part 2 49
- 65 Reinventing Careers: Transitions and Later-Life Strategies for Psychiatrists 68
- 88 Grandparents and Grandchildren: Child Psychiatric and Family Perspectives 74
- 106 Challenges When Psychiatrists Seek Treatment for Themselves 88
- 118 Women as Leaders: Opportunities and Strategies for Success 91
- 124 Treating Physicians in a Cultural Context: Some Unique Issues 91

TOPIC 59: RELIGION, SPIRITUALITY, AND PSYCHIATRY

COURSE

- 5 Transpersonal Psychiatry: Clinical Applications 1

FORUM

- 8 Culture, Spirituality, and Folk Belief 74

COMPONENT WORKSHOP

- 46 The Conflicting Worldviews of Sigmund Freud and C.S. Lewis 72

ISSUE WORKSHOPS

- 61 Religious and Spiritual Assessment in Clinical Practice 67
- 117 World View and Spirituality in Clinical Practice 91

TOPIC 60: RESIDENT AND MEDICAL STUDENT CONCERNS

DISCUSSION GROUPS

- 6 Tips on How to Be an Effective Psychiatrist (*For Residents Only*) 20
- 9 The Role of Culture in Psychiatric Practice (*For Residents Only*) 41
- 13 Career Building in Academic and Nonacademic Psychiatry (*For Residents Only*) 45

FORUM

- 9 ABPN Update: Certification in Psychiatry and Its Subspecialties 74

RESIDENTS' SESSION

- Meet the Experts: Sunny-Side Up 13

COMPONENT WORKSHOP

- 30 Quotes and Misquotes: Resident Physicians Working With the Media 49

ISSUE WORKSHOPS

- 2 Oral Boards Boot Camp Updated 19
- 39 Drug Companies in Training Clinics: Economic Necessity Versus Undue Influence 44

TOPIC 61: STIGMA/ADVOCACY

COMPONENT WORKSHOP

- 3 What Not to Do: The Media Talks Back About Public Affairs 17

ISSUE WORKSHOP

- 67 The Marketing of Psychiatric Medications to Patients: Where Do We Stand? 68

TOPIC 62: TELEPSYCHIATRY

COURSE

- 61 Expanding Health Care Delivery? Let Telepsychiatry Help! 40

ISSUE WORKSHOP

- 54 American Indian Telepsychiatry: Bridging Culture and Distance 50

TOPIC 63: WOMEN'S HEALTH ISSUES

COURSE

- 87 Management of Psychiatric Disorders in Pregnant and Postpartum Mothers 63

INDUSTRY-SUPPORTED SYMPOSIA

- 33 Advances in the Treatment of Mood and Anxiety Disorders in Women, Part 1 13
- 34 Advances in the Treatment of Mood and Anxiety Disorders in Women, Part 2 39

MASTER EDUCATOR CLINICAL CONSULTATIONS

- 9 Managing Menopause 66
- 10 Premenstrual Mood Disorders 66
- 11 Psychiatric Aspects of Reproduction in Chronically Mentally Ill Women 69

| | Page # | | Page # |
|---|--------|---|--------|
| MEDICAL UPDATE | | ISSUE WORKSHOP | |
| 2 Stress-Induced Anovulation: Mind Over Matter | 46 | 18 Treatment of Depression During Pregnancy | 25 |
| SYMPOSIA | | | |
| 5 A Sex/Gender Research Agenda for <i>DSM-V</i> | 30 | | |
| 41 Maternal Depression and Comorbidities: Impact on Infants | 57 | | |
| 44 Perinatal Depression: Prevalence, Screening Accuracy, and Intervention | 58 | | |
| 89 Leadership in Psychiatry: Women Leaders in Advocacy and Services | 93 | | |

- Brady, Kathleen T..... 2, 31, 70
 Bragg, Jr., John E..... 87
 Brandt, Lena..... 23
 Brasch, Jennifer S..... 72
 Braslow, Joel T..... 49
 Bray, Robert M..... 90
 Bregman, Joel D..... 66
 Breitbart, William..... 49, 89
 Breiter, Hans C..... 81
 Bremner, J. Douglas..... 20, 60
 Brendel, David H..... 33
 Brenner, Ronald..... 43
 Brockman, Richard M..... 60
 Brod, Thomas M..... 63, 74
 Brodkey, Amy C..... 60
 Brody, Seth..... 58
 Brook, David W..... 52, 91
 Brooks, Beth Ann..... 17
 Brooks, John O..... 90
 Brown, E. Sherwood..... 36
 Brown, Eric..... 7
 Brown, Frank N..... 1, 47, 72
 Brown, Larry K..... 50
 Brown, Regina..... 54
 Brown, Richard P..... 22, 40, 59, 68, 85
 Brown, Steve..... 72
 Brown, Thomas E..... 1, 5, 51
 Brundage, Richard..... 80
 Brunette, Mary F..... 29, 36
 Buchanan, Robert W..... 62, 80
 Buchsbaum, Monte..... 7, 98
 Buckley, Peter F..... 12, 36, 68
 Budman, Cathy L..... 68
 Buesching, Don..... 25
 Buie, Stephen E..... 74
 Bulik, Cynthia M..... 6, 59, 71
 Bullon, Antonio E..... 88
 Burdman, Daphne F..... 93
 Burke, Michael..... 71
 Burkholder, Page..... 91
 Burneister, Margit..... 79
 Burmester, Bill..... 64
 Burns, Kathryn A..... 49
 Bursztajn, Harold J..... 20
 Bush, George..... 12, 57
 Butler, Jeremy R..... 14
 Butler, Lisa D..... 99
 Butterfield, Cory..... 43
 Butterfield, Marian I..... 10, 20, 28, 42, 57, 82
 Buysse, Daniel J..... 53
- C
- Cabaj, Robert P..... 49
 Caballero, Maria C..... 54
 Caine, Eric D..... 55
 Calabrese, Joseph R..... 11, 25, 67, 76, 90
 Caldas de Almeida, Jose M..... 18
 Caley, Charles F..... 48
 Calgor, Eve..... 7
 Callahan, Jr., William E..... 44, 49, 56
 Callaway III, Enoch..... 94
 Campbell, William H..... 7, 41, 65
 Campo, Ana E..... 25
 Campo, John..... 14, 40
 Cancro, Robert..... 58
 Candilis, Philip..... 59
 Candillis, Philip..... 26
- Caraballo, Angel A..... 24
 Caracci, Giovanni..... 43
 Cardinali, Daniel P..... 71
 Cardoni, Alex A..... 70
 Cardoso, Graca..... 73
 Carlson, Gabrielle A..... 36
 Carpenter, Linda L..... 4, 37
 Carpenter, Jr., William T..... 15
 Carter, Cameron..... 54, 94
 Carter, Debbie..... 92
 Carter, Diana..... 63
 Carter, Grady..... 59
 Casadebaig, Francoise..... 55
 Casey, David A..... 47, 69
 Casimir, Andy..... 89
 Castellanos, Daniel..... 43
 Castilla-Puentes, Ruby C..... 22, 54
 Castilla-Puentes, Sandra R..... 22, 54
 Castilla-Puentes, Wilma I..... 22, 54
 Castro, Carl A..... 34
 Caton, Carol L.M..... 29
 Caubel, Josephine..... 50
 Chamberlain, John R..... 18
 Chan, Carlyle H..... 26, 40, 51
 Chang, Jacquelyn B..... 67
 Chang, Kiki D..... 11, 48, 76
 Chang, Stella..... 89
 Chaplin, Bill..... 61
 Chapman, Daniel P..... 46, 74, 90
 Chappel, John N..... 64
 Charrow, Robert P..... 52
 Chaudhary, Navjot..... 58
 Chaudhry, Haroon R..... 81
 Chaudhry, Nadeem..... 23
 Chaudhry, Zubaida..... 89
 Chaudron, Linda H..... 25
 Chavez, Mark..... 25
 Chavez-Eakle, Rosa A..... 23
 Cheema, Fahd A..... 81
 Chelminski, Iwona..... 90
 Cheng, Hu..... 24
 Cheng, Jennifer K..... 66
 Cheong, Josepha A..... 46, 65, 86
 Chester, Adam R..... 18
 Chiles, John A..... 45
 Chism, Larissa..... 40
 Chiu, Charles..... 51
 Christodoulou, George..... 28
 Christopher, Eric J..... 81
 Chrzanowski, Daniel T..... 42
 Chu, James A..... 7
 Chung, Christopher K..... 72
 Ciechanowski, Paul S..... 84, 98
 Citrome, Leslie L..... 71
 Clark, Connie..... 74
 Clark, David L..... 5
 Clark, Lee Anna..... 95
 Clark, Marlene..... 73
 Clark, Michelle O..... 66, 76
 Clarkin, John F..... 7
 Classen, Catherine..... 99
 Clauw, Daniel J..... 10
 Clayton, Paula..... 31
 Clemens, Norman A..... 72
 Clothier, Jeffrey L..... 19
 Cocco, Emil F..... 32
 Cocozza, Joseph J..... 78
 Coerver, Katie..... 19
- Coffey, C. Edward..... 15, 47
 Cohen, Carl I..... 43, 96
 Cohen, Judith A..... 2
 Cohen, Lee S..... 66, 99
 Cohen, Lisa J..... 95, 96
 Cohen, Mary Ann..... 18, 91
 Cohen, Michael..... 63, 74
 Cohen, Sheldon B..... 71
 Cole, Steven A..... 25, 89
 Coleman, Yolonda R..... 24, 43
 Coll, Patrick..... 47
 Collins, Gary R..... 91
 Combrinck-Graham, Lee..... 66
 Compton III, Wilson M..... 26, 60, 77
 Conti, Luciano..... 22
 Cook, Ian A..... 17
 Cook, William L..... 30
 Cooke, Edi..... 25
 Coon, Kim A..... 88
 Cooper, Lisa A..... 22
 Cora-Locatelli, Gabriela..... 56
 Cornblatt, Barbara A..... 30
 Cornelius, Jack R..... 50
 Corpuz, Virginia..... 46
 Corrado, Filomena..... 70
 Corral, Maria R..... 63
 Correale, Jennifer..... 91
 Correia, Nestor..... 23
 Corrigan, Patrick W..... 68
 Corwin, Rebecca L..... 96
 Costa, Jr., Paul T..... 32
 Cotter, Gad..... 54
 Courmos, Francine..... 43, 50, 54, 75, 88, 89
 Cowdry, Rex W..... 83
 Cox, John L..... 81
 Cox, Joyce..... 87
 Cox, Paul D..... 88
 Cozza, Stephen J..... 94
 Cozzolino, Edoardo..... 70
 Craft, Suzanne..... 37
 Craven, Marilyn..... 72
 Crivile-Le-Nestour, Annick..... 57
 Crofford, Leslie J..... 10
 Crone, Catherine C..... 47
 Crosby, Alex..... 74
 Crosby, Ross D..... 97
 Crossett, Judith H. W..... 13
 Crow, Scott J..... 6
 Crowley, Brian..... 94
 Cuerdon, Timothy..... 87
 Cullen, Ken..... 95
 Cummings, Jeffrey L..... 9, 13, 39
 Currell, Christoph..... 30
 Curtis, Klara I..... 44
 Curtis, Rodney C..... 44
 Guthbert, Bruce..... 26
 Czobor, Pal..... 71
- D
- D'Alli, Richard E..... 15, 42
 Dalton, Marc E..... 68
 Daly, Patricia A..... 20
 Danforth, Nicole..... 54
 Daumit, Gail L..... 12, 49, 55, 93
 Dave, Nilesh..... 53
 Davenport, Cheryl..... 43
 Davidoff, Donald A..... 75

- Davine, Jonathan S. 30, 86
 Davis, Elizabeth A. 87
 Davis, Jack 7
 Davis, John M. 15
 Davis, Lori L. 3
 de Chiara, Margherita 70
 De Contreras, Gilma R. 54
 De Souza, Claire M. 78
 Deas, Deborah 3, 36
 DeBattista, Charles 4, 89
 Debord, Kurt A. 48
 DeFigueiredo, John 66
 DeFrancisci, Lea E. 29
 Deitch, David 87
 Dejean, Deirdre 89
 Dekker, Jack J. 5
 De-la-Cámara, Concepción 47
 DelBello, Melissa P. 3, 35, 77
 Delgado, Pedro L. 55, 64
 Dell, Diana 66
 Dell, Mary Lynn 91
 Dell'Osso, Bernardo 22
 Delucia-Deranja, Evan 89
 DeMaso, David 14, 40
 Dement, William C. 62
 Demitrack, Mark 84
 Dennehy, Ellen B. 5
 Denno, Deborah 2
 Dervaux, Alain 55
 Desai, Abhilash K. 13
 Deva, M. Parameshva 61
 Devanand, Davangere P. 2
 Devin, Michael 1
 Devlin, Michael J. 59, 97
 Devouche, Emmanuel 24, 57
 Dew, Mary A. 94
 Dewan, Mantosh J. 3, 18, 54, 79
 Dhaliwal, Gagan 47
 Dia, José-Luis 47
 Diaz, Naelys 82
 Diaz-Martinez, Angelica 59
 Dickerson, Daniel 24
 Dickstein, Daniel P. 16, 34, 35
 Dickstein, Leah J. 21, 27, 35, 43, 73, 83, 88, 91
 Dietrich, Allen J. 34
 Difede, JoAnn 19, 34
 Dilbaz, Nesrin 22
 DiMartini, Andrea F. 40
 Dixon, Lisa B. 29, 55, 84, 93
 Docherty, John P. 31, 70
 Doebbeling, Caroline C. 93
 Doepfner, Manfred 34
 Doghranji, Karl 9, 26, 73, 89
 Dolan-Sewell, Regina 70
 Donegan, Nelson H. 98
 Dorer, David J. 97
 D'Orio, Barbara 71
 Dossenbach, Martin 89
 Downer, Allison V. 42
 Downey, Jennifer I. 46
 Doyle, Alys E. 57, 80
 Drake, Robert 29, 36
 Drescher, Jack 20, 49, 88
 Drossman, Douglas A. 53
 Drury, Laura 51
 Druss, Benjamin G. 84, 93
 Dryden-Edwards, Roxanne 18
 Du, Nang 18
 Dube, Sanjay 28, 67
 Duckworth, Kenneth S. 45
 Duffy, Farideh F. 48
 Dunn, David W. 95
 Dunn, Kent E. 49
 Dunn, Laura B. 44, 59
 Dunner, David L. 37
 Dyachkova, Y. 89
 Dyck, Ingrid R. 96
- E
- Ebert, Dieter 98
 Ebert, Michael H. 49, 74
 Ebner-Priemer, Ulrich W. 80
 Eckermann, Gabriel 41
 Edersheim, Judith G. 87
 Edman, Jeanne L. 48
 Ednie, Kathryn J. 43
 Edwards-Loidl, Susan M. 96
 Egeland, Janice A. 90
 Egger, Helen L. 19
 Ehrenreich, Mark J. 91
 Eidelman, Polina 48, 70
 Eist, Harold I. 45
 Ekbohm, Anders 23
 Ekeberg, Oivind 58
 Elbogen, Eric B. 81, 82
 Elhaj, Omar 25, 67
 Elliot, Mark B. 88
 Ellison, James M. 75
 Emre, Sukru 54
 Ernsle, Graham J. 42, 66
 Endicott, Jean 90
 Engel, Anna G. 71
 Engel, Charles C. 34
 England, Mary Jane 43, 83
 English, Joseph T. 29
 Epstein, Steven A. 22, 46
 Erickson, Jeffrey Lee 71
 Erman, Milton K. 9
 Ernst, Carrie L. 22, 43, 47
 Escobar, Javier I. 18, 59, 64
 Eth, Spencer 18, 24, 29
 Evans, Karleyton C. 6
 Everett, Anita S. 18, 59
 Eynan, Rahel 58
 Eytan, Ariel 72
- F
- Faber, Raymond A. 1
 Factor, Robert M. 60
 Faggiano, Sheri A. 92
 Fagiolo-Petrillo, Laura 66
 Fahrer, Rodolfo D. 71, 92
 Faison, Warachal E. 9, 43, 47
 Falco, Mathea 92
 Falissard, Bruno 34
 Fallon, Brian A. 58
 Fan, Alexander H. 25
 Fan, Jin 33
 Fanelli, Joseph G. 89
 Faraone, Stephen V. 12, 57, 62, 80
 Farchione, Tiffany R. 66
 Faries, Douglas E. 25
 Fassler, David 66
 Faull, Robert 71
 Fava, Maurizio 4, 24, 31, 55, 70, 89, 90
 Feibelman, Nathan D. 35
 Feijen, Rudolf A. 50
 Feinberg, David T. 78
 Feiner, Joel S. 72
 Feldman, Marc D. 88
 Felthous, Alan R. 97
 Fenton, Wayne S. 59, 89
 Ferguson, Yvonne B. 8
 Fernandez, Francisco 20, 43, 51
 Ferrando, Stephen J. 43
 Fichtner, Christopher G. 18
 Fieve, Ronald R. 48
 Finch, Manley 70
 Findling, Robert L. 2, 25
 Fine, Carla 19
 Fineberg, Naomi 79
 First, Michael B. 14, 26, 29, 95
 Fischbein, Ellen R. 19
 Fishbain, David A. 4
 Fisher, Sebern F. 74
 Flack, James N. 19
 Flaherty, Joseph A. 71
 Flaherty, Lois T. 20, 85
 Flashman, Laura A. 68
 Flory, Janine 7, 33
 Flynn, Heather 19
 Fochtman, Laura J. 17
 Folstein, Marshal 68
 Fonagy, Peter 57
 Fong, Timothy W. 2, 78
 Foote, Brad 69
 Foote, William W. 1
 Ford, Daniel E. 62
 Fordis, John 23
 Forester, Brent P. 75
 Forman, Robert F. 60
 Forstein, Marshall 43, 50, 54, 67
 Foti, Mary Ellen 91
 Foulks, Edward F. 14, 74
 Fradkin, Howard 64
 Francis, Paul T. 9
 Frank, Ellen 4
 Franko, Debra L. 97
 Frasure-Smith, Nancy 65
 Freedman, Robert 41
 Freeman III, Arthur M. 68
 Freire, Rafael C. 71
 Fricchione, Gregory L. 32
 Friedman, Joseph I. 68
 Friedman, Matthew 19, 34, 95
 Frieks, Gerhard 6
 Fris, Svein 30
 Fromson, John A. 43
 Fuchs, Lara R. 66
 Fullilove, Mindy J. 26
- G
- Gabbard, Glen O. 24, 27, 65, 79, 97
 Gabrielli, Maria 71
 Gaeta, Raymond R. 9
 Gagliardi, Jane P. 81
 Gajic-Veljanoski, Olga 33
 Galanter, Marc 31
 Gale, Tim M. 79
 Galea, Sandro 19, 58
 Gallofin, Leo L. 25, 87

- Galynker, Igor I 95, 96
 Ganzini, Linda K 30, 35
 Gao, Keming 90
 Gara, Michael A 59
 Garcia, Manuel 45
 Garlow, Steven J 22
 Garrett, Michael 68
 Gartner, Richard 64
 Garza, Daniel 25
 Gatchel, Robert 98
 Gavin, Norma I 58
 Gaw, Albert C 94
 Gaynes, Bradley N 58
 Gaytan, Jr., Osvaldo 79
 Geist, Rose 74, 78
 Gelenberg, Alan J 22, 70
 Geller, Barbara G 34
 Geltman, David J 88
 Gendel, Michael H 31
 George, Mark S 6, 15, 47
 Georgiopoulos, Anna M 82
 Gerberg, Patricia L 40, 59
 Germain, Anne 53
 Getter, Elizabeth V 18, 63
 Gex-Fabry, Marianne 72
 Ghaemi, S. Nassir 33, 36, 54, 56, 77
 Ghalib, Kareem D 68
 Ghodse, A. Hamid 81
 Gianoli-Valente, Marina 24, 57
 Giese-Davis, Janine 99
 Giggie, Marisa A 66
 Gignac, Martin 22
 Gilbert, Jennifer 80
 Gilbert, Kenneth G 49
 Giles, Lisa L 71
 Gill, Mary K 34
 Gill, Mona H 18
 Gilliam, John H 7
 Gironde, Stephanie V.M 48, 90
 Gise, Leslie H 14, 30
 Gitlin, David 67
 Glassman, Alexander H 20
 Glick, Ira D 15, 33, 59, 82
 Glucksman, Myron L 23
 Goethe, John W 48, 70
 Goff, Donald C 7
 Goin, Marcia K 83
 Goisman, Robert M 64
 Gold, Liza H 8
 Gold, Philip W 31
 Gold, Wayne L 48
 Goldberg, David A 80
 Goldberg, Ivan K 63
 Goldberg, Joseph F 23, 71, 77
 Goldberg, Richard L 55
 Goldberger, Celine 55
 Golden, Robert N 69
 Goldfinger, Stephen M 45, 68, 74, 92
 Goldman, Charles R 92
 Goldman, Morris B 27
 Goldwasser, Alberto M 72
 Golshan, Shanokh 59
 Gomez, Ivan S 22, 54
 Gomez-Caminero, Andres 54
 Gonzales, Junius J 73, 98
 Gonzalez, Gerardo 14
 Gonzalez, Luisa S 24
 Gonzalez-Franco, Francisco J 20
 Good, Byron J 83
 Goodkin, Karl 43
 Goodman, David 32
 Goodman, Marianne 7, 24, 33, 98
 Goodwin, Frederick K 36, 56
 Goodwin, James S 67
 Gordon, Edward 66
 Gordon, Lawrence 44
 Gordy, Tracy R 14, 49, 66
 Goren, Gayle 54
 Gorman, Jack M 21, 54, 91
 Gorscak, Bonnie 41
 Gottlieb, Diane B 26, 44
 Gotto, Jennifer G 20
 Graap, Ken 70
 Grady-Weliky, Tana A 45
 Graff, Marc 17
 Graignic-Philippe, Rozenn 57
 Granacher, Jr., Robert P 41
 Grant, Bridget F 30
 Grant, Jon E 15, 78
 Graognic-Philippe, Rozenn 24
 Grass, Henry J 19
 Gray, Gregory E 56
 Gray, Kevin F 1
 Gray, Sheila Hafter 72
 Grebchenko, Yuli 95, 96
 Greden, John F 11, 20, 37, 41, 49, 84
 Green, Alan I 29, 36, 50
 Green, Melva I 43
 Greenberg, Benjamin D 6, 90
 Greenberg, Roger P 54
 Greene, James A 49
 Greenfield, Shelly F 70
 Greenhill, Laurence L 23
 Greiner, Carl B 43, 64
 Greist, John H 90
 Griffith, James L 67, 94
 Grigoriadis, Dimitri E 32
 Grilo, Carlos M 24, 77
 Grimaldi, Jr., John A.R 18
 Grisso, Thomas 78
 Gropper, Rachel 74
 Gross, Raz 58
 Grossberg, George T 9, 13
 Grossman, Linda S 71
 Grunhaus, Leon J 51
 Gude, Tore 58
 Guglielmino, Livia 70
 Guido, Frank 97
 Guinjoan, Salvador M 71
 Gunatilake, Sarath 46
 Gunderson, John G 77
 Guo, Xiaodong 24
 Gur, Merav 59
 Gur, Raquel E 30
 Guschwan, Marianne T 73
 Guyker, Wendy 24
- H
- Haahr, Ulrik 30
 Haapea, Marianne 46
 Habeych, Miguel 54
 Hackman, Ann L 44
 Hadley, Sallie J 79
 Hafziger, Silvia 88
 Hagen, Matthew 80
 Hahless, William 22
 Hako, Helinä 46
 Halajian, Hasmig 78
 Hales, Deborah J 16, 20, 27, 44, 66, 88
 Hales, Robert E 13, 24, 39
 Hall, Molly J 2, 43
 Haller, Ellen 67
 Halmi, Katherine A 1, 30, 97
 Halper, James P 87
 Hamid, Hamada 7
 Hamilton, Tom 43
 Hammond, W. Rodney 45
 Hanes, Ken 20
 Hann, Della M 25
 Hansen, Thomas E 19
 Hanson, Annette L 49
 Hara, Belinda A 46
 Harden, Cynthia L 95
 Harding, Richard K 87
 Harmer, Catherine J 55
 Harmon, Larry J 67
 Harpold, Theresa L 80
 Harris, Patrice A 85
 Harrison, David G 42
 Harrow, Martin 71
 Hart, Carl 50
 Hartman, David E 87
 Hartmann, Lawrence 11, 83
 Harvey, Philip D 12
 Hasin, Deborah S 29
 Hatata, Hisham 95
 Hatters-Friedman, Susan J 73
 Hatti, Shivkumar 88
 Haupt, Daniel W 7
 Hazlett, Erin 7, 33, 98
 Healy, David T 56
 Heath, Jennifer 71
 Heffner, Gary 87
 Heinszen, Robert K 30
 Heinze, Gerardo 18
 Heller, David C 90
 Hem, Eriend 58
 Hen, Rene 11
 Henderson, David C 1, 32, 56
 Henderson, Shanta P 18
 Hendriksen, Mariëlle 5, 83
 Henin, Aude I 90
 Hennig, Juergen 98
 Henry, Fran 45
 Henry, Robert 59
 Henry, Shannan 97
 Hensley, Paula L 31, 70
 Herbert, Sarah E 29, 45
 Herman, Barry 45
 Herman-Stahl, Mindy 90
 Herpertz, Sabine 80
 Herrman, Helen 33, 34, 93
 Hersh, Richard G 63, 88, 89
 Hersh, Stephen 75
 Heru, Alison M 51
 Herzog, Alfred 43, 63
 Herzog, David B 97
 Hiatt, John F 1
 Hicks, Daniel W 49
 Higgins, Jr., Napoleon B 50, 66
 Hill, Britton A 67
 Hinrichs, Bruce W 43
 Hirsch, Alan R 87

PARTICIPANT INDEX

Hirschfeld, Robert M.A. 77
 Hirshkowitz, Max 40
 Ho, Caroline 78
 Hochman, Karen M. 30
 Hoebel, Bartley G. 31
 Hoffman, Perry D. 57, 88
 Hoffman, Rosalind G. 91
 Hoge, Charles W. 34
 Holder-Perkins, Vicenzio 22
 Holland, Jimmie C. 51
 Hollander, Eric 3, 33, 61, 79, 98
 Holmes, William 64
 Hooper, Lisa M. 22
 Hope, Thomas D. 71
 Horton, Leslie A. 24
 Horton, Richard 64
 Hostetter, Abram M. 72, 90
 Houghtalen, Rory P. 25
 Howe, Edmund G. 35, 51
 Hsiung, Robert C. 40, 63
 Hu, Rona 11
 Huang, Frederick Y. 24
 Huang, William 73
 Hudson, James I. 6
 Hughes, Catherine 89
 Hughes, Michael C. 73
 Huremovic, Damir 68, 74
 Hurford, Matthew O. 49
 Hurwitz, Thomas D. 26, 40
 Hussain, Mohammad Z. 89
 Hussain, Seema 89
 Hutchinson, Janice G. 56
 Hutto, Mark 71
 Hwang, Cindy H. 23
 Hyler, Steven E. 14, 40

I

Iqbal, Muhammad M. 81
 Inderbitzin, Lawrence B. 43
 Insel, Thomas R. 45
 Interian, Alex. 59
 Iosifescu, Dan V. 48
 Ironson, Gail 53
 Irvin, Tracey L. 41
 Isbey, JoAnne 73
 Ishak, Waguih W. 69, 73, 75
 Ismail, Saleem 77
 Isohanni, Matti K. 23, 46, 89
 Israel, Joshua A. 4

J

Jabbarpour, Yad 72
 Jackson, Safia C. 97
 Jackson-Siegel, Jeanne 13, 39
 Jacobs, Douglas G. 90
 Jacobs, Selby C. 18
 Jacobson, Wendy 64, 85
 Jaffe, Richard L. 26
 Jain, Vivek 74
 James, Kisha 90
 Jamison, Kay Redfield 36
 Janicak, Philip G. 27
 Jannappagari, Vanni 54
 Jaros, Bonita 91
 Jarvis, Gilbert 50
 Javed, Afzal 58

Jayaram, Geetha 23, 43, 52, 75
 Jayasinghe, Nimali 34
 Jeavons, Michael M. 78
 Jeste, Dilip V. 30, 59, 77
 Jiang, Wei 81
 Jibson, Michael D. 25
 Jimerson, David C. 1
 Jobe, Thomas H. 71
 Joffe, Hadine 3, 9
 Johannessen, Jan O. 30
 Johnson, Bankole A. 31, 56
 Johnson, Bradley R. 8
 Johnson, Hillary 87
 Johnson, Jeffrey 95
 Johnson, Leigh G. 61
 Jones, Ian R. 99
 Jones, Peter B. 89
 Jonston, Lindsay 53
 Jorge, Ricardo 32
 Jorgenson, Linda M. 5, 43, 50
 Joseph, Llewelyn W. 23
 Joseph, Megan F. 23, 90
 Joseph, Robert C. 19, 54, 87
 Josephson, Allan M. 22, 86, 91
 Joukamaa, Matti 46
 Joy, Charles R. 44
 Juneja, Tony 63
 Juthani, Nalini 18, 67

K

Kaaya, Sylvia 53
 Kahn, Henry S. 30
 Kahn, Jeffrey P. 72
 Kalali, Amir H. 56
 Kaleem, Mustafa 95
 Kalim, Mustafa 96
 Kalin, Ned H. 9
 Kalm, Michael A. 73
 Kam, Raymond 24
 Kamins, Daniel 59
 Kandel, Eric R. 16
 Kane, John M. 10, 82
 Kang, Shimi 63
 Kaplan, Alicia J. 79
 Kaplan, Allan S. 59
 Kaplan, Gabriel 64
 Kaplan, Sandra J. 18
 Kapur, Shitij 12, 80
 Karasic, Dan H. 67
 Karasu, T. Byram 23, 26
 Kardos, Marianne 54
 Karnik, Niranjana S. 18
 Karp, Jordan F. 94
 Kasapinovic, Sonja 48
 Kasan, Connie 87
 Kashiwamura, Shinichiro 71
 Kastrup, Marianne C. 33, 34, 93
 Katon, Wayne J. 4, 25, 47, 53, 65, 84, 89, 98
 Katsavdakis, Kostas 95
 Katz, Ira R. 23, 30
 Katz, Nathaniel P. 60
 Kartzelnick, David J. 84
 Kay, Jerald 68, 79
 Kaye, David L. 27, 68
 Kaye, Walter H. 12, 97
 Keck, Jr., Paul E. 3, 4, 39
 Keefe, Richard S.E. 4

Keel, Pamela K. 70
 Kehayan, V. Alex. 14
 Kekilidze, Zurab 76
 Keller, Martin B. 2, 11
 Kellner, Charles H. 26
 Kelly, Robert 24
 Kelsey, Douglas K. 34
 Kennedy, Robert S. 26
 Kennedy, Sidney H. 32
 Kent, Justine M. 6
 Kernberg, Otto F. 7, 60, 64, 85
 Kestenbaum, Clarice J. 92
 Ketter, Terence A. 13, 36, 76
 Khalil, Afaf Hamed 95
 Kim, C.Y. 89
 Kim, Scott Y. 18, 44, 59
 Kim, Suah 79
 Kim, Thomas M. 64
 King, Bryan H. 66
 Kingdon, David G. 8, 92
 Kirsh, Gillian 74
 Kirson, Joel 23, 71
 Kisely, Stephen R. 81
 Kleber, Herbert D. 15, 60, 80
 Kleiman, Andrew M. 91
 Klein, Ehud M. 51
 Klibanski, Anne 97
 Kline, Linda 71
 Kockmann, W.M.J. 29
 Koeningberg, Harold W. 7, 24, 33
 Kollins, Scott 11
 Kolodner, George F. 73
 Komorowski, James 70
 Kong, B. Waive 76
 Koob, George F. 56, 62, 96
 Kool, Simone 5, 83
 Kopelowicz, Alex J. 87
 Koplin, Brett A. 14
 Koponen, Hannu J. 23
 Koran, Lorrin M. 79
 Kores, Robert 68
 Kornstein, Susan G. 13, 39, 66
 Koskinen, Johanna 89
 Koskoff, Harriett 45
 Kosza, Ida 58
 Kotwiczki, Raymond J. 30
 Koutsemok, Igor 87
 Kovaszny, Beatrice 72
 Koz, Gabriel 17
 Koziupa, Diana M. 60
 Krahn, Lois 40, 62
 Krakowski, Menahem I. 71
 Kramer, Milton 8, 23
 Kramer, Thomas A.M. 26
 Kranzler, Henry R. 31
 Krasnov, Valery N. 76
 Kratochvil, Christopher J. 23, 34, 62
 Kraus, Jr., John E. 4
 Krishnan, K. Ranga R. 2, 41, 62, 81
 Kroenke, Kurt 25
 Kroutil, Larry A. 90
 Kruse, John S. 67
 Krystal, John H. 11, 29
 Kudler, Harold 16, 42, 94
 Kumar, Anil 23
 Kumar, Manoj 88
 Kumari, Veena 23, 89
 Kunik, Lauren 95, 96

- Kunkel, Elisabeth J.S. 40, 91, 96
 Kuo, Jack 73
 Kupfer, David J. 9, 20, 30
 Kwon, Anne 35, 80
 Kyomen, Helen H. 96
- L
- Lacy, Timothy J. 61
 LaFrance, Jr., W. Curt 95
 Laje, Gonzalo E. 24, 70
 Lam, Raymond W. 61
 Lamb, H. Richard 43
 Lamdan, Ruth M. 26, 44
 Lamprecht, Friedhelm 48
 Lancaster, Kathy 97
 Landa, Rebecca 98
 Landgraf, Jeanne 32
 Lane, Richard D. 53
 Lang, Joan A. 69, 80
 Langer, Sam 95
 Langlieb, Alan 72
 Lanus, Ruth A. 84
 Lara, Carmen 81
 Larsen, Tor K. 30
 Latif, Umar 40, 51
 Latoussakis, Vassilios 91
 Laughren, Thomas P. 93
 Lauriello, John 70
 Lauronen, Erika 89
 Lauterbach, Edward C. 5, 48, 71, 89
 Lautin, Andrew L. 7
 Lavretsky, Helen 62, 64
 Lawson, William 25, 56
 Lazarus, Arthur L. 22
 Lazin, Malcolm 45
 Le Nestour, Annick 24
 Lebowitz, Barry D. 30, 77
 Leck, Pamela 19, 34
 Leckman, James F. 49
 Lee, Jennifer R. 17, 24, 88
 Lee, Joseph 80
 Lee, Karen L. 74
 Lee, Li-Ching 98
 Lee, P. 89
 Lee, Steven J. 25
 Lee, Susan 91
 LeFebvre, Arlette M. 78, 87
 Lehmann, Laurent S. 94
 Leibenluft, Ellen 35
 Leigh, Hoyle 22, 44
 Leli, Ubaldo 25
 Lencz, Todd 30
 Lenze, Eric J. 6
 Lenox, Jeff D. 54
 Leonard, Henrietta L. 34
 Lesperance, Francois 32
 Leucht, Stefan M. 10
 Levendusky, Philip G. 64
 Levenson, Alan I. 19
 Levenson, James L. 40, 67, 91
 Levi, Lennart 61
 Levin, Frances R. 50, 81
 Levin, Ronald W. 78
 Levounis, Petros 20, 63
 Levy, Joslyn 25
 Lewis, David 92
 Lewis, David A. 12, 78, 79
- Lewis, Roya 26, 44
 Lewis-Fernandez, Roberto 6, 82
 Lewy, Alfred J. 2, 9
 Lichtmacher, Jonathan E. 19
 Lieb, Klaus 32, 60, 98
 Lieberman, Jeffrey A. 4, 12, 31, 51
 Lieberman, Paul B. 88
 Liebowitz, Michael R. 3, 6
 Lim, Kelvin 80
 Lim, Key-Ming 25
 Lim, Russell F. 1, 42, 82
 Lim, Sabina 18
 Limosin, Frederic 55
 Lin, Elizabeth H.B. 84, 98
 Lin, Heather 91
 Lin, W.W. 89
 Lindeman, Jeffrey 45
 Lindeman, Sari 23
 Lindenmayer, Jean-Pierre 68
 Lineham, Marsha 7
 Links, Paul S. 58
 Lippy, Robert D. 61
 Lipsitt, Don R. 19, 44, 92
 Lipsitz, Joshua D. 59
 Lipsius, Steven H. 23
 Lisanby, Sarah H. 6, 37, 47, 51, 69
 Little, Martha J. 48
 Livesley, John 15, 57, 83, 95
 Lobo, Antonio 47
 Loboprabhu, Sheila M. 25, 45
 London, Eric B. 61
 Long, Stacey 89
 Loonen, Anton J.M. 26
 Lopes, Fabiana L. 71
 Lopes-Cardozo, Barbara 74
 Lopez, Frank A. 48
 Lopez, Sandra 22
 Lore, Jean-Yves 55
 Lorenzo, Maria J. 34
 Louie, Alan 82
 Louie, Marie 48
 Lowenkopf, Eugene M. 63
 Loza, Nasser F. 81
 Lu, Francis G. 1, 24, 45, 50, 67, 88
 Luby, Joan L. 19, 24
 Ludman, Evette J. 84, 98
 Ludwig-Noble, Antonia 73
 Luo, John 18, 40, 42, 51, 63
 Lurie, Lawrence B. 17
 Lusskin, Shari 63
 Lutgendorf, Susan 53
 Lydiard, R. Bruce 9
 Lyketsos, Constantine 28, 67, 76
 Lymberis, Maria T. 94
 Lynch, Thomas R. 80
 Lyons, Lisa 69
- M
- Macbeth, JoAnn 18
 MacCourt, Duncan C. 87
 Macfadden, Wayne 48
 Mack, Avram H. 49
 MacKenna, Holly V. 43
 MacQueen, Glenda M. 32
 Magen, Jed G. 68
 Magera, Michael 91
 Maggi, Julie D. 91
- Maguire, Gerald A. 9
 Major, Ishmeal 87
 Maki, Pirjo H. 46
 Malcolm, S. 34
 Maldonado, Jose R. 1, 8, 15, 90
 Mallinckrodt, Craig H. 90
 Mallios, Ronna 22
 Mallott, David B. 44, 92
 Malmquist, Carl P. 25, 43
 Mancini, Catherine L. 89, 90
 Mandhate, Custodia 53
 Manevitz, Alan Z.A. 87
 Mannelli, Paolo 70
 Manning, John 79
 Manthena, Prasanth 53
 Manu, Peter 50, 68
 Manzo, Mary Patricia 97
 Marangell, Lauren B. 6
 Marazziti, Donatella 22
 March, John S. 31, 42, 66, 92
 Marcos, Guillermo 47
 Marcus, Eric R. 92
 Marcus, Sheila M. 57
 Marder, Stephen R. 27, 55, 93
 Margolis, Philip M. 35
 Mann, Humberto 64
 Markov, Dimitri D. 40, 73, 96
 Markowitz, John C. 5, 57
 Marlone, David 6
 Marmar, Charles R. 34
 Marrocco, Mary K. 8
 Marshall, Randall D. 6, 31, 58, 71
 Martin, Janet A. 18, 25, 87
 Martin, Michael J. 74
 Martinez, Cervando 55
 Martinez, Humberto 58
 Martinez, James M. 4
 Marx, Christine E. 52
 Marzilli, Gianna 23
 Marzorati, Paolo 70
 Masand, Prakash S. 3, 21, 70
 Mason, Barbara J. 56
 Massie, Mary Jane 20, 40
 Mathew, Sanjay 21
 Mathews, Maju 98
 Matos, Manuel 92
 Matthews, Annette M. 54
 Mattson, Marlin R.A. 72
 Maullin, Nathalie 9
 Maurer, Martin H. 25
 Maxey, Randall 76
 Maxwell, Edward J. 18
 May, Matthew 8, 15
 Mayberg, Helen S. 12, 27, 46, 54
 Mayer, Laurel 6
 McAfee, Scot G. 29
 McBride, Margaret E. 89
 McCall, W. Vaughn 26, 47
 McClure, Erin 35
 McConaha, Claire 97
 McCunn, Kara L. 69
 McDonaki, William M. 84
 McDougale, Christopher J. 2, 87
 McDowell, David M. 80, 81, 92
 McElroy, Susan L. 3, 6
 McEvoy, Joseph P. 12
 McEwen, Bruce S. 21, 60, 67
 McFarlane, William R. 30

- McGeer, Allison.....48
 McGeoch, Pamela.....95
 McGlashan, Thomas H.....30, 77, 98
 McHugh, Paul R.....8, 33, 43
 McHugo, Greg.....36
 McIntyre, Jack S.....17, 25, 51, 67
 McKay, Judy S.....24
 McLain, Jennifer L.....25, 73
 McLaren, Tom.....44
 McLean, Alexandra.....55
 McLean, Diane E.....43
 McLean, Sarah.....78
 McLellan, A. Thomas.....92
 McLeod-Bryant, Stephen.....92
 McNicholas, Laura F.....14
 McQuery, Joy D.....49
 Meaney, Michael.....27, 81
 Medina, Rolando A.....55
 Medina-Mora, Maria E.....81
 Mee-Lee, David.....14
 Mehrotra, Ravi.....23
 Meili, Trisha.....36
 Melle, Ingrid.....30, 77
 Mellman, Lisa A.....42, 68
 Melonas, Jacqueline M.....19, 44, 63
 Meltzer, Herbert Y.....7
 Meltzer-Brody, Samantha E.....58, 84
 Mendelsohn, Michaela.....18
 Mendoza, Ricardo P.....25
 Menvielle, Edgardo J.....29
 Mendeth, Philip T.....18, 24
 Messer, Stephen C.....34
 Metzner, Jeffrey L.....67, 72
 Metzner, Richard J.....90
 Meyer, Donald Jay.....19
 Meyer-Lindenberg, Andreas.....53
 Mezzasalma, Marco A.....71
 Michaeli, Danni.....69
 Michels, Robert.....94
 Mick, Eric.....57, 80, 90
 Miettunen, Jouko.....89
 Mikalac, Cecilia M.....15, 41
 Mikhail, Albert A.....75
 Miodowitz, David J.....5
 Milham, Michael.....35
 Milk, Eric.....35
 Milke, Dennis J.....72
 Miller, Alexander L.....33, 51
 Miller, Andrew H.....20
 Miller, Claudia.....69
 Miller, Del D.....33
 Miller, Karen K.....97
 Miller, Paul R.....51, 63, 89
 Miller, Sheldon I.....66
 Millman, Robert.....92
 Milone, Richard D.....18
 Milrod, Barbara L.....79
 Minshew, Nancy.....87
 Mintun, Mark A.....9
 Mintz, David L.....15
 Mintzer, Jacobo E.....55, 64
 Minzenberg, Michael J.....33
 Miotto, Karen A.....2
 Mirnics, Karoly.....79
 Mischoulon, David.....32
 Misra, Sahana.....35
 Misri, Shaila.....63
 Mistler, Lisa A.....29
 Mitchell, Alex J.....47, 88
 Mitchell, James E.....1, 97
 Mitelman, Serge A.....98
 Moeller, Frederick G.....97
 Mohamed, Mahmoud A.....91
 Mohl, Paul C.....49, 82
 Monahan, Patrick.....48
 Montañés, José-Ángel.....47
 Montgomery, Richard.....40, 51
 Moore, Heidi.....90
 Morey, Leslie C.....77
 Moser, David J.....59
 Mothersell, Jeffrey.....25
 Moul, Douglas E.....53
 Moussaoui, Driss.....24
 Mrazek, David A.....14, 74
 Mudaliar, Sunder.....59
 Muenzenmaier, Kristina H.....18
 Mueser, Kim T.....36
 Mufti, Khalid A.....81
 Munday, Cheryl.....73
 Mundt, James C.....90
 Munoz, Rodrigo A.....18, 33, 61, 67, 82, 87, 93
 Murray, Heather.....70
 Murrer, Cyndi R.....88
 Murthy, Srinivasi.....61
 Muskin, Philip R.....22, 28, 51, 67
 Myers, Michael F.....19, 27, 43, 88, 91
 Myers, Tricia.....97
 Myers, Wade C.....18, 24
 Myrick, Hugh.....62
- N
- Nace, David.....17
 Nadelson, Carol C.....16, 57, 68, 83, 93
 Nagel, DeeAnna Merz.....63
 Nahas, Ziad H.....51
 Nakajima, Gene A.....67
 Nakayama, Emilie.....30
 Nand, Surinder S.....18, 33
 Napoli, Joseph C.....14
 Naqvi, Syed S. A.....25, 91
 Nardi, Antonio E.....71
 Narrow, William E.....19, 26, 30, 48, 83, 96
 Nascimento, Isabella.....71
 Naser, Jeffrey A.....94
 Nasra, George S.....92
 Nasrallah, Henry A.....71
 Navarre, J. Richard.....70
 Nazarey, Margaret.....63
 Ndlela, J. Charles.....1
 Nelson, Christian.....89
 Nelson, J. Craig.....55
 Nemeroff, Charles B.....42
 Neria, Yuval Y.....58
 Nesse, Randolph M.....75
 Nestler, Eric J.....81
 Neubauer, David N.....62
 Neumeister, Alexander.....11
 New, Antonia S.....7, 24, 33, 98
 Newcomer, John W.....37
 Newkirk, Cassandra F.....43, 49, 66
 Newmark, Randall.....98
 Newport, Donald J.....99
 Newschaffer, Craig.....98
 Ng, Anthony T.....2, 19, 43, 61
 Ng, David.....23
 Nguyen, Long H.....90
 Nicholi, Jr., Armand M.....65, 72
 Nierenberg, Andrew A.....5, 23, 48, 70, 84, 90
 Ninan, Philip T.....3, 11
 Ning, Autumn.....26, 44
 Nininger, James E.....8
 Njenga, Frank G.....33, 53, 61, 81
 Noble, Florence.....32
 Nonacs, Ruta M.....2, 66
 Norko, Michael A.....10
 Norman, Matthew W.....18
 Norquist, Grayson S.....31
 Norris, Donna M.....94
 Norrow, Gary.....99
 North, Carol S.....19
 Northcott, Colleen J.....49
 Notman, Malkah T.....19, 25, 43
 Novac, Andrei.....91
 Novik, Torunn S.....34
 Novins, Douglas K.....50
 Novotny, Sherie L.....61
 Nunes, Edward V.....81
 Numberg, H. George.....70
 Nykiel, Sherry A.....88
- O
- O'Bannon, R. Michael.....63, 74
 Obenchain, Robert.....89
 O'Brien, Charles P.....62
 O'Connell, Anne.....82
 O'Connor, Margaret.....72
 Oddone, Eugene.....82
 Oele, Bastiaan L.....50
 Oesterheld, Jessica R.....41
 Offsay, Julian.....49
 Ofili, Elizabeth.....42
 Okamura, Haruki.....71
 Okasha, Ahmed M.F.....24, 53, 83, 95
 Okasha, Tarek A.....25, 95
 Okay, Tuncer.....22
 Okereke, N. Kalaya.....66
 Okura (Posthumously), K. Patrick.....42
 Olarte, Silvia W.....25, 46, 83
 Oldham, John M.....24, 64, 85, 97
 Olds, Jacqueline.....67
 Olíson, Mark.....51
 Olmer, Ahikam.....22
 Olsen, Ruth.....30
 O'Malley, Mary B.....73
 Opler, Lewis A.....8, 18, 92
 Oquendo, Maria A.....15, 82
 Orav, E. John.....47
 Ordonica, Patricia I.....52
 Ortiz-Fragola, Alfredo.....71
 Osby, Urban P.....23
 O'Shea, Noelle.....89
 Oslin, David.....64
 Osman, Ossama T.....24, 72, 95
 Osser, David N.....56
 Ostacher, Michael J.....5, 48
 Otto, Michael W.....2
 Oulvey, Eugene A.....74

- P
- Paczkowski, M 34
- Pagano, Maria E 77, 96
- Paine, Susan 70
- Pallanti, Stefano 79
- Pally, Regina 27, 78
- Palmer, Barton W 59
- Pandya, Anand 92
- Pao, Maryland 73
- Pappadopulos, Elizabeth 2
- Parameswaran, Sharat 46
- Pardes, Herbert 20
- Pardo, Jose 80
- Pardo, Tamara B 54
- Parikh, Rajesh M 32
- Parikh, Sagar V 74
- Parks III, Joseph J 15
- Patkar, Ashwin A 70
- Pato, Carlos N 65
- Pato, Michele T 3, 27, 49, 65
- Patten, Scott B 71
- Paul, Robindra K 20
- Peele, Roger 56, 83, 94
- Pelton, Gregory H 2
- Peltz, Louis 78
- Penn, Joseph V 78
- Pennell, Jennifer K 61
- Penney, Dixianne 88
- Pereira, Rob R 34
- Perez, Carol B 43
- Perez, Jon 72
- Perez, Oscar E 67
- Perez-De-La-Hoz, Ricardo 71
- Pericak-Vance, Margaret A 86
- Perilla, Julia L 18
- Perkins, Diana O 30, 52, 77
- Perlis, Roy H 4, 47
- Perring, Christian D 82
- Pescosolido, Bernice A 68
- Peselow, Eric D 19, 24, 48, 70
- Peteet, John R 65, 72, 86, 91
- Petersen, Ronald C 62
- Petersen, Timothy J 4
- Peterson, Christopher B 17
- Petirjean, Francois C 55
- Petry, Nancy M 78
- Petunati, Helen M 62
- Peyser, Herbert S 72
- Pflanz, Steven E 44, 91
- Pfohl, Bruce M 29
- Phelan, Jo C 68
- Philippe, Alain 55
- Phillips, Ann 61
- Phillips, Katharine A 24, 30
- Phillips, Lawrence S 42
- Pi, Edmond H.T. 25
- Piazza, Pier V 96
- Pies, Ronald W 41, 63
- Pigott, Teresa A 13
- Pincus, Harold Alan 52
- Pine, Daniel S 35
- Pinn, Vivian 26
- Pipe, Beth 89, 90
- Pirl, William 49
- Pittman, Mary 45
- Pitts, Gloria 49
- Plakun, Eric M 15, 42, 50, 67
- Pleak, Richard R 29, 45
- Poirier, Marie France 55
- Pollack, Mark H 6, 84
- Pollock, Jonathan 81
- Polubinskaya, Svetlana 76
- Popkin, Michael K 76
- Popovian, Robert 67
- Posey, David J 2
- Post, Jerrold M 41, 93
- Post, Robert M 56, 77
- Posternak, Michael 90
- Potter, William 84
- Pouncey, Claire L 82
- Powell, June A 85, 91
- Powers, Pauline 97
- Powsner, Seth M 44
- Pressman, Mary Anne 24, 48, 70
- Preter, Maurice 20
- Preuss, Ulrich 34
- Price, Lawrence H 6
- Price, Marilyn 25
- Price, Trevor R.P. 92
- Primm, Annelle B 76, 82, 92
- Primm-Spencer, India 43
- Prince, Jefferson B 1, 5, 51
- Prohovnik, Isak 24
- Puchalski, Christina M 67
- Puddester, Derek 8
- Punwani, Manisha R 91
- Purselle, David C 22
- Q
- Quercioli, Leonardo 79
- Quesada, Gonzalo F 67
- Quinn, Gary M 94
- Quirk, Gregory 60
- R
- Rabins, Peter V 17, 77
- Rae, Donald S 48, 96
- Ragan, Kimberly A 99
- Rainey, Charles J 40, 51
- Raison, Charles 51
- Raj, Y. Pritham 81
- Rajparia, Amit D 25, 72
- Ralston, Stephen J 34
- Ramchandani, Dilip 96
- Ramirez, Luis F 39
- Ramirez, Paul M 8
- Ramsay, J. Russell 22, 85
- Rao, Aruna S 50
- Rao, Nyapati 68, 91
- Rapaport, Mark H 9, 16, 20, 27
- Raphael, Beverley 16
- Räsänen, Pirkko 89
- Rasgon, Natalie L 37, 63
- Rasmussen, Steven A 6
- Rathod, Shanaya 92
- Ratna, Lawrence 87
- Rauch, Scott L 6
- Raviola, Giuseppe 45
- Ravitz, Paula 64
- Razavi, Maryam 22, 94
- Razavi, Mehdi 22
- Reaven, Gerald 7, 37
- Recupero, Patricia R 72
- Regier, Darrel A 26, 30, 48, 51, 59, 76
- Reich, James H 33, 57
- Reich, Walter J 76
- Reifler, Burton V 74
- Reiss, David 77
- Reissman, Dorit B 61
- Reikin, Norman 62
- Renner, John 73
- Resendez, Cynthia I 43
- Resnick, Phillip J 5, 8, 14, 27, 40, 63
- Resnikoff, Roy O 5
- Restall, Wenda 87
- Retter, Martin 34
- Reus, Victor I 44, 74
- Reyes, Raymond M 88
- Reynolds, Carson 73
- Reynolds III, Charles F 30, 94
- Rezai, Ali 6
- Riba, Michelle B 8, 10, 13, 17, 28, 35, 43
49, 53, 67, 83, 92, 93
- Rich, Brendan 35
- Richardson, Gary S 62
- Richelson, Elliott 32
- Richman, Judith A 71
- Rieder, Ronald O 94
- Rigaud, Marie-Claude 19
- Riley, Anne W 34
- Rittberg, Barry 80
- Ritvo, Eva C 67, 73
- Rivera, Maribel 69
- Roberts, David C.S. 96
- Roberts, Jennifer 19
- Roberts, Laura W 19, 44, 50, 64, 69, 86, 91
- Robinowitz, Carolyn B 8, 68
- Robinson, Gail E 5, 79
- Robinson, Mia J 43
- Robinson, Michael J 40
- Robinson, Rebecca 89
- Robinson, Robert G 32
- Roca, Catherine A 43, 99
- Rodgers, Phillip 98
- Roecklein, K.A. 61
- Roerig, James 97
- Roffman, Mark 70
- Rogers, Kenneth M 92
- Rohan, Kelly J 61
- Rolland, John S 14
- Roose, Steven P 2, 6, 94
- Rosario, Vernon A 29
- Rosen, Cherise 71
- Rosenbaum, Jerrold F 1
- Rosenberg, Mark L 45
- Rosenberg, Stanley 28, 50, 55
- Rosenbluth, Michael B 32
- Rosenfeld, Barry D 89
- Rosenheck, Robert A 77
- Rosenthal, Minam 69
- Rosenthal, Norman E 31, 61
- Rosenthal, Richard N 83
- Roskes, Erik 43
- Rosko, Thomas J 87
- Rospenda, Kathleen 71
- Rostain, Anthony L 22, 68, 85
- Roth, Andrew J 49, 89
- Roth, Loren H 76
- Rothbaum, Barbara 9, 70
- Rothe, Eugenio M 43
- Rothenberg, Albert 8

- Stein, Murray B. 3, 84
 Steinberg, Joel L. 97
 Steiner, Jeanne L. 91
 Steinfeld, Matthew 95, 96
 Steinglass, Joanna E. 59
 Steinhilber, Hans-Christoph 34
 Stern, Harriet C. 18
 Stern, Michael P. 55
 Stern, Theodore A. 75, 76, 99
 Stevens, Emily 63, 74
 Stewart, Deborah C. 22
 Stewart, Donna E. 24, 33, 40, 93
 Stewart, S. Evelyn 90
 Stickgold, Robert 94
 Stigler, Kimberly A. 2
 Stinnett, James L. 96
 Stoff, David 50
 Stolar, Andrea G. 25, 67
 Stoller, Kenneth 70
 Stone, Michael H. 60
 Stotland, Nada L. 8, 15, 49, 83, 85
 Stout, Chris 93
 Stout, Robert L. 77
 Stowe, Zachary N. 63, 85, 99
 Strain, Eric C. 14
 Straker, Norman L. 39
 Straus, Joshua 63
 Strauss, Jennifer L. 57, 82
 Streim, Joel 1, 64
 Streltzer, Jon M. 68
 Strober, Michael 34, 59
 Strollo, Patrick J. 53
 Stroup, Thomas S. 12
 Stuart, Scott 19, 54, 64
 Struber, Margaret L. 54
 Stuck, Craig A. 87
 Styra, Rima 48
 Sudak, Donna M. 98
 Sudak, Howard S. 98
 Sugden, Steve 66
 Sullivan, Ann Marie T. 25
 Sullivan, Carl R. 68
 Sultzer, David L. 4, 13
 Sumner, Calvin R. 34
 Sunderland, Trey 30
 Suppes, Trisha 3, 11
 Surman, Craig B. 11
 Susser, Ezra S. 50
 Sutton, Virginia 34
 Swan-Kremier, Lorraine 97
 Swann, Alan C. 97
 Swanson, James M. 48
 Swanson, Jeffrey W. 81
 Swartz, Marvin S. 28, 81
 Swedo, Susan E. 92
 Swindle, Ralph W. 89
 Sysko, Robyn 59
 Szarek, Bonnie L. 48
 Szigethy, Eva M. 14, 40, 73
- T
- Taintor, Zebulon 58, 83
 Takeda, Masatoshi 71
 Talbott, John A. 49, 55
 Tandon, Rajiv 15, 27, 59
 Tang, Tianlai 7
 Tantiolo, Mary 92
- Tapp, Andre 33
 Tariot, Pierre N. 13, 39, 47, 62, 77
 Tasman, Allan 80, 92
 Tasman, Cathy 18
 Tebartz Van Elst, Ludger 98
 Temblador, Brenda 87
 Templeton, Bryce 98
 Temporini, Humberto 26
 Ten Doesschate, Roelof J.A. 29
 Thase, Michael E. 23, 26, 70, 89
 Thielke, Stephen M. 49
 Thielman, Samuel B. 86
 Thienhaus, Ole 64
 Thistlethwaite, Timothy L. 67
 Thomas, Christopher R. 78
 Thomas, Jean M. 24
 Thomas, Prakash K. 66
 Thompson, Leonti H. 20
 Thompson, Thomas R. 48
 Thornton, Charles 70
 Thornton, Steven L. 44
 Tiamson, Maria L.A. 88
 Tierney, Lindsey K. 61
 Tillman, Jane G. 50
 Titchener, Kay 15
 Tivnan, Trish 66
 Tobin, Marie B. 68
 Tolley, Julia B. 71
 Ton, Hendry 51
 Tong, Lowell D. 66
 Touchet, Bryan K. 88
 Tracy, Martin G. 19, 44
 Tran, Tanya B. 23, 90
 Trawick, Elizabeth O. 78
 Treede, Rolf-Detlef 98
 Treisman, Glenn J. 70
 Tremereau, Fabien 71
 Trestman, Robert L. 26, 73
 Trimble, Michael R. 15
 Trinh, Nhi-Ha T. 43
 Trinidad, Anton C. 82
 Trivedi, Madhukar H. 4, 31, 67, 73
 Truman, Benedict I. 26
 Truman, Christine J. 23
 Trzepacz, Paula T. 12, 76
 Tsai, Guochuan 68
 Tschan, Werner 50, 67
 Tsuang, John W. 2
 Tucker, Lawrence V. 78
 Tucker, Pamela G. 74
 Tucker, Phebe M. 2
 Tucker, William M. 40
 Tuinebreijer, Willem C. 50
 Tully, Tim 81
 Tuma, Farris 19
 Tunis, Sandra L. 25
 Turgay, Atilla 23
 Turkel, Ann R. 60
 Turkel, Susan B. 73
 Turkington, Douglas 8, 50, 92
 Turkoglu, Ali 22
 Turner, Hillarie 49
 Turvey, Carolyn L. 32
 Tyssen, Reidar 58
- U
- Ueda, Haruyasu 71
 Urbaitis, John C. 94
 Ursano, Robert J. 19, 95
 Ustun, Bedirhan T. 83
- V
- Vaccarino, Viola 42
 Vaglum, Per 30, 58, 77
 Valdes, Ignacio H. 97
 Valdiseri, Ronald O. 26
 Valencia, Alexandre M. 71
 Valera, Eve M. 57
 Valeri, Sylvia 34
 Van, Henricus L. 5, 83
 van Aalst, Gerda 5, 83
 Van Ameringen, Michael A. 89, 90
 Van Brunt, David L. 90
 Van Rheenen, Fredric J. 68
 Vansickle, Kaycia L. 64
 Van Wel, E. Bass 29
 Vanderpool, Donna 19
 Varma, Sudeepa 43
 Vaswani, Meera 23, 48, 90
 Vaughan, Susan C. 57
 Veijola, Juha M. 46, 89
 Velligan, Dawn I. 87
 Velyvis, Vytas P. 74
 Ventura, Tirso 47
 Verheul, Roel 95
 Vermetten, Eric 60
 Viamontes, George I. 27, 68
 Videon, Tami 47
 Viederman, Milton 78
 Vigezzi, Pierluigi 70
 Vigo, Daniel E. 71
 Viguera, Adele C. 66, 99
 Villalba, Rendueles 88
 Villarreal, Roberto 55
 Viswanathan, Ramaswamy 44
 Vitiello, Benedetto 42, 92
 Vlasveld, Laurens 34
 Vocci, Francis J. 50
 Vogel, Albert V. 72
 Vogel-Scibilia, Suzanne E. 88
 Volfson, Elena 44
 Volkman, Edward A. 26, 44
 Volkow, Nora D. 26, 60, 81, 96
 Volpp, Serena Yuan 25, 49
 Von Esenwein, Silke 84
 Von Korff, Michael 84, 98
- W
- Wachtel, Dana 82
 Wagner, Angela 97
 Wagner, Ann 87
 Wagner, Karen D. 4, 63
 Waheed, Waqar 89
 Wahlstrom, Jr., Carl M. 87
 Walker, David M. 71, 89
 Walkup, John T. 42, 68, 93
 Walsh, B. Timothy 59, 71
 Wapenyi, Khakasa H. 25
 Warman, Melissa 59
 Warren, Stephen 88
 Warshaw, Carole L. 18, 79

- | | |
|-------------------------------|------------------------------|
| Warshowski, Adam..... | 89 |
| Wasdell, Michael..... | 23 |
| Wasserman, Stacey..... | 61, 79 |
| Waterman, G. Scott..... | 33 |
| Weathers, Frank W..... | 34 |
| Webb, Carmen T..... | 91 |
| Webster, Christopher..... | 72 |
| Weerasekera, Priyanthy..... | 79 |
| Wehr, Thomas A..... | 61 |
| Weiden, Peter J..... | 51, 87 |
| Weinberg, Pamela A..... | 72 |
| Weinberger, Daniel R..... | 11, 52 |
| Weinberger, Morris..... | 82 |
| Weine, Stevan M..... | 93 |
| Weiner, Elyse D..... | 19 |
| Weiner, Richard D..... | 26 |
| Weinfurt, Kevin P..... | 22 |
| Weinstein, Henry C..... | 43, 49, 58, 88 |
| Weintraub, Daniel..... | 13 |
| Weiss, Jeffrey..... | 91 |
| Weiss, Margaret D..... | 23, 32 |
| Weissman, Myrna M..... | 30 |
| Weitzner, Eric..... | 74 |
| Weker, Jonathan L..... | 17 |
| Welsh, Christopher J..... | 63 |
| Weitzin, Theodore E..... | 70 |
| Wengel, Steven..... | 64 |
| West, Joyce C..... | 48, 59, 96 |
| Westen, Drew..... | 97 |
| Wetzler, Scott..... | 47 |
| Weyand, Cornelia M..... | 42 |
| Wheeler, Susan..... | 45 |
| White, Patti Obrow..... | 45 |
| Widiger, Thomas A..... | 30, 77, 95 |
| Wigal, Sharon B..... | 23, 48, 62 |
| Wilens, Timothy E..... | 12, 22, 48, 62, 80 |
| Wilhelm, Sabine..... | 90 |
| Wilk, Joshua E..... | 48, 59 |
| Wilkins, Jeffery..... | 73, 87 |
| Williams, Adedapo B..... | 98 |
| Williams, Caroline B..... | 24, 48, 70 |
| Williams, Eric R..... | 50 |
| Williams, Jill..... | 26 |
| Williams, Richard..... | 76 |
| Williamson, David J..... | 51 |
| Wilson, Janice..... | 93 |
| Winkelman, John W..... | 9, 26, 37, 53 |
| Winslow, James T..... | 61 |
| Winstead, Daniel K..... | 86 |
| Wise, Michael E..... | 87 |
| Wise, Robert A..... | 43 |
| Wise, Thomas N..... | 94 |
| Wisner, Katherine L..... | 2, 23, 30, 41, 58 |
| Wisniewski, Stephen R..... | 23, 31 |
| Wohlschlag, Madelaine M..... | 90 |
| Wolfe, Nicole..... | 64, 69 |
| Wolkin, Adam..... | 7 |
| Womack, William M..... | 29, 66 |
| Wompler, Timothy..... | 82 |
| Wonderlich, Stephen A..... | 97 |
| Wood, Julia..... | 80 |
| Wood, William C..... | 49 |
| Woods, Scott W..... | 30, 77 |
| Woolley, Stephen B..... | 70 |
| Worley, Linda L.M..... | 19 |
| Wozniak, Janet..... | 35 |
| Wright, Harry H..... | 24 |
| Wright, Jesse H..... | 8, 26, 50 |
| Wu, Yelena..... | 70 |
| Wung, Jay..... | 88 |
| Wynn, John D..... | 42 |
| Wyshak, Grace..... | 54 |
| X | |
| Xu, Yong..... | 24 |
| Y | |
| Yager, Joel..... | 1, 6, 17, 25, 45, 68, 83, 97 |
| Yamada, Mitsuhiro..... | 33 |
| Yates, Alayne..... | 48 |
| Yen, Shirley..... | 77 |
| Yeomans, Frank E..... | 7 |
| Yeung, Albert..... | 24, 32 |
| Yin, Paul..... | 24 |
| Ying, Patrick..... | 68 |
| Yonkers, Kimberly A..... | 13, 30 |
| Young, Keith W..... | 44, 49, 56 |
| Yu, Van..... | 74 |
| Yu-Chin, Rose..... | 91 |
| Yudofsky, Stuart C..... | 12, 13, 39, 69 |
| Yuschok, Theresa A..... | 73 |
| Z | |
| Zachar, Peter..... | 33, 82 |
| Zachariae, Robert..... | 88 |
| Zagursky, Karen..... | 61 |
| Zanarini, Mary..... | 7 |
| Zatzick, Douglas F..... | 34 |
| Zee, Phyllis C..... | 9, 53 |
| Zerbe, Kathryn J..... | 21, 75, 97 |
| Zervakis, Jennifer..... | 82 |
| Ziedonis, Douglas M..... | 26 |
| Zil, John S..... | 49 |
| Zimmerman, Mark..... | 90 |
| Zin, Walter A..... | 71 |
| Zipursky, Robert B..... | 10, 12, 77 |
| Zisook, Sidney..... | 31, 82 |
| Zito, Fran..... | 64 |
| Zlatoper, Kenneth W..... | 71 |
| Zohar, Joseph..... | 79 |
| Zolovska, Beata A..... | 20 |
| Zonana, Howard V..... | 72 |
| Zubieta, Jon-Kar..... | 58 |
| Zucker-Goldstein, Marion..... | 21 |
| Zuckoff, Allan..... | 41 |



AMERICAN PSYCHIATRIC ASSOCIATION – 159TH ANNUAL MEETING

MAY 20-25, 2006

Toronto, Canada

CALL FOR PAPERS

PRESIDENT'S THEME:

From Science to Public Policy: Advocacy for Patients & the Profession

Steven S. Sharfstein, M.D.
President

Marian I. Butterfield, M.D., Chairperson
Scientific Program Committee

THE SUBMISSION SCHEDULE

| Format | Deadline |
|------------------------------|---|
| Industry-Supported Symposium | June 1, 2005 |
| Course | September 6, 2005 |
| Reports | September 6, 2005 |
| Symposium | September 6, 2005 |
| Workshops | Issue: September 6, 2005 Component: September 20, 2005 |
| New Research | December 2, 2005 |

Incomplete and/or Incorrect Forms Will Not Be Considered.

You are encouraged to complete your submissions online by visiting www.psych.org, click on the Annual Meeting logo, then click on the submission form box.

You may also fill out and download a PDF version of the forms. Feel free to contact the APA toll free at 1-888-357-7924, and speak directly with an Answer Center Coordinator.

If you want to volunteer to chair a session, please send a letter to the attention of Dr. Butterfield at the American Psychiatric Association. Please indicate your name, address, area of expertise, and the type of session you would like to chair. Please be aware that we receive more requests than available slots. If you are selected as a chairperson, you will be notified by the end of November.



57th Institute on Psychiatric Services

APA's Leading Educational Conference on Public and Community Psychiatry

October 5-9, 2005, San Diego CA

Recovery and Community

Save the date now to attend the 57th Institute on Psychiatric Services, APA's leading educational conference on clinical issues and community mental health to meet the service needs of people with severe mental illness.

With 100 exhibits that complement the educational program, and popular networking events, and over 175 expertly-led educational sessions on topics including:

- Recovery issues
- Social and community psychiatry
- Psychopharmacology
- Resident and medical student concerns
- Substance abuse
- Child and adolescent issues
- AIDS and HIV related disorders
- Cross-cultural and minority issues
- Psychiatric administration and services
- Treatment techniques and outcome studies
- Cognitive disorders
- Health service research
- Mood disorders
- Schizophrenia and other Psychotic disorders
- Psychopharmacology
- Violence and trauma
- And much more...

Who Should Attend?

- All APA Members
- Psychiatrists and mental health professionals in community practice or the public sector including state, community, and Veterans Affairs hospitals, community clinics, and jails and prisons.
- Psychiatric administrators
- Mental health professionals interested in social issues that have an impact on patients and their families
- Minority psychiatrists and International Medical Graduates
- Psychiatric Residents
- Medical Students
- Consumers interested in recovery issues

Why Should You Attend?

- Earn up to 48 hours of category 1 CME credit
- Receive a 40% discount on APA member registration fees
- Industry-supported lunch and dinner symposia presented each day

How Will You Benefit?

- Learn the latest knowledge and skills in clinical psychiatry, which can be utilized to improve patient care
- Acquire a deeper understanding of how the current health care system affects patient care
- Gain new knowledge and skills useful in clinical and public psychiatric settings
- Recognize and improve mental health disparities in the community
- Understand all aspects of recovery and how this affects the community

Continuing Medical Education Credit

The American Psychiatric Association is accredited by the Accreditation Council on Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 48 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spends in the educational activity.

The IPS Preliminary Program, which includes registration, housing, and travel information is available online at www.psych.org or call 888-35-PSYCH and request a copy. Online registration will begin June 6, 2005 at www.psych.org.

For further information, please contact:



American Psychiatric Association
1000 Wilson Blvd., Suite 1825
Arlington, VA 22209-3901

Phone: (888) 35-PSYCH
or (703) 907-7300

Fax: (703) 907-1090

Three Nights, Three Special Programs

Join us for three evening events at the 2005 APA Annual Meeting



Saturday, May 21, 2005

**APF's 2005 Annual Benefit
"Georgia on My Mind"
The High Museum of Art
7:00 – 10:00 p.m.**

Spend a wonderful evening with the foundation featuring a silent auction of artwork created by Skyland Trail clients, a tour of the High Museum's galleries, nouvelle southern cuisine and live music. Silent auction proceeds will benefit Skyland Trail, the foundation's 2005 community partner for the event. Skyland Trail is the winner of the APA 2004 Psychiatric Services Gold Achievement Award for community-based programs.

**Tickets - \$150 per person
(\$100 tax deductible)
Call 703.907.8512
or visit www.psychfoundation.org**

Supported by:



Abbott Laboratories
Cyberonics
Forest Laboratories
Eli Lilly and Company
Otsuka America Pharmaceutical
Professional Risk Management Services

Monday, May 23, 2005

**Psychiatry Film Fest
Sheraton Atlanta, Grand
Ballroom
7:00 – 10:00 p.m.
Open to all Annual Meeting attendees**

Join us for a viewing of "The Son's Room," the Best Picture Award winner at the 2001 Cannes Film Festival. The film, presented in Italian with English subtitles, portrays a psychiatrist and his family grappling with grief. The film will be followed by a discussion of depression and culture, moderated by Steven Hyler, M.D., Clinical Professor of Psychiatry at Columbia University College of Physicians and Surgeons. Light refreshments will be served.

**Supported through an unrestricted
educational grant from:**



Tuesday, May 24, 2005

**"Conversations"
Sydney J. Marcus Auditorium
World Congress Center
5:30 – 6:30 p.m.
Open to all Annual Meeting attendees**



Greg Louganis, Guest Speaker

Join us for our 4th annual "Conversations" event, an interactive discussion series that offers psychiatrists an opportunity to hear unique perspectives on mental illness. Greg Louganis, winner of five Olympic medals for diving, will be our guest. Louganis will share his experiences with depression, substance abuse, and an HIV-positive diagnosis.

**Supported through an unrestricted
educational grant from:**



The *First and Last Word* in Psychiatry

APPI Bookstore at the 2005 APA Annual Meeting in Atlanta!

Psychiatry's premiere publisher brings the cutting-edge titles you've been waiting for directly to you! Come check out APPI's latest groundbreaking selection, from the newest textbooks, review series, and journals, to electronic products for your handheld or online. Update subscriptions, complete your series collections, browse through hard to find titles, and even develop your course adoptions all in one stop. Don't miss the Author Book Signings. See you there!



Psychodynamic Psychiatry in Clinical Practice, Fourth Edition

Glen O. Gabbard, M.D.

2005 • 640 pages • ISBN 1-58562-185-4
Hardcover • \$89.95 • Item #62185



Manual of Clinical Psychopharmacology, Fifth Edition

Alan F. Schatzberg, M.D., Jonathan O. Cole, M.D., and Charles DeBattista, D.M.H., M.D.

2005 • 672 pages • ISBN 1-58562-209-5
Paperback • \$69.00 • Item #62209



The American Psychiatric Publishing Textbook of Psychosomatic Medicine

Edited by James L. Levenson, M.D.

2005 • 1124 pages • ISBN 1-58562-127-7
Hardcover • \$169.00 • Item #62127



Textbook of Traumatic Brain Injury

Edited by Jonathan M. Silver, M.D., Thomas W. McAllister, M.D., and Stuart C. Yudofsky, M.D.

2005 • 796 pages • ISBN 1-58562-105-6
Hardcover • \$99.00 • Item #62105



The American Psychiatric Publishing Textbook of Personality Disorders

Edited by John M. Oldham, M.D., M.S., Andrew E. Skodol, M.D., and Donna S. Bender, Ph.D.

2005 • 816 pages • ISBN 1-58562-159-5
Hardcover • \$85.00 • Item #62159



The American Psychiatric Publishing Textbook of Psychoanalysis

Edited by Ethel S. Person, M.D., Arnold M. Cooper, M.D., and Glen O. Gabbard, M.D.

2005 • 656 pages • ISBN 1-58562-152-8
Hardcover • \$95.00 • Item #62152

APPI Bookstore Hours

| | |
|-------------------|------------------|
| Saturday, May 21 | 10:00am – 5:00pm |
| Sunday, May 22 | 10:00am – 4:30pm |
| Monday, May 23 | 10:00am – 5:30pm |
| Tuesday, May 24 | 10:00am – 6:00pm |
| Wednesday, May 25 | 10:00am – 3:00pm |

Special Benefits for American Psychiatric Association Members!

10% Discount for All APA Members

25% Discount for Members-in-Training

Prices subject to change without notice.

Please reference priority code AP512 when ordering.

The *First and Last Word* in Psychiatry



1000 Wilson Boulevard, Suite 1825
Arlington, VA 22209-3901
Phone: 703-907-7322 or 1-800-368-5777
Mon.-Fri., 9 am to 5:30 pm, ET
Fax: 703-907-1091
Email: appi@psych.org
Web: www.appi.org



Clinical Manual to Psychosomatic Medicine A Guide to Consultation-Liaison Psychiatry

Michael G. Wise, M.D., and James R. Rundell, M.D.

2005 • 368 pages • ISBN 1-58562-201-X
Paperback • \$37.95 • Item #62201



Clinical Manual of Women's Mental Health

Vivien K. Burt, M.D., Ph.D., and Victoria C. Hendrick, M.D.

2005 • 240 pages • ISBN 1-58562-186-2
Paperback • \$35.95 • Item #62186

At Your Annual Meeting Bookstore

Review of Psychiatry, Volume 24

Series Editors: John M. Oldham, M.D., M.S., and Michelle B. Riba, M.D., M.S.

Sleep Disorders and Psychiatry

Edited by Daniel J. Buysse, M.D.

2005 • pages TBA • ISBN 1-58562-229-X
Paperback • \$34.95 • Item #62229

Mood Disorders During Pregnancy and the Postpartum

Edited by Lee S. Cohen, M.D., and Ruta M. Nonacs, M.D., Ph.D.

2005 • pages TBA • ISBN 1-58562-225-7
Paperback • \$34.95 • Item #62225

Psychiatric Genetics

Edited by Kenneth S. Kendler, M.D., and Lindon Eaves, Ph.D., D.Sc.

2005 • pages TBA • ISBN 1-58562-228-1
Paperback • \$34.95 • Item #62228

Advances in Treatment of Bipolar Disorder

Edited by Terence A. Ketter, M.D.

2005 • pages TBA • ISBN 1-58562-230-3
Paperback • \$34.95 • Item #62230

SET of Review of Psychiatry, Volume 24

2005 • \$109.00 • Item #5088

JANUARY

Research Advances in Genetics and Genomics Implications for Psychiatry

Edited by Nancy C. Andreasen, M.D., Ph.D.

2005 • 159 pages • ISBN 1-58562-200-1
Paperback • \$24.95 • Item #62200

FEBRUARY

Understanding and Treating Borderline Personality Disorder A Guide for Professionals and Families

Edited by John G. Gunderson, M.D., and Perry D. Hoffman, Ph.D.

2005 • 192 pages • ISBN 1-58562-135-8
Paperback • \$29.95 • Item #62135

MARCH

Menopause A Mental Health Practitioner's Guide

Edited by Donna E. Stewart, M.D., F.R.C.P.C.

2005 • 240 pages • ISBN 1-58562-160-9
Paperback • \$34.95 • Item #62160

Fatal Flaws

Navigating Destructive Relationships With People With Disorders of Personality and Character

Stuart C. Yudofsky, M.D.

2005 • 496 pages • ISBN 1-58562-214-1
Paperback • \$33.95 • Item #62214

APRIL

Study Guide to the American Psychiatric Publishing Textbook of Psychosomatic Medicine

James A. Bourgeois, O.D., M.D.,
Robert E. Hales, M.D., M.B.A., and
Nariman C. Shahrokh

2005 • 208 pages • ISBN 1-58562-235-4
Paperback • \$19.95 • Item #62235

What Your Patients Need to Know About Psychiatric Medications

A Resource Book of Medication Information

Robert E. Hales, M.D., M.B.A., Stuart C. Yudofsky, M.D.,
and Robert H. Chew, Pharm.D.

2005 • 352 pages • ISBN 1-58562-203-6
Spiralbound • \$59.95 • Item #62203

Psychiatry, Psychoanalysis, and the New Biology of Mind

Eric R. Kandel, M.D.

2005 • 432 pages • ISBN 1-58562-199-4
Hardcover • \$57.95 • Item #62199

Handbook of Essential Psychopharmacology, Second Edition

Ronald W. Pies, M.D.

2005 • 528 pages • ISBN 1-58562-168-4
Paperback • \$65.00 • Item #62168

Competency in Combining Pharmacotherapy and Psychotherapy Integrated and Split Treatment Core Competencies in Psychotherapy

Michelle B. Riba, M.D., M.S., and Richard Balon, M.D.

Series Editor: Glen O. Gabbard, M.D.

2005 • 160 pages • ISBN 1-58562-143-9
Paperback • \$33.95 • Item #62143

Clinical Study Guide for the Oral Boards in Psychiatry, Second Edition


Nathan R. Strahl, M.D., Ph.D.

2005 • 330 pages • ISBN 1-58562-179-X
Paperback • \$39.95 • Item #62179

Announcing

PsychiatryOnline.com

Built around the resources you use daily in your practice and research
We are pleased to announce the launch of **PsychiatryOnline.com**. This site features the most trusted and reliable references in psychiatry, including the **DSM-IV-TR®** and *The American Journal of Psychiatry*.



PsychiatryOnline.com, an easy-to-use reference and research tool, harnesses the power of the Internet to bring you instant access to classic, must-have resources such as

- *Diagnostic and Statistical Manual of Mental Disorders*, the most widely used psychiatric reference in the world
- *The American Journal of Psychiatry* and four other APPI psychiatric journals
- *DSM-IV-TR® Handbook of Differential Diagnosis*
- *DSM-IV-TR® Casebook* and its *Treatment Companion*
- *APA Practice Guidelines for the Treatment of Psychiatric Disorders*
- *The American Psychiatric Publishing Textbook of Clinical Psychiatry*, Fourth Edition

All available with the convenience of state-of-the-art searching and cross-referencing tools custom-designed for psychiatric information that is critical to education, research, and practice in psychiatry. Delivering you the information you are looking for – whenever and wherever you need it.

PLUS...

- Access unlimited PDA downloads and self-assessment tools to help you prepare for certification and recertification and earn CME credits



For more information or to subscribe, visit **PsychiatryOnline.com**.
Please use priority code: **AP516**



American Psychiatric Publishing, Inc. 1000 Wilson Blvd., Suite 1825 Arlington, VA 22209-3901
Toll-Free: (800) 368-5777 Telephone: (703) 907-7322 Fax: (703) 907-1091 Web: www.appi.org / www.psychiatryonline.com

INDUSTRY-SUPPORTED SYMPOSIUM 1
 Saturday, May 21, 2005, 12:30 PM - 3:30 PM
 Grand Ballroom, Second Floor, Hilton Atlanta



Anxiety: Diverse Populations and Presentations, Unique Individuals and Treatments

Hilton Atlanta - Grand Ballroom • May 21, 2005 • 12:00 PM Lunch • 12:30 PM Symposium • 158th APA Annual Meeting

Presenters

Untangling the Role of Gender: The Course and Treatment of Anxiety Disorders in Women

Chairman: Naomi M. Simon, MD, MSc
 Associate Director, Center for Anxiety and Traumatic Street Related Disorders
 Massachusetts General Hospital
 Assistant Professor of Psychiatry
 Harvard Medical School
 Boston, MA

Evaluation and Treatment of Anxiety in Patients With Comorbid Mental Illness

Peter P. Roy-Byrne, MD
 Professor and Vice Chair
 Department of Psychiatry & Behavioral Sciences
 University of Washington School of Medicine
 Chief of Psychiatry
 Harborview Medical Center
 Seattle, WA

Improving Treatment of Anxiety One Individual at a Time

Jerrold F. Rosenbaum, MD
 Chief of Psychiatry
 Massachusetts General Hospital
 Professor of Psychiatry
 Harvard Medical School
 Boston, MA

Bridging Culture and Languages: Modifying Therapy for Refugees With PTSD

Michael W. Otto, PhD
 Professor of Psychology
 Boston University and the Center for Anxiety and Related Disorders
 Boston, MA

Anxiety and Substance Abuse: Complexities and Solutions

Kathleen T. Brady, MD, PhD
 Professor, Department of Psychiatry
 Director of Clinical Neuroscience
 Institute of Psychiatry, Medical University of South Carolina
 Charleston, SC



Objectives

At the conclusion of this activity, the participant should be able to:

- Recognize the diverse manifestations of anxiety in a variety of patient populations and the implications for tailoring care to the unique individual
- Understand what is known about the impact of gender and comorbid medical conditions on anxiety disorders and treatment
- Identify predictors of inadequate treatment responses in the anxious patient, and treatment strategies to improve outcomes
- Demonstrate strategies that address the language limitations and culturally distinct syndromes that complicate the process of offering Western-based psychotherapy to refugee populations
- Describe the prevalence of the concomitant presence of anxiety and substance abuse disorders, including their common neural circuitry

Attendees must be registered for the APA (Annual Meeting or Institute on Psychiatric Services) to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7104 (within the U.S. or Canada) or 703-967-7300.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Sponsored by the American Psychiatric Association

Supported by an unrestricted educational grant provided by UCB Pharma, Inc.



INDUSTRY-SUPPORTED SYMPOSIUM 2
 Saturday, May 21, 2005, 12:30 PM - 3:30 PM

Marquis Ballrooms III & IV, Convention Level, Marriott Marquis Atlanta

APA 158th
 Annual Meeting

**The Impact of Depression and Anxiety
 ON WELL-BEING ACROSS THE LIFE CYCLE**

Saturday, May 21, 2005 • 12:30 PM - 3:30 PM • Atlanta Marriott Marquis • Marquis Ballrooms III and IV, Convention Level • Atlanta, Georgia

AGENDA

12:00 noon Lunch

12:30 PM Welcome and Introduction
 Steven P. Roose, MD
 Program Chairperson
 Professor of Clinical Psychiatry
 College of Physicians and Surgeons
 Columbia University
 Director, Neuropsychiatry
 Research Clinic
 New York State Psychiatric Institute
 New York, New York

12:40 Comorbid Depression and Anxiety: When to Start and Continue with Psychotherapy and Pharmacotherapy
 Martin B. Keller, MD
 Mary E. Zuckerman, MD
 Department of Psychiatry and Human Behavior
 Brown University
 Executive Psychiatrist-in-Chief
 Brown Affiliated Hospitals
 Providence, Rhode Island

1:05 Comorbid Depression and Anxiety in Youth with Asthma
 Marcia J. Slattery, MD, MHS
 Associate Professor of Psychiatry
 Head, Division of Child and Adolescent Psychiatry
 University of Wisconsin
 Medical School
 Madison, Wisconsin

1:30 Depression and Anxiety in Elderly Patients with Dementia
 Davangere P. Devriendt, MD
 Professor of Clinical Psychiatry and Neurology
 College of Physicians and Surgeons
 Columbia University
 New York, New York

1:55 Depression and Anxiety as it Relates to Cardiovascular Illness
 K. Ranga Rama Krishna, MD
 Professor of Psychiatry
 Chairman, Department of Psychiatry and Behavioral Sciences
 Duke University Medical Center
 Durham, North Carolina

2:20 Impact of Depression and Anxiety in Women of Reproductive Age
 Ruta M. Nonack, MD, PhD
 Staff Psychiatrist
 Perinatal and Reproductive Psychiatry
 Research Program
 Massachusetts General Hospital
 Boston, Massachusetts

2:45 Question and Answer Session
 Faculty Panel

3:30 Adjournment



OBJECTIVES


At the conclusion of this program, participants should be able to:

- Review the relationship between comorbid anxiety and depression and assess the impact one has on the other.
- Distinguish the issues involved in the treatment of depression and anxiety in patients with dementia.
- Explain the relationship between the symptoms of depression and anxiety with asthma in children.
- Recognize depression and anxiety in cardiac patients.
- Explain how depression and anxiety may affect female reproductive functioning and assess the long-term effects of untreated depression on the child.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Attendees must be registered for the APA 2005 Annual Meeting to attend this symposium. Seating is limited and will be on a first-come, first-served basis. For more information about the meeting, please visit the APA Web site at www.psych.org or contact the APA toll free at 1-888-357-7104 (within the United States and Canada) or at 703-967-7300.



INDUSTRY-SUPPORTED SYMPOSIUM 3
 Saturday, May 21, 2005, 12:30 PM - 3:30 PM
 Grand Ballroom, North Tower, Grand Ballroom Level, Omni Hotel



Management of Disruptive Behavioral and Pervasive Developmental Disorders

Christopher J. McDougle, MD (Chair)

May 21, 2005 - 12:30 PM - 3:30 PM

Grand Ballroom, North Tower, Grand Ballroom Level, Omni Hotel, Atlanta, GA

Agenda

12:00 PM - 12:30 PM
Lunch

12:30 PM - 12:35 PM
Welcome and Introduction
Christopher J. McDougle, MD (Chair)
Indiana University School of Medicine

12:35 PM - 1:05 PM
The Unmet Treatment Needs of Youth With Severe Behavioral Problems
David J. Posey, MD
Indiana University School of Medicine

1:05 PM - 1:40 PM
Pharmacologic Management of Aggression in Disruptive Behavioral Disorders

Robert L. Findling, MD
Case Western Reserve University
University Hospitals of Cleveland

1:40 PM - 2:15 PM
Pharmacotherapy of Behavioral Symptoms in Pervasive Developmental Disorders
Christopher J. McDougle, MD

2:15 PM - 2:45 PM
Nonpharmacologic Approaches to the Management of Behavioral Symptoms
Eirich A. Pappadopulos, PhD
Center for the Advancement of Children's Mental Health
Columbia University

2:45 PM - 3:30 PM
Questions and Answers

3:30 PM
Symposium Adjourned

At the conclusion of this symposium, the participant should be able to:

- Understand that aggression is a common behavioral symptom in children and adolescents with psychotic/behavioral spectrum disorders
- Recognize the consequences of untreated aggressive behavior to caregivers and society, and the importance of early intervention
- Discern which types of behavioral symptoms across psychiatric/behavioral disorders are responsive to pharmacologic treatment (eg, aggressive behavior and its subtypes)
- Compare and contrast effectiveness and safety data for current psychotropic options for the treatment of behavioral symptoms in conduct disorders and autism

A symposium to be held during the APA 2005 Annual Meeting

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should only claim those credits that he/she actually spent in the educational activity.

Supported by an unrestricted educational grant from JANSSEN

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7524 (within the U.S. or Canada) or at 703-907-7300.

Sponsored by the American Psychiatric Association

INDUSTRY-SUPPORTED SYMPOSIUM 4
 Saturday, May 21, 2005, 6:00 PM - 9:00 PM
 Grand Ballroom, Second Floor, Hilton Atlanta

Psychosomatic Illness

A 21st Century Perspective

A CONTINUING MEDICAL EDUCATION SYMPOSIUM TO BE HELD AT THE AMERICAN PSYCHIATRIC ASSOCIATION 158TH ANNUAL MEETING

SPONSORED BY THE AMERICAN PSYCHIATRIC ASSOCIATION
 SUPPORTED BY AN UNRESTRICTED EDUCATIONAL GRANT FROM GLAXOSMITHKLINE

Program Objectives

After attending this continuing medical education symposium, the psychiatrist should be able to:

- Understand the complex relationships between physical illnesses and anxiety and mood disorders
- Recognize the role of the psychiatrist in treating chronic pain and health problems unique to women
- Identify ways to improve outcomes in medically ill patients with anxiety problems.

Saturday, May 21, 2005
5:30 pm to 9:00 pm
 HILTON ATLANTA
 GRAND BALLROOM (SECOND FLOOR)
 255 COURTLAND STREET NE
 ATLANTA, GEORGIA

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or 703-907-7300.

Agenda

5:30 PM DINNER

6:00 PM WELCOME, INTRODUCTION, AND PROGRAM OBJECTIVES
 Murray B. Stein, MD, MPH, Program Chair
University of California San Diego
 AND
 Prakash S. Masand, MD, Program CoChair
Duke University Medical Center

6:05 PM IMPACT OF ANXIETY AND MOOD DISORDERS ON PHYSICAL DISEASE: THE WORRIED NOT-SO-WELL
 Murray B. Stein, MD, MPH

6:35 PM FACILITATING TREATMENT FOR ANXIOUS PATIENTS WITH COMORBID MEDICAL ILLNESS
 Peter P. Ray-Byrne, MD
University of Washington School of Medicine

7:05 PM CHRONIC PAIN SYNDROMES: A PSYCHIATRIC PERSPECTIVE
 Prakash S. Masand, MD

7:35 PM INTERFACE OF WOMEN'S MENTAL AND REPRODUCTIVE HEALTH
 Hadine Jaffe, MD, MSc
Harvard Medical School

8:05 PM PANEL DISCUSSION

9:00 PM ADJOURNMENT

INDUSTRY-SUPPORTED SYMPOSIUM 5
 Saturday, May 21, 2005, 6:00 PM - 9:00 PM
 Imperial Ballroom, Convention Level, Marriott Marquis Atlanta

The Developmental Trajectory of Impulsivity

An educational symposium to be presented at the
 2005 Annual Meeting of the American Psychiatric Association

Saturday, May 21, 2005

Dinner: 5:30 PM - 6:00 PM
 Scientific Program: 6:00 PM - 9:00 PM

Imperial Ballroom
 Convention Level
 Marriott Marquis
 Atlanta, GA

Program Agenda

| | |
|-------------------|--|
| 5:30 PM - 6:00 PM | Dinner |
| 6:00 PM - 6:25 PM | Comorbidities of Impulse Control Disorders Across the Lifespan Eric Hollander, MD, Program Chairperson Mount Sinai School of Medicine |
| 6:25 PM - 6:30 PM | Questions and Answers |
| 6:30 PM - 6:55 PM | The Relationship of Trauma and Impulsivity in Posttraumatic Stress Disorder Lori L. Davis, MD University of Alabama at Birmingham |
| 6:55 PM - 7:00 PM | Questions and Answers |
| 7:00 PM - 7:25 PM | Adolescent Substance Abuse and Impulse Dyscontrol Deborah Deas, MD, MPH Medical University of South Carolina |
| 7:25 PM - 7:30 PM | Questions and Answers |
| 7:30 PM - 7:55 PM | Bipolar Disorder From Adolescence to Adulthood Melissa P. DelBello, MD University of Cincinnati College of Medicine |
| 7:55 PM - 8:00 PM | Questions and Answers |
| 8:00 PM - 8:25 PM | Potential Treatments for Impulsivity: Drive vs Brake Larry J. Siever, MD Mount Sinai School of Medicine |
| 8:25 PM - 8:30 PM | Questions and Answers |
| 8:30 PM - 9:00 PM | Panel Discussion |
| 9:00 PM | Adjournment |

The American Psychiatric Association is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.

The American Psychiatric Association designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA Web site at www.psych.org or contact the APA, toll free, at 1-888-357-7924 (within the U.S. or Canada) or 703-907-7300.

Educational Objective

At the conclusion of this symposium, participants should be able to describe the psychiatric disorders that may be comorbid with impulse control disorders; the differential manifestation of bipolar disorder across childhood, adolescence and adulthood; the role of impulsivity in affective disorders; the association of trauma and impulsivity in posttraumatic stress disorder; and the neurobiologic basis of different aspects of impulsivity.



Sponsored by the American Psychiatric Association



Supported by an unrestricted educational grant from Ortho-McNeil Pharmaceutical, Inc.

INDUSTRY-SUPPORTED SYMPOSIUM 6
 Saturday, May 21, 2005, 6:00 PM - 9:00 PM
 Marquis Ballrooms I & II, Convention Level, Marriott Marquis Atlanta

Integrating Neurobiology and Psychopathology into Evidence-Based Treatment of Social Anxiety Disorder

APA 2005 ANNUAL MEETING • Saturday, May 21, 2005 • 6:00-9:00 p.m., Dinner 5:30-6:00 p.m.
 Marquis Ballroom, Salons I & II • Convention Level, Marriott Marquis Atlanta • Atlanta, Georgia

AGENDA

6:00 - 6:10 p.m.

Welcome and Introduction

MICHAEL R. LIEBOWITZ, MD
 Symposium Chairperson
 Columbia University College of Physicians & Surgeons
 New York State Psychiatric Institute

6:10 - 6:40 p.m.

Social Anxiety Disorder: Epidemiology, Diagnosis, and Comorbidities

MICHAEL R. LIEBOWITZ, MD

6:40 - 6:45 p.m.

Questions

6:45 - 7:15 p.m.

Recent Advances in the Cognitive Neuroscience of Social Behavior

PHILIP T. NINAN, MD
 Emory University School of Medicine

7:15 - 7:20 p.m.

Questions

7:20 - 7:50 p.m.

Neurobiological Mechanisms of Social Anxiety Disorder

FRANKLIN R. SCHNEIER, MD
 Columbia University College of Physicians & Surgeons
 New York State Psychiatric Institute

7:50 - 7:55 p.m.

Questions

7:55 - 8:25 p.m.

Evidence-Based Pharmacotherapy of Social Anxiety Disorder

CARLOS BLANCO, MD
 Columbia University College of Physicians & Surgeons
 New York State Psychiatric Institute

8:25 - 9:00 p.m.

Questions

Upon completion of this symposium, participants should be able to:

- recognize the demographic and clinical characteristics of SAD, and the importance of improving detection;
- understand the neurobiology involved in fear conditioning and anxiety, and its role in SAD;
- have gained improved knowledge about emerging new evidence-based theories for the effective pharmacological treatment for SAD, including suggested first-line treatment, duration, and management of treatment-resistant patients.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APR. Each physician should claim only those credits that he/she actually spent in the activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA, toll free at 1-888-357-7924 (within the U.S. or Canada) or 703-907-7300.

This program is sponsored by the American Psychiatric Association and supported by an unrestricted educational grant from Forest Pharmaceuticals, Inc.



Forest Pharmaceuticals, Inc.

INDUSTRY-SUPPORTED SYMPOSIUM 7
 Saturday, May 21, 2005, 6:00 PM - 9:00 PM
 Marquis Ballrooms III & IV, Convention Level, Marriott Marquis Atlanta

APA 158th Annual Meeting

Bipolar Disorder:

PSYCHIATRIC AND MEDICAL IMPLICATIONS FOR OPTIMAL PATIENT MANAGEMENT



Saturday, May 21, 2005 • 5:30 PM - 6:00 PM - Dinner • 6:00 PM - 9:00 PM - Symposium
 Atlanta Marriott Marquis • Marquis Ballrooms III and IV, Convention Level • Atlanta, Georgia

AGENDA

6:00 PM
 Welcome and Introduction
 Paul E. Keck, Jr, MD
 University of Cincinnati College
 of Medicine
 Cincinnati, OH

6:10 PM
 Psychiatric Comorbidity in Bipolar
 Disorder
 Susan L. McElroy, MD
 University of Cincinnati College
 of Medicine
 Cincinnati, OH

6:35 PM
 Bipolar Disorder Complicated by Medical
 Comorbidity
 Roy H. Peris, MD
 Harvard Medical School
 Boston, MA

7:00 PM
 Treatment and Monitoring Guidelines
 for the Patient With Bipolar Disorder
 Trisha Suppes, MD, PhD
 University of Texas Southwestern
 Medical Center at Dallas
 Dallas, TX

7:35 PM
 Management of the Complicated
 Bipolar Patient
 Paul E. Keck, Jr, MD

8:15 PM
 Question-and-Answer Session
 Faculty Panel

9:00 PM
 Adjournment

OBJECTIVES

- At the conclusion of this program, participants should be able to:
- Recognize and manage the implications of medical and psychiatric comorbidities in the patient with bipolar disorder
 - Recognize and manage the challenges posed by bipolar disorder and the comorbid conditions that complicate the illness
 - Recognize the importance of comprehensive medical and psychiatric evaluations for the patient with bipolar disorder
 - Recognize the importance of clinical treatment guidelines while also understanding the need to adapt guidelines to individual patients
 - Recognize the potential for adverse events when treating the patient with bipolar disorder and adjust patient-management strategy appropriately

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity. Attendees must be registered for the APA 2005 Annual Meeting to attend this symposium. Seating is limited and will be on a first-come, first-served basis. For more information about the meeting, please visit the APA Web site at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the United States or Canada) or 703-907-7300.

Sponsored by the American Psychiatric Association

Supported by an unrestricted educational grant from Pfizer Inc

INDUSTRY-SUPPORTED SYMPOSIUM 8
 Saturday, May 21, 2005, 6:00 PM - 9:00 PM
 International Ballroom, North Tower, Ballroom Level, Omni Hotel

APA 2005 ANNUAL MEETING

**EXPANDING USES OF
 ATYPICAL ANTIPSYCHOTICS:
 ADDRESSING REAL-WORLD CHALLENGES**

Chairperson: Karen Dineen Wagner, MD, PhD

| | | |
|--|--|---|
| <p>PRELIMINARY AGENDA</p> <p>5:30hr to 6:30hr Dinner</p> <p>6:30hr to 6:35hr Welcome and Introduction Karen Dineen Wagner, MD, PhD University of Texas Medical Branch Galveston, Texas</p> <p>6:35hr to 7:00hr Differential Pharmacology of Antipsychotic Agents: Clinical Implications Jeffrey A. Lieberman, MD Columbia University New York, New York College of Physicians and Surgeons New York, New York</p> <p>7:00hr to 7:25hr Use of Atypical Antipsychotic Medications in Children Karen Dineen Wagner, MD, PhD</p> <p>7:25hr to 7:50hr Comparative Effectiveness of Antipsychotic Medications for Optimizing the Management of Psychosis in Geriatric Patients David L. Sullivan, MD David Geffen School of Medicine at UCLA Los Angeles, CA</p> | <p>7:50hr to 8:15hr Managing Psychosis in the Acute Care Setting John E. Kratoch, MD, PhD University of North Carolina Chapel Hill, North Carolina</p> <p>8:15hr to 8:40hr Improving Neurocognition With Atypical Antipsychotics Richard S.E. Keefe, PhD Duke University Durham, North Carolina</p> <p>8:40hr to 9:25hr Panel Discussion Moderator: Karen Dineen Wagner, MD, PhD</p> <p>9:25hr to 9:30hr Closing Remarks Karen Dineen Wagner, MD, PhD</p> | <p>Omni Hotel International Ballroom, North Tower Atlanta, Georgia</p> <p>Saturday, May 21, 2005 from 6:00hr to 9:00hr</p> <p>TARGET AUDIENCE This educational activity is intended for psychiatrists and other mental health care professionals attending the 2005 Annual Meeting of the American Psychiatric Association (APA).</p> <p>LEARNING OBJECTIVES After attending this symposium, participants should be better able to:</p> <ul style="list-style-type: none"> • Discuss the different pharmacologic profiles of atypical antipsychotics and their clinical implications • Review the evidence for the use of atypical antipsychotics in childhood psychiatric disorders and recognize their potential side effects • Assess the effectiveness of atypical antipsychotics for psychosis and agitation occurring in AD outpatients • Describe the state-of-the-art management of psychosis in the acute care setting and the impact emerging therapies may have on patient care • Recognize the role of atypical antipsychotics in improving neurocognition in patients with schizophrenia and their implication on patients' long-term outcomes <p>ACCREDITATION STATEMENT The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.</p> <p>The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should only claim those credits that he/she actually spent in the activity.</p> |
|--|--|---|

Supported by an unrestricted educational grant from Bristol-Myers Squibb Company and OTSUKA AMERICA PHARMACEUTICALS, INC.

SPONSORED BY The American Psychiatric Association

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or 703-907-7300.

INDUSTRY-SUPPORTED SYMPOSIUM 9
 Saturday, May 21, 2005, 6:00 PM - 9:00 PM
 Grand Ballroom, North Tower, Grand Ballroom Level, Omni Hotel

Achieving Remission in Depression:

Presented at the APA 2005 Annual Meeting
 Sat., May 21, 2005 • Omni Hotel • Atlanta, GA

Is the Bar Set Too High or Too Low?

Jonathan E. Alpert, MD, PhD, Massachusetts General Hospital, *Symposium Chairperson*

5:30 p.m. Dinner

5:50 p.m. Welcome and Announcements

6:00 p.m. **Remission in Depression: Definition and Treatment Approaches**

Joshua Israel, MD
 University of California San Francisco

6:30 p.m. **Augmentation and Combination Strategies in Partial and non-Responders to Antidepressants**

Charles DeBattista, MD
 Stanford School of Medicine

7:00 p.m. **The Role of Psychotherapy to Enhance the Efficacy of Antidepressants**

Timothy Petersen, PhD
 Massachusetts General Hospital

7:30 p.m. **Pharmacological Approaches to the Treatment of Residual Symptoms**

Maurizio Fava, MD
 Massachusetts General Hospital


8:00 p.m. **Neurotherapeutics in Resistant Depression**

Linda Carpenter, MD
 Butler Hospital, Brown Medical School

8:30 p.m. Discussion

9:00 p.m. Adjourn

Supported by an unrestricted educational grant from Cephalon



Sponsored by the American Psychiatric Association



Overview: At the conclusion of this symposium, participants will be familiar with the definition and assessment of response and remission in the treatment of depressive disorders and have a greater appreciation for the therapeutic potential and limitations of advances in the pharmacological, psychotherapeutic and neurotherapeutic treatment of unremitted depression.

Accreditation/Registration Information: The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or 703-907-7300.

INDUSTRY-SUPPORTED SYMPOSIUM 10
 Saturday, May 21, 2005, 6:00 PM - 9:00 PM
 Peachtree Ballroom, Level 8, Westin Peachtree Plaza

A Dinner Symposium Held During the APA 2005 Annual Meeting

Dealing With Depression:
 The Added Burden to Medical Patients

Saturday, May 21, 2005

5:30PM-6:00PM Dinner • 6:00PM-9:00PM Educational Activity
 The Westin Peachtree Plaza • Level 8, Peachtree Ballroom • Atlanta, Georgia

5:30PM-6:00PM
 Dinner

6:00PM

Welcome and Introduction

Madhukar H. Trivedi, MD
 Program Chairperson
 University of Texas Southwestern Medical Center

6:30PM

General Medical Comorbidities Associated With Depression

Wayne J. Katon, MD
 University of Washington Medical Center

6:55PM

The Impact of Psychosomatic Symptoms (Chronic Pain or Fatigue) on Depression and Its Treatment

David A. Fishbein, MD, FAPA
 University of Miami School of Medicine
 The Regional Comprehensive Pain and Behavioral Center

7:00PM

Strategies and Tactics of Treatment for Complicated Depression: An Algorithmic Approach

Madhukar H. Trivedi, MD
 Program Chairperson

7:25PM

The Role of Psychotherapy in the Treatment of Complicated Depression

Ellen Frank, PhD
 Western Psychiatric Institute and Clinic
 University of Pittsburgh School of Medicine

7:50PM

Maintaining Remission in Depression

James M. Martinez, MD
 Baylor College of Medicine

8:15PM

Question and Answer Session

9:00PM

Program Adjournment

Learning Objectives

Upon completion of the activity, participants should be able to:

1. Identify key aspects related to the long-term repercussions of depression, the appropriate treatment methods using pharmacotherapy, along with effective strategies for maintaining remission.
2. Discuss efficacy and safety of treatment and time of onset and remission of all symptoms of depression.
3. Use critical decision points based on TMAP and STAR*D in routine clinical practice, and evaluate evidence-based treatments for depression.
4. Summarize the prevalence and adverse impact of major depression in patients with chronic medical illness.
5. Assess the concept of fibromyalgia as a psychosomatic disease, and explain the relationship between chronic pain and fatigue.
6. Differentiate the mechanisms by which antidepressants alleviate pain in the context of depression.
7. Summarize the role of psychotherapy in the treatment of depression complicated by medical illness and the data to support the efficacy of this treatment approach.
8. Define remission as the goal of treatment in patients with major depression, recognize risks of achieving inadequate treatment response, and identify strategies to achieve and maintain remission.

Accreditation Statement

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement

The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Sponsored by the American Psychiatric Association



Supported by an educational grant from Eli Lilly and Company



Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA Web site at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or 703-907-7300.



INDUSTRY-SUPPORTED SYMPOSIUM 11

Sunday, May 22, 2005, 8:00 AM - 11:00 AM
Grand Ballroom, Second Floor, Hilton Atlanta



SYSTEMATIC TREATMENT OF BIPOLAR DISORDER: BRINGING EVIDENCE INTO PRACTICE

Sunday, May 22, 2005
7:30 am - 11:00 am
Hilton, Atlanta, Grand Ballroom, Second Floor
Atlanta, GA, USA

Sponsored by the American
Psychiatric Association
APA 2005 Annual Meeting



Funded by an educational grant
from GlaxoSmithKline



REGISTRATION STATEMENT:

Attendees must be registered for the American Psychiatric Association Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the United States or Canada) or 1-703-907-7300.

ACCREDITATION STATEMENT:

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION:

The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirements of the APA. Each physician should claim only those credits that he/she actually spent in the educational activity.

STATEMENT OF NEED:

In 1998, the NIMH sponsored Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) began to conduct effectiveness studies for patients with bipolar disorder. The project utilized a common approach to disease management based on evidence and expert guidelines available at the start of enrollment, but planned to revise its recommendations regularly as new data accumulated.

New findings also impact views of bipolar disorder as a clinical entity. An interesting picture of bipolar disorder emerges from the assessments completed by >3700 individuals seeking treatment at STEP-BD treatment centers. In this sample of bipolar disorder, the most common co-morbidities are anxiety disorders, psychoactive substance abuse, obesity, and ADHD. Gender, ethnicity, and socioeconomic status appear as strong influences on entry into treatment. Each month, about 5% of recovered patients relapse and depression accounts for 80% of these relapses. Quasi-experimental data comparing outcomes for acute bipolar depression treated with or without standard antidepressants finds little evidence that standard antidepressants offer efficacy.

This symposium presents the STEP-BD disease management model, and broad reviews of treatment study data for depression, mania, and rapid cycling that has become available over the course of the project. Based on this information, revised treatment pathways are offered to guide clinical management.

INTENDED AUDIENCE:

Psychiatrists

EDUCATIONAL OBJECTIVES:

- At the conclusion of this session, participants should be able to:
- Describe the STEP-BD disease management model
 - Summarize STEP data and other studies over the past 7 years
 - Discuss treatment study data for depression
 - Discuss treatment study data for mania
 - Discuss treatment study data for rapid cycling
 - Describe suicide prevention strategies for bipolar patients at risk for suicide

SCIENTIFIC AGENDA AND DISTINGUISHED FACULTY:

| | |
|----------|--|
| 7:30 am | Breakfast |
| 8:00 am | Effectiveness Research for Bipolar Disorder: Context and Process Gary Sachs, MD, Harvard Medical School |
| 8:10 am | Approach to Treatment: Integration of Measurement and Management Andrew A. Nierenberg, MD Massachusetts General Hospital |
| 8:30 am | View of the Illness: Course and Comorbidity Findings Claudia Baldassano, MD, University of Pennsylvania |
| 8:50 am | What is the Best Treatment for Manic and Mixed Episodes? Gary Sachs, MD, Harvard Medical School |
| 9:05 am | What is the Best Treatment for Bipolar Depression? Michael J. Ostacher, MD, MPH, Harvard Medical School |
| 9:25 am | What is the Best Treatment for Rapid Cycling? Christopher Schneck, MD University of Colorado Health Sciences Center |
| 9:40 am | Managing Comorbidity Michael J. Ostacher, MD, MPH, Harvard Medical School |
| 9:55 am | Psychosocial Interventions David J. Miklowitz, Ph.D., University of Colorado, Boulder |
| 10:10 am | Multiphase Suicide Prevention Strategies in Bipolar Disorder Ellen B. Denney, Ph.D., Purdue University |
| 10:20 am | Q&A |
| 11:00 am | Adjourn |

PROGRAM ADMINISTRATION AND AMERICANS WITH DISABILITIES ACT:

Event staff will be glad to assist you with any special needs (e.g., physical, dietary). Please contact Brandee Johnson or Connie Maslow prior to the live event at 720-748-8800 or e-mail at bjohnson@intellyt.com or cmaslow@intellyt.com.

INDUSTRY-SUPPORTED SYMPOSIUM 12

Sunday, May 22, 2005, 8:00 AM - 11:00 AM
Imperial Ballroom, Convention Level, Marriott Marquis Atlanta

Too Little, Too Much: What Is Disordered Eating?

Program Agenda

| | |
|---------------------|---|
| 7:30 AM - 8:00 AM | Breakfast |
| 8:00 AM - 8:10 AM | Welcome and Introduction Joel Yager, MD, Program Chairperson University of New Mexico School of Medicine |
| 8:10 AM - 8:35 AM | Medical Morbidity of Eating Disorders Laurel Mayer, MD Columbia College of Physicians and Surgeons/NYSPJ |
| 8:35 AM - 8:40 AM | Questions and Answers |
| 8:40 AM - 9:05 AM | Genetic Epidemiology of Eating Disorders James I. Hudson, MD, ScD Harvard Medical School/McLean Hospital |
| 9:05 AM - 9:10 AM | Questions and Answers |
| 9:10 AM - 9:35 AM | Psychiatric Comorbidity of Eating Disorders: Understanding the Contribution of Impulsivity Susan L. McElroy, MD University of Cincinnati College of Medicine |
| 9:35 AM - 9:40 AM | Questions and Answers |
| 9:40 AM - 10:05 AM | Psychotherapy for Eating Disorders: When Yes, When No Cynthia M. Bulik, PhD University of North Carolina School of Medicine |
| 10:05 AM - 10:10 AM | Questions and Answers |
| 10:10 AM - 10:35 AM | Pharmacotherapy Trends in the Eating Disorder Spectrum Scott Crow, MD, University of Minnesota |
| 10:35 AM - 10:40 AM | Questions and Answers |
| 10:40 AM - 11:00 AM | Panel Discussion |
| 11:00 AM | Adjournment |

An educational symposium to be presented at the
2005 Annual Meeting of the American Psychiatric Association

Sunday, May 22, 2005

Breakfast: 7:30 AM - 8:00 AM

Scientific Program: 8:00 AM - 11:00 AM

Imperial Ballroom
Convention Level
Marriott Marquis
Atlanta, GA

The American Psychiatric Association is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.

The American Psychiatric Association designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information, attend the meeting, please visit the APA Web site at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or 703-907-7300.

Educational Objectives

At the conclusion of this symposium, participants should be able to describe the current evidence for potential psychotherapeutic treatments; the potential pharmacologic treatments; the genetic epidemiology, the potential medical consequences, and the underlying role of impulsivity in the expression of eating disorders.

Sponsored by the American Psychiatric Association



Supported by an unrestricted educational grant from Ortho-McNeil Pharmaceutical, Inc.

INDUSTRY-SUPPORTED SYMPOSIUM 13
 Sunday, May 22, 2005, 8:00 AM - 11:00 AM
 Marquis Ballrooms I & II, Convention Level, Marriott Marquis Atlanta

Spotlight on the Uniqueness of Depression & Anxiety in the Elderly

- 7:30 AM **Breakfast**
- 8:00 **Introduction**
 Katherine Shear, MD—Chairman
 University of Pittsburgh School of Medicine
- 8:15 **Late-Onset Depression: A Distinctive Disease Associated With the Elderly**
 Steven P. Roose, MD
 Columbia University College of Physicians & Surgeons
- 8:45 **Recognizing Depressive Disorders Comorbid With Medical Illnesses in the Elderly**
 Eric Lenze, MD • University of Pittsburgh School of Medicine
- 9:15 **Bereavement-Related Depression and Anxiety**
 Katherine Shear, MD
- 9:45 **Antidepressants and Anxiolytics in the Elderly: A Focus on Safety**
 George Alexopoulos, MD
 Weill Medical College of Cornell University
- 10:15 **Question-and-Answer Session**
- 11:00 **Conclusion**

Sponsored by the  American Psychiatric Association

Supported by an unrestricted educational grant from  **Forest Pharmaceuticals, Inc.**
Pharmaceuticals • Therapeutics • Healthcare • Technology • Managed Care • Biotech India

Held at the APA 2005 Annual Meeting

Sunday, May 22, 2005
 Breakfast 7:30 AM–8:00 AM
 Scientific Program 8:00 AM–11:00 AM
Marriott Marquis
 Ballrooms I & II, Convention Level
 Atlanta, Georgia

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for up to 3 hours in category 1 credit toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on a first-come, first-served basis. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or (703) 907-7300.

Educational Objectives

- Recognize and differentiate late-onset depression from other depressive disorders
- Understand and implement an appropriate treatment strategy for comorbid depression and systemic illness in the elderly population
- Recognize symptoms of major depression and anxiety disorders in the context of bereavement and their risk factors, differentiate traumatic grief from other psychiatric conditions, and understand the data available related to treatment efficacy in bereavement-related conditions
- Implement appropriate antidepressant and anxiolytic treatment strategies for comorbid depression and anxiety in the elderly

INDUSTRY-SUPPORTED SYMPOSIUM 14
 Sunday, May 22, 2005, 8:00 AM - 11:00 AM

Marquis Ballrooms III & IV, Convention Level, Marriott Marquis Atlanta

BRAIN STIMULATION:
 New Treatments for Mood Disorders

To be held at the APA 2005 Annual Meeting
 Sunday, May 22, 2005 • 8:00 AM - 11:00 AM
 Marriott Marquis Atlanta • Convention Level • Marquis Ballrooms III and IV

OBJECTIVES

- At the conclusion of this program, the participant should be able to:
1. Identify the mechanisms of action and evidence for safety and efficacy of five major methods to stimulate the brain to treat depression: ECT, rTMS, MST, VNS, & DBS.
 2. Develop an appreciation of the roles of stimulus dosage, stimulus waveform, and focality of stimulation in determining the efficacy and safety of electroconvulsive therapy.
 3. Be familiar with new findings regarding rTMS as an antidepressant.
 4. Demonstrate knowledge of the current state of development of magnetic seizure stimulation in treatment-resistant mood disorders.
 5. Discuss the long-term efficacy and safety data for the use of vagus nerve stimulation in treatment-resistant mood disorders.
 6. Understand the scientific rationale for deep brain stimulation to intractable OCD and intractable depression, its ethical and regulatory context, and developments to date.

PROGRAM CHAIR

A. John Rush, MD
 Betty Jo Hay Distinguished Chair in Mental Health
 Rosewood Corporation Chair in Biomedical Sciences
 Professor and Vice-Chairman for Research
 Department of Psychiatry
 University of Texas Southwestern Medical Center at Dallas
 Dallas, Texas

Sponsored by the:



Supported by an unrestricted educational grant from:

Cyberonics

AGENDA

- 7:30-8:00 AM
 Breakfast
- 8:00-8:10 AM
Welcome and Introductions
 A. John Rush, MD
- 8:10-8:35 AM
Optimizing the Therapeutic Elements of Electroconvulsive Therapy (ECT)
 Harold A. Sackeim, PhD
- 8:35-9:00 AM
Current Status of Repeated Transcranial Magnetic Stimulation (rTMS)
 Mark S. George, MD
- 9:00-9:25 AM
Current Status of Magnetic Stimulation Therapy (MST)
 Sarah H. Lisanby, MD
- 9:25-9:50 AM
Current Status of Vagus Nerve Stimulation (VNS)
 Lauren B. Marangell, MD
- 9:50-10:15 AM
Current Status of Deep Brain Stimulation (DBS)
 Benjamin D. Greenberg, MD, PhD
- 10:15-11:00 AM
 Discussion and Q&A

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for up to 3 hours in category 1 credit toward the AMA Physician's Recognition Award and for the CME requirements of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on a first-come, first-served basis. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or (703) 907-7300.

INDUSTRY-SUPPORTED SYMPOSIUM 15
 Sunday, May 22, 2005, 8:00 AM - 11:00 AM
 International Ballroom, North Tower, Ballroom Level, Omni Hotel

Presented at the
APA 158th Annual Meeting
 Omni Hotel, North Tower
 Atlanta, Georgia

Panic Disorder: Current Concepts and Future Directions

Mark H. Pollack, MD - Chair
 Sunday, May 22, 2005
 8:00 AM - 11:00 AM
 International Ballroom, Ballroom Level

Agenda

| | |
|---------------------|---|
| 7:30 AM - 8:00 AM | Breakfast |
| 8:00 AM - 8:05 AM | Welcome and Opening Remarks <i>Mark H. Pollack, MD, Massachusetts General Hospital, Boston, Massachusetts</i> |
| 8:05 AM - 8:30 AM | Window Into the Brain: Imaging Panic Disorder and the Neurocircuitry of Fear <i>Justine M. Kent, MD, Columbia University, New York, New York</i> |
| 8:30 AM - 8:55 AM | Genetics of Panic Disorder: What Have We Learned? <i>Jordan W. Smoller, MD, Massachusetts General Hospital, Boston, Massachusetts</i> |
| 8:55 AM - 9:20 AM | Cross-Cultural Aspects of Panic and Other Anxiety Disorders <i>Michael R. Liebowitz, MD, Columbia University, New York, New York</i> |
| 9:20 AM - 9:45 AM | Panic Symptoms at the Interface of Mind and Body <i>Karleyton C. Evans, MD, Harvard Medical School, Boston, Massachusetts</i> |
| 9:45 AM - 10:10 AM | Treating Panic Disorder: Acute Therapy and Beyond <i>Mark H. Pollack, MD, Massachusetts General Hospital, Boston, Massachusetts</i> |
| 10:10 AM - 10:55 AM | Discussion/Questions and Answers |
| 10:55 AM - 11:00 AM | Closing Remarks |
| 11:00 AM | Adjournment |

Target Audience

This activity is designed specifically for psychiatrists.

Learning Objectives

Upon completion of this symposium, the participants should be able to:

- List current pharmacologic and psychosocial therapies for the treatment of panic disorder and discuss their use for both acute and long-term therapy
- Discuss cross-cultural issues that influence prevalence and expression of anxiety disorders and their symptoms
- Review recent developments in the identification of the genetic basis of panic disorder

Accreditation

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Participation

Attendees must be registered for the APA [Annual Meeting or Institute on Psychiatric Services] to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA web-site at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or 703-907-7300.



Sponsored by the American Psychiatric Association.
 Supported by an unrestricted educational grant from Wyeth.

INDUSTRY-SUPPORTED SYMPOSIUM 16
 Sunday, May 22, 2005, 8:00 AM - 11:00 AM
 Grand Ballroom, North Tower, Grand Ballroom Level, Omni Hotel

Antipsychotic Drugs, Mood Stabilizers, and the Metabolic Syndrome

Herbert Y. Meltzer, MD (Chair), and Donald C. Goff, MD (Co-Chair)

May 22, 2005 - 8:00 AM - 11:00 AM

Grand Ballroom, North Tower, Grand Ballroom Level, Omni Hotel, Atlanta, GA

Agenda

| | |
|-------------------|--|
| 7:30 AM - 8:00 AM | Breakfast |
| 8:00 AM - 8:10 AM | Welcome and Introduction <i>Herbert Y. Meltzer, MD (Chair), Psychiatric Hospital at Vanderbilt University</i> |
| 8:10 AM - 8:35 AM | <i>Donald C. Goff, MD (Co-Chair), Massachusetts General Hospital</i> |
| 8:35 AM - 9:00 AM | Effect of Atypical Antipsychotics on Weight, Glucose Metabolism, and Diabetes Mellitus <i>Daniel W. Haupt, MD, Washington University in St. Louis</i> |
| 9:00 AM - 9:25 AM | The Effect of Antipsychotic Drugs on Lipids and Other Elements of the Metabolic Syndrome <i>Herbert Y. Meltzer, MD</i> |

9:25 AM - 9:50 AM
 Insulin Resistance, Dyslipidemia, and Cardiovascular Disease
Gerald M. Reaven, MD, Stanford University

9:50 AM - 10:15 AM
 Metabolic Sequelae of Atypical Antipsychotics: Obesity and Type 2 Diabetes
Marilyn Ader, PhD, University of Southern California

10:15 AM - 10:40 AM
 A Clinician's Guide to Managing Cardiac Risk Factors
Donald C. Goff, MD

10:40 AM - 11:00 AM
 Questions and Answers

11:00 AM
 Symposium Adjourned

At the conclusion of this symposium, the participant should be able to:

- Assess the effect of antipsychotic drugs and mood stabilizers on induction of the elements of the metabolic syndrome, with major attention to weight gain, diabetes mellitus, and lipid changes
- Understand the metabolic syndrome and its clinical significance for the risk of diabetes mellitus and cardiovascular disease
- Understand the pathophysiology of the metabolic syndrome
- Weigh the metabolic side-effect profiles and clinical effectiveness of antipsychotic drugs and mood stabilizers

A symposium to be held during the APA 2005 Annual Meeting

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should only claim those credits that he/she actually spent in the educational activity.

Supported by an unrestricted educational grant from JANSSEN

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or at 703-907-7300.

Sponsored by the American Psychiatric Association

INDUSTRY-SUPPORTED SYMPOSIUM 17
 Sunday, May 22, 2005, 8:00 AM - 11:00 AM
 Peachtree Ballroom, Level 8, Westin Peachtree Plaza

A Breakfast Symposium Held During the APA 2005 Annual Meeting

*Borderline Personality Disorder:
 Pathophysiology, Treatment, and Course*

*Sunday,
 May 22, 2005*

7:30AM-8:00AM Breakfast
 8:00AM-11:00AM Educational Activity
 The Westin Peachtree Plaza
 Level 8, Peachtree Ballroom
 Atlanta, Georgia

7:30AM-8:00AM Breakfast

8:00AM Welcome and Introduction

Mary C. Zanarini, EdD
 Program Chairperson
 McLean Hospital
 Harvard Medical School

8:10AM Ten-Year Course of Borderline Personality Disorder

Mary C. Zanarini, EdD
 Program Chairperson

8:35AM Neurobiology of Borderline Personality Disorder: An Update

Christian G. Schmahl, MD
 Central Institute of Mental Health

9:00AM Borderline Personality Disorder: Pharmacotherapy Steps Up

S. Charles Schulz, MD
 University of Minnesota Medical School

Learning Objectives

- Upon completion of the activity, participants should be able to:
1. Recognize that borderline personality disorder (BPD) has a substantially better prognosis than previously known.
 2. Recognize recent findings in the neurobiology of BPD.
 3. Discuss the newest data about medication treatment of BPD, the symptom patterns that are affected by medications, and novel outcome measures.
 4. Identify the likely brain regions that have impaired function in patients with BPD who have emotional instability and aggression.
 5. Explain the applications of dialectical behavioral therapy (DBT) in patients with BPD.
 6. Describe the latest data on the combination of DBT and the atypical antipsychotic, olanzapine.
 7. Discuss the most recent knowledge about the course, treatment, and neurobiology of BPD.

Accreditation Statement

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

9:25AM Neural Circuitry Dysfunction in Borderline Personality Disorder

Antonia S. New, MD
 Mount Sinai School of Medicine
 Bronx VA Medical Center

9:50AM Update on Dialectical Behavioral Therapy for Borderline Personality Disorder

Marsha M. Linehan, PhD
 University of Washington

10:15AM Question and Answer Session

Larry J. Siever, MD
 Program Discussant
 Mt. Sinai School of Medicine
 Bronx VA Medical Center

11:00AM Program Adjournment

Credit Designation Statement

The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Sponsored by the American Psychiatric Association




Supported by an educational grant from Eli Lilly and Company



Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA Web site at www.psych.org or contact the APA toll free at 1.888.357.7924 (within the US or Canada) or 703.907.7300.

INDUSTRY-SUPPORTED SYMPOSIUM 18
 Sunday, May 22, 2005, 1:30 PM - 4:30 PM
 Grand Ballroom, Second Floor, Hilton Atlanta

Sponsored by the American Psychiatric Association
 APA 2005 Annual Meeting
**Joining Night and Day:
 Insomnia and the Sleep/Wake Cycle**
 Sunday, May 22, 2005 ★ 1:00 – 4:30 p.m. ★ 2nd Floor Grand Ballroom ★ Hilton Atlanta ★ Atlanta, Georgia


Program Chair

Karl Dogramji, MD
 Professor of Psychiatry and Human Behavior
 Jefferson Medical College
 Director, Sleep Disorders Center
 Thomas Jefferson University Hospital
 Philadelphia, Pennsylvania

Agenda


| | | |
|----------------|---|---|
| 1:00 - 1:30 pm | Lunch | |
| 1:30 - 1:40 pm | Welcome and Introduction | Karl Dogramji, MD (Chair) Jefferson Medical College |
| 1:40 - 2:05 pm | Insomnia: Prevalence, Impact and Current Approaches to Evaluation and Management | Karl Dogramji, MD Jefferson Medical College |
| 2:05 - 2:30 pm | Medical Causes of Insomnia | Gerald Maguire, MD University of California, Irvine College of Medicine |
| 2:30 - 2:55 pm | The Sleep/Wake Cycle and Circadian Phase in Psychiatric Disorders | Alfred Lewy, MD, PhD Oregon Health & Science University School of Medicine |
| 2:55 - 3:20 pm | Current and Emerging Treatments for Insomnia | Milton Erman, MD University of California, San Diego |
| 3:20 - 3:45 pm | Special Concerns in Aging | Sonia Ancoli-Israel, PhD University of California, San Diego School of Medicine |
| 3:45 - 4:30 pm | Question-and-Answer Session | Entire Panel |

Learning Objectives

- Recognize the variety of disorders that are associated with insomnia and develop a rational approach in their evaluation and management.
- Identify the role of medical conditions in sleep disorders.
- Recognize the roles of the sleep/wake cycle and circadian rhythms in psychiatric disorders.
- Discuss currently available medications for sleep and review their mechanisms of action and clinically relevant characteristics.
- Discuss emerging pharmacological treatments for sleeplessness which feature novel mechanisms of action.
- Identify behavioral and pharmacologic interventions for insomnia in elderly patients.
- Cite risk factors for sleep disturbances in elderly populations.

Accreditation

 The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Supported by an unrestricted educational grant from Takeda Pharmaceuticals North America, Inc.


INDUSTRY-SUPPORTED SYMPOSIUM 19
 Sunday, May 22, 2005, 1:30 PM - 4:30 PM
 Imperial Ballroom, Convention Level, Marriott Marquis Atlanta

APA 158th Annual Meeting

CLINICAL INTERVENTIONS
For the Treatment of Insomnia



ASSOCIATED WITH PSYCHIATRIC AND COMORBID MEDICAL ILLNESSES

Sunday, May 22, 2005 • 1:00 PM - 1:30 PM - Luncheon • 1:30 PM - 4:30 PM - Symposium
 Marriott Marquis Atlanta • Convention Level, Imperial Ballroom • Atlanta, Georgia

AGENDA

1:30 PM
 Welcome and Introduction
 Alan F. Schatzberg, MD, Program Chair
 Stanford University School of Medicine
 Stanford, CA

1:40 PM
 Interrelationship of Insomnia to Medical
 Illnesses and Neurological Disorders
 Phyllis C. Zed, MD, PhD
 Northwestern University
 Chicago, IL

2:05 PM
 Effect of Chronic Pain Syndromes
 on Sleep
 Raymond R. Gaeta, MD
 Stanford University School of Medicine
 Stanford Hospital & Clinics
 Stanford, CA

2:35 PM
 Clinical Approaches to Insomnia
 David J. Kupfer, MD
 University of Pittsburgh School of Medicine
 Western Psychiatric Institute and Clinic
 Pittsburgh, PA

3:00 PM
 Gender-Specific Sleep Considerations
 in Women
 Hadine Jorife, MD, MSc
 Massachusetts General Hospital
 Boston, MA

3:20 PM
 New Pharmacologic Approaches for the
 Treatment of Insomnia
 John W. Winkelman, MD, PhD
 Harvard Medical School
 Brigham and Women's Hospital
 Boston, MA

3:45 PM
 Question-and-Answer Session
 Alan F. Schatzberg, MD
 Ned H. Kalin, MD, Program Co-Chair
 University of Wisconsin Medical School
 Madison, WI

Faculty Panel

4:30 PM
 Adjournment

OBJECTIVES

- At the conclusion of this program, participants should be able to:
- Identify the need for careful evaluation of insomnia that may present with psychiatric disorders and comorbid medical illnesses
 - Review the diagnostic strategies that are important for the assessment of insomnia in psychiatric and comorbid medical illnesses. Evaluate the medical-psychiatric aspects of insomnia
 - Recognize the interrelationship between insomnia, psychiatric disorder, and comorbid medical illnesses and understand how treating the insomnia can impact clinical outcome
 - Evaluate the behavioral and pharmacologic approaches for the treatment of insomnia

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity. Attendees must be registered for the APA 2005 Annual Meeting to attend this symposium. Seating is limited and will be on a first-come, first-served basis. For more information about the meeting, please visit the APA Web site at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the United States or Canada) or 703-907-7300.

Sponsored by the American Psychiatric Association



Sponsored by an unrestricted educational grant from Neurocrine Biosciences and Pfizer Inc.

INDUSTRY-SUPPORTED SYMPOSIUM 20
 Sunday, May 22, 2005, 1:30 PM - 4:30 PM
 Marquis Ballrooms I & II, Convention Level, Marriott Marquis Atlanta

Alzheimer's Disease Pathways To Practice:

ASSESSING DIAGNOSIS AND OUTCOME MEASURES

Agenda and Faculty

| | | |
|---------|---|--|
| 1:00 PM | Lunch | |
| 1:30 PM | Introduction | George T. Grossberg, MD (Chairman) Professor, Department of Psychiatry & Human Behavior Director, Geriatric Psychiatry St. Louis University Health Sciences Center Adjunct Professor for Department of Internal Medicine Wolf Clinic St. Louis, Missouri |
| 1:40 PM | The Interplay of Neurotransmitters in Alzheimer's Disease | Paul T. Francis, PhD Reader in Neurochemistry Wolfson Centre for Age-Related Diseases King's College London, UK |
| 2:05 PM | Formulating a Clinical Practice Care Plan for the Diagnosis and Assessment of Alzheimer's Disease | Warachal Faison, MD Assistant Director, Institute for Research Minority Training on Mental Health & Aging Alzheimer's Research & Clinical Programs Medical University of South Carolina North Charleston, South Carolina |
| 2:30 PM | Utilizing Advanced Imaging and Seroologic Markers across the Spectrum of Alzheimer's Disease | Mark A. Mintun, MD Professor of Radiology Mallinckrodt Institute of Radiology Washington University Medical Center St. Louis, Missouri |
| 2:50 PM | Rationalizing Therapeutic Approaches in Alzheimer's Disease | George T. Grossberg, MD |
| 3:15 PM | Behavioral and Neuropsychiatric Outcomes in Alzheimer's Disease | Jeffrey L. Cummings, MD, FAAN UCLA Alzheimer's Disease Center Los Angeles, California |
| 3:40 PM | Discussion/Q&A | Faculty |
| 4:25 PM | Concluding Remarks & Close | George T. Grossberg, MD |

A CONTINUING MEDICAL EDUCATION
 SYMPOSIUM AT THE APA 158TH ANNUAL MEETING

Sunday, May 22, 2005
 1:00 PM - 1:30 PM Lunch
 1:30 PM - 4:30 PM Scientific Program
 Marriott Marquis
 Marquis Ballroom, Salons 1 and 2

Educational Objectives

- Upon completion of this program, participants will be better able to:
- Review the role of neurotransmitters in Alzheimer's disease
 - Understand the basis of differential diagnosis in dementia
 - Comprehend the value of advanced imaging techniques and serologic markers in Alzheimer's disease
 - Discuss the therapeutic rationale for Alzheimer's disease
 - Recognize the cognitive and behavioral implications in Alzheimer's disease

This program is sponsored by the American Psychiatric Association.



The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education (CME) for physicians. The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity. Attendees must be registered for the APA to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or 703-907-7300.

This program is made possible by an unrestricted educational grant from



INDUSTRY-SUPPORTED SYMPOSIUM 21
 Sunday, May 22, 2005, 1:30 PM - 4:30 PM
 International Ballroom, North Tower, Ballroom Level, Omni Hotel

Anxiety Disorders:
 Understanding the
 Interconnection Between
 Emotional and Physical
 Symptoms

*Presented at the
 APA 158th Annual Meeting
 Omni Hotel, North Tower
 Atlanta, Georgia*

Mark H. Rapaport, MD - Chair
 Sunday, May 22, 2005
 1:30 PM - 4:30 PM
 International Ballroom, Ballroom Level

Agenda

- 1:00 PM - 1:30 PM Lunch
- 1:30 PM - 1:35 PM Welcome and Opening Remarks
Mark H. Rapaport, MD, Cedars-Sinai Medical Center, Los Angeles, California
- 1:35 PM - 2:10 PM Worried Sick: How Patients Experience General Anxiety Disorder
R. Bruce Lydiard, PhD, MD, Southeast Health Consultants, Charleston, South Carolina
- 2:10 PM - 2:45 PM Addressing the Full Spectrum of Symptoms of Social Anxiety Disorder
Nathalie Maullin, MD, Cedars-Sinai Medical Center, Los Angeles, California
- 2:45 PM - 3:20 PM Pharmacotherapy and Psychotherapy in the Treatment of PTSD
Barbara Rothbaum, PhD, Emory School of Medicine, Atlanta, Georgia
- 3:20 PM - 3:50 PM Panic Disorder: The Interconnection Between Emotional and Physical Symptoms
Mark H. Rapaport, MD, Cedars-Sinai Medical Center, Los Angeles, California
- 3:50 PM - 4:25 PM Discussion/Questions and Answers
- 4:25 PM - 4:30 PM Closing Remarks
- 4:30 PM Adjournment

Target Audience

This activity is designed specifically for psychiatrists.

Learning Objectives

Upon completion of this symposium, the participants should be able to:

- Discuss the importance of physical symptoms that coexist with anxiety disorders
- Recognize the interplay between emotions and physical symptoms in panic disorder and the treatment interventions that seem to work most effectively
- Describe the presentation and impact of social anxiety disorder and current treatment options available to best achieve remission

Accreditation

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Participation

Attendees must be registered for the APA [Annual Meeting or Institute on Psychiatric Services] to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or 703-907-7300.



Sponsored by the American Psychiatric Association.
 Supported by an unrestricted educational grant from Wyeth.

INDUSTRY-SUPPORTED SYMPOSIUM 22
 Sunday, May 22, 2005, 1:30 PM - 4:30 PM
 Grand Ballroom, North Tower, Grand Ballroom Level, Omni Hotel

Relapse Prevention in Schizophrenia: Defining a Path from Pharmacologic Intervention to Long-term Functional Recovery

Sunday, May 22, 2005

1:00 PM Lunch, 1:30 - 4:30 PM Symposium
 Omni Hotel, North Tower, Grand Ballroom, Atlanta, Georgia

Agenda

- 1:00 - 1:30 PM Lunch
- 1:30 - 1:40 PM Opening Remarks
John M. Kane, MD
The Zucker Hillside Hospital
The Albert Einstein College of Medicine
- 1:40 - 2:00 PM The Neurobiology of Relapse in Schizophrenia—Implications for Disease Course and Patient Outcomes
Robert B. Zipursky, MD
University of Toronto
- 2:00 - 2:10 PM Question and Answer Session
- 2:10 - 2:30 PM Defining Key Clinical Parameters That Contribute to Relapse in Schizophrenia
Stefan Leucht, MD
Technische Universität München
- 2:30 - 2:40 PM Question and Answer Session
- 2:40 - 3:00 PM Can Relapse Be Prevented Through Pharmacologic Intervention?
John M. Kane, MD
- 3:00 - 3:15 PM Question and Answer Session
- 3:15 - 3:35 PM Remission and Functional Recovery in Schizophrenia—Raising the Bar for Clinical Outcomes
Nina R. Schooler, PhD
Washington DC VA Medical Center
Georgetown University
School of Medicine
- 3:35 - 3:45 PM Question and Answer Session
- 3:45 - 4:25 PM Panel Discussion
- 4:25 - 4:30 PM Concluding Remarks
John M. Kane, MD

Accreditation and Credit Information:

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Learning Objectives:

- At the end of the presentation, participants should be able to:
- Understand the current state of the science with regard to the neurochemistry of relapse in schizophrenia
 - Describe the potential pathophysiologic consequences of relapse, as well as the impact on patient outcomes
 - Describe the key clinical factors that contribute to relapse in patients with schizophrenia
 - Understand how relapse can be reduced/prevented from a pharmacologic perspective
 - Discuss the criteria for determining functional recovery in schizophrenia

Attendees must be registered for the APA [Annual Meeting or Institute on Psychiatric Services] to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the United States or Canada) or 703-907-7300.

Sponsored by the American Psychiatric Association
 Supported by an unrestricted educational grant from




APA 2005 Annual Meeting




Symposium
 Announcement

INDUSTRY-SUPPORTED SYMPOSIUM 23
 Sunday, May 22, 2005, 1:30 PM - 4:30 PM
 Peachtree Ballroom, Level 8, Westin Peachtree Plaza





Fibromyalgia:

A DISORDER AT THE MEDICINE AND PSYCHIATRY INTERFACE




Sunday, May 22, 2005 • 1:30 PM - 4:30 PM • Westin Peachtree Plaza Hotel • Peachtree Ballroom, Level 8 • Atlanta, Georgia

| | | |
|--|---|--|
| <p>AGENDA</p> <p>1:00 PM Lunch</p> <p>1:30 Welcome and Introduction Lesley M. Arnold, MD Program Chairperson Associate Professor of Psychiatry Department of Psychiatry Director, Women's Health Research Program University of Cincinnati College of Medicine Cincinnati, Ohio</p> <p>1:45 The Pathophysiological Basis of Fibromyalgia: Emerging Evidence Daniel J. Clauw, MD Professor of Medicine Division of Rheumatology Director, Chronic Pain and Fatigue Research Center Director, Center for the Advancement of Clinical Research University of Michigan Ann Arbor, Michigan</p> <p>2:15 Management of Psychiatric Comorbidity in Patients with Fibromyalgia Lesley M. Arnold, MD</p> | <p>2:45 Recent Developments in the Pharmacotherapy of Fibromyalgia Leslie J. Crofford, MD Professor of Internal Medicine Chief, Division of Rheumatology Gloria W. Singletary Chase and Director, Women's Health Program University of Kentucky Lexington, Kentucky</p> <p>2:15 Nonpharmacological Treatment of Fibromyalgia Shay B. Stanford, MD Assistant Professor of Psychiatry and Family Medicine Department of Psychiatry Assistant Director, Women's Health Research Program University of Cincinnati College of Medicine Cincinnati, Ohio</p> <p>3:45 Question and Answer Session Faculty Panel</p> <p>4:30 Adjournment</p> | <p>OBJECTIVES At the conclusion of this program, participants should be able to:</p> <ul style="list-style-type: none"> • Recognize the possible pathophysiological link between fibromyalgia and mood and anxiety disorders. • Discuss the emerging evidence for the etiology of fibromyalgia. • Manage patients with fibromyalgia in a psychiatric setting using both pharmacological and nonpharmacological treatments. <p>The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.</p> <p>The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.</p> <p>Attendees must be registered for the APA 2005 Annual Meeting to attend this symposium. Seating is limited and will be on a first-come, first-served basis. For more information about the meeting, please visit the APA Web site at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the United States and Canada) or at 703-907-7300.</p> |
|--|---|--|


INDUSTRY-SUPPORTED SYMPOSIUM 24
 Sunday, May 22, 2005, 7:00 PM - 10:00 PM
 Grand Ballroom, Second Floor, Hilton Atlanta




Presented at the APA 158th Annual Meeting
Sunday, May 22, 2005 • 7:00-10:00 PM

Exploring Cognitive Function: From Brain to Bedside

Supported by an unrestricted educational grant from



| | |
|---|--|
| <p>PROGRAM AGENDA</p> <p>6:30-7:00 PM Dinner</p> <p>7:00-7:10 PM Welcome and Introduction Philip T. Ninan, MD (Chair) Emory University</p> <p>7:10-7:35 PM The Neurology of Cognition: A Glimpse into the Brain Daniel R. Weinberger, MD NIMH, Clinical Brain Disorders Branch</p> <p>7:35-8:00 PM Remission in Major Depression: The Vitality of Cognition Philip T. Ninan, MD Emory University</p> <p>8:00-8:25 PM Can Clinicians Impact Cognition in Schizophrenia? Roni J. Hu, MD Stanford University</p> <p>8:25-8:50 PM The Complexities of Cognitive Dysfunction in Late-Life Depression George S. Alexopoulos, MD Weill Medical College of Cornell University</p> <p>8:50 - 9:15 PM The Evidence and Relevance of Cognitive Dysfunction in ADHD Scott H. Kollins, PhD Duke University Medical Center</p> <p>9:15 - 10:00 PM Panel Discussion/Q&A</p> | <p>LEARNING OBJECTIVES</p> <ol style="list-style-type: none"> 1. Identify pathways in the brain that are linked to cognitive functioning. 2. Evaluate targeted pharmacological and non-pharmacological treatments for executive dysfunction to improve patient outcomes. 3. Translate the evidence related to the treatment of executive dysfunction in late-onset depression, major depressive disorder, schizophrenia, and ADHD to improved functional outcomes. <p>ACCREDITATION STATEMENT</p> <p>The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.</p> <p>The APA designates this educational activity for a maximum of 3.0 category 1 credits toward the AMA Physician Recognition Award and for the CME requirement of APA. Each physician should claim only those credits that he/she actually spent in the activity.</p> <p>Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or 703-907-7300.</p> |
|---|--|



Hilton Atlanta / Grand Ballroom, Second Floor / Atlanta, Georgia

INDUSTRY-SUPPORTED SYMPOSIUM 25
 Sunday, May 22, 2005, 7:00 PM - 10:00 PM
 Imperial Ballroom, Convention Level, Marriott Marquis Atlanta



This symposium will be held at the APA 2005 Annual Meeting

BIPOLAR DISORDER: TREATING THROUGH the ENTIRE SPECTRUM

SUNDAY, MAY 22, 2005 • DINNER: 6:30–7:00 PM • SYMPOSIUM: 7:00–10:00 PM

IMPERIAL BALLROOM, CONVENTION LEVEL • MARRIOTT MARQUIS ATLANTA • ATLANTA, GEORGIA

AGENDA:

| | | | |
|--------------|---|---------------|--|
| 6:30–7:00 PM | Dinner | 8:15–8:45 PM | The Acute Setting: Achieving Stabilization TRISHA SUPPES, MD, PhD University of Texas Southwestern Medical Center |
| 7:00–7:15 PM | Welcome and Introductions TRISHA SUPPES, MD, PhD (CHAIRPERSON) University of Texas Southwestern Medical Center | 8:45–9:15 PM | From Acute to Maintenance Therapy GARY S. SACHS, MD Massachusetts General Hospital |
| 7:15–7:45 PM | The Neuroscience of Bipolar Disorder Across the Age Spectrum KIKI D. CHANG, MD Stanford University | 9:15–10:00 PM | Question and Answer Session ALL FACULTY |
| 7:45–8:15 PM | Issues in Treating Bipolar Depression JOSEPH R. CALABRESE, MD Case Western Reserve University | 10:00 PM | Adjourn |

LEARNING OBJECTIVES:

- Understand the current data and theories regarding the neurobiology of bipolar disorders from childhood to adulthood
- Identify the unmet need in the treatment of bipolar depression, describe the recent advances in the treatment of bipolar depressive episodes, and apply these data to current treatment paradigms of bipolar depression
- Outline the treatment goals for acute stabilization of patients diagnosed with mania associated with bipolar disorder as well as describe the expanding data supporting current and emerging treatments
- Understand the significance of the enriched designs employed by studies demonstrating prophylactic benefit for bipolar disorder

CME STATEMENT:

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
 The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Attendees must be registered for the APA 2005 Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA Web site at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or (703) 907-7300.

If any participant in this educational activity is in need of accommodations, please call 800-434-1632 by April 22, 2005, in order to receive service.



Sponsored by the American Psychiatric Association



INDUSTRY-SUPPORTED SYMPOSIUM 26

Sunday, May 22, 2005, 7:00 PM - 10:00 PM

Marquis Ballrooms I & II, Convention Level, Marriott Marquis Atlanta

Untangling Depression and Anxiety: A Challenge for Scientists and Clinicians

Sunday, May 22, 2005

Dinner 6:30 PM - 7:00 PM

Scientific Program 7:00 PM - 10:00 PM

Marriott Marquis Atlanta

Marquis Ballrooms I & II, Convention Level

Atlanta, Georgia

6:30 PM **Dinner**

7:00 Introduction

Martin Keller, MD—Chairman
 Brown University School of Medicine

7:10 Genetic Models of Depression and Anxiety

Rene Hen, PhD
 Columbia University College of Physicians and Surgeons

7:35 Serotonergic Targets as Mediators of Anxiety

Alexander Neumeister, MD
 Yale University School of Medicine

8:00 Neuroanatomical Pathways Underlying Major Depression and Anxiety Disorders

John Krystal, MD
 Yale University School of Medicine

8:25 Presentation and Diagnosis of Comorbid Major Depression and Anxiety Disorders

Naomi Simon, MD • Massachusetts General Hospital

8:50 Making Treatment Decisions for Comorbid Major Depression and Anxiety Disorders

Martin Keller, MD

9:15 Question-and-Answer Session

10:00 Conclusion

Held at the APA 2005 Annual Meeting

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for up to 3 hours in category 1 credit toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on a first-come, first-served basis. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or (703) 907-7300.

Educational Objectives:

- Understand the role neurogenesis plays in anxiety and depression
- Recognize the functional importance of serotonin and its receptors in depression and anxiety
- Convey knowledge about brain circuits implicated in the pathophysiology of mood and anxiety disorders
- Recognize, diagnose, and understand the implications of comorbid major depression and anxiety disorders
- Treat patients who present with comorbid major depression and anxiety disorders

Sponsored by the



American Psychiatric Association

Supported by an unrestricted educational grant from

Forest Pharmaceuticals, Inc.

Pharmaceuticals • Therapeutics • Prescription • Research • Diagnostic Care • Specialty Drugs



INDUSTRY-SUPPORTED SYMPOSIUM 27
 Sunday, May 22, 2005, 7:00 PM - 10:00 PM
 Marquis Ballrooms III & IV, Convention Level, Marriott Marquis Atlanta

APA 2005 Annual Meeting

ADHD Through the Lifecycle: New Findings and Clinical Implications

6:30 PM - 7:00 PM

Dinner

7:00 PM

Welcome/Introduction

Thomas J. Spencer, MD, Chair

7:10 PM

Adult ADHD Diagnostic and Self-Report
 Symptom Scales: Assessment Methodology
 for Diagnosing and Monitoring Treatment of
 Adults With ADHD

Craig B. Surman, MD

7:35 PM

Functional Impairments in Adult ADHD:
 Implications for Diagnosis

Stephen V. Faraone, PhD

Joseph Biederman, MD, Co-author

8:00 PM

New Research on ADHD and Substance
 Use Disorders

Timothy E. Wilens, MD

8:25 PM

Long-term Tolerability and Effectiveness of
 Once-Daily Mixed Amphetamine Salts in
 Children With ADHD

Thomas J. Spencer, MD

8:50 PM

Long-term Outcome of Adults Treated With
 Extended-Release Mixed Amphetamine Salts

Joseph Biederman, MD

Thomas J. Spencer, MD, Co-author

9:15 PM - 10:00 PM

Question & Answer Session

Faculty

Learning Objectives

At the conclusion of this symposium, the participant should be able to:

1. Identify the different instruments and rating scales available to aid in the diagnosis of ADHD in adults.
2. Recognize the functional impairments commonly seen in adults with ADHD and understand their implications for diagnosis.
3. Identify the developmental relationship of ADHD and SUD, the course of substance abuse in ADHD individuals, preventive influence of ADHD medications on later SUD, and empirically based treatment strategies for patients with ADHD and SUD.
4. Discuss long-term study outcomes of mixed amphetamines in both children and adults with ADHD.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for up to 3 hours of category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Sunday, May 22, 2005

Dinner 6:30 PM - 7:00 PM

Program 7:00 PM - 10:00 PM

Marriott Marquis Atlanta
 Convention Level
 Marquis Ballrooms III & IV

Attendees must be registered for the APA 2005 Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or 703-907-7300.

Sponsored by the
 American Psychiatric Association



Supported by an unrestricted
 educational grant from

Shire

INDUSTRY-SUPPORTED SYMPOSIUM 28
 Sunday, May 22, 2005, 7:00 PM - 10:00 PM
 International Ballroom, North Tower, Ballroom Level, Omni Hotel

APA 2005 ANNUAL MEETING

EMERGING "BEST PRACTICES" IN THE MANAGEMENT OF BEHAVIORAL EMERGENCIES

Chairperson Peter F. Buckley, MD

AGENDA

| | | |
|---|--|---|
| <p>6:30pm to 7:00pm 7:00pm to 7:05pm 7:05pm to 7:30pm 7:30pm to 7:55pm</p> | <p>Dinner Welcome and Introduction Peter F. Buckley, MD Medical College of Georgia Augusta, Georgia</p> <p>Is Agitation Inevitably a Precursor to Aggression? Heather A. Wood, MD University of New Mexico Health Sciences Center Albuquerque, New Mexico</p> <p>Assessment of the Acutely Agitated Patient With Psychosis Joseph P. McEvoy, MD Duke University Durham, North Carolina</p> | <p>7:55pm to 8:20pm 8:20pm to 8:45pm 8:45pm to 9:10pm 9:10pm to 9:55pm 9:55pm to 10:00pm</p> <p>Considering Consumer Choice During the Management of Behavioral Emergencies Michael H. Allen, MD University of Colorado Health Sciences Center Denver, Colorado</p> <p>Do Atypical Antipsychotics Work Fast Enough in Behavioral Emergencies? Robert A. Zipursky, MD University of Toronto Toronto, Ontario</p> <p>Acute Stabilization With Atypical Antipsychotics: New Therapeutic Options Peter F. Buckley, MD</p> <p>Panel Discussion Moderator: Peter F. Buckley, MD</p> <p>Closing Remarks Peter F. Buckley, MD</p> |
|---|--|---|

Omni Hotel
 International Ballroom, North Tower
 Atlanta, Georgia

Sunday, May 22, 2005
 from 7:00pm to 10:00pm

TARGET AUDIENCE
 This educational activity is intended for psychiatrists and other mental health care professionals attending the 2005 Annual Meeting of the American Psychiatric Association (APA).

LEARNING OBJECTIVES
 After attending this symposium, participants should be better able to:

- Differentiate between agitation as a symptom and agitation as a precursor to a behavioral emergency
- Apply current practice standards (including the appropriate level of laboratory/medical assessment) in the evaluation of the acutely agitated patient
- Discuss management options for behavioral emergencies that are consistent with consumers' medical needs and preferences
- Evaluate the emerging role of atypical antipsychotics in behavioral emergencies and discuss the mechanism of action for the early-onset antipsychotic effect in the acute management of agitation and aggression
- Describe the emerging role and clinical impact of orally disintegrating and intramuscular formulations of atypical antipsychotics in the acute management of agitation and aggression

ACCREDITATION STATEMENT
 The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should only claim those credits that he/she actually spent in the activity.

Sponsored by The American Psychiatric Association

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or 703-907-7300.

INDUSTRY-SUPPORTED SYMPOSIUM 29
 Sunday, May 22, 2005, 7:00 PM - 10:00 PM
 Grand Ballroom, North Tower, Grand Ballroom Level, Omni Hotel

A Dinner Symposium Held During the APA 2005 Annual Meeting

Beyond Neurochemistry:

The Implications of Neurocircuitry for Understanding and Managing Psychiatric Disorders

Sunday, May 22, 2005

6:30PM-7:00PM Dinner
 7:00PM-10:00PM Educational Activity

Omni Hotel at CNN Center
 North Tower, Grand Ballroom Level
 Grand Ballroom
 Atlanta, Georgia



6:30PM-7:00PM
 Dinner

7:00PM
Welcome and Introduction
 Stuart C. Yudofsky, MD
 Program Co-Chairperson
 Baylor College of Medicine

7:10PM
Neuroanatomy of Behavior 101
 Paula T. Trzepak, MD
 Program Chairperson
 Eli Lilly and Company
 University of Mississippi School of Medicine
 Tufts University School of Medicine

7:45PM
Neurocircuitry of Schizophrenia
 David A. Lewis, MD
 Western Psychiatric Institute and Clinic
 University of Pittsburgh School of Medicine

8:10PM
Neurobiological Substrates of ADHD
 George Bush, MD
 Massachusetts General Hospital
 Harvard Medical School

8:30PM
In Search of Depression Circuits
 Helen S. Mayberg, MD
 Emory University School of Medicine

8:55PM
Neural Pathways and Behavior in Anorexia Nervosa
 Walter H. Kaye, MD
 Western Psychiatric Institute and Clinic
 University of Pittsburgh School of Medicine

9:15PM
Question and Answer Session

10:00PM
Program Adjournment

Learning Objectives

- Upon completion of the activity, participants should be able to
1. Explain brain anatomy as it relates to behavior, perception, and cognition.
 2. Identify the neural circuitry abnormalities that contribute to cognitive dysfunction in schizophrenia and illustrate how this knowledge informs the development of new treatment interventions.
 3. Discuss the functional and structural neuroimaging evidence that supports the most current theories and findings of the neural basis of ADHD, the potential role of neuroimaging in the diagnosis of ADHD, and the role of neuroimaging in drug development.
 4. Explain the nature of functional brain changes seen in patients with major depression and the different regions targeted by various antidepressant interventions.
 5. Recognize the neuroanatomy of anorexia nervosa.
 6. Discuss the aberrant brain circuits and regional neuroanatomical dysfunctions that play a role in psychiatric disorders and the need for new treatment paradigms.

Accreditation Statement

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement

The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.



Sponsored by the American Psychiatric Association



Supported by an educational grant from Eli Lilly and Company

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA Web site at www.psych.org or contact the APA toll free at 1.888.357.7924 (within the US or Canada) or 703.907.7300.

INDUSTRY-SUPPORTED SYMPOSIUM 30
 Sunday, May 22, 2005, 7:00 PM - 10:00 PM
 Peachtree Ballroom, Level 8, Westin Peachtree Plaza

APA 158th
 Annual Meeting

FROM
Molecular Insight to Clinical Outcomes:
RECENT ADVANCES IN SCHIZOPHRENIA TREATMENT

Sunday, May 22, 2005 • 7:00 PM - 10:00 PM • Westin Peachtree Plaza Hotel • Peachtree Ballroom, Level 8 • Atlanta, Georgia

AGENDA

- 6:30 - 7:00 PM **Dinner**
- 7:00 **Welcome and Introduction**
 Jeffrey A. Lieberman, MD
 Chairman, Department of Psychiatry
 Columbia University College of Physicians and Surgeons
 Director, New York State Psychiatric Institute
 New York, New York
- 7:15 **How Antipsychotics Work: From Receptors to Reality**
 Shing Kapur, MD, PhD, FRCP
 Vice-President of Research
 The Centre for Addiction and Mental Health (CAMH)
 Canada Research Chair
 Professor of Psychiatry
 University of Toronto
 Toronto, Ontario, Canada
- 7:40 **Clinical Effectiveness of Atypical Antipsychotic Therapy**
 Scott Stroup, MD, MPH
 Associate Professor
 Department of Psychiatry
 University of North Carolina at Chapel Hill
 Chapel Hill, North Carolina

- 8:05 **Cognitive Effectiveness of Atypical Antipsychotic Therapy**
 Philip D. Harvey, PhD
 Professor
 Department of Psychiatry
 Mount Sinai School of Medicine
 New York, New York
- 8:30 **Enhancing Clinical Care in Schizophrenia: Primary Health Care Needs**
 Gail L. Daams, MD
 Assistant Professor
 Johns Hopkins School of Public Health
 Baltimore, Maryland
- 8:55 **Translating Scientific Research into Clinical Practice**
 Jeffrey A. Lieberman, MD
- 9:20 **Question and Answer Session**
- 10:00 **Adjournment**



OBJECTIVES

At the conclusion of this program, participants should be able to:

- Differentiate among the conventional and atypical antipsychotic agents with respect to their effects on neurotransmitter systems and discuss their putative differences in effect on mood symptoms in patients with schizophrenia.
- Address the importance of evaluating new options in the context of "real-world" scientific studies, such as the highly innovative CATIE, which is examining both patient and clinician choices among a range of antipsychotic medications.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Attendees must be registered for the APA 2005 Annual Meeting to attend this symposium. Seating is limited and will be on a first-come, first-served basis. For more information about the meeting, please visit the APA Web site at www.psych.org or contact the APA toll free at 1.888.357.7924 (within the United States and Canada) or at 703.907.7300.



Sponsored by the American Psychiatric Association



Supported by an educational educational grant from Pfizer Inc

INDUSTRY-SUPPORTED SYMPOSIUM 31
 Monday, May 23, 2005, 7:00 a.m. - 8:30 a.m.
 Tuesday, May 24, 2005, 7:00 a.m. - 8:30 a.m.
 Imperial Ballroom, Convention Level, Marriott Marquis Atlanta



This symposium will be held at the APA 2005 Annual Meeting.

AGITATION and PSYCHOSIS in ALZHEIMER'S DISEASE and PARKINSON'S DISEASE

MONDAY, MAY 23 AND TUESDAY, MAY 24, 2005 • BREAKFAST: 6:30-7:00 AM • SYMPOSIUM: 7:00-8:30 AM
 IMPERIAL BALLROOM, CONVENTION LEVEL • MARRIOTT MARQUIS ATLANTA • ATLANTA, GEORGIA

AGENDA:

MONDAY, MAY 23

- 6:30-7:00 AM Breakfast
- 7:00-7:05 AM Welcome and Introductions
JEFFREY L. CUMMINGS, MD
 (CHAIRPERSON)
 University of California, Los Angeles
- 7:05-7:25 AM Diagnosis and Assessment of Parkinson's Disease and Alzheimer's Disease
DANIEL WEINTRAUB, MD
 University of Pennsylvania
- 7:25-7:45 AM Imaging and Neurobiological Underpinnings of Psychosis and Agitation
DAVID L. SULTZER, MD
 University of California, Los Angeles
- 7:45-8:05 AM Treatment of Psychosis in Parkinson's Disease
JEFFREY L. CUMMINGS, MD
 University of California, Los Angeles
- 8:05-8:30 AM Question and Answer Session
ALL FACULTY
- 8:30 AM Adjourn

TUESDAY, MAY 24

- 6:30-7:00 AM Breakfast
- 7:00-7:05 AM Welcome and Introductions
JEFFREY L. CUMMINGS, MD
 (CHAIRPERSON)
 University of California, Los Angeles
- 7:05-7:35 AM Efficacy and Tolerability of Atypical Antipsychotics in Agitation and Psychosis: Research Results
PIERRE N. TARIOT, MD
 University of Rochester
- 7:35-8:05 AM Efficacy and Tolerability of Atypical Antipsychotics in Agitation and Psychosis: Clinical Applications
JEANNE M. JACKSON-SIEGAL, MD
 Yale University School of Medicine
- 8:05-8:30 AM Question and Answer Session
ALL FACULTY
- 8:30 AM Adjourn

LEARNING OBJECTIVES:

- Recognize how psychosis and agitation can present differently in Parkinson's disease (PD), Alzheimer's disease (AD), and related disorders, such as mixed dementia of Lewy bodies (DLB); understand how to assess psychosis and agitation in PD, AD, and related dementias; understand the utility of diagnostic instruments for psychosis and agitation in clinical research and clinical care
- Describe neurobiological factors that contribute to psychosis and agitation in degenerative disorders and recognize implications for improved treatment
- Identify PD, recognize psychosis in PD; understand the optimal use of atypical antipsychotics in PD
- Understand the essential research findings from placebo-controlled trials of atypical antipsychotics for agitation and psychosis
- Organize a cogent paradigm for the treatment of agitation and psychosis in the patient with dementia by correlating the known data on different tolerability and side-effect profiles of atypical antipsychotics with individual patient's risk factors and comorbidities

CME STATEMENT:

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Attendees must be registered for the APA 2005 Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA Web site at www.psych.org or contact the APA toll free at 1-888-257-7924 (within the US or Canada) or 703-907-7300.

If any participant in the educational activity is in need of accommodations, please call 840-434-1450 for April 22, 2005, in order to receive service.



INDUSTRY-SUPPORTED SYMPOSIUM 32
 Monday, May 23, 2005, 7:00 a.m. - 8:30 a.m.
 Tuesday, May 24, 2005, 7:00 a.m. - 8:30 a.m.
 International Ballroom, North Tower, Ballroom Level, Omni Hotel

MANAGING THE SPECTRUM OF BIPOLAR DISORDER: MINIMIZING THE BURDEN OF DISEASE

Program Chairs Robert E. Hales, MD, MBA, and Stuart C. Yudofsky, MD

AGENDA

Monday, May 23, 2005

- 6:30AM to 7:00AM Breakfast
- 7:00AM to 7:05AM Welcome and Introduction
 Robert E. Hales, MD, MBA
 University of California, Davis
 Sacramento, California
 Stuart C. Yudofsky, MD
 Baylor College of Medicine
 Houston, Texas
- 7:05AM to 7:35AM Practical Approaches to the Diagnosis of Bipolar Disorders
 Claudio E. Boffa, MD
 University of Pennsylvania
 Philadelphia, Pennsylvania
- 7:35AM to 8:05AM Optimizing Pharmacotherapy in the Treatment of Acute Mania
 Terence A. Klerman, MD
 Stanford University School of Medicine
 Stanford, California
- 8:05AM to 8:25AM Panel Discussion
 Moderators Robert E. Hales, MD, MBA
 Stuart C. Yudofsky, MD
- 8:25AM to 8:30AM Closing Remarks
 Robert E. Hales, MD, MBA
 Stuart C. Yudofsky, MD

Each presentation will be followed by a brief question and answer session.

Sponsored by an unrestricted educational grant from Bristol-Myers Squibb Company and AstraZeneca Pharmaceuticals, Inc.

Tuesday, May 24, 2005

- 6:30AM to 7:00AM Breakfast
- 7:00AM to 7:05AM Welcome and Introduction
 Robert E. Hales, MD, MBA
 Stuart C. Yudofsky, MD
- 7:05AM to 7:35AM The Impact of Safety and Tolerability on Patient Satisfaction With Therapy
 Paul E. Keck, Jr., MD
 University of Cincinnati College of Medicine
 Cincinnati, Ohio
- 7:35AM to 8:05AM The Impact of Bipolar Maintenance Therapy on Patient Outcomes
 Lori Altbauer, MD
 University of California, Los Angeles
 Los Angeles, California
- 8:05AM to 8:25AM Panel Discussion
 Moderators Robert E. Hales, MD, MBA
 Stuart C. Yudofsky, MD
- 8:25AM to 8:30AM Closing Remarks
 Robert E. Hales, MD, MBA
 Stuart C. Yudofsky, MD

Omni Hotel
 International Ballroom, North Tower
 Atlanta, Georgia

Monday, May 23, 2005
 Tuesday, May 24, 2005
 from 7:00AM to 8:30AM

TARGET AUDIENCE

This educational activity is intended for psychiatrists and other mental health care professionals attending the 2005 Annual Meeting of the American Psychiatric Association (APA).

LEARNING OBJECTIVES

- After attending this symposium, participants should be better able to:
- Discuss the latest research on the pathophysiology of bipolar disorder and identify key issues impacting the differential diagnosis of bipolar disorders (type I, type II, and other affective disorders)
 - Effectively utilize pharmacotherapy in the management of patients with acute mania and differentiate between atypical antipsychotics and mood stabilizers with respect to their efficacy, tolerability, and safety profiles, integrating the long-term clinical implications of adverse effects
 - Identify metabolic and other drug-related adverse effects that can exacerbate the tendency of patients with bipolar disorder to be nonadherent to treatment
 - Describe strategies for improving adherence with maintenance therapy to optimize outcomes in patients with bipolar disorder

ACCREDITATION STATEMENT

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should only claim those credits that he/she actually spent in the activity.

Sponsored by The American Psychiatric Association

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-257-7924 (within the US or Canada) or 703-907-7300.

INDUSTRY-SUPPORTED SYMPOSIUM 33
 Monday, May 23, 2005, 7:00 a.m. - 8:30 a.m.
 Tuesday, May 24, 2005, 7:00 a.m. - 8:30 a.m.
 Grand Ballroom, North Tower, Grand Ballroom Level, Omni Hotel

**Advances in the Treatment of
 Mood and Anxiety Disorders
 in Women (Parts 1 and 2)**

Target Audience

This activity is designed specifically for psychiatrists.

Learning Objectives

Upon completion of this symposium, the participants should be able to:

- Develop a management plan for women who have bipolar disorder during their childbearing years
- Recognize the association between the menopausal transition and the occurrence of mood and sleep disturbances
- Recognize that the onset of anxiety disorders, course, risk of comorbid conditions, and treatment response may be different in women compared with men
- Demonstrate knowledge of how to diagnose and treat premenstrual syndrome and premenstrual dysmorphic disorder

Accreditation

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Participation

Attendees must be registered for the APA (Annual Meeting or Institute on Psychiatric Services) to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or 703-907-7300.

Susan G. Kornstein, MD - Chair
 Monday, May 23, 2005
 Tuesday, May 24, 2005
 7:00 AM - 8:30 AM
 Grand Ballroom, Grand Ballroom Level

Agenda

Monday, May 23, 2005 - Part 1

- 6:30 AM - 7:00 AM Breakfast
 7:00 AM - 7:05 AM Opening Remarks
Susan G. Kornstein, MD, Chairperson
Virginia Commonwealth University, Richmond, Virginia
- 7:05 AM - 7:25 AM Anxiety Disorders in Women
Teresa Pigott, MD, University of Florida, Gainesville, Florida
- 7:25 AM - 7:45 AM Antidepressant Treatment of PMS and PMDD
Susan G. Kornstein, MD, Chairperson
Virginia Commonwealth University, Richmond, Virginia
- 7:45 AM - 8:05 AM Perinatal Consequences of Mood and Anxiety Disorders
Kimberly A. Yonkers, MD, Yale University School of Medicine, New Haven, Connecticut
- 8:05 AM - 8:30 AM Discussion/Questions and Answers
 8:30 AM Adjournment

Tuesday, May 24, 2005 - Part 2

- 6:30 AM - 7:00 AM Breakfast
 7:00 AM - 7:15 AM Opening Remarks With Brief Overview of Day 1
Susan G. Kornstein, MD, Chairperson
Virginia Commonwealth University, Richmond, Virginia
- 7:15 AM - 7:40 AM Menopausal Transition: Impact on Mood, Sleep, and Quality of Life
Claudio Soares, MD, PhD, McMaster University, Hamilton, Ontario, Canada
- 7:40 AM - 8:05 AM Managing Bipolar Disorder in Women
Lesley M. Arnold, MD, University of Cincinnati, Cincinnati, Ohio
- 8:05 AM - 8:30 AM Discussion/Questions and Answers
 8:30 AM Adjournment



Sponsored by the American Psychiatric Association.
 Supported by an unrestricted educational grant from Wyeth.

Presented at the
APA 158th Annual Meeting
 Omni Hotel, North Tower
 Atlanta, Georgia

INDUSTRY-SUPPORTED SYMPOSIUM 34
 Monday, May 23, 2005, 7:00 p.m. - 10:00 p.m.
 Grand Ballroom, Second Floor, Hilton Atlanta

TO BE HELD AT THE APA 2005 ANNUAL MEETING

BIPOLAR DISORDER MANAGEMENT

A NEW EDITION | MONDAY • MAY 23

6:30-7 PM DINNER • 7-10 PM CLINICAL PROGRAM
HILTON ATLANTA & TOWERS • GRAND BALLROOM, 2ND FLOOR

| | |
|--|--|
| <p>7:00 PM - Introduction FREDERICK K. GOODWIN, MD <i>Symposium Chair & Speaker</i></p> <p>7:10 PM - When & How to Use Antidepressants for Bipolar Depression S. NASSIR GHAEMI, MD <i>Harvard Medical School</i></p> <p>7:35 PM - Clinical Strategies for Bipolar Depression TERENCE A. KETTER, MD <i>Stanford University School of Medicine</i></p> <p>8:00 PM - How to Combine Medications for Long-Term Stabilization FREDERICK K. GOODWIN, MD <i>George Washington University Medical Center</i></p> | <p>8:25 PM - Recognizing & Treating Bipolar Disorder in Children GABRIELLE A. CARLSON, MD <i>Stony Brook University School of Medicine</i></p> <p>8:50 PM - New Understanding of Psychological Issues & of Effective Psychotherapy KAY R. JAMISON, PhD <i>Johns Hopkins University School of Medicine</i></p> <p>9:15 PM - Question & Answer Session 10:00 PM - Program Concludes</p> |
|--|--|

EDUCATIONAL OBJECTIVES
 Define use of antidepressants in bipolar depression; compare different mood stabilizers, anticonvulsants, and atypical antipsychotics in the management of bipolar depression; inventory practical issues toward optimal use of drug combinations; examine bipolar disorder in youth over the past 15 years, including areas of agreement, controversy, progress, and recent research; and illustrate the efficacy of psychotherapy in combination with medication toward relapse prevention and medication compliance.

Sponsored by the American Psychiatric Association.
 The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
 The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.
 Attendees must be registered for the APA 2005 Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll-free at 1-888-357-7924 (within the US or Canada) or 703-907-7300.
 Supported by an unrestricted educational grant from GlaxoSmithKline

INDUSTRY-SUPPORTED SYMPOSIUM 35
 Monday, May 23, 2005, 7:00 PM - 10:00 PM
 Imperial Ballroom, Convention Level, Marriott Marquis Atlanta



This symposium will be held at the APA 2005 Annual Meeting

DUAL DIAGNOSIS: THE SCOPE OF THE PROBLEM

MONDAY, MAY 23, 2005 • DINNER: 6:30-7:00 PM • SYMPOSIUM: 7:00-10:00 PM

IMPERIAL BALLROOM, CONVENTION LEVEL • MARRIOTT MARQUIS ATLANTA • ATLANTA, GEORGIA

AGENDA:

- | | | | |
|--------------|--|---------------|---|
| 6:30-7:00 PM | Dinner | 8:25-8:50 PM | Treatment of Bipolar Disorder and Substance Abuse E. SHERWOOD BROWN, MD, PhD The University of Texas Southwestern Medical Center |
| 7:00-7:10 PM | Welcome and Introductions ALAN I. GREEN, MD (CHAIRPERSON) Dartmouth Medical School | 8:50-9:15 PM | Treatment of Schizophrenia and Substance Abuse ALAN I. GREEN, MD Dartmouth Medical School |
| 7:10-7:35 PM | Prevalence and Consequences of Dual Diagnosis PETER F. BUCKLEY, MD Medical College of Georgia | 9:15-10:00 PM | Question and Answer Session ALL FACULTY |
| 7:35-8:00 PM | Adolescent Substance Abuse and Psychiatric Comorbidities DEBORAH DEAS, MD, MPH Medical University of South Carolina | 10:00 PM | Adjourn |
| 8:00-8:25 PM | Psychosocial Intervention for Dual Diagnosis MARY F. BRUNETTE, MD Dartmouth Medical School | | |

LEARNING OBJECTIVES:

- Understand the prevalence and etiopathogenic mechanisms underlying the association between substance abuse, schizophrenia, and bipolar disorder
- Identify the risk factors of substance use and the role of comorbidities among adolescents
- Demonstrate an understanding of the stages of treatment of dual disorders, recognize which psychosocial interventions are appropriate at each treatment stage, and comprehend the skills necessary to deliver these psychosocial interventions
- Discuss the available literature on the treatment of substance use in people with bipolar disorder
- Describe the potential pharmacologic treatment approaches to lessening comorbid alcohol and substance use in patients with schizophrenia and learn about the likely neurobiologic basis of the effects of these pharmacologic agents

CME STATEMENT:

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
 The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.
 Attendees must be registered for the APA 2005 Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA Web site at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or 703-907-7300.
 If you participate in this educational activity, it is in need of accommodations, please call 866-434-1150 by April 22, 2005, in order to receive services.



Sponsored by the American Psychiatric Association



INDUSTRY-SUPPORTED SYMPOSIUM 36
 Monday, May 23, 2005, 7:00 PM - 10:00 PM
 Marquis Ballrooms I & II, Convention Level, Marriott Marquis Atlanta

Insomnia in Special Populations: ? Is This Insomnia or Something Else?

May 23, 2005 ■ 7:00 - 10:00 PM ■ Marriott Marquee, Atlanta, Georgia ■ Salons 1 and 2, Convention Level

APA 2005 Annual Meeting - *INTERACTIVE, DEBATE-STYLE FORMAT!*

Agenda

- | | |
|---------------|---|
| 6:30-7:00 PM | Dinner |
| 7:00 PM | Introduction - Chair Ruth M. Benca, MD, University of Wisconsin Medical School, Madison, Wisconsin |
| 7:10 PM | Insomnia in the Elderly Sonia Ancoli-Israel, PhD, University of California San Diego, San Diego, California <i>5 Minutes Audience Question and Answer</i> |
| 7:45 PM | Insomnia in Depressed Patients Ruth M. Benca, MD, University of Wisconsin Medical School, Madison, Wisconsin <i>5 Minutes Audience Question and Answer</i> |
| 8:20 PM | Insomnia in Women: An Overlooked Epidemic? Claudio N. Soares, MD, Massachusetts General Hospital, Boston, Massachusetts <i>5 Minutes Audience Question and Answer</i> |
| 8:55 PM | Novel Strategies to Treat Insomnia John W. Winkelman, MD, Brigham and Women's Hospital, Newton, Massachusetts |
| 9:30-10:00 PM | Audience Question and Answer |
| 10:00 PM | Meeting Adjourns |

Learning Objective

At the conclusion of this symposium, the participant should be able to recognize the impact of insomnia in the elderly, in depressed patients, and among subgroups of women. The participants will also have the opportunity to learn about treatment options in these special populations.

Registration Policy

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or 703-907-7300.

Accreditation

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
 The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.



Sponsored by the American Psychiatric Association
 Supported by an unrestricted educational grant from Sepracor



INDUSTRY-SUPPORTED SYMPOSIUM 37
 Monday, May 23, 2005, 7:00 PM - 10:00 PM
 International Ballroom, North Tower, Ballroom Level, Omni Hotel

APA ANNUAL 2005 MEETING

INSULIN RESISTANCE & METABOLIC SYNDROME IN NEUROPSYCHIATRY

Program Chair Natalie Rasgon, MD, PhD

Monday, May 23, 2005
 6:30-10:00 PM
 International Ballroom,
 North Tower,
 Ballroom Level
 Omni Hotel © CNN Center

Educational Objectives

At the conclusion of this program, the participant will be able to:

- Examine preclinical data on pathophysiology of metabolic syndrome.
- Review prevalence of metabolic syndrome in patients with affective disorders, schizophrenia and Alzheimer's disease.
- Review current metabolic data for medications used to treat psychiatric illness.
- Discuss clinical implications of metabolic syndrome, weight gain, insulin resistance and lipid disorders.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Sponsored by the American Psychiatric Association.

Agenda

8:30 PM
Dinner

7:00 PM
Welcome and Introduction
Natalie Rasgon, MD, PhD - Program Chair
Stanford University School of Medicine

7:10 PM
The Insulin Resistance Syndrome: What is it? Why is it important?
Gerald Reaven, MD
Stanford University School of Medicine

7:35 PM
Insulin Resistance and Metabolic Risk During Antipsychotic Treatment
John W. Newcomer, MD
Washington University School of Medicine

8:00 PM
Risk, Assessment and Management of Insulin Resistance in Affective Disorders
Brent H. Solvason, PhD, MD
Stanford University School of Medicine

8:25 PM
Insulin Resistance and Cognitive Disorders
Suzanne Craft, PhD
University of Washington School of Medicine

8:50 PM
Insulin Resistance: The Link Between Affective Disorders and Alzheimer's Disease
Natalie Rasgon, MD, PhD

9:15 PM
Panel Discussion-Q & A
All Faculty

10:00 PM
Adjournment

The APA designates this educational activity for a maximum of 3.0 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA Web site at www.psych.org or contact the APA toll free at 888-357-7924 (within the US or Canada) or 703-907-7300.

Supported by an unrestricted educational grant provided by Bristol-Myers Squibb Company and Otsuka America Pharmaceutical Inc.

Bristol-Myers Squibb Company
Otsuka America Pharmaceutical, Inc.

INDUSTRY-SUPPORTED SYMPOSIUM 38
 Monday, May 23, 2005, 7:00 PM - 10:00 PM
 Grand Ballroom, North Tower, Grand Ballroom Level, Omni Hotel

Overcoming Traditional Dilemmas in Treating Depressive Illnesses: Evidence-Based Updates

John F. Greden, MD - Chair
 Monday, May 23, 2005
 7:00 PM - 10:00 PM
 Grand Ballroom, Grand Ballroom Level

Agenda

6:30 PM - 7:00 PM Dinner

7:00 PM - 7:05 PM Welcome and Opening Remarks
John F. Greden, MD, Chairperson, University of Michigan, Ann Arbor, Michigan

7:05 PM - 7:35 PM Improved Remission Rates: Do Any Antidepressants Stand Out?
Linda L. Carpenter, MD, Brown Medical School, Butler Hospital, Providence, Rhode Island

7:35 PM - 8:05 PM Influence of Comorbidity on the Treatment of Depression
David L. Dunner, MD, University of Washington, Seattle, Washington

8:05 PM - 8:35 PM Combining Antidepressant Treatment for Better Efficacy: What Does the Literature Say?
Thomas L. Schwartz, MD, SUNY Upstate Medical University, Syracuse, New York

8:35 PM - 9:05 PM Brain Stimulation in Psychiatric Treatment: State of the Evidence
Sarah Lisanby, MD, Columbia University, New York, New York

9:05 PM - 9:35 PM Effectiveness of Antidepressant Treatments for Preventing Recurrences: Several Decades of Evidence
John F. Greden, MD, Chairperson, University of Michigan, Ann Arbor, Michigan

9:35 PM - 10:00 PM Discussion/Questions and Answers

10:00 PM Adjournment

(Interactive audience polling to follow each presentation.)

*Presented at the
 APA 158th Annual Meeting
 Omni Hotel, North Tower
 Atlanta, Georgia*

Target Audience
 This activity is designed specifically for psychiatrists.

Learning Objectives
 Upon completion of this symposium, the participants should be able to:

- Recognize the comorbidities that affect the outcome of depression and how comorbidities may best be treated to optimize outcomes
- Describe the consequences associated with recurrences of major depression
- Objectively define remission of depression
- Analyze the medical literature regarding the efficacy and tolerability of combining medications for the treatment of depression

Accreditation
 The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Participation
 Attendees must be registered for the APA [Annual Meeting or Institute on Psychiatric Services] to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or 703-907-7300.

Sponsored by the American Psychiatric Association.
 Supported by an unrestricted educational grant from Wyeth.

INDUSTRY-SUPPORTED SYMPOSIUM 39
 Tuesday, May 24, 2005, 7:00 PM - 10:00 PM
 Grand Ballroom, Second Floor, Hilton Atlanta



To be held at the APA 2005 Annual Meeting

SEASONAL AFFECTIVE DISORDER

NEW CONCEPTS, PRACTICAL STRATEGIES

TUESDAY ~ MAY 24 6:30-7 PM DINNER
 7-10 PM CLINICAL PROGRAM
 HILTON ATLANTA & TOWERS ~ GRAND BALLROOM, 2ND FLOOR

7:00 PM - Introduction
Norman E. Rosenthal, MD
 Symposium Chair & Speaker

7:10 PM - The Clinical Picture & Epidemiology of SAD
Norman E. Rosenthal, MD
 Georgetown University Medical School

7:35 PM - Pathophysiology of SAD
Thomas A. Wehr, MD
 Bethesda, Maryland

8:00 PM - Light Treatment for Winter Depression: Status Report
Raymond W. Lam, MD
 University of British Columbia Hospital

8:25 PM - Medical Treatment Including Mechanism of Action, New Study Data
Jennifer K. Pennell, MD
 Cary, North Carolina

8:50 PM - Integrating Cognitive-Behavioral Therapy Into Seasonal Affective Disorder Treatment
Kelly J. Rohan, PhD
 Uniformed Services University of the Health Sciences

9:15 PM - Question & Answer Session

10:00 PM - Program Concludes

EDUCATIONAL OBJECTIVES

To diagnose a common but under-recognized disorder by describing the neurochemical changes that may be responsible for the symptoms of SAD and how these aberrant systems may suggest useful treatment strategies, including light therapy, pharmacologic therapy, cognitive-behavioral therapy, or combined therapy.

Attendees must be registered for the APA 2005 Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or 703-907-7300.



Sponsored by the American Psychiatric Association.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Supported by an unrestricted educational grant from GSK/GlaxoSmithKline

INDUSTRY-SUPPORTED SYMPOSIUM 40
 Tuesday, May 24, 2005, 7:00 PM - 10:00 PM
 Imperial Ballroom, Convention Level, Marriott Marquis Atlanta

ALCOHOLISM TRANSLATING EMERGING SCIENCE INTO CLINICAL PRACTICE

Symposium to be held at the APA 2005 Annual Meeting

Tuesday, May 24, 2005 • 6:30 PM - 7:00 PM Dinner • 7:00 PM - 10:00 PM Scientific Session
 Imperial Ballroom • Marriott Marquis • 265 Peachtree Center Ave. • Atlanta, GA 30303

FACULTY

Raymond Anton, MD (Co-chair/Moderator)
 Distinguished University Professor in Psychiatry
 Department of Psychiatry and Behavioral Sciences
 Director, Center for Drug and Alcohol Programs
 Medical University of South Carolina
 Charleston, South Carolina

George F. Koob, PhD
 Professor
 Department of Neuropharmacology
 The Scripps Research Institute
 La Jolla, California

Charles P. O'Brien, MD, PhD (Co-chair)
 Vice-Chair, Department of Psychiatry
 Director, Treatment Research Center
 University of Pennsylvania School of Medicine
 Philadelphia, Pennsylvania

Helen M. Pettinati, PhD
 Research Professor, Department of Psychiatry
 Research Division Director, Treatment
 Research Center
 University of Pennsylvania School of Medicine
 Philadelphia, Pennsylvania

Hugh Myrick, MD
 Associate Professor
 Department of Psychiatry and Behavioral Sciences
 Medical University of South Carolina
 Charleston, South Carolina

ACCREDITATION STATEMENT

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION

The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirements of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

REGISTRATION

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or 703-907-7300.



Sponsored by the American Psychiatric Association




Supported by an unrestricted educational grant from Alkermes, Inc.

SCIENTIFIC PROGRAM AGENDA

- 7:00 PM - 7:10 PM
Welcome and Introduction
Raymond Anton, MD (Co-chair)
- 7:10 PM - 7:30 PM
Animal Models Point the Way to Novel Therapies
George Koob, PhD
- 7:30 PM - 7:40 PM
Question-and-Answer Session
- 7:40 PM - 8:10 PM
Brain Imaging of Craving and the Effects of Anti-craving Medications
Charles O'Brien, MD, PhD (Co-chair)
- 8:10 PM - 8:20 PM
Question-and-Answer Session
- 8:20 PM - 8:55 PM
Advances in the Pharmacotherapy of Alcoholism
Helen Pettinati, PhD
- 8:55 PM - 9:05 PM
Question-and-Answer Session
- 9:05 PM - 9:20 PM
Treatment of Alcoholism Combined with Other Mental Disorders
Hugh Myrick, MD
- 9:20 PM - 9:40 PM
Question-and-Answer Session
- 9:40 PM - 10:00 PM
Panel Discussion/Question-and-Answer Session
Raymond Anton, MD, (Moderator)
- 10:00 PM
Meeting Adjourns





INDUSTRY-SUPPORTED SYMPOSIUM 41
 Tuesday, May 24, 2005, 7:00 PM - 10:00 PM
 Marquis Ballrooms I & II, Convention Level, Marriott Marquis Atlanta



Advances in Cholinergic Therapy

ALZHEIMER'S DISEASE AND BEYOND

Tuesday, May 24, 2005 • 7:00 PM - 10:00 PM • Atlanta Marriott Marquis • Marquis Ballrooms I and II, Convention Level • Atlanta, Georgia

| | | |
|--|--|---|
| AGENDA | | |
| <p>6:30 pm Dinner</p> <p>7:00 Welcome and Introduction Pierre Tariot, MD Program Chairperson Professor of Psychiatry, Medicine, and Neurology University of Rochester Medical Center Rochester, New York</p> <p>7:05 Revisiting the Cholinergic Hypothesis: Are Cholinesterase Inhibitors More Than Symptomatic Treatments for Alzheimer's Disease? Norman Raskin, PhD, MD Associate Professor of Clinical Neurology and Neuroscience Director, Cornell Memory Disorders Program Weill Cornell Medical College New York, New York</p> <p>7:30 The Role of Imaging in the Study and Treatment of Dementia K. Banga Rama Kristman, MD Professor of Psychiatry Chairman, Department of Psychiatry and Behavioral Sciences Duke University Medical Center Durham, North Carolina</p> | <p>7:55 Clinical Trials in Mild Cognitive Impairment Ronald Peterson, MD Ctrial Kanow Professor of Alzheimer's Disease Research Mayo Medical School and Mayo Foundation Professor of Neurology Mayo Medical School Rochester, Minnesota</p> <p>8:20 Pharmacological Treatment of Cognitive Impairments in Schizophrenia Robert Buchanan, MD Professor Chief, Outpatient Research Program Maryland Psychiatric Research Center Baltimore, Maryland</p> <p>8:45 Behavioral Disturbances in Alzheimer's Disease: Diagnosis and Treatment Helen Lavretsky, MD Assistant Professor Neuropsychiatric Institute University of California, Los Angeles Los Angeles, California</p> <p>9:10 Concluding Remarks Pierre Tariot, MD</p> <p>9:15 Question and Answer Session</p> <p>10:00 Adjournment</p> | <div style="display: flex; justify-content: space-around;">  </div> <p>OBJECTIVES At the conclusion of this program, participants should be able to:</p> <ul style="list-style-type: none"> • Identify the impact of cholinergic therapy beyond symptomatic treatment for Alzheimer's disease (AD) • Recognize the potential role of anticholinesterase inhibitors (AChEis) in neuroprotection. • Describe the benefits of magnetic resonance imaging in assessing AD. • Discuss the outcome of recent clinical trials in mild cognitive impairment. • Describe the rationale for cholinergic treatment of schizophrenia. • Treat behavioral disturbances associated with AD. <p style="font-size: x-small;">The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.</p> <p style="font-size: x-small;">The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.</p> <p style="font-size: x-small;">Attendees must be registered for the APA 2005 Annual Meeting to attend this symposium. Seating is limited and will be on a first-come, first-served basis. For more information about the meeting, please visit the APA Web site at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the United States and Canada) or at 202-967-7300.</p> <div style="display: flex; justify-content: space-between; align-items: center; font-size: x-small;">    <p>Supported by an unrestricted educational grant from Eli Lilly and Pfizer Inc.</p> </div> |

INDUSTRY-SUPPORTED SYMPOSIUM 42
 Tuesday, May 24, 2005, 7:00 PM - 10:00 PM
 International Ballroom, North Tower, Ballroom Level, Omni Hotel

AN INDUSTRY SUPPORTED SYMPOSIUM AT THE 158TH AMERICAN PSYCHIATRIC ASSOCIATION ANNUAL MEETING
 CHAIRPERSON, DAVID N. NEUBAUER, MD, JOHNS HOPKINS UNIVERSITY

CHALLENGES AT THE INTERFACE OF PSYCHIATRIC, MEDICAL, AND SLEEP DISORDERS

TUESDAY, MAY 24, 2005



6:30 PM - 10:00 PM
 Omni Hotel
 International Ballroom
 North Tower, Ballroom Level
 Atlanta, Georgia

LEARNING OBJECTIVES:

At the conclusion of this symposium, the participants should be able to recognize results and conclusions from epidemiologic studies examining the impact of sleep disturbances, such as insomnia on psychiatric morbidity.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Attendees must be registered for the American Psychiatric Association 158th Annual Meeting to attend this symposium. Seating is limited to a first-come, first-served basis. For more information about the meeting, please visit the APA Web site at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the United States or Canada) or 202-967-7300.

This educational activity is sponsored by the American Psychiatric Association.



Supported by an educational grant from Sanofi-Synthelabo Inc., a member of the sanofi-aventis Group.

AGENDA

6:30 PM **Registration and Dinner**

7:00 PM **Welcome and Introductions**
 David N. Neubauer, MD, Chairperson - Johns Hopkins University

7:10 PM **Epidemiological and Longitudinal Perspectives on Insomnia and Psychiatric Illness**
 Daniel E. Ford, MD - Johns Hopkins University

7:30 PM **Changing Women's Sleep Vulnerabilities Across the Life Cycle**
 Lois E. Krahn, MD - Mayo Clinic, Scottsdale

7:50 PM **Sleep Disturbances and Neurodegenerative Disorders**
 R. Robert Auger, MD - Mayo Clinic, Rochester

8:10 PM **Metabolic Consequences of Insomnia: Implications for Medicine and Psychiatry**
 Gary S. Richardson, MD - Henry Ford Hospital

8:30 PM **Therapeutic Challenges in Treating Insomnia With Comorbid Psychiatric and Medical Disorders**
 David N. Neubauer, MD - Johns Hopkins University

8:50 PM **Discussion: Sleep and Health in Our Society**
 William C. Dement, MD, PhD - Stanford University

9:10 PM **Question and Answer Session**
 Faculty Panel

9:55 PM **Summary and Conclusions**
 David N. Neubauer, MD - Johns Hopkins University

10:00 PM **Adjournment**

INDUSTRY-SUPPORTED SYMPOSIUM 43
 Tuesday, May 24, 2005, 7:00 p.m. - 10:00 p.m.
 Peachtree Ballroom, Level 8, Westin Peachtree Plaza

APA 2005 Annual Meeting
It's Not Just for Kids: ADHD in Adolescence and Adulthood

6:30 PM - 7:00 PM

Dinner

7:00 PM

Welcome/Introduction

Timothy E. Wilens, MD, Chair

7:10 PM

The Course of ADHD From Adolescence into Adulthood

Christopher J. Kratochvil, MD

7:35 PM

Neurobiological Update on ADHD in Adolescence and Adulthood

Stephen V. Faraone, PhD
 Joseph Biederman, MD, Co-author

8:00 PM

College Considerations in Young Adults With ADHD

Sharon B. Wigal, PhD

8:25 PM

New Psychotherapies Directed at Young Adults With ADHD

Steven A. Safren, PhD

8:50 PM

Medication Considerations in Young Adults With ADHD

Timothy E. Wilens, MD

9:15 PM - 10:00 PM

Question & Answer Session
 Faculty

Learning Objectives

At the conclusion of this symposium, the participant should be able to:

1. Recognize the course of ADHD from adolescence into adulthood
2. Categorize the biological underpinnings that are common between youth and adults with ADHD
3. Recall special considerations in preparing young adults with ADHD for college
4. Outline empirically based psychotherapies and pharmacotherapies for adolescents and young adults with ADHD

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for up to 3 hours of category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the educational activity.

Tuesday, May 24, 2005

Dinner 6:30 PM - 7:00 PM

Program 7:00 PM - 10:00 PM

**Westin Peachtree Plaza
 Level 8
 Peachtree Ballroom**

Attendees must be registered for the APA 2005 Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or 703-907-7300.

Sponsored by the
 American Psychiatric Association



Supported by an unrestricted
 educational grant from

Shire

INDUSTRY-SUPPORTED SYMPOSIUM 44
 Wednesday, May 25, 2005, 7:00 a.m. - 8:30 a.m.
 Thursday, May 26, 2005, 7:00 a.m. - 8:30 a.m.
 Grand Ballroom, Second Floor, Hilton Atlanta

BIPOLAR DISORDER ACROSS THE LIFE CYCLE: Special Considerations

158th APA Annual Meeting
**Wednesday, May 25 &
 Thursday, May 26, 2005**
6:30 am - 8:30 am
Atlanta, Georgia
Grand Ballroom, Second Floor
Hilton Atlanta

REGISTRATION STATEMENT:

Attendees must be registered for the American Psychiatric Association Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the United States or Canada) or 703-907-7300.

ACCREDITATION STATEMENT:

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

DESIGNATION STATEMENT:

The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirements of the APA. Each physician should claim only those credits that he/she actually spent in the educational activity.

STATEMENT OF NEED

Bipolar disorder (BPD) affects 0.5 to 1.5 percent of individuals in the United States and has several well recognized subtypes depending on the frequency and characteristics of the mood episodes. General guidelines for the treatment of BPD are available from the American Psychiatric Association, but additional issues arise when applying these guidelines to children, adolescents, women across the reproductive life, and the elderly, for the most part, limiting the clinical impact of these guidelines in such special populations. Because the typical age of onset in patients with BPD is late adolescence or early adulthood, the diagnostic and treatment issues encountered in pre-pubertal and early adolescence will be discussed. Also, additional emphasis will be placed on the treatment of BPD in women across the reproductive life cycle, specifically the impact of alterations in hormones such as the menstrual cycle, pregnancy, postpartum, and the transition to menopause, as well as critical components of the risk/benefit assessment for treatment options during pregnancy and lactation. The symposium will close with the final phase of life - focusing on issues in the diagnosis and treatment of BPD in the elderly. Overall, the symposium will provide special emphasis on the therapeutic monitoring guidelines for mood stabilizers in these special populations. These presentations will be augmented by a panel discussion with all symposium participants.

INTENDED AUDIENCE: Psychiatrists

EDUCATIONAL OBJECTIVES

At the conclusion of this session, participants should be able to:

- Assess the risks and benefits of pharmacologic treatment in order to best manage the treatment of children who are diagnosed with bipolar disorder and identify appropriate time frames for assessing the effectiveness of a treatment regimen before adding a second or third medication
- Assess the impact of reproductive hormones on women with bipolar disorder and identify any associated side effects related to treatments in order to optimize patient management strategies
- Assess the risks and benefits of prenatal pharmacologic treatment in order to counsel, educate, and manage patients with bipolar disorder who are currently pregnant or may potentially become pregnant
- Discuss issues related to the diagnosis and treatment of bipolar disorder in the elderly

SCIENTIFIC AGENDA AND DISTINGUISHED FACULTY

Wednesday, May 25

6:30 am: Breakfast

7:00 am: Introduction

7:05 am:

BIPOLAR DISORDER IN CHILDREN: IMPORTANCE OF EARLY INTERVENTION

Karen Doreen Wagner, MD, PhD

Division of Child & Adolescent Psychiatry, University of Texas Medical Branch

7:35 am:

BIPOLAR DISORDER: IMPACT OF REPRODUCTIVE HORMONES

Natalie Raagon, MD, PhD

Department of Psychiatry and Behavioral Sciences, Stanford School of Medicine

8:05 am:

Question & Answer Session, Adjourn at 8:30 am

Thursday, May 26

6:30 am: Breakfast

7:00 am: Introduction

7:05 am:

BIPOLAR DISORDER IN PREGNANCY: A CLINICIAN'S DILEMMA

Zachary N. Stowe, MD

Director, Women's Mental Health Program, Emory University School of Medicine

7:35 am:

BIPOLAR DISORDER IN THE ELDERLY: SPECIAL TREATMENT CONSIDERATIONS

John Beyer, MD

Department of Psychiatry & Behavioral Sciences, Duke University Medical Center

8:05 am:

Question & Answer Session, Adjourn at 8:30 am

Program Administration and Americans with Disabilities Act: Event staff will be glad to assist you with any special needs (e.g., physical, dietary). Please contact Sarah Cooper or Kim Fenton prior to the live event at 720-748-8800 or e-mail at skcooper@intellist.com or kfenton@intellist.com.



Sponsored by the American Psychiatric Association
 Funded by an educational grant from Shire/Intellist

Impact of Stress and Anxiety

Presented at the APA 2005 Annual Meeting
 Wed., May 25, 2005 • Omni Hotel • Atlanta, GA

on Brain and Body

Samantha Meltzer-Brody, MD *Symposium Chairperson*

| | | | |
|-----------|--|------------|--|
| 6:30 p.m. | Dinner | 8:30 p.m. | Neuroimaging and the Traumatized Brain: PTSD and Emotion Ruth A. Lanius, MD, PhD |
| 6:55 p.m. | Welcome and Announcements | | |
| 7:00 p.m. | Sick & Tired: Anxiety, Stress and Insomnia Murray B. Stein, MD, MPH, FRCPC | 9:00 p.m. | Treatment of Anxiety: The Pharmacotherapy of Psyche and Soma Mark Pollack, MD |
| 7:30 p.m. | Impact of Anxiety on Women's Health: Focusing on the Link between Trauma and Chronic Pain Samantha Meltzer-Brody, MD | 9:30 p.m. | Panel Discussion |
| 8:00 p.m. | Health Effects of Exposure to Violence in Women Soraya Seedat, MD | 10:00 p.m. | Adjourn |

Supported by an unrestricted educational grant from Cephalon



Sponsored by the American Psychiatric Association



Overview: After attending this continuing medical education symposium, the participant should be able to:

- Understand the relationship between anxiety and stress-related disorder and sleep problems, including the impact of treatment on health-related outcomes
- Describe the presentation of functional somatic pain syndromes and the association of chronic pain with a history of maltreatment and PTSD
- Recognize psychiatric and general medical health effects of intimate partner violence
- Recognize the neuronal circuitry proposed to underlie PTSD and its relationship to chronic pain
- Understand the impact of pharmacotherapy on both somatic and psychologic symptoms of anxiety

Accreditation/Registration Information: The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada or 703-907-7300).



Visit the APA Member Center

Find out how APA can help you in your professional life

Learn about the benefits of membership in the nation's oldest medical specialty society. APA's mission is to promote the highest **quality care** for individuals with mental disorders and their families, promote psychiatric **education and research** advances, **represent the profession** of psychiatry, and serve the **professional needs** of its members. Whether you're a prospective, new, long-time, or international member, visit the APA exhibit and find out how APA can help you in your professional life.



At the APA Member Center you can:

- ▶ Apply for APA membership on-site and find out how you may be eligible for a rebate
- ▶ Pick up your *APA Membership Information and Resource Handbook*
- ▶ Participate in APA advocacy efforts
- ▶ Search the Job Bank for the latest employment opportunities
- ▶ Activate your online subscriptions to APA journals
- ▶ Find out about the new Medicare pharmacy benefit and how it impacts your practice
- ▶ Learn how "OMNA On Tour" can help your community eliminate mental health disparity
- ▶ Find out about CME training for office-based treatment of opiate addiction
- ▶ Pick information about updates on the APA Practice Guidelines
- ▶ Check out training and clinical resources on HIV psychiatry
- ▶ Find out about the new ParentsMedGuide.org
- ▶ Keep up to date on the DSM-V Prelude Project: Research and Outreach
- ▶ Learn how the APA Foundation's public education programs promote awareness of mental illness
- ▶ And more!

While at the exhibit, learn about the key roles of these APA subsidiaries



Our mission is to contribute to psychiatry's science base and to improve the quality of psychiatric care through research, education, health policy analysis and dissemination.



The charitable and educational subsidiary, our mission is to advance public understanding that mental illnesses are real and can be effectively treated.

The Member Center is located in the exhibit hall next to the APPI Bookstore

Hours:

| | |
|-------------------|------------|
| Saturday, May 21 | 10:00-5:00 |
| Sunday, May 22 | 10:00-4:30 |
| Monday, May 23 | 10:00-5:30 |
| Tuesday, May 24 | 10:00-6:00 |
| Wednesday, May 25 | 10:00-3:00 |